<SEC-DOCUMENT>0001144204-16-098767.txt : 20160504
<SEC-HEADER>0001144204-16-098767.hdr.sgml : 20160504
<ACCEPTANCE-DATETIME>20160504060504
ACCESSION NUMBER:		0001144204-16-098767
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20160504
DATE AS OF CHANGE:		20160504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-210144
		FILM NUMBER:		161617301

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>v438712_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>

     <HEAD>

          <TITLE></TITLE>

     </HEAD>

<BODY>

<DIV style="text-align: center; min-width: 708">


<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Filed pursuant to Rule 424(b)(4)<BR>Registration Statement No. 333-210144</B></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">18,750,000 Shares of Common Stock </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="361"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=3><B><FONT STYLE="font-size: 14pt">Warrants to Purchase 18,750,000 Shares of Common Stock</FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR><B>Aytu BioScience, Inc.</B></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left"><IMG SRC="logo_aytu-bioscience.jpg" WIDTH="180" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are offering 18,750,000 shares of common stock and warrants to purchase up to an aggregate of 18,750,000 shares of common stock. The shares of common stock and the warrants are immediately separable and will be issued separately in this offering. Each warrant will have a term of five years from issuance and an exercise price equal to $0.50 per share, which is 125% of the public offering price of the shares and warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are also offering the shares of common stock that are issuable from time to time upon exercise of the warrants being offered by this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is listed on the OTCQX Market operated by OTC Markets Group, Inc. (or OTCQX) under the ticker symbol &#147;AYTU.&#148; On May 2, 2016, the last reported sale price of our common stock on the OTCQX was $0.40. There is no established trading market for the warrants. The warrants issued in this offering are approved for trading on the OTCQX under the ticker symbol &#147;AYTUW&#148;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">10</a> of this prospectus, and under similar headings in any amendments or supplements to this prospectus.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="361"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Per Share</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Per Warrant</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Total</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.40</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discounts and commissions<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0273</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0007</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.028</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds to us, before expenses<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.3627</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0093</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.372</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 11pt; font-size: 9pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Joseph Gunnar &amp; Co., LLC, the representative of the underwriters. See &#147;Underwriting&#148; for a description of compensation payable to the underwriters. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 11pt; font-size: 9pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Does not include proceeds from the exercise of the warrants, in cash, if any. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted a 45-day option to the representative of the underwriters to purchase up to 2,812,500 additional shares of common stock and/or up to 2,812,500 warrants solely to cover over-allotments, if any. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters expect to deliver the shares and warrants to purchasers in the offering on or about May 6, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="297"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="344"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Sole Book-Running Manager&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B>Joseph Gunnar &amp; Co.</B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 16pt"><B></FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right">Lead Manager<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B></B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 16pt"><B>Fordham Financial Management</FONT></B></TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The date of this prospectus is May 2, 2016</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v433932_ifc.jpg" WIDTH="579" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="TOC"></a>TABLE OF CONTENTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="552"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="40"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t1PRO">Prospectus Summary</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t1PRO">1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t2THE">The Offering</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t2THE">8</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t3RIS">Risk Factors</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t3RIS">10</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t4SPE">Special Note Regarding Forward-Looking Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t4SPE">48</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t5USE">Use of Proceeds</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t5USE">49</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t6MAR">Market for Common Stock</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t6MAR">50</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t7DIV">Dividend Policy</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t7DIV">51</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t8DIL">Dilution</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t8DIL">52</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t9CAP">Capitalization</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t9CAP">53</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t10MAN">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t10MAN">55</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t11BUS">Business</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t11BUS">68</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t12MAN">Management</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t12MAN">108</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t13TRA">Transactions with Related Persons</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t13TRA">116</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t14SEC">Security Ownership of Certain Beneficial Owners and Management</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t14SEC">119</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t15DES">Description of Capital Stock</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t15DES">121</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t16UND">Underwriting</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t16UND">126</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t17LEG">Legal Matters</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t17LEG">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t18EXP">Experts</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t18EXP">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t19WHE">Where You Can Find More Information</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t19WHE">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t20FIN">Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t20FIN">F-1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should rely only on the information contained in this prospectus, as supplemented and amended. We have not authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus may only be accurate on the date of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We urge you to read carefully this prospectus, as supplemented and amended, before deciding whether to invest in any of the common stock being offered. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Aytu,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company&#148; and &#147;our business&#148; refer to Aytu BioScience, Inc. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including Luoxis, MiOXSYS, Natesto, Primsol, ProstaScint, RedoxSYS, Vyrix, and Zertane. All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this prospectus, appear with the trade name, trademark or service mark notice and then throughout the remainder of this prospectus without trade name,
trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">
i
<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t1PRO"></a>PROSPECTUS SUMMARY</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in shares of our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities, you should read the entire prospectus carefully, including &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">10</a>, and the financial statements and related notes included
in this prospectus.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Company Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage specialty healthcare company focused on acquiring, developing and commercializing novel products in the field of urology. We have multiple urology-focused products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs in the field of urology. We are initially concentrating on prostate cancer, urinary tract infections, male sexual dysfunction and male infertility and plan to expand into other urological indications for which there are significant medical needs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently market ProstaScint&reg; (capromab pendetide), the only radioimaging agent indicated to detect prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. ProstaScint is approved by the U.S. Food and Drug Administration, or FDA, for use in both newly diagnosed, high-risk prostate cancer patients and patients with recurrent prostate cancer. We also market Primsol&reg; (trimethoprim hydrochloride)&nbsp;&#151;&nbsp;the only FDA-approved trimethoprim-only oral solution for urinary tract infections. We recently acquired exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone), a
novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we plan to launch Natesto in the United States with our direct sales force in July 2016. Natesto is FDA-approved for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. Importantly, as Natesto is delivered via the nasal mucosa and not to the skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning associated with all other topically applied TRTs, including the market leader AndroGel&reg;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have a focused pipeline, including MiOXSYS, a novel in vitro diagnostic device that is currently CE marked (which enables it to be sold within the European Economic Area (see &#147;Business&nbsp;&#151;&nbsp; Foreign Regulatory Approval&#148;)) and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our MiOXSYS<sup>TM</sup> system is a novel, point-of-care semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. Male infertility is a prevalent and underserved condition and oxidative stress is widely implicated in its pathophysiology. MiOXSYS was developed from our core oxidation-reduction potential research platform known as RedoxSYS&reg;.We are advancing MiOXSYS toward FDA clearance and believe we are adequately funded to complete the required clinical study. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our late-stage therapeutic candidate is Zertane<sup>TM</sup>, an oral therapeutic that has been studied for the treatment of premature ejaculation, or PE. PE is the most common sexual dysfunction for which there is not an FDA-approved treatment and affects up to 23% of men in the U.S. and major European countries. Zertane, which has demonstrated safety and efficacy in two European pivotal studies, has the potential to be the first oral therapeutic approved in the United States for the treatment of PE. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, we are actively looking to acquire additional urology products, including existing products we believe can offer distinct commercial advantages. Our management team&#146;s prior experience has involved identifying clinical assets that can be re-launched to increase value, with a focused commercial infrastructure specializing in urology. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>ProstaScint&reg; (capromab pendetide).</I>&nbsp;&nbsp;We became a commercial stage company by virtue of our acquisition of ProstaScint in May 2015 and are generating sales of this FDA-approved prostate cancer imaging agent. As prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused product portfolio and pipeline. Prostate cancer is the most common cancer among men in the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2,200,000 men were alive with some history of prostate cancer in 2006, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion by 2017, a compound annual growth rate, or CAGR, of 7.5%. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Natesto</I><sup>TM</sup> <I>(testosterone)</I>. On April 22, 2016, we entered into an agreement to acquire the exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee&#146;s rights, expected to occur on June 30, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with
active lifestyles as Natesto is small, portable, Transportation Security Administration, or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly to the patient&#146;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a proprietary nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&#146;s female partner or children&nbsp;&#151;&nbsp;as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery directly onto the skin. We intend to launch Natesto in the U.S. in July 2016 with our direct sales force, and we expect to position Natesto as the ideal treatment solution for men with active, busy lifestyles who suffer from hypogonadism. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Primsol&reg; (trimethoprim solution).</I>&nbsp;&nbsp;On October 5, 2015, we purchased Primsol from FSC Laboratories, Inc. Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections, or UTIs. This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (&#147;sulfa&#148;). It is estimated that 150 million cases of urinary tract infection occur annually worldwide,
and the annual estimated incidence is 0.5&nbsp;&#150;&nbsp;0.7/persons per year. Importantly, there are more than 1 million catheter-associated UTIs in the U.S. alone. As many of these patients are elderly and unable to swallow pills, an oral liquid formulation represents a convenient formulation for easier administration. The acquisition of Primsol adds a second established brand to our product portfolio. We expect to benefit from and continue to grow Primsol&#146;s established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. We can thus utilize the same sales channel as ProstaScint, leading to potential commercial synergies and product growth. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>MiOXSYS.</I>&nbsp;&nbsp;MiOXSYS<sup>TM</sup> is a rapid <I>in vitro</I> diagnostic semen analysis test used in the quantitative measurement of static oxidation reduction potential, or sORP, in human semen. MiOXSYS is a recently CE marked system and is an accurate, easy to use, and fast infertility assessment tool. It is estimated that 72.4 million couples worldwide experience infertility problems. In the United States, approximately 10% of couples are defined as infertile. Male infertility is responsible for between 40&nbsp;&#150;&nbsp;50% of all infertility cases and affects approximately 7% of all men. Male infertility is
often unexplained (idiopathic), and this idiopathic infertility is frequently associated with levels of oxidative stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to measure oxidative stress should provide a practical way for male infertility specialists to improve semen analysis and infertility assessments without having to refer patients to outside clinical laboratories. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess the
degree of oxidative stress, sperm motility and morphology, and potentially enable the monitoring of patients&#146; responses to antioxidant therapy as a treatment regimen for infertility. The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in March 2016. We expect to advance MiOXSYS into clinical trials in the United States in order to enable 510(k) clearance. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the MiOXSYS system, we are continuing to develop the global market for the RedoxSYS System across a range of applications. Specifically, we have begun initial commercializing of the RedoxSYS System for research use through distribution partners, primarily outside the U.S. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The technology underpinning the RedoxSYS and MiOXSYS systems was developed by Luoxis Diagnostics, Inc. in the two years immediately preceding the merger between Luoxis, Vyrix Pharmaceuticals, Inc., and us (under our former name of Rosewind Corporation) in April 2015. Upon the consummation of the merger, the RedoxSYS System and MiOXSYS System became our assets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Zertane.</I>&nbsp;&nbsp;The FDA has accepted an Investigational New Drug, or IND, application for our product candidate Zertane for the treatment of premature ejaculation. However, depending on our success in raising additional funds, we may decide to focus our capital resources on other strategies and not pursue clinical testing of Zertane in the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic options to maximize the value of Zertane, inclusive of divestiture, out-licensing, and strategic commercial collaborations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The global premature ejaculation market is expected to reach over $12 billion in annual sales by 2017, representing a CAGR of 4.1% from 2010. According to published analyses, PE is a highly prevalent male sexual dysfunction affecting up to 23% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge, only two other prescription products have been approved elsewhere in the world. Treatment options for PE have
traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Strategy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Key elements of our strategy include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We have begun commercializing ProstaScint in the U.S. and in key markets around the world. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Launch Natesto in the U.S. for the treatment of hypogonadism with our direct sales force. We expect to launch Natesto in July 2016 and target high-prescribing TRT prescribers with a primary emphasis on urologists and male health practitioners. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved Primsol for the treatment of uncomplicated urinary tract infections. We are re-launching Primsol to urologists in the U.S. and in key markets around the world where appropriate. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Establish MiOXSYS as a leading in vitro diagnostic device in the assessment of male infertility. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Acquire additional marketed products and late-stage development assets within our core urology focus that can be efficiently marketed through our growing commercial organization. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">Develop a pipeline of urology therapeutics, with a focus on identifying novel products with sufficient clinical proof of concept that require modest internal R&amp;D expense. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Future Products</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to augment our core in-development and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related to urological disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through asset purchases, licensing, co-development, or collaborative commercial arrangements (co-promotions, co-marketing, etc.). </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management team has extensive experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized, and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect that we will build a substantial portfolio of complementary urology products. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Recent Developments</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 5, 2015, we entered into and closed on an asset purchase agreement with FSC Laboratories, Inc. (the &#147;Seller&#148;). Pursuant to the agreement, we purchased assets related to the Seller&#146;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in process and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We paid $500,000 at closing for the Primsol Business and paid an additional $142,000 of which $102,000 went to inventory and $40,000 toward the Primsol Business, for the transfer of the Primsol-related product inventory, which we now own. As agreed, we paid $500,000 on April 1, 2016, and also agreed to pay an additional $500,000 no later than June 30, 2016, and $250,000 no later than September 30, 2016 for a total purchase price of $1,892,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The agreement also provides that for a period of one year after the closing the Seller will not directly or indirectly sell, market, promote, advertise or distribute anywhere in the world any urinary tract anti-infective pharmaceutical or treatment product containing trimethoprim. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 8, 2015, we and Biovest International, Inc., or Biovest, (whose contract manufacturing business is now known as Cell Culture Company, or C3) entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us. The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of our products. The
agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, we may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over at least a four-year period at a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order, an additional $500,000 on January 4, 2016 and an additional $500,000 on April 1, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 20, 2016, each of Joshua R. Disbrow, our Chief Executive Officer, and Jarrett T. Disbrow, our Chief Operating Officer, purchased 153,846 shares of our common stock at a price of $0.65 per share, resulting in gross proceeds to us of $200,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 10, 2016, we completed the conversion of $4,125,000 in convertible notes and $143,000 of accrued interest. The notes were issued in financings that closed in July and August 2015. Upon the conversion, we issued an aggregate of 7,879,096 shares common stock. An aggregate of $1,050,000 of principal of convertible notes remains outstanding. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Effective April 11, 2016, our Board appointed Carl C. Dockery as our first independent director. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. For more information on Mr. Dockery, see &#147;Management.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">we will acquire effective upon the expiration of the current licensee&#146;s rights, expected to occur on June 30, 2016. The licensee&#146;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We paid Acerus an upfront fee of $2,000,000 upon execution of the agreement. On September 5, 2016 we will pay an additional $2,000,000 (the &#147;Second Upfront&#148;). On January 1, 2017, we will pay an additional $4,000,000 (the &#147;Third Upfront&#148;).</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37,500,000):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">$2,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $25,000,000 (the &#147;First Milestone&#148;);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">$5,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $50,000,000;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">$7,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $75,000,000;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">$10,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $100,000,000; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#9642;</TD>

          <TD STYLE="text-align: left">$12,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $125,000,000.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will also purchase an aggregate of 12,245,411 shares of Acerus common stock for Cdn.$2,534,800 (approximately US$2,000,000), with a purchase price per share of Cdn.$0.207.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the term of the agreement, we will purchase all of our Natesto product need from Acerus. Each month we will provide Acerus with a two-year forecast of our product needs, the first three months of which will be noncancelable. Pursuant to the agreement, we will pay Acerus a supply price per unit of the greater of (i) 115% of Acerus&#146; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains constant after that. Upon the expiration or
invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of the Acerus&#146; cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus&#146; cost of goods sold (but not exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus&#146; cost of goods (but not to exceed the fixed ceiling price). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of any termination of the agreement prior to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will, unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after the termination date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of any termination of the license agreement prior to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will, unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after the termination date.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the agreement, we and Acerus are forming a cross-functional transition team to ensure a fully-integrated and timely transition to us from Endo. We and Acerus also will form a joint marketing committee to oversee brand marketing and overall planning related to Natesto.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be responsible for all aspects of managing the NDA and complying with any regulatory or other legal obligations arising in connection therewith&nbsp;&#151;&nbsp;excluding any additional safety or (except as set out below with </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">respect to a twice a day study) efficacy studies. Notwithstanding the foregoing, we will, in our capacity as the holder of the NDA for Natesto, provide all assistance and cooperation as may reasonably be required by Acerus in connection with the conduct of such safety or efficacy studies.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be responsible for directly or indirectly manufacturing Natesto subject to our obligation to purchase Natesto from Acero, and Acero&#146;s obligation to sell Natesto to us, as set forth above. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We agreed to undertake the cardiovascular postmarketing requirement, or PMR, for Natesto; however, Acerus must reimburse us for all costs of such obligation, including any PMR trial. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event that Acerus decides to dispose of any intellectual property licensed to us under the agreement in any territory in the world (other than Brazil or the countries of the European Union), Acerus must notify us and negotiate exclusively with us for a period of 60 days for an agreement to assign, transfer or license such intellectual property to us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may terminate the agreement at any time upon six months&#146; notice, provided that we must make any milestone payment to Acerus that would otherwise become due during such six month period, and may be responsible for the Second Upfront, Third Upfront and First Milestone payments as referenced above. Either Party may terminate the agreement for material default or breach that remains uncured or the bankruptcy or insolvency of the other party. Acerus may terminate the agreement upon six months&#146; notice if it determines that the reimbursable amounts in connection with the cardiovascular PMR obligations would no longer make
the agreement economically viable for Acerus, provided that it must pay us all reimbursable amounts outstanding prior to such termination, and also fulfill any valid purchase orders submitted by us prior to the effective date of termination.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the quarter ended March 31, 2016 we estimate that our total revenue has grown to approximately $669,000 compared to $469,000 for the quarter ended December 31, 2015. This represents quarter over quarter growth of 42%. As of March 31, 2016 we have approximately $8,666,000 of cash and cash equivalents compared to $10,960,000 at December 31, 2015. During the quarter ended March 31, 2016 we anticipate that we will have a material non-cash expense related to the derivative features that were triggered upon the conversion of the convertible debt that occurred during the quarter. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are in the process of finalizing our results for the quarter ended March 31, 2016, and this unaudited preliminary financial information for the quarter ended March 31, 2016 is based upon estimates and subject to completion of our financial closing procedures. Moreover, these data have been prepared solely on the basis of currently available information by, and are the responsibility of, management. This preliminary financial information is not a comprehensive statement of our financial results for this period, and our actual results may differ materially from these estimates due to the completion of our financial closing
procedures, final adjustments, and other developments that may arise between now and the time that the closing procedures for the quarter are completed. There can be no assurance that these estimates will be realized, and estimates are subject to risks and uncertainties, many of which are not within our control. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Corporate Information</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Vyrix Pharmaceuticals, Inc., or Vyrix, was incorporated under the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out of the sexual dysfunction therapeutics business, including the late-stage men&#146;s health product candidates, Zertane and Zertane-ED, from Ampio, which carve out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws of the State of Delaware on January 24, 2013 and was majority owned by
Ampio immediately prior to the completion of the Merger. Luoxis was focused on initially developing and advancing the RedoxSYS System, from which the MiOXSYS System was developed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 20, 2015, Rosewind formed Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger, and on April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis, and </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with Rosewind as the surviving corporation (herein referred to as the Merger). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Concurrent with the closing of the Merger, Rosewind abandoned its pre-merger business plans to develop a sailing school, and we now solely pursue the specialty healthcare market, focusing on urological related conditions, including the business of Vyrix and Luoxis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 8, 2015, we (i) reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder received one share of common stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split). All share and per share amounts in this prospectus have been adjusted to reflect the effect of the Reverse Stock Split. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal executive office is located at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112. Our telephone number at our principal executive office is (720) 437-6580. Our corporate website is <I>www.aytubio.com</I>. The information on our corporate website is not part of, and is not incorporated by reference into, this prospectus. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t2THE"></a>THE OFFERING</Font> </H1>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Issuer </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Aytu BioScience, Inc. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Securities offered by us </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">18,750,000 shares of common stock and warrants to purchase shares of common stock. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Public offering price </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">$0.39 per share and $0.01 per warrant </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Option to purchase additional shares </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We have granted the underwriters an option for a period of 45 days to purchase up to 2,812,500 additional shares of common stock and/or 2,812,500 warrants, at the public offering price, less the underwriting discount. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Warrants </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Each warrant will be exercisable for five years from issuance and have an exercise price equal to $0.50 per share, which is 125% of the public offering price. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Common stock to be outstanding immediately after this offering </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">44,856,459 shares, or 47,668,959 shares if the underwriters exercise in full their option to purchase an additional 2,812,500 shares of common stock.<sup>&#040;1&#041;</sup> </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Use of proceeds </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We intend to use the net proceeds from this offering to fund the expansion of our commercial infrastructure for the planned launch of Natesto and the planned expansion in the commercialization of ProstaScint and Primsol, the acquisition of additional complementary products and product candidates, completion of clinical development activities for the MiOXSYS system, working capital and general corporate and administrative expenses. See &#147;Use of Proceeds&#148; on page <a href="#t5USE">49</a>. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Risk factors </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">This investment involves a high degree of risk. You should read the description of risks set forth under &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">10</a> of this prospectus for a discussion of factors to consider before deciding to purchase our securities. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">OTCQX Trading Symbol for Common Stock </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&#147;AYTU&#148; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">OTCQX Trading Symbol for Warrants </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&#147;AYTUW&#148; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Lock-up </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We and our directors and executive officers and certain stockholders have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus in the case of our directors and executive officers, and 60&nbsp;&#150;&nbsp;90 days in the case of us and certain stockholders. See &#147;Underwriting&#148; beginning on page <a href="#t16UND">126</a>. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Registered Securities </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">This prospectus also relates to the offering of the shares of common stock issuable upon the exercise of the warrants and the Underwriters&#146; warrants. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Conversion of Outstanding Notes </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Upon the closing of this offering, an aggregate of $1,050,000 in principal and $78,000 in accrued interest on the 2015 convertible notes outstanding will automatically convert into an aggregate of 3,659,978 shares of our common stock, at the combined public offering price of $0.40 per share and related warrant.</TD>

</TR>

</TABLE></DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Based on 22,446,481 shares outstanding on February 12, 2016, and after giving effect to the conversion of outstanding notes discussed above. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless otherwise indicated, all information in this prospectus assumes no exercise by the underwriters of their option to purchase up to 2,812,500 shares of common stock and/or up to 2,812,500 warrants to cover over-allotments, if any, and excludes as of February 12, 2016 (i) 3,717,500 shares of our common stock issuable upon exercise of outstanding stock options under our stock incentive plans at a weighted average exercise price of $1.55 per share, (ii) 102,613 shares of our common stock issuable upon exercise of outstanding warrants with an exercise price of $4.53 per share, (iii) 267,052 shares of our common stock issuable
upon exercise of outstanding warrants with an exercise price of $0.65, (iv) 18,750,000 shares of common stock issuable upon exercise of the warrants offered hereby and (v) shares of common stock underlying the warrants to be issued to the underwriters in connection with this offering.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t3RIS"></a>RISK FACTORS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Investing in our securities includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed below, together with all of the other information contained in this prospectus. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our common stock to decline and could cause you to lose all or part of your investment.</I> </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Our Financial Condition and Capital Requirements</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have limited operating history, have incurred losses, and can give no assurance of profitability.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage healthcare company with a limited operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did not have a focus on profitability. As a result, we have not generated material revenue to date and are not profitable, and have incurred losses in each year since our inception. Our net loss for the years ended June 30, 2015 and 2014 was $7.7 million and $5.6 million, respectively. Our net loss for the six months ended December 31, 2015 was $5.6 million. We have not demonstrated the ability to be a profit-generating enterprise to date, and without significant
financing, there is substantial doubt about our ability to continue as a going concern. We expect to incur substantial losses for the foreseeable future. Our ability to generate significant revenue is uncertain, and we may never achieve profitability. We have a very limited operating history on which investors can evaluate our potential for future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">U.S. regulatory approval of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">foreign regulatory approval of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of sufficient capital;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">uncertain market acceptance of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unanticipated problems, delays, and expense relating to product development and implementation;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of sufficient intellectual property;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">competition; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">technological changes. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of our limited operating history, and the increasingly competitive nature of the markets in which we compete, our historical financial data, which, prior to April 16, 2015, consists of allocations of expenses from Ampio, is of limited value in anticipating future operating expenses. Our planned expense levels will be based in part on our expectations concerning future operations, which is difficult to forecast accurately based on our stage of development. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not received any material revenues from the commercialization of our products or product candidates and might not receive significant revenues from the commercialization of products and our product candidates in the near term. Even though ProstaScint is an approved drug that we are marketing, we only acquired it in May 2015 and have limited experience on which to base the revenue we could expect to receive from its sales. To obtain revenues from our products and product candidates, we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products
and completing clinical trials of our product candidates, obtaining positive results from the clinical trials, achieving marketing approval for these product candidates, manufacturing, marketing and selling our existing products and those products for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">government payors. We, and our collaborators, if any, may never succeed in these activities and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our product expansion and development efforts or other operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are currently advancing our product candidates through clinical development. Developing product candidates is expensive, lengthy and risky, and we expect to incur research and development expenses in connection with our ongoing clinical development activities with the MiOXSYS System. In addition, we are expending resources to expand the market for ProstaScint and Primsol, which might not be successful or might take longer and be more expensive than we anticipate. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015, our cash and cash equivalents were $11.0 million. Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, our product candidates. Raising funds in the current economic
environment, as well our lack of operating history, may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to expand any existing product or develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of
additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not obtain the capital necessary to fund our operations, we will be unable to successfully expand, develop, obtain regulatory approval of, and commercialize, our products and product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The development of pharmaceutical products, medical diagnostics and medical devices is capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">progress in, and the costs of, our pre-clinical studies and clinical trials and other research and development programs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the scope, prioritization and number of our research and development programs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of securing manufacturing arrangements for commercial production;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of establishing, expanding or contracting for sales and marketing capabilities for any existing products and if we obtain regulatory clearances to market our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual property rights. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our technologies, research or development programs or our commercialization efforts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We no longer can rely on funding from Ampio to support our operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a part of the Merger, Ampio forgave debt incurred by Luoxis and Vyrix in exchange for shares of our common stock and also committed an additional $10.0 million for additional shares of our common stock, which was due in April 2016 and which Ampio paid in full in December 2015. We have no agreement with Ampio for future funding. Consequently, we will need to support our business with revenue from our operations or from financing from third party sources. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our investment in Acerus Pharmaceuticals Corporation could decline in value.</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to purchase approximately $2,000,000 worth of shares of common stock of Acerus Pharmaceutics Corporation as a condition to our licensing of Natesto, and are to close on that purchase on April 28, 2016. Pursuant to Canadian securities laws, we cannot sell that stock until August 29, 2016. During the time that we own those shares, there can be no assurance that the value of that stock will not decline and we could lose our entire investment in that stock.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance with public company reporting and other requirements.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we incur significant legal, accounting and other expenses that Vyrix and Luoxis did not incur as private companies. In addition, the rules and regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our corporate governance practices, with which we will need to comply. Further, we will continue to be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results. Based on currently available information and
assumptions, we estimate that we will incur approximately $500,000 in expenses on an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management will be required to deliver a report that assesses the effectiveness of our internal control over financial reporting for the year ending June 30, 2016. Due to the short period of time between the Merger and June 30, 2015, we did not conduct an assessment of our internal control over financial reporting (in accordance with the SEC&#146;s guidance under Section 215.02 of the SEC&#146;s Compliance and Disclosure Interpretations on Regulation S-K). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we conclude that our internal control over financial reporting is not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will not identify one or more material weaknesses in our internal controls in connection with evaluating our
compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could require us to restate our operating results. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to conclude that we have effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an attestation report on the effectiveness of internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to obtain listing on a securities
exchange such as the NYSE MKT or NASDAQ. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Product Development, Regulatory Approval and Commercialization</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be able to develop our current or any future product candidates. Our product candidates will require substantial additional clinical development, testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale
of any product candidate, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are not permitted to market a product in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not be able to demonstrate that a product candidate is safe and effective to the satisfaction of the FDA;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may require that we conduct additional clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not approve the formulation, labeling or specifications of any product candidate;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients or the public in general;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not accept data generated at our clinical trial sites;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px; text-align: left"></TD>

          <TD STYLE="width: 24px; text-align: left"></TD>

          <TD STYLE="text-align: left">may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may change its approval policies or adopt new regulations. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These same risks apply to applicable foreign regulatory agencies from which we may seek approval for any of our product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate. Moreover, because a substantial portion of our business is or will be dependent upon our existing products and product candidates, any such setback in our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to successfully acquire new products, we may lose market position.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Acquiring new products is an important factor in our planned sales growth, including products that already have been developed and found market acceptance. If we fail to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue source to help pay for our development activities as well as possible acquisitions. This failure would delay implementation of our business plan, which could have a negative adverse effect on our business and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not secure collaborations with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may enter into collaborations with third parties to conduct clinical testing, as well as to commercialize and manufacture our products and product candidates. If we are able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration
revenues are not guaranteed, even when efficacy and safety are demonstrated. The current economic environment may result in potential collaborators electing to reduce their external spending, which may prevent us from developing our product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize our products or product candidates. Collaborations involving our product candidates pose a number of risks, including the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing their own or another party&#146;s product candidate; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may decide to terminate or not to renew the collaboration for these or other reasons. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result, collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example, our former collaborator that licensed Zertane conducted clinical trials which we believe demonstrated efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated the collaboration agreement. The Merger also created a potential conflict with a principal customer of the acquired company, which sells a product to treat premature ejaculation in certain European markets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Collaboration agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&#146;s objectives and meet our expectations, we may be unable to advance our products or product candidates and may not generate meaningful revenues. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We or our strategic partners may choose not to continue an existing product or choose not to develop a product candidate at any time during development, which would reduce or eliminate our potential return on investment for that product.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At any time and for any reason, we or our strategic partners may decide to discontinue the development or commercialization of a product or product candidate. If we terminate a program in which we have invested significant resources, we will reduce the return, or not receive any return, on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic partners terminates a program, we will not receive any future milestone payments or royalties relating to that program under our agreement with that party. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our pre-commercial product candidates are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pre-clinical testing and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical testing and clinical development necessary to commercialize a drug or biologic, and delays or failure can occur at any stage. Interim results of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number
of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in one or more trials would be a major set-back for that product candidate and for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development programs, which could have a material adverse effect on our business, prospects and financial condition and on the value of our common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with clinical testing and trials, we face a number of risks, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic, or has unacceptable side effects;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">patients may die or suffer other adverse effects for reasons that may or may not be related to the product candidate being tested;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results may not confirm the positive results of earlier testing or trials; and</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to establish the safety and efficacy of the product candidate. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we do not successfully complete pre-clinical and clinical development, we will be unable to market and sell products derived from our product candidates and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs and biologics in development in the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization, and only a small number achieve
widespread physician and consumer acceptance following regulatory approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive regulatory approval of any of these product candidates and our business, prospects and financial condition will be materially harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Delays, suspensions and terminations in our clinical trials could result in increased costs to us and delay or prevent our ability to generate revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Human clinical trials are very expensive, time-consuming, and difficult to design, implement and complete. We currently expect clinical trials of our therapeutic product candidates could take up to 24 months to complete, but the completion of trials for these candidates may be delayed for a variety of reasons, including delays in:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">validating test methods to support quality testing of the drug substance and drug product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining sufficient quantities of the drug substance or device ports;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">manufacturing sufficient quantities of a product candidate;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining approval of an IND from the FDA;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">determining dosing and clinical design and making related adjustments; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the relevant disease and the eligibility criteria for the clinical trial. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The commencement and completion of clinical trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of effectiveness of product candidates during clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse events, safety issues or side effects relating to the product candidates or their formulation or design;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">inability to raise additional capital in sufficient amounts to continue clinical trials or development programs, which are very expensive;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve resources;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to enter into collaborations relating to the development and commercialization of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability or the inability of our collaborators to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect to clinical trial results;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure of our collaborators to advance our product candidates through clinical development;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">difficulty in patient monitoring and data collection due to failure of patients to maintain contact after treatment;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">varying interpretations of our data, and regulatory commitments and requirements by the FDA and similar foreign regulatory agencies. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Many of these factors may also ultimately lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, we may encounter delays or product candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">diminishment of any competitive advantages that such product candidates may have or attain. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Furthermore, if we fail to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">diminishment of any competitive advantages that such product candidates may have or attain;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays or termination in clinical trials or commercialization;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">product recalls or seizures;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">suspension of manufacturing;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawals of previously approved marketing applications; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">fines, civil penalties, and criminal prosecutions. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We or our collaborators intend to seek FDA approval for some of our product candidates using an expedited process established by the FDA. If we, or our collaborators, are unable to secure clearances to use expedited development pathways from the FDA for certain of our drug product candidates, we, or they, may be required to conduct additional pre-clinical studies or clinical trials beyond those that we, or they, contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals and of any product revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Assuming successful completion of clinical trials, we expect to submit NDAs to the FDA at various times in the future under Section 505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA. NDAs submitted under this section are eligible to receive FDA approval by relying in part on the FDA&#146;s findings of safety and efficacy for a previously approved drug. The FDA&#146;s 1999 guidance on Section 505(b)(2) </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">applications states that new indications for a previously approved drug, a new combination product, a modified active ingredient, or changes in dosage form, strength, formulation, and route of administration of a previously approved product are encompassed within the Section 505(b)(2) NDA process. Relying on Section 505(b)(2) is advantageous because we or our collaborators may not be required (i) to perform the full range of safety and efficacy trials that is otherwise required to secure approval of a new drug, and (ii) obtain a &#147;right of reference&#148; from the applicant that obtained approval of the previously approved
drug. However, a Section 505(b)(2) application must support the proposed change of the previously approved drug by including necessary and adequate information, as determined by the FDA, and the FDA may still require us to perform a portion or the full range of safety and efficacy trials. There can be no assurance that we would be successful under any Section 505(b)(2) application. We specifically intended to do this for Zertane and any future collaborator could as well. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The medical device regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals could prevent us from broadly commercializing the MiOXSYS System for clinical use.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System is subject to 510(k) clearance by the FDA prior to its marketing for commercial use in the United States, and to regulatory approvals beyond CE Marking required by certain foreign governmental entities prior to its marketing outside the United States. In addition, any changes or modifications to a device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, may require the submission of a new application for 510(k) clearance, pre-market approval, or foreign regulatory approvals. The 510(k)
clearance and pre-market approval processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve months from submission to obtain 510(k) clearance, and from one to three years from submission to obtain pre-market approval; however, it may take longer, and 510(k) clearance or pre-market approval may never be obtained. We have limited experience in filing FDA applications for 510(k) clearance and pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The approval process for pharmaceutical and medical device products outside the United States varies among countries and may limit our ability to develop, manufacture and sell our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to market and sell our products in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing. We may conduct clinical trials for, and seek regulatory approval to market, our product candidates in countries other than the United States. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may decide to first seek regulatory approvals of a product candidate
in countries other than the United States, or we may simultaneously seek regulatory approvals in the United States and other countries. If we or our collaborators seek marketing approval for a product candidate outside the United States, we will be subject to the regulatory requirements of health authorities in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit a European Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining regulatory approvals from health authorities in countries outside the United States is likely to subject us to all of the risks associated with obtaining FDA approval described above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and approval by foreign health authorities does not ensure marketing approval by the FDA. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or they market our products, which could materially impair our ability to generate revenue.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we receive regulatory approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or the patient population that may utilize the product, or may be required to carry a warning in its labeling and on its packaging. Products with boxed warnings are subject to more restrictive advertising regulations than products without such warnings. These restrictions could make it more difficult to market any
product candidate effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any of our products and product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of our approved products and product candidates for which we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such products, among other things, are or will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of
records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the FDA requirement to implement a REMS to ensure that the benefits of a drug or biological product outweigh its risks. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we, or our collaborators, do not market any of our product
candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed, and our business will be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product.
The achievement of many of these milestones may be outside of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our available capital resources or capital constraints we experience;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll patients who meet clinical trial eligibility criteria;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other actions, decisions or rules issued by regulators;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the efforts of our collaborators with respect to the commercialization of our products; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business, prospects and results of operations may be harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely, and will rely in the future, on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the third parties do not successfully carry out their contractual duties or fail to meet regulatory obligations or expected deadlines;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we replace a third party; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the quality or accuracy of the data obtained by third parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, for Zertane, we are using, and relying on, single suppliers and single manufacturers for drug supply for our planned Phase 3 clinical trials and our commercial supply. Although there are potential alternative suppliers and manufacturers for Zertane if need be, we have not qualified these vendors to date. If we or a collaborator were required to change vendors, it could result in a failure to meet regulatory requirements or projected timelines and necessary quality standards for successful manufacturing of the various required lots of material for our development and commercialization efforts, any of which could
have an adverse effect on any business, prospects and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Even if collaborators with which we contract in the future successfully complete clinical trials of our product candidates, those product candidates may not be commercialized successfully for other reasons.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we contract with collaborators that successfully complete clinical trials for one or more of our product candidates, those candidates may not be commercialized for other reasons, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to receive regulatory clearances required to market them as drugs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">being subject to proprietary rights held by others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">being difficult or expensive to manufacture on a commercial scale;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">having adverse side effects that make their use less desirable; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failing to compete effectively with products or treatments commercialized by competitors. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization as a result of these regulations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The manufacturing processes and facilities of third-party manufacturers we engage are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of
previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recall or seizure of the product in question;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">total or partial suspension of production or distribution;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA&#146;s refusal to grant pending future clearance or pre-market approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical holds;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">warning letters;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal to permit the export of the product in question; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">criminal prosecution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We face substantial competition from companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We compete with companies that design, manufacture and market already-existing and new urology products. We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and/or our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest
in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">expand the market for any approved products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">successfully commercialize our product candidates alone or with commercial partners;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">discover and develop product candidates that are superior to other products in the market;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtain required regulatory approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">attract and retain qualified personnel; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtain patent and/or other proprietary protection for our product candidates. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Established pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are developing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the MiOXSYS System and ProstaScint, we compete with companies that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging systems and radio-imaging agents for cancer detection. Additionally, with respect to Primsol, we compete with numerous companies who produce antimicrobial treatments for various pathogens inclusive of products containing trimethoprim as contained in Primsol. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While no oral medication has been approved by the FDA for PE, Priligy (dapoxetine) has been approved in some countries. Many commonly prescribed oral medications may delay orgasm and be prescribed alone or in combination with other treatments. These medications include antidepressants, treatments for erectile dysfunction and tramadol for the treatment of pain. We also are aware of topical products which are over-the-counter, or OTC, monograph products for premature ejaculation which include brands such as Promescent (Absorption Pharmaceuticals), a topical spray approved by the FDA in 2013, EjectDelay (Innovus Pharma) and
PreBoost (Aspen Park Pharmaceuticals), all of which would compete with Zertane. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in new product development, greater regulatory expertise,
more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any new product we develop or commercialize that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our or our collaborators&#146; ability to set a price we believe is fair for our approved products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to generate revenues and achieve profitability; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the availability of capital. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2010 enactments of the Patient Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act, are expected to significantly impact the provision of, and payment for, health care in the United States. Various provisions of these laws have only recently taken effect or have yet to take effect, and are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide
additional support </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and medical devices and reduce demand and prices for our products and product candidates, if approved. This could harm our or our collaborators&#146; ability to market any products and generate revenues. As we expect to receive significant revenues from reimbursement of our ProstaScint, Natesto and Primsol products by commercial third-party
payors and government payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products and product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in some foreign countries, the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our products and product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. For example, adverse events associated with tramadol use in general and observed in the PE clinical trials included: gastrointestinal, or GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, headache) and decreased blood pressure. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, if a product candidate receives marketing approval and we or others identify undesirable side effects caused by the product after the approval, or if drug abuse is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could result, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may withdraw or limit their approval of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may decide to remove the product from the marketplace;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we could be sued and held liable for injury caused to individuals exposed to or taking the product; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our reputation may suffer. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing an affected product or product </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">candidates and significantly impact our ability to successfully commercialize or maintain sales of our product or product candidates and generate revenues. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint may prove to be difficult to effectively commercialize following our acquisition of the product from Jazz Pharmaceuticals.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues following our acquisition of ProstaScint in May 2015. Specifically, we may encounter difficulty by virtue of:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to secure continuing prescribing of ProstaScint by current or previous users of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to effectively transfer and scale manufacturing as needed to maintain an adequate commercial supply;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to gain regulatory clearance required as the new distributor of the product in the U.S. and elsewhere where we seek to commercialize ProstaScint;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to adequately resource a manufacturing site transfer, which, we expect, will be required in order to guarantee ongoing commercial supply;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of ProstaScint; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to effectively identify and align with commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed to enable commercial success of ProstaScint. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto may prove to be difficult to effectively commercialize following our exclusive licensing of the product from Acerus Pharmaceuticals.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Various commercial, regulatory, and manufacturing factors may impact our ability to grow revenues from our acquisition of the exclusive U.S. rights to Natesto in April 2016. Specifically, we may encounter difficulty by virtue of: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to secure prescribing of Natesto by current or previous prescribers of testosterone replacement therapies; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of Natesto </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol may prove to be difficult to effectively commercialize following our acquisition of the product from FSC Laboratories.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues following our acquisition of Primsol in October 2015. Specifically, we may encounter difficulty by virtue of:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to secure continuing prescribing of Primsol by current or previous users of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to scale manufacturing as needed to maintain an adequate commercial supply;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to gain regulatory clearance required as the new distributor of the product in the U.S. and elsewhere where we seek to commercialize Primsol;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of Primsol; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to effectively identify and align with commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed to enable commercial success of Primsol. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our financial results will depend on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our future success depends on the acceptance by our target customers, third-party payors and the medical community that our products and product candidates are reliable, safe and cost-effective. Many factors may affect the market acceptance and commercial success of our products and product candidates, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to convince our potential customers of the advantages and economic value our products and product candidates over existing technologies and products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the relative convenience and ease of our products and product candidates over existing technologies and products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the introduction of new technologies and competing products that may make our products and product candidates less attractive for our target customers;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our success in training medical personnel on the proper use of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the willingness of third-party payors to reimburse our target customers that adopt our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acceptance in the medical community of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the extent and success of our marketing and sales efforts; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">general economic conditions. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If third-party payors do not reimburse our customers for the products we may sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While ProstaScint, Natesto and Primsol are already FDA-approved and, in the case of ProstaScint and Primsol, generating revenues in the U.S., the products may not receive, or continue to receive, physician, hospital, or laboratory acceptance, or they may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product candidates is approved and reaches the market, the product may not achieve physician, hospital, or laboratory acceptance, or it may not obtain adequate reimbursement from third party payors. We expect to sell our Primsol products and possibly other product candidates to target
customers substantially all of whom receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#146;s determination that use of a product is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a covered benefit under its health plan;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appropriate and medically necessary for the specific indication;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">cost effective; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">neither experimental nor investigational. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining coverage and reimbursement approval for a product from each government or third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a profit or even cover their
costs. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which would result in a significant shortfall in achieving
revenue expectations and negatively impact our business, prospects and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing risks and inefficiencies may adversely affect our ability to produce our products.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the acquisition of ProstaScint from Jazz Pharmaceuticals, we terminated the relationship with the third-party manufacturer of ProstaScint. We have initiated the process of transferring the manufacturing to Biovest International, which we believe is a qualified manufacturer and with whom we have entered into a Master Services Agreement. In the event that this manufacturing transfer does not occur by the time our current inventory expires, we may not be able to supply sufficient quantities and on a timely basis, while maintaining product quality, acceptable manufacturing costs and complying with regulatory
requirements, such as quality system regulations. In addition, we expect to engage third parties to manufacture components of the MiOXSYS and RedoxSYS systems. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing capabilities. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing any products, there could be significant differences between our estimates and the actual amounts of product we require. If we do not effectively transition sites with our manufacturing and development partners to enable to production scale of ProstaScint, or if we do not secure collaborations with manufacturing and development partners to enable production to scale of the MiOXSYS system, we may not be successful in
selling ProstaScint or in commercializing the MiOXSYS system in the event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products and product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reliance on third parties for regulatory compliance and quality assurance;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible breaches of manufacturing agreements by the third parties because of factors beyond our control;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible regulatory violations or manufacturing problems experienced by our suppliers; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition our site of ProstaScint manufacturing. We may not be able to meet the demand for the RedoxSYS System if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products or product candidates in a timely manner and on terms acceptable to us. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization as a result of these regulations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The manufacturing processes and facilities of third-party manufacturers we engage are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recall or seizure of the product in question;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">total or partial suspension of production or distribution;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA&#146;s refusal to grant pending future clearance or pre-market approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical holds;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">warning letters;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal to permit the export of the product in question; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">criminal prosecution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have limited experience selling our current products as they have been acquired from another company or are newly approved for sale. As a result, we may be unable to successfully commercialize our products and product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite our management&#146;s extensive experience in launching and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution experience with our current products and product candidates. Our ability to achieve profitability depends on attracting and retaining customers for our current products and product candidates, and building brand loyalty. To successfully perform sales, marketing, distribution and customer support functions, we will face a number of risks, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to attract and retain skilled support team, marketing staff and sales force necessary to increase the market for our approved products and to commercialize and gain market acceptance for our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the ability of our sales and marketing team to identify and penetrate the potential customer base; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the difficulty of establishing brand recognition and loyalty for our products. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, we may seek to enlist one or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world. If we do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners, or we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those of any third-party sales and distribution partners, are not successful, our currently approved products may not achieve increased market acceptance and our product candidates may not gain market acceptance, which
would materially impact our business and operations. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our future profitability will depend, in part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to primarily rely on collaboration with third parties. If we commercialize our products or product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to directly control commercial activities because we are relying on third parties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">import or export licensing requirements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">longer accounts receivable collection times;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">longer lead times for shipping;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">language barriers for technical training;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to our products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">foreign currency exchange rate fluctuations;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our customers&#146; ability to obtain reimbursement for our products in foreign markets; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Foreign sales of our products or product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We are subject to various regulations pertaining to the marketing of our products.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential patients to request our products and services. Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly
and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payer, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction of our product candidates, which may have a material adverse effect on our business,
operating results and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Favorable results in the prior clinical trials of Zertane outside of the United States may not be predictive of the results in any future Phase 3 clinical trials of Zertane in the United States or the designs of our Phase 3 clinical trials may be inadequate for FDA approval.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in earlier-stage development. The prior </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">clinical trials of Zertane showed favorable safety and efficacy data; however, we will have different enrollment criteria in our planned Phase 3 clinical trials. In the Phase 2 clinical trials, we were able to enroll patients utilizing a broader definition of PE. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ejaculation latency, most commonly quantified using intravaginal ejaculation latency time, or IELT, is a dominant component of PE assessment in clinical trials. IELT is defined as the time between vaginal intromission and intravaginal ejaculation. Although a standard cut-off for ejaculatory latency does not exist, it has been suggested that an IELT of two minutes or less may serve as an adequately sensitive criterion for defining PE and some studies have used IELT values from one to two minutes for defining PE. In a pre-IND meeting with FDA, we agreed to use an IELT of less than or equal to 1 minute as one of the enrollment
criteria for our planned Phase 3 clinical trials. The previous European Phase 3 trials allowed for an IELT of less than two minutes however a significant proportion of enrollees had an IELT of one minute or less. In our then-planned Phase 3 clinical trials, we would be utilizing the definition of lifelong PE adopted by the International Society for Sexual Medicine, or the ISSM: &#147;premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.&#148; As a result, we could encounter difficulty enrolling a sufficient number of patients in a timely fashion and we may not observe a similarly favorable safety and efficacy profile as our prior clinical trials. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, Ampio obtained guidance from the FDA on our planned Phase 3 trials at a pre-IND meeting held in June 2012, including information to help us define the target patient population, select co-primary endpoints and design an acceptable patient-reported outcome measure. As a result of direction provided at the meeting, along with the existing data from six clinical trials of Zertane conducted outside the U.S. to date, we believe Zertane is positioned to advance into Phase 3 clinical trials in the United States. However, we can provide no assurance that the FDA will not change its guidance about the Phase 3 clinical
trials and require us or a collaborator to significantly modify the design of, or endpoints for, our planned clinical trials. Any change in the guidance we have received could delay and/or render more expensive a Phase 3 trial for Zertane. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were not involved in any of the prior clinical studies for Zertane and are relying on the data collected from those prior clinical trials by various third parties, including a previous partner of Ampio Pharmaceuticals. Dr. David Bar-Or (now the Chief Scientific Officer of Ampio Pharmaceuticals) discovered the utility of tramadol hydrochloride for the treatment of PE in June 1999, and this discovery and accompanying intellectual property were at that time the property of DMI BioSciences, Inc., or DMI BioSciences. DMI BioSciences conducted various clinical trials, prior to licensing the worldwide rights to tramadol
hydrochloride for PE to Biovail Laboratories International, or Biovail. Biovail also conducted several clinical trials and began two Phase 3 clinical trials, which trials were completed by Ampio upon its acquisition of DMI Biosciences, to whom the rights had reverted. This lack of prior involvement may have a negative impact on our understanding of these prior clinical trials and the design of the Phase 3 trial. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Zertane and Natesto contain, and future our other product candidates may contain controlled substances, the manufacture, use, sale, importation, exportation, prescribing and distribution of which are subject to regulation by the DEA.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto, which is approved by the FDA, is regulated by the DEA as a Schedule III controlled substance. Before any commercialization of Zertane, and potentially our other product candidates, the DEA will need to determine the controlled substance schedule, taking into account the recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially diminish any regulatory exclusivity periods for which we may be eligible. Natesto is and Zertane, if approved, will, and our other product candidates may, if approved, be regulated as &#147;controlled substances&#148; as
defined in the Controlled Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is regulated by the DEA as a Schedule III controlled substance. We expect that Zertane will, and our other product candidates may, be listed by the DEA as Schedule IV controlled substances under the CSA. Consequently, the manufacturing, shipping, storing, selling and using of the products will be subject to a high degree of regulation. Also, distribution, prescribing and dispensing of these drugs are highly regulated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because of their restrictive nature, these laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If testosterone replacement therapies are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected and our business could be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent publications have suggested potential health risks associated with testosterone replacement therapy, such as increased cardiovascular disease risk, including increased risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development of clinical prostate disease, including prostate cancer, and the suppression of sperm production. Prompted by these events, the FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further. The FDA has also asked health care professionals and patients to report side effects involving
prescription testosterone products to the agency.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At the T-class Advisory Committee meeting held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom testosterone replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with testosterone replacement therapy. At the meeting, the Advisory Committee voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study or controlled clinical trial) to
further assess the potential cardiovascular risk. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It is possible that the FDA&#146;s evaluation of this topic and further studies on the effects of testosterone replacement therapies could demonstrate the risk of major adverse cardiovascular events or other health risks or could impose requirements that impact the marketing and sale of Natesto, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">mandate that certain warnings or precautions be included in our product labeling;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">require that our product carry a &#147;black box warning&#148;; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limit use of Natesto to certain populations, such as men without specified conditions.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Demonstrated testosterone replacement therapy safety risks, as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement, could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our business.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FDA action regarding testosterone replacement therapies could add to the cost of producing and marketing Natesto.</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA is requiring post-marketing safety studies for all testosterone replacement therapies approved in the U.S to assess long-term cardiovascular events related to testosterone use. Depending on the total cost and structure of the FDA&#146;s proposed safety studies there may be a substantial cost associated with conducting these studies. Pursuant to our license agreement with Acerus Pharmaceuticals is, Acerus is obligated to reimburse us for the entire cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able to reimburse us for the cost of any required safety studies, we may be
forced to incur this cost, which could have a material adverse impact on our business and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Generic tramadol hydrochloride is available in the United States and abroad for treatment of pain.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although the generic drug is not available in the same dosage or formulation as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of PE instead of Zertane, which would adversely affect our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Even if any of our product candidates are commercialized, they may not be accepted by physicians, patients, or the medical community in general.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any existing medicines or treatments. We cannot predict the degree of market acceptance of any product candidate that receives marketing approval, which will depend on a number of factors, including, but not limited to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the demonstration of the clinical efficacy and safety of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the approved labeling for the product and any required warnings;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the advantages and disadvantages of the product compared to alternative treatments;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our and any collaborator&#146;s ability to educate the medical community about the safety and effectiveness of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the reimbursement policies of government and third-party payors pertaining to the product; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the market price of our product relative to competing treatments. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the case of Zertane, tramadol hydrochloride is a well-established centrally acting synthetic analgesic that has been used for more than 30 years as a treatment for moderate to severe pain. As an opioid, tramadol hydrochloride has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. As a result, physicians may be reluctant to prescribe Zertane to treat premature ejaculation. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development processes may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the
discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Intellectual Property Risks Related to Our Business</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to compete may decline if we do not adequately protect our proprietary rights.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our commercial success depends on obtaining and maintaining proprietary rights to our products and product candidates as well as successfully defending these rights against third-party challenges. We will only be able to protect our products and product candidates from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our products and product candidates is uncertain due to a number of factors, including that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not have been the first to make the inventions covered by pending patent applications or issued patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not have been the first to file patent applications for our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may independently develop identical, similar or alternative products, compositions or devices and uses thereof;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any or all of our pending patent applications may not result in issued patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our compositions, devices and methods may not be patentable;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may identify prior art or other bases which could invalidate our patents. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we have or obtain patents covering our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices, and some of these relate to our products and product candidates. These could materially affect our ability to sell our products and develop our product candidates. Because patent applications can take many
years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our products and product candidates may infringe. These patent applications may have priority over patent applications filed by us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in
the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">32</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">enforce our intellectual property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Pharmaceutical and medical device patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent positions of pharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with
certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter partes review in the USPTO. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, changes in or different interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and commercialize our technology and products and product candidates without providing any compensation to us, or may limit the number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to obtain and maintain patent protection and trade secret protection of our products and product candidates, we could lose our competitive advantage and competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Developments in patent law could have a negative impact on our business.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From time to time, the United States Supreme Court, other federal courts, the United States Congress or the USPTO may change the standards of patentability and any such changes could have a negative impact on our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system, changes the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed regulations and procedures to govern the
full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions, became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a material adverse effect on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to patent protection, because we operate in the highly technical field of discovery and development of therapies and medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">33</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#146;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may not be able to enforce our intellectual property rights throughout the world.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the misappropriation of our other
intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Third parties may assert ownership or commercial rights to inventions we develop.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have or expect to have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from
a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#146;s materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&#146;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">34</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We might employ individuals who were previously employed at universities or other biopharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend
against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is significant litigation in the pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products or product candidates infringe the intellectual property rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us
from using the patented drugs, compositions or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could
lead to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#146;s patent rights;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business, prospects and financial condition. As a result, we could be prevented from commercializing our products and product candidates. </TD>

</TR>

</TABLE>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Our Organization, Structure and Operation</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We intend to acquire, through asset purchases or in-licensing, businesses or products, or form strategic alliances, in the future, and we may not realize the intended benefits of such acquisitions or alliances.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to acquire, through asset purchases or in-licensing, additional businesses or products, form strategic alliances and/or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses or assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses or assets if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or
acquisition </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">35</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition or alliance, we will achieve the expected synergies to justify the transaction. These risks apply to our acquisition of ProstaScint in May 2015, Primsol in October 2015 and Natesto in April 2016. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio could influence us, including influencing the election of our directors, and its interests may conflict with or differ from your interests as stockholders.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of February 12, 2016, Ampio owned 5.5% of our outstanding common stock. In addition, three of our four directors all have current or prior connections to Ampio. Michael Macaluso, is the Chief Executive Officer and a director of Ampio, and Josh Disbrow, our Chief Executive Officer, was Chief Executive Officer of Luoxis and Chief Operating Officer of Ampio. Jarrett Disbrow, our Chief Operating Officer, was Chief Executive Officer of Vyrix. Gregory Gould, our Chief Financial Officer, is also the Chief Financial Officer of Ampio. Further, we have entered into a services agreement with Ampio pursuant to which Ampio provides us
with corporate overhead services. As a result of its stock ownership and current relationship with us, Ampio may be able to influence our management and affairs as well as matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets or other major corporate transactions. This potential influence may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock. This potential influence may delay, deter or prevent acts that would be favored by our other stockholders, as the interests of Ampio may not always coincide with our interests or the interests of our other stockholders. For example, Ampio may seek to cause us to take courses of action that, in its judgment, could enhance its investment in us, but which might involve risks to our other stockholders or adversely affect us or our other
stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may be unable to achieve some or all of the benefits that we expect to achieve from our separation from Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a stand-alone, independent public company, we believe that our business will benefit from, among other things, allowing our management to design and implement corporate policies and strategies that are based primarily on the characteristics of our business, allowing us to focus our financial resources wholly on our own operations and implement and maintain a capital structure designed to meet our own specific needs. However, as a result of our separation of our business from Ampio in April 2015, as a result of the Merger, there is a risk that we may be more susceptible to market fluctuations and other adverse events than we
would have been if we were still a part of Ampio. We may not be able to achieve some or all of the benefits that we expect to achieve as a stand-alone healthcare company or such benefits may be delayed or may not occur at all. For example, there can be no assurance that analysts and investors will place a greater value on our company as a stand-alone healthcare company than on our business as a part of Ampio. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our historical financial information as a business conducted by Ampio may not be representative of our results as an independent public company.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The historical financial information included herein does not necessarily reflect what our financial position, operating results or cash flows would have been had we been an independent entity during the historical periods presented. The historical costs and expenses reflected in our financial statements include amounts for certain corporate functions historically provided by Ampio, including costs of finance and other administrative services, and income taxes. These expense allocations were developed on the basis of what we and Ampio considered to be reasonable prices for the utilization of services provided or the benefits
received by us. The historical financial information in our audited financial statements may not be indicative of what our results of operations, financial position, changes in equity and cash flows would have been had we been a separate stand-alone entity during the periods presented or will be in the future. We have not made adjustments to reflect many significant changes that will occur in our cost structure, funding and operations as a result of our separation from Ampio, including changes in our employee base, changes in our tax structure, potential increased costs associated with reduced economies of scale and increased costs associated with being a publicly traded, stand-alone company, such as compliance costs, nor have we made offsetting adjustments to reflect the benefits of this offering, as these factors are presently difficult to quantify. These same risks will apply to the financial information of any business we acquire when it is included in our financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">36</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may have received better terms from unaffiliated third parties than the terms we received in our agreements with Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The agreements related to our separation from Ampio, including the assignment and assumption agreement, services agreement and the other agreements, were negotiated in the context of our separation from Ampio while we were still part of Ampio and, accordingly, may not reflect terms that would have resulted from arm&#146;s-length negotiations among unaffiliated third parties. The terms of the agreements we negotiated in the context of our separation related to, among other things, allocation of assets, liabilities, rights, indemnifications and other obligations among Ampio and us. We may have received better terms from third
parties because third parties may have competed with each other to win our business. One of our directors is also a member of the Ampio board. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to operate our business effectively may suffer if we or Ampio terminate our services agreement, or if we are unable to establish on a cost-effective basis our own administrative and other support functions in order to operate as a stand-alone company after the expiration or termination of our services agreement with Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the Merger, we relied on administrative and other resources of Ampio to operate our business. We have entered into a services agreement to retain the ability for specified periods to use certain Ampio resources. We may elect to continue this agreement for an indefinite period of time. Any decision by us to terminate this agreement would be approved by disinterested members of our management and board of directors under our procedures regarding related party transactions. After the termination of this agreement, we will need to create our own administrative and other support systems or contract with third parties to
replace Ampio&#146;s services. These services may not be provided at the same level, and we may not be able to obtain the same benefits that we received prior to the separation. These services may not be sufficient to meet our needs, and if our agreement with Ampio is terminated, we may not be able to replace these services at all or obtain these services at prices and on terms as favorable as we currently have with Ampio. Any failure or significant downtime in our own administrative systems or in Ampio&#146;s administrative systems during the transitional period could result in unexpected costs, impact our results or prevent us from paying our suppliers or employees and performing other administrative services on a timely basis. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Adverse developments at Ampio could negatively impact our company.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We acquired the businesses of Luoxis (the MiOXSYS and RedoxSYS systems) and Vyrix (Zertane) from Ampio in the Merger. In addition, Joshua Disbrow and Jarrett Disbrow held executive positions at Ampio and/or its subsidiaries prior to the Merger. Michael Macaluso, one of our directors, is the Chief Executive Officer and a director of Ampio. Gregory Gould, our Chief Financial Officer, is currently the Chief Financial Officer at Ampio. Further, prior to January 2016, Ampio owned approximately 81.5% of our outstanding common stock. As a result, negative developments, including negative publicity, at Ampio could be imputed to our
company and have an adverse impact on our business and prospects, including our ability to raise capital or enter into collaborations, and on the price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any disputes that arise between us and Ampio with respect to our past and ongoing relationships could harm our business operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disputes may arise between Ampio and us in a number of areas relating to our past and ongoing relationships, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with non-compete provisions applicable to Ampio and us;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">labor, tax, employee benefit, indemnification and other matters arising from our separation from Ampio;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">distribution and supply obligations;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">employee retention and recruiting;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">business combinations involving us;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sales or distributions by Ampio of all or any portion of its ownership interest in us;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">37</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the nature, quality and pricing of transitional services Ampio has agreed to provide us; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">business opportunities that may be attractive to both Ampio and us. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable than if we were dealing with an unaffiliated party. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The agreements we have entered into with Ampio may be amended upon agreement between the parties. Given our past and present relationship with Ampio, Ampio may be able to influence us to agree to amendments to these agreements that may be less favorable to us than the original terms of the agreements or that we might obtain from others. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We only have one independent director, which could result in a Board of Directors that does not thoroughly represent the interests of minority shareholders and could prevent our common stock from being listed on a securities exchange.</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Currently, we have only one independent director, Carl Dockery, who only recently joined our board of directors in April 2016. To have our stock listed on a securities exchange we will be required to have a majority of independent directors, which we may never have. In the absence of a majority of independent directors, we would be prevented from listing our stock on an exchange. In addition, the Board, which includes our Chief Executive Officer and Chief Operating Officer, who are also brothers, could establish policies and enter into transactions over the objections of the sole independent director. This could present the
potential for a conflict of interest between us and our shareholders generally and the controlling officers, shareholders or directors. The absence of more independent directors who could provide a more neutral point of view could jeopardize your interests.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Some of our management may have conflicts of interest because of their ownership of Ampio common stock, options to acquire Ampio common stock and positions with Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Two of our four directors and two of our four executive officers own Ampio common stock and/or options to purchase Ampio common stock. In addition, one of our directors is also the Chief Executive Officer and a director of Ampio and our Chief Financial Officer is also the Chief Financial Officer of Ampio. Ownership of Ampio common stock and options to purchase Ampio common stock by our directors and officers and the presence of a director of Ampio on our board of directors could create, or appear to create, conflicts of interest with respect to matters involving both us and Ampio. For example, corporate opportunities may arise
that are applicable or complementary to both of our businesses and that each business would be free to pursue, such as the potential acquisition of a particular business or technology. However, we do not believe that Ampio intends to acquire businesses that are focused on urological disorders. We have not established at this time any procedural mechanisms to address actual or perceived conflicts of interest of these individuals and expect that our board of directors, in the exercise of its fiduciary duties, will determine how to address any actual or perceived conflicts of interest on a case-by-case basis. If any corporate opportunity arises and if our directors or officers do not pursue it on our behalf, we may not become aware of, and may potentially lose, a significant business opportunity. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 31, 2016, we had seventeen full-time employees, and in connection with being a public company, we expect to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our
limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the planned expanded commercialization of our approved products and the development of our product candidates. If our management is unable to effectively manage </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">38</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to expand the market for our approved products and develop our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our success depends to a significant degree upon the technical and management skills of our officers and key personnel. The loss of the services of any of these individuals would likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key personnel. The loss of any of our key executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on
our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We compete for such personnel against numerous companies, including larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical and medical device products. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration of a patient&#146;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. These lawsuits may divert our management from pursuing our
business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial condition and operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we maintain general liability, clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products and product candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm our reputation, which may adversely affect our
collaborators&#146; ability to commercialize our products successfully. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In order to satisfy our obligations as a public company, we may need to hire additional qualified accounting and financial personnel with appropriate public company experience in the event that we no longer utilize the finance and administrative functions of Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we must establish and maintain effective disclosure and financial controls. We may need to hire additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit and maintain such personnel. Even if we are able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion of management resources from product development efforts. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">39</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our product candidates which could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will need to upgrade our enterprise resource planning systems.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As we grow our business, we will need to upgrade our enterprise resource planning, or ERP, system. Our ERP system is critical to our ability to accurately maintain books and records, keep track of product inventory, marketing and sales, and prepare our financial statements. The implementation of a new ERP system will require the investment of significant financial and human resources. In addition, we may not be able to successfully complete the full implementation of the ERP system without experiencing difficulties. Any disruptions, delays or deficiencies in the design and implementation of the new ERP system could adversely
affect our ability to monitor our business and prepare our financial statements on an accurate and timely basis. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015, we had federal net operating loss carryforwards of approximately $21.6 million. The available net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 and will completely expire in 2035. Under the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and the regulations promulgated thereunder, including, without limitation, the consolidated income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards and other tax attributes (such as research tax credits) to offset our income.
Because Ampio&#146;s equity ownership interest in our company fell to below 80% in January 2016, we will be deconsolidated from Ampio&#146;s consolidated federal income tax group. As a result, certain of our net operating loss carryforwards may not be available to us and we may not be able to use them to offset our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible that certain other tax attributes and benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our company and Ampio do not have a tax sharing agreement that could mitigate the loss of net operating losses and other tax attributes resulting from the deconsolidation or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint and several liability of group members. In addition to the deconsolidation risk, an &#147;ownership change&#148; (generally a 50% change (by value) in equity ownership over a
three-year period) under Section 382 of the Code could limit our ability to offset, post-change, our U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Either the deconsolidation or the ownership change scenario could result in increased future tax liability to us. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Securities Markets and Investment in our Common Stock</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">There is not now, and there may never be, an active and orderly trading market for our common stock.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An active trading market for our shares may never develop or be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite period of time. Although our common stock is quoted on the OTCQX, an over-the-counter quotation system, trading of our common stock is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing standards of any national securities exchange, and we presently anticipate that our common stock will continue to be quoted on the OTCQX or another over-the-counter quotation system for the
foreseeable future. In those venues, our stockholders may find it difficult to obtain accurate quotations as to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">40</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the market value of their shares of our common stock, and may find few buyers to purchase their stock and few market makers to support its price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair our ability to raise capital by selling additional equity in the future, and may impair our ability to enter into strategic partnerships or acquire companies or products by using shares of our common stock as consideration. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to comply with the continued trading standards of the OTCQX U.S. Premier tier, it may result in our common stock moving tiers in the OTC Markets.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is currently quoted for trading on the OTCQX U.S. Premier tier, and the continued quotation of our common stock on the OTCQX U.S. Premier tier is subject to our compliance with a number of standards. These standards include the requirement of our common stock to have a minimum bid price of $1.00 per share as of the close of business for at least one of every thirty consecutive calendar days. On February 10, 2016, the OTC Markets Group, Inc. notified us that we were not in compliance with the above listing standards relating to the trading price of our common stock, and that if in the following 180 calendar
days, our common stock did not close at or above $1.00 for ten consecutive trading days, our common stock would be moved from the OTCQX U.S. Premier tier to the OTCQX U.S. tier, which may negatively affect the trading and price of our common stock. There can be no assurance that we will meet this quotation standard of the OTCQX U.S. Premier tier within the 180 day time period allotted. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The trading price of our common stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the products or product candidates we acquire for commercialization;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">actual or anticipated adverse results or delays in our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our failure to expand the market for our currently approved products or commercialize our product candidates, if approved;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unanticipated serious safety concerns related to the use of any of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse regulatory decisions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">additions or departures of key scientific or management personnel;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our dependence on third parties, including CROs and scientific and medical advisors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">actual or anticipated variations in quarterly operating results;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to meet or exceed the estimates and projections of the investment community;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">41</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">introduction of new products offered by us or our competitors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to maintain an adequate rate of growth and manage such growth;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">issuances of debt or equity securities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">trading volume of our common stock;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">general political and economic conditions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">effects of natural or man-made catastrophic events; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other events or factors, many of which are beyond our control. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;Risk Factors,&#148; could have a dramatic and material adverse impact on
the market price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FINRA sales practice requirements may limit a stockholder&#146;s ability to buy and sell our stock.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#146;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or
low-priced securities will not be suitable for at least some customers. Because these FINRA requirements are applicable to our common stock, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any trading market for our common stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one
or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">42</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may be exposed to additional risks as a result of &#147;going public&#148; by means of a reverse merger transaction.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be exposed to additional risks because the business of Vyrix and Luoxis has become a public company through a &#147;reverse merger&#148; transaction. There has been increased focus by government agencies on transactions such as the Merger in recent years, and we may be subject to increased scrutiny by the SEC and other government agencies and holders of our securities as a result of the completion of that transaction. Additionally, our &#147;going public&#148; by means of a reverse merger transaction may make it more difficult for us to obtain coverage from securities analysts of major brokerage firms following the
Merger because there may be little incentive to those brokerage firms to recommend the purchase of our common stock. As a result, our business or stock price could suffer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Because we became public by means of a &#147;reverse merger,&#148; it may be more difficult to list on a national exchange such as the NASDAQ, New York Stock Exchange or NYSE MKT.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It may be more difficult to list on a major exchange because we have conducted a reverse merger. In 2011, the SEC approved new rules of the three major U.S. listing markets that toughen the standards that companies going public through a reverse merger must meet to become listed on those exchanges. Under the rules, NASDAQ, the New York Stock Exchange (or NYSE) and NYSE MKT impose more stringent listing requirements for companies that become public through a reverse merger. Specifically, the rules prohibit a reverse merger company from applying to list on either the NASDAQ, NYSE or NYSE MKT until:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the company has completed a one-year &#147;seasoning period&#148; by trading in the U.S. over the counter market or on another regulated U.S. or foreign exchange following the reverse merger, and filed all required reports with the SEC, including audited financial statements; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the company maintains the requisite minimum share price for a sustained period, and for at least 30 of the 60 trading days, immediately prior to its listing application and the exchange&#146;s decision to list. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It is possible for a reverse merger company to be exempt from these special requirements, but only if a listing is in connection with a substantial, firm commitment underwritten public offering. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have a substantial number of shares of authorized but unissued capital stock, and if we issue additional shares of our capital stock in the future, our existing stockholders will be diluted.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation authorize the issuance of up to 300,000,000 shares of our common stock and up to 50,000,000 shares of preferred stock with the rights, preferences and privileges that our Board of Directors may determine from time to time. As of February 12, 2016, we had 22,446,481 shares of our common stock issued and outstanding, which represents 7.48% of our total authorized shares of common stock. In addition to capital raising activities, which we expect to continue to pursue in order to raise the funding we will need in order to continue our operations, other possible business and financial uses for our
authorized capital stock include, without limitation, future stock splits, acquiring other companies, businesses or products in exchange for shares of our capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting and retaining employees by the issuance of additional securities under our equity compensation plans, or other transactions and corporate purposes that our Board of Directors deems are in the best interest of our company. Additionally, shares of our capital stock could be used for anti-takeover purposes or to delay or prevent changes in control or our management. Any future issuances of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value, they may have rights, preferences and privileges that are superior to those of our common stock, and they may have an adverse effect on our business or the trading price of our common stock. The issuance
of any additional shares of our common stock will reduce the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">43</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could cause our stock price to fall.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the legal restrictions on resale discussed in this prospectus lapse or after those shares become registered for resale pursuant to an effective registration statement, the trading price of our common stock could decline. We have registered for resale under the Securities Act an aggregate of 2,463,080 shares of our common stock held by former Luoxis and Vyrix shareholders and those shares are freely tradable without restriction, except for shares held by our affiliates, and any sales of those
shares or any perception in the market that such sales may occur could cause the trading price of our common stock to decline. Additionally, an aggregate of 12,629,684 shares subject to lock-up agreements entered into in connection with the Merger became freely tradable in December 2015. We also recently registered for resale 7,879,096 shares issued in February 2016 upon the conversion of 2015 convertible notes and 267,052 shares of common stock issuable upon the exercise of warrants at an exercise price of $0.65 per share issued in March 2016 to the placement agents for the 2015 convertible notes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also have outstanding convertible notes that we issued in July and August 2015, in the aggregate principal amount of approximately $1,050,000. The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of our common stock equal in an amount equal to 120%-130% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of our next public offering of our stock resulting in proceeds to us of at least $5,000,000 in gross proceeds (excluding indebtedness converted in
such financing) prior to the maturity date of the notes, referred to as a Qualified Financing. The principal and accrued interest under the notes will automatically convert into a number of shares of such equity securities of our company sold in such financing equal to 120% in the case of $25,000 and 130% in the case of $1,025,000 of the principal and related accrued interest under such note divided by the lesser of (i) the lowest price paid by an investor in such financing or (ii) $4.63. In the event that we sell equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of our capital stock in an amount equal to 120%-130% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a)
the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. If these notes are converted, the shares of common stock issuable upon conversion could be sold. The perception of such issuance and sale could negatively impact the price of our common stock. Upon the closing of this offering, an aggregate of $1,050,000 in principal and $78,000 in accrued interest on the 2015 convertible notes outstanding will automatically convert into an aggregate of 3,659,978 shares of our common stock, at the combined public offering price of $0.40 per share and related warrant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, shares of common stock that are reserved for future issuance under our 2015 Stock Plan and any future equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, Rule 144 and Rule 701 under the Securities Act, and any future registration of such shares under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges
senior to those of holders of our common stock. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock to decline. Any future </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">44</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">grants of options, warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Some provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Provisions in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limiting the removal of directors by the stockholders;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">allowing for the creation of a staggered board of directors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions
are approved by the board of directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or beneficial to our stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation and our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive officers provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the Delaware law and, subject to certain conditions, advance the expenses incurred by any director or
officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We do not intend to pay cash dividends on our capital stock in the foreseeable future.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">45</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">operations, anticipated cash requirements and other factors and will be at the discretion of the our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to this Offering</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Investors in this offering will experience immediate and substantial dilution in net tangible book value.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The public offering price will be substantially higher than the net tangible book value per share of our outstanding shares of common stock. As a result, based upon the assumptions set forth in &#147;Dilution&#148;, investors purchasing shares in this offering will incur immediate dilution of $0.07 per share, based on the combined public offering price of $0.40 per share and related warrant. See &#147;Dilution&#148; for a more complete description of how the value of your investment in our common stock will be diluted upon the completion of this offering. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have not determined a specific use for a portion of the net proceeds from this offering, and we may use these proceeds in ways with which you may not agree.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we currently intend to use the net proceeds received from this offering to fund the expansion of our sales force for the planned launch of Natesto and the planned expansion in the commercialization of ProstaScint and Primsol, the acquisition of complementary urology products and/or product candidates, completion of clinical development activities for the MiOXSYS system and possibly Zertane, and for working capital and for other general corporate purposes, our management will have considerable discretion in the application of the proceeds received in connection with this offering. You will not have the opportunity, as part
of your investment decision, to assess whether the proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may be used for corporate purposes that do not improve our profitability or increase our share price. The net proceeds from this offering may also be placed in investments that do not produce income or lose value. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">There may not be an active liquid trading market for the warrants in this offering.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is no established public trading market for the warrants being offered in this offering. Although the underwriters plan to submit an application to have the warrants trade on the OTCQX, there is no assurance an active trading market will develop. Without an active market, the liquidity of the warrants will be limited. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sales of a substantial number of shares of our common stock following this offering may adversely affect the market price of our common stock and the issuance of additional shares will dilute all other stockholders.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales of a substantial number of shares of our common stock in the public market or otherwise following this offering, or the perception that such sales could occur, could adversely affect the market price of our common stock. After completion of this offering (including the conversion of all of the outstanding 2015 convertible notes into common stock), our existing securityholders will own approximately 58.2% of our common stock assuming there is no exercise of the underwriters&#146; over-allotment option. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After completion of this offering (including the conversion of all of the outstanding 2015 convertible notes into common stock), there will be approximately 44,856,459 shares of our common stock outstanding. In addition, our Certificate of Incorporation permits the issuance of up to approximately 255,143,541 additional shares of common stock after the completion of this offering, as well as up to 50,000,000 shares of preferred stock. Thus, we have the ability to issue substantial amounts of common stock in the future, which would dilute the percentage ownership held by the investors who purchase shares of our common stock in
this offering. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We and our officers, directors and certain stockholders have agreed, subject to customary exceptions, not to, without the prior written consent of the Representative during the period ending 180 days from the date of this offering in the case of our directors and officers and 90 days from the date of this offering in the case of us and certain stockholders, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of our common stock, enter into any swap or other derivatives transaction that transfers to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">46</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">another any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for our common stock or any other securities of ours or publicly disclose the intention to do any of the foregoing. After the lock-up agreements with our directors and officers pertaining to this offering expire 180 days from the date of this offering unless waived earlier by the managing
underwriter, all of our outstanding shares will be eligible for sale in the public market. Sales of a significant number of these shares of common stock in the public market could reduce the market price of the common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The warrants are speculative in nature.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrants to be issued to investors in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to purchase shares of common stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the warrants may exercise their right to acquire shares of common stock at an exercise price of $0.50 per share, prior to five years from the date of issuance after which date any unexercised warrants will expire and have no further value. There can be no assurance that
the market price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever be profitable for holders of the warrants to exercise the warrants. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In the event we are unable to maintain an effective registration statement with respect to the shares issuable upon exercise of the warrants, holders of the warrants may be unable to exercise the warrants.</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No warrants will be exercisable unless at the time of exercise a prospectus relating to common stock issuable upon exercise of the warrants is current and the common stock has been registered or qualified or deemed to be exempt under the federal securities laws and the securities laws of the state of residence of the holder of the warrants. Under the terms of the warrant agent agreement, we have agreed to meet these conditions and use our reasonable and best efforts to maintain a current prospectus relating to common stock issuable upon exercise of the warrants until the exercise or expiration of the warrants. However, we
cannot assure you that we will be able to do so, and if we do not maintain a current prospectus related to the common stock issuable upon exercise of the warrants, holders may be unable to exercise their warrants. If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the warrant will only be exercisable on a cashless basis, as described in the warrant agent agreement.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">47</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t4SPE"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus, including the sections entitled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our need for, and ability to raise, additional capital;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the number, designs, results and timing of our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the regulatory review process and any regulatory approvals that may be issued or denied by the U.S. Food and Drug Administration or other regulatory agencies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our need to secure collaborators to license, manufacture, market and sell any products for which we receive regulatory approval in the future;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the medical benefits, effectiveness and safety of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to manufacture sufficient amounts of our product candidates for clinical trials and our products for commercialization activities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the commercial success and market acceptance of any of our products and product candidates that are approved for marketing in the United States or other countries;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the safety and efficacy of medicines or treatments introduced by competitors that are targeted to indications which our products and product candidates have been developed to treat;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our current or prospective collaborators&#146; compliance or non-compliance with their obligations under our agreements with them; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other factors discussed elsewhere in this prospectus. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and
which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus. Actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to this prospectus completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">48</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t5USE"></a>USE OF PROCEEDS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that the net proceeds from the sale of the shares of common stock we are offering will be approximately $6.7 million (or approximately $7.7 million if the underwriters exercise in full their option to purchase additional shares of common stock and/or warrants), after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The principal purposes of this offering are to obtain additional capital to fund the expansion of our commercial infrastructure for the planned launch of Natesto and the planned expansion in the commercialization of ProstaScint and Primsol, to purchase complementary urology products and/or product candidates that will enhance our product portfolio and enable expansion of our commercial operations, fund the remaining clinical development activities for MiOXSYS, to enable FDA clearance and working capital for general corporate and administrative expenses. While we are actively pursuing the acquisitions of additional products and
product candidates, we currently have no agreements for the acquisition of any products or product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development efforts, the timing and progress of any collaborative or strategic partnering efforts, and the competitive environment for our planned products. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend
to temporarily invest the proceeds in short-term, interest-bearing instruments. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">49</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t6MAR"></a>MARKET FOR COMMON STOCK</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is quoted on the OTCQX under the symbol &#147;AYTU.&#148; Prior to December 14, 2015, our common stock was quoted on the OTCQB Market. The following table sets forth the range of bid and asked closing quotations for our common stock on the OTCQX or OTCQB, for the periods shown. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent actual transactions. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30, 2014</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.04</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.43</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.43</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.17</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10.35</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.45</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30, 2015</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.45</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.31</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.31</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.04</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.95</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11.81</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.43</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ending June 30, 2016</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.63</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.50</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.57</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter (through May 2, 2016)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.61</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.31</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On May 2, 2016, the closing price as reported on the OTCQX of our common stock was $0.40. As of April 22, 2016, there were 469 holders of record of our common stock. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Equity Compensation Plan Information</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, our shareholders approved the adoption of a stock and option award plan (the &#147;2015 Plan&#148;), under which 10,000,000 shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2015 Plan permits grants of equity awards to employees, directors and consultants. The following table displays equity compensation plan information as of June 30, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Plan Category</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Securities to be<BR> Issued upon<BR> Exercise of<BR> Outstanding<BR> Options<BR> (a)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted-Average<BR> Exercise Price of<BR> Outstanding<BR> Options<BR> (b)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Securities<BR> Remaining Available<BR> for Issuance under<BR> Equity Compensation<BR> Plans (Excluding<BR> Securities Reflected in<BR> Column (a))<BR>(c)</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Equity compensation plans approved by security holders</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Equity compensation plans not approved by security holders</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>10,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015 we had outstanding options to purchase an aggregate of 3,695,000 shares of our common stock at a weighted average exercise price of $1.55 per share.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our private placement of approximately $5.2 million of convertible notes in July and August 2015, we are obligated to issue to the placement agents warrants for an amount of shares equal to 8% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest. The placement agents&#146; warrant has a term of five years from the date of issuance of the related notes in July </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">50</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and August 2015, will have an exercise price equal to 100% of the price per share at which equity securities are sold in our next equity financing, and provides for cashless exercise. At December 31, 2015, the shares issuable upon exercise of the warrant could not be calculated because no notes had converted and therefore no shares are reflected in the table above. This warrant was not approved by our stockholders. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t7DIV"></a>DIVIDEND POLICY</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not paid any cash dividends on our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined by the Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements and other factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the dividend:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we would not be able to pay our debts as they become due in the usual course of business; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as set forth above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely to limit materially the future payment of dividends on common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board of Directors has the right to authorize the issuance of preferred stock, without further stockholder approval, the holders of which may have preferences over the holders of our common stock as to payment of dividends. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">51</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t8DIL"></a>DILUTION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If you purchase shares in this offering, your interest will be diluted to the extent of the difference between the public offering price per share and the net tangible book value per share of our common stock after this offering. Our net tangible book value as of December 31, 2015 was $4.0 million, or $0.28 per share of common stock. &#147;Net tangible book value&#148; is total assets minus the sum of liabilities and intangible assets. &#147;Net tangible book value per share&#148; is net tangible book value divided by the total number of shares of common stock outstanding. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After giving effect to the sale by us in this offering of 18,750,000 shares and warrants to purchase 18,750,000 shares of common stock at the combined public offering price of $0.40 per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses that we will pay, our net tangible book value as of December 31, 2015 would have been approximately $10,700,000, or $0.33 per share of common stock. This amount represents an immediate increase in net tangible book value of $0.05 per share to existing stockholders and an immediate dilution of $0.07 per share to purchasers in this
offering. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table illustrates the dilution: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Combined offering price per share and related warrant</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.40</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net tangible book value per share as of December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1> 0.28</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in net tangible book value per share attributable to this offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.05</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Pro forma net tangible book value per share after this offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.33</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dilution per share to new investors</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.07</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This table:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of options to purchase an aggregate of 1,120,000 shares of common stock issued under our 2015 Stock Plan and outstanding and exercisable on December 31, 2015;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 102,613 shares of common stock with an exercise price of $4.53 per share issued by Luoxis and assumed by us in April 2015, and outstanding on December 31, 2015;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no conversion of the $5,175,000 in principal and $162,000 in interest on the 2015 convertible notes outstanding on December 31, 2015 (an aggregate of $4,125,000 in principal and $142,810 in accrued interest converted into an aggregate of 7,879,096 shares of common stock on February 10, 2016, and no automatic conversion of the remaining $1,050,000 of principal and $78,000 of accrued interest into 3,659,978 shares of our common stock at the close of this offering; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of the warrants issued to the placement agents for our 2015 convertible note private placement to purchase a number of shares of our common stock equal to 8% of the gross number of shares of our common stock issuable upon conversion of the 2015 convertible notes, with an exercise price that will be the lowest conversion price per share at which the 2015 convertible notes are converted into our common stock (an aggregate of 267,052 shares after giving effect to the February 2016 conversion of $4,125,000 of principal and $143,000 of accrued interest on the convertible notes. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based on the table above, if the underwriters exercise in full their option to purchase 2,812,500 additional shares and/or 2,812,500 additional warrants, our net tangible book value per share after giving effect to this offering would be $0.33 per share, which amount represents an immediate increase in net tangible book value of $11,800,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we issue any additional shares in connection with outstanding options or warrants, there will be additional dilution. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">52</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t9CAP"></a>CAPITALIZATION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth our cash and cash equivalents and our capitalization as of December 31, 2015 on:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an actual basis;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on an as adjusted basis to give effect to (i) the issuance of 307,692 shares of common stock on January 20, 2016, (ii) the conversion of an aggregate of $4,125,000 in principal and $142,810 in interest on the 2015 convertible notes into 7,879,096 shares of our common stock, which conversion took place on February 10, 2016, and (iii) the conversion of an aggregate of $1,050,000 in principal and $78,000 in interest on the 2015 convertible notes into 3,659,978 shares of common stock at the combined public offering price of $0.40 per share and related warrant, which conversion will take place automatically upon the closing of this offering; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on a pro forma as adjusted basis to give effect to the sale by us in this offering of 18,750,000 shares of common stock and warrants to purchase 18,750,000 shares of common stock at the combined public offering price of $0.40 per share and related warrant after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should read this table in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited financial statements for the years ended June 30, 2015 and 2014, and the related notes thereto, and our unaudited condensed financial statements for the quarterly period ended December 31, 2015 and the related notes thereto, included in this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="248"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=19>At December 31, 2015</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Actual</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Adjustments<BR> for Note<BR> Conversion<BR> and Stock<BR> Subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As Adjusted<BR> for the Note<BR> Conversion<BR> and Stock<BR> Subscriptions</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Adjustments<BR> for Offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro Forma<BR> Adjusted for<BR> the Offering</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>10,960,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>11,160,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>6,700,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>17,860,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Long-term debt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,337,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,087,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,087,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, $0.001 par value: 300,000,000 shares authorized, actual, as adjusted and pro forma; 14,259,693 shares issued and outstanding, actual, 22,446,481 shares issued and outstanding, as adjusted, and 43,015,608 shares issued and outstanding, pro forma as adjusted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,247,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,449,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>43,696,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,785,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,481,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(23,990,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(23,990,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(23,990,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total stockholder&#146;s equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>15,258,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,450,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>19,708,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,785,0000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>27,495,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total capitalization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>20,595,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>200,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>20,795,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>6,700,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>27,495,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of shares to be outstanding immediately after giving effect to this offering as shown above is based on 14,259,693 shares outstanding as of December 31, 2015 and:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of options to purchase an aggregate of 1,120,000 shares of common stock issued under our 2015 Stock Plan and outstanding and exercisable on December 31, 2015;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 102,613 shares of common stock with an exercise price of $4.53 per share issued by Luoxis and assumed by us in April 2015, and outstanding on December 31, 2015;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">53</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">does not include shares of common stock underlying warrants to be issued to the placement agents for the 2015 convertible notes in an amount equal to 8% of the gross number of shares of our common stock issuable upon the automatic conversion of those notes at the close of this offering; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants issued to the placement agents for our 2015 convertible note private placement to purchase a number of shares of our common stock equal to 8% of the gross number of shares of our common stock issuable upon conversion of the 2015 convertible notes, with an exercise price that will be the lowest conversion price per share at which the 2015 convertible notes are converted into our common stock (an aggregate of 267,052 shares after giving effect to the February 2015 conversion of $4,125,000 of principal of the convertible notes (and accrued interest). </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">54</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t10MAN"></a>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF<BR> FINANCIAL CONDITION AND RESULTS OF OPERATIONS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. We are currently focused on addressing significant medical needs in the areas of urological cancers, hypogonadism, urinary tract infections, male infertility, and sexual dysfunction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) and Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stock holder received one
share of common stock for each every 12.174 shares outstanding (herein referred to as the Reverse Stock Split). All share and per share amounts in this prospectus have been adjusted to reflect the effect of the Reverse Stock Split. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2015, we entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc., pursuant to which we purchased assets related to Jazz Pharmaceuticals&#146; product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of Jazz Pharmaceuticals&#146; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0 million. We also agreed to
pay an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory and $227,000 payable on September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 5, 2015, we entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC&#146;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of FSC&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We paid $500,000 at closing for the Primsol Business and
we paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 no later than March 31, 2016, (b) $500,000 no later than June 30, 2016, and (c) $250,000 no later than September 30, 2016 (together, the &#147;Installment Payments&#148;), for a total purchase price of $1,892,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2016, we entered into a license and supply agreement to acquire the exclusive U.S. rights to Natesto nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee&#146;s rights, expected to occur on June 30, 2016. We paid Acerus an upfront fee of $2,000,000 upon execution of the agreement. On September 5, 2016 we will pay an additional $2,000,000 (the &#147;Second Upfront&#148;). On January 1, 2017, we will pay an additional $4,000,000 (the &#147;Third Upfront&#148;). We also agreed to purchase on April 28, 2016, an aggregate of
12,245,411 shares of Acerus common stock for Cdn.$2,534,800 (approximately US$2,000,000), with a purchase price per share equal to Cdn.$0.207 or approximately US$0.16 per share. We cannot dispose of these shares until August 29, 2016. We also agreed to make various payments up to an aggregate of $37,500,000 based on net sales of Natesto. During the term of the agreement, we will purchase all of our Natesto product need from Acerus at a designated price. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To date, we have financed operations through a combination of private and public debt and equity financings including the net proceeds from the private placement of stocks as well as a convertible note. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at least the next 12 months. See &#147;Liquidity and Capital Resources&#148;. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">55</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not received any significant revenues from the commercialization of our product candidates and do not expect to receive significant revenues from the commercialization of our product candidates in the near term. However, we have recognized limited revenue from ProstaScint sales. We have incurred accumulated net losses since our inception, and as of December 31, 2015, we had a deficit accumulated of $24.0 million. Our net loss $7.7 million for the year ended June 30, 2015 and $5.6 million for the year ended June 30, 2014, and was $5.6 million for the six months ended December 31, 2015. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Significant Accounting Policies and Estimates</Font> </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Basis of Presentation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These historical financial statements prior to April 16, 2015 include the financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to the Vyrix Acquired Assets from March 23, 2011, the date Ampio originally acquired the Vyrix assets (the &#147;Vyrix Acquired Assets&#148;) through its merger with DMI BioSciences, Inc. (&#147;BioSciences&#148;) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statement of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, <I>General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements</I>. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and Luoxis have not been segregated as
a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio&#146;s books. In addition, we allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. We also prepared a calculation of income tax expense and deferred income tax assets and liabilities on a &#147;separate return&#148; basis (see Note 4&nbsp;&#151;&nbsp;Income Taxes). These financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as stand-alone entities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;We&#148;, &#147;us&#148; and &#147;our&#148; as referred to herein include Vyrix and Luoxis, collectively. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Cash and Cash Equivalents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Our investment policy is to preserve principal and maintain liquidity. We periodically monitor our positions with, and the credit quality of, the financial institutions with which we invest. Periodically, throughout the year, we have maintained balances in excess of federally insured limits. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Accrued Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accrued compensation consists of a 2016 employee bonus accrual. As of the date of this prospectus, a majority of the bonus had not been paid. The Board of Directors will evaluate the payment of the bonus after the close of fiscal 2016. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue Recognition/Deferred Revenue</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product &amp; Service Sales</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognize revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License Agreements and Royalties</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval in the territories, cumulative sales targets, and other projected milestones and are recognized at the time the milestone requirements are achieved. Royalties will be recognized as revenue when earned. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">56</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Estimated Sales Returns and Allowances</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We record estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of our reported revenue could result. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fixed Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fixed assets are recorded at cost and after being placed in service, are depreciated using the straight-line method over estimated useful lives. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In-Process Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In-process research and development, or IPRD, relates to the Zertane product and clinical trial data acquired in connection with the 2011 business combination of BioSciences. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. Once the Zertane product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If Aytu decided to abandon
the Zertane product, the IPRD would be expensed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Patents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $500,000, acquired in connection with the 2011 acquisition of BioSciences is being amortized over the remaining U.S. patent life since our acquisition of approximately 11 years. The fair value of the Luoxis patents was $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent life since our acquisition of approximately 15 years. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combinations</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#146;s, or FASB, Accounting Standards Codification, or ASC, 805, &#147;Business Combinations&#148;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree; and establishes the acquisition date as the fair value measurement point. Accordingly, we recognize assets acquired and liabilities assumed in business combinations, including contingent assets and
liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, we recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Goodwill</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ProstaScint and Primsol purchase price allocations were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We test our goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If we determine that an impairment has occurred, we are required to record a write-down of the carrying value and </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">57</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, we must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred in May 2015 and the acquisition of Primsol that occurred in October 2015. There was no impairment of goodwill at
December 31, 2015. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Use of Estimates</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the fair value of warrant derivative liability, hybrid debt instruments, valuation allowances, stock-based compensation,
useful lives of fixed assets, estimates of contingent consideration in business combinations and assumptions in evaluating impairment of indefinite lived assets. Actual results could differ from these estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Derivatives</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We account for financial instruments (convertible debt with embedded derivative features&nbsp;&#151;&nbsp;conversion options and conversion provisions) and related warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The warrants related to the convertible promissory notes were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value at issuance compared to the fair value as of December 31, 2015. Changes in the fair value in
subsequent periods will be recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Income Taxes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are included in the consolidated tax returns of Ampio. Our taxes are computed and reported on a &#147;separate return&#148; basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amount of income taxes and related income tax positions taken would be subject to audits by federal and state tax authorities if we filed these taxes on a separate basis. We have adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. We believe that we have no material uncertain tax positions. Our policy is to record a liability for
the difference between the benefits that are both recognized and measured pursuant to the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 740-10, Accounting for Uncertainty in Income Taxes&nbsp;&#151;&nbsp;an interpretation of FASB Statement No. 109 (&#147;ASC 740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. We report tax-related interest and penalties as a component of income tax expense. During the periods reported, our management has concluded that no significant tax position requires recognition under ASC 740-10. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">58</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stock-Based Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We account for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant fair value using the Black-Scholes option pricing model and recognize compensation costs ratably over the vesting period using the graded method. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs are expensed as incurred with expense recorded in the respective periods. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fair Value of Financial Instruments</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities and convertible notes are carried at cost which approximates fair value due to the short maturity of these instruments. The fair value of warrants issued in connection with the Aytu convertible notes was valued using a Monte Carlo option pricing model. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impairment of Long-Lived Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We routinely perform an annual evaluation of the recoverability of the carrying value of our long-lived assets to determine if facts and circumstances indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is warranted. Based on its evaluation as of June 30, 2015 and 2014, respectively, no impairment existed for long-lived assets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Adoption of Newly Issued Accounting Pronouncements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2015, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2015-16, &#147;Business Combinations (Topic 805): Simplifying the Accounting for Measurement&nbsp;&#151;&nbsp; Period Adjustments,&#148; which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period&#146;s financial statements, the effect on earnings of changes in depreciation, amortization, or
other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of December 31, 2015, the Company has early adopted this standard. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2015, the FASB issued ASU 2015-03, &#147;Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&#148; to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, &#147;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit
Arrangements&nbsp;&#151;&nbsp; Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting&#148; which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. As of December 31, 2015, the Company early adopted this standard and will record any debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs previously. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 &#147;Income Taxes: Balance Sheet Classification of Deferred Taxes.&#148; The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">59</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Recently Issued Accounting Pronouncements, Not Adopted as of December 31, 2015</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2016, the FASB issued Accounting Standards Update 2016-02, &#147;Lease (Topic 842)&#148;. The new standard established a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 5, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required
for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. We are currently evaluating the impact of our pending adoption of this standard on our financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2016, the FASB issued ASU 2016-01, &#147;Financial Instruments&nbsp;&#151;&nbsp;Overall (Subtopic 825-10): Recognition and measurement of Financial Assets and Financial Liabilities,&#148; which requires that all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting
from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, the FASB issued ASU 2015-11, &#147;Simplifying the Measurement of Inventory.&#148; ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company&#146;s financial position or
results of operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In August 2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the
impact the adoption of ASU 2014-15 will have on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating
the effect that the updated standard will have on its financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">60</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Results of Operations&nbsp;&#151;&nbsp;Year Ended June 30, 2015 Compared to Year Ended June 30, 2014</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of operations for the year ended June 30, 2015 (&#147;2015&#148;) and the year ended June 30, 2014 (&#147;2014&#148;) reflected losses of approximately $7,723,000 and $5,579,000, respectively. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not generated significant revenue in our operating history, although we do expect to begin generating material revenues in the next fiscal year. We recognized revenue during 2015 and 2014 of $262,000 and $59,000, respectively. In 2012, we received a payment of $500,000 under our license agreement for Zertane with a Korean pharmaceutical company. This payment was deferred and is being recognized over 10 years. In 2014, we received a payment of $250,000 under our license agreement for Zertane with a Canadian-based supplier. This payment was deferred and is being recognized over seven years. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The $176,000 product and service revenue recognized in 2015 represents sales of our ProstaScint product and the RedoxSYS System. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Expenses</Font> </H3>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs consist of clinical trials and sponsored research, labor, stock-based compensation, sponsored research&nbsp;&#151;&nbsp;related party and consultants and other. These costs relate solely to research and development without an allocation of general and administrative expenses and are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Clinical trials and sponsored research</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,244,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,411,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>411,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>195,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>517,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>244,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sponsored research&nbsp;&#150;&nbsp;related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>204,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>126,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Consultants and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>47,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>83,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,423,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,059,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Comparison of Years Ended June 30, 2015 and 2014</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses decreased $636,000, or 15.7%, in 2015 over 2014. This was due primarily to decreased costs in clinical trial and sponsored research related to the Zertane trials. Research and development expenses could increase in 2016 as compared to the 2015 level depending on how we proceed with the Zertane trials. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">General and Administrative</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses consist of personnel costs for employees in executive, business development and operational functions and director fees; stock-based compensation; patents and intellectual property; professional fees including legal, auditing and accounting; occupancy, travel and other including rent, governmental and regulatory compliance, insurance, investor/public relations and professional subscriptions. These costs are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>979,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>557,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>256,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patent costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>488,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>582,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Professional fees</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,189,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>238,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Occupancy, travel and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,227,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>714,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,383,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,347,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">61</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Comparison of Years Ended June 30, 2015 and 2014</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative costs increased $2,036,000, or 86.7%, in 2015 over 2014. The increase in professional fees, labor costs and stock-based compensation primarily relates to increased costs related to the Merger and associated SEC filings and legal expenses, professional staffing, bonuses earned and stock options granted as well as the continuing vesting of stock option awards granted in previous years. Occupancy, travel and other increased due to the additional travel to commercialize the RedoxSYS System. We expect general and administrative expenses to increase in 2016 due to the expected overall growth of our company.
</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Operating Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2015, our operating activities used $6.6 million in cash. The use of cash was approximately $1,089,000 lower than the net loss due primarily to non-cash charges for stock-based compensation, depreciation and amortization, amortization of prepaid research and development related party, an increase in accounts payable and an increase in contingent consideration related to the ProstaScint asset purchase. Cash used in operating activities also included a $24,000 deferred tax benefit and $561,000 decrease in payable to Ampio. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2014, our operating activities used $5.5 million in cash. The use of cash was approximately $77,000 lower than the net loss due primarily to non-cash charges for stock-based compensation, depreciation and amortization and an increase in related party payable. Cash used in operating activities also included a $814,000 deferred tax benefit, a $497,000 increase in prepaid expenses and a $465,000 increase in research and development&nbsp;&#151;&nbsp;related party. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Investing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2015, cash of $1.0 million was used to acquire ProstaScint as well as deposits for office space. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2014, cash of $9,000 was used to purchase fixed assets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash from Financing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities in 2015 was $12.4 million which reflects a $7.4 million loan from Ampio which was later converted to stock, $5.0 million stock subscription payment from Ampio, $27,000 paid out to Luoxis option holders pursuant to the Merger and $20,000 paid out for liabilities pursuant to the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities in 2014 was $5.2 million which reflects a $4.6 million loan from Ampio and $637,000 in contributions from Ampio. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Results of Operations&nbsp;&#151;&nbsp;Three and Six Months Ended December 31, 2015 Compared to Three and Six Months Ended December 31, 2014</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of operations for the three months ended December 31, 2015 and the three months ended December 31, 2014 reflected losses of approximately $3.3 million and $1.6 million for each period, respectively. These losses include in part non-cash charges related to stock-based compensation, depreciation, amortization and accretion, amortization of debt issuance costs, amortization of prepaid research and development&nbsp;&#151;&nbsp;related party and derivative expense collectively in the amount of $552,000 for the three months ended December 31, 2015 and $331,000 for the three months ended December 31, 2014. The non-cash charges
increased in the three months ended December 31, 2015 primarily due to the increase in amortization of intangible assets and derivative expense. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of operations for the six months ended December 31, 2015 and the three months ended December 31, 2014 reflected losses of approximately $5.6 million and $3.7 million for each period, respectively. These losses include in part non-cash charges related to stock-based compensation, depreciation, amortization and accretion, amortization of debt issuance costs, amortization of prepaid research and development&nbsp;&#151;&nbsp;related party and derivative expense offset by deferred taxes collectively in the amount of $780,000 for the six months ended December 31, 2015 and $564,000 for the six months ended December 31, 2014.
The non-cash charges increased in the six months ended December 31, 2015 primarily due to the increase in amortization of intangible assets, derivative expense, depreciation, amortization and accretion offset by a decrease in stock-based compensation. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">62</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product and Service Revenue</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognized $448,000 and $7,000 for the three months ended December 31, 2015 and 2014 respectively, related to the sale of our products ProstaScint and Primsol, as well as the RedoxSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognized $914,000 and $13,000 for the six months ended December 31, 2015 and 2014 respectively, related to the sale of our products ProstaScint and Primsol, as well as the RedoxSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include discounts, chargebacks, distributor fees, processing fees, as well as allowances for returns and Medicaid rebates. Provision balances relating to estimated amounts payable to direct customers are netted against accounts receivable and balances relating to indirect customers are included in accounts payable and accrued liabilities. The provisions recorded to
reduce gross product sales and net product sales are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gross product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>693,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,164,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Provisions to reduce gross product sales to net product and service sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>448,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>914,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Percentage of provisions to gross sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>-35.4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>-21.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License Revenue</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The $21,000 license revenue recognized in each of the three months periods ended December 31, 2015 and 2014, and the $43,000 license revenue recognized in each of the six month periods ended December, 2015 and 2014, respectively, represents the amortization of the upfront payments received on our license agreements. The initial payment of $500,000 from the license agreement for Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement for Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.
</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Expenses</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Cost of Sales</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The cost of sales of $244,000 and $281,000 recognized for the three and six months ended December 31, 2015, respectively, are related to the ProstaScint and Primsol products and the RedoxSYS System. Our cost of sales for the three and six months ended December 31, 2014 were nominal. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Clinical trials and sponsored research</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,179,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,906,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,301,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>96,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>124,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>211,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>183,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>117,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>207,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sponsored research&nbsp;&#150;&nbsp;related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>48,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>54,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>96,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>108,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Consultants and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>22,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>33,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,356,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>844,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,832,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">63</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs consist of drug and device development and clinical trials, labor, as well as stock-based compensation. Costs of research and development increased $512,000, or 60.7%, for the three months ended December 31, 2015 compared to the three months ended December 31, 2014. Costs of research and development increased $428,000, or 23.4%, for the six months ended December 31, 2015 compared to the six months ended December 31, 2014. The increase in both periods is primarily due to an increase in clinical trials and sponsored research primarily related to attempting to reproduce our manufacturing process with
a new manufacturer for our ProstaScint product. During the fiscal year of 2016, we anticipate our clinical trials and sponsored research to be more than the previous fiscal year as we evaluate how to proceed with the Zertane trial as well as the MiOXSYS trials. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Selling, General and Administrative</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Selling, general and administrative costs are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>493,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>212,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,312,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>325,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>163,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>226,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>271,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patent costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>84,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>138,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>165,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>201,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Professional fees</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>294,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>574,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>438,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Occupancy, travel and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>740,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>233,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,149,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>628,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,774,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>750,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,863,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Selling, general and administrative costs increased $1,024,000, or 136.5% for the three months ended December 31, 2015 compared to the three months ended December 31, 2014. Selling, general and administrative costs increased $1,563,000, or 83.9% for the six months ended December 31, 2015 compared to the six months ended December 31, 2014. The increase in both periods is primarily due to labor as a result of increased staffing due to our commercialization efforts for our ProstaScint and Primsol products, an increase in professional fees related to the additional expenses to meet the requirements of being a public company as well
as increased occupancy, travel and other. We anticipate our selling, general and administrative costs for the remainder of our fiscal year 2016 to follow closely to the first six months of the fiscal year. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Amortization of Finite-Lived Intangible Assets</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Amortization of finite-lived intangible assets increased $91,000 or 513% for the three months ended December 31, 2015 and $131,000 or 369% for the six months ended December 31, 2015. This expense increased in both the three month and six month periods ended December 31, 2015 due to the acquisition of the ProstaScint and Primsol businesses and the corresponding amortization of their finite-lived intangible assets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Operating Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the six month period ended December 31, 2015, our operating activities used $5.6 million in cash which was approximately equal to the net loss of $5.6 million primarily as a result of the increases to non-cash stock-based compensation, depreciation, amortization and accretion and the increase in accrued compensation offset by increases in inventory and prepaid expenses and other. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the corresponding 2014 period, our operating activities used $3.6 million in cash which was slightly less than the net loss of $3.7 million primarily as a result of a decrease in accounts payable and related party payable offset by non-cash stock-based compensation. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Investing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the six month period ended December 31, 2015, cash of $125,000 was used to purchase fixed assets and $540,000 was used to acquire the Primsol business. We also received a security deposit back of $2,000 during the period. During the six month period ended December 31, 2014, we used cash of $2,000 for a security deposit. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">64</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash from Financing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities in the six month period ended December 31, 2015 of $9.9 million was primarily related to the issuance of convertible promissory notes which reflects gross proceeds of $5.2 million offset by the cash portion of the debt issuance costs related to the convertible notes of $298,000, as well as the $5.0 million stock subscription payment from Ampio. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the corresponding 2014 period, the only proceeds in financing activities was a $1,100,000 contribution from Ampio. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Contractual Obligations and Commitments</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of December 31, 2015: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Remaining<BR> 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Thereafter</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Management fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,620,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>180,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol business</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing agreement</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Office Lease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>385,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>68,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>142,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Sponsored research agreement with related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>315,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>35,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,570,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,283,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>822,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>575,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>460,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>430,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Management Fee</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol Business</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into an agreement with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1). </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&#147;Biovest&#148;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $1.0 million for time and materials as they develop a plan to reproduce the
manufacturing process. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Office Lease</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, Aytu entered into a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $8,500 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are
classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Rent expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">65</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement with Related Party</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Liquidity and Capital Resources</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not generated significant revenue as we have been operating as a commercial-stage company only since the acquisition of ProstaScint in May 2015. As of December 31, 2015, we had cash and cash equivalents totaling $11.0 million available to fund our operations as well as $300,000 of accounts receivable offset by $2.2 million in accounts payable and the Primsol payable. Based upon this and our expectation to generate revenues in excess of $2.0 million in calendar year 2016, we believe we have adequate capital to continue operations through calendar year 2016 and into calendar year 2017. This projection is based on a number
of assumptions that may prove to be wrong, and we could exhaust our available cash and cash equivalents earlier than presently anticipated. We intend to seek additional capital within the next six to 12 months to acquire additional urology assets, develop our pipeline assets, and expand our commercial operations. In addition, we intend to evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional capital during the next six to 12 months at such time as we conclude that such capital is available on terms that we consider to be in the best interests of our company and our stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have prepared a budget for our fiscal year ending June 30, 2016 which reflects cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead at an average cash burn rate of approximately $500,000 per month. We plan to expend additional funds for regulatory approvals, clinical trials, outsourced research and development and commercialization. Accordingly, we will need to raise additional capital and/or enter into licensing or collaboration agreements. At this time, we expect to satisfy our future cash needs through private or public sales of our securities or debt financings. We
cannot be certain that financing will be available to us on acceptable terms, or at all. Over the last three years, volatility in the financial markets has adversely affected the market capitalizations of many bioscience companies and generally made equity and debt financing more difficult to obtain. This volatility, coupled with other factors, may limit our access to additional financing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October of 2015, we acquired the Primsol business for $1.9 million which we will pay over a one year period and entered into a manufacturing agreement with Biovest to serve as the contract manufacturer for ProstaScint over a four year period at a total cost of $5.0 million of which $2.0 million is expected to be paid in fiscal 2016. We have updated our forecast for fiscal 2016 and 2017 as of February 10, 2016 and we still believe that we have adequate capital as of this date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of our plan to raise capital, during July and August 2015, we sold in a private placement convertible promissory notes with an aggregate principal amount of $5.2 million. The notes are our unsecured obligations. For the notes that were not converted as of February 11, 2016 the notes will mature 18 months from their respective dates of issuance which will be on January 22 and February 11, with an option to extend up to six months at our discretion (provided that in the event we exercise such extension option, the then applicable interest rate shall increase by 2% for such extension period). We do not have the right to
prepay the notes prior to the maturity date. Interest will accrue on the notes in the following amounts: (i) 8% simple interest per year for the first six months and (ii) 12% simple interest per year thereafter if not converted during the first six months. Interest will accrue, and be payable with the principal upon maturity, conversion or acceleration of the notes and may be paid in kind or in cash, in our sole discretion. The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of our common stock equal in an amount equal to 120%-130% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. In the event that we sell equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing
of such financing into a number of shares of our capital stock in an amount equal to 120% in the case </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">66</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">of $25,000 and 130% in the case of $1,025,000 of the number of such shares calculated by dividing the outstanding principal and related accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63. A holder of notes will be obligated to convert on the terms of our next public offering of our stock resulting in proceeds to us of at least $5,000,000 in gross proceeds (excluding indebtedness converted in such financing) prior to the maturity date of the notes (a &#147;Qualified Financing&#148;). The principal and accrued interest under the notes will
automatically convert into a number of shares of such equity securities of our Company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the lesser of (i) the lowest price paid by an investor in such financing or (ii) $4.63. On February 10, 2016, an aggregate of $4,125,000 of principal and $143,000 of accrued interest on the notes converted into an aggregate of 7,879,096 shares of our common stock. Upon the closing of this offering, an aggregate of $1,050,000 in principal and $78,000 in accrued interest on the 2015 convertible notes outstanding will automatically convert into an aggregate of 3,659,978 shares of our common stock, at the combined public offering price of $0.40 per share and related warrant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we cannot raise adequate additional capital in the future when we require it, we will be required to delay, reduce the scope of our commercialization efforts or to eliminate expenses associated with our late-stage development programs. We also may be required to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. This may lead to impairment or other charges, which could materially affect our balance sheet and operating results. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Off Balance Sheet Arrangements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not have off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &#147;variable interest entities.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impact of Inflation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, we believe that our operating expenses can be negatively impacted by increases in the cost of clinical trials due to inflation and rising health care costs.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">67</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t11BUS"></a>BUSINESS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological conditions. We are focused primarily on the urological disorders market and specifically urological cancers, hypogonadism, urinary tract infections, male infertility, and sexual dysfunction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are currently focused on commercializing our ProstaScint&reg; product, which has been re-launched in the U.S. through a focused commercial infrastructure and we are working on developing corporate relationships outside the U.S. to launch ProstaScint in major healthcare markets around the world. We are also preparing to launch Natesto in the U.S. for the treatment of hypogonadism, or low testosterone, and we plan to expand our commercial infrastructure to support this launch and grow ProstaScint revenues. We acquired ProstaScint in May 2015 from Jazz Pharmaceuticals. ProstaScint, which is approved by the FDA, is a marketed
biologic imaging agent specifically indicated for the diagnostic staging of prostate cancer patients. In April 2016, we acquired the exclusive U.S. rights to Natesto&#154; (testosterone) nasal gel from Acerus. Natesto is an FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. We are also commercializing our Primsol&reg; product, which we plan to launch through a focused commercial infrastructure in the U.S. while developing corporate relationships outside the U.S. to launch Primsol in major healthcare markets around the world. We acquired Primsol in October 2015 from FSC Laboratories. Primsol, which also is approved by the FDA, is a marketed anti-infective specifically indicated for the treatment of uncomplicated urinary tract infections. In April 2016, we entered into a co-promotion agreement for Primsol with Allegis Pharmaceuticals, LLC, or Allegis, a commercial-stage pharmaceutical
company focused on the pediatric market in the U.S. Under the co-promotion agreement, Allegis will have the exclusive right to commercialize Primsol for the pediatric market in the United States, while we will retain the exclusive right to commercialize Primsol for the non-pediatric market. Given Aytu&#146;s strategic focus on urology, and our intent to promote Primsol for urinary tract infections, we believe that establishing this co-promote with Allegis makes sense to enable prescription growth in the pediatric market, where a significant portion of Primsol&#146;s historical sales have been derived.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, we have developed the MiOXSYS<sup>TM</sup> System as a diagnostic device for the detection of infertility in semen analysis. The MiOXSYS System is CE Marked and approved for sale in Europe and other markets around the world, so we are initiating efforts to build a global distribution network comprised of companies focused on infertility and urological diseases. Along with the development of the MiOXSYS System, we have launched the RedoxSYS&reg; oxidation-reduction potential system, or the RedoxSYS&reg; System, into the global research market and are developing numerous clinical applications beyond infertility.
Further, Zertane is now subject to an accepted Investigational New Drug application by the FDA, and a Phase 3 clinical development program has been designed and accepted by the FDA. Depending on our success in raising additional funds, we may decide to focus our capital resources on other strategies and not pursue clinical testing of Zertane in the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic options to maximize the value of Zertane, inclusive of divestiture, out-licensing, and strategic commercial collaborations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our Strategy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to create value by implementing a focused, four-pronged strategy. Our primary focus is on growing our current, revenue-generating products, launching the recently acquired Natesto in the U.S., and building a complementary portfolio of aligned urology assets. In less than one year since our inception we have acquired or in-licensed three FDA-approved, marketed assets, launched a specialty urology sales force, initiated ex-U.S. partnering discussions for our commercial products ProstaScint and Primsol and pipeline asset Zertane, advanced our lead diagnostic asset MiOXSYS to CE Marking, engaged in asset purchase and
licensing discussions for products aligned to our strategy, and have begun preparing to launch Natesto in the U.S. through our own sales force.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe the strategy of focusing on commercializing assets prescribed by urologists makes sense for several reasons. First, urology is a large yet concentrated specialty practice area that can be efficiently targeted. There are approximately 10,000 active urologists in the U.S., and we believe that this audience can be efficiently reached with a relatively small, focused sales force. Additionally, 90% of urologists practice in </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">68</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">metropolitan areas where concentrated sales targeting can be achieved and &#147;windshield&#148; or sales representative driving time between targets can be minimized. Importantly, 81% of urologists practice in group practices, and over 60% are in practices of four or more physicians. Further, and important in building a balanced yet focused product portfolio, sub-specialization within large urology clinics is common whereby there is frequently individual clinical focus on specific areas within urology including prostate cancer and conditions, infertility, sexual dysfunction, urinary incontinence, etc. This enables a company to
offer multiple products to the various sub-specialties within these focused, concentrated customer targets.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, urologists treat a wide range of therapeutic areas and are thus appropriate targets across a broad range of clinical assets (ProstaScint &#150; prostate cancer; Natesto &#150; hypogonadism; Primsol &#150; urinary tract infections; MiOXSYS &#150; male infertility; Zertane (if approved) &#150; premature ejaculation). Importantly, in urology, direct physician office purchasing of drugs, devices, and diagnostics is common. Along with this, a significant proportion of urology groups are privately-owned and often own and operate their own outpatient surgery centers and in-office laboratories. Further, large urology group
practices have substantial payer influence and can have the ability to negotiate as large groups to achieve better reimbursement and coverage for favored treatments and procedures. Perhaps as important as these other factors, urologists are exposed to relatively limited promotional focus by &#147;Big Pharma&#148; and we believe can therefore be accessed and impacted more readily by an emerging company such as Aytu over time.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aytu BioScience&#146;s Four Strategic Value Drivers</Font> </H2>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v433932_chrt-org.jpg" WIDTH="349" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The primary elements of our strategy are:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Launching ProstaScint, Primsol, and MiOXSYS outside the United States via a developing distribution network launching (Natesto) and expanding commercialization of ProstaScint and Primsol, our revenue-generating, FDA-approved products in the United States via a direct commercial infrastructure.</I> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Ex-U.S</I>.&nbsp;&nbsp;As neither ProstaScint nor Primsol have been previously approved and marketed outside the U.S., we believe we can realize commercial opportunities through efficient corporate partnerships in key markets around the world. Also, with MiOXSYS now CE Marked we can develop a distribution network to launch this first-in-class in vitro diagnostic device. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>United States</I>.&nbsp;&nbsp;We have launched a commercial infrastructure in the U.S. in order to support increased sales and distribution of ProstaScint and Primsol in the U.S. We have a highly experienced sales force that is </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">69</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">distinctly focused on impacting the prescribing of urologists, and through this efficient sales channel we are able to increase prescribing of our unique urology assets. Now, with our recent acquisition of the U.S. rights to Natesto we plan to expand our commercial footprint in order to effectively support a planned product launch of Natesto in July 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint has several unique selling features that we believe will enable significant sales growth and regular use by healthcare providers diagnosing and treating prostate cancer. ProstaScint is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. In multiple clinical studies researchers have shown that when SPECT/CT scans were used in patients pre-treated with ProstaScint, ProstaScint imaging was highly sensitive in detecting prostate cancer and significantly predictive of 10-year biochemical disease free survival in prostate cancer patients
(86.6% vs. 65.5%; p=0.0014). Additionally, the American Cancer Society specifically recognizes ProstaScint by name in current prostate cancer diagnosis guidelines. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2,200,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is a novel, recently FDA-approved testosterone replacement therapy, or TRT, indicated for the treatment of hypogonadism in men. Natesto is the only nasal formulation of testosterone and is delivered via a proprietary nasal gel to enable simple, discreet use of testosterone into the nostrils. By virtue of applying Natesto to the nasal muscosa, and not to the man&#146;s skin, there is no risk of transference to others. As such Natesto is the only TRT that does not have a black box warning associated with this potential for transference. Additionally, Natesto is a convenient form of testosterone that does not require
application to large areas of the man&#146;s body (arms, shoulders, upper torso, under arms) as required with market-leading products AndroGel and Axiron. A convenient form of TRT, applied two-to-three times in the nostrils, may be an appropriate option for men over 45 with hypogonadism who have active lifestyles, travel frequently, and value having a discreet way to treat their hypogonadism.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Low testosterone is a condition affecting approximately 13 million U.S. men, with U.S. revenues estimated at $2.4 billion in 2013. The market is expected to grow to $5.0 billion by 2017, and we believe multiple factors are in place to position Natesto favorably in gaining market share in this large, growing market. By gaining less than a 5% share of the current U.S. market (assuming similar pricing and reimbursement), a novel TRT product could achieve annual revenues in excess of $120,000,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is an antimicrobial agent that is indicated to treat uncomplicated urinary tract infections (UTIs). Primsol is the only oral solution containing trimethoprim and offers a novel solution for UTI patients who are either allergic to sulfamethoxazole (which is commonly combined with trimethoprim) or have difficulty swallowing pills. Because many prostate cancer patients have temporary urinary catheters placed, they are frequently diagnosed with recurrent urinary tract infections. Primsol offers a solution to those patients and enables us to sell multiple products to a similar base of U.S. prescribing clinicians.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Developing a pipeline of novel urological therapeutics through assertive acquisition, licensing, or co-promotion, inclusive of both marketed and late-stage development assets.</I> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to diversify our product portfolio and create more value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize including marketed assets. Initially, the focus will be on acquiring products or product candidates for urological conditions but we will opportunistically consider other products or product candidates based on their ability to create value and complement our focus. We plan to pursue product acquisitions, inclusive of therapeutics, diagnostics, and devices, which we will evaluate for their strategic fit and potential for near-term and/or accretive value to
us. In less than nine months from the Company&#146;s inception we are generating revenue from the acquisition of both ProstaScint and Primsol, and are planning to launch Natesto. We expect to continue to identify and acquire additional, complementary urology assets in the future.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">70</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Completing U.S. studies in male infertility with the MiOXSYS System to enable 510k de novo clearance by FDA</I> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With MiOXSYS now CE marked and available for sale in many markets outside the U.S., we are positioned to initiate our clinical studies in the U.S. to enable 510k de novo clearance. We expect to received guidance from FDA on clinical study design and patient criteria and implement the required clinical program as soon as possible. If approved, MiOXSYS would be the first and only semen analysis diagnostic test for the detection of oxidative stress in infertility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we have bolstered our research focus in this area with the MiOXSYS System to complement our focus on urologic conditions. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men.
With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress and monitor patients&#146; responses to antioxidant therapy and improve diagnosis of male infertility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through our extensive network of researchers developed at one of our predecessor companies Luoxis, the RedoxSYS System has demonstrated the potential to have broad clinical applications inclusive of male infertility in semen analysis studies. Studies have been completed at a major U.S. university and major hospital outside the U.S. in the evaluation of male infertility. As such, we developed the MiOXSYS System as a line extension to RedoxSYS to specifically assess oxidative stress in semen as a tool to assess male infertility. In January 2016, the MiOXSYS System received CE Marking and is now available for sale in multiple
ex-U.S. markets including Europe, the Middle East, and parts of Asia. In March 2016, the MiOXSYS System obtained Health Canada Class II Medical Device approval. With Health Canada approval in place, the Company will begin initial marketing of the product in Canada.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Maximizing the value of Zertane, our product candidate for the on-demand treatment of premature ejaculation through pursuit of global or regional licensing partners or asset sale.</I> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our therapeutic product candidate is Zertane, a Phase 3-ready oral product for the treatment of PE. The premature ejaculation market in the U.S. and Europe is expected to reach over $1.3 billion in annual sales in 2017, representing an increase of 10.3% over 2010. According to published analyses, PE is a highly prevalent male sexual dysfunction affecting 20&nbsp;&#150;&nbsp;30% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane is in advanced clinical studies, and we have already completed pivotal study-enabling studies in Europe that demonstrate favorable efficacy and safety in more than 600 patients with PE. In addition, Zertane obtained an active IND with the FDA. We also expect to seek collaboration agreements to commercialize Zertane outside the U.S. We already have such agreements in place to commercialize Zertane in South Korea and Brazil, Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America which will&nbsp;&#151;&nbsp;if approved&nbsp;&#151;&nbsp;provide royalty and milestone-based
revenue for us. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our FDA&nbsp;&#150;&nbsp;Approved Urology Products</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Three of our products have received FDA approval for marketing in the U.S.: ProstaScint, Primsol and Natesto. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint for the Detection of Prostate Cancer</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On May 20, 2015, we acquired ProstaScint&reg; from Jazz Pharmaceuticals. ProstaScint Kit, or capromab pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint targets prostate specific membrane antigen, or PSMA, a protein uniquely expressed by prostate tissue. A radioactive substance called Indium (In 111) is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody is infused into the patient and is taken up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography,
or SPECT). ProstaScint has been shown to be clinically effective in determining the course of treatment for a patient who </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">71</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">has had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in patients classified as high risk or with recurrent prostate cancer. ProstaScint has been approved by the FDA and Health Canada, and significant clinical data exist demonstrating the significant predictive value in prostate cancer staging. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Prostate Cancer Market</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to the American Cancer Society prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2,200,000 men are alive with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012. Importantly,
ProstaScint is the only FDA-approved radiopharmaceutical (for use in radioimmunoscintigraphy) specifically indicated for prostate cancer screening and is specifically highlighted in the American Cancer Society practice guidelines for prostate cancer screening and staging. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prostate cancer is classified into four stages based on severity: Stages 1 through 4. Stage 3 is considered &#147;high risk&#148; and Stage 4 is when cancer has become metastatic. Radioimmunoscintigraphy has been established as a diagnostic to stage cancer malignancy and one of the most widespread clinical uses has been for the detection of prostate cancer. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">72</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Clinical Data</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Multiple clinical studies have been conducted in the United States and published in peer-reviewed publications that consistently demonstrate substantial clinical efficacy of ProstaScint in staging prostate cancer patients and specifically identify whether the cancer is confined to the prostate or has metastasized to other parts of the body. Through more accurate clinical staging and identification of metastatic prostate cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings for ProstaScint from select studies are summarized below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE BORDER="1" BORDERCOLOR="black" CELLPADDING="2" CELLSPACING="0" STYLE="vertical-align: text-top; text-indent: 0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; *margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt" WIDTH="608">

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Principal Investigator(s)/ Primary Authors</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Publication</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Patient Population</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Conclusion/Results</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ellis RJ et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Int. J. Radiation Oncology Biol. Phy. (2010)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Patients presenting for primary radiotherapy having a clinical diagnosis of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and SPECT/CT (N=239)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Haseman MK et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Urology (2007)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Men with prostate cancer who underwent imaging with ProstaScint pretreatment; Patients were divided according to the presence or absence of central abdominal uptake (CAU) (N=341)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were 10 times higher in patients identified with ProstaScint as having central abdominal uptake (p=0.005).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ellis RJ et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Brachytherapy (2005)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Men with prostate cancer of all risk categories who underwent imaging with ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical disease recurrence regardless of the patient&#146;s risk category; 7-year outcomes data from brachytherapy patients with treatment based on the ProstaScint scan showed a significant difference in biochemical disease-free survival.</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Radiation oncology experts have published numerous papers expressing the potential for expanded use of ProstaScint in prostate cancer imaging due to advances in imaging technologies since the product&#146;s initial approval. Since the early 2000s, significantly greater image resolution has been enabled due to the advent of dual head cameras (and improved imaging in general) along with the use of co-registered images where radiologists now combine the images of SPECT and computerized tomography, or CT, or magnetic resonance imaging, or MRI. Because of these factors, we believe there is significant commercial opportunity for
ProstaScint. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Product Information</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is provided as a two-vial kit which contains all of the non-radioactive ingredients necessary to produce a single unit dose for administration by intravenous injection. The ProstaScint vial contains 0.5 mg of capromab pendetide in 1 mL of sodium phosphate buffered saline solution adjusted to pH 6; a sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. The vial of sodium acetate buffer contains 82 mg of sodium acetate in 2 mL of water for injection adjusted to pH 5&nbsp;&#150;&nbsp;7 with glacial acetic acid; it is a sterile, pyrogen-free, clear, and colorless solution.
Neither solution contains a preservative. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each kit also includes one sterile 0.22 &#956;m Millex&reg; GV filter, prescribing information, and two identification labels. The hospital is responsible for addition of Indium In 111. ProstaScint may also be helpful in conjunction with other scans (CT or MRI) for higher risk patients, by detecting lymph nodes in the abdomen that are involved with prostate cancer cells, but may still appear falsely normal on CT or MRI scans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The procedure to administer ProstaScint is as follows: the patient is given an intravenous, or IV, infusion of the monoclonal antibody, and 30 minutes later, a scan is performed. A second scan is done between 96 and 120 hours (4&nbsp;&#150;&nbsp;5 days) after the infusion. The first scan (on the day of the infusion) takes approximately 1 hour, while the second scan takes approximately 2.5 hours. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Uses</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (e.g. chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated in patients who are not at high risk. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium In 111 ProstaScint following radiation therapy has not been studied. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information provided by Indium In 111 ProstaScint imaging should be considered in conjunction with other diagnostic information. Scans that are positive for metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu of histological confirmation. ProstaScint is not indicated as a screening tool for carcinoma of the prostate nor for re-administration for the purpose of assessment of response to treatment. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint was initially marketed by Cytogen Corporation, which was acquired by EUSA Pharma. Jazz Pharmaceuticals acquired EUSA in June 2012 but significantly reduced promotion of ProstaScint due to a lack of strategic focus. Despite limited commercialization efforts, peak annual unit sales of ProstaScint of 8,216 kits were achieved. At current pricing, this unit sales volume would equate to approximately $14.6 million in annual revenue.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto for Testosterone Replacement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone) nasal gel from Acerus. Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee's rights, expected to occur on June 30, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as
Natesto is small, portable, TSA-compliant, and easy to use.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, Natesto is not applied directly to the patient&#146;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a patented nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&#146;s female partner or children&nbsp;&#151;&nbsp;as other topically (primarily gels) administered TRTs do by virtue of their delivery directly onto the skin. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">74</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v434644_img-testnasal.jpg" WIDTH="224" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of Natesto (testosterone) nasal gel</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The unique delivery of Natesto also enables simple, discreet use by a single three times daily application into the nose and may improve compliance over topical forms that are applied to large sections of the arms, shoulders, and other large areas of the man&#146;s upper torso. It also offers a more discreet method of TRT administration compared to films/patches (Androderm &amp; Testoderm, which is applied to the scrotum) and doesn&#146;t involve the pain, potential for site injection infections, and the administration inconvenience of the injectable TRTs such as Testopel and Aveed.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A concern associated with the use of the currently marketed testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact with the man&#146;s application site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms. Natesto, as it is nasally administered, does not present this potential
complication of &#145;transference&#146; and thus does not have a black box warning as is associated with the topically applied testosterone supplements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter&#146;s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) above the normal range.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The U.S. Testosterone Replacement Therapy Market</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe we have an opportunity to increase revenue with Natesto in the U.S. following our planned launch later this calendar year. Natesto competes in a large, growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2013 of $2.4 billion. Revenues are expected to increase to $5 billion by 2017. If the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve sales of $250 million. Even at the current market size of over $2 billion, a product with 5% market penetration could achieve sales in excess of $100 million annually, assuming
comparatively similar product pricing and reimbursement levels as seen with other TRTs.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">75</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The actively marketed, FDA-approved TRTs include:</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="93"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="144"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="128"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="85"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="93"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Brand Name</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Form of Delivery</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Company</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Year Approved</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Black Box Warning</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Androderm&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Film/Patch</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Actavis</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1995</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>AndroGel&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">AbbVie</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2000</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Aveed&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Injection</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Axiron&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Solution</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Eli Lilly &amp; Company</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2010</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Fortesta&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2010</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Striant&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Extended Release Tablet</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2003</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testim&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2002</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testoderm&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Film/Patch</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Johnson &amp; Johnson</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1993</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testopel&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Injection</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1972</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Vogelxo&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Upsher-Smith</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AndroGel&reg;, marketed by AbbVie, is the leading TRT and had 2012 revenues of $1.15 billion. AndroGel commanded over half of the total TRT market across its 1.0% and 1.62% formulations of the product. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, however, AndroGel is beginning to face generic threats with the expiration of key patents for its 1.0% formulation, and Teva Pharmaceuticals has a competitive generic product in waiting. AbbVie has attempted to block Teva&#146;s launch through the filing of a citizen&#146;s petition. Products with significant shares of the TRT market and promotional spending include Axiron, Testim, Fortesta, Androderm, and Testopel.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">About Hypogonadism</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male hypogonadism is a condition in which the body does not produce enough testosterone &#151; the hormone that plays a key role in masculine growth and development during puberty &#151; or has an impaired ability to produce sperm or both. Men can be born with male hypogonadism, or it can develop later in life from injury or infection.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hypogonadism is formally defined as deficient or absent male gonadal function that results in insufficient testosterone secretion. Hypogonadism may be caused primarily by testicular failure, or secondarily by hypothalamic-pituitary axis dysfunction, resulting in the production or release of insufficient testosterone to maintain testosterone-dependent functions and systems. It can also result from a combination of testicular failure and hypothalamic-pituitary axis dysfunction.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hypogonadism affects an estimated approximately 13 million men in the United States, and although it may occur in men at any age, low testosterone levels are especially common in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. Studies suggest that hypogonadism in adult men is often underdiagnosed and under treated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Low testosterone, as male hypogonadism is also known, is associated with a number of signs and symptoms, most notably loss of libido and erectile dysfunction (ED). Other signs of low testosterone include depressive symptoms, a decrease in cognitive abilities, irritability and lethargy or loss of energy. Deficient endogenous testosterone also has negative effects on bone mass and is a significant risk factor for osteoporosis in men. Progressive decrease in muscle mass and muscle strength and testicular dysfunction, often resulting in impaired sperm production, are also associated with low testosterone levels.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A younger patient may have pure hypogonadism as a primary event, whereas an older man may have an age-related decline in testosterone production that is a part of his ED profile. However, because both ED and loss of libido are hallmarks of hypogonadism, for a patient who presents with ED it is recommended that he have a basic hormone profile to determine if he has low testosterone. Treatments to normalize testosterone can not only improve libido, energy level and the potential to have normal erections, but can also improve the response to sildenafil, if that is deemed appropriate treatment. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">76</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Clinical Studies Demonstrating Safety and Efficacy</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto has been shown to be safe and effective in men with hypogonadism. It was approved by the FDA in May 2014.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In its pivotal clinical trial, Natesto was evaluated for efficacy in a 90-day, open-label, multicenter study of 306 hypogonadal men. Eligible patients were 18 years of age and older (mean age 54 years) and had morning serum total testosterone concentrations less than 300 ng/dL. Patients were Caucasian (89%), African-American (6%), Asian (5%), or of other ethnicities (less than 1%).</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients were instructed to self-administer Natesto (11 mg of testosterone) intranasally either two or three times daily.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The primary endpoint was the percentage of patients with an average serum total testosterone concentration (C<sub>avg</sub>) within the normal range (300 to 1050 ng/dL) on Day 90.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The secondary endpoint was the percentage of patients with a maximum total testosterone concentration (C<sub>max</sub>) above three predetermined limits: greater than 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A total of 78 hypogonadal men received Natesto (11 mg of testosterone) three times daily (33 mg of testosterone daily). Of these, a total of 73 hypogonadal men were included in the statistical evaluation of efficacy (total testosterone pharmacokinetics) on Day 90 based on the intent-to-treat (ITT) population with last observation carried forward (LOCF). Ninety percent of these 73 patients had a C<sub>avg</sub> within the normal range (300 to 1050 ng/dL) on Day 90. The percentages of patients with C<sub>avg</sub> below the normal range (less than 300 ng/dL) and above the normal range (greater than 1050 ng/dL) on Day 90 were 10%
and 0%, respectively.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The table below (Table 3 from the Natesto Prescribing Information) summarizes the mean (SD) serum total testosterone concentrations on Day 90 in 69 patients who had a full pharmacokinetic sampling profile and were treated with Natesto (11 mg of testosterone) three times daily for 90 days.</P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v434644_chrt-table.jpg" WIDTH="519" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">77</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the same clinical trial studying the safety and efficacy of Natesto, which was conducted at 39 U.S. outpatient sites, it was shown that 70% of the per protocol patients in the twice-daily &#145;titration arm&#146; (n=141) achieved normal testosterone levels. Ninety-one percent of the per protocol patients in the thrice-daily group (n=77) achieved normal testosterone levels, demonstrating that the majority of men in both treatment groups achieved normalization of testosterone levels while taking Natesto. The efficacy of both B.I.D. (twice daily) and T.I.D. (three times daily) dosing of Natesto is demonstrated in the graphs
below: </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v434644_chrt-line.jpg" WIDTH="359" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Product Features and Patient Benefits</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe Natesto has a unique opportunity to gain market share in the $2+ billion U.S. market given the product&#146;s novel features and patient benefits including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Ease of administration; Appropriate for men with busy, active lives;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Established efficacy in pivotal FDA trials with a unique, low dose of testosterone; Effective in improving serum testosterone levels while using a proven, lower dose of testosterone;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Discreet product presentation and ease of transport (TSA compliant); Important for men who travel frequently and desire a simple, portable solution that travels easily with them;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">No risk of secondary exposure to testosterone due to dermal transference, an important consideration when thinking about a hypogonadal man&#146;s partner&#146;s or child&#146;s safety; and </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">78</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Safety, with a lower incidence of rising PSA levels than the market leading product AndroGel; Natesto demonstrates a 5.5% rate of rising PSA levels in clinical trials, while AndroGel demonstrated a rising PSA rate of over 11% in clinical trials. This is an important consideration as physicians concerned with understanding and tracking prostate cancer risk frequently monitor PSA levels in men over 50 years of age.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto has proven efficacy and a product profile well suited for men suffering from hypogonadism who have active, busy lifestyles who want a simple, discreet TRT option. We believe Natesto can play an important role in the treatment of hypogonadism, a condition affecting approximately 13 million U.S. men.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Market Opportunity</Font></H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Two recent developments have presented a unique opportunity for Natesto that we believe will enable us to effectively compete and be well positioned in the $2+ billion TRT market. As previously indicated, AndroGel&#146;s patent expired in 2015 and, unless a citizen&#146;s petition filed by AbbVie to delay a Teva Pharmaceuticals generic is successful long-term, we expect a generic entrant to begin eroding AbbVie&#146;s market share. As a result, we expect there to be diminished promotional support in the form of fewer physician details and lower overall promotional spending by AbbVie. In conjunction with the market leader&#146;s
diminished intellectual property position and potential diminished promotional spending, the TRT market has received increased scrutiny from the FDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 31, 2014 and subsequently on March 3, 2015, the FDA issued Safety Announcements relating to the possible increased risk of non-fatal heart attacks and strokes in patients taking testosterone. While the FDA has not concluded that the FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death, this recent safety consideration has caused patient advocates and consumer groups to ask for increased scrutiny on the direct to consumer advertising associated with the leading testosterone replacement products, most notably AndroGel and Axiron. As a result, we expect decreased advertising spending
in the TRT category to enable newer, less established products like Natesto to more effectively infiltrate the market through on-label, physician-directed promotion with a direct selling effort. While the potential safety concerns may cause a decrease in physician prescribing, we expect that physicians will continue to prescribe TRTs for patients for whom TRT treatment is appropriate. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Leading urology groups including the American Urological Association, or AUA, have strongly commented in favor of continued prescribing of TRTs for appropriate patients, and the safety data precipitating the FDA&#146;s comments have been called into question. Importantly, the FDA has not called for discontinuation of TRTs. Rather, patients were encouraged to speak with their health care professional and not stop taking TRTs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the FDA&#146;s initial statement about the potential cardiovascular risks associated with TRT treatment, the agency commented:</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>&#147;Patients should not stop taking their prescribed testosterone products without first discussing their questions or concerns with their health care professionals. ... The prescribing information in the drug labels of FDA-approved testosterone products should be followed.&#148;</I></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, following the FDA&#146;s statement, the AUA issued a strong response reiterating the clinical importance of low testosterone and maintaining their support for the appropriate use of testosterone replacement therapy:</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>&#147;Men with hypogonadism may also experience reduced muscle mass and strength and increased body fat. Hypogonadism may also contribute to reduced bone mineral density and anemia. Testosterone therapy is appropriate treatment for patients with clinically significant hypogonadism, including those with idiopathic clinical hypogonadism that may or may not be age-related, after full discussion of potential adverse effects.&#148;</I></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additional publications publicly refuted the validity of the data that precipitated the FDA&#146;s safety concern in a subsequent statement following the 2014 annual meeting of the AUA:</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>&#147;During the last several months there has been a firestorm of negative media attention regarding testosterone deficiency and its treatment, precipitated by a study reporting an increased rate of nonfatal myocardial infarction (MI) associated with testosterone prescriptions.</I></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">79</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>This public judgment of T therapy demands a response. As researchers and clinicians with extensive experience with T deficiency and its treatment, we disagree that the recent study published in PLoS One presents any credible evidence that T prescriptions increase health risks, and we find baseless the general assertion that testosterone is prescribed to men &#147;who are simply reluctant to accept the fact that they are getting older.&#148; We object to comments questioning whether T deficiency is real, regardless of whether it is called hypogonadism or &#147;low T&#148; as used in advertisements.&#148;</I></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AbbVie&#146;s sales of AndroGel dropped 5% in the first half of 2014, following the FDA&#146;s initial Safety Announcement and the subsequent reaction of the AUA and others. In the face of significant new competitive entrants (Aveed, Vogelxo) at that time and the FDA&#146;s expressed safety concerns, this represents a relatively insignificant sales decline. We believe this decline speaks to a real, present need in hypogonadism and a substantial opportunity for newly marketed products like Natesto. Natesto has proven safety, a recent FDA approval that speaks to the product&#146;s efficacy, and unique product features and patient
benefits we believe will set Natesto apart from the topically administered competitive products in the +$2 billion U.S. TRT market. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol for the Treatment of Urinary Tract Infections</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015 we acquired Primsol (trimethoprim hydrochloride oral solution) from FSC Laboratories, Inc. Primsol is the only FDA-approved trimethoprim-only oral solution for urinary tract infections and is standard therapy for such infections. Primsol is a sulfa-free, pleasant tasting, dye-free liquid that is appropriate for patients that are sulfa allergic and individuals that have difficulty swallowing pills. Primsol has demonstrated efficacy in eradicating key pathogens implicated in urinary tract infections including <I>E. coli</I> and has demonstrated similar efficacy to trimethoprim-sulfamethoxazole combination agents.
Primsol addresses a significant issue as many patients experience an allergic reaction to sulfamethoxazole. As the only oral solution containing only trimethoprim, Primsol offers distinct advantages over sulfa-containing antibacterial agents. Primsol was approved by the FDA in 2000 and was originally marketed by Ascent Pediatrics. FSC Laboratories acquired Primsol from Taro Pharmaceutical. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 4, 2016, we entered into a co-promotion agreement for Primsol oral solution with Allegis Pharmaceuticals. Under the agreement, the third party will exclusively promote Primsol to pediatricians across the U.S. We retain all other rights in the U.S. and around the world and will continue to market the product in urologic indications. This co-promotion enables us to focus exclusively on the urology channel while monetizing Primsol by virtue of a relationship with a company focused on selling to a non-core non-urology audience than can drive prescription growth of Primsol.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">About Primsol</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is a solution of the synthetic antibacterial trimethoprim in water prepared with the aid of hydrochloric acid. Each 5 mL for oral administration contains trimethoprim hydrochloride equivalent to 50 mg trimethoprim and the inactive ingredients bubble gum flavor, fructose, glycerin, methylparaben, monoammonium glycyrrhizinate, povidone, propylparaben, propylene glycol, saccharin sodium, sodium benzoate, sorbitol, water and hydrochloric acid and/or sodium hydroxide to adjust pH to a range of 3.0&nbsp;&#150;&nbsp;5.0. Primsol is indicated for the treatment of initial episodes of uncomplicated urinary tract infections in
adults due to susceptible strains of the following organisms: <I>Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter</I> species and coagulase-negative Staphylococcus species, including <I>S. saprophyticus</I>. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the treatment of uncomplicated urinary tract infections the usual oral adult dosage of Primsol is 100 mg (10 mL) every 12 hours or 200 mg (20 mL) every 24 hours, each for 10 days. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Urinary tract infections, or UTIs are among the most common diagnoses in the U.S., where the prevalence is estimated at 8.1 million physician office visits. Additionally, one fourth of women will have recurrent UTIs requiring the repeated use of oral antibiotics. Current UTI treatment recommendations include the use of trimethoprim-containing products given the compound&#146;s longstanding, established efficacy profile in effectively eradicating the key pathogens implicated in UTIs. Primsol has demonstrated efficacy in the eradication of the key pathogens implicated in urinary tract infections as demonstrated by a series of
quantitative methods and clinical studies. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations, or MICs, to eradicate pathogens implicated in urinary tract infections. These MICs provide estimates of the susceptibility </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">80</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trimethoprim powder. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MIC values should be interpreted according to the following criteria: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For testing aerobic microorganisms isolated from urinary tract infections: </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MIC (mcg/mL) Interpretation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&le; 8</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Susceptible (S)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&ge; 16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Resistant (R)</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A report of &#147;Susceptible&#148; indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of &#147;Intermediate&#148; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small
uncontrolled technical factors from causing major discrepancies in interpretation. A report of &#147;Resistant&#148; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; and other therapy should be selected. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprim powder as contained in Primsol provides the following MIC values against E. coli demonstrating significant susceptibility of this primary causal organism in urinary tract infections: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="418"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; font-weight: bold" ROWSPAN=1 COLSPAN=1>Microorganism MIC</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left"><B>(mcg/mL)</B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; font-style: italic" ROWSPAN=1 COLSPAN=1>Escherichia coli</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">0.5&nbsp;&#150;&nbsp;2</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trimethoprim has been shown to be active against the following microbial strains as indicated below and demonstrated through in vitro and clinical studies. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aerobic gram-positive microorganisms</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Staphylococcus species</I> (coagulase-negative strains, including <I>S. saprophyticus</I>)</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Streptococcus pneumoniae</I> (penicillin-susceptible strains) </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aerobic gram-negative microorganisms</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Enterobacter species</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Escherichia coli</I></TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Haemophilus influenza</I> (excluding beta-lactamase negative, ampicillin resistant strains)</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Klebsiella pneumonia</I></TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Proteus mirabilis</I> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol has demonstrated efficacy in the treatment of uncomplicated urinary tract infections without the potential side effects and allergic reactions sometimes attributed to sulfa-containing trimethoprim formulations. Importantly, and despite the fact that FSC Laboratories did not historically promote Primsol to urologists, 26% of Primsol prescriptions over the six-year period of September 2009 through August 2015 were written by urologists. This, we believe, underscores the unmet market opportunity for Primsol in presenting this treatment option more assertively to urologists. As our sales team will already be accessing
urologists through their promotion of ProstaScint, Primsol can be positioned as a first-line treatment option for urologists treating uncomplicated UTIs. With two FDA-approved products directed at urologists, we are able to efficiently drive awareness and increase through a focused field effort. ProstaScint and Primsol are commercially complementary and enable us to utilize our field sales force&#146;s synergies to affect prescription growth on both products while directing promotional efforts to our urology customers. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">81</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol was previously marketed by FSC Laboratories. Due to FSC&#146;s strategic refocusing and new product acquisitions to which sales efforts were diverted, Primsol had only limited commercial emphasis in the three to four years preceding our acquisition of the product. Despite FSC&#146;s limited commercial focus, annual unit sales of 7,842 units were achieved. At current pricing, this would result in annual revenues of approximately $5.3 million. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS In Vitro Diagnostic System for Male Infertility</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is a significant medical condition that urologists and infertility specialists treat frequently in the office setting or specialized fertility centers around the world. Of all sexually active couples, 8&nbsp;&#150;&nbsp;12% are infertile and male infertility is the sole cause or contributing factor up to 50% of the time. The global male infertility market is large and growing. The market for male infertility diagnosis and treatments is expected to grow to more than $300 million globally by 2020, with a CAGR of nearly 5% from 2014 to 2020. Despite the prevalence of male infertility, difficulties remain in
effectively diagnosis root causes. Oxidative stress assessment is considered a standard practice in complex andrology laboratories around the world, but due to various factors oxidative stress testing is not routinely employed in clinicians&#146; offices or standard laboratory settings. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Seminal oxidative stress has been well established throughout the peer-reviewed literature to play a substantial role in unexplained male infertility, and researchers and clinicians actively consider oxidative stress when conducting laboratory infertility assessment. While oxidative stress is well established as a leading contributing factor to male infertility, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen and plasma. This lack of standardization has resulted in poor implementation of
semen and plasma analysis around the world. Further, current testing platforms are cost-prohibitive for small office settings or local medical laboratories and require extensive training and on-site expertise. Additionally, antioxidant supplementation is frequently recommended to patients by clinicians without an effective method of measuring treatment success. As such, we believe introducing the MiOXSYS System to assess oxidative stress levels in semen and seminal fluid represents a significant commercial opportunity and novel way for clinicians to assess male factor infertility and assess therapeutic responses of patients in a simple, reliable, and cost-effective way. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System was CE Marked in January 2016, and we expect to initiate early commercialization efforts outside the U.S. by the end of fiscal 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An attractive aspect of the reproductive health market relates to reimbursement as infertility treatments and the associated diagnostic tests are generally paid directly by patients. The current infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced oxidative stress test would consume nominal relative costs while providing specific, actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications that lower oxidative stress (e.g., smoking cessation,
exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS System could effectively guide treatment in the infertile patients. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The global male infertility market is expect to grow to more than $300 million by 2020. With a substantial base of conditions for which the MiOXSYS System may present utility, we believe there is significant revenue potential from this first-in-class system. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of our strategy to develop future clinical applications of the RedoxSYS System (the MiOXSYS System&#146;s predecessor product for plasma and whole blood detection), we have conducted initial studies in male reproductive health. Male infertility is a significant medical condition in which oxidative stress is well known to play a substantial role. As such, we believe developing a clinical application to assess oxidative stress levels with the uniquely designed and programmed MiOXSYS System for semen analysis represents a significant commercial opportunity. Oxidative stress is well established as a leading contributing
factor to male infertility. Further, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen and seminal plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. Further, currently available tests are cumbersome, time consuming to perform, and costly. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">82</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted initial proof-of-concept clinical studies in male infertility with a leading research center in the United States, which demonstrated that oxidation-reduction potential effectively measures oxidative stress levels in semen and seminal plasma&nbsp;&#151;&nbsp;and that these levels strongly correlate with established markers of infertility. Semen analysis studies are routinely conducted to assess causes of infertility, so we expect clinicians and oxidative stress researchers to readily integrate the MiOXSYS System into routine use upon the completion of more extensive studies and regulatory clearance for this use.
Additional studies are now in the late planning stages that will evaluate the MiOXSYS System&#146;s performance in the detection of oxidative stress levels and correlations with key semen parameters in both healthy and infertile males. The MiOXSYS System must receive 510(k) de novo clearance from the FDA before we can market it for clinical use in the United States. Of the $300 million male infertility market projected for 2020, the North American, Middle Eastern, and Asia Pacific markets dominate due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already established distribution relationships and direct access to major oxidative stress researchers in many of these important markets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following our initial proof of concept studies with a leading center in the United States with the MiOXSYS system, we conducted our CE Mark-enabling study with over 300 infertile patients. The two key studies conducted with these leading centers are presented below. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States-Based Proof-of-Concept Clinical Study</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fifty-one (51) male patients were seen in a national clinic for suspected infertility. In addition to standard semen analyses (WHO 5<sup>th</sup> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<sup>6</sup> sperm/mL) and compared across six semen parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen samples that had fewer normal sperm had slightly, but not significantly, higher sORP values. Thus, most abnormal semen parameters appear to be associated with higher measures of oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When samples that achieve all six parameters of associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<sup>6</sup> sperm/mL separated those that met fertility standards from those that did not. In the current study, 85.7% of samples that met standards fell below this cutoff value, whereas 71.8% of those that failed one or more parameters had sORP values above this cutoff. The probability that a semen sample with a measured sORP value higher than the
cutoff is abnormal in at least one of the semen parameters, is 96.5%. Lastly, the more parameters that a semen sample falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or two. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Data derived from patients of the national clinic confirms the results obtained in an international fertility clinic. Overall, semen that falls into the abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are uniquely obtained using the MiOXSYS System for semen analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2016, we observed encouraging data from two prospective studies of MiOXSYS System that demonstrated its clinical utility as a tool for measuring ORP to assess the degree of oxidative stress levels in human semen. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The first study measured sORP in the semen samples of infertile men that correlated well with the sperm concentration, motility, and morphology. The second study further suggests that sORP is an easy to determine one-step indicator of increased oxidative stress in semen samples of infertile men especially with leukocytospermia. The results are currently being validated in a larger cohort of infertile men. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">83</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">International Pivotal Clinical Study</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Three-hundred sixty-six (366) male partners from couples seeking fertility advisement in an international clinic were recruited. In addition to standard semen analyses (WHO 5<sup>th</sup> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<sup>6</sup> sperm/mL) and compared across six semen parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen samples that had fewer normal sperm had significantly higher sORP values than those that fell into the range of normal morphology. Thus, most abnormal semen parameters appear to be associated with higher measures of
oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When samples that achieve all six parameters associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<sup>6</sup> sperm/mL separated those that met fertility standards from those that did not. In the current study, 91.43% of samples that met fertility standards fell below this cutoff value whereas 59.5% of those that failed one or more had sORP values above this cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff
is abnormal in at least one of the semen parameters, is 98.6%. Lastly, the more parameters that a semen samples falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or two. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Data derived from patients at this international clinic confirms the results obtained in United States fertility clinic. Overall, semen that falls into the abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are obtained uniquely using the MiOXSYS System for semen analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proof of concept clinical studies have been conducted at the Cleveland Clinic&#146;s Department of Urology, and two posters were presented at the 2015 American Society for Reproductive Medicine in November 2015. These abstracts are presented below. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Establishing the Oxidation-Reduction Potential in Semen and Seminal Plasma</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A. Agarwal,<sup>1</sup> S. S. Du Plessis,<sup>1,2</sup> R. Sharma,1 L. Samanta,<sup>1,3</sup> A. Harlev,<sup>1,4</sup> G. Ahmad,<sup>1,5</sup> S. Gupta,<sup>1</sup> E. S. Sabanegh<sup>6</sup>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South Africa, 3. Redox Biology Laboratory, School of Life Sciences, Ravenshaw University, Orissa, India, 4. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic, Cleveland, OH
</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Abstract:</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Objective:</B>&nbsp;&nbsp;Oxidation-reduction potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological samples. Static ORP (sORP) provides an integrated measure of the balance between total oxidants and reductants in a biological system, whereas capacity ORP (cORP) equates to the amount of antioxidant reserves. sORP has been shown to correlate well with illness and injury severity that accompanies the state of oxidative stress; cORP correlates with the ability to respond to illness or injury. Our objectives were to evaluate whether 1) ORP can be measured in semen and seminal plasma samples and
2) ORP levels correlate with sperm motility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Design:</B>&nbsp;&nbsp;Prospective study measuring ORP in both semen and seminal plasma. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Materials and Methods:</B>&nbsp;&nbsp;Semen samples (n=18) from normal control subjects were divided into two fractions and the seminal plasma was isolated from one fraction (300 x g, 7min). Sperm count and motility were assessed manually. sORP (mV/106 sperm) and cORP (&#956;C/106 sperm) were measured in </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">84</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">both fractions (RedoxSYS&reg;, Aytu BioScience). Values are reported as Mean &plusmn; SEM. Spearman correlation and Receiver Operating Characteristic curves (ROC) were used for statistical analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Results:</B>&nbsp;&nbsp;sORP and cORP levels in semen correlated significantly with the levels in seminal plasma. A significant negative correlation existed between sperm motility and sORP in both semen (r=-0.609; p=0.004) and seminal plasma (r=-0.690; p=0.002). Furthermore, a sORP cutoff of 4.73mV/106 sperm in semen (sensitivity = 100%, specificity = 89.5%, AUC=0.947) and 4.65mV/106 sperm in seminal plasma (sensitivity = 100%, specificity = 93.8%, AUC = 0.969) was highly predictive of abnormal sperm motility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Conclusions:</B>&nbsp;&nbsp;RedoxSYS&reg; accurately measured sORP and cORP in both semen and seminal plasma samples. Based on high sensitivity as assessed by ROC analysis, sORP levels can be used to screen infertile men with oxidative stress. These results are being validated in a larger cohort of infertile men. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Effect of Time on Oxidation-Reduction Potential in Semen and Seminal Plasma</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">R. Sharma,<sup>1</sup> S. S. Du Plessis,<sup>1,2</sup> A. Agarwal,<sup>1</sup> A. Harlev,<sup>1,3</sup> L. Samanta,<sup>1,4</sup> G. Ahmad,<sup>1,5</sup> S. Gupta,<sup>1</sup> E. S. Sabanegh<sup>6</sup>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South Africa, 3. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 4. Redox Biology Laboratory, School of Life Science, Ravenshaw University, Orissa, India, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic,
Cleveland, OH </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Abstract:</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Objective:</B>&nbsp;&nbsp;Oxidation-reduction potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological fluids. Reactive oxygen species (ROS) are highly reactive and have a very short half-life. ROS levels in the seminal ejaculate should be measured within an hour after collection to prevent a reduction in ROS levels over time. The traditional methods of measuring seminal ROS are time sensitive and time consuming, making it difficult to use them for diagnostic purposes. It would be highly advantageous to employ a method that is independent of semen age and provides results in real time. The
objective was to assess the effect of time on static ORP (sORP), which provides a snapshot of current redox balance, and capacity ORP (cORP) which is indicative of the amount of antioxidant reserves available. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Design:</B>&nbsp;&nbsp;Prospective study measuring ORP in semen and seminal plasma samples at time 0 and 120 minutes. Materials and Methods: The sORP and cORP of both semen (n=18) and seminal plasma (n=15) samples from normal control subjects were measured after liquefaction (time 0) and after 120 minutes of incubation at room temperature (RedoxSYS&reg;, Aytu BioScience). Values are mean &plusmn; SEM. Spearman correlation was used for statistical analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Results:</B>&nbsp;&nbsp;A significant correlation was seen between sORP at time 0 and 120 minutes in semen and seminal plasma. Similar correlations were found for cORP values at both time intervals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Conclusions:</B>&nbsp;&nbsp;ORP values are not affected by the age of semen or seminal plasma for up to 120 minutes, making it easier to employ this new technology for diagnostic use. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">RedoxSYS System for Research Use</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We completed the development of the RedoxSYS System (MiOXSYS&#146; predecessor product) during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. This enabled the launch of the RedoxSYS System into the research market around the world. We also received a CE marking in Europe and Health Canada clearance to begin the market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched sales efforts into the research
market in late 2014 and since that time have placed the RedoxSYS System at a number of prominent research centers in the United States, Europe, and Israel. We expect to leverage these research relationships and build numerous applications in areas where researchers are studying oxidative stress. Currently, there are no available research platforms that measure oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue, and cells). While oxidative stress is commonly studied in research settings around the world (both academia and industry), the current </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">85</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To position the RedoxSYS System effectively in the research market, we have placed key personnel in the United States, Europe, and Asia to develop direct research business relationships as well as distribution networks. Through these proof of concept studies and clinical exploratory studies, we identified the application of oxidation-reduction potential in male infertility assessment. As such, MiOXSYS was developed specifically for assessing semen and seminal plasma ORP levels. While we expect additional clinical
applications to be developed through these applications, our near-term focus is on completing the development of MiOXSYS for use in semen analysis for male infertility assessment. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Background on the MiOXSYS System</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">MiOXSYS is a novel, portable device that measures oxidation-reduction potential, or ORP, a global measure of oxidative stress. MiOXSYS is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide range of both acute and chronic conditions. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Potential Role of ORP in Diagnosing Male Infertility</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Oxidation-reduction potential is defined in the published literature as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;ORP in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents contribute to the ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include thiols, vitamin C, tocopherol, &#946;-carotene, lycopene, uric acid, bilirubin, and flavinoids. Enzymes such as superoxide dismutase, or SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less
reactive species. ORP monitoring of plasma represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of the system.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Given that ORP represents a single, global measure of oxidative stress in a biological system, we believe the potential for ORP to serve as a standardized marker in semen analysis and other aspects of infertility assessment is significant. A major limitation of oxidative stress assays relates to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress (e.g., free radical proliferation, antioxidant depletion, DNA damage, etc.), it is important to have an integrated measure that combines all known and unknown oxidants and reductants in the respective system into one measurement. We
believe ORP is an integrated measure of oxidative stress that can be easily and quickly measured with the MiOXSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the context of infertility, having an integrated value representing all relevant biologic constituents contributing to oxidative stress will enable simple, robust analysis in a two to three minute test. There are various techniques in use to assess semen in cases of male infertility. The most commonly implemented techniques involve DNA fragmentation, oxidative stress analysis, microscopic examination, sperm penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available oxidative stress analysis tools are widely considered expensive and cumbersome to use in routine clinical
practice. In both developed countries as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly impossible to implement with regularity. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS System Overview</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System is comprised of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant capacity of a biological fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a working electrode, and a reference electrode at equilibrium. The RedoxSYS System has been specifically studied in human whole blood, serum, semen, seminal plasma, blood plasma, and other biological fluids. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System measures two distinct elements to determine a patient&#146;s oxidation reduction potential:</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">86</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Static ORP&nbsp;&#151;&nbsp;the standard potential between a working electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance of redox agents and is what is classically defined as ORP. Low ORP values mean that the biological sample is in the normal range of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Capacity&nbsp;&#151;&nbsp;the measure of antioxidant reserve available in the body&#146;s system. High capacity values mean that the biological sample has levels of antioxidant reserves. Lower than normal capacity values means that the biological sample has below normal antioxidant reserves. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS Analyzer</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer is a portable, lightweight desktop platform that may be used in a clinical or research laboratory or near a patient care area. The analyzer is a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional specimen collection procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader consists of a Galvanostat analog circuit with greater than 1012 MHz input impedance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The analyzer contains a 10 MHz external crystal (internal 4X PLL for 40 MHz operation), and a programming/serial header is externally accessible. The device has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte) SPI Flash (3.3V) (Bulk data storage), and secondary storage of 2Mbit (256Kbyte) SPI FRAM (3.3V) (Hi-Speed Storage). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer contains a user-friendly interface that is flexibly designed to accommodate multiple endpoints depending upon the specific clinical condition being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators are visible through front panel mounted lenses. Further, the reader contains three DPDT push-button switches (Left, Center, Right), power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection, and test completion signals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, the MiOXSYS analyzer enables data transfer, has USB serial communication, and is configured for data download to a connected PC. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer&#146;s power management consists of an external 5VDC power jack with input capacitance and filtering, a boost converter supplied by external 5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader functions with or without the battery connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged use outside of a laboratory setting. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of the MiOXSYS Analyzer</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v433932_img1.jpg" WIDTH="178" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS Sensor Strips</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS sensor strips, via standard biological specimen collection techniques, receive 20&nbsp;&#150;&nbsp;40 microliters of a specimen from which the ORP clinical analysis is performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated with the sensors. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">87</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of the RedoxSYS Sensor Strips</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v433932_img2.jpg" WIDTH="232" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Regulatory Pathway</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We achieved ISO 13485: 2003 in early 2014 following the successful development of a compliant medical device quality system. Following the issuance of our ISO certification, we were awarded a CE marking for the RedoxSYS System, which has enabled initial market development in Europe and markets that accept a CE marking. In January 2016, we achieved CE Marking for MiOXSYS following technical validation and clinical study completion in male infertility. In March 2016, we obtained Health Canada Class II Medical approvals for MiOXSYS. In the United States, we intend to pursue 510k de novo clearance with the FDA for the MiOXSYS
System. We have recent, ongoing correspondence with the FDA and have confirmed that MiOXSYS is appropriate for the 510k de novo pathway, and we are pursuing regulatory clearance through this pathway. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States Commercial Strategy</Font> </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Commercial Strategy</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the clinical studies to measure oxidative stress in male infertility are successful, we expect to pursue that intended use for the MiOXSYS System via the FDA 510k de novo pathway. If cleared for the infertility intended use, we intend to seek to commercialize MiOXSYS System as a new tool for the assessment of oxidative stress in infertility in men. We envision pursuing a direct sales effort to high priority urology/andrology laboratories, infertility clinics and reference centers across the United States. We have identified the primary, influential centers in the United States and believe our commercial deployment will be
efficient through a focused sales and marketing effort. We intend to seek to sell the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the repeat ordering of the disposable, single use MiOXSYS sensor strips. We expect to realize a favorable gross margin on the basis of estimated low cost of goods sold on both components of the system. We envision an average selling price for the disposable sensors of approximately $25&nbsp;&#150;&nbsp;$40. We envision selling the MiOXSYS analyzers for $2,500&nbsp;&#150;&nbsp;$5,500 but will also pursue an instrument rental agreement model with minimum disposable sensor purchase requirements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also intend to leverage our urology commercialization efforts with other products with a focus on urology centers, infertility clinics, and reproductive health laboratories around the United States. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe a focused sales force at the onset of commercialization will enable effective representation of our products and penetration of the reproductive health market. Our sales efforts into the research markets will be enabled initially through a full-time business development professional who will focus on collaborative research and research sales to major oxidative stress centers in the United States. We expect to pursue identical pricing in the research market and the clinical diagnostics markets. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ROW Commercial Strategy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to undertake a similar strategy outside the United States for the RedoxSYS and MiOXSYS systems while complementing our efforts in infertility and research with adjunct applications in critical care conditions. To efficiently execute across our strategy, we intend to utilize a network of established distributors in the target markets in Europe and Asia. We have already engaged with distributors in multiple countries, while many other potential distributors are in advanced stages of discussions with us. We anticipate slightly reduced pricing outside the U.S. for the disposable sensors given the anticipated lower pricing
observed ex-US for diagnostic and research products. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our Business Development Strategy&nbsp;&#151;&nbsp;Identifying &amp; Acquiring Complementary Urology Assets</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A key growth and value driver for the Company is the ongoing identification and acquisition of novel urology products for commercialization. We seek to identify unique products with urologic indications that may be </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">88</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">non-strategic, undervalued or under-resourced by the company that currently markets the product. We believe that we can continue to acquire strategically aligned products at an appropriate valuation and grow those products via our focused sales and marketing efforts. We will also consider acquiring novel, late-stage development products that represent unique commercial opportunities and can be efficiently developed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are actively identifying unique product assets to acquire based on specific attributes including but not limited to: therapeutic area/indication; growth potential; intellectual property position (patents, regulatory, manufacturing or development technicalities, etc.), valuation, strategic fit, commercial orientation and other factors. Indications of interest include products to treat conditions such as urinary incontinence, sexual dysfunction, hypogonadism, prostate and other urological cancers, urinary tract infections, and other urological conditions. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Zertane, Our Phase 3-Ready Candidate for the Treatment of Premature Ejaculation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for the on-demand treatment of premature ejaculation, or PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section 505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial product approved by the FDA for PE. The FDA
accepted the IND for Zertane in late 2015. The IND would allow for initiation of Phase 3 clinical studies by virtue of the positive clinical data generated to date and the well-established safety profile of tramadol hydrochloride. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">By virtue of significant development work performed by a previous partner of Ampio, Zertane has already been evaluated outside the United States in two Phase 1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. The two Phase 1 safety trials were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89 mg) in healthy volunteers. Two randomized, placebo-controlled, blinded Phase 2 clinical trials were conducted in a total of 102 patients. These trials evaluated doses of tramadol hydrochloride between 25 and 120 mg in male
subjects with PE. Two placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight hours before a sexual event. This development work has demonstrated a favorable safety and efficacy profile of Zertane in men with PE. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized, which should eliminate the need for us to conduct additional pre-clinical studies and safety trials. Based on guidance received at a recent consultation meeting with the FDA, we believe Zertane is well positioned to initiate a Phase 3 clinical program in the United States. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The premature ejaculation market in the U.S. and Europe is expected to reach over $1.3 billion in annual sales in 2017, representing an increase of 10.3% since 2010. According to published analyses, premature ejaculation, or PE, is a highly prevalent male sexual dysfunction affecting 20&nbsp;&#150;&nbsp;30% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge, only two other prescription products have been
approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. In addition, approximately 23% of the more than 12,000 men with PE surveyed in a 2007 study published in European Urology also suffered from ED. Accordingly, we believe that a combination product candidate to treat both PE and ED represents another significant worldwide market opportunity for us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for the on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section 505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If the FDA approves Zertane, we believe it will be the first commercial prescription product approved by the FDA for PE and would be attractive to a commercial
partner. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">89</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We already have partnerships in place to market Zertane in South Korea and Brazil, which could provide near-term revenue for us if, working with our partners, we are able to successfully obtain regulatory approval in those countries. In addition, we recently entered into an agreement with Endo Ventures Limited, which recently acquired Paladin Labs Inc., or Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to published analyses, PE is a highly prevalent male sexual dysfunction affecting 20&nbsp;&#150;&nbsp;30% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction. Presently, there are no approved prescription pharmaceuticals in the United States to treat PE and only two pharmaceuticals known to be approved elsewhere in the world. Current &#147;off label&#148; or unapproved therapies used to treat PE carry with them unwanted side effects and inconsistent or limited effectiveness. Topical over-the-counter, or OTC, options
are not preferred due to route of administration and may also have an impact on partner satisfaction. Oral therapeutics, specifically selective serotonin reuptake inhibitors, or SSRIs, carry potentially significant side effects most notably of which is diminished libido. PDE-5 inhibitors have been prescribed &#147;off label&#148; for PE but have not demonstrated efficacy. Outside of oral or topical therapeutics, non-medical options include behavioral therapy and relationship counseling, both of which can be time consuming and stressful and frequently ineffective for men and their partners. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane contains 89 mg tramadol hydrochloride in an orally dissolving tablet, or ODT. Tramadol hydrochloride is a well-established, centrally acting synthetic analgesic and has been used for more than 30 years as a treatment for moderate to severe pain. The drug and its active metabolite (M1, <I>O</I>-desmethyltramadol) act as an opiate agonist, apparently by selective activity at the &#956;-receptor. Although the mechanism by which tramadol hydrochloride delays ejaculation has not been identified, numerous laboratory studies have shown that tramadol hydrochloride also acts as an <I>N</I>-methyl-D-aspartate receptor antagonist,
5-hydroxytryptamine type 2C receptor antagonist, 5 nicotinic acetylcholine receptor antagonist, M1 and M3 muscarinic acetylcholine receptor antagonist, and a serotonin and norepinephrine modulator. It is possible that one or a combination of these effects leads to a delay in ejaculation. The relative contribution of tramadol hydrochloride versus its M1 metabolite to delay ejaculation is unknown. However, the metabolite is six times more potent than the parent drug in producing analgesia in animal models and 200 times more potent in &#956;-receptor binding. As a pain medication, tramadol hydrochloride has been associated with certain adverse effects including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. However, we intend that our labeling for Zertane, if regulatory approval is obtained, will suggest &#147;as required&#148; dosing before sexual intercourse and not to exceed one tablet per day. Based on previous clinical studies, we believe that limiting
the dosing to no more than once per day will minimize any side effects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Clinical Data</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Six European clinical trials have been completed with Zertane: two Phase 1 trials in healthy volunteers and two Phase 2 and two Phase 3 trials in men with lifelong PE. The two Phase 1 safety trials were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89 mg) in healthy volunteers. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Two randomized, placebo-controlled, blinded Phase 2 clinical trials were conducted in a total of 102 patients. The first of these showed that a single 25-mg dose of conventionally formulated immediate release tramadol hydrochloride (i.e., immediate-release gelatin capsules) was safe, well-tolerated and prolonged time to ejaculation in some, but not all, patients. The second trial evaluated three higher doses of tramadol hydrochloride: 65 mg, 85 mg and 120 mg. In this trial, a clear dose response was seen for both efficacy and safety, leading DMI Biosciences to conclude that the optimal tramadol hydrochloride dose to treat PE
was likely to be in the range 60&nbsp;&#150;&nbsp;90 mg. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Two placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight hours before a sexual event. A total of 677 patients were randomized in the trials and received either the 62 or 89 mg ODT or a matching placebo ODT. Our claim that Zertane was efficacious in the Phase 3 trials is based on at least one of the two doses resulting in statistically significant improvements in both IELT and PEP measures (i.e., co-primary endpoints) from baseline to the end of the trial. Using
IELT in </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">90</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">combination with a self-report questionnaire (e.g., PEP or POPE) has gained acceptance as meaningful measures of pharmacoactivity and efficacy in the scientific and regulatory communities. The results of the Phase 3 trials suggest that tramadol hydrochloride 89 mg ODT is consistently more effective as a treatment for PE than tramadol hydrochloride 62 mg ODT. In accordance with the definitions from the clinical trial protocols, only the tramadol hydrochloride 89 mg ODT dose satisfied the claim for effective treatment of PE in both Phase 3 trials. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes the six prior clinical trials of Zertane. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE BORDER="1" BORDERCOLOR="black" CELLPADDING="2" CELLSPACING="0" STYLE="vertical-align: text-top; text-indent: 0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; *margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt" WIDTH="608">

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Trial Name<BR> (Dates/Sponsor)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Phase</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Demographic<BR> (Age)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Enrollment</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Design</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Duration<BR> of Double-<BR>blind<BR> Treatment</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Zertane<BR> Dose (mg)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Noteworthy Findings</FONT></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>BVF-324-101 (June 26, 2009 to July 5, 2009/ Biovail*)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Healthy males<BR> and females<BR> (18&nbsp;&#150;&nbsp;55 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">20</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Comparative</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">N/A</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">89</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Overall systemic exposure of tramadol hydrochloride and 2 metabolites were similar following 89 mg ODT and the reference 89 mg tramadol hydrochloride solution.<BR> &nbsp;<BR>13 subjects experienced a total of 37 adverse events (AEs) during the study. Most common AEs were GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, and headache).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>BVF-324-102 (July 14, 2009 to July 30, 2009/Biovail*)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Healthy males<BR> (19&nbsp;&#150;&nbsp;55 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">424</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Alcohol<BR> interaction study</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">N/A</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">89</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">There was no significant difference in the peak and total systemic exposures of tramadol hydrochloride compared to when tramadol hydrochloride 89 mg ODT was taken with water, or with either strength of alcohol.<BR> &nbsp;<BR>Tramadol hydrochloride was well tolerated with alcohol. 7 subjects experienced 11 AEs, most frequently decreased blood pressure and dizziness.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>KNL 40237 (March 13, 2003 to July 7, 2003/DMI**)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Men with PE<BR> (18&nbsp;&#150;&nbsp;70 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">37</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Double-blind,<BR> randomized<BR> placebo-controlled</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3 weeks</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">25</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Treatment with tramadol hydrochloride 25 mg had no statistically different effect than placebo in subjects with a baseline IELT of 2 minutes or less (n=30; <I>P</I>=0.4560) or in a subpopulation of subjects with a baseline IELT of 1 minute or less (n=19; <I>P</I>=0.1796).<BR> &nbsp;<BR>46 AEs emerged during treatment (28 with tramadol hydrochloride and 18 with placebo). There were no deaths, serious or other significant AEs. All AEs were of mild intensity. Most common AEs were GI disorders (nausea) and central nervous system disorders (headache).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>KNL 40491 (September 28, 2004 to October 18, 2005/DMI**)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Men with PE<BR> (18&nbsp;&#150;&nbsp;70 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">68</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Double-blind,<BR> randomized<BR> placebo-controlled</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">12 weeks</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">65, 85,<BR> 120</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Tramadol hydrochloride significantly increased the median IELT compared to both Baseline and placebo. Statistically significant increases in IELT compared to Baseline were observed to be 3.0-fold (<I>P</I>=0.0013), 4.2-fold (<I>P</I>&lt;0.0001), and 5.1-fold (<I>P</I>&lt;0.0001) for the 65-, 85-, and 120-mg dose levels, respectively.<BR> &nbsp;<BR>Doses of 65 and 85 mg were generally well tolerated. 120 mg was less well tolerated with adverse events known to be associated with tramadol hydrochloride (headache, dizziness, somnolence, insomnia) and related to sexual function (penile hypoaesthesia, anorgasmia, and ED).</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">91</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE BORDER="1" BORDERCOLOR="black" CELLPADDING="2" CELLSPACING="0" STYLE="vertical-align: text-top; text-indent: 0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; *margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt" WIDTH="608">

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Trial Name<BR> (Dates/Sponsor)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Phase</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Demographic<BR> (Age)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Enrollment</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Design</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Duration<BR> of Double-<BR>blind<BR> Treatment</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Zertane<BR> Dose (mg)</FONT></TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Noteworthy Findings</FONT></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>BVF-324-301 (August 17, 2009 to September 9, 2010/Biovail*)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Men with PE<BR> (18&nbsp;&#150;&nbsp;65 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">221</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Double-blind,<BR> randomized<BR> placebo-controlled</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">12&nbsp;weeks</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">62, 89</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 89 mg compared to placebo (p = 0.002). The significant difference was apparent at the first visit during the double-blind treatment period and each visit thereafter (p &le; 0.05 for all Visits). Tramadol hydrochloride 62 mg and 89 mg ODT demonstrated statistically significant improvements in PEP measures compared with placebo.<BR> &nbsp;<BR>During the double-blind treatment or open-label extension periods, 21 subjects experienced at least 1 treatment-emergent AE. There were no deaths or serious AEs during the study.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>BVF-324-302 (September 30, 2009 to August 23, 2010/Biovail*)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Men with PE<BR> (18&nbsp;&#150;&nbsp;65 yr)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">456</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Double-blind,<BR> randomized<BR> placebo-controlled</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">12&nbsp;weeks</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">62, 89</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 62 and 89 mg compared to placebo (p = 0.01 and p = 0.02). Tramadol hydrochloride 62 mg and 89 mg ODT demonstrated statistically significant improvements in both IELT and PEP measures compared with placebo.<BR> &nbsp;<BR>A total of 28 out of 399 subjects (7.5%) experienced at least 1 treatment-emergent AE during the double-blind or open-label treatment period. No subject died or experienced a severe AE.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; font-weight: bold" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><B>896</B></TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">&nbsp;&nbsp;</TD>

</TR>

</TABLE></DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left"><I>Biovail Laboratories International, SRL</I> </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left"><I>**</I></TD>

          <TD STYLE="text-align: left"><I>DMI BioSciences, Inc.</I> </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Phase 3-Ready Clinical Program in United States&nbsp;&#151;&nbsp;Ready for a Strategic Partner to Engage</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With the approval of the IND the regulatory pathway has been agreed upon with the FDA. As in the Phase 3 trials conducted in Europe, co-primary endpoints will be used for determination of efficacy. Both improvement in IELT, which will be captured by the partner in a blinded diary, and PE-related frustration or bother, which will be assessed after each sexual intercourse attempt as well as at the final study visit by a single question in the POPE, will be evaluated as co-primary endpoints to determine efficacy. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, clinical trial supplies are already manufactured and packaged and would simply require appropriate clinical labeling of the product candidate. Additionally, our manufacturing process has already been validated at the site of commercial manufacture, and clinical study sites in the U.S. have been identified and validated. Depending on our success in raising additional funds, we may decide to focus our capital resources on other strategies and not pursue clinical testing of Zertane in the U.S. If we decide not to pursue clinical testing of Zertane, we will seek strategic options to maximize the value of Zertane,
inclusive of divestiture, out-licensing, and strategic commercial collaborations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ex-U.S. Partnering Has Begun</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have already demonstrated that there is partnering interest for Zertane around the world as evidenced by the partnerships we have in place with notable regional pharmaceutical companies. We plan to leverage these partnerships to gain approval and eventual marketing authorization for Zertane in several key markets around the world. We already have partnerships in place with Daewoong Pharmaceuticals Co., Ltd. in South Korea and FBM Industria Farmaceutica Ltda. in Brazil, thereby providing potential royalty and milestone-based revenue if, working with our partners, we are successfully able to obtain regulatory approval in those
countries. In addition, our recent agreement with Paladin (an operating unit of Endo Pharmaceuticals plc) provides Paladin with exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. Before marketing any </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">92</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">products in Brazil and South Korea, approval must be received from the Brazilian Health Surveillance Agency (Anvisa) and the Ministry of Food and Drug Safety (MFDS, previously the Korean Food and Drug Administration), respectively. We intend to leverage the expertise of our local collaborators in these jurisdictions to navigate the regulatory requirements and help determine an efficient and effective pathway to bringing Zertane to market. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Government Regulation</Font> </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Approval Process for Pharmaceutical Products</Font> </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FDA Approval Process for Pharmaceutical Products</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending
NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pharmaceutical product development in the United States typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA&#146;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated current good manufacturing requirements, or cGMP, including a quality system regulating manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may begin in the United States, obtaining the approval of Institutional Review
Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pre-clinical tests generally include laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before human clinical trials can
begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well as international scientific standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The
IRB considers, among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&#146;s GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical trials, a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">93</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The main purpose of the trial is to assess a product candidate&#146;s safety and the ability of the human body to tolerate the product candidate. Phase 1 clinical trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy of the product candidate for specific target diseases or medical conditions, and
(iii) assess dosage tolerance and determine the optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which is intended to demonstrate the candidate product&#146;s clinical efficacy and adequate information for labeling of the approved drug. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are three main types of NDAs, which are covered by Section 505 of the FDC Act: (1) an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1)); (2) an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the application has not obtained a right of reference (Section 505(b)(2)); and (3) an application that contains information to show that the proposed product is identical in active ingredient, dosage form,
strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (Section 505(j)). Section 505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the pre-IND briefing meeting with Ampio and in June 2012, the FDA agreed that our NDA may be submitted under Section 505(b)(2). As such, we intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and 21-692) to support the safety and efficacy demonstrated in our clinical program. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2.3 million and the manufacturer and/or sponsor under an approved
NDA are also subject to annual product and establishment user fees, currently approximately $0.1 million per product and $0.6 million per establishment. These fees are typically increased annually. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the FDA&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed in six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or
provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#151;&nbsp;typically a panel that includes clinicians and other experts&nbsp;&#151;&nbsp;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not
approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">94</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or problems are identified following initial marketing. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The Hatch-Waxman Act</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths
and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#147;generic equivalents&#148; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#146;s Orange Book that: 1) the required patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or 4) the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the applicant
does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the
infringement case that is favorable to the ANDA applicant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ANDA application also will not be approved until any non-patent exclusivity listed in the Orange Book for the referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients during which ANDAs for generic versions of those drugs cannot be submitted, unless the submission contains a Paragraph IV challenge to a listed patent&nbsp;&#151;&nbsp;in which case the submission may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity during which FDA cannot grant
effective approval of an ANDA based on the approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use; the approval of which was required to be supported by new clinical trials conducted by, or for, the applicant. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">95</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Post-Approval Regulation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required to register their
establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. We cannot be certain that we or our present or future contract manufacturers or suppliers will be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the FDA approves one or more of our product candidates, we and the contract manufacturers we use for manufacture of clinical supplies and commercial supplies must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product or medical devices, also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which
include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Approval Process for Medical Devices</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, the FDCA, FDA regulations and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA regulates the design, manufacturing, servicing, sale and distribution of medical devices, including molecular diagnostic test kits and instrumentation systems. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless an exemption applies, each medical device we wish to distribute commercially in the United States will require marketing authorization from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval, also called PMA approval. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of
regulatory control deemed necessary to ensure the device&#146;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification and adherence to the FDA&#146;s current Good Manufacturing Practices, or cGMP, known as the Quality System Regulations, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls and include life sustaining, life-supporting or implantable devices,
devices of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">96</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Most Class I devices and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III generally require PMA approval or 510(k) de novo clearance prior to commercial marketing. The PMA approval process is more stringent, time-consuming and expensive than the 510(k) clearance process, however, the 510(k) clearance process has also become increasingly stringent and
expensive. The FDA has provided initial guidance to us that the RedoxSYS System is appropriate for the 510(k) clearance process, likely through the de novo pathway. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">510(k) Clearance. To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the device is &#147;substantially equivalent&#148; to a device legally marketed in the United States that is not subject to PMA approval, commonly known as the &#147;predicate device.&#148; A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics or (ii) different technological characteristics and the information submitted demonstrates that the device is as safe and effective
as a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may extend to a year or more. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the device&#146;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at
any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before we can submit a medical device for 510(k) clearance, we may have to perform a series of generally short studies over a period of months, including method comparison, reproducibility, interference and stability studies to ensure that users can perform the test successfully. Some of these studies may take place in clinical environments, but are not usually considered clinical trials. For PMA submissions, we would generally be required to conduct a longer clinical trial over a period of years that supports the clinical utility of the device and how the device will be used. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although clinical investigations of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations of diagnostic tests, including our products and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations by intended users for intended uses of our products generally do not require the FDA&#146;s prior approval but may require approval of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing is non-invasive, does not require an invasive sampling procedure that
presents a significant risk, does not intentionally introduce energy into the subject and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition, our products must be labeled per FDA regulations &#147;for research use only-RUO&#148; or &#147;for investigational use only-IUO,&#148; and distribution controls must be established to assure that our products distributed for research, method comparisons or clinical evaluation studies are used only for those purposes. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Regulation after FDA Clearance or Approval</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any devices we manufacture or distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which include, among other things, testing, control and documentation requirements. Noncompliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the government to grant 510(k) clearance or PMA approval of
devices, withdrawal of marketing approvals and criminal prosecutions, fines and imprisonment. Our contract manufacturers&#146; facilities operate under the FDA&#146;s cGMP requirements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">97</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Foreign Regulatory Approval</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Outside of the United States, our ability to market our product candidates will be contingent also upon our receiving marketing authorizations from the appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and differ from those required for FDA approval.
</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Union, we are required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE mark to certain of our products in order to sell the products in member countries of the European Union. The CE mark is an international symbol that represents adherence to certain essential principles of safety and effectiveness mandated in the European Medical Device Directive, which are referred to as the &#147;essential requirements&#148;. Once affixed, the CE mark enables a product to be sold within the European Economic Area, or EEA, which is composed of the 28 member states of the EU plus
Norway, Iceland and Liechtenstein as well as other countries that accept the CE mark. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To demonstrate compliance with the essential requirements, we must undergo a conformity assessment procedure which varies according to the type of medical device and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile) where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a
notified body. Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The notified body issues a CE certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we modify our devices we may need to apply for permission to affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for any new products that we may develop in the future. Certain products regulated as medical devices according to EC-Directives are subject to vigilance requirements for reporting of adverse events. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be subject to additional regulations in other countries in which we market, sell and import our products, including Canada. We or our distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The International Standards Organization, or ISO, promulgates internationally recognized standards, including those for the requirements of quality systems. To support ISO certifications, surveillance audits are conducted by a notified body yearly and recertification audits every three years that assess continued compliance with the relevant ISO standards. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Other Regulatory Matters</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also
comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">98</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead
the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States Patent Term Restoration and Marketing Exclusivity</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depending upon the timing, duration and other specific aspects of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval
date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, if any of our NDA&#146;s are approved, we intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently, the FDA stated that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each
drug substance in a fixed-combination drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5 year NCE exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a Section 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">99</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active
agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Reimbursement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not anticipate that the sales of two of our product candidates (Zertane and the MiOXSYS System), once approved for sale, will be heavily dependent upon reimbursement by third-party payors. Traditionally, sales of pharmaceutical products that are not &#147;life style&#148; indications depend, in part, on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. ProstaScint is dependent upon reimbursement for continued
use in the U.S. market, and ProstaScint does have a reimbursement code as assigned by the American Medical Association. ProstaScint is currently reimbursed by Medicare, Medicaid, and various private health plans. However, reimbursement is not universally available throughout the United States for ProstaScint. Primsol is also dependent upon reimbursement for continued use in the U.S. market, and Primsol is covered under a Rebate Agreement between us and Centers for Medicare and Medicaid Services. This, in turn, enables states to offer public payer coverage of Primsol through their separate Medicaid and public assistance programs. Primsol is also covered by many private payers who offer coverage benefits to patients for branded, prescription antibiotic treatments. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Lack of third-party reimbursement for our product candidate or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">DEA Regulation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto, already approved by the FDA, is a &#147;controlled substance&#148; as defined in the Controlled Substances Act of 1970, or CSA, because it contains testosterone. As a result, the U.S Drug Enforcement Agencies, or DEA, regulate Natesto and have listed it as a Schedule III substance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane, because it contains tramadol, will be regulated as a &#147;controlled substance&#148; as defined in the CSA and the DEA. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V. The DEA implements regulations, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">100</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA for controlled substances. These requirements are directly applicable to us and also applicable to our manufacturers and to distributors, prescribers and dispensers of Natesto and, if approved Zertane. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging in order to prevent loss and diversion into illicit channels
of commerce. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect that Zertane will be listed by the DEA as Schedule IV controlled substances under the CSA. Consequently, any importation of API for Zertane, as well as the manufacture, shipping, storage, sales and use of Zertane, will be subject to a high degree of regulation. Also, distribution and dispensing of these drugs are highly regulated. We do not expect this designation will affect our ability to align with a strategic partner to commercialize Zertane. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. Similarly, separate registrations are also required for separate facilities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA typically inspects a facility to review its security measures prior to issuing a registration and on a periodic basis. Reports must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special permits and notification requirements apply to imports and exports of narcotic drugs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA establishes annually an aggregate quota for how much of a controlled substance may be produced in total in the United States based on the DEA&#146;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. Our or our manufacturers&#146; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by
the DEA in establishing our or our manufacturers&#146; quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations could result in criminal proceedings.
</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Individual states also independently regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution of these products, including, for example, state requirements for licensures or registration. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Intellectual Property</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have an extensive range of intellectual property across our primary assets, Zertane, MiOXSYS, and RedoxSYS. We have patent protection in the United States and several other large markets worldwide. Specifically, we have numerous patents issued and pending for the RedoxSYS/MiOXSYS systems and their use in the U.S., Europe, Canada, Israel, and in Japan. Further, we have patent protection in the United States and several other large markets worldwide for the use of tramadol hydrochloride to treat PE. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have restructured our patent portfolio related to Zertane to focus on our patent family for the use of tramadol to treat premature ejaculation. Issued patents in this family in the United States, Australia, Canada, China, Hong Kong, Japan, Korea and South Africa will be maintained and issued patents in all European countries, Mexico, New Zealand, Philippines and Singapore will be allowed to lapse through non-payment of annuities. The standard 20-year expiration for patents in this family is in 2022. The other two families related </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">101</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">to Zertane for a combination of tramadol and a phosphodiesterase inhibitor to treat comorbid premature ejaculation and erectile dysfunction and to treat sexual dysfunction side effects associated with administration of tramadol will be allowed to lapse worldwide through non-payment of annuities for issued patents and non-response to outstanding actions for pending applications. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have restructured our patent portfolio related to RedoxSYS/MiOXSYS to focus on the United States and core foreign jurisdictions which include Europe, Japan, Canada and Israel. In other foreign jurisdictions, patents and pending applications will be allowed to lapse through non-payment of annuities for issued patents and non-response to outstanding actions for pending applications. The portfolio to be supported in the United States and core foreign jurisdictions consists of 10 issued patents and 18 pending applications. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The portfolio primarily consists of four families filed in the United States and in core foreign jurisdictions. The first family includes four issued patents and five pending applications with claims directed to the measurement of the ORP of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family is in 2028. The second family includes two pending United States applications, and three pending applications in core foreign jurisdictions with claims directed to the measurement of the ORP capacity of a patient sample to evaluate various conditions. The standard 20-year expiration
for patents in this family is in 2033. The third family includes six issued patents and three pending applications with claims directed to devices and methods for the measurement of ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2032. The fourth family includes one pending United States application and four pending applications in core foreign jurisdictions with claims directed to multiple layer gel test strip measurement devices and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2033.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is protected by significant trade secrets and manufacturing know-how related to the production of the product and linkage of the base monoclonal antibody and imaging component. The antibody in the ProstaScint product is produced by a proprietary cell line. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is protected by a formulation patent and its regulatory designation. By virtue of the fact that Primsol was approved as an NDA and the extremely large backlog of Abbreviated New Drug Applications at FDA (2&nbsp;&#150;&nbsp;3 year review time currently), we don&#146;t expect generic competition for Primsol in the next 3&nbsp;&#150;&nbsp;4 years. There are currently no generic competitors filed with the FDA under Paragraph IV, which is required of potential generic competitors seeking to genericize an on-patent NDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has an exclusive license from Acerus Pharmaceuticals SRL for the United States to intellectual property related to a nasal gel drug product containing testosterone to treat hypogonadism in males, including the FDA approved product Natesto&reg;, as well as an authorized generic version and OTC versions thereof. The license includes sublicense rights to intellectual property owned by Mattern Pharmaceuticals and exclusively licensed to Acerus by Mattern Pharmaceuticals. The sublicensed intellectual property includes four Orange Book listed patents directed at nasal gel formulations containing testosterone or methods of
testosterone replacement therapy by nasal administration of the same. It further includes a pending unpublished application, and two patents that are not listed in the Orange Book directed at a method of making a testosterone formulation and a method for reducing physical or chemical interactions between a nasal testosterone formulation and a plastic container. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Acerus license also grants rights to intellectual property owned by Acerus which includes twelve nonprovisional patent applications, some of which may be abandoned. These patent applications include at least three pending applications directed to testosterone titration methods, intranasal testosterone bio-adhesive gel formulations, and controlled release testosterone formulations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also maintain trade secrets and proprietary know-how that we seek to protect through confidentiality and nondisclosure agreements. These agreements may not provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. If we do not adequately protect our trade secrets and proprietary know-how, our competitive position and business prospects could be materially harmed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to seek United States and foreign patent protection for drug and diagnostic products we discover, as well as therapeutic and diagnostic products and processes. We expect also to seek patent protection or rely </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">102</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">upon trade secret rights to protect certain other technologies which may be used to discover and characterize drugs and diagnostic products and processes, and which may be used to develop novel therapeutic and diagnostic products and processes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent positions of companies such as ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any certainty. Our issued and licensed patents, and those that may be issued to us in the future, may be challenged, invalidated or circumvented, and the rights granted under the patents or licenses may not provide us with meaningful protection or competitive advantages. Our competitors may independently develop similar technologies or duplicate any technology developed by us, which could offset any advantages we might otherwise realize from our intellectual property.
Furthermore, even if our product candidates receive regulatory approval, the time required for development, testing, and regulatory review could mean that protection afforded us by our patents may only remain in effect for a short period after commercialization. The expiration of patents or license rights we hold could adversely affect our ability to successfully commercialize our pharmaceutical drugs or diagnostics, thus harming our operating results and financial position. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be able to protect our proprietary intellectual property rights from unauthorized use by third parties primarily to the extent that such rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate to protect our intellectual property from infringement, we may incur substantial costs and our officers may be forced to devote significant time to litigation-related matters. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. Our pending patent applications, or those we may file or
license from third parties in the future, may not result in patents being issued. Until a patent is issued, the claims covered by an application for patent may be narrowed or removed entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition, or conclude that without patent rights the risk of bringing product candidates to market exceeds the returns we are likely to obtain. We are generally aware of the scientific research being conducted in the areas in which we focus our research and development efforts, but patent applications filed by others are maintained in secrecy for at least 18 months and, in some cases in the United States, until the patent is issued. The publication of discoveries in scientific literature often occurs substantially later than the date on which the underlying discoveries were made. As a result, it is possible that patent applications for products similar to our drug or diagnostic products and product candidates may
have already been filed by others without our knowledge. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights, and it is possible that our development of products and product candidates could be challenged by other pharmaceutical or biotechnology companies. If we become involved in litigation concerning the enforceability, scope and validity of the proprietary rights of others, we may incur significant litigation or licensing expenses, be prevented from further developing or commercializing a product or product candidate, be required to seek licenses that may not be available from third
parties on commercially acceptable terms, if at all, or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our business. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Competition</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The healthcare industry is highly competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality and breadth of an organization&#146;s technology; skill of an organization&#146;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average selling price of, products; the availability of raw materials and qualified manufacturing capacity; manufacturing
costs; intellectual property and patent rights and their protection; and sales and marketing capabilities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our competitors may also succeed in obtaining FDA or other regulatory approvals for their product candidates more rapidly than we are able to do, which could place us at a significant competitive disadvantage or deny us marketing exclusivity rights. Market acceptance of our product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies or tests, (ii) the actual or </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">103</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and distribution capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We cannot assure you that any of our products that we successfully develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our currently approved products compete in highly competitive fields whereby there are numerous options available to clinicians including generics. These generic treatment options are frequently less expensive and more widely available. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Currently, there are several FDA approved imaging techniques for cancer in general, however there is only one specifically targeting prostate cancer&nbsp;&#151;&nbsp;ProstaScint. The other imaging methods are F18-fluorodeoxyglucose (F18-FDG), C11-Acetate, and C11-Choline. The primary advantage of these methods is that they all use PET imaging, a technique with better resolution than SPECT. The use of PET is also a disadvantage, however, since it uses radiolabels with short half-lives necessitating the need for a local or on-site cyclotron to generate the labels. The half-life of fluorine-18 (F18) and of carbon-11 (C11) are
approximately 110 and 20 minutes, respectively. The radiolabel used by ProstaScint is Indium-11, with a half-life of about 2&nbsp;&#150;&nbsp;3 days. This longer time period allows the radiolabel to be made remotely and shipped to the imaging facility; however it does use SPECT as the imaging modality. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As indicated, ProstaScint is the only radio-imaging marker that is specific for prostate cancer. ProstaScint is based on radiolabeling the antibody against prostate specific membrane antigen, or PSMA, a protein express by prostate cells. This specificity for prostate cells is what allows ProstaScint to detect the metastases of prostate cancer regardless of location. The mechanism of labeling for F18-FDG, C11-Acetate, and C11-Choline is the intracellular accumulation of these markers in cancer cells, due to the fact that cancer cells typically have a higher cellular metabolism than non-cancerous cells. Thus, these markers can
accumulate in any type of cancer cell with a high metabolism, unfortunately prostate cancer cells tend to have a lower cellular metabolism resulting in higher false positives attributed to hyperplasia and prostatitis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In a meta-analysis of 21 studies evaluating accuracy, sensitivity, specificity, positive/negative predictive values, ProstaScint using combined SPECT/CT imaging was comparable to PET/CT imaging based on F18-FDG and C11-Choline. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto</Font></H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto competes in a large, growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2013 of $2.4 billion. Revenues are expected to increase to $5 billion by 2017. If the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve sales of $250 million. Even at the current market size of approximately $2 billion, a product with 5% market penetration could achieve sales of approximately $100 million annually, assuming comparatively similar product pricing and reimbursement levels as seen with other TRTs.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are any number of antibiotics available on the market that could compete with Primsol. However, Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating UTIs. Further, Primsol is the only trimethoprim oral solution on the U.S. market that does not contain sulfamethoxazole, or sulfa. Therefore, Primsol is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfa. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS/RedoxSYS</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to MiOXSYS competitive offerings, there are other oxidative stress diagnostic tests available throughout the world, although none are approved in the United States for clinical use. Diagnostic systems that are marketed for clinical use outside the United States include the FRAS 4 system (H&amp;D srl), FREE </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">104</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Carpe Diem (Diacron International), and the FORM and FORMPlus systems (Callegari srl). These systems are used in both research and clinical settings but do not generate significant sales in the clinical setting. If approved in the United States for clinical use, these systems could present competition to the MiOXSYS System. However, their testing parameters differ significantly from MiOXSYS and would need to demonstrate clinical superiority to MiOXSYS in order to substantially detract from MiOXSYS prescribing and sales. Additionally, to our knowledge these systems have not demonstrated clinical feasibility in human semen or
seminal plasma. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Zertane</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">PE has traditionally been treated by behavioral or psychosexual therapy, antidepressant drugs, such as SSRIs, or topical desensitizing agents, all of which have significant drawbacks. Behavioral and psychosexual therapy as a treatment for PE requires an understanding partner and can be frustrating, embarrassing, time consuming and expensive, among other things. Antidepressant drugs are sometimes prescribed &#147;off-label&#148; and have numerous shortcomings, including side effects such as nausea, headaches, drop of libido, ED, need for chronic dosing, ramp up periods, variable responses and unwanted drug-drug interactions.
Topical agents, including lidocaine-based products affect spontaneity, can numb a partner and be messy. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dapoxetine (brand name Priligy), owned by Allergan, is currently the only approved oral prescription drug to treat PE, with approval in several European countries. Priligy is not approved in the United States. In addition, we are aware of a topical product in late-stage development for PE by Plethora Solutions referred to as PSD502 and studies of Botox for the treatment of PE are being conducted in the United States. These products&nbsp;&#151;&nbsp;if approved in the United States&nbsp;&#151;&nbsp;would represent competition and alternative choices for physicians and potential patients. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, generic tramadol hydrochloride is available in the United States and abroad for treatment of pain. Although the generic drug is not available in the same dosage as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of PE instead of Zertane, if Zertane is approved for commercialization. Patients could use generic tramadol hydrochloride dosages that are either higher or lower than what will be approved for Zertane or they could attempt to split dosages to arrive at the dosages approved for Zertane. While any such
&#147;off label&#148; use of generic tramadol hydrochloride for treatment of PE may constitute infringement of our patent portfolio, liability in that circumstance would be at the level of the physician or the patient making enforcement difficult or impractical. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our strategy is to minimize our research and development activities. When we do conduct research and development, we intend to utilize consultants with domain experience for research, development and regulatory guidance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our MiOXSYS System has been developed in conjunction with numerous medical device and diagnostic development consultants. Further, we have relationships with regulatory consultants who are actively assisting in the development of our regulatory strategy with the FDA. To complement our internal clinical research efforts with the MiOXSYS System, we have engaged with numerous universities around the world to identify and develop research and clinical applications for the MiOXSYS System. Through these engagements we have access to data and analyses that enable us to develop new uses for the MiOXSYS and RedoxSYS systems.
Additionally, we have formal research agreements in place with two prominent U.S.-based universities and one prominent European university for which we are paying a research fee. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our business strategy is to use cGMP compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial supplies if required by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners when possible. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have acquired a two-year supply of ProstaScint through our asset purchase agreement with Jazz Pharmaceuticals. Further, we intend to intend to transfer the manufacturing of ProstaScint to a new contract manufacturer, and have initiated discussions with the contract manufacturer and expect to sign an agreement </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">105</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">whereby we will transfer the production to a similar facility operated by the new contract manufacturer. Accordingly, we also expect to put a supply agreement in place for an extended duration. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 8, 2015, we and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us. The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of our products. The agreement provides customary terms and conditions, including those for performance of
services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, we may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto</Font></H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into a license and supply agreement with Acerus pursuant to which we will pay Acerus a supply price per unit of the greater of (i) a fixed percentage of Acerus&#146; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) a low double digit percentage of the net selling price for the first year of the agreement, that increases in each of the second and third years and remains constant after that. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into a supply agreement for Primsol with the same manufacturer used by FSC Laboratories, from whom we purchased Primsol. Pursuant to the agreement, we can order supply as needed at a fixed price for the first two years of the agreement; thereafter we will negotiate the price but do not expect the supply price to increase by more than 25%. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS/RedoxSYS</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have completed the technical development of the RedoxSYS System by engaging contract development and manufacturing companies in the United States. We secured supply and quality agreements with manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS and MiOXSYS sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical device manufacturers. Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers have been audited by our quality engineers and are fully compliant. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Zertane</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are party to a 10-year supply agreement with an established manufacturer of tramadol hydrochloride for Zertane. Importantly, product supply has been produced for our planned clinical trials for Zertane. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Employees</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 31, 2016, we had 17 full-time employees and utilized the services of a number of consultants on a temporary basis. Overall, we have not experienced any work stoppage and do not anticipate any work stoppage in the foreseeable future. None of our employees is subject to a collective bargaining agreement. Management believes that relations with our employees are good. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Properties</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On August 19, 2015, Aytu entered into a 37 month non-cancellable operating lease for new office space effective September 1, 2015. The new lease has initial base rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">106</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">rent abatements. We have also opened a 1,333 square foot office in Raleigh, North Carolina for which the lease runs until July 31, 2018. We believe our current office space is sufficient to meet our current needs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognize rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Legal Proceedings</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are currently not party to any material legal or administrative proceedings and are not aware of any material pending or threatened legal or administrative proceedings in which we will become involved.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">107</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t12MAN"></a>MANAGEMENT</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth the names and ages of all of our directors and executive officers. Our Board of Directors is currently comprised of four members, who are elected annually to serve for one year or until their successor is duly elected and qualified, or until their earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors and are appointed by the Board of Directors. Each of the directors and executive officers listed below joined us upon the closing of the Merger on April 16, 2015, except for Jonathan McGrael who joined us in late September 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="200"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="32"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="344"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Age</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Position</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Joshua R. Disbrow</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">40</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Executive Officer and Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Jarrett T. Disbrow</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">40</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Operating Officer and Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Gregory A. Gould</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">50</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Financial Officer, Secretary, and Treasurer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Jonathan H. McGrael</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">45</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Vice President of Sales</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Michael Macaluso</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">64</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Carl C. Dockery</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">53</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a biographical summary of the experience of our executive officers and directors during the past five years, and an indication of directorships held by the director in other companies subject to the reporting requirements under the federal securities law. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Michael Macaluso&nbsp;&#150;&nbsp;Director</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Michael Macaluso has been a member of our Board of Directors since April 16, 2015. Mr. Macaluso is also the Chairman and Chief Executive Officer of Ampio. Mr. Macaluso has been a member of Ampio Pharmaceuticals&#146; Board of Directors since March 2010 and Ampio&#146;s Chief Executive Officer since January 2012. Mr. Macaluso served in the roles of president and Chief Executive Officer of Isolagen, Inc. (AMEX: ILE) from June 2001 until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005. From October 1998 until June 2001, Mr. Macaluso was the owner of Page International
Communications, a manufacturing business. Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from 1989 until 1997, when he sold that business to a private equity firm. Mr. Macaluso&#146;s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Carl C. Dockery&nbsp;&#150;&nbsp;Director</I></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Carl Dockery joined our Board in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery&#146;s career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr.
Dockery worked at Lloyd&#146;s and the London Underwriting Centre brokering various types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn Inc. (OTCQB: &#147;CYDY&#148;), a biotechnology company. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities. Mr. Dockery&#146;s financial expertise and experience, as well as his experience as a director of a publicly traded biopharmaceutical company, led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Joshua R. Disbrow&nbsp;&#150;&nbsp;Chief Executive Officer and Director</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Joshua R. Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow was also the Chief Operating Officer of Ampio since December 2012. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company&#146;s second full-time employee. Mr. Disbrow led the company&#146;s commercial efforts from inception to the company&#146;s acquisition in 2010 and growth to over </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">108</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">$127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on
neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University. Mr. Disbrow&#146;s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a director of our Company in light of our business and structure. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Jarrett T. Disbrow&nbsp;&#150;&nbsp;Chief Operating Officer and Director</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jarrett Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix from November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals&#146; acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding
Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcom, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow&#146;s experience in executive management and operations within the pharmaceutical industry led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Gregory A. Gould&nbsp;&#150;&nbsp;Chief Financial Officer, Secretary, and Treasurer</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Gregory A. Gould has been our Chief Financial Officer since April 16, 2015. Mr. Gould is also the Chief Financial Officer of Ampio where he has been employed since June 2014. Prior to joining Ampio, he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC from April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until April 2012 Mr. Gould also served as the Interim President and Chief Executive
Officer of SeraCare Life Sciences. Mr. Gould has held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould&#146;s tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855 million. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard&reg; products. Mr. Gould was the Chief Financial Officer at Colorado MedTech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company to KRG Capital Partners. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company pursuing
anti-viral agents for the treatment of HIV. Mr. Gould graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Jonathan H. McGrael&nbsp;&#150;&nbsp;Vice President of Sales</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jonathan McGrael joined us on September 30, 2015. Mr. McGrael has spent 17 years in the pharmaceutical industry and has held positions of increasing responsibility in sales, sales training, marketing, sales management, and leadership development. Until September 15, 2015, he was Director of Sales at Arbor Pharmaceuticals, which he joined in 2010 as that company&#146;s 14<sup>th</sup> employee. Under his leadership the sales organization grew from 10 sales representatives to over 400 and achieved significant, consistent revenue growth throughout his leadership tenure. Mr. McGrael also designed comprehensive leadership
development and training programs for sales leaders, as well as a marketing structure that ensured &#147;plug-and-play&#148; </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">109</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">incorporation of new products. Mr. McGrael began his career at TAP Pharmaceuticals (now Takeda) where he held positions within the sales and marketing divisions. He received an MS in Public Health from Missouri State University and a BS in Human Bio-Dynamics also from Missouri State University. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Family Relationships</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jarrett T. Disbrow, our Chief Operating Officer, is the brother of Joshua R. Disbrow, our Chief Executive Officer. There are no other family relationships among or between any of our current or former executive officers and directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Involvement in Certain Legal Proceedings</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of our directors or executive officers has been involved in any legal proceeding in the past 10 years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the Securities Act. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Executive Compensation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with Item 402 of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation for our company&#146;s directors, former directors and named executive officers, in certain cases for each of the last three completed fiscal years. On April 16, 2015, we acquired Luoxis and Vyrix in the Merger. Because our sole director was a director on the boards of directors of Luoxis and Vyrix, and our named executive officers were, prior to the April 16, 2015, employed by Luoxis and Vyrix, we are providing past compensation information concerning such director and
executive officers with respect to Luoxis and Vyrix. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Compensation of Directors</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In establishing director compensation, our Board is guided by the following goals:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the directors for work required for a company of our size and scope;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should align the directors&#146; interests with the long-term interests of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should assist with attracting and retaining qualified directors. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jarrett T. Disbrow, who served as a member of Vyrix&#146;s board of directors during 2014, did not receive any compensation, equity awards or non-equity awards for his service as a director, although Mr. Disbrow did receive compensation in 2014 from and with respect to his employment with Vyrix. James B. Wiegand, who served as the sole director of Rosewind in 2014, did not receive any compensation, equity awards or non-equity awards for his service as a director. Mr. Wiegand was appointed President, Chief Executive Officer and Secretary and a director of Rosewind on August 9, 2002. He resigned from all of his positions with us
on April 16, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not yet established a compensation package for our director, Michael Macaluso, our non-employee and sole director, and future non-employee directors other than reimbursement of expenses incurred in connection with their service as director. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table provides information regarding all compensation paid to non-employee directors of Vyrix and Luoxis during the fiscal year ended June 30, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="253"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fees Earned<BR> or Paid in<BR> Cash</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Stock<BR> Option<BR> Awards<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other Compensation<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael Macaluso<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gary V. Cantrell<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>John A. Donofrio Jr<sup>&#040;4&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Nicholas J. Leb<sup>&#040;5&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">This column reflects the aggregate grant date fair value computed in accordance with Financial Accounting Standards Board, or &#147;FASB&#148;, issued Accounting Standards Update, or &#147;ASC&#148;, Topic 718. Pre-Merger awards made to Mr. Macaluso in August 2014 were cancelled in April 2015 and the expenses were reversed. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">110</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Michael Macaluso was appointed a director of Luoxis in January 2013 and a director of Vyrix in November 2013. In connection with the Merger, he resigned from the boards of Luoxis and Vyrix and was appointed a director of Aytu upon the closing of the Merger on April 16, 2015. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Gary V. Cantrell was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the appropriate corporate governance structure. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">John A. Donofrio Jr. was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the appropriate corporate governance structure. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Nicholas J. Leb was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April 16, 2015 as we continue to assess the appropriate corporate governance structure. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Executive Officer Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From fiscal year 2012 to the completion of the Merger on April 16, 2015, no compensation was earned by or paid to James B. Wiegand, the former President, Chief Financial Officer and Secretary of Rosewind. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth all cash compensation earned, as well as certain other compensation paid or accrued for the years ended June 30, 2015 and 2014 to each of the following named executive officers. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Summary Compensation of Named Executive Officers</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="112"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="29"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Name and Principal Position</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Year</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Salary<BR> ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Bonus<BR> ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Stock<BR> Award<BR> ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Option<BR> Award<BR> ($)<sup>&#040;1&#041;</sup></FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Non-Equity<BR> Incentive<BR> Plan <BR>Compensation ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Change in<BR> Pension<BR> Value and<BR> Nonqualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">All Other<BR> Compensation<BR> ($)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Total<BR> ($)</FONT></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1><B>Joshua R. Disbrow<sup>&#040;2&#041;</sup></B><BR> <I>Chief Executive Officer<BR> since December 2012</I></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>246,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>202,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,045</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;3&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>653,545</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>227,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>472,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=35>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1><B>Jarrett T. Disbrow<sup>&#040;4&#041;</sup></B><BR><I>Chief Operating Officer,<BR> Secretary and Treasurer</I></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>218,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>223,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>223,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>368,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=35>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1><B>Gregory A. Gould<sup>&#040;5&#041;</sup></B><BR> <I>Chief Executive Officer,<BR> since June 2014</I></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=35>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1><B>Vaughan Cliff, M.D.<sup>&#040;6&#041;</sup></B><BR> <I>Former Chief Medical<BR> Officer</I></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=35>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Option awards are reported at fair value at the date of grant. See Item 15 of Part IV, &#147;Notes to the Financial Statements&nbsp;&#151;&nbsp;Note 7&nbsp;&#151;&nbsp;Equity Instruments.&#148; Pre-Merger option awards made in August 2014 to Josh Disbrow and Greg Gould were cancelled in April 2015 and the expenses were reversed. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Joshua R. Disbrow received a salary increase to $250,000 effective April 16, 2015 when he was appointed Chief Executive Officer of Aytu. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">This was a cash payout of in-the-money options issued to Mr. Disbrow by Luoxis, which options were cashed out in the Merger. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Jarrett T. Disbrow received a salary increase to $250,000 effective April 16, 2015 when he was appointed Chief Operating Officer of Aytu. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Mr. Gould was appointed to Chief Financial Officer, Secretary and Treasurer effective April 16, 2015. His compensation expense is part of the shared service agreement with Ampio. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Dr. Clift resigned from his position as Chief Medical Officer of Vyrix on March 31, 2015, prior to the Merger. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. Executives are reimbursed for business expenses directly related to Aytu </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">111</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">business activities, such as travel, primarily for business development as we grow and expand our product lines. On average, each executive incurs between $1,000 and $2,000 of out-of-pocket business expenses each month. The executive management team meets weekly and determines which activities they will work on based upon what we determine will be the most beneficial to our company and our shareholders. No interest is paid on amounts reimbursed to the executives. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Outstanding Equity Awards</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2015, there were no outstanding equity awards. See &#147;Description of Capital Stock&nbsp;&#151;&nbsp;Options&#148; for a discussion of options granted since June 30, 2015. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Grants of Plan-Based Awards</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information regarding grants of plan-based awards to the Named Executive Officers as of June 30, 2015: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="232"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant Date</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other<BR> Option Awards:<BR> Number of<BR> Securities<BR> Underlying<BR> Options<BR> (#)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Exercise Price of<BR> Option Awards<BR> ($/Share)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant Date<BR> Fair Value of<BR> Option Awards<BR> ($)<sup>&#040;1&#041;</sup></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-style: italic" ROWSPAN=1 COLSPAN=1>Named Exective Officers<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joshua R Disbrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8/11/2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.60</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gregory A. Gould</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8/11/2014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.60</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left"><sup></sup>The amounts reported in this column represent the aggregate grant date fair value computed in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and may not correspond to the actual value that will be realized by the named executive officer. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left"><sup></sup>These Luoxis options were cancelled in connection with the Merger. Because the consideration paid to these holders of common stock of Luoxis was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation and keeping with applicable accounting standards, the unvested portion of the option expense was reversed. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Employment Agreements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We entered into an employment agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries of the grant date.
Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his employment with us. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries of the
grant date. Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2015, we entered into an employment agreement with Jonathan McGrael, our Vice President of Sales, in connection with his employment with us. The agreement is at will, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. McGrael is entitled to receive $175,000 in annual salary, plus a discretionary performance bonus with a target of 43% of his base salary and 200,000 stock options. Mr. McGrael will also receive up to $20,000 for </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">112</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">relocation reimbursement. Mr. McGrael is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Payments Provided Upon Termination for Good Reason or Without Cause</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the employment agreements, in the event Mr. Joshua Disbrow&#146;s or Mr. Jarrett Disbrow&#146;s employment is terminated without Cause by us or either officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base salary in effect at the date of termination, as well as continued participation in the health and welfare plans for up to two years. All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long as a Change in Control is not in effect,
then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to &nbsp;1/24<sup>th</sup> the number of option shares multiplied by the number of full months of such officer&#146;s employment shall be deemed vested and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by such officer. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Good Reason&#148; with respect to the agreements with Mr. Joshua Disbrow and Mr. Jarrett Disbrow, means, without the officer&#146;s written consent, there is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in the officer&#146;s responsibilities or authority);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below certain specified amounts); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material change in the principal geographic location at which the officer must perform his services. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Good Reason&#148; with respect to the agreement with Mr. McGrael, means, without the officer&#146;s written consent, there is: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below certain specified amounts); or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the Company&#146;s material breach of the employment agreement. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Cause&#148; with respect to the agreements with Mr. Joshua Disbrow and Mr. Jarrett Disbrow, means:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic violation which is a misdemeanor;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful malfeasance or willful misconduct by the officer in connection with his employment;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">gross negligence in performing any of his duties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful and deliberate violation of any of our policies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unintended but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction of the board;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful and deliberate breach of his obligations under the employment agreement; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">113</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Cause&#148; with respect to the agreement with Mr. McGrael means: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, a felony or misdemeanor involving moral turpitude; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful malfeasance or willful misconduct by the officer in connection with his employment; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">gross negligence in performing any of his duties; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material failure to comply with our workplace rules, policies or procedures which is not cured within fifteen days of written notice;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material breach of our Proprietary Information and Inventions Agreement; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material breach of the employment agreement which is not cured within fifteen days of written notice; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful failure or refusal to perform his material duties under the employment agreement or failure to follow any specific lawful instructions of the Chief Executive Officer or his designee which is not cured within fifteen days of written notice. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The severance benefits described above are contingent on each officer executing a general release of claims. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Payments Provided Upon a Change in Control</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the employment agreements, in the event of a Change in Control of us, all stock options, restricted stock and other stock-based grants granted or may be granted in the future by us to the officers will immediately vest and become exercisable. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Change in Control&#148; means: the occurrence of any of the following events:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (the &#147;Acquiring Person&#148;), other than us, or any of our Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding voting securities of us entitled to vote generally in the election of directors (excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acquisition of us by another entity by means of any transaction or series of related transactions to which we are party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes) other than a transaction or series of related transactions in which the holders of the voting securities of us outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of shares in us held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such other surviving or resulting entity is a
wholly-owned subsidiary immediately following such acquisition, its parent); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Payments Provided Upon Termination for Cause or Without Good Reason, Death or Disability</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the employment agreements, in the event we end the officer&#146;s employment for Cause, if such officer resigns as an employee for reasons other than an event of Good Reason, such officer dies or disability occurs, then we shall pay to the officer the accrued compensation but shall have no obligation to pay the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">114</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">officer any amount, whether for salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the employment, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be forfeited immediately upon the end of the employment. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date we end the employment for Cause, or the date of the officer&#146;s death or disability, remain outstanding and exercisable to
the extent provided in the applicable award agreement or plan, by the officer or his personal representative or executor. The table below is as of June 30, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Receipient and Benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Cause;<BR> Without Good<BR> Reason</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Without<BR> Cause: Good<BR> Reason</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Death;<BR> Disability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Change in<BR> Control</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Joshua Disbrow<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Salary</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Value of health benefits provided after termination<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>56,510</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>556,510</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Jarrett Disbrow<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Salary</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Value of health benefits provided after termination<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>56,510</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>556,510</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">The value of such benefits is determined based on the estimated cost of providing health benefits to the Named Executive Officer for a period of two years. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">115</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t13TRA"></a>TRANSACTIONS WITH RELATED PERSONS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Related Party Transactions</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We describe below all transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal years, to which we were a party or will be a party, in which:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the amounts involved exceeded or will exceed $120,000; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Merger</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, pursuant to the Merger Agreement entered into among Rosewind, Luoxis, Vyrix and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the first stage, each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive shares of our common stock. The Vyrix stock and the Luoxis stock were each converted at an exchange factor. The exchange factor for each of them was determined upon the basis of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Vyrix were converted into
shares of Vyrix as the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation. After completion of the first stage, Vyrix and Luoxis became subsidiaries of Rosewind. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the second stage, which occurred on the same day as the first stage, each of Vyrix and Luoxis merged with Rosewind with Rosewind surviving. The first and second stage mergers are referred to collectively as the &#147;Merger.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Concurrently with the Merger:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from the board immediately thereafter. The board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer, Jarrett Disbrow as Chief Operating Officer and Gregory A. Gould as our Chief Financial Officer, Secretary and Treasurer.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Ampio purchased 4,761,787 shares of our common stock for (i) issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger; (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">James Wiegand entered into a consulting agreement with us with a one year duration, providing for compensation of $50,000 to him.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Each of James Wiegand and Michael Wiegand executed a release in our favor.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Each of Ampio, James Wiegand, Michael Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated with Jarrett Disbrow entered into a lock-up agreement with us agreeing not to sell its shares of our company for two years (except for the one with Ampio, more than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on or prior to June 30, 2015. All of the lock-up agreements were terminated in December 2015.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Joshua Disbrow entered into an employment agreement with us.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Jarrett Disbrow entered into an employment agreement with us.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">116</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The sailing boat owned by Rosewind was transferred to James Wiegand upon the closing of the Merger in exchange for cancellation of indebtedness owing to James Wiegand in the amount of approximately $30,000 (being the approximate value of the sailing boat). We paid James Wiegand $20,000 in May 2015 for accrued interest on this indebtedness and other expense that he had incurred prior to the Merger being completed. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Rosewind</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2014, Rosewind has a secured promissory note to the sole officer and director for $31,000 for working capital. The loan carries a 6% interest rate, matures on demand and is secured by the sailing vessel. Accrued interest payable on the loan totaled $18,000 as of August 31, 2014. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the year ended August 31, 2014, the sole officer of Rosewind contributed services valued at $4,000. This amount has been booked to additional paid in capital. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Luoxis and Vyrix</Font> </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio Loan Agreements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of
converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. On April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, Ampio received 4,761,787 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">117</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Services Agreements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2013, Luoxis entered into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in exchange for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio provides corporate overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. Both agreements
were assigned to us upon the closing of the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, the prior service agreements were canceled and Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis&#146; RedoxSYS System. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire
March 2019 and cannot be terminated prior to March 2017. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Review, Approval or Ratification of Transactions with Related Persons</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Due to the small size of our Company, we do not at this time have a formal written policy regarding the review of related party transactions, and rely on our Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviews any such transaction in light of the particular affiliation and interest of any involved director, officer or other employee or stockholder and, if applicable, any such person&#146;s affiliates or immediate family members. Management aims to present transactions to our Board of Directors for approval before they are entered into
or, if that is not possible, for ratification after the transaction has occurred. If our Board of Directors finds that a conflict of interest exists, then it will determine the appropriate action or remedial action, if any. Our Board of Directors approves or ratifies a transaction if it determines that the transaction is consistent with our best interests and the best interest of our stockholders. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Director Independence</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is not listed on any exchange. Consequently no exchange rules regarding director independence are applicable to us. Audit Committee members must satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory
fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Only one of our four directors, Carl Dockery, is independent under the definition of either the NYSE or Nasdaq. The other three directors are not independent under either definition due to (i) being an executive officer of our Company, in the case of Josh Disbrow and Jarrett Disbrow, and (ii) the payments we make to Ampio under the services agreement with Aytu, in the case of Mr. Macaluso. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">118</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t14SEC"></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth information with respect to the beneficial ownership of our common stock as of April 15, 2016 for:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each beneficial owner of more than 5% of our outstanding common stock;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each of our director and named executive officers; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">all of our directors and executive officers as a group. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60 days of April 15, 2016. The percentage ownership information shown in the table is based upon 22,446,481 shares of common stock outstanding as of April 15, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of April 15, 2016. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained by us from public filings made by the
stockholders. Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Shares Beneficially Owned</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>5% Stockholders:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio Pharmaceuticals, Inc.<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,226,406</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Directors and Named Executive Officers:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joshua R. Disbrow<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>153,846</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jarrett T. Disbrow<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>153,846</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gregory A. Gould<sup>&#040;4&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jonathan H. McGrael</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael Macaluso<sup>&#040;5&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>582,350</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.6</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Carl C. Dockery<sup>&#040;6&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>147,591</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>All directors and executive officers as a group (six persons)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,287,633</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">Represents beneficial ownership of less than 1%. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">The address of Ampio Pharmaceuticals, Inc. is 373 Inverness Parkway, Suite 206, Englewood, CO 80112. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left"><sup></sup>Does not include 558,567 shares are held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&#146;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">119</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Does not include 558,567 shares are held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&#146;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Includes options to purchase 225,000 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 100,000 shares of common stock held by Mr. Dockery and 47,591 shares of common stock beneficially held by Alpha Venture Capital Partners, LP. As the manager of the General Partner of Alpha Venture Capital Partners, LP, Mr. Dockery has voting and dispositive power over these shares. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">120</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t15DES"></a>DESCRIPTION OF CAPITAL STOCK</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">General</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are authorized to issue up to 300,000,000 shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred stock, $0.0001 par value per share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of February 12, 2016, a total of 22,446,481 shares of our common stock were issued and outstanding and no shares of our preferred stock were issued and outstanding. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to hold our annual meeting of shareholders on May 24, 2016, at which meeting we intend to ask our shareholders to approve (1) an amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock from 300,000,000 to 100,000,000 and to reduce the number of authorized shares of preferred stock from 50,000,000 to 10,000,000, and (2) an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number between 1-for-4 and 1-for-12, as determined by our Board of Directors, at any time before November 24, 2016, if and as determined by our Board
of Directors. Our Board&#146;s primary reason for approving the amendment to our Certificate of Incorporation to reduce our authorized capital stock is to reduce the amount of our annual franchise tax in the State of Delaware, while still maintaining a sufficient number of authorized shares to permit us to act promptly with respect to future financings, acquisitions, additional issuances, and for other corporate purposes. The Board believes that the Reverse Stock Split will enhance our ability to obtain an initial listing on a national securities exchange. The NYSE MKT and The NASDAQ Capital Market each requires, among other items, an initial bid price of least $4.00 per share and, following initial listing, maintenance of a continued price of at least $1.00 per share in the case of The NASDAQ Capital Market and an undesignated &#147;low selling price&#148; in the case of the NYSE MKT. Reducing the number of outstanding shares of our common stock should, absent other factors, increase
the per share market price of our common stock, although we cannot provide any assurance that the minimum bid price would be achieved following any reverse stock split or that any listing on an exchange would be obtained. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Common Stock</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The holders of common stock are entitled to one vote per share. Our Certificate of Incorporation does not expressly prohibit cumulative voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued in the future. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Preferred Stock</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation provides our Board of Directors with the authority to divide the preferred stock into series and to fix and determine the rights and preferences of the shares of any series of preferred stock established to the full extent permitted by the laws of the State of Delaware and the Certificate of Incorporation. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Convertible Notes</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of February 12, 2016, we had outstanding convertible notes that we issued in July and August 2015, in the aggregate principal amount of approximately $1,050,000. The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of our common stock equal in an amount equal to 120%&nbsp;&#150;&nbsp;130% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of our next public offering of our stock resulting in proceeds to us of at least $5,000,000 in gross proceeds
(excluding indebtedness converted in such financing) prior to the maturity date of the notes, referred to as a Qualified Financing. The principal and accrued interest under the notes will automatically convert into a number of shares of such equity securities of our company sold in such financing equal to 120% in the case of $25,000 </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">121</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and 130% in the case of $1,025,000 of the principal and related accrued interest under such note divided by the lesser of (i) the lowest price paid by an investor in such financing or (ii) $4.63. In the event that we sell equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of our capital stock in an amount equal to 120% of the number of such shares calculated by dividing the
outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. If these notes are converted, the shares of common stock issuable upon conversion could be sold. The perception of such issuance and sale could negatively impact the price of our common stock. Upon the closing of this offering, an aggregate of $1,050,000 in principal and $78,000 in accrued interest on the 2015 convertible notes outstanding will automatically convert into an aggregate of 3,659,978 shares of our common stock, at the combined public offering price of $0.40 per share and related warrant. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants Outstanding Prior to this Offering</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of February 12, 2016, we had outstanding warrants to purchase an aggregate of 369,665 shares of our common stock. Of these warrants, 102,613 were originally issued by Luoxis in 2013 and, in connection with the Merger, were converted into warrants to purchase shares of our common stock at a purchase price of $4.53 per share. These warrants expire on May 30, 2018. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The remaining 267,052 warrants to purchase shares of our common stock were issued to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $0.65, and provide for cashless exercise. We are also obligated to issue warrants to the placement agents for an amount of shares to be equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the remaining $1.05 million of convertible notes
and all accrued interest thereon. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants Issued in this Offering</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>The following summary of certain terms and provisions of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of the warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part of. Prospective investors should carefully review the terms and provisions set forth in the form of warrant.</I></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Exercisability</I>.&nbsp;&nbsp;The warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). Unless otherwise specified in the warrant, the holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates)
would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Cashless Exercise</I>.&nbsp;&nbsp;In the event that a registration statement covering shares of common stock underlying the warrants, or an exemption from registration, is not available for the resale of such shares of common stock underlying the warrants, the holder may, in its sole discretion, exercise the warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, elect instead to receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant. In
no event shall we be required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of common stock underlying the warrants.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Exercise Price</I>.&nbsp;&nbsp;The initial exercise price per share of common stock purchasable upon exercise of the warrants is 125% of the public offering price of our common stock in this offering. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">122</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Certain Adjustments</I>.&nbsp;&nbsp;The exercise price and the number of shares of common stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our common stock.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Transferability</I>.&nbsp;&nbsp;Subject to applicable laws, the warrants may be transferred at the option of the holders upon surrender of the warrants to us together with the appropriate instruments of transfer.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Warrant Agent and Exchange Listing</I>.&nbsp;&nbsp;The warrants will be issued in registered form under a warrant agency agreement between VSTock Transfer, LLC, as warrant agent, and us.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Fundamental Transaction</I>.&nbsp;&nbsp;If, at any time while the warrants are outstanding, (1) we consolidate or merge with or into another corporation and we are not the surviving corporation, (2) we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets, (3) any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed pursuant to which holders of our shares of common stock are permitted to sell, tender or exchange their shares of common stock for other securities, cash or property and has been accepted by the holders
of 50% or more of our outstanding shares of common stock, (4) we effect any reclassification or recapitalization of our shares of common stock or any compulsory share exchange pursuant to which our shares of common stock are converted into or exchanged for other securities, cash or property, or (5) we consummate a stock or share purchase agreement or other business combination with another person or entity whereby such other person or entity acquires more than 50% of our outstanding shares of common stock, each, a &#147;Fundamental Transaction,&#148; then upon any subsequent exercise of the warrants, the holders thereof will have the right to receive the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration
payable as part of the Fundamental Transaction.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Rights as a Stockholder</I>.&nbsp;&nbsp;Except as otherwise provided in the warrants or by virtue of such holder&#146;s ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Options</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the closing of the Merger, each of Vyrix and Luoxis had an option plan and had made equity grants thereunder. On April 16, 2015, upon the closing of the Merger, an aggregate of $27,476 was paid to holders of in-the-money options and all equity compensation plans of Vyrix and Luoxis were terminated and all the awards granted thereunder were cancelled. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 1, 2015, our stockholders approved the 2015 Stock Option and Incentive Plan, which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of February 12, 2016, we had outstanding options to purchase an aggregate of 3,717,500 shares of our common stock at a weighted average exercise price of $1.55 per share. Of these, an aggregate of 1,477,500 are exercisable. The remainder has vesting requirements with an aggregate of 1,550,000 vesting one third on each of November 11, 2016, 2017 and 2018, an aggregate of 640,000 vesting one quarter on each of November 11, 2016, 2017, 2018 and 2019 and an aggregate of 50,000 vesting one quarter on each of August 7, 2016, 2017, 2018 and 2019. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2015 Plan is administered by our Board or a committee designated by the Board (as applicable, the Administrator). The Administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2015 Plan. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options and other awards to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange
Act and not subject to Section 162(m) of the Code, subject to certain limitations and guidelines. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">123</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Persons eligible to participate in the 2015 Plan are full or part-time officers, employees, non-employee directors, directors and other key persons (including consultants and prospective officers) of our company and its subsidiaries as selected from time to time by the Administrator in its discretion. Approximately 30 individuals are currently eligible to participate in the 2015 Plan, which includes officers, employees who are not officers, non-employee director, former employees and other individuals who are primarily consultants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2015 Plan provides that upon the effectiveness of a &#147;sale event&#148; as defined in the 2015 Plan, except as otherwise provided by the Administrator in the award agreement, all stock options, stock appreciation rights and other awards will be assumed or continued by the successor entity and adjusted accordingly to take into account the impact of the transaction. To the extent, however, that the parties to such sale event do not agree that all stock options, stock appreciation rights or any other awards shall be assumed or continued, then such stock options and stock appreciation rights shall become fully exercisable
and the restrictions and conditions on all such other awards with time-based conditions will automatically be deemed waived. Awards with conditions and restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with a sale event in the Administrator&#146;s discretion. In addition, in the case of a sale event in which our stockholders will receive cash consideration, we may make or provide for a cash payment to participants holding options and stock appreciation rights equal to the difference between the per share cash consideration and the exercise price of the options or stock appreciation rights in exchange for the cancellation thereto. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Quotation on the OTCQX Market</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is quoted on the OTCQX Market under the symbol &#147;AYTU&#148;. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Transfer Agent</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The transfer agent of our common stock is Vstock Transfer. Their address is 18 Lafayette Place, Woodmere, NY 11598. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Delaware Anti-Takeover Law and Provisions of Our Certificate of Incorporation and Bylaws</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Delaware Anti-Takeover Law.</I>&nbsp;&nbsp;We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding specified shares; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&nbsp;2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Section 203 defines a &#147;business combination&#148; to include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any merger or consolidation involving the corporation and the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">124</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, Section 203 defines an &#147;interested stockholder&#148; as any person that is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the owner of 15% or more of the outstanding voting stock of the corporation;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an affiliate or associate of the corporation who was the owner of 15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant date; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the affiliates and associates of the above. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under specific circumstances, Section 203 makes it more difficult for an &#147;interested stockholder&#148; to effect various business combinations with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation&#146;s certificate of incorporation or bylaws, elect not to be governed by this section, effective 12 months after adoption. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our certificate of incorporation and bylaws do not exclude us from the restrictions of Section 203. We anticipate that the provisions of Section 203 might encourage companies interested in acquiring us to negotiate in advance with our board of directors since the stockholder approval requirement would be avoided if a majority of the directors then in office approve either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Certificate of Incorporation and Bylaw.</I>&nbsp;&nbsp;Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change of control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limiting the removal of directors by the stockholders;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">allowing for the creation of a staggered board of directors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">125</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t16UND"></a>UNDERWRITING</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Joseph Gunnar &amp; Co., LLC is acting as representative of the underwriters (the &#147;Representative&#148;). We have entered into an underwriting agreement dated May 2, 2016 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock and warrants listed next to its name in the following table: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Warrants</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joseph Gunnar &amp; Co., LLC</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fordham Financial Management, Inc.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Axiom Capital Management, Inc.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total:</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,750,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,750,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are committed to purchase all the shares of common stock and warrants offered by us other than those covered by the option to purchase additional shares and/or warrants described below, if they purchase any shares or warrants. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&#146; obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&#146;
certificates and legal opinions. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are offering the shares and warrants, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriters to purchase a maximum of 2,812,500 additional shares (15% of the shares sold in this offering) and/or 2,812,500 additional warrants (15% of the warrants sold in this offering) from us to cover over-allotments, if any. If the underwriters exercise all or part of this option, they will purchase shares and warrants covered by the option at the public offering price that appears on the cover page of this prospectus, less the underwriting discount. If this option
is exercised in full, the total price to the public will be $8,625,000 and the total net proceeds, before expenses, to us will be $7,946,250. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Discounts</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="258"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Per Share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Per Warrant</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total Without<BR> Over-Allotment<BR> Option</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total With Full<BR> Over-Allotment<BR> Option</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,625,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discount (7%)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0273</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0007</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>525,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>603,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Non-accountable expense allowance (1%)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0039</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0001</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds, before expenses, to us</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.3588</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0092</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,900,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,946,250</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters propose to offer the shares and warrants offered by us to the public at the public offering price set forth on the cover of this prospectus. In addition, the underwriters may offer some of the shares to other securities dealers at such price less a concession of $0.016 per share. If all of the shares and warrants </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">126</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">offered by us are not sold at the public offering price, the Representative may change the offering price and other selling terms by means of a supplement to this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to pay the Representative a non-accountable expense allowance of 1% of the public offering price at the closing, excluding the over-allotment option. We have paid an expense deposit of $50,000 to the Representative, which will be applied against such non-accountable expense allowance. The advance will be returned to the Company to the extent not actually incurred in accordance with FINRA Rule 5110(f)(2)(c). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have also agreed to pay the following expenses of the Representative relating to the offering: (a) all fees, expenses and disbursements relating to background checks of our officers and directors in an amount not to exceed $5,000 per individual and $15,000 in the aggregate; (b) all filing fees and communication expenses associated with the review of this offering by FINRA; (c) all fees, expenses and disbursements relating to the registration, qualification or exemption of securities offered under the securities laws of such states and foreign jurisdictions designated by the Representative; (d) the fees and expenses of the
Representative&#146;s legal counsel, not to exceed $75,000; (e) $29,500 for the underwriters&#146; use of Ipreo&#146;s book-building, prospectus tracking and compliance software for this offering; and (f) $20,000 of the Representative&#146;s actual accountable road show expenses for the offering. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount, will be approximately $200,000. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Discretionary Accounts</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Lock-Up Agreements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to &#147;lock-up&#148; agreements, we and our executive officers and directors and certain stockholders, have agreed, subject to limited exceptions, without the prior written consent of the Representative not to directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic
benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of the Company or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the date of this prospectus, in the case of our directors and officers, and 60&nbsp;&#150;&nbsp;90 days from the date of this prospectus, in the case of us and certain stockholders. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Underwriters&#146; Warrants</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to issue to certain of the Underwriters warrants to purchase up to a total of 1,312,500 shares of common stock (7% of the shares of common stock sold in this offering, excluding the over-allotment option). The warrants will be exercisable at any time, and from time to time, in whole or in part, during the four-year period commencing one year from the effective date of the offering, which period shall not extend further than five years from the effective date of the offering in compliance with FINRA Rule 5110(f)(2)(G). The warrants are exercisable at a per share price of $0.50, which is equal to 125% of the public
offering price per share in the offering. The warrants have been deemed compensation by FINRA and are therefore subject to a 180 day lock-up pursuant to Rule 5110(g)(2) of FINRA. The underwriters (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the date of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">127</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Right of First Refusal</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Until 12 months after the closing date of the offering, certain of the Underwriters will have a right of first refusal to each act as an investment broker, book-runner and/or placement agents for any future public or private equity and debt offering that we conduct during such 12-month period. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Electronic Offer, Sale and Distribution of Shares</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members. The Representative may agree to allocate a number of shares and warrants to underwriters and selling group members for sale to its online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the
registration statement of which this prospectus forms a part, has not been approved or endorsed by us, and should not be relied upon by investors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stabilization</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Over-allotment transactions involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing shares in the open market.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Syndicate covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Penalty bids permit the Representative to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our shares of common stock or preventing or retarding a decline in the market price of our shares of common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected in the over-the-counter
market or otherwise and, if commenced, may be discontinued at any time. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">128</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Passive market making</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the OTCQX in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, then that bid must then be lowered when specified purchase limits are
exceeded. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Other Relationships</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain of the underwriters and their affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which they may in the future receive customary fees. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Offer restrictions outside the United States</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons
into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Australia</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made
available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">China</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&#146;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to &#147;qualified domestic institutional investors.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">European Economic Area&nbsp;&#151;&nbsp;Belgium, Germany, Luxembourg and Netherlands</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&#147;Prospectus Directive&#148;), as implemented in Member States of the European Economic Area (each, a &#147;Relevant Member State&#148;), from the requirement to produce a prospectus for offers of securities. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">129</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(a)</TD>

          <TD STYLE="text-align: left">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(b)</TD>

          <TD STYLE="text-align: left">to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than &#8364;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than &#8364;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(c)</TD>

          <TD STYLE="text-align: left">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(d)</TD>

          <TD STYLE="text-align: left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">France</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&eacute;taire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers (&#147;AMF&#148;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d&#146;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial
Code and any implementing regulation. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ireland</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &#147;Prospectus Regulations&#148;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of
the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Israel</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">130</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Italy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&nbsp;&#151;&nbsp;$$&nbsp;&#151;&nbsp;Aga e la Borsa, &#147;CONSOB&#148; pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&#147;Decree No. 58&#148;), other than:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">to Italian qualified investors, as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 (&#147;Regulation no. 1197l&#148;) as amended (&#147;Qualified Investors&#148;); and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Japan</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#147;FIEL&#148;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional
Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Portugal</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissao do Mercado de Valores Mobili&aacute;rios) for approval
in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">131</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">securities in Portugal are limited to persons who are &#147;qualified investors&#148; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sweden</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#147;qualified investors&#148; (as defined in the Financial Instruments Trading Act). Only such investors may receive
this document and they may not distribute it or the information contained in it to any other person. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Switzerland</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the
securities may be publicly distributed or otherwise made publicly available in Switzerland. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is personal to the recipient only and not for general circulation in Switzerland. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United Arab Emirates</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the
allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United Kingdom</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&#147;FSMA&#148;)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#147;qualified investors&#148; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document,
any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">132</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&#147;FPO&#148;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &#147;relevant persons&#148;). The investments to which this document relates are
available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Canada</Font></H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t17LEG"></a>LEGAL MATTERS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Wyrick Robbins Yates &amp; Ponton, LLP, Raleigh, North Carolina. Certain legal matters in connection with this offering have been passed upon for the underwriters by Sichenzia Ross Friedman Ference LLP, New York, New York. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t18EXP"></a>EXPERTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The financial statements of Aytu BioScience, Inc. at June 30, 2015 and 2014, and for each of the two years in the period ended June 30, 2015, included in this prospectus have been audited by EKS&amp;H LLLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t19WHE"></a>WHERE YOU CAN FIND MORE INFORMATION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus, which constitutes a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, you should refer to the registration statement and the exhibits filed as part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other
document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">133</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SEC filings, including the registration statement, over the Internet at the SEC&#146;s website at <I>http://www.sec.gov</I>. We also maintain a website at <I>http://www.aytubio.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, (720) 437-6500.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">134</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t20FIN"></a>INDEX TO THE FINANCIAL STATEMENTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="545"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page No.</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><U>Year Ended June 30, 2015:</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfRIR">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfRIR">F-2</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfBS">Balance Sheets</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfBS">F-3</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSO">Statements of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSO">F-4</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSSE">Statement of Stockholders&#146; Equity (Deficit)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSSE">F-5</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSCF">Statements of Cash Flows</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSCF">F-6</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfNCF">Notes to Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfNCF">F-7</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="545"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page No.</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><U>Quarter Ended December 31, 2015 (unaudited):</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tf1BS">Balance Sheets</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tf1BS">F-24</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tf1SO">Statements of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tf1SO">F-25</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tf1SSE">Statement of Stockholders&#146; Equity (Deficit)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tf1SSE">F-26</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tf1SCF">Statements of Cash Flows</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tf1SCF">F-27</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tf1NCF">Note to Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tf1NCF">F-28</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfRIR"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the Board of Directors and Stockholders<BR> Aytu Bioscience, Inc.<BR> Englewood, Colorado </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying balance sheets of Aytu Bioscience, Inc. (the &#147;Company&#148;) as of June 30, 2015 and 2014, and the related statements of operations, stockholders&#146; equity, and cash flows for each of the periods then ended. The Company&#146;s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Aytu Bioscience, Inc. as of June 30, 2015 and 2014, and the results of its operations and its cash flows for each of the periods then ended, in conformity with accounting principles generally accepted in the United States of America. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">/s/ EKS&amp;H LLLP </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">September 28, 2015<BR> Denver, Colorado </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfBS"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Balance Sheets</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="text-align: center; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,639,650</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>157,058</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,442</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>370,888</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>521,322</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid research and development&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred tax asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>18,897</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,083,859</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,301,852</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fixed assets, net (Note 2)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29,706</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>57,246</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Developed technology, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>780,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Customer contracts, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>711,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Trade names, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>79,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In-process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>628,776</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>699,563</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term portion of prepaid research and development&nbsp;&#150;&nbsp;related party<BR> (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>335,454</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>457,438</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,142,947</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,714,247</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,226,806</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>12,016,099</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="text-align: center; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Liabilities and Stockholders&#146; Equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,196,817</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>649,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued liabilities&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>196,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Payable to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>561,059</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Notes to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Interest payable to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>46,002</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,479,034</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,092,278</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>425,893</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>511,607</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Noncurrent deferred tax liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>42,807</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,610,354</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,646,692</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Commitments and contingencies (Note 5)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 in 2015 and 7,901,426 in 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>790</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,996,367</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,026,554</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(10,657,937</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,369,407</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total liabilities and equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,226,806</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>12,016,099</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfSO"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Operations</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="424"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>176,068</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>License revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>58,929</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>261,782</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>58,929</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost of sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>88,109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,219,361</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,933,619</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>203,992</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>125,587</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,382,640</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,346,557</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(7,632,320</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(6,346,834</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Interest (expense) income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(114,994</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(45,553</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss, before income tax</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(7,747,314</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(6,392,387</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred income tax benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>813,697</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(5,578,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Weighted average number of Aytu common shares outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,207,917</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>6,949,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Basic and diluted Aytu net loss per common share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.84</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.80</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfSSE"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Stockholders&#146; Equity</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="160"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Parent&#146;s<BR> Equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional<BR> paid-in<BR> capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Ampio<BR> Stock<BR> Subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated<BR> Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total<BR> Stockholders&#146;<BR> Equity</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,437,158</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>544</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,471,515</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,418,385</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,079,247</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,811,197</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Investment from Ampio in Vyrix</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>637,210</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>637,210</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock in exchange for Vyrix Acquired Assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,464,268</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>246</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(11,108,725</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,108,479</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>499,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>499,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,578,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,578,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,901,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>790</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,026,554</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,657,937</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,369,407</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,164,448</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>216</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,999,784</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock to Ampio in exchange for Aytu debt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,597,339</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>260</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,999,740</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Liabilities paid pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis options paid-out pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Reverse merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,596,468</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>160</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(160</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>14,259,681</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>38,996,367</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfSCF"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Cash Flows</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="439"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="76"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="79"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from operating activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,578,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>499,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation and amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>118,202</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>97,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of prepaid research and development&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,984</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>35,579</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred taxes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(813,697</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(157,058</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(39,442</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Decrease (increase) in prepaid expenses, other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>150,434</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(497,322</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in prepaid research and development&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(465,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Decrease) increase in interest payable to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(46,002</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>46,002</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accounts payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>547,314</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>421,870</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>196,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Decrease) increase in payable to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(561,059</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>561,059</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>(Decrease) increase in deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>191,071</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(6,634,214</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,501,962</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows used in investing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchase of ProstaScint Business</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchase of fixed assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(9,298</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,004,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(9,298</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from financing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from convertible note from Ampio converted to stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis option payout pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Liabilities paid out pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Contribution from Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>637,210</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,352,511</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,237,210</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net change in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,713,411</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(274,050</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at beginning of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,639,650</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,913,700</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at end of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,639,650</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Non-cash transactions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio unpaid debt converted to stock, received prior to 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration related to the ProstaScint purchase</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock in exchange for Vyrix acquired assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,803,356</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Related party research and development liability included in prepaid research and development&nbsp;&#150;&nbsp;related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business/Acquisition of Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tfNCF"></a>Aytu BioScience, Inc. (&#147;Aytu&#148; or the &#147;Company&#148;) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a specialty healthcare company concentrating on developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction, urological cancer and male infertility. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Basis of Presentation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s current business was formed through a reverse triangular merger (the &#147;Merger&#148;) in which Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) and Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the &#147;Vyrix Acquired Assets&#148;) from March 23, 2011, the date, its parent company Ampio
Pharmaceuticals, Inc. (&#147;Ampio&#148;) originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (&#147;BioSciences&#148;) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in separate legal entities. Although Vyrix and Luoxis have not been segregated as a
separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio&#146;s books. In addition, the Company allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. The Company also prepared a calculation of income tax expense and deferred income tax assets and liabilities on a &#147;separate return&#148; basis (see Note 4&nbsp;&#151;&nbsp;Income Taxes). These financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as stand-alone entities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The &#147;Company&#148; as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s activities, being primarily research and development, have not generated significant revenue to date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2015, Ampio is the majority shareholder of 81.5% of Aytu&#146;s outstanding common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 8, 2015, in connection with the reincorporation as a Delaware corporation, we effected a reverse stock split in which each common stock holder received one share of common stock for each every 12.174 shares then outstanding (the &#147;Reverse Stock Split&#148;). All share and per share amounts in this Annual Report have been adjusted to reflect the effect of the Reverse Stock Split. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation &nbsp;&#150;&nbsp;(continued)</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combination&nbsp;&#151;&nbsp;ProstaScint</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the &#147;Seller&#148;). Pursuant to the agreement, Aytu purchased assets related to the Seller&#146;s product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The purchase price consists of the upfront payment of $1.0 million. Aytu also agreed to pay an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory and $227,000 payable on September 30, 2015 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s allocation on consideration transferred for ProstaScint as of the purchase date May 20, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="470"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Estimated<BR> Fair Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>727,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,590,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets acquired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The intangible assets will be amortized over a ten year period. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Future amortization from the year ended June 30, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="472"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Thereafter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>775,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,570,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation &nbsp;&#150;&nbsp;(continued)</H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Pro Forma Information</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The unaudited pro-forma results presented below include the effects of the ProstaScint acquisition as if it has been consummated as of July 1, 2013, with adjustments to give effect to pro forma events that are directly attributable to the acquisition which includes adjustments related to the amortization of acquired intangible assets. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings which may result from the consolidation of ProstaScint. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the
actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented nor are they indicative of future results of operations and are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been consummated as of July 1, 2013. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="376"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,371,106</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,736,139</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost of sales&nbsp;&#150;&nbsp;ProstaScint</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,818,690</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,054,786</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,065,626</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,933,619</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development&nbsp;&#150;&nbsp;related party (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>156,988</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>125,587</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,417,884</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,388,665</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Amortization and impairment of intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>131,989</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(8,220,071</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(6,866,518</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Interest (expense) income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(114,994</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(45,553</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss, before income tax</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(8,335,065</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(6,912,071</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred income tax benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>813,697</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(8,311,155</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(6,098,374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Cash and Cash Equivalents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu&#146;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue Recognition</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License Agreements and Royalties</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product &amp; Service Sales</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recognizes revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Estimated Sales Returns and Allowances</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&#146;s reported revenue could result. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Accounts Receivable</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2015 and 2014, no allowance for doubtful accounts has been recorded. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Inventories</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#146;s judgment, Aytu capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory approval process, potential impediments to the approval process, such as safety or efficacy, anticipated research and development initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. For product candidates that have not been
approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and development expense. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fixed Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="269"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="112"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Estimated<BR> Useful Lives in years</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Lab equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;&#150;&nbsp;5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(33,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Fixed assets, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>57,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recorded the following depreciation expense in the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In-Process Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In-process research and development (&#147;IPRD&#148;) relates to the Company&#146;s Zertane product and clinical trial data acquired in connection with the 2011 acquisition of BioSciences. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. Once the Zertane product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the
Company decided to abandon the Zertane product, the IPRD would be expensed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Patents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, is $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of BioSciences and are being amortized over the remaining U.S. patent lives of approximately 11 years which expires in March 2022. The cost of the Luoxis patents was $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent lives of approximately 15 years which
expires in March 2028. Patents consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="397"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(251,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(180,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>629,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>700,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recorded the following amortization expense in the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="397"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Future amortization from the year ended June 30, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="482"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Thereafter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>274,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>629,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combinations</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#146;s (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 805, &#147;Business Combinations&#148;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquire; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations,
including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Goodwill</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ProstaScint purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Jazz Pharmaceuticals. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made.
In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May 20, 2015. There was no impairment of goodwill for the year ended June 30, 2015. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Use of Estimates</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent
consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Income Taxes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu is included in the consolidated tax returns of Ampio. Aytu&#146;s taxes are computed and reported on a &#147;separate return&#148; basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amount of income taxes and related income tax positions taken would be subject to audits by federal and state tax authorities if Aytu filed these taxes on a separate basis. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&#146;s
policy is to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, &#147;Accounting for Uncertainty in Income Taxes&nbsp;&#151;&nbsp;an interpretation of FASB Statement No. 109&#148; (&#147;ASC 740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the
Company has concluded that no significant tax position requires recognition under ASC 740-10. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stock-Based Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs are expensed as incurred with expenses recorded in the respective period. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fair Value of Financial Instruments</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carrying amounts of financial instruments, including cash and cash equivalents, accounts payable and other current assets and other liabilities are carried at cost which approximates fair value due to the short maturity of these instruments. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impairment of Long-Lived Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu routinely performs an annual evaluation of the recoverability of the carrying value of its long-lived assets to determine if facts and circumstances indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is warranted. Based on its evaluation as of June 30, 2015 and 2014, respectively, no impairment existed for long-lived assets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Newly Issued Accounting Pronouncements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, the FASB issued Accounting Standards Update (&#147;ASU&#148;) 2015-10, &#147;Technical Corrections and Improvements&#148;. The amendments represent changes to clarify the codification, correct unintended application of guidance, or make minor improvements to the codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost. In addition, some of the amendments will make the codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the
codification. The amendments that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon issuance. The Company is evaluating the impact of ASU 2015-10 on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2015, the FASB issued ASU 2015-03, &#147;Interest&nbsp;&#151;&nbsp;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.&#148; The update requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The update requires retrospective application and represents a change in accounting principle. The update is effective for
fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-03 on its financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2015, the FASB issued ASU 2015-01, &#147;Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.&#148; The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. The Company is evaluating the impact the adoption of ASU
2015-01 will have on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In August 2014, the FASB issued ASU No. 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the
impact the adoption of ASU 2014-15 will have on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted but not prior to the original public organization effective date of December 15, 2016. The Company is evaluating the accounting, transition and disclosure requirements
of the standard and cannot currently estimate the financial statement impact of adoption. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 3&nbsp;&#151;&nbsp;License Agreement/Revenue Recognition </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&#147;PE&#148;) and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront payment has been deferred and is
being recognized as license revenue over a ten year period. Milestone payments of $3,200,000 may be earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several years. In addition, Aytu may earn a royalty based on 25% of net sales, as defined, if the royalty exceeds the transfer price of the Zertane product. No royalties have been earned to date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2014, Vyrix entered into a Distribution and License Agreement (the &#147;Paladin Agreement&#148;) with Endo Ventures Limited, which recently acquired Paladin Labs Inc. (&#147;Paladin&#148;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of fifteen years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $250,000 to
Vyrix upon signing the Paladin Agreement and is obligated to make milestone payments aggregating up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment has been deferred and is being recognized as license revenue over a seven year period. In addition, the Paladin Agreement provides that Paladin pay royalties based on sales volume. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 4&nbsp;&#151;&nbsp;Income Taxes </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As previously discussed in Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies, the Company is included in Ampio&#146;s consolidated tax returns. For purposes of these financial statements, the Company&#146;s taxes are computed and reported on a &#147;separate return&#148; basis. Ampio and Aytu do not have a tax sharing agreement. Accordingly, certain tax attributes, e.g., net operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In the event that Ampio&#146;s ownership interest in Aytu falls below 80% and Aytu is deconsolidated from Ampio&#146;s consolidated
income tax return, the net operating loss carryforwards originated prior to the incorporation of Vyrix and Luoxis would no longer be available to Aytu and the related deferred income tax asset would be removed and recorded as a deemed dividend to the parent, Ampio. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Aytu&#146;s financial statements. The following table reflects the reconciliation for the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="397"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Benefit at federal statutory rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(34.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(34.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>State, net of federal income tax benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2.79</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2.89</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.51</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.84</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Change in valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30.95</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22.29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Effective tax rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.30</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(12.73</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="370"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current deferred income tax asset:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue short-term</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>32,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>32,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>73,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(64,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current deferred income tax asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>19,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deferred income tax assets (liabilities):<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net operating loss carryforward</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,337,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,847,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Section 197 intangible</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>453,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>482,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue long-term</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>158,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>190,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Share-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Acquired in-process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,779,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,779,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less: Valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,210,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,863,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total long-term deferred income tax assets (liabilities)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(43,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total deferred income tax assets (liabilities)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(24,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has recorded income tax benefits in its statements of operations since inception, stemming from its operating losses, and is expected to incur operating losses for the foreseeable future. During the year ended June 30, 2015, the net deferred tax liability was reduced to zero based upon the operating losses, thus Aytu established a valuation allowance offsetting any future net deferred tax asset. As such, Aytu would no longer record income tax benefits in its results of operations after the year ended June 30, 2015 because management is currently unable to conclude that it is more likely than not that a benefit will be
realized. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 4&nbsp;&#151;&nbsp;Income Taxes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these
deductible differences, net of the valuation allowance provided. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has federal net operating loss carryforwards of approximately $17.1 million and $10.4 million as of June 30, 2015 and June 30, 2014, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 through 2034. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL
utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2015 and 2014, the Company has no liability for gross unrecognized tax benefits or related interest and penalties. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company&#146;s accounting policies and estimates, however, involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax
return. Under the general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for years prior to 2011 and 2010, respectively. However, given the net operating losses generated since inception, all tax years since inception are subject to examination. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 5&nbsp;&#151;&nbsp;Commitments and Contingencies </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Commitments and contingencies are described below and summarized by the following table as of June 30, 2015: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="152"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Thereafter</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Management fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,800,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>ProstaScint Inventory Transfer</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sponsored research agreement with related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>350,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Clinical research and trial obligations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Office Lease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>35,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>36,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>36,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,222,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,427,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>466,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>466,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>433,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>430,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Management Fee</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 5&nbsp;&#151;&nbsp;Commitments and Contingencies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Inventory Transfer Fee</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu is obligated to pay $500,000 for the ProstaScint-related product inventory upon the inventory transfer in July 2015. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement with Related Party</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Clinical Research and Trial Obligations</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the Zertane clinical trials and RedoxSYS research studies, the remaining commitment is $329,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aytu Manufacturing and Commercial Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu entered into agreements with manufacturing companies to build its RedoxSYS system. The current remaining commitment is $133,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Office Lease</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, Aytu entered into a 37 month operating lease. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="413"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Rent expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 6&nbsp;&#151;&nbsp;Common Stock </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Capital Stock</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At June 30, 2015 and 2014, Aytu had 300 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Equity Instruments </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Options</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 million shares of common stock, both of which were terminated on April 16, 2015 upon the closing of the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were in the money and all outstanding Vyrix options issued under the 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option, if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $27,000. The company
recognized compensation of $422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $433,000 of previously recognized compensation was reversed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Luoxis 2013 Stock Option Plan, 1,102,761 shares of its common stock were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the
contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="330"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="92"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="100"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>79&#37;&nbsp;&#150;&nbsp;108&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>79&#37;&nbsp;&#150;&nbsp;82&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1.62&#37;&nbsp;&#150;&nbsp;2.09&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.75&#37;&nbsp;&#150;&nbsp;1.53&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5.5&nbsp;&#150;&nbsp;7.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5.0&nbsp;&#150;&nbsp;6.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock option activity is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="237"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="82"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="82"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual Life</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Aggregate<BR> Intrinsic Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>396,994</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.96</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,272,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>33,083</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>430,077</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,374,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>195,189</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7.25</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(625,266</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>5.40</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Exercisable at June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Available for grant at June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Vyrix 2013 Stock Option Plan, 616,067 shares of its common stock were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the
contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. In accordance with the Vyrix 2013 Stock Option Plan, no additional options were granted during the year-ended June 30, 2015. The assumptions are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="434"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year Ended<BR> June 30, 2014</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>63&#37;&nbsp;&#150;&nbsp;76&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.90&#37;&nbsp;&#150;&nbsp;2.02&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5.0&nbsp;&#150;&nbsp;6.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock option activity is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="237"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="82"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="82"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual Life</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Aggregate<BR> Intrinsic Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>117,053</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>117,053</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.54</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>417,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(117,053</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>5.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Exercisable at June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Available for grant at June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the years ended June 30 2015 and 2014: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="381"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>427,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>206,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vyrix</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>316,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>152,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Vyrix</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>183,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>104,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,018,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Unrecognized expense at June 30, 2015<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vyrix</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average remaining years to vest<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vyrix</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 1, 2015, Aytu&#146;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#147;2015 Plan&#148;), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. As of
September 28, 2015, no grants have been made under the 2015 Plan. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu issued warrants in conjunction with its 2013 private placement. A summary of all warrants is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average Remaining<BR> Contractual Life</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,613</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.41</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,613</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.92</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,613</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.92</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant
for treasury securities of similar maturity. The offering costs and the additional paid-in capital for the warrants associated with the common stock offering were valued at $313,000 using the Black-Scholes valuation methodology. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Related Party Transactions </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio Loan Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $1,600,000 with interest rates from 3.11%-3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of
converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11%&nbsp;&#150;&nbsp;3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, Ampio received 4,761,787 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Services Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has service agreements with Ampio which are described in Note 5. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This
agreement is set to expire March 2019 and cannot be terminated prior to March 2017. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 9&nbsp;&#151;&nbsp;Litigation </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2015, Aytu was not party to any legal matters or claims, and none of its property is subject to any legal proceedings. In the future Aytu may become party to legal matters and claims arising in the ordinary course of business, the resolution of which it does not anticipate would have a material adverse impact on its financial position, results of operations or cash flows. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Employee Benefit Plan </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu allows its employees to participate in Ampio&#146;s 401(k) plan. The plan allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. Aytu does not match employee contributions. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 11&nbsp;&#151;&nbsp;Subsequent Event </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes with an aggregate principal amount of $5.2 million. The sale of the notes was pursuant to a private placement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu intends to use the net proceeds of the offering to conduct clinical studies for both Zertane&reg; and RedoxSYS<sup>TM</sup> and for working capital to begin commercializing FDA-approved ProstaScint&reg;, as well as general corporate purposes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The notes are an unsecured obligation. Unless earlier converted, the notes will mature 18 months from their respective dates of issuance which will be on January 22, February 11 and February 28, 2017, with an option to extend up to six months at our discretion (provided that in the event Aytu exercises such extension option, the then applicable interest rate shall increase by 2% for such extension period). Aytu does not have the right to prepay the notes prior to the maturity date. Interest will accrue on the notes in the following amounts: (i) 8% simple interest per annum for the first six months and (ii) 12% simple interest
per annum thereafter if not converted during the first six months. If there has not been a registration statement on Form S-1 filed with the SEC for the registration of the shares of common stock underlying the notes by the expiration of the first six-month period then (a) the interest rate will increase to 14% for the remainder of the period in which the notes remain outstanding and (b) any notes held by officers and directors of the Company will be subordinated to the remaining notes. Interest will accrue, is payable with the principal upon maturity, conversion or acceleration of the notes and may be paid in kind or in cash, in Aytu&#146;s sole discretion.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The notes are convertible at any time in a noteholder&#146;s discretion into that number of shares of Aytu common stock equal in an amount equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of notes will be obligated to convert on the terms of Aytu&#146;s next public offering of its stock resulting in proceeds to it of at least $5,000,000 in gross proceeds (excluding indebtedness converted in such financing) prior to the maturity date of the notes (a &#147;Qualified Financing&#148;). The principal and accrued interest under the
notes will automatically convert into a number of shares of such equity securities of the Company sold in such financing equal to 120% of the principal and accrued interest under such note divided by the lesser of (i) the lowest price paid by an investor in such financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Newbridge Securities Corporation, Member FINRA/SIPC, through LifeTech Capital, acted as sole placement agent for the institutional portion of the offering. Aytu sold the balance of the notes to individuals and entities with whom Aytu has an established relationship. For notes sold by the placement agents, Aytu paid the placement agents 8% of the gross proceeds of notes sold by the placement agents and a warrant to purchase shares of Aytu&#146;s common stock equal to 8% of the gross proceeds of the notes sold by the placement agents divided by the price per share at which equity securities are sold in Aytu&#146;s next equity
financing, in addition to a previously paid non-refundable retainer fee of $20,000. The placement agent warrant has a term of five years from the date of issuance of the related notes in July and August 2015, will have an exercise price equal to 100% of the price per share at which equity securities are sold in Aytu&#146;s next equity financing, and provides for cashless exercise. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 11&nbsp;&#151;&nbsp;Subsequent Event &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On August 19, 2015, Aytu entered into a 37 month non-cancellable operating lease for new office space effective September 1, 2015. The new lease has initial base rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tf1BS"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Balance Sheets</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="426"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>December 31,<BR> 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>June 30,<BR> 2015</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="text-align: center; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,959,546</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>288,466</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>157,058</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>653,115</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,442</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses, other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>741,544</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>370,888</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,764,654</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,042,432</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fixed assets, net (Note 2)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>143,826</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29,706</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Developed technology, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,242,569</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>780,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Customer contracts, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,456,875</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>711,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Trade names, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>210,139</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>79,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>221,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In-process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>593,382</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>628,776</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term portion of prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>274,463</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>335,454</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,888</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>11,645,142</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,142,947</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>24,409,796</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,185,379</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="text-align: center; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Liabilities and Stockholders&#146; Equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,076,295</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,195,368</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,111,057</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>492,584</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>196,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Related party payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>38,451</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,804,101</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,477,585</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Convertible promissory notes, net of amortization discount of $253,448 (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,921,552</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>687,685</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>383,036</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>425,893</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>161,988</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,694</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,449</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrant derivative liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>180,969</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9,151,025</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,568,927</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Commitments and contingencies (Note 7)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,693 and 14,259,681, respectively as of December 31, 2015 and June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,247,254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,996,367</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(23,989,909</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>15,258,771</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total liabilities and stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>24,409,796</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,185,379</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tf1SO"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Operations<BR>&nbsp;<BR> (unaudited)</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="253"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>447,786</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,906</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>913,742</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,060</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>License revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>21,428</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>21,429</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>42,857</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>42,858</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>469,214</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>28,335</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>956,599</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>55,918</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost of sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>244,100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>281,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>225</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,308,460</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>789,967</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,164,334</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,723,720</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>47,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>53,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>95,996</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>107,996</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sales, general and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,774,167</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>749,837</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,425,971</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,863,416</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Amortization of finite-lived intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>108,489</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,697</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>165,936</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>35,394</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total operating expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,483,214</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,611,499</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,133,662</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,730,751</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,014,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,583,164</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,177,063</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,674,833</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Other (expense) income<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest (expense)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(240,214</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(37,547</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(353,467</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(74,849</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Derivative (expense)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(78,166</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(78,038</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total other (expense) income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(318,380</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(37,547</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(431,505</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(74,849</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss, before income tax</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,332,380</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,620,711</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,608,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,749,682</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred income tax benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(3,332,380</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,620,711</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(5,608,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(3,725,772</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Weighted average number of Aytu common shares outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>14,259,693</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,901,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>14,259,687</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,901,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Basic and diluted Aytu net loss per common share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.23</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.21</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.47</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tf1SSE"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statement of Stockholders&#146; Equity</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="168"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=2 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional<BR> paid-in<BR> capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Ampio<BR> Stock Subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated<BR> Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total<BR> Stockholders&#146;<BR> Equity</TD>

</TR>

<TR>

          <TD STYLE="width: 6px; vertical-align: bottom; font-weight: normal; font-size: 10pt; text-align: center" ROWSPAN=1><!-- NEW-GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,259,681</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,996,367</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustment for rounding of shares due to conversion (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,887</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,887</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,608,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,608,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;December 31, 2015 (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>14,259,693</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,426</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>39,247,254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(23,989,909</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>15,258,771</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tf1SCF"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Cash Flows<BR>&nbsp;<BR> (unaudited)</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="429"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from operating activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,608,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,725,772</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,887</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>477,660</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation, amortization and accretion</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>242,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>49,164</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amoritzation of debt issuance costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>147,805</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Derivative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>78,038</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,992</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred taxes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments to reconcile net loss to net cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(131,408</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(6,906</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(613,673</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,453</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) decrease in prepaid expenses, other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(370,656</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>485,889</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Decrease) in accounts payable and accrued liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(126,781</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(298,677</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase (decrease) in related party payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,451</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(561,059</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>296,081</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>94,247</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in interest payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>161,988</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74,936</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,245</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>(Decrease) in deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(42,857</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(42,858</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,607,030</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,576,747</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows used in investing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchases of fixed assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(125,161</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchase of Primsol business</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(663,163</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from financing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from convertible promissory notes, net (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,175,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Debt issuance costs (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(298,322</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Contribution from Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9,876,678</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net change in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,606,485</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,478,745</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at beginning of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,639,650</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at end of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>10,959,546</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>160,905</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Non-cash transactions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,931</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,077,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fixed asset purchases included in accounts payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,708</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tf1NCF"></a>Business/Acquisition of Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu BioScience, Inc. (&#147;Aytu&#148; or the &#147;Company&#148;) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a specialty healthcare company concentrating on acquiring, developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction, urological cancer, urinary tract infections and male infertility. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Basis of Presentation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These unaudited financial statements represent the financial statements of Aytu BioScience, Inc. (&#147;Aytu&#148; or &#147;the Company&#148;). These unaudited financial statements should be read in conjunction with Aytu&#146;s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (&#147;GAAP&#148;). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods
presented. The results of operations for the period ended December 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended December 31, 2015 is unaudited. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s current business was formed through a reverse triangular merger (the &#147;Merger&#148;) in which Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) and Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the &#147;Vyrix Acquired Assets&#148;) from March 23, 2011, the date its parent company, Ampio
Pharmaceuticals, Inc. (&#147;Ampio&#148;), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (&#147;BioSciences&#148;) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and Luoxis have not been segregated as a
separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio&#146;s books. In addition, the Company allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. The Company also prepared a calculation of income tax expense and deferred income tax assets and liabilities on a &#147;separate return&#148; basis. These financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entity. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The &#147;Company&#148; as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015, Ampio is the majority shareholder of 81.5% of Aytu&#146;s outstanding common stock. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares then outstanding (the &#147;Reverse Stock Split&#148;). All share and per share amounts in this Report have been adjusted to reflect the effect of the Reverse Stock Split. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combination&nbsp;&#151;&nbsp;ProstaScint</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the &#147;Seller&#148;). Pursuant to the agreement, Aytu purchased assets related to the Seller&#146;s product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The purchase price consisted of the upfront payment of $1.0 million. Aytu also paid an additional $500,000 for the ProstaScint-related product inventory and $227,000 that was paid prior to December 31, 2015 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow estimate as of the acquisition date. The total fair value consideration for the purchase was $2.4 million. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fair Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>727,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,590,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets acquired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015 the contingent consideration had increased to $688,000 due to accretion. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combination&nbsp;&#151;&nbsp;Primsol</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the &#147;Seller&#148;). Pursuant to the agreement, Aytu purchased assets related to the Seller&#146;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of the Seller&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 payable no later than March 31, 2016, (b) $500,000 payable no later than June 30, 2016, and (c) $250,000 payable no later than September 30, 2016 (together, the &#147;Installment Payments&#148;). </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fair Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>182,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,470,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets acquired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,799,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Included in tangible assets is $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets is developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which will be amortized over a six-year period. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Adoption of Newly Issued Accounting Pronouncements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2015, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2015-16, &#147;Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,&#148; which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period&#146;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects,
if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of December 31, 2015, the Company has early adopted this standard. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2015, the FASB issued ASU 2015-03, &#147;Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&#148; to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, &#147;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit
Arrangements&nbsp;&#151;&nbsp; Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting&#148; which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. As of December 31, 2015, the Company early adopted this standard and will record any debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs previously. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 &#147;Income Taxes: Balance Sheet Classification of Deferred Taxes.&#148; The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Acquisition of Assets and Basis of Presentation &nbsp;&#150;&nbsp;(continued)</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Recently Issued Accounting Pronouncements, Not Adopted as of December 31, 2015</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2016, the FASB issued ASU 2016-01, &#147;Financial Instruments&nbsp;&#151;&nbsp;Overall (Subtopic 825-10): Recognition and measurement of Financial Assets and Financial Liabilities,&#148; which requires that all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting
from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, the FASB issued ASU 2015-11, &#147;Simplifying the Measurement of Inventory.&#148; ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company&#146;s financial position or
results of operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In August 2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the
impact the adoption of ASU 2014-15 will have on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating
the effect that the updated standard will have on its financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Fixed Assets </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="300"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Estimated<BR>Useful Lives in years</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As of<BR> December 31,<BR> 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As of<BR> June 30,<BR> 2015</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Office equipment and furniture</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;&#150;&nbsp;5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>108,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Lab equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;&#150;&nbsp;5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Leasehold improvements</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated depreciation and amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(79,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Fixed assets, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>144,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 3&nbsp;&#151;&nbsp;In-Process Research and Development </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In-process research and development (&#147;IPRD&#148;) relates to the Zertane product candidate. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. If the Zertane product candidate obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the Company decides to abandon the Zertane product, the IPRD would be expensed. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 4&nbsp;&#151;&nbsp;Patents </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $500,000, is being amortized over the remaining U.S. patent life since Aytu&#146;s acquisition of approximately 11 years. The cost of the ORP related patents was $380,000 when they were acquired and is being amortized over the remaining U.S. patent life since Aytu&#146;s acquisition of approximately 15 years. Patents consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="373"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As of<BR> December 31,<BR> 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As of<BR> June 30,<BR> 2015</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated armortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(287,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(251,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>593,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>629,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 5&nbsp;&#151;&nbsp;Revenue Recognition </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The $448,000 and $7,000 product and service revenue recognized during the three months ended December 31, 2015 and 2014, respectively, represents sales of the Company&#146;s ProstaScint and Primsol products and the RedoxSYS System. The $914,000 and $13,000 product and service revenue recognized during the six months ended December 31, 2015 and 2014, respectively, represents sales of the Company&#146;s ProstaScint and Primsol products and the RedoxSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The license revenue of $21,000 and $43,000 recognized in the three and six months ended 2015 and 2014 respectively, represents the amortization of the upfront payments received from the Company&#146;s license agreements. The initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-32</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 6&nbsp;&#151;&nbsp;Fair Value Considerations </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes is approximately the face value of the notes, $5,175,000 based upon the valuation that the Company had completed of all components of the convertible notes at inception and as of December 31, 2015. The valuation policies are
determined by the Chief Financial Officer and approved by the Company&#146;s Board of Directors. Subsequent to December 31, 2015, the majority of the Company&#146;s convertible notes converted into common stock (see Note 12 for more information). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu.
Unobservable inputs are inputs that reflect Aytu&#146;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;1:</TD>

          <TD STYLE="text-align: left">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;2:</TD>

          <TD STYLE="text-align: left">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;3:</TD>

          <TD STYLE="text-align: left">Unobservable inputs that are supported by little or no market activity. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&#146;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table presents Aytu&#146;s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015, by level within the fair value hierarchy: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="317"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=15>Fair Value Measurements Using</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 1</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 2</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 3</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B><U>December 31, 2015</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>LIABILITIES<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>181,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>181,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-33</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 6&nbsp;&#151;&nbsp;Fair Value Considerations &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></B></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrant derivative liability for the warrants was valued using the Monte Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of December 31, 2015 and at issuance: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="290"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="112"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>At Issuance</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>Warrants:</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercise price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#36;0.98</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#36;1.51&nbsp;&#150;&nbsp;$1.95</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75.0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75.0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Equivalent term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.67</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.0&nbsp;&#150;&nbsp;5.11</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk-free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.57&#37;&nbsp;&#150;&nbsp;1.60&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.54&#37;&nbsp;&#150;&nbsp;1.74&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Potential number of shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>126,000&nbsp;&#150;&nbsp;215,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>139,000&nbsp;&#150;&nbsp;224,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Derivative<BR> Instruments</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance as of June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant issuances</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>103,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Included in earnings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>78,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance as of December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>181,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Commitments and Contingencies </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of December 31, 2015: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="170"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Remaining<BR> 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Thereafter</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Management fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,620,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>180,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol business</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing agreement</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Office Lease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>385,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>68,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>142,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Sponsored research agreement with related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>315,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>35,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,570,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,283,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>822,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>575,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>460,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>430,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Management Fee</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-34</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Commitments and Contingencies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol Business</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into an agreement with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1). </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&#147;Biovest&#148;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $1.0 million for time and materials as they develop a plan to reproduce the
manufacturing process. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Office Lease</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, Aytu entered into a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $8,500 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are
classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="317"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Rent expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement with Related Party</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Convertible Promissory Notes </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Convertible Promissory Notes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (&#147;Notes&#148;) with an aggregate principal amount of $5.2 million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $401,000 which included the $103,000 fair value of the warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Notes are an unsecured obligation. Unless earlier converted, the Notes will mature 18 months from their respective dates of issuance which will be on January 22, February 11 and February 28, 2017, with an option to extend the maturity date up to six months at Aytu&#146;s discretion (provided that in the event Aytu exercises such extension option, the then applicable interest rate shall increase by 2% for such extension period). Aytu does not have the right to prepay the Notes prior to the maturity date. Interest will accrue on the Notes in the following amounts: (i) 8% simple interest per annum for the first six months and
(ii) 12% simple interest per annum thereafter if not converted during the first six months. If there had not been a registration statement on Form S-1 filed with the SEC for the registration of the shares of common stock underlying the Notes by the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-35</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Convertible Promissory Notes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">expiration of the first six-month period then (a) the interest rate would have increased to 14% for the remainder of the period in which the Notes remain outstanding and (b) any Notes held by officers and directors of the Company would have been subordinated to the remaining Notes. Interest will accrue, is payable with the principal upon maturity, conversion or acceleration of the Notes and may be paid in kind or in cash, in Aytu&#146;s sole discretion. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 4% increase in the interest rate is triggered automatically with the passage of time and is not a contingent feature, thus, there is no initial accounting for this feature. However, the periodic interest cost will be calculated using a constant effective interest over the life of the Notes. As management does not intend to utilize the extension option, the expected life of the Notes is 18 months. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company did not give recognition to the registration rights arrangement as management did not believe at issuance that probable payment under the contingent escalation clause would be required, thus there was no impact on the initial measurement of the Notes. The Company satisfied the registration rights arrangement in October 2015 upon the effectiveness of a registration statement on Form S-1. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Notes are convertible at any time at the noteholder&#146;s discretion into that number of shares of Aytu common stock equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated to convert on the terms of Aytu&#146;s next public offering of its stock resulting in gross proceeds of at least $5,000,000 (excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a &#147;Qualified Financing&#148;). The principal and accrued interest under the Notes will automatically convert into a
number of shares of such equity securities of the Company sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the lesser of (i) the lowest price paid by an investor in the Qualified Financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company determined that the conversion option is not required to be bifurcated and accounted for as an embedded derivative liability. There was no intrinsic value to the beneficial conversion feature as it was determined that the effective conversion price exceeded the commitment date valuation price. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Notes contain a purchase premium option in the event of a sale transaction by the Company as defined in the Notes. A holder of the Notes will be entitled to receive, at the holder&#146;s option, (i) repayment of the Note balance plus the amount equal to 25% of the original purchase amount or (ii) the consideration the holder would have received on an as-converted basis. Given that the payment under the purchase premium is contingent upon a sale transaction and involves a substantial premium of 25%, the purchase premium is an embedded derivative that must be bifurcated and accounted for as an embedded derivative. No value
was recorded related to this derivative at issuance and December 31, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Placement agents for the offerings sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agents, Aytu paid the placement agents 8% of the gross proceeds of Notes sold by the placement agents and is obligated to issue warrants for an amount of shares to be equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents in the private placement, in addition to a
previously paid non-refundable retainer fee of $20,000. The placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, will have an exercise price equal to the lowest </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-36</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Convertible Promissory Notes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">conversion price per share at which the Notes are converted into common stock. Change in fair value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrants were recorded at fair value as long-term liabilities on the Balance Sheet (see Note 6). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon Aytu&#146;s adoption of ASU 2015-3, the costs associated with the Notes were recorded as a long-term liability and are presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2015, the carrying value of the Notes was $4.9 million inclusive of an unamortized debt discount of $253,000. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 9&nbsp;&#151;&nbsp;Common Stock </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Capital Stock</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At December 31, 2015 and June 30, 2015, Aytu had 300 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Options</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 million shares of common stock, both of which were terminated on April 16, 2015 upon the closing of the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were in the money and all outstanding Vyrix options issued under the respective 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option; if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $27,000.
The Company recognized compensation of $422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date during the period ended June 30, 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $433,000 of previously recognized compensation was reversed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 1, 2015, Aytu&#146;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#147;2015 Plan&#148;), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. The fair
value of the options are calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-37</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the six months ended December 31, 2015 using the following assumptions: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="444"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="94"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>75.00&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1.08&#37;&nbsp;&#150;&nbsp;2.08&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3.0&nbsp;&#150;&nbsp;7.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock option activity is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="300"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Life in Years</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,695,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.55</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,695,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>1.55</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>9.80</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Exercisable at December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,120,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>1.51</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>9.87</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Available for grant at December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>6,305,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three and six months ended December 31, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three and six months
ended December 31, 2014: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="301"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended<BR> December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Six Months Ended<BR> December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>117,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>207,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Selling, general and administrative expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Stock options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>163,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>226,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>271,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>183,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>276,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>251,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>478,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Unrecognized expense at December 31, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,890,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average remaining years to vest</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.16</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Of the options that Aytu issued during the six months ended December 31, 2015, 1,440,000 were to Ampio board members and employees. This was recorded as a return of capital to Ampio and Ampio will take a stock-based compensation expense equal to $1.3 million on their financial statements related to these option grants. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-38</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu issued warrants in conjunction with its 2013 private placement. A summary of these warrants is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="300"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Life in Years</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,613</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.92</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding December 31, 2015 (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,613</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.53</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.41</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrant Obligation related to the Convertible Promissory Notes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has the obligation to issue warrants to the private placement agents for the 2015 convertible note financing as part of their fees for the financing. These warrants are classified as a derivative warrant liability due to the fact that the number of shares and exercise price have not been set as of December 31, 2015. The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The
exercise price will be the lower of the lowest conversion price per share at which the Notes are converted into Company common stock or $4.63. The warrants have a term of five years from the date of issuance of the related notes in July and August 2015 (see Note 6). </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 11&nbsp;&#151;&nbsp;Related Party Transactions </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio Loan Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $1,600,000 with interest rates from 3.11%&nbsp;&#150;&nbsp;3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of
converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11%&nbsp;&#150;&nbsp;3.32%. On </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-39</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 11&nbsp;&#151;&nbsp;Related Party Transactions &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, Ampio received 4,761,787 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Services Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has entered into a service agreement with Ampio which is described in Note 7. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the RedoxSYS platform. In March 2014, Luoxis also agreed to pay $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term assets on the balance sheet; this amount has been paid in full. This agreement is set to expire
March 2019 and cannot be terminated prior to March 2017. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Convertible Promissory Notes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The convertible promissory notes (see Note 8) include $275,000 invested by relatives of senior management of the Company. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 12&nbsp;&#151;&nbsp;Subsequent Events </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January, 4, 2016, Ampio distributed a portion of its shares of common stock of Aytu to the Ampio shareholders on a pro rata basis. This transaction changed Ampio&#146;s ownership from 81.5% down to 8.6% of Aytu&#146;s outstanding shares on that date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 5, 2016, Aytu accelerated the vesting of 335,000 options to employees of Ampio and Ampio will recognize the expense related to this modification. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 20, 2016, Aytu entered into subscription agreements with Joshua R. Disbrow, Aytu&#146;s Chief Executive Officer, and Jarrett T. Disbrow, Aytu&#146;s Chief Operating Officer, pursuant to which each officer agreed to purchase 153,846 shares of Aytu common stock at a price of $0.65 per share. The stock sales were consummated the same day resulting in gross proceeds to the Company of $200,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2016, Aytu&#146;s Board appointed Joshua R. Disbrow and Jarrett Disbrow as directors, to hold office until the Company&#146;s next annual meeting of stockholders, which is scheduled for May 24, 2016. In April 2016, the Company added a fourth director. He will also hold office until the Company&#146;s next annual meeting of stockholders.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April, the Board granted to each of Aytu&#146;s two non-executive Directors options to purchase 100,000 shares of Aytu common stock for board fees in fiscal year 2016. The options vested upon grant and have an exercise price of $0.56 per share, which was the closing price of Aytu common stock on the date of grant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Per the convertible promissory note agreements, if Aytu sells equity securities at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, the holders of the convertible promissory notes have the option, but not the obligation, to convert the outstanding principal and accrued interest as of the as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-40</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 12&nbsp;&#151;&nbsp;Subsequent Events &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. As a result of Aytu&#146;s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, for a period of ten business days (which was extended to 15 business days by the Company, or February 11, 2016) following receipt of the notice, noteholders have the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common
stock equal to 120% of the number of shares calculated by dividing such note balance by $0.65, which was the per share purchase price paid in the equity financing described above. On February 10, 2015, the date of the conversion, an aggregate of $4,125,000 of principal and $142,810 of accrued interest on the notes converted into an aggregate of 7,879,096 shares of Aytu&#146;s common stock. After giving effect to the conversion, Aytu had 22,446,481 shares of common stock outstanding on February 10, 2016. Convertible notes in the aggregate principal amount of $1,050,000 remain outstanding. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the conversion of the Aytu notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu&#146;s common stock for the notes sold by the placement agents issued upon conversion of the notes. As a result of the optional note conversion, on March 15, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of 267,052 shares of our common stock at an exercise price of $0.65 per share. These warrants are exercisable for five years from the date of issuance of the related notes in July and
August 2015. The warrants have a cashless exercise feature. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, the Company entered into and closed a license and supply agreement for the exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone) nasal gel from Acerus Pharmaceuticals Corporation (&#147;Acerus&#148;). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The license&#146;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu paid Acerus an upfront fee of $2,000,000 upon execution of the agreement. On September 5, 2016, Aytu will pay an additional $2,000,000 (the &#147;Second Upfront&#148;). On January 1, 2017, Aytu will pay an additional $4,000,000 (the &#147;Third Upfront&#148;).</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the upfront payments, Aytu must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$2,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $25,000,000 (the &#147;First Milestone&#148;);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$5,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $50,000,000;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$7,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $75,000,000;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$10,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $100,000,000; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$12,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $125,000,000.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company also agreed to purchase on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn.$2,534,800 (approximately US$2,000,000), with a purchase price per share of Cdn.$0.207. We cannot dispose of these shares until August 29, 2016.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the term of the agreement, Aytu will purchase all of its Natesto product need from Acerus. Each month Aytu will provide Acerus with a two-year forecast of its product needs, the first three months of which </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-41</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Notes to Financial Statements<BR> (unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 12&nbsp;&#151;&nbsp;Subsequent Events &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">will be noncancelable. Pursuant to the agreement, Aytu will pay Acerus a supply price per unit of the greater of 115% of Acerus&#146; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus&#146; cost of goods sold (but not to
exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus&#146; cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus&#146; cost of goods sold (but no to exceed the fixed ceiling price). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of any termination of the agreement prior to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will, unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after the termination date.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-42</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<H2 STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR> </H2>

<DIV  STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">18,750,000 Shares of Common Stock</Font> </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><FONT STYLE="font-size: 14pt">Warrants to Purchase 18,750,000 Shares of Common Stock&nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> </Font></H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="logo_aytu-bioscience.jpg" WIDTH="180" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR> &nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR> </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">PROSPECTUS</Font> </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="672" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="312"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="344"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Sole Book-Running Manager&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B>Joseph Gunnar &amp; Co.</B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 16pt"><B></FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right">Lead Manager<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B></B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 16pt"><B>Fordham Financial Management</FONT></B></TD>

</TR>

</TABLE></DIV>

<DIV STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">



</DIV>

</B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B>

</I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_aytu-bioscience.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_aytu-bioscience.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( '4!2 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M7E^:4,5@JDG4H-LHHHKZX\X**** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>5Y7+$2]I3R/(\IA[+"NMB,+1]&\(?\@V?_ *_I?_2>VKJJY7PA_P @V?\
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M/NK#4)O#'C;POJ.M>$/$]OI^H:??W/A_7-2@LM0L;J2*[A_U^/V6?VE?A?\
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M27L[K4[.WN[FR3RM2DE6:*VG99(D!C92PK[#K\G/^"Z/_*)3]N+_ +));_\
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M6LR:AXI^$M]>VO@[7;F]UF+Q5J6G6OAGQMJNFZ1I/CW1[.X_TG*_(C_@M?\
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M_C\?\%"?VU?B!_P4#_:U^+/[3WCXWVGQ^,]:-AX \&76J3:I:?#;X7:$7L/
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MF6+S3&8FTJ=3#UL34<J=#+ZO-.O@\)@J$,+@L%AH594J6#P6&HSI5;595?\
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M(_VC)])OM#3P]!?V2ZA/ _P2\,:SKWA36K>WU;3YX?'_ (P^('A3Q7X?75/
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M_8V_[N&_]:K^.590W?I^J-9[+U_1G[?4445J9'X@_P#!QY_RAC_;)_[MY_\
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M$\&>#--U36]*@\0>.?%^I:'X.\,0WL5]XBUS2[#?<K_L8_L__"+2?V?O@/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v433932_ifc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v433932_ifc.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$(!QP$V@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHKP?]GSXM6WQ8\#VNHS3VY\0V0G.NV<,L>ZT%QK&LV^F%K=]2U*^@$]EIZR
MWCIYF=]ONB(5/>*^(X2XIR;C;AK).+.'\5'&9/GV7X?,<#7BX\WLJ\%*5&M&
M,I^RQ.&J<V'Q5"4N>AB*=2C42G!H_MG.,IQN19ICLHS&DZ&-R_$U,-B*;3MS
MTY-*<&TN>E4C:I2J)<M2G*,XMQDF%%%%?1'FA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\$VVH>(M$U^UT&X\2#PC:6,.OV=A_:.ER,L]O+Y?GPS?[)/_!/']N;X7?\
M!0G]E[X<_M#_  TN[.-]>\.>$4\<^&(O$OA?Q-?^!OB#JGP\\$^./$W@K5KS
MPO>SP1ZIX9/C6PT^_@U'3_#^JI,!+=^'M)2XMX" ?<5%%?R5?MB_\'67@?\
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M<OV6O^C(/C]_X</X=_\ R/0*_K]Q_;M17\1/_$;E^RU_T9!\?O\ PX?P[_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@?X$\07^N>//&W@_Q)'9:;\6[7Q?\*/#-A:^%7\2?#7XP>*O"/CWPA9MXO\
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M (*E_P#1)S_X0G[1/_SB*/\ B&I_X*E_]$G/_A"?M$__ #B*_P!>^B@+/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?A?_ ,%Y/V((/VG_ -DSQ)\7=%E_XN!^S)X*\=^.?#FF#3_$
M&HR:UI=[J/P\UCQQ!;C1M3$-O=P^#O &H_8_MWAS7+::ZDA\RXT"!+K5X_\
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M6WN=5OYHAA9KRZF\VYE]M_XBUO\ @EI_T"_V@?\ P"_9V_\ HD*_RDJ* /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>N;&VO[C1(=-5/\ 1/\ ^#AS0_\ @H5\6OV3+;]FS]@/]G?Q)\:-5^-'G?\
M"R/%FB>(OAOHD?PQ_P"%=?$KX*>/?!_G:/\ $NQ2S\5?\)I;:;XRTV/^R-?T
M?^PVTJ6ZU#^T)9;"R/\ GL_\0X7_  6Q_P"C"OB!_P"%_P#!'_YY]?IQ\J>;
M_P#!#[]@32/^"DG_  4,^&W[-WB[RXOAS)X,^*7COXCZA+%-=II7A[PMX'U:
M/1;MM/L?&'@?6M0\_P"(.J^"M,%OH>M_;H3J O[JSN-&L]5:+_4Y_P"'*O\
MP22_Z1S_ +(7_AD?!7_RKK\K_P#@VC_X(]>//^"='P9\7_%/]I'P1>>#OVG?
MB)J>OZ/)IM_J5G=7>@_"SQ;X5^ _B)_"TT?A/XC^+_!-U)I?Q!\$:[;R:K+I
M.G>)YY+5U=[326MK:Y_J-H _,+_ARK_P22_Z1S_LA?\ AD?!7_RKH_X<J_\
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M2_\ "4>#M*U6R2_^*/\ PE>J_ 3P5HGD77C7XF>&?#'A3_A"?!'@[Q)JLO\
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M[UN_TS3(OL.@:'JNI2?:;Z#S(K-XH?-N'BAD_P OO_B'"_X+8_\ 1A7Q _\
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M ))-?SB_\0X7_!;'_HPKX@?^%_\ !'_YY]'_ !#A?\%L?^C"OB!_X7_P1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV]I_8_T%_%7BC]N7PNCK&_B3PK\*-!1V8JJ/K'@'Q[IZNS"&X*JIN 2PMYR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\
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M9?\ R)7BM%'_ !%[Q9_Z.CXC_P#B=\7?_1"'^J7"O_1,\/?^&/*?_G>>U?\
M#1?QM_Z*-KWYV7_R)1_PT7\;?^BC:]^=E_\ (E>*T4?\1>\6?^CH^(__ (G?
M%W_T0A_JEPK_ -$SP]_X8\I_^=Y[5_PT7\;?^BC:]^=E_P#(E'_#1?QM_P"B
MC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\ T0A_JEPK_P!$SP]_X8\I_P#G
M>>U?\-%_&W_HHVO?G9?_ ")1_P -%_&W_HHVO?G9?_(E>*T4?\1>\6?^CH^(
M_P#XG?%W_P!$(?ZI<*_]$SP]_P"&/*?_ )WGM7_#1?QM_P"BC:]^=E_\B4?\
M-%_&W_HHVO?G9?\ R)7BM%'_ !%[Q9_Z.CXC_P#B=\7?_1"'^J7"O_1,\/?^
M&/*?_G>>U?\ #1?QM_Z*-KWYV7_R)1_PT7\;?^BC:]^=E_\ (E>*T4?\1>\6
M?^CH^(__ (G?%W_T0A_JEPK_ -$SP]_X8\I_^=Y[5_PT7\;?^BC:]^=E_P#(
ME'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\ T0A_JEPK_P!$
MSP]_X8\I_P#G>>U?\-%_&W_HHVO?G9?_ ")1_P -%_&W_HHVO?G9?_(E>*T4
M?\1>\6?^CH^(_P#XG?%W_P!$(?ZI<*_]$SP]_P"&/*?_ )WGM7_#1?QM_P"B
MC:]^=E_\B4?\-%_&W_HHVO?G9?\ R)7BM%'_ !%[Q9_Z.CXC_P#B=\7?_1"'
M^J7"O_1,\/?^&/*?_G>>U?\ #1?QM_Z*-KWYV7_R)1_PT7\;?^BC:]^=E_\
M(E>*T4?\1>\6?^CH^(__ (G?%W_T0A_JEPK_ -$SP]_X8\I_^=Y[5_PT7\;?
M^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\
MT0A_JEPK_P!$SP]_X8\I_P#G>>U?\-%_&W_HHVO?G9?_ ")1_P -%_&W_HHV
MO?G9?_(E>*T4?\1>\6?^CH^(_P#XG?%W_P!$(?ZI<*_]$SP]_P"&/*?_ )WG
MM7_#1?QM_P"BC:]^=E_\B4?\-%_&W_HHVO?G9?\ R)7BM%'_ !%[Q9_Z.CXC
M_P#B=\7?_1"'^J7"O_1,\/?^&/*?_G>>U?\ #1?QM_Z*-KWYV7_R)1_PT7\;
M?^BC:]^=E_\ (E>*T4?\1>\6?^CH^(__ (G?%W_T0A_JEPK_ -$SP]_X8\I_
M^=Y[5_PT7\;?^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"C
MH^(__B=\7?\ T0A_JEPK_P!$SP]_X8\I_P#G>>U?\-%_&W_HHVO?G9?_ ")1
M_P -%_&W_HHVO?G9?_(E>*T4?\1>\6?^CH^(_P#XG?%W_P!$(?ZI<*_]$SP]
M_P"&/*?_ )WGM7_#1?QM_P"BC:]^=E_\B4?\-%_&W_HHVO?G9?\ R)7BM%'_
M !%[Q9_Z.CXC_P#B=\7?_1"'^J7"O_1,\/?^&/*?_G>>U?\ #1?QM_Z*-KWY
MV7_R)1_PT7\;?^BC:]^=E_\ (E>*T4?\1>\6?^CH^(__ (G?%W_T0A_JEPK_
M -$SP]_X8\I_^=Y[5_PT7\;?^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK
M11_Q%[Q9_P"CH^(__B=\7?\ T0A_JEPK_P!$SP]_X8\I_P#G>>U?\-%_&W_H
MHVO?G9?_ ")1_P -%_&W_HHVO?G9?_(E>*T4?\1>\6?^CH^(_P#XG?%W_P!$
M(?ZI<*_]$SP]_P"&/*?_ )WGM7_#1?QM_P"BC:]^=E_\B4?\-%_&W_HHVO?G
M9?\ R)7BM%'_ !%[Q9_Z.CXC_P#B=\7?_1"'^J7"O_1,\/?^&/*?_G>>U?\
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M^J7"O_1,\/?^&/*?_G>>U?\ #1?QM_Z*-KWYV7_R)1_PT7\;?^BC:]^=E_\
M(E>*T4?\1>\6?^CH^(__ (G?%W_T0A_JEPK_ -$SP]_X8\I_^=Y[5_PT7\;?
M^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\
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M9?\ R)7BM%'_ !%[Q9_Z.CXC_P#B=\7?_1"'^J7"O_1,\/?^&/*?_G>>U?\
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M^J7"O_1,\/?^&/*?_G>>U?\ #1?QM_Z*-KWYV7_R)1_PT7\;?^BC:]^=E_\
M(E>*T4?\1>\6?^CH^(__ (G?%W_T0A_JEPK_ -$SP]_X8\I_^=Y[5_PT7\;?
M^BC:]^=E_P#(E'_#1?QM_P"BC:]^=E_\B5XK11_Q%[Q9_P"CH^(__B=\7?\
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MBB@ HHHH **** "BBB@#YW_:N_Y(#X]_[E;_ -33PY7XSU^S'[5W_) ?'O\
MW*W_ *FGAROQGK_$+]I3_P GRX5_[-;DO_K4<7']I?1S_P"2)S3_ +*?&?\
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M6XMIY;+4M)U6QE_?:?J^D:A;W.GZE9R;O*N;=S#+/;/#<2_S??\ !8KXN?\
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M"SC2K_4<MA.M7K485)QINOS0I.?N+GG:G+^DFBOYS/V9_P#@LW\7],^.6D_
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M_P"R?%6IPKHSZ5J]I/J6B0W6H0VUI_.'^P/^TG^TA^S+\1?&?BO]FCX4Z?\
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M&%Q<\IADLZ3R6ARTI55A\6JD?[6E74T^6#@X<S5_=/TPHK^8OPI_P68_;/\
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M7;CP] L6N:?KMZ]^-0MM,U:0R6YT=(UM_LH603LQE0Q@-^77[;'_  6G\9^
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M /3?;UO5@^%?^18\.?\ 8!T?_P!-]O6]7_5GD/\ R(LC_P"Q)DO_ *ILH/\
M+G'?[]CO^PW&_P#J9BPHHHKU3E"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#YW_:N_Y(#X]_[E;_ -33PY7XSU^S'[5W_) ?'O\
MW*W_ *FGAROQGK_$+]I3_P GRX5_[-;DO_K4<7']I?1S_P"2)S3_ +*?&?\
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MF_Y$C]EO_L:OBG_Z:/!-?&/Q&_X)C_\ !0JX_:4^'OQ3\<^';WXV^*/%.O>
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MY+_]F']K[P=JWPO^,'A:"S\.^%?&?B"71/$!O[GP<UK?_#OQX#H&N:DTLZ6
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M![X@?!^YU3QEJFE>.M=M+M_$'BC5Y_%FKVNNW>MR0?'+P>CW6EW]D_ANS/\
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M*998XP=\B@_V5U\'^T2:?TC*R33:\/\ @>Z33:O0X@:NKW5UJKI76JNM3V_
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MK3LXR<HIPT^ ?V2/^"''PD^ OQ!T+XH?%SXBW'QSU[PM>PZOX:\+'PA;^$_
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MA?M*?^3Y<*_]FMR7_P!:CBX_M+Z.?_)$YI_V4^,_]5F4A1117^>A^_!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R0_P""I?\
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MGJ3:BM(QC"$(0A$HHHKX@]@**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^@+PK_ ,BQX<_[ .C_ /IO
MMZWJP?"O_(L>'/\ L Z/_P"F^WK>K_JSR'_D19'_ -B3)?\ U390?Y<X[_?L
M=_V&XW_U,Q84445ZIRA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXW-#*LJ+DD?,\99 <J006!&.<9%'Z;^7SO;\1_U_2W^=K>9<ICR*FT-NRQP
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M&"1M; !Z$G&.>B\_,V5&6!%-$\1QA\ELX #$G&<\ $\8.>..]?AM_P %F_\
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M.GXG^-_ 'B6_\*?&/XJ:MHGP2^#^N:/>?8=:T/Q-XQ%[?Z_XFTN[C/VNPO\
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MOX!NO$?A74[S2[#7KOPMXF\#ZKK,FG^$=(\2V,%Q8;'_  74_:F_X*#?"_\
MX*??L0_ #]A?XQ>+O"'B;XW?"&W\.:+\/X]9F3X<:QX\\=>/_B%X"M/&'B_P
M]<+<:%=MX5L+BUUX:OK6G:C8:,/#EGJE]87UGILEG-0_X.4->T;]H+]J?_@E
MS^PW\,[K3O$GQWUOXY'Q1J^B6$5O?ZIX*\/>-M=\!^%_#-]KDR7D;Z/IVL"P
M\2^(+R"ZCCB_L7P@^N7]UI]A;VDUY9_X*\_&/P#\ _\ @X(_X).?%3XGZA::
M/X$T'X<V.EZ_K>H,D>G:!%XS\>_%OP/8^(=3GDCD2UTS0-3\266L:C>NH6RL
MK*>[,D(A\U 2U<9-)MPFVK*SM>SMMKY)7L5OVL?^";7_  50_81_9]\5_MQ?
M _\ X*W_ +47QN^-/P4\/M\5_C5\,OB+KGB?6_A?XR\.>&M..I>.KOPWX2\3
M^+O%?A:_TKP5IB:OJ=AX6\7^$KRSNO"UI=1Z3<^'=2L;'3K_ .E/VJO^"FOQ
M!_:+_P"#<WQ_^WM\$_%NL?!/XXR:/\'-$\2:G\-M;O\ 1-7\ ?$S2_VH_A5\
M-OB78^'M1ANYM5TO1_$5E<:M=Z/:W-]<W[>!_%>GVVHW5U-/<2R?K3_P52^.
M?P^_9_\ ^"=G[7WQ!^(.M66FZ5?_  #^)?@;PY!+=P03^)O''Q'\':QX-\#^
M&=)#L6NKW6_$&M6,)^S17+VFG+?:M+"UEI]TZ?R@>#OA=XL^&O\ P:!?'C4?
M%=O>V7_"U?B1X,^*/AJQOYI&EM_">J?MC_ ;POH]Q#:R00G3[+6CX1N?$-A"
MK7$=[9ZQ!K,<^S5%AA C[RBY)752*3LE=/=.R2=O3R/??V!OV//^"Q?_  4/
M\ ?LN_MY_$/_ (*<?$[X*^$))/A[HWASX3^&_$GQ&M+SQ9\%OAOJVA>#/&'B
M_P 2P:+XCTWPK?\ COXLQ>#]=\5:A+XLT'Q6/&NIWVF:KXBU6QTN\L]-T3T/
M7OVE/V_/^"UW_!0?]H3]EK]CG]ISQ3^Q9^Q)^R'K4OAWXC_&3X4?VA;?$?QY
MK-IX@UOPO8:A8^)]#U#PYXG2_P#'^L>&O%\G@;0[#Q7X7\,Z;X*\/7GB3Q#;
M^(?$-K::5=_O-_P2 BBA_P""77[!20QQQ(?V7_A/*5C18U,L_ABSGGD*J #)
M--))-*Y&Z261Y'+.S$_@/_P;>>,-&^ 7[:/_  5._8F^*NH?\([\=;GXTIXJ
M\-Z5XBOUCU?QUIOP]\3?$_2/&$VE_:VA;6+NQLM?\->+()+%+B?6?#VN7GB"
M)#I>F3W*@KWYW97CI%65DG)INUM;6W=[7,/]J]/^"FW_  0!U_X3?M):3^V7
M\6/^"@/[$_B+QEHWP\^+?PU_:&N]:USQ/X-^WF6_M[/2]=UGQ+XKN] FUS3-
M/UM/!WCO0KW1-(T;Q/'I?A[Q?X/\0Z9<Z?;ZU[Y_P5G_ &T?CG^R'^UC_P $
MPO\ @H7\+?CG\3I_V _CX?!>B?&#X9P^(]8G^&%UH>M6T'B$>*[KP<#)I2Z]
MXL^#?CK5-?\ #T4$ER#XA^%J:H(+:[A^U7W?_P#!U=\</AYX0_X)YZ-\"-2U
M+3;OXJ_'+XP>!)? GA(6\E]KYT3P%?R^(/%'BRSAAEC.GVEC(-(\,O?2I</>
M7'BE=,LK.8S7EYIGT1^V5_P3TUWX\_\ !!CP3^R7JVC2W7QJ^ /[('P&USP/
M9O9K;ZK%\9_V=OA%X?@FT2RM9A="RU3Q;9Z5XJ^'AC>7_1T\67,3WL*AKI :
M:M"4DM7*+T2O&R5]$E=-[Z;'US_P5X_;(C_8I_X)U_M"?'GP[KRZ=XYOO!H\
M _!C4M.GBDNV^)GQ/ \,^$-=T64,;>XE\)QZA>?$')D,4NF>%;QXQ<-Y<$WX
M^ZK^W_\ M)_\$LO^"%/P+_:"^.GCGQ7\=OVU?VG=0L]4\!GXY:YKOBI_#=[\
M5K/4?&/AHZU9WMU;:U#X?^'?P>T72=0U'PPUU9)_PL753IM\]K%J]UL_&SP_
M^TWXD_X+2V/_  1)_P"":,MSK6L0?#>2\\3?M@W!4O;WFC?!Z^UOP=HVIW>J
M0IMBUZ+]GCP7XCOEU*_BB6Z\3_%S3+"6>\OYTDN_UF_X.W_ACJUQ^R!^RCXZ
MT?09I/AO\+?CS=>&O%6G:!]DTV/1K#QCX'N8/#7D!-*OH=&TY5\)7N@V=_\
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M &?O^)7?Z7^_L=>TV^,-[H6JV6H:7JD-K?6-U!%Y%_P2T_9A_P"";WB+5/\
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M>(? W_"2^'M(L-8TK3W\>>)!XW/C3Q/%X@MM-MO#EAX:MK&/S/X4_$+]N_\
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MIZ'X\UC3-5>?1-5TG5]&OKU-2UF\\6^'KKQ5 O9>+_$^A?L7_P#!U1K?Q/\
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MTK4=/M-!UGQ=X:\(66B>'=6T'6/$_BUM7FU+Q5:>#-.NU/A?[97P,_X*=?\
M!$CX?:/^W!\&?^"BOQL_;0^"'@+QAX?LOC_\#OVJ-4U[Q583Z3\0?$]IH0UZ
MROM;\6^*)+>PUWQCK.CZ3=77AI_#?BW0->UVVUN+4?$&GZAXBM8OSYN?V&/@
M-\>_^#A?]N']E_\ ;"^+/QR^ %Q\8/$WB_XD_ 7Q#\'_ !AX;^'=W\0?$7C6
M]\-?$'P[X1FUKQ?X(\;Z=JEMK?@G6==FTF"SM[/[;XI\+7&A17LFM/;:1/\
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MWWAJ'Q?JJZU9>$?!'PQO=6M[>&_EMKC06?%+_@D+_P %8O@1\(->_:!^!O\
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ML][X?^$'Q_AB\;)!MV:7I/Q#\)ZMH6D^(+O=(F+2W\2Z?H_AW,:RR_;?%%D
M@A,\B!4K>T4+146XMZ)-O5[]+V2/Q]_9F^ /_!Q%_P %;/ .M?M@>#OVVO'_
M ,-_!-QKVM-X"3Q!^T1\5/@%X>\;:QX<FU2RU%_A!\/?@KX>G\):9;Z3J<FH
M>$X_$VJ:?X2TV;4H[W25U^Z72M6DL/O?_@AW_P %@?VO-&_;'UO_ ()A_P#!
M2'7_ !'XF\=2:QXL\#_#SQ?X^MK>Z^)7A#XM^"_MM]J7PY\;>*K5U_X2_P .
M>)M,TS6I_"_BO4Y=;U5M<BT:PLM;U;PYXBTU]%^\O^""?_!2C]B]?^"87P>^
M'7COX]_"#X.>//V:?#?B3PO\4?"GQ%\:>%OA]=6=C;^+?$FN:5XTTNW\0ZO9
M/KVA^(-$U*RO+[6--68)XFDU73KJ&"[%NMS_ #J_LX>)4_X*&?\ !S'8_'#]
MG:PU'4_AO!^TU+\8SXCM;&?3[1?A+\%-$T[2KOQUJ:.%FTO2O'C^'=,AL5U-
M+6[N]2\;Z-I-]:VVJ:D;%0/B]I&44HQ3LTK6:VUZW/HW_@J+_P %//VS/VA/
M^"JGB_\ 81^'?[:K?\$\/V??AW\2+CX51_$F?QOKWP>T2PU?PUH+:EK_ (]^
M)/Q0\'6FF>.!9>*M>LI-'\)Z9)K6G^![2TOO#HU*XL+.^U_Q9+WW@S]F;_@X
M8_8Y^+GP=\9_L=?M:ZU_P4N^$7B*.:^?^R?V@7^)WP#F@T/4K$:]X%\;6GQK
M\=6_AGP;_;UMKD<NG>(_!WB;3]7N+:2^U'3=;TO4M$E:VZ?_ (*2?#__ ((D
M_P#!2#_@H-XB^$9^//Q>_9$_;7U+Q7XC^$GQ ^)^K_#*RTW]G_5_B-\-;&^T
M.&+XEZ;\0=9\%73^)[M]!M_"7A_7_#VO^&=,\636.E6-S=WEYJVDZK<_BU^V
M;^QI^U)_P0S^)_PL\<_!O]NCP-K.L?$&Z\07/A36OV=_B#K_ (<\>VUKX4-C
M'<W'Q)^'9:XTL>&-7CUI;"SAN]9\7Z#K,L6N:/J%N(K<K>@U9J,4DFX_#*&D
MM-^9:_B?OG_P=2?#7]LCQ/\ !CX4?'B/Q@W@;]E'3/!OPV\.?%_X!3_$*\OI
ME^/NO>*?$FIZ;=MX=T;3;CPEXGE\,6%Y;Z._BZ/6+=7_ +.<Z?#-;M 9.8_X
M-B/V?_\ @H1::=\+/VB;WXVO<_\ !/2;1?CEHNC_  +B^)'B2:6'QY%KFI:3
M+JT?PR.BKX;C>3Q=:ZIJ27RZXT[M<"\\H3RF-?HC_@M=\7O'/Q__ .#=+]GG
MXX?$VRAL/B#\6K7]D+XA>,8K:T73[6X\0>+/#9UG4=3L]/2*".PLM9GNVU>R
MLH8Q!:6M]#;P,\,:2-ZC_P &]/[5_P %?AK_ ,$>M$T-/B'X"UWXP?":V_:I
M^(-[\#X/&>B6_P 4-6M?"&N>+_B2T%AX,$\_BFZMK[P\]C=IJ>G:'J%K%!>!
MP9)()H4";OV5K+XW':_?7UOU/S]^(?P2_P"#D#_@IA^U?\3]'U?QG\:/^"?'
MP1TV/Q)J?A'1]1^(GB;X4_##2/!4^L7-AX8\"MJWP(>_NOC%XXN[5EFUS4]7
MN-8M([>&_P!1-_I6ER^'-&N_F;]CO]MW_@I;_P $Y_\ @KQ\+OV"?V@_VL->
M_:I\"^,?CG\(_@1XST_Q%\4_$GQO\%W.D_&F]\)>'O#'BCP#XE\=7,OBSP5J
MW@Z3Q-I-U?Z!:RZ3!9:EI6N>']5T?4HI/M%QY1^Q#JW[3_\ P< _M1_%_P *
M_M>?\%%_'7P1\ >'/"EW\1(/A!X2\17.A^&=;TR;4Y+2?PS\-?AO+XCT3P-I
M^E>#M'S<^)/%6M6/BOQ-_9L6G2:O%KCWNJ:]IGRA;?!;]F']FC_@O)^RC\$_
MV3_BEK'Q=^"WPO\ VV?V*-"7XF>(_$'AKQ$^N>+[?XE_"J^^(S6_B#PKH_A_
MP[=Z7H/B^YUG08I;#3H[:V;29[<7NJ+ -6O0M+XHM1T@WRJ&BTT?.]6SWW_@
MYE^$G[6_P^_;47QA^T%\3O\ A-_@Y\5=>^)?B']E3PM_PFFL^)?^%;_#^PN/
M!MOXBT/^Q-2TVRL_!_VW4KO2I_[,TBZU&UN?LWFO.AA16_H'_8R^(W[</_!)
M3_@F3^T]^UE_P4"^+EK^T%I,7@+X':Y^R3X-E^*/BKQG!;+XAT6Y\.>#_ <G
M]K^'=.NO".G:KK/BKP,-9M]%M]2&GZ!I&J:@Q6/1PS?GI_P>,?\ )3?V$?\
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MZ_X?\4:DC:Y;#PUXGL-:U[Q!!J/AN#1/QG_X(T?\$_OV>OVW?V?O&FH^(_\
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M*:+[-XUU;Q!K%] -OF_\29HS!(0,E49OE4N0&!)7.&%?U\R':A/!Z  XP22
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M;ZTJ*7MI5:<HN=.#BI7M4]QSC>5WI[K:7,_[XO\ @J%H/B;Q/_P3V_:Q\/\
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M(?\ XD-\:O\ YLJ <I-6<FTNC_K7YW/A?_@G/XJ_X-MO^"8WQM\4_'KX"_\
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MN",9X!VXYK^[;]D#P%XH_8B_X(1Z[9ZY83VVN:W\/?'OC$6DA*RV\'Q+TP+
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M!U;3Y?$^BZ1HO@S4KC3%O_$(UDWUS<6OA/6-*O/P0\4?M6?\'0OP>_9WT/\
MX*,^._'%W<_ 2_M/#_C74O"VJ^!/V>;A=/\ AYXBDL8M U_Q5\)]!\'Z;XM\
M/>"]8M[K3%FU+3I=/\6:78:A'X@UJYT=)KO6U!*FVD[I7=ES.UWY?D?Z -%?
MB3^QU_P5/N_V\/\ @E)\<_VOO!5A8?#'X\?"'X3?''2_'&@Z6++6](\'?&CX
M<_"Z]\8:1XA\-6'B$:N;WPEK$-YX=\5:%IWBBTU)+<W%]X6U.;Q$-%O-4U+^
M3+]F;_@LQ_P7]_;:M?%'[-_[-_C'4OC/\9KV2W^(5UXY\.?"S]GSPMXG\#?#
MKPO&-.U72[6Z3P1X+^'FAZ+KVO:YH_\ :VO^*DU#7;K4(M \/^%;W2&U#4[7
M70%3D^;9<KL[NUO/T/\ 2#HK\W/^"34O[;=[^Q#\--9_X*#ZYKFK?M+ZWK'C
M>]\1:=XG\*^%O"7B;PKX:M/%6I:)X/\ #^OV/@_1]$T>]U%]$TFW\0'539O>
MW=MKUM'>WE[-;FX>/_@K!_P4)T3_ ()H?L=>+_VBI]"T[Q=XYO-<T7X=?"#P
M5JUU<V>E>*/B7XHBU"[TZ'6)[)DO1H>@:!HOB/Q?K4%G-:7>I:;X=N-(L]0T
MZ]U&VOK<)L^;E6KO;39^GD?I/7XH?\$I_P#@IQ\5_P!OGX__ /!1KX1_$;X?
M_#SP9HW[&?QA\-_#GP-J?@H>)!JGBK3-:\:_'KPS/?>*_P"W=;U:T^WQ6GPG
MT:XA_L>WTZW^T:EJ>^%H_LJ6_P"<'PM^%/\ P<S_ !+^$/A[]LJ']L[X*Z+X
MN\3>&+3XL^$?V,O$'PS\)V6EZOX:U'3(-7T3X=^(KFW^'=M;^&_$'B#0)VA@
MTN\\4OJNDZE<Z;!XA\>^'O$']J:EX?\ '_\ @U#\;^(OB9\9O^"O'Q'\7Z''
MX9\6_$#XG?L_^-_%'AN*VOK.+P]XB\5^*OVMM>UO0X[/5'DU.UCTG4[^YL$M
MM1D>^@6W$5V[7"R,0OD2C-WC*R6S>CYK/HNG75']EU%?R7Z!^WG_ ,%0O^"Q
M'[27QQ^'W_!,;XG?#C]D;]C?]GKQ%?\ @[6_VF/$GA;0OB%XF^*^IO>7EKHM
MYX=M_$'AOQ$L8\36VES>)M!T;PW8>')?#WA.>*^\7^-7U;6=!\/W'1>&_P!O
M7_@I;_P2Q_;'^ /[,?\ P5'\??#S]J+]G']JG6M/\(?"G]JCP?X6TOP1K_@G
MQ(M]IF@W5IXCTWP[X:\-6U[!H^L^)?#C>+[#Q!I.I:E_PCVK6'BO0/&VH2Z=
MX@\-$%R/:ZYK7Y;^]:U^UKVUM>_ST/U^_P""@W_!33X<?L!>+_V3?AGXC\!>
M*?B#\1?VQ?B[9?"SX:Z=I%Y8:-X;T2WMO%OPW\,^,/%?B[7[M;VZMK?P]%\3
MM O=*T73-%U&[\2W8ETY[O0;59]9M?TPK^%7_@XJ^&7[:5M_P4-_X)^:EK?[
M2GA74/ _Q0_:$U>S_8E\.0?#?PM#>_LR^(++Q!^RYI7B;6/%E_'X6M[GXE0Z
MQXYU#PIXHMK+Q7?>*X+6ST"YTN&*UM+^YM+C]L/VN_V^/VC/^"/O_!.OP=XC
M_:O^(GA']LW]N#QWX]UWP#\-M0T?P=I_P[\(^--7U75-4UO3+_6O"_@70?"0
M@\.?#SP:+&SU:'0],T_5?$NNRZ'HRZC93:]+K]B#<-(6:;E?37OZ625K/7?R
MU/WZHK^6#0?V;_\ @YU\6?#VT^/][^WO\#_!7Q5OM%MO%6E?LH77PI^&ZZ#:
MV]Q$^HK\.O$7B&7X57&B:;XE-M*-)N)I[[6_L>H2>1-\1+3[&FMV_P!^?\$C
M/^"K\/[>_P"S=\7_ !?\=?"VF?!?XY_LGZU>^&/VFO#</V^#0M(AT_2]6U.'
MQY9Z9?-=ZUX>TS4(_#/BZPU'P[J,U_?Z/KGA#7[:*ZO+3[&[!+C9-IJ23L[-
MZ7VW2T\U='[1T5_'K\!_VLO^"R__  6T\;_%_P")G[%?QN\!?L$?L8?"[QU?
M>"?!6O:SX$TGQ=XX^(.L6]L+^RMM5N]5\,^*[K4M?L_#NJ:1K'C&TTC5O"?A
M/PZ_B#0M-L[7Q9J-M/JL/O\ ^R-^V3_P50^%G[8OQ3_X)0_MQ>)O"GCSXL^,
M/@CXN\4_LJ?MJ^$/A[;PZ)8ZW<>%/%-UX"\0>.]/TSP?I?A#6?#C7NA7UBG]
MO^$-,U>U\<^#]3\+ZU=_$!/$5AJ,8-P:OK&Z5W&^J6E^EM+ZI-L_6/\ 9U_X
M*8?##]IW]N3]J']BGX=>"?%MMJ7[)>BNOQ'^(7B233].TO6/&T/BY/"U]X<\
M(:':R7]]>Z+IK+/)/XFU6[TB:[O(VMK+0I;%8M6N>4T_]KG]LZY_X*KZ[^R)
M=?LJZQ;?L7Z?\,H?%6G?M6-\-OBJFC7_ (N?P)H_B!_#"?$F1A\*99D\27U]
MH1T^!3J8DLFLC_I\4Q'\J'_!,+X(_P#!2S7?^"N/_!03PQ\,/VT_ 7@?XW?#
M_P"(7G_M8_$K4/@UX%UO1_CWI5C\6O)\56?AKP[?^ [_ $OP)-K.HQ7=U:R>
M'='\-O:QW0CAFM$A2,?O#HO[=/[5%W_P<3^+_P!A2X^*7F?LJZ7\ [;QK8_"
MS_A"/ARGD>)I/A#X7\4/J?\ PFZ>$5^(TN==U&\OOL<WB^33QYWV46@LXXK=
M IP2;2L_<ON]-%KMUO=+:V]C^B&BOY;OVL_^"E'_  4 _:X_X*&>-_\ @F'_
M ,$HKSX?_"V\^"UO+/\ M!?M6>.]"LO$R^$KK0)M-M_&=AI&G>(= \4Z!IND
MZ'K.L67P_:,^"_$GBSQ+XU-T=!O/"^@:7<^)6\0_:!_:7_X+>?\ !%J\^&OQ
MS_:X^-OPU_X*"_L=>)?&&F^"?B/#HO@KPYX(\<> ]3U<7]W VGZQI7@[PGKF
MGW^JV=C<GPYK&N7GC+P7+J-B?#>K:;X:OM8T2_OPE0;MK%-JZBWJ^W2ROT3:
M/[ **_FS_P""['_!3CXV_LP_L4?L<?M5?L1_%5?#6B?'CXJ>"-5;6E\(> /$
MP\<?"+Q;\*?$'Q#TS2_(^(?A#QI::"VL6\&DW#:EIEA;ZQ8MF);DIYT$GSU?
M_#S_ (.7/VD?@[>?MB>$?VL?A!^SO=>*O"C?%/X5_L:^&_ GA^\URP\(W-K)
MXF\-^#=5U7Q)\)_% F\=:KI#VT-II7B[6]?^V7]U9Z7XFU'PPTE_IVD *#:3
M;C%-M:M[K?2S_K<_K1HK\7O^"%7_  4A\=_\%+/V-;WXE_%[2]'T_P",OPN^
M).L_"CXAWWAS3&T?P]XLGLM$\/\ BCP_XPTS2Q=7D.F2ZIH7B6UL-:T^">.V
M3Q!I&JWMA8:9I%_IEC!^T-!+33:>Z=F%%?R<M^T]_P %F?\ @J?^U-^TA\.O
MV(?'OAC]@/\ 98_9Q\3KX4@^(/Q*^&!N_B%\4Y)-1U[3] UF!?&/@KQ+J-U+
MXFG\,ZCX@_L_PO;>#M'\*^%;C2].U[5_$.LW,2ZSYQ<?MA_\%>/^"47[>_[(
MOP$_;O\ C_X%_;&_9T_;(\;:/X*T3Q7IW@?0O#VM^'K^^\2^%?!'B2^T*_TG
MPIX.URPUSP3JWC7P;K6J:%J]QXM\-ZUX9U!1I,6D>(-4O+BP"N1]XWM?EOK:
MU^UKVUM<_L-HK^8[_@N]_P %,_VQ_P!@']I?]@_P_P#LOZC;:]HWQ=LOBE#X
MI^"M[X2\'ZU8_%WQ=::IX)\._#G0K[7-3\.7_CC1K)=?\3QK=VG@/Q/X1U/6
M;:66Q75K*ZEM=0L_F?\ :>\'_P#!RS^RW\!_%_[<?BG]N+X,>+)/AGIQ^)?Q
M-_9M\'_#[P+=:)X7\ 6-EYWB:SL'U#X56.D>(K;P=I7F3>(+:SUZWU1M+L=4
MU_0_%^M>(;:TGU !0;2?-%<VUV[O6W9]>NVJ/[":*_&/X4?\%>?!>K_\$==-
M_P""IGQ.\,6EC-I/PXUB?Q;\._#=^;:#4OC#H/CN]^$=OX.T*YU%[ZZTG3/&
MGQ&MM.;1Y+\ZK>:'X:\06E]=_P!K&SDDNOR=_9BC_P"#C/\ X**_"33_ -MK
MP5^V?\%?V5O!/C^;5=?^!OP*O/ACX=N=*UKPSIFIZE#IMUJZW_PS\:ZK8^&-
M<O;4V>BZKXKUSQ9KVN:*O]NR6-IH]SHLNI@*#UNU%)V;;Z]E9.Y^I_[-W_!3
MCXK_ !I_X+&_M@_\$X-=^'_P\TKX7_LZ?!Z\^(WACQWI \2?\)[KFIVVH?L_
MV:6.O&\UNY\/?8&3XN:TS?V?HUG<;],TO$P'VL7'[7U_#U_P0L^(WQU^*W_!
M?W]O'QC^TYX-TKP#^T&W[*7C_P +?%_PMH<,T&B6/COX>_%7]D[X?:[>:/'-
M=7R_V5K=SX7.O:>]I?W^FRVFIPRZ3?WNF/:74O\ <+0$THM)?RQ;MKJUJ_F%
M%?RT_MJ?MQ_\%#?VG_\ @JMXI_X)2_\ !/OXR_#/]E-?A%\-M+\<?$WXP^/-
M!T;6_$_BV^O/"G@SQYJ&G^$+;Q#X?\4/-#IFD>//"]A8:'X:T*SUV_:T\8>(
MK_Q%'X5L,VN=HOQ(_P""[?\ P3N_:_\ V<_A]^T'XJO_ /@I?^RM\??%O_"/
M>*O%7PE^ EY=^-OA#I2:SH>C>(?%VM?\*[\"6.K^$7\,V7B#2_%D<'BG4?$_
M@SQ%HNG>(M*T^_T/5+>[U?3P.1V6L4VN9)NSMOVMJME<_7O_ (*!_P#!3+X:
M_L!^+OV3_AKXF\#^*?'WQ%_;#^+MG\*_AIIFC7-CI/A_1X;?Q5\._#7BWQ;X
MMU^[6ZFM;3PZ/B9X=NM/T;3=)U"_\1W3R6*S:1:QW6KVGZ65_"K_ ,'%7PR_
M;2MO^"AO_!/S4M;_ &E/"NH>!_BA^T)J]G^Q+X<@^&_A:&]_9E\067B#]ES2
MO$VL>++^/PM;W/Q*AUCQSJ'A3Q1;67BN^\5P6MGH%SI<,5K:7]S:7'[7?MC?
MM=_MZ?\ !+;_ ()L>&=<^)NI6/[=/[<7BWXAZSX#T?Q_X2^$EQHW@'3;76)O
M$_BC3_%OBGP1\,_#/A6T&F>"?!^E6NA16,$&@2Z_XBN;"XNKZYM8M4>0&X:0
MLTW*^E_-]TDDK6>N_<_?RBOY5F_8\_X.:O%'P^'Q;N?^"E?PD\*?%?5- 3QA
M%\ +3X<_#VUT?1-9\A;ZP^'+^(HOA!=^$5U"VMDM](O;BYM=5\/RZX)XM2\1
MZSI[W/BJ[^N/^")7_!5CQS^VS^QI\;/BA^UK#H/A/XC?LG^)M?T7XP^,]*T<
M^'M U?P?HOA,^,%\::EH5N\L&B:]IUC8>([/Q5IFE6\&EB718=2TRRL4U,Z3
MIX2XV3:<9)-)V;TOMNE^!^^-%?Q[? /]I7_@M;_P6G\3_%+XZ_L=_'CP+^P'
M^QSX$\;:AX(^&$/B#P/HGB[Q5X^U+3H;&YFFU6^U/P5XHO=?U"RT^[M+OQ+=
M6.H:#X-T?4=4A\,Z1IWB'4-+UC5+?B_"?_!2+_@L7\(O^"LO[&__  3H_:]^
M(7@6R2;QSINE?$GQ5\.OA[\.CX7_ &H_AKXQ;5+_ ,)^/K.\U;X=VNN>%9H&
MTS5O#=]+X!D\!V_V_2+K3+SPYI^LZ/J5[J8/V;U5XW2;:OJK*_:U_1NW4_>G
MQY^US^V=X>_X*K_!7]D3PW^RIK&O?L7^.OAGJOBKX@?M61_#?XJWNC>"O%UG
MX#^+7B"R\,7'Q)L&_P"%4Z3-=^)/!W@G05T_6U_M.63Q;!91?Z?J>D&OU4K^
M=WXP_MT_M4>%O^#BC]E3]A/0?BE]@_95^)/P$\1>-?&OPL_X0CX<W7]M>)K#
MX0?M(^*;34_^$WO/"-Q\1M.\K7? /A*^^QZ3XOL-/?\ LG[+):/9W^IV]Y\@
M_P#!0K_@II_P4Y^%?_!8B]_8/_8SU+PIXY3XM?!OP#H'P@^&7C?P=X(?PMX&
M^(OBW3(/$GB?XQ:SXGM_#MKX]U&R\$^#]!\7:Y/I6J>+[OPII\2OK%_X;UVT
MTC^P-0 Y&^6UE[G-N]4F[MWV?II9=S^N"BOXN/VS/B5_P<$_\$CO"W@3]KCX
MR?ME_"+]KOX./XXT7PU\5OAY%X$\)Z1HMA>:_<O=66FS11?#7P+XAM-!UN2T
MN='L/$O@?4M*U/1+^:SCN= 32YBK?M3_ ,%'O^"N'A3]CC_@G%\/?VSOA_H>
MG>*_''[2?ACX;/\ LU^"M>FN+C3-2U[XK^"HO'NFZSXF&D/#>W7AOP=X0:\U
MS54L)K%=;U*#1O"\6K:-/XEM-3M0.1^[9J7,[)J^ZZ.Z5N_H?L]17\H7@KX0
M?\'/,GPIM?VM)OVO_@O>_$34?#5M\1D_8?\ %7PJ\$P0:CI!CL]8@^%6HWUE
M\.=)M_#7C"]TBV33Y++2_%VDZM;ZO(^D:A\2-.OKW5M8A]4_X-Z?^"EW[6?_
M  49^(G_  42U7]I7Q1'/X;^&_C3X-:A\'?AA%X1\$Z!%\&-$^)6N?M#W.K^
M H]<\.^#O"WBGQ?'HMAX0\)>'DU;X@76MZ^Z^'!>3W$.HZEK$EX X.S:E%J-
MKV;ZNW9??MYG]--%?CW^Q7I/_!7&S_;K_;#OOVRO$^AZK^P_=ZY\4V_9%T>P
MM_@)'J.F:)+\85F^&"7TOP\\/:;\2I&MOA%NM9CX^U34+EI_FUII]?\ ](K]
MA*"6K/=/1;;:_P"74****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %13[O*D
MV<OMRF1D;P<ID8.1NP2 "2,@<XJ6D8$@@=3[9_3(_G_A1_7]6#^M-_EMK\T?
MRU?M\_ K_@MO^T?XT^*'@;X<>*=#\'? /Q TVEZ-IND7"VNJZCH4R/'-!J#
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MQS\"BZN;G0O%GAJ[LH$^PS3--!;7L5Y.LT=V@D"$C<K%&4,VTX_TEV#'&,X
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M@[2I[*_'1X3RVE65:3Q%17DY4Y345+F?,U)P]^479*T7%RVE=ML_S=OVK?\
M@@C^WA\.OV@_B-X-_9^^ OB?XI_!G3-4L3X#\>6%_IRQ:KH]SI&FSR"X6>=9
MUN[*^FO;:Y5E4F2'> 0VYOKS]@[_ ((N?\%=_AYXCTC5?"7Q<U+]D?2;[6=)
MOO%UFFL2B;5-,T^]@OI[*XMM-^T&1;E%>(-'&26<JS$)(%_O-$;#E2!ST*J&
MSGDDH57;WV@'.,G+'%*$()RH?)Z[$&,@?,?F!*CN,;B<]1BIK^)>>XC!1P57
M#9;->RA2J5JV&>)G6<(\KG4IUI2P[E.7[R35-)3]Y12?*G2X5R^CB?K5*>(A
M+GE*,(2C3A%2=[)\LII13M%:-J]Y7NW_ "7?\%.O^#>;QS^T?X\N_C]\#OBG
M'<?$G7M/LI_B%I'C9Y;N+Q%K5K9PV]Q>:%<@+':)=R0^<L4Y5PTC*01@G\N/
MV=/V</\ @O!_P37\17UQ\%/A#XL\1>!+6],MQX;FO=/U?P'JMSN=([J327F:
M6-F"9)2,,0489^]7^@T0^#MQN.,$D@=.3R&QS_#CWSD\0G((5@&=ER.HSL&<
M<AQ@D<G* Y VBN3!\>YO0P$<LQV&R_-\%&"I*ECZ,E)4DFHP4Z/*GR)\L&XP
M<8VA%I15]Z_#N#EB?K>'J8C!UK\SE0DG'F;U;C4N[R=FUS2CS>]:[T_B"^,G
MQ=_X.,/VT?#%Y\/H/V?]0^$?AG4H3IFNWGP^,&@M<6EPCQW%MJ-Q=7+W$D4\
M,KB182!Y9"L%"C&C^Q;_ ,&POC[7==TOQU^V1X[MM.\/FXBU*Z^'WAR25_$=
M[>13>>T&LZBY>W\F:17BNUWEV6=G0.<X_MH#*S.I*$_N_,7)#ID KE,*P."I
M7GN1R2*LQ%2I969@QR"Q)/0#&3DXXSUZDCCH$^/,RH86>#R? 99D5&KK.67X
M>3K2]VR;K5W)1DE=0DE4DD_=DNC_ -7L+6KPKXW$8K'S@O=5>I:"LUS**@W)
M1;MSQ4X1;TE#5I^;?"SX3>!/@MX"\.?#/X:^&-,\*^"_"EA#INB:)ID$,5M!
M;6Z! \^U(S/<W!+R3W#*TKDX=CP*_'K_ (*Z_P#!&SP=_P %$M)TOQQX(UC3
M_AY\?/#%JUKI?B&[MPVE>(K &0FPUQ+8^:]P!LCLKEW9$0LD@CP#7[HE@O7C
M@GH3T^@Z^W4]A49?=]PDG"D #!PQ(Y+ X'&>@QC).&%?,X#-<?EF/CF>$Q,X
M8R,Y2E6F_:.ISMNI&NIM^UA4;?.JE]7=.+2:]7$X/#8K#/"5J2E0<4N2*Y>7
ME^%P<$G%QU2Y6KIR3O=W_P R7XA?\$&_^"G/@W7[[0M$_9ZU7XAV%M-)%%XA
M\-7^EIIUXJL=L\2SW"RQ[N65#AURK!@&!/MOP9_X(O\ _!8#Q_96_P -M?TO
MQG\'? EXZVMQ;>+/%+3:/#:[P3)-:V=]*[PIS\D;%F(V!2% '^C8N2/D)4$\
M_(O!VJ?]G(YV@[3R#VP:,29#84GT8$<#/=689[CY3UZ\<?=3\4L]JTHPE@LJ
MYXQ]VM*C4G)32M[2,)5)TE/F7,K>[S>6B^>APCE]-MQK8OE<KN*E%)IN[C?W
M9<MK)KE325N[E^!W[!O_  1NT#_@G3\#_B9XO\#/IOQ-_;&USX?^)X?#_CW5
MH5?2]'\6S:)>+H,.@K?[KFSLHM6DA:>9_P!Y*WF%G6$B1/P\_:K_ ."37_!9
M7]MGQ)IOBS]H+Q'HOB2XT:(Q:-I%M=C^Q=, WKYUG;;DBBN)(]D<LB*=W0,
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M54ZU3E<6HSFHPYH3YZ;:@HRFXSU3<ES-*\;+E:PH8X8HR<F.-$)X&2BA2<
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MO].U./Q78360>.^L]2@_M+_X*(_\%:/V.O\ @FEXA^#NF?M(#QIJ_B;XH_\
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M@TK2M/\ M33?^"6W]G_\%;]?_P""IO\ PO3SO[<^%D/PT_X45_PK+R_LOD^
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MR+*RL=8\2:OI,!L) +Q<HS<K6Y;QL[WBDM'M9V6]K:GXU?\ !7SP?XE\"?\
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MO.U]&]6GKV.*_P""\JJ__!6[_@@:CJKH_P"U%X)5T8!E96_:8_9S#*RD$,K
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M A^6?BA_P0:D_:9_84\"?LM?M>_MI_%OX_?'CX2?$'QQ\0?A)^U]K^CZQ?\
MCKPJ/'5M8)J'@;Q+HGCOXE>/]4\>>"4N;"TFGMY/'7AK5IET?PW#HVH^&K?2
MI[?4 $X6AS/X;IQL^K;3[-;76YX*/^"3/_!5'XC^$=5\8_MT_P#!</XM^ ?#
M%IX?G\1_$7PO^S]IUWX$\.:9H]GI@O?%<=_XWT;Q'\+M!L=#TG3+"<73R?#J
MZT>>,WFH3VL,0N8]0_,?_@A1X$UWXH?\$F/^"W7P[^%]SKFNZ]XU\*_$KPWX
M'$-I->^(/%MUJWP#\>6FB:0UFD0NIM1\8K)!H]Q'%;FZ\W5I/*MGG"0M^M&F
M?\$,?VS_ (I:1!\(?VT/^"Q/[1?QV_9@LFTG3]3^$7@[PQ<?#O5OB;X;T>=V
MM]$^(7C34/'GC"^O-.N88+%]1L-8MO&DMY<D70U6'4M)TW5#]4_\$W_^"66E
M_P#!("Z_;2\<>#OC-J?Q8^"7Q:N#\2/#/P8L_A/_ &1XU^&NE_#B3Q[J_A_P
MOI/C[4?BKX@?XD:F?"7B./PK+/K.C>%O[;U;1M-UH2Z*;[4K68'S+E:YDW>+
M24>5:2O;9:^O3K<\(_X-<_B1X(\8?\$J?!'@KPYJ.F3>*_A-\5?BYX;^(>E6
M\KKJEAJWB3QEJ'CW0;W4K6:YED\C4O"WB?28=.U"W@M=.NAIEW91+-J.E:K*
M?BG_ (*5_$WP#XO_ .#DW_@ECX"\,ZC::GXP^%&G^#]*^(QM+J:8Z)J7BOQ!
MXY\5>'O#.H0,HM[;4[?P[?6?B1_)9Y9=.\5Z9]H*[(D7$_9O_P""=?['7_!1
MKQ9\5OVU?^"1_P#P4%_:H_8,N?'GBW5])^.'PL\!2W7A_6M,\1W]U'XCU,)X
M<\+_ !*\'>(/#?A/7!KTNI>&[6XU_P 4^%+#67O7\(R:=#HYT+3OC?P#^QA\
M!_@M_P '#/[#/[//[-'Q3^('[0?CKX5V>J_%;]L#XV>.?$K>.M?U;XN:1IOQ
M,\;>(H_$VH0W@TS1KNQ\/6?@[0[RUCEGNM-UCQ)I^EZUJ&O^+Q?PR TH\TY7
M=^6;<6FG%M:W>UKO2V]T?H=^T#_RMO\ [#?_ &:WXM_]4!^V#2>)41O^#N#X
M?%E5C'^RY>NA902CG]G_ ,;H60D95BCNA88.QV7.&(/ZV_$#_@EK_P )U_P5
MP^!O_!4W_A>G]E?\*8^%NK_#7_A17_"LOMW_  DG]J_#_P",'@7^VO\ A9W_
M  L*S_L?R/\ A:_]J?V;_P *]U7S?[ ^P_;X_P"U?MFG+J7_  2V_M#_ (*W
MZ!_P5-_X7IY/]A_"R;X:?\**_P"%9>9]J\[P!K?@;^VO^%G?\+"3R-O]L?VI
M_9O_  KV;/V?[%]O'G?:X@GF5EK_ ,NG'KO=NW]:'SC_ ,'-7_*(/X[_ /8]
M_ G_ -6]X3K\2?\ @K[H^I:-_P $G?\ @WS^-U[HMWJWPZ^$OP]_9A3QXR6<
MMUID"Z_^SQ\&->TNWU5HX;M88]3LO 7B&RM_.LKE)Y'>W56EECMKK^K/_@IK
M^PU_P\8_9!\>?LI_\+0_X4[_ ,)MKW@36_\ A/?^$)_X6%_9G_"%>+])\5?9
MO^$7_P"$N\#_ &W^T_[+^P>=_P )%:?8O/\ M7E7?E?9Y/BW]OFX_8J_85_X
M)5? G]EO]O\ T;X@_&C]G&/P+\#OV.=5\:_#OP98P:P/%_P]^%H_X13XF#0G
M\:G6/ ]RTOPLOO%.CW&BZEXO?0=8@LM%O9=8@NU74P(2LHI7;YV[+>SC;3SW
M^X_9[2_B#X'UOP%8?%+2O%>@WOPXU/PG;^/+#QO%J5L/#5QX,NM(77H/$ZZM
M)(EHFBOHKKJAOY)$@2RS/(Z(K$?R0_\ !K?XQ\,_$3]I#_@L[\0/!94^#O'7
MQN^#'C'PF4M6L5/AGQ/X\_:_UO02MDT<+6:G2[ZUVVK0Q-;C$1CC*%1V_AO_
M (()?"?PI\#9M4UG_@L;^U)-_P $TI-%M/'M[\+D^(EOX4^$%]\-I9VU34?[
M:\51^-V^&PT37=.N9+:_NK+X9Z0LM_,EU+:27\-K;08?_!IWX%T.#P[_ ,%&
M?C+X%\-S:#\*_B-^T#X)\'_#4L=:%L/#/P[M_B/XBTS1+5=<N;^^9?#^B?%;
M1(9)[W4M0U9VO!%JUW/<VXFD 2BH3LV[\JV:2]Z]M>NG38_KSHK\>_V*_P#@
ME;XE_9&_;K_;#_;-U3]J77/BUI/[56N?%/6=-^#=_P##V_\ #>G?"Q/B1\85
M^*MO9V/BBX^*?BVV\1+X<MA_PBL,MOX-\*B^@/\ :*0Z;'_Q*J_82@S:2>CO
MHM;6]5KVV"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 $XKS7XL_$S0?A-X%UKQMX@;=::9"!;6JK(TFH
M:A,)/L=A $1R9KB2-@JXP0K E0<UZ+,6$3E20P5BN#CD*3U_7Z@5\C_M'>'%
M^)/C7X%_#.Y(.FW?B^\\9ZO;R?ZNYL_".F33K!( RI(FZ]$@0L2S1CY2>OL\
M/X/"8[.,'1S"<X9=!U\7F$J3:JK X#"UL;B53DDW&=6&'C0C-)\CQ"E]FY\M
MQIF>993PUF>)R6G2J9W6CA,NR6&(7-0_M;.,?@\IP,ZT;KGI8>MC9XRI"Z]I
M#!.E?]Z>:_#"#Q;JL5W^T[\>_%%YX9TB.RN-0\/>"Q,;:QT72$2:6VEO(89?
M+N+VZB2';$I9G:-EPN2PJZ3^TU\=OB[/=7OP*^#UK=^$TGE6P\3>,;W^R&U&
M**22-7A@N)84:!WCE*E0)&W1X#;E)7]NV[FN-!^%OPRC0V_A[QKXRTK3]60#
M;']@M)K:(6C",E1%)$YB" D8\SMMK[J\.^'M)\,:)8^'M#LXK#2=,M8;.SM[
M=/)CBBB3&Y-A'[QRQ8MO!!QD*"17W>8YEEE#*,OXCQ^19?CL;G=?'87(,JK^
MUIY+D&191B(86,7A\%5P];'8^O7K-.KB<1S25.M7J2J2K0:_)<ER7/,7Q'G7
M!.4<6YSE&5\+87*,=Q=Q!AGAZ_%G&'%W$N$K9A.HL;FE#,<+E.583!8>,XT<
MOP,8QG7H83"T\/0P<U/YI^#?QN^)7B;QSJ'PT^+/PQD\&^)].T9=535+"X>]
MT348%D?YX+C8T8D4 D1-*'.4^3DAOJU+RV200RS1Q3%(0(G<+(2^[ $3'S1\
MV?O+T(.>#CF/&!TRST+5[R]U2S\.YTRXLQX@N988FT^.5021=3,DFX!BZQX8
M[@3DEL5^,/QHT_X?^&]!GU_X>?M&>/\ 4_BI9Z_;R6MQ)JFH3Z!J2O.2+*..
M2);62'),:JC[RLC$%3EJX<EX>P''.8REA*4N&8R^J818? Y5G&<Y=]=J0JNK
MBZN)C6:RS!2G&$JE.K6Q,Z";E"#I*R]/BGC7-?"7)(K,J\>.YTO[1S&6,S;B
M'A?AC//[*HU<.\+E]# U:%/^W\VITIUX4:U#"Y=3QLDH5J]+$U(QE^Z)D0$9
M)&02"5;;QZMMV@XYP2"0"0,*2(([ZSF9DAN89F4X98I%D*G&>0A8@8Z$\'L:
M_,SXTZIXT^(.I?LM?":#QCJ_AF7X@Z);:OXOO-&OFLM2N;>.PM99HBZAGC\P
M)=%BPR@8#(9T)Q_C3\"]>_9HT6Q^,_PC^(?C-V\*ZGIR^)M!\3ZRVJ6FL:;<
M7<-M,A#+'B0++*R&-I3NE&1B-B8P? V#K?V7A,7Q'A\%G&>O'1RC!2RW%U<+
M6EA,PQN6X;ZUF$*RCA8YEB\%5IX:7U:JJ?-2EB'%5+QVS+Q:S+"OB',,NX(Q
MF:\-<(+*9\2YK#/<LPV88:&8Y-E6?XW^SLDJX>=;,)9'EF;8>MF$)8["3K2I
MXBG@H5)TDJGZH>?%P V[)P-BL^>G(VJ<KR 6^Z"<$YIL=U;REQ%/%(8V*2!'
M5C&XZJX4G8WLV#G@<U^='QX\5>+OB1X\^"?PH\->)-1\)6?C[PS8>(_$-UHE
MQ):WD5G<JLLL,<L.XHJC<JL3P" #OW8XOXE^&=4_9[NM$^$'PF\8>++[Q?\
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M'VUY:KX,FT^6!KN:V\I#.+E8II'+*-SE&",PVH SG;7RK^RU^SYX1^&WPO\
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M\DO_  D7VQ3_ &[JNV.PGCVMO\R/].Z!M-;]D_D]@HHK\J_^"A__  5#\/\
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MZ1=7'AG3_%=SK/B34H2K6]K:0QP-MN%#AP6-N%4;"0T@)("L:^UC"S,"PSL
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M+):=2%:E0]E@L/DN K8*A0PCC#VBC6E7JXBNYM.566C<5I^<'QK\-^,OA/\
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M+_P3*U[5KF#Q7X=^/.E?#KX/":^:,^(?"?QMU:]^&?Q-U&U+QV]\-.U3X*^
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MS2Y?#D^HS26\NOIIMNUI?>;]CG!.R@E:Z]HUMK96V\VM-MNG4_-_X1?M7_\
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MWQ3)=:%/K?B"+3]8\-:YK7A0_P!L^'-<U?PEXNTWQ1::MHT>CVD-LNJ^^?\
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M]A.L-$/# C;6BCC14^Y:?Z66)#_H[^S%^VM^UY^P]_P3J^(_[3G_  5*\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XY_\
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M!_C#1M+TU[_PW8ZU!J>KZY_0+10'/*][K:UK*UNUMK'\J'C?_@C5_P %4O\
M@H-XO^&^B_\ !67]N[X1>(OV<OAOXBMO%+_!S]EG0=5TX^-M4MHS;23:I?7_
M ,,/A)8:1K5YI]WJ&F0>*=2T_P <W'AO3KB_M_#&CZ9/KVIWB?L)_P %!?\
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MYH;.\N;JXDG^C?\ @BG_ ,$L?B'_ ,$V/V:_C?\  ;X[^+_A?\6A\7?BA?\
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M'^BZ;XHL?V>?AG\+KCXC>'K#4-5\-6WCOX5ZEX6\5^&O$-MIM^NBZK?^'O\
MA+_!^D37EI,NG:A/I1N8T\BX9,?&?[#G_!)C]N+PS^S=\<OV$_\ @HU^T?\
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M>(M$MM:T.?4-+N;6X6+^S]<TG4-)O=2TJZ^V:* N[)7V=UZNVOX(_E0^'?\
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M'4-3GUG0?@_JWAJ:W$=S'K$6F1'4KD&HMJZM;:[:5WV5VKL_:?\ 8E_X*8_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?R)_\
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M9^9%_:/C3X>Z5::_#96VCV&NZSH_C&Z\.^-['1X]3F\(>%=;GBAL?8OV1?\
M@E/^W)^T!^W[X3_X*:_\%;?%_P ,6\??":WMHO@7^S?\*9EUCPEX(OM#_M*;
MPA<7MX)M6TW2="\$Z]K>K>-_#NF:9XH\7>(M6\=/8>(?$7BN.#3Y]&U<+<E>
M4DX6:=FDW)W6S5]'KJWIU/(_$?\ RMO^ /\ LUJ]_P#5 ^-:RO\ @JWI\O\
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M^-/B>VMI8F6."?3O@7<& 0S;KBZL_P#!4O\ Y6,?^"/7_8I>'_\ U9'Q6K]
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M_9!_:J\00V-O'K6I_M):9HVH:DJ8NKO2]"^&'A:]T>QF?/S6^GW?B+7+BV3
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MTG0M1U[X?_%JP;6[S4+B_G\->!/&WC_P_INHW,EQHTLT<VH7%U]W_P#!,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?CY_P5S_X)>:__ ,%-
M?#_[-VBZ#\8='^$3_ ;XL77Q)NY]7\'7OB]?$D%S9:=:#2;9++Q!H!TR9#8E
M_M<K7J,)0/(!3+?L'7R%^VG^W1^SA_P3\^%N@?&7]I_Q;JW@WP#XF\?Z5\,M
M(U/1O"?B/QC=3^,-9\.^*O%6GV$FF>&-.U._@@ET7P9X@N&OYH$LXI+6*WDF
M6:ZMTD!Q;37+OTLK]^GWGU[17X#?\1-7_!(/_HN_CO\ \,3\7O\ YDZ^^_V2
M?^"I7[ O[<NL7/A?]F+]I/P;\0?&=I93ZC-X!O\ 3_%/@#Q_)86<:2:A?:=X
M*^(^@>$O$FN:=I8D0:GJN@Z;JFEV1>-I[U$EB=P;C):N,DN[3_R/OZBBB@D*
M*J:A?V&E6%[JFJ7MIINF:;:7-_J.HZA<PV=A86%G"]Q=WM[=W#QV]K:6MO')
M/<W,\D<,$,;RRNJ*S#R/PI^T/\%O'WP8U+]H7X>_$/P[\0/@QINF^/\ 5S\0
MO!-X/$WAW4M/^%^K^(] \;76A7VE"XBUZWTC6O"7B#3H[G2#>6VI3:<\FESW
MMO-;SS 'L]%?*?['/[:?[/O[>7PCG^.'[-7BG5/%_P .K;Q=K/@:75M7\+^(
M/"-VOB/0+/2;_4[0:5XEL-.U%H8;;6].=+L6_P!GF:5TBD9HI OU90&VCT84
M444 %%%<MXV\<>"_AKX4UWQY\1/%OAKP'X(\+V$FJ>)/&'C'7-,\->&- TV)
MD22_UG7=9N;/3--M$>2.,W%Y=0Q>9(D>[>ZJ0#\S?^"I/[)'[=?[5GAWX3:=
M^Q!^V7>_LBZEX9N?'>G_ !/DAO\ Q+IMMX]\-^,;?PI;:>Z7?A:PO-3M]<\(
M?V)K$VA7$4NG2Q-K]\MOJ5C+*+J'N/\ @EM_P3?^'O\ P3)_9IMO@GX6\03>
M/_'7B;Q!=^//C'\5+W3CI=[X^\=ZC;V]DT]MITE[J4^D^'-"TNSM-(\/Z0^H
MW;1QQ7NL7<LFL:YJT\_Z!>$?%?AWQYX4\,>.?"&J6^N>$_&?A[1?%?A?6[59
MDM=8\.^(M-MM8T75+9;B*&X6WU#3;RVNX5GABF6.91+%&X91T- ^9VY>E[[+
M7U>[MTOL%%%% @HHHH _'O\ 9]_X)>:_\$O^"LW[5W_!2JZ^,.C^(="_:1^$
M]W\-K'X36_@Z]T[5O"D]S?? R\&K7?BV3Q#=V>K0H/@_=1_9(=!L'8Z[ WGC
M[#(MS^PE%?&/[.W[?G[,G[4_QH_:._9_^#'C'6/$'Q/_ &4O%]_X&^-6C:AX
M/\3^'[/P]XCTSQ7XH\%7EIIVL:SIMGI?B&&/Q#X.UZU6[T6ZO+>2*VBNDD:W
MN8)'!MMZ[V26VR6B_P C[.HKSG1OB_\ "WQ'\1_%GP@\/_$#PEKOQ0\!:+HO
MB'QSX$T?6['4_$O@W1_$D]Y;^'KSQ3IEE--/X?\ [<?3[YM)M]56TNM0@M)[
MJU@EMHVF'SOX:_;\_9D\6_MH?$']@#1/&.L7'[3OPP\(67CGQAX.D\'^)[;1
M[#PYJ'AOP1XLM;NW\8SZ:GAB_F?1/B'X6N6M+/4I;A)+V>V:,3V5U'$!9]GH
MKOT[^A]G4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKSG7?B_\
M+?#'Q$\#?"/7_B!X2TKXI?$N#7+SP%\.[O6[%/&?BK3O#.EWVL^(=6TCPX)F
MU6XT71=/TZZDU+6OLJZ5:3B"QFO%OKRSMKCT:@ HHHH ***^,?AU^WY^S)\5
M?VOOBY^PMX+\8ZQJ/[1_P.\(3>.?B+X2N/!_B?3])TGPY!/X"MI;NT\67NFP
M^'-6F6;XE^$5^R:=J-Q<$7T[",K8W9B LW\M7Y+N?9U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445YS;_ !?^%MW\5+WX'V?Q \)7OQ@TSP>?
MB!JWPULM;L;SQEHW@HZEIND0>)M;T*VFEOM%TF^U+5[&TTJZU2*T75Y'N#I?
MVM+&^>V /1J*** "BO+_ (U_&+P'^SY\)/B-\</BCJ=SHOPZ^%7A#6_'/C35
MK/3+_6;O3_#GAZREO]4N[?2M+@NM1U":&VB=TM+*WFN)F 2*-F(%?./AS_@H
MA^ROXK_8FN/^"A6B^-=:N/V6[70?%7B6;QG)X+\56^LKI/@SQUK'PXU^<>#)
MM+3Q2TEMXLT+4K&* :89;J&)+Z!7M)8YF!V?9[V^;V7J?;U%>)?LX_M#?"W]
MJ[X)^ ?VA/@IK5[XA^%WQ+TZ_P!5\(ZSJ.BZIX>O;^RTW6M3\/W<D^C:U:V>
MJ6+)JFD7T*QWEM$[I&LR*8I$9O;:!!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB;Q!X*\1Z?;VFEZ+XVL+2>-[2::P\47-U])_"#_@D;_P6]\2?";X7^(O"/\
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M?$W[&6EZGI.M:8TMS':ZMHFM:?J.C:D+.\U#3)+RPFFTK4]3TV2TO[G^E/\
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M'Q'HM_KL4=D\.BZ!XI;7K&PM=/GGT%?!\LU_'XG\*1:#=:OJ&MQ:?%\9Q_\
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M(>(=<O?&F^"(7M_J_@/2[>6ZD@TA+2/[P_:J_:8_X+*?M;?LY?&?]FWXA?\
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MXI^%]KH'C[]I;_@D_P#MS_ #]G_7]3TZRA^-?B;PSJZZ0EMK4J-HMY#;>*_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNK:QBUCXA:3HEU?Z)K?]?M%!:GM[L6XI)-WV6VE[/UL?SL?L3_LJ_M)^.O\
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MGZ?HUM<Z->:AX;?Q"US\6O&=[=V.AW5]H6D6BZ'I-MJ-^UI<RK^9?[#>H_\
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MI\+_  _%\//AE^T!X+^)5Q+X9UCP_P"&;.;3/"^J^.T\/Z#XUM_%S6^GVUA
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MA<RZ#>W/A)+P:-X?LKC5M-TF;4M4^2OV2]=_X+7_ /!%WP5K/[(^I?L&W?\
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MJWUNUU'3-0ET;^R6B@.=W>BLTH\NJ5EMMKH];WN^I_#W_P %3/A)_P %N_\
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M]VKW?72[:6O8****" HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBHTT];GNXR4,!P57E"]"%+AE\LJ?\18C$Y127-?5<SQ6(YU*UDXIRTU?3_\
M!*#]JG3OVC?V5?A[H^IW\U[\0OA7X/T'PSX^4:(=(L@UKJOBKPSX<FLI(&:Q
MO%N=)\(1SSR6GDL)2KSV]O),]O%^G\'ELZE&+>66CR00!M4_(,J"0N<Y/)W?
M>8C _AG_ ."._P"U#;?LP_M2NOBPW$'@+XI^#M9\-Z^]SJ<>D6=G?Z%I=_XJ
M\.ZI"-2U'3]&NXS-IMYIW^FL9H&UJ,V,FZ659_[EH&!DB,9W1,I4E!NC.U"0
MX96V@.&&UL'> .G!KO\ &#A%<*\:8WZI"I'*LYE+-\#/>"J8NKB:V.PD):V6
M$Q52I2C!V:PU:C"-U'F?%X><0//>',-]9DI8_+[9?BHNRJ2CA^2GA<3)-+3$
MX>G3K3:7\6-3JM="LVY,9)64;4)<.W.6!Z(NTG!*9P2J@$<L.^E7S;^U'^T+
MX8_9G^#GC/XI^*$BECT32M>;0;!]0T_3VUKQ)8>%/$7B33-)CN=1N[%8Y+X:
M#<6X^Q?;;]6;S+>SF\M]OYOA<)B<?BL/@L'2J5\5BJU/#8>E2CS3G6KU*=*F
ME'1.TYQDVVE&,)R;2@S[3$XBCA</5Q&(G"G1HPG5JSJ? J=.$YU+OIS04HKO
M)P2NVD_S)_;*_;2FTO\ X*$?LD_LB^&[TQVL/Q<^#WC?QT9?#\<DCS:Q:^/;
M!=/MM9NIS^YET[5/"MR4L=/22*9I\:BI2ZMZ_;2 I(FY 5$X+(#_ '9"65CR
MQ&0P8C)QDC Q@?YX'PJ^,GBSQI^V1\&_C+XTDNKOQ)=_&GX0W.H2W=WJ4Y,.
MD:SX7T&"W2^U:]N[\0'3M/C8^?=NJ2-*B(L 5!_H+_#S4?[<^'O@374"1KK7
M@WPUJ3(IW )J.BV-V ) S"0J),!SD/G?G!Y_8?%_@S#\%8#@7+\.HN=#)L5A
MLRK0?+2Q69QQRQ6*KJSES0<ZE&%",G[M.E!RE)GYWX?<25>),3Q/BZ\KTZF8
MT:N I.$H5,/E[P_U?#PGS6?.HJ<I^ZGS5''E7+(_+;_@J/\ \%'X?V(_#5AX
M%\$H]S\;_'W@[4]9\#->^&/[<\.:)#:ZWI^C)K&M7%QK>C6X:&#^W;JQM8H=
M:+W>E1'4-.DMIH+74?Y^?"WPC_X*=_\ !1P7GQIT&;PKKNG^)-3U!/[5O;OX
M5>$-)FNM%<+-;V>EK9G7H%M1?""%[VW59A#*TDTS>7--S/[>.K7'CS_@I%?:
M/\09;I?#>G_&BZ\&M->3O<6T'@NW^._C*W:-/[;,EA;V+6<]S&MN5_LIXV:,
MPI%YF[^S7]GC0/#_ (?_ &>_@GHO@^&RMO#-A\+/ ":)'I<%E;6\EH_A;3)4
MO!#I<<>G^;?K*]]=SVBB.YN[F:X&X3%C]ABL9@?!_@GA?&95DF69EQ1Q+AUB
M,9GF9X>6+A0P\Z,,9+#TX>UA4LEB,&Z>'IUJ<7*CB,54G*56G&CX%##8KQ X
MESNCF&98O!Y'DM:%+"95@:RP[J5H3^KQQ4ZJI223=#$*I5J4YW=2E2I\D8U'
M/^:#]B[X*_MM_LA?M>?"GP1\>KG1M"T7XE'09[*/1+SX?^(K'7K:P^)WP^TB
M_MUN=*T^XUK39I+34I%0SC34,-Q'(D\5W$PB_K0"&-@R%B-V#G9R2A^;H#D#
M"8X7 SM+?,>+\1>!O#/BK4_#>J>(-)T_4;_PCJ8U/0+N[T_3[V]TV_%Q9W"W
MUG<7MK/-8R";3K67[39203>;#$XD#PQLOG/[27QPT?\ 9Z^$VM_%+6[47\&E
M7NAZ?#I3W]KIZWMQK&KVNG*AFNY(T!AAFGO!L#NWV8*(MH>5/Q[B[B;%>(.:
M9-76787"YS/#TLMQ,,OHQHX?$XJMBZTL-6H4KRE"3PLH0J2JU:T82B_?4%RR
M_1>&L@I\-8;&8*CB\5C,)+$O$87Z]5=?$4X>PHQJ4IU53I0DO:Q;@E3A>.LE
M=JW@/[8?[<G@?]F6QAT6 7.M?$?4FO+;2M&&@7U]86TD>@6^I6LVJW;ZIX=L
MO(FN=5\/@_8=2N9A!<72O%%)$[Q_D5\<?"7_  41^/=QX.UGQ_8^%[W3/&2-
MH&@VWA^Z^'.E6,"1:Y;:/)!J N;@:O$[ZR$N&FBN;I?L\RE'15>VB^P_V??V
M"/AG^TUX.\$?M5?$7QCXZO?&/Q5N/^%A>(-"D.@:AH,%Z^OW<DNBVQUW2-9U
M2724BLXM.1;W4;F8V421L44+%'^TEEIL6GV\-I;"-;>$R;5:%=VV1VD8 QF-
M%R[N6(CPRD C(+-Z<<ZR?@KV&%R?+\/FN=X:>+H9SCLSPTKT,53YL/+#Y;)5
M(\E&C5C4@JD;JM3I1E)WFDOH'%U-6XQB[-<D7>5M8WDY-6OK.RO);6OI_+C\
M9_\ @F!\4/AU\*/!GQ'TVTM-;\8ZD\#^/]&C\7Z2T>E7>IPH(?[-2\TW1-.=
M+>ZG>TO1!K6ICS'1[3[1;JURN-'HW[</[$6B^'/B9.^@>'/#VKK9:A;V=T_@
M3Q1-)#;II>F);W<%C%<SQQ31>*[.Q_T;4%N [W$YN(1!'='^K)8L-EBI&3PJ
M;01G" Y9L[%P/0D9 4?*/'_C?\%?"7QX^'^N?#GQ@US%I.M6(LGOK"#3)M0L
MV2^L=0BN+8ZI8ZA;+<V]WIMI/&Y@RDBB1=DJQ2)T8/Q0S"NZ&$S_  > Q^75
M,156.E/#RJS6!K-J-&AAY5/9\^'A/EA.S<J=-4[<W+-RZ"M:#=][M\MWS7E>
MVCBELM';K?;XZ_8Z_;\\-?M*K#X%UU!HWQB=-=O?['@\.ZC8^&[[1]*DL[J.
M>VOX]7\0+'<_8+IG>.YOK0O+93*L:[K=;O\ 2$,&+!L,=HPJ[A^[;=L))P.=
MK X.1W'0U_*5^W#^S=X5_8Q^(OA.+X7>,O&L][J.@Z9JB7>HW6G6\]H=8?QM
MIEXEK=>'K?09<M!H$8,8C0F.ZN?-FE0+'7[U_L/?M-6W[3WPD_X2&?35TGQ!
MX/N=)\,>)(&OX[UKK58?#.BWUQJQ+W%Q>P6U_>W5^ENE^S7+&SGWSS2K,4\W
MB_A? 4<%A^*.'/K$\@Q]1J=*K&<7@:\YNG!PIU+36'J5(\BIR]I*E4@I.;52
M*5TZC^"?+S\J=DVY-.]FV];2Y6EV:M=JQ_-1_P %??\ A,OV=?VM+?PU\+O%
MFK:)X<\;^!O OB2#3[JS\)ZWY&HZA_;_ (4NY4N=6\.75]#Y@\(I(L,UU=0(
MSM*@59A!#_0O_P $U_AY;>#OV3/@YXOO[V\U#Q=\2? /A[Q/XMU2\FMG6ZU#
M5;C5]?M6MK/3-/T[3K)!'KDRM#;6:QH(XHV9F1Y)OP7_ ."_AV?M7?"YE5!+
M_P *Q^&[-*%PS@^-?BM'L8@[B,;>KD84#& ,?TB_L+VRM^QG^RXZL8V/P,^&
MLAV !69_"VFO(' P71W)9U+ M_$Q/S5^A\?XNK4\(/#FI)*-?-)WS+$0C"-;
M'+"8'&QINK.,5.4N=4ZL7.4O>BF_>U7Y/PM0@O$#C&$;N.#2>#IR=Z6'^L8J
MBZCIKM;FC/1-\VES\AOC;XJ^)7CSXK^.]:UF\AET_P  ^,?$FC>)]5AMM&M;
M?X:^ -*\3ZK/X>U"TMHX3?Z[>B4>*%F$=CXVO'31;$3V -PK:K^O'[(?BS6_
M&'P*\(WVMZC!K=A:V-UI7AW7X[2.QEUCP]I/B+7M'T&^NK6"UTTQ2RZ!I.D,
MPDTC2[AI&D>ZLH;AIDC]=\4_!'X<>-=3L-8\3>%/#>J:C8,5>XNO#6A7;:I:
MBX6ZCL];?4+"]GU&WBN&NYXXS/#&LVH7TJQA[F5F]$T[1+#2-.LM(TJTL=-T
MS3;6*QT_3+&RAM-,LK2W5([:VM=/MO*M[>"WAC6*"&!8XHEXC15PH_+\_P")
M\)FN2X'+,/EKPU3"^Q<:E-T(1H^RP\:53V24&Y5,1-.?M/<A"DW2JTJN(OB9
M?<99DN(P&8XO&2QGM85XS?LY1GS3G.M*:<Y*I;DA%Z1E%U/:\LZ=2G17L5?M
ME*Q[2I&#C)();"J-S8)7<>X4*N>B@58IB*47!.X]2<8).!R>3DG&2<T^OBTD
ME9)+5Z*UM7)O9):MM[;R?F?2?\#\E9?)62\D@HHHI@%%%% !1432A6(*G:%R
M6S_%OV[<'C_:SNSCM3D;<"04('&4?>,]P>!C''OST'=<T;VNKW:MUNE=V[V[
M[ /HHHI@%%(2!DGMCZ\G%-1]^2%8 %AEAC)5BN1UR#@G.>./7A77XVVZ_P!?
MUH ^BHA*#TVL,L"4</C:,@'@88]-N>..3FI:=T]FGZ-/\@"BBB@ HHHH ***
M* "BBB@ HHK_ #QO^"['_!8#_@H;\./^"C7Q?^ _PA^-OQ#_ &=OAI\ M2\)
M:+X2\+^ [JT\/7/BF34/!WASQ;/XU\7ZC:1W-UXHM_$LVN"XTG2-3NIM!M?#
M::7;R:'!JDNM2785"#F[*RTOJ?Z'-%?F?_P1[_:C^+G[9G_!.C]F_P#:'^.M
MA';?%'QGHOBW3?$^JV^F6NBV?B^7P1\0/%7@:Q\<6NDV2PVVG_\ "6Z=X<M-
M:O;>TLM.TW^U;J_DT2PM]!DTL-^F% FK-I[IM?<%%%% C!\4^)_#_@GPQXC\
M9^+-5M-!\+>$=!U?Q/XEUR_<QV&C>'] T^XU76=5O9%5C'::=IUI<WERX5BD
M,+L%)&#_ !D:#\?_ /@JG_P<%?&3XEV_[(/QD\1?L&?\$[?AGXIU'P-+\3]"
MGUC1O&WC9G#W%L-2N?"^IZ%XN\9>/-6\-W6FZQKWPZT3QGX7^'W@K1-7T[3O
M$.N:CJNH:;J7B/\ ?/\ X+H>(];\+?\ !)7]N+4_#]U-:7]U\(X/#EQ+!OWO
MHGC#QGX5\)>)K5MA5O)OO#>MZM97&3L\BXE\P-'N4^4_\&ZG@KPWX-_X) ?L
MGS>'X+87/C*'XK>-?$VH0*@EU7Q)JGQD\?6,\]ZT;LDESI>E:5I'AI&^5UL]
M"M(ID$T<F0TC[L7*R;YE%75TM+MVVOT5S\QO'?\ P0V_X*I_LM^%KSXL_L.?
M\%;OCW\4OC'X<M[O7KCX6?$F]\0>&?#?Q+U.%%O)[2T7Q?\ %/XC?#N]U;5+
MJ*5;'2?B7X?NO#]W=W$"ZOXJTR&.>]?])?\ @B3_ ,%9]3_X*.?#7X@?#KXW
M>%H/AY^U]^SA=Z=H/QD\+V]A<:+I_BBQGGO=&MO'6E:%?$7F@:DNO:-JVA^.
M_"6)8?"^OQV,L$EM8>(M-TO3_P!S*_C6_9EMH_A)_P ':W[7W@CX?B[T_P +
M_$;X::SJGC*QM)K4VEY?>-_@/\%?CCXDNM01Y+??'/\ $Z234(_LL-S?07MS
M''*IMCJ%T@"?.I)I7BN9-))Z-73LE=._R/[!IO&'A&W@\074_BGPY!;>$H9;
MCQ5<3:WID<'AF"%+B2:?Q!,]TL>C0PQVEW)+)J+6R1I:W#NP6&0KSG@/XP_"
M/XIOJ,?PQ^*?PY^(TFCR/%JR> _&_AGQ>^ERQ3O:RQ:BOA_4]0:QDCN8WMW2
MY$3).CQ,!(I4?PM_ 3]A"W_X*+_\%M/^"JO[/WQ/^)'C_P +?LM:%\=_%OQE
M^-/@#P#XC'AZ?XM>+?!'Q(U_PW\(]"UB4VMXHTS1F\>^/-5EOUA>ZL4,MOIK
M66J:C9:QI?4_\%3/V!?A5_P1-_:7_8 _:[_8$U_Q_P##)O%7QI7P1XU\ ZGX
MSUSQ/INK6FD7WA75+JRCU35KB76;KPUXTT"YU[P]XV\-ZUJ>I:?>12:;/IBZ
M>T<XH#D5U'F?,U=*VFJO9N_KLC]1/^"_GQ^^._P:_:\_X(O>&OA!\:_BW\*O
M#GQ3_:0\:Z'\3O#_ ,-OB1XQ\#:)\1M$M/B=^R786NC^/-*\,:SI=AXOTJVL
M/$GB*RM]/\00:A:0VFO:U;1PK#JE\D_],:>)/#LFLR^'(]>T63Q#!&)9]!35
M+%M9AB,,=R))=+6<WT<9MYH;@.\ 4PRQR@^7(K'^4'_@Y%_Y/6_X(1?]G2>/
M?_5L_L8UR_\ P6GTNZ_X)X?\%9_^"?W_  5D\.0R:;\//'7B+3O@A^TG>68D
M:&6UTW3Y_"^LZAJUK# C:CJ>O_ KQ'K47AZ*26^CCO\ X0Z?<FWLI[*RFN@?
M+S*"V;C-K3=J3LNF^RW/Z^;JZM;&UN;V]N8+.RLX)KJ[N[J:.WM;6UMXVFN+
MFYN)F2*""")'EFFE=8XHU9W954D5M+U?2=<LH]2T34].UC3IFD6&_P!+O;;4
M+*5H7:*58[JTEF@=HI%:.0+(2CJR, P('\]__!RE^U=>_!G_ ()X/\%OAU>-
MJ'Q0_;9\9:'\#?!]AHDB7>JZCX&NVM]>^(M]I$4<A34++6M*CT3X=77D+=-(
MOQ+LS;QJ\B7=M^KG_!/W]EK2_P!BS]C+]G?]F;3X[07GPO\ AQH^G^+;JRCM
MX[?5OB%K'F^)/B-K49ME$<L>K>.-8U^^@D9YI3;3PK)<7#*97"+6BI7W;27D
MMW][L>,_\%B/'?CCX8_\$R/VR?'WPV\9>*_A[XZ\+_".ZU+PSXT\#^(M7\)^
M+/#NHKKNB0K?Z%XCT&\T_6-(O5AEEB%UI]Y;SB.61!)M=@?YK?\ @G#_ ,$U
MO^"D?_!0/]C'X-_M=_\ #]O]M_X2?\+;_P"%A_\ %O?^$A^//CW_ (1__A O
MBKXY^&7_ "-G_#6W@O\ M7^U?^$+_MO_ )%K3?L/]I?V;_IGV/[?=?T3_P#!
M<#_E$Y^W-_V1:\_]2+0*_F7_ ."3W_!0'_@KS\$?V /@'\,/V7O^"8/_  T1
M\"_#'_"T_P#A!OC%_:'B2#_A,/[:^-7Q&\0^)OW5AJ5O:+_PC_C#5O$'A;]U
M"F[^Q-TFZ4NS!I"_(^7EOSK67+MR_P!Y,_5[X5?\$.O^"A/P_P#BA\-_'GB7
M_@OA^V7\1O#G@GQ]X/\ %WB#X>Z[9?&Y=$\=Z)X;\0Z=K.J^#=8:_P#VRM<L
M%TKQ/864^B:@;W1-8M!:7TQN=+U"'?:3?,__  7$\1?M6?$#_@K3^P%^QY\
MOVS_ -H3]DKPY^T+\*].T;6=8^$'Q%^(^A:)8ZW??$7XB6__  E>J>!?!?Q"
M^'UCXHU2.QTJTT_S+O6-/NWM(;>#^T$AMHXJ_2']@3]NW_@JW\?OVA]+^'?[
M7'_!-G_AF3X-W7A;Q1JM_P#%7^T/$$_V+7M+LXIM!T;RM2U"YMF_MFY9[?\
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M+VRLO"_C/2O%OP_U'Q)KFL^(-!\7^%]=AO?$J>&=;;2'Z+_@O1\)?B7\>_\
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MOBA83^)=36QO?$WASP[KD/A/QK:36(@6UN=5L]3ADM!$(7,(2OSI_P""1_\
MP3F\&_\ !:A?CK_P4J_X*<:GXR^-MWXZ^*_B+P%\+/AA;?$#QGX0\)^'-$\/
MVUMJ>J?99/"NIZ/XBT_PIX>O/$=EX7^'WAC0?$VE:9ID?A[7;O7;+6;C5+>>
M+QGQU^P%%_P3J_X+[?\ !-KX-?#[QOXT\4?LU^*/'=A\2O@-X:\;^))O$NH?
M"Y->U#7M.^(?@*SNIK>TQIEOXET:#7=-EBMPUQIFN6)U2[U7Q)%KVL:@%QC%
M2:O>2C*ZMI?E>S[KT7D?WOU^"G_!>[_@H%\:OV'_ (&? R+]G7QGX4\)^//C
M'^T+X5^&'B_6;VQTG7O%/AGP!JF@>(-8U._\.Z;J<L]EH^HZC+IEK8)XAU+2
M-1%A:37+Z4MGJK6>IV7[UU_&'_P=0_L=_ :V?]FS]JJ'PSJ2_&GXP_M!_#WX
M&^//$)\2Z\VGZI\.=,\'>)[BSTFV\/M?'1=,NXY;&V+:MI]G;ZC($(>X(=LA
M$$G))[>E[Z/T_I']BJ^-O!C:2^OKXM\,-H4=R+)]:77M*.DI>$*1:/J0N_L:
MW)#H1 9A+AU.SYAG&F^+7PKM_&>G?#B?XF?#Z#XAZQ91ZEI/@.;QGX<C\9ZI
MITL#745_IWA=]277+VRDMD>XCNK:QE@>!&F60QJ6'\K_ /P72_8L_9]_8-_X
M(C^+/@?^S5X6U3PA\.KG]J3X9^.9=)U?Q1X@\77;>(]?D>PU.[&J^);_ %'4
M5AFMM$TY$M!<"WA:)WBC5I9"VU_P3(_X(!_ ;QC\./V-?^"@'[3/Q'^.OQ _
M:KU]OA!^U9J$&H>*M'@\$0RO9:'XV^&/@+6/#FI>$+GQ"=.\*:##X2L]4LAX
MBLY;?4=*GT73AIWAJVM=%A Y8\O,Y-*[25M6TK]]//MYGZM_L'?LS_M7_!K]
MKC]OKXF_'3]L<_M"?";XT?%+6_$7P(^#?_"V_B1X]_X9V\,7GQ,^(WB"Q\)?
M\(CXPED\-> /L'AK7?#WA7^RO!RQZ?!_PC']F0C[!IMB!^G=[\0O &FZ-K/B
M/4?''@^P\/>')$B\0Z]>^)M%M=&T&62>.VCBUG5)[V.QTN1[F6*W1+Z>!FGD
MCB4&1U4_RK_\$'/^4N/_  7T_P"SI/&__K3/[1M?E=_P1U_X)C^"?^"DW[27
M[>UC^T?XP^(<W[+WP-_: UG7_P#A3'A#QM?^$]&^(GQD\>>*?B%IFF^(?$@T
MP/>&T\&^#_"^J6RW-H^CZV;KQ-80:-KD>F?\)5INH!3C=R<I6Y5!NT=[I622
M:U_/=G]^O@;XD?#OXGZ0?$'PU\>^"_B'H(D2(ZWX&\4Z'XMT@2RP1W,<9U+0
M+[4+,226TT5PB&;<\$L<J@QNK'&\._&SX->,/%%_X(\)?%OX8^*/&FER7<6I
M^$/#OCWPKK?BC3I; 9OH[_0-,U6ZU:TDL@0;M+BTC:V!_?!*_@M_:'_X)WZK
M^Q]_P6B\ ?\ !.?]BCXZ_%W]G?X$_P#!0#X/> G^((T'QA>:EX@TSX4WGB3Q
MW-\0/#5CK%[,+Z^NU;X*>)9?#.I:O/-K%I;>)]3\.W5]?>'=9UBQU7W?_@M9
M_P $=?V:/^"7_P"S!\)OVS_V%]5^+OPH^,WP@^-_P_T:Z\27'Q%O_$4VJ6^M
M6.N2V/BQVU/R9-&\4Z3XFT;1#;MX72RT*[L-5UFQU'PQ<6TUM=Z0"Y(WBN9^
M\DX^[WO\6NFJ:TOW/[J*\RE^-?P:@\81_#R?XM_#*'Q_+/-:Q>!I?'OA6/QA
M)=6VS[1;1^&7U4:T\\'F)YT*V1DBWIO5=PS_ #'_ /!=?_@I5\:OAY^PA^P;
MX+^#OQ!C^"_Q'_X*)>'O#>L>,/BO'J4GA2;P)\.X_!7PVU?QNMKXAT^9Y_ Z
M:GKOQ6\,KJGB/3[M[S2_"FF>)K33I"]T;ZT^5+#_ ()R?\&RD?P#D^'>J?MU
M_"W4OCI<Z"RS_M/G]J)H?%L'C22V,C^(;3X>1^+%^%S:*NKM]I30+[PQ>:D^
MF@6,OBEM19M;H$H:)MO5M+EBY;.S;\K_ #9_:SJ>JZ9HMC/J>LZC8:3IMMY?
MVG4-3O+>PL;?SIH[>'S[NZDB@B\V>6*"/S)%\R:2.)<NZJ?Y\?\ @A3_ ,%%
M_CA^WC??ML^*_P!H[QYX2EOO#GQ_TGP7\(O NA6ND^&M!\,>$;;2-:F.B^$]
M-:>?6];\R58+B_U76-3\0:W>2F+[3J+01VL,/Q'_ ,$/OB;;?\%3/V,/VQ/^
M"9?[='BV^_:)\*? 7QI\-]&L?'%CXWUS^U?B#\*8_&UYXB\%0V?Q%T?58]>U
M[3?"GCSX.07^D:]]O6>_\):[X?T:6XO=.A*CY5_X-DOV!/V8_BWXW_: _:,\
M<>#-6U'XL?LG_M,Z78?!37K;QCXITZS\/VBZ1K;1Q:EHECJD.C^(?+:(,LFL
MV=W(2S"1W7:JA7*HJHGNN6S2ON]+7:WZ]EWV/T>_X)8_M%_&OQI_P68_X+#?
M#OXH_';XI>+/A'\*/$7B?_A O OC[XG^+-=^'/PUL+/XMW>GK_PB/ACQ#KEU
MX9\'6EKI:"Q7^QK'3H8+!!;#;;KL'](?@3XN?"CXHC4#\,OB=\/?B*-)D:+5
M3X$\:>&_%PTR5;BXLVBU ^']2U#[%(MW:W5JR7/EL+BVN("!+#(J_P )WP _
MX)]Z)_P45_X+F_\ !4WX3?%#XC>/O"7[//A'XO?$/Q]\8/ _P_\ $-SX=O/C
M%/IWQ8%EX%\$:[=PEHXO#=KJUYJ'B/4+MK6\O+>72+6#2!IFK7MGX@T;N?\
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M'+-J6NFYNXAI-A#%+%)+>:A]GMXXY(W>0*ZD_P ?W[)FB^*?^",?_!<_P_\
M\$[/!/CWQ3K_ .Q+^VEX#A\>?#3P1XPUY]>?X?ZYK&F>.AX<OK2:<VL%IXAA
M^(WPV\5> [JXM(XKGQ+X-U[PY?\ B.'5]=TS2[R#XK^)G['5Q^W]_P ''W[;
M/[*6O_$GQI\//@MXQ&A^-?CW#X#U"TTW7O&O@+X;_#;X0ZUI/A&*XOK>\L3'
M?>/;OPE<EK[3]5M-/DM$UQ=*NM0TC3Y+<#D5_B]WEYT[=+VV[]/7R/ZH?^"E
M/P^^+'[;?[(&EZ)^PG^VWX3_ &?O$\OQ5\*:['\>_!7QO\2>$="U#P[I6C>(
MDUCP=!\0/@[J-UJ%S)JTNKZ-J#:0MTUC=1Z?%<72[H;5C^A?@2;_ (5[\+?A
MEHOQ&\=:3J/B#3/!?@_PYK/B_5_$&^+Q=XGT[P[8VFJZO!J^NS0WNKW&MWMK
M=ZHMS=,VH7JS-=7*F5Y"/XY/^"U7_!,_]G;_ ()E?\$?/%WPZ_9ZG\<:II/Q
M,_;B^$?CW6]8^(NLZ7KWB='MOAEXWT#3/#B:EH^A^'+*;0=%:QU/4=*232Q?
MQ7'B'4UO+Z]'DNG5_P#!R+J-[H__  2@_P""96K:;.UKJ.E^._@KJ-A=(J.]
MM>V7[-VOW-K.J2J\;-#/%'(JR(Z,5 =64D$!1ORI/1RDDW&SV3N];^5KZ;G]
M>7B/XW?!?P?XJT_P)XM^+OPP\+>-]6:V32O!OB/Q]X4T3Q5J;WA46BZ?X>U/
M5K75[UKHN@MEMK.0SEU\H-N&=WQQ\1?A]\,=&/B/XE>._!OP]\/"8VYU[QQX
MGT3PGHPG6WGNV@.J:]?:?8B86MM<W)C\_>+>WGF*^7%(R_R<?'C_ (-POV8]
M)_X)Y?&;XR?$_P 8_&3Q_P#MV:/\ ?'/QX\8_'KQK\0_$-Y+KGQBT'P-?>/]
M6T+6?#-Z=0T^;PE=ZUI\_AJZN]3M=6\:1Z;-+J<NN76JQQH/G;_@C1_P3 \%
M?\%:OV6]&_:>_P""D'Q6^-G[05K\/[_4OV=?V=_AY<_$S6M#\/\ PZ^&GP[T
M_14FO9+O1_LVN7FMWVLW\NGP*VIQ1'3-!LKC6SK\US8C1@.6-G+F=D[/W=6W
MM;7;?>Q_;-X<\3>&_&&CV?B+PCXAT/Q3X?U!7?3]=\.:M8:WH]\D4CPR-9ZG
MIEQ=65RL<T;Q.T,[A)$=&(92!N5_'S_P0Y\,ZC^Q9_P6)_X*5_\ !-'P/XU\
M7ZY^SWX+\"W'Q=\"^'/$FIC5H=%O=(\4?"2VTB\,C16<-OXC?PI\9[;P_P"(
M]1TK3;)/%/\ PCFFW6K"1M'T@1?V#4$R7*[7NFDT]M&KHR];US1/#6E7NN^(
M]8TO0-$TV'[1J.LZWJ%II6E6$&]8_/O=0OIH+2UA\QT3S)YHTWNJ[LL >2\#
M?%KX5_$]+R3X:?$SX??$./3YKBWOY/ WC/PYXM2QGM)_LMW!>-H&I:@MM-:W
M7^C7$<Q1X9_W,BK)\M?QU?$?PCXY_P""[O\ P6A_:,_9/^*GQ3\:>%?V#_V#
M[C7]'UCX7^"/$1T$^,/%G@7Q)IW@+6/MD2PW-M?^)?$_Q)C\22S>)[_3;J;P
MOX&\.+H.A7&EZQ?)J-]TO_!6/_@CM\+?^":?P0A_X*._\$NO$/Q#_9?^*_[,
MFK>%;_Q?H6E?$7Q=XNTGQ9X,\2^(M%\'ZAJ$,_Q UKQ)JIO[75=9TRY\2>&=
M0U._\$>*O"DNO:7>>&&=;2&<*Y%=)RM*232MHK[)N][O39:7/[&]9U_0O#MK
M'>^(-:TG0K*6=;6*[UG4;/3+62Z>.69+:.XO9H(GG>*":585<R-'#*X4K&Y'
M,1?%7X7S^.I_A?!\2/ 4WQ,M;:*]NOAW%XP\/2>.K:SGM9[Z&[G\(IJ)U^&V
MFLK6YO(IY-/6*2UMY[A',,,CK_')_P %\_VF&_;&_P"""'[ G[35QIUMH^J_
M%W]H_P"#'B+Q+I-BQ;3M-\96WP$_::T3QM8:8S22RG2[3Q;I6M0:9Y[FZ^P)
M;BZ"7'FHOZ"_\$^_^#?C]GOX4>)_V8OVZ?BW\2OC=\4_VQ-.:T^/OQ'N_$7B
M;P_'\.?$?Q=\?^&=1UB^6[T/_A#G\5^3X.\3^)8]6TS53XL34-7U_08M5UBV
M;3K^;PW; N5*-Y2L[R225]8^=]O,_H:\=_$_X:?"W3H=8^)OQ#\#?#G2;EKA
M;?5/'?BW0/"&G7#6<!NKM8;WQ!J&GVTK6MLK7%P(Y6,$ ,TH6,%J=X$^)OPW
M^*6F2ZW\,OB#X(^(NC020Q3:OX$\6:#XNTR&6YMX[NWCEO\ P_?ZA:1R3VDL
M5U"CRAI;>2.9 T;JQ_DK\+?\$C/A9XH^./Q[_:>_X.%?VG/@GX@\?>+_ !IY
M_P *? 3_ +6=_P##;X5Z'\.W-Q?_ .A:EKMW\*/%^D^%K*:0>%_!WAK2;OP[
M;Z9IWA[5+_4K:[U#4H;FW_.'3[W]B7]AC_@N!^P2O_!)S]H>[\7?!SXW_$;X
M:?"GXW^#/!WQ"U+XC>"M,F^*'Q(3X97OA67Q-J-S-%XN\/7FB>)]/\0V-EK.
MJ>*K[PQKVE)X@L-7;41I5OIP-03NDVVDW?E]W17:O^%[;G[6_P#!2'X_?'?P
M-_P7K_X)5_![P3\:_BWX.^$?Q$\,:'<?$#X6>%OB/XQ\/?#GQS/-X_\ B992
MS^,?!&DZS:>&?$TTMG86-I))K6F7KO;65I S&*VA1/Z?*_DH_P""I?\ RL8_
M\$>O^Q2\/_\ JR/BM7]:] I;0_PO_P!*9GZMJ^DZ!IE]K6NZGIVBZ-I=M+>Z
MGJVK7MMIVF:=9P*7GN[Z_O)8;6TMH4!>6>XECBC4%G< 9KSKP'\=O@A\4[VZ
MTWX8_&3X5?$;4;+S_MMAX#^(?A'Q?>VGV5Q'<_:K7P_K&HSV_P!GD(2?S8T\
MIR%DVL0*_DK_ .#E_P <QQ_M>?\ !/'X6?M3>(/BSX:_X)M>(Y+SQ'\8S\,X
M[J)-?\7Z;XN^R>)6O?L45R^N:EX2\)2>$[NSLC8W^M:'HGB+Q+J'@RTFUW4I
M5/#>)O\ @E5_P2K_ &N-+^%?CK_@AE^V#\+_ (#?M6^ O%V@^(M,-[^T%\5Y
M/$-_H5K8W$U_K5QX \=W'B'XU^%O%UI=OIMSI][I&A:)X<D1-<T/5=+5I0^G
M U!<J;;7-?51O%6NO>?3;L?VQ5Y8_P <_@G'XL;P"_QB^%B>.DF:W?P6_P 0
M?"2^+$G6,S- WAPZN-8698096C-F'$8+E=O-?SC_ /!P3^UU^U+\'_@O^Q3^
MPM\&_B$OAS]H_P#;@\2:7\.OB+\3O!UQ?>%)V@TB7X?>$=9L?#6KV,=G?^$]
M+^)'Q#\>6?VJ]TI8-1M_"6CZSH4D,%GK,\4O9VW_  :R?\$WC\ ?^%>Z@OQ7
MG^/,^AH]S^TX/B)XED\3Q>-WTTBXUBV^'W]HV_PRE\,'Q S:BF@7?AE]??35
M337\:+>E]88$HJR<FU>]K*^B=FWJM+_,_HD^)%U=6/P\\>WME<SV=[9^"_%-
MU:7=K-);W5K=6^AWTUO<VUQ"R2P3P2HDL,T3K)%(JNC*R@C^>3_@UY^/GQF^
M._\ P3Y^,OCW]H3XT_$[XR^)M#_:^^(F@6WC/XR_$;Q5\0]=T?PGIGP2_9_U
MF'18/$7C?6=8U#3_  ]I^H:QK6JQ:;'>0Z;:7FJ:I?)#'/>W<LOCG_!![]K[
M]H3QA\,?^"@W_!/G]JKQK=_$'XJ?L(WGB[P5X;\8:YJTVL^([_PEITOC_P"'
M?B7PG<ZK?[=7UW2?A_XM\#1_V%K&KM=ZG'I'C&QT*>YAT[1M&LX?G'_@WV_Y
M0#_\%+/^Q\_;)_\ 6+O@O0/EM&:=OBA9^3O9KU31_9=I.M:/KUFNH:'JVFZU
M8-))$M]I-_:ZC9M+$0)8UN;.6:$R1D@2('+(2 P!J%O$.@+K">'6US1U\020
MFX30FU.R&L/ (VF,Z:89_MK0B)'E,@@*>6C/NVJ2/YX_^#6?_E%'X:_[+M\9
MO_3CHU?+GB/_ )6W_ '_ &:U>_\ J@?&M N3WIJ_PIN]M[6^[<^LOCM_P4E^
M,>C_ /!>[]CC]A/0/B+X'\/?LL:I\+?'?Q&^)8T]='.H^,/%S_!/]H^[TW1O
M%_C&^O+N.QT7PYKW@_PMJ6E:!I*Z'+)KT<<^M3ZM_P 2VUL?K+]N?]G']J7X
MY_M7?\$_?BW^S]^V?!\!_@U\(_B7X>\6?&SX36GQA^(G@NU_:3\'1_$CX;^)
MIO#5OX8\%3CPK\18-6\*Z+KWAJ&P\6^=I=W'XI73W+:=J=[N_F-_:&_X);?L
M:3?\'&W[/_[&#_#_ %\_L_\ QZ^$_CCXO?$OPN/'_C(:GJ_CF]^&G[27Q N-
M2L_% UC_ (2#2+9O$_@;PY>#3=-O[>Q6&TELUA%K=W,4GV=_P6+^&7@_X*?\
M%'O^#<'X-?#VPGTKP#\)/C+\%OAEX'TRZO[S5+K3?!_@+X[?LP^%?#5A<ZGJ
M$UQ?ZC/9Z+I5E;S7]]//>7DD;7%S-)-([L%V5X<KLW!MWBM=)ZO5ZNUO+1I]
M#^Q*XN(+2">ZNIX;:VMH9+BYN;B1(8+>"%&DFGGFD98XH8HU:2221E1$5F9@
MH)KS;PC\;/@UX_UF_P##G@3XM_#'QMXATN1XM3T'PCX]\*^)-9TZ6*".YDCO
M]+T;5;V^M)([::*X=+B"-D@ECE8"-U8_RE_\%9?$_P <O^"CO_!7?X(?\$<O
M!_Q-\7_"K]FG2O!FB_$']I,>#M2N-*O/&MK/X?U#XE^('UN6.U>WUBRT[P7;
M>&/#_@70M8@U;PS:>/M?.OZU8WTMK81Z1Z/^W=_P;H?LD_!W]EOQG\<_V"4^
M*_P"_:H_9I\&ZK\7_ 7CK0_B_P"/M5U+QMJWPYL+KQ/J%IJC:OJFI2:!XGU+
M2;"]C\+ZK\.SX'6P\3IH\ES%)IC:A;SA'*O=YI6<E=65TDW9-NZW\KV6I_5=
MJ.I:=I%E/J6K7]EI>G6JJ]S?ZC=065E;H[K&K3W5S)%!"K2.D:M)(H9W5 2S
M '@/&?QI^#GPXLM(U+XA_%GX9^ ].U^*&XT*_P#&?COPMX7LM:@N'MHK>;2+
MK7-5L8-2BGDO+..&2SDF25[NV1&9IX@_\IOBG]MGQ[^WE_P:Y?M$?%SXLW:Z
MM\6O"7AZT^$'Q)\2):I9KXN\0>!/C'\,3IWBV:VA2.VCU7Q!X1U?PSJ'B-K*
M.&PF\3RZU/86FGV<D&G6G)?\$K?^"$7[-7[;'[$WP6_:F_;J\3_%_P"-?Q,^
M*?PRT;P[\/["+XEZQX<T#X/?!SX<Q7'PX^$OA3PK!H?DS7$ND>$?#6G72P:O
M<WVA60N(+!/#ZW5OJ=]JH'(DFY.UI<MDKMNU]-5^)_8WI.KZ3K^F6.M:%J>G
M:UHVJ6T5[IFK:3>VVHZ9J-G.H>"[L;^SEFM;NVF0AXI[>62*12&1R#FJD7B;
MPW/K$WAV#Q!H<WB"W4O/H46K6$FL0(L:3,TVF)<&]B58I(Y2SP*!'(CD[64G
M^1__ (-\8O'O[*7_  4*_P""EO\ P3)C^(OB?QU\"O@9J.I^+_AC9>)KE+IM
M$ET?X@6GAY=6M8+?[-I^D:QXO\,>+] F\;6^C:=::5JFO:%%J$%K8LC)<_M%
MX!_X)*_!GX??\%+/B'_P4[TWXD_$Z]^+'Q%TS5=+U/X?WS>%?^%=V,6K^"_#
M_@F>2P%OX?A\2^9'8>'K:[B%QKDRB\GGWAX?+B4$XJ+:;Z)IVWNDTGKIH]=S
M]6:***"0HHHH **** "BBB@#Y_\ VI/^2$^.O^Y8_P#4Q\/5_*K_ ,$%?^3H
M=9/^SIW_ *@/QG_QK^JG]J92_P !_'2J54G_ (1C!8E0,>,O#QY(!(X&.G7B
MOX.?V1O!O[47C7XCW-I^ROXQ\6^"_&T>Q+K4_">H>,+"[+7&C^*GLG,O@_2M
M7O4$.GV_B)-QMD;R+JX5-\)G,/\ 1_A'EL,W\/O$/+:F.PN6PQSPU"6.QO,L
M)A+8:I*-7$.#4U2;O%N-FFNSNOQKQ QDLOXMX2QT<+B,:\)&K-87"I.O74JT
M8RC24HR3G!<LN5I*2E\2L?Z"WB_Q7HG@K0[[Q)XEOCI^A6 M4NKI+6ZO)8IK
MN]@M+?\ T>S@N)W62:>*,F.)]A?>^U%9E_A!^.GB/5?^"@?_  4*\1WW@&!-
M5\,>._C+HFF>%VNTA\+7;>!FUOPE\/UU&\2^N)9+:]FMK71YBKA[I6GFG^P1
MD26L/W=9?\$FO^"E/[1]FMO\:_VGYXM-E=I)1X[UKXQ>*)\Z4?\ B7D^'_$'
MAK1M/G)GN)1;W$EZLD$8DEA\QE$0_?']B7_@GI\&/V+_  XBZ!I.A^(OB;>^
M&++1/%?Q+32]4M=3UH6NHSZM.D2:QXC\2/86D][+8LUI9S6L4QT>P>:,BVM8
M;7#(\?PAX08?-\PP/$^!XSXMS'!U,LP.&RBABJ.7972J<TGB<37Q5*5.I*55
MI3=*NZLXX>E35*"E[9/-<+Q!XBUL#@<9D&,X;X?P6)I9ABJN9U,+5Q.8U*:]
MW"T:.&J^VA[+D4I^VI0HWK/EJ2<91?T5\:M)LM#_ &:_C1I%K)(T%K\'OBI&
M!(QD=UF\)^(;R0;S%'D@W3A20@' Y W'^5#_ ((_[(_^"B'Q@8\ )XY2/=DE
M1_POWP3MW;<Y("C/7H>M?UF_M$MC]G_XYYW'?\'_ (F;0O)4+X)UG(/((Y!8
MX[$FOX8?V:OV7O%?[7'[5'Q9^&_@SXEQ?##5=/\ $7C_ %Z7Q!*-6)N+5?BK
M9^'VT]6T34=/O6DCN=;MKI5>X\M!9% J2"-DGP@I8?%\#^*-#,LQCEN#Q.&P
M:QN9UJ%;$TL'%T6IXJI0H*5>I!1I-.G34YN4E)*T9-;<?U*N'XGX'JX3"2QV
M)H8C%RP^#A6I4*F(<)<RI0J5;4U-NHGSR2C%1:=G."/[1OVH?VQO@Q^RYX$U
M_P 6?$+7KVVN]+T35;_1](L?#>N:S<ZOJ5A/;6$=I']CMX+&-6U2]TZ%S?ZM
MI<312O(MTB(\B?R8_!?P9XE_X*@_\%)/''C=+2*+P5XIN_'?BO4;N6ZM?"EU
MIO@[P_X?70?!]H+6.77[P7Y:^\&?;$ACU&23[5=R3WD8BN5@^1=8^#MQ\"?V
MLO!_PW_:OAUGQ!X,T'QXNE^,)[Y=>L9/$7@]/%>J^%+C7M$O/$M[X5OXM-GO
M-*NM4>X@US3;:2U3$FJ;A-Y?]R7['_PW_9]\ _ 7X:WG[.WA/PUX<^'OB;PS
MIGBC3[C0Q:S7>K3>(=-LKJ]O=<UF'5->GO\ 5YI88(M5:?Q!K)BN[&.R%Y-'
M9PLGJ8W"95X)<.U<7DD\=Q#GG&&6U<'EW$T:4<-DN7X>:52'U>G*=6O]9?)#
M&1I<]1U;JI*=.%*5)>?AZN8^)6;QPN9QHY+EO#N84L3C,FC753,L96C&SC7J
M*"HRPEJ\Z$JG+3]G*,HP;<XU)?4MI$MO%#;0#;;VMO;6\.2694A5HT!+99@(
MU7E@6)!+<GG^.O\ X+UMN_;<\#\DD?"WX7!B<=?^$M\>GC&.,$?CFO['Y/OI
M_O+_ #-?QP_\%[@?^&W/!&#C_BUWPM_/_A+/'A_E7QG@'?\ XB!%R=V\BSR[
MZMJE0O)]^;G^5NI]-XI-+A1Q2LEFN5M>CJ5K+Y<OSOT/Z@OV*!G]CW]EL8SG
M]GWX4#'KGP/H7':OQS_X.$_&,FE_"/X6^&X6&-;MO&UW=JT ?%OIWBOX/W,6
MR8NNPDVUR655=FX7*Y7'[&_L3@G]CG]ET9P3^S]\)AGL"? NB<_@>:_G>_X.
M']9N+_XU?LO> 8C(MG?>!O%\]U"6!MW.M^*='LH?,B5#,2TFD!<[U#D*L89E
M<&/#+"+%^,M+GNX83..*,=./+=-8.OF];F>J2Y7;5WMN'&^(EA_#RMRNTZ^
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M54Y58PDVX*G[L7?GQG>,X6M&-GS-1;;]Y62=[)W?9Z?-GYY?\%_O^3KOA?\
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M%]M+(\;"<L/*I@OKT%4<LO\ K=/ZVHTU.4O=M[/VCITYU(4'55:2CR^S53W
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M!E8'% N97@[/W4D_.S;T^\_CH_X+G?L^^)-8_P"">/\ P1P_;&TWX=_\++\
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MQ%X]\3>';F_N)[BYN?"FL_$;7?%M]X3N6%U<6<5QX:FTJ:VTF5M%MGATC%B
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M7@G5_A3\-_V>_P!H2T^+^B^,VF\66-OK^IR>'H/%OC'5?A]8:)HDVI^)-/\
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MQ?$V>^T_M;,J%# 0HUXM5*&"P<I)-\T8RYJ]32+E&$Y4X<SIQ=2[_"C_ (.
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MCQ'H]O=H^MZ*]JK:=$=5TYH[:[M1++93!9I;2&&;"2P_N9HF?TB.=V.&0CD
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M"^UL_A)^T?;:UI?C/1FOY[GXG:N;'1_ _B6UU)GU[21;ZGK\/A(I=V]I?2Z
M((M.G22\\/W&RYD8SI:^CG>&K9A4S>E@9*K4PV=U<96P=*I%SQ5&OEV!I4<3
M"E";6)^J2HUJ+C"4JL7BDZ=*<95)1+\DHJ3]YIK52O%0:3:T22;:;O=[.*MS
M'WMJ&GVVJ65S8W\+26U[:75G<A7DB8P741@N0&5D9"R,=KC!'WEQP:_'3PQI
M4 _X)V?&OP(@/]AZ-\0=/\-Z:RN^Y]-UW7OA;K=]_IKKF8G4?$VK1BX<*T+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;@L#PN58
M/@$L1N^4+SP02>BMU&1C%6JAD R6+$G:H1 3PP+?-C/S9)7J#C9QG-)WZ:/O
MV>MG]]OE<-&FGU5O^#\F<MKWAO0_$UM#::U9?;(H+A+N.W>>]MV22.&>W28M
M9W%I(ZA+B6/;NV;WRV2@"XX^'?@V&ZL;E-(+364HN8+@ZEJ)%G-"4E0>2MX%
ME!>)%VS"0C'S9R<]_P"7'P64%]@!.]A( 6W%?4+N.0,X!P H&*:$5F(&T#.2
M&1<MW]R_3YF;D]3FMZ>(Q-.*A#$5J<$IVA&M644ZJ:J\L5-04)7;Y7%W<I7T
M9A.A3D^9TJ<Y2<>:<J=-N\&G!OW>;F6GOIK9:::RP*J1*JXP-V-N<<L2<99C
MU/\ >//ITI)V91'M7.Z558Y V*<Y?D$';UQWJ&-F)15+Q#:6\MHP6QN9<G<=
MP);D#D;<'/.!+&QD W@X(+[7&UUW$,BLH'RE%.P\\D9/)XYTH\O*OA7NI62L
MHV25K-=-M5Z:-;MR;;:]YV=WJFWJWOS-;ZO6]M]3 UK0=/UF 6>K6POHF +#
MS9[3<8YDN(P3!/&Q"R11D['7(4JQP2*Y=_AAX#N519M%5A#(LP']IZNOE3IN
MV.'740I"9?Y7WJ?XL[3GTEX8W8,P8D @8DD4#(P<*K!?QQG//6@01 $!!@@@
M]?FSUW<_,>OS-D\GGDYVA7Q-."IT\3B*5-7]VE4<8^]\=XMV=UUW;^)N.BRE
M0I3DYRI4YR=KNI&,KN.L+245*R:6C;2W6I3RS%(]JJK*0 '5\*JY60,#SGKC
M/\ [-S2U*Q@O[-[.[@%U YC,D?FO;!C&X:,ED=9<KL3)215<@G: 2M;0BC&W
M" ;%"J>X4#&,]>G!YR>]'E1YR5).<_,S,.F/NDE<>@Q@'D#/-8Q3A+FCI)2<
ME)-QDI)>[*,H.,E).\[\U^:4N5J+25RBIQ<)I<LH\DDE%IQ>LHN,XRC)7T5U
MLE?4\]M?A_X0L+F&\T[2@E]:;/+)OM4D6-A(DHC EO3$Y\ZWB/S!VPF""K-E
M#\-O![O*?[)0+*?-D)N=:8,XB6 L6&IJ /)0)A=H!7/+DD]TL2+N947<79\&
M5QYAX*R@X)49SA%!0;B0?6&XNK:QMI;F]NH;2VMD,D]S<S)!:Q1GY-DLTSI&
MFYG!!DP-S*!SM-='UG%<RDL36YE[O-SR<W%R4^5S<[\JFE-*UU)<ZES&?L:-
MN5T:?)[SLHJ-.$M4I*,8O5PTG=>\W;579A:?X2\/Z-IU[I^EV"V]K?P317<3
M7&H.MR)_M#NBR7-X\D8E:ZN"&AF!C$@&X;8RO/K\+? *(MNF@;8?+D0)_:NM
M'$4GF&5"QU$N2^^3#[@5WC ^49]!MIK:^A@N;:6.XMIXEFAG@F$]K-"P79)!
M+&[1,"I&&CRIR<,0,FYY:==HSTS[>GZG\Z(XC$P<Y+$5U*I)SJ-5JL7.>RG)
MQFG)K725UT;:$Z%&I&"E2I2C#2/-3A))7]Z,8N-HJ223:L]%:QFZ)IECHVEV
MNEZ;;BTL+,2QVMN)IIQ%$9Y7 \VXEFF<DN6)DD9@6(^4 *--ONGG'OQQSUYX
MX]^*4*%& ,#DX^I)/ZFE(!&#R/2LI-R;E)N4I-N3DVW)MW;;=VVW=MMN[-DE
M%))))))):)):)+R2LEY(IB%8I'DC5FE)$C* RQN=JQ???<H(0+\JN"2N<<MD
M)(*/'\^_(?!  C)7+*2#N(& 0N6)/ '2K14'G+=<\,P[8Z @8QVZ9YQGFD$:
M   8"A@!D\!CD@<],@8]!P,#BI]Z]W)ST<6I=8R5N6Z6RW7GNQ<L;<J7*KJ5
MUOS)IK\ON9Q.O^"/#>OWR:OJ^G&\U"W@2UBE-W?P 01&641^5:75O%O!GF82
M.C':V"K80BKI_@3PIIMW#J5CI'V>_384F.HZA(2OF0S+&89[MXB-\$!!$8<K
M&!N(=RW>RH"IP<$YY)+ $HR;BK':< YP1@XP<9S4&W(*JOSH@ =D 61@H"LI
MP=@7'.P'82 ,X%;+$XI4O8_6*RI>S]DJ:JU&E36T''GC%TVVW*-G=MZMLCV%
M)S53V--S4N>[A%IU-N>,M*D:JC>WO6MLDCSWQA\*O 7CZ!HO%NB'5K:1'BE0
M:AK5@76::.=L/INHVCJ'G6-\KV7:I52PKD?"?[.GP>\&7[7GAOP;_9=PIN2M
MPWB#Q5=G-TJK*3#J&N7*MOA"ID(%4C<@1MPKWO8H&T 8X&.W'3'ICMCIVZ4;
M%].?7)S^><^WTXZ5I',,RI4?J]''8JE1:471CB:\:/+=MI4XR:U[-<B=[16Y
M$\)A*E3VU3#49UNM65.$IO1+64HR?2VZ=K;V2*0RDD2QE2!L5OG0@*& PJYW
M#OC+,QZ9)Y-^F"*,$$(H(((.!G(Z<]>*?7*E9;MZW;?+JWJ[))6U[W;WN=%]
MM$K*RLY6LMM)-I>D;+YD$G#8W*/,!!0HQ9P,# 8. G7&[;@;@2#BJ&H:=;:A
M::C97<!N+:_LI=/N8-\D)N[:XBFBDA:6)D:'<MQ*BRQ&)TW;MY*J5CGU73DU
M!=.>]M8[YBBI;274*7#B3R.886D\X\S0!BB#YI8>273-]2YEV,Y92,'"A<X#
M,#D'*$$\%3DD Y&!AN,U9WDG;GBU)QM:4;?#J]4G\KW32$I)MI/5.W_DCGOZ
M*WKW6WCF@? /X4>&/$W_  F&C>%7T_Q#MO&>\76_$EZRG4T"WJ?9;G5KFRD$
MN\_-':#RL QF,'GTK1_#NCZ#!)!I%F;:&1E<AKBZG7*H$3:]Q-(=JH %.Y@>
MK,QYKHMBY!P<@8SELD8QR<Y/09R3D@$\C- 10"H'RGL22![ $G:HQPHPH[ 5
MI7Q&,Q#_ 'V*KU/<A!^TJSJ>Y3CRPIVGS7IPBVH)ZJ[3;6@63T<>;6^K;L[W
MNO/MV&)@-M'S9&\OV)R%QP,= .A[=*EJ)_W:,4P#QC\2,@9S@8R< 8SD]236
M=<ZO8V#PQ7U[:VDUY=O:V$%W<6]M-?2@QJL-E'+(CW3L\D:*L(>1GD1=N64'
M-+9+T2_I)+\ ;M_GI\NO5Z+\;+4XR;X:>"IM[OHK2//())0;W60SR+$L"LSI
M?+&BB&.-<*B9*@[M[$F1/AMX(V*AT([(QM0?VCK("D<.,F_);##&23TX.#7H
MA4'C&/IP>#GJ,'J/6FB-5)(!^;&069AGU"L2JDDDL5 +'YFR>:UAB,3",8QQ
M%>,81C&*5:HM(IQBDHN,(QBFU&,8I15TMS.5&C)R;HTFY.[;I0YN_P"B['GK
M?#7P,%8KH1W!25_XF>L#D#CEKXJ.>Y! [C%=)I6E6&D6MK96%L+2VMA-]GA,
M\UP4%S*]Q<,99I9';=/(6^9B%\P(F%"@= 54@@@8/!X%1&"(DDALD;>))  "
M5)"@. O*K]T#ICH2**M?$58\M2O6J0O?V=2K.<>9;25V^6:6BET3>EW<<*%"
MG+FA3C"7PN<(0A+D>K5TG)IO5I-)A"Q=7PQ.UV0%D*D8 QP0N<9SG&#TSQ1M
M?;O*YE4X7D#(/'KMZ,W4?KS39'V$)'M#-@]0",G!;;@[B0#UQDKUZD41JM@^
MIG1VO[-=2$'VDZ>+N 7S6_'[_P"RAUN5CR?OA#&0N=W) RY?=LM59[Z:7L]G
MW?1W*YM;/>ZCHK*[3DM+::+M:_J8R^$M!%V]]_9O^ENXG:7[9>E3,&63(C^T
M^6N9 #R"G!PNTX'4*N5!*L"N04)P ')5CN(YPO) /& .">9=J^G;'?\ SGWZ
M^]9MQJ>G6=U!8W.H6=O=W;?Z)9SWL27EX/E#?9K>619I@ISGR@X'.<'(HDYS
MLISG.R<8\S;<8Z.R[*R72^BUW*VZM+K?75;/17OY[?FI;JV@N(7AE'F12*\+
MH2RB2.965XA(A3&5^3>K;TQRP;).-I'AO1M$+OI=B;-Y<-*!<7ET0^QTX,T\
MR\"1U)"[6Z@ @$="H#X#*2!O8$9"89\KR"!YBJ0,XW A\-R29@H&< #/7'!/
MXCG/OUIJ=51<%4G&E*W-3C.48STM[\=82ZVNKZL32;3Y8W6JDXW=]U=]KZKR
M*H"M(N<L8U+ 'Y6!^9"&3 ;&'9@< 8*CG&2@2..-(P,JB Q*JR*!&JA8P[L7
MRR@8)+*6!)*#:35GRTW;L?,>"V3D@ #!.<D<#@\9&>O-,DVK@>D;X7JV%V_,
M 3D[<X.>"6&X]*R<(\LH*/NS=Y)O1MV3;5GT2LK6TV*N[7OJE?;32[[I;M]K
M7W,'4?#VC:R4N-2LOM$@"#<L]Y$$6%W*-^XG1"5))VD$MG!!XJTEI:VEO!;6
ML!:".)K80"20E+9MH+Y8O,Y0*HP&W9?!RVW&BH*Q^67\S!W;D11N .\J$4X&
MX KD'J<XS328H@9"\2B))9)3*XC,4;$2EI'.XQI&HY#$(%P<J$45;=1PC3=2
M<J4'I3E)R2LO<<%91BXNTTVFTTM]G"5GS.,4[)WY5U]&WIU_"Z=QD9VK*7&Q
MI&)DQD%ML:#(1BS A HP,[N" <\H(HQ)%<*6+(LB [6WQI-M9R4_CW/%&,>7
MN .X$*&RS3[S3M4@:YL+VUU* 2-%]KL[B&Y@=U5"X26WEDC+(&5'PP<%=K?=
M6K^Q,8QZ#J<\<#G.?UY[U*@XKEYIM65TVDVWO*\%!IN]^UW=*+U5;V;2=MG;
M[M'LUM\NNMZ<4"0LJJ,89VC*ARJAU"#>&:0M]T<[D'4D5#?:99:M ]CJ,8N+
M=G25H/,EB;>@&QO,@ECDP"<XS@YYSQ6F$4'<,YP!RS$8&<8!) ZGD#)XST&
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M%W8W]G+#=6ES"X#Q3V\L<L; ,C@C-?S\_#WXB?$";_@T6U#X@3>.?&,OCU?
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M[5)?Z;H&NK!;_#[]GCP+]NN8I9[VZ\(:?:V&L:7=*+!;EOAE+<(MI#LTU_\
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MQ7XB^-?PI\!^%M9U#2?#6B)-XR^)[VFHW&G0WVD6M[/JFAZ88+<6][J GN/
MFNV5TEO.D4=MJ*_:(KRWFEM9)Y):6V?71K=1M=:=5)=;.SU*4H_S)ZM62=W9
MM)V>MFXRC?:ZOLSZNUC6=,T:V:ZU/4K#3(4>-3/J-[;Z?;[I"513<74D4(+G
M(0%\NP*J"V0/S=_;<-CK'Q5_8TN+2ZM+BU?XQV:K=6OEW-M-#+XC\!/''(T;
MLD\)C82%5D"&.0$A1*K&O\"+WQ+^V%XN\1_%?Q+XG\26_P &K<S^&- ^&2Z[
MJVF(-;T?2_#,TFM7DWAG4O#PE)O-7UR1(;R*]R?LTC2DPV267+_M)_#6^\&?
M'3]DZ&T\0ZA?>#-2^*VA'3="UC4=9UF;1M43QAX00-:ZAK>IZQJ"P2Z4]I9M
M;17-M9AM/2=HFGE,BTHQ4DFXNZGHWU45)2V^'W5;7F6K:29#E-KF5XKGC:26
M\8NZ25^;F;G)2]WE<5:,KJY^KDVHV%OY_P!HO+>W^S0O<W!GE6$06\2>9)/,
MTA41Q1QY=Y'(14!9B%!-+!J-A=6?]H6UY;7%AY3S"\@FCEM3#'O\R59T9HVC
M38^YU8J-K<\5^6OCBS^*_P 2_P!MOXB?"+1_BAXB\(^ Y_ASIFH:O86.KZNZ
M6T9T/PF+NVT>WM+[2[FREU2>\MDGNM.U;29(UO-1E)E,EPEY9N-3\;ZW\4O"
M_P"RCX'\=^*-$T;X50MJ?Q"\2R:WK"ZIXXTBZOO!WGZ.+UM2F\30O]G\6ZQ;
MK*_BN5%:&"1)(S%8/9+D4FHPE[W(IN+6KNW&T;;*Z;YI::-;V*YFDW)+24K\
MMVHP27O-MJ[3DDXQ[IJR/TRTSQ+X=UIY8]&U[1M7>!MDR:7J=EJ#0R;7;RY1
M:33&.3;&[;'P^%8XP#6N)HSDACA25)*L%R"58;B #M8%6P3M;"MAB ?AO]H/
MX8-\+OAOKWQ/^$&N>(?!&O?#S2KOQ=<65OXK\6WMEXJMM&GL+_4;74;/5->U
M#1+B2?1+75[&%]8TC5 )=2\S9')&L@\DN_CIX\^/'@?]F_P#\/?%&M> _'?Q
M5TS7]<\7>*;8VJSV<?@7P_\ ;-1M83:Q:8;AM<UBXMIY)-.NM($*0NDB7<$K
MP-*BW9JSC>TFFG;?2[LD]KWT2>_0;ERW3T:M9--*5]-&G*^O:S=FK7U/T6;Q
M3X6O;Z*SM/%&@SWT<KV_V*#6M.EN/M#L8U@>V2Y,QE#HZ^3M$BLK @'I^=EN
MJ?\ #U.Z<L5C3]GM9UC93'&CEK:V\\1N 4D*N8=V Y1B ?+;!^J-<_9P\)SZ
M%/#X<U/Q+X=\6FV@_L_Q=;^,/'LUW;:R)(635;B(^,(VO6EG5GECN9)E FF)
M63S)5E^$_'/AOQ%XK_X*6R:#H'C&[\(7+_ 6VFU77;..Y;4GTR"<RK#:O:W5
MI=0M-J)TR&06^I6K&UAG\QY(99K2=P2=D[2M=W5^KDOM):QW>EOY;DSO&\[2
MA=Q7O65]':_*Y>[+DY5M)-.^CN?K?8Z[HFIRRP:;J^FW\\.[SHK.^MKF2+;)
MY3>8D,CLF),QX8#YP5Z@BOSN_:3M[>;]M;]D>X(4S*-4$;X0<1WEPR!MR[RR
MNS&+#I\[ (I<'=P/[2>D^*OV9_&'P@\<?#CXA>*X=,\2_$31_"WC+PQ=^(/$
MNJP:OICRZ-J,J_\ %4:SXEL(6O1I>IB:>TMK2\5M6<-<R*9@WH/[1$L8_;1_
M9&2159Y5UED(SNS!=W4C'&T*N %*X;YB#N [M1MRRTEHW;>[^S*.WN[WNDTU
MV:82DU=)N+;Y7NG&+34U/6UVG=.+<6MS]%GN[:UCEENIX8([>-GN)YI%1(4"
MF5WFD<A8(T1&=FE(78I<L%0FJ>F>(M UKS3HVM:5JP@(69M,O[6_2%F5G59G
MM)95B9E1V59"I8*2 <&OSSO?&7B[]H7]JGQQ\&=+\6>(/!/@3X."VU7Q18Z9
M?W6G2^/4FD\(VD^AR7GARYT+6;.PD@G\2VLD]SK-]&G]H07$6GO)'"UIUO[0
M_@O4?@9X*N_C)\*M?USP[#\/AI^M>)O#,?B+Q#<V'BW2H->TB"XM;FTUC5M8
MT0RC1[K6H#<W>CWEP_VB)@&GMK-X944FDY)MJ32O9MMM^ZK-6C=W3:;2?+TO
M7,[7<7%:>]:Z48I)N7O)IS2BX.*E%<R<[*]OO W=LLR6YF03R(72'/[UT&[Y
ME0#<R_(QR 1A2W09KYV_: \':S\7/"5EHG@'XHW/@?4=%\2?:]3U7P[?,UPZ
MP:9J5I)H]Z]EXC\/F']_=17,D$UW(P>V0FVROFQ_ 7BKXM?%;XO?&O\ 9Q;X
M9^/=;\#O\1_@+IGBF]TY]3NAH\>I1CXD-JT\NF6]L-,N;J231H[:.X&G6F8X
M898UB$4<3=M^T%X!\9?L]?!4G1_BOXYU/7?%GQ:TB\O==?7?$\6H2)-X3\7?
M:[2*74?%NMR6UA?WD$%Y)96US96:3P0L;,M&DB6HI-7ZWBTW;F>J?+:SVLUJ
MK;W=[*>9MK9QNI74;M1LGJI7BVF[;-2OHE:Y^F^CVLNDZ3;VVH:G)>R6QE-Q
MJ%X70R;[F2:/S/.GF*&-7BB!DN'S&@P$5E"<AXXUO1=5\%^/['3M8TG4[NU\
M(^*A>:=8ZE975S"JZ7>PRM/!#/+);A93Y3^=%\LD@1OFRK?*O[0OQ(\22ZI\
M+/V?/"^LZQX8\4_%#Q3X=.K>,+749Q-IOA.2[\6W.MV\4\174C>3V/A9H;>3
M3=3TZ\1KB%8;ZT"2/76^,?V>CX;^&6N7/@OQEXFTSQI;^#=8CU?Q%>^)/&6J
M)XON8]#NI9EU"QU?Q9J=G;1ZIJD,5W<&6WNU16>&2.:)I(Y)2V<Y)2;D^6S:
M:O;W=&V^OO-)V2U=P5M8Q7NJ*]]7;4E>7O:Z6Y;-14FF[V2.2_X)P1PV/[,V
MG G:DGC'Q;.7*;25%Q;1EY6 QD&$H&<*=B*H!"@G[=A\4>&KG4)-)M_$&BW&
MJPAC-ID.IV4NH0A%#.9K..9KB+:K*6\R-=H(SC-?AWX#^-VO?#/]F#X3?#RP
MUF^\(:I\5_&'C"SN_&FFMN_X1K2H/''AK3[K4(X+"QFU-YI["[U2TCBTB2QO
M(9%%PDZ2S1SQ^]^+_$/PBT_X302>"/C+XIT[XT6UCH@N/B-YOQ;GN]7U22\L
MH_$<EY::G>R64D-[9/J4<%O=K<6EL%@:SBMI;>Q\I\B3BF[*3Y8OW8K2%U&T
MFFI62;^PE?6^B.>4H\R]Z5G.::G=)RLYOE4DUS/EC&_/)I.W+=GZQ"6-L8;J
M >01@'INR!LS@@!L$D$=014E?//[-7Q.O?BQ\*/#7BK5+6:#5I=-T6VU-KBX
M@GDO;W_A&M$U2YO";6UMK9//N=1G)C2)0K E3L*(OT%$'"*)&#OSE@, \G'
M Q@8'3M6>S:NFNC2:NGMN7KU5GJI:I\LD[6?YZ]"2BBB@84444 %%%% !111
M0 4444 %%%% !1110!Y-\=_@MX(_:-^#/Q.^ _Q*AU*X\ ?%SP7KW@+QA!HV
MH/I.JR^'_$=C+IVI)I^I1QRO8W9MYG\BY6.0Q/AMC8P?E'2?^"9/[+NB_L"R
M_P#!-BQT[QNO[,LVF:UI+Z?)XOGD\:FSU_XJ7_QBU%1XM-F)Q(WC/4;F6*3[
M)F+32E@ 5025^@]% [M:)O>_S6S]3Q3]G+X ?#S]EGX'_#;]GOX3V^K6OPY^
M%/AV/PQX2M]=U236M7BTN*ZNKQ5O]4ECADO9S/=S,9FB3*E5"@**\$^&7_!/
M#]G'X2?MJ_&?]OKP?I_C"']H/X\^"YO 7Q OM0\53WWA*?P_/<?#NZD32?#+
MVJ0Z9=F;X7>%2+E+J4@1WZA,7C;/N:B@+O75Z[^=]=?F?F'^W9_P1^_83_X*
M):QIWC#]H;X7WZ?$S2=,@T.R^*_P\\17W@KQZ^A6BWIL]&U6\M4N]$\26%C-
M?27&G#Q-H.LW&F/&L&G7%K937EK=?+N@_P#!N#_P2W\.?#CP]\/-+^&/CN.Y
MT+XAZ#\3+CXBS?$/4)_B9X@U_P -6&J:?HVGZQXBELFM+;PM:QZO>7,OA?PY
MI&@:->ZB+?4K^UN;ZU@G3]WJ*!\TDK*3MVNSX9_;,_X)X?LX_MX:I\#-7^/U
MAXPOKO\ 9X\:7GC[X<_\(KXIG\-10^(+ZX\.W,[ZRD%K<G5+0R^%]*V6S-"%
M47 W'SLK[=^TA^S%\!OVNOA7K?P6_:,^&?ASXI?#G76CN)M$\06\@N-,U.".
M6.SU_P -ZU92VNM^%_$=@EQ.EAX@\/ZAINKVL5Q<V\5V+:ZN89O>**!7>FKT
MV\O0_G[^'G_!LK_P2A^'WQ$M/B!)\,/B-X\M].U.WU33OA[\0_B=JOB#X=V\
MUKN:&VN]&MK+2]4\0:9YQCFN-+\4:[KEA?>2MM?07-C)<VD_ZA_M<_L&?LK?
MMQ?!ZP^!W[17PJTCQ5X&\/R1W7@G^R9KKPKKOP[U.WTN71K'4_ FM^'Y;"[T
M"2RT^1;9=-B\[P_?V]O:V>L:/J5A;QVH^P:*!N4FTW)MK9W>GH?@O\$?^#;?
M_@EG\%?B!I'Q#E^&7CWXOWOAN]2_\+^&/C9\0;OQIX#T":*\NK^&%?!]CIOA
M_1_$6G175Y//_9/C2'Q/I4\[M<W5G<73R3O][?L8_P#!.+]FO]@C7_CCKG[.
M5EXU\/6O[0'BBR\7^-_"VM>+9]=\(V&M:=>^(KRSE\(Z)-:0Q^&X88_$U]IQ
MAM99!-IEKI-I.TJZ7:,GWE10#E)[R;OW?S/QTT7_ ((3?\$]/"?[76C_ +:O
M@;P+XY\!?%_0_B8OQ=L=.\(_$#5=-^'R>-WU%M5O[M/"$L%W#::7JM[+>/?^
M'M.O++0C!?W=E::?:6316\/LG[</_!)+]A/_ (*%:EI'B;]H[X/KJ'Q T.VC
MT_3_ (G>"=<U/P+X^?28@1%HVL:UH<L4'B;2K;.=/M?%%AK(T?,HT9M/%U=B
MX_2>B@7-*Z=W=:)W=TNQ^.W[&?\ P0C_ ."<O[#GQ#TWXN_"WX5Z]XR^*N@2
M1S^%/'GQ@\5W/CK5/!UVL=S$^I^%M)6TT?PGI.M21W(6/7H_#KZWIX@C_LG4
M-/,EV;G]%OVC/V:?@7^UM\*-?^"/[17PWT'XH_#+Q)):7.H>'-=%Y UOJ.GR
M&73M9T36-*NM/UWPYKVGN\@L=<T#4]-U6VBGN;>*[6WN[F*;W.B@')MW;;?>
M^I^ /PL_X-G_ /@E9\+/&\_CF'X=_$OQU=);7<>A:!\1/B9?:[X7\+W]S;2V
MT.MZ5I5AINC/J6J::)6N=+_X2Z[\3:?9WZ6^H)IYO;2UGA_4S]BW]BWX(_L$
M?!&S_9]_9]L_$MC\.['Q+X@\600>+/$$WB;5_P"U_$TT$^J.^J3P6SM SVT0
M@@$06%00"Q8FOK*B@;E)[MOU85\,_LD?\$\/V<?V)_B)^TO\4/@;I_C"R\5?
MM9>--,\>_%V3Q-XJG\0V%UX@TC7/B#XALW\/V<UK;KHEHNH_$WQ0TEM&\XDA
MDL8BX%FI?[FHH%=ZKOOY]?S/SI_;A_X)3?L._P#!0V70]6_:6^#]OK7C?PU:
M?V;H?Q-\(ZOJ/@CXBVFCAIY(]"O?$N@RV\GB'0;6>YN;K3M%\46^MZ9I-Y=7
MEWI5K97%]?27'@G[&G_!!O\ X)P_L0?$32?B_P##+X6^(?&_Q6\-SB[\(^//
MC'XNNO'.H^#KW_21_:7AG0X;31/!NGZU&L\:V?B!O#,^OZ4;6"72-3T^>2]E
MN_V1HH#FE:W,[=KNQ\,_MF?\$\/V<?V\-4^!FK_'ZP\87UW^SQXTO/'WPY_X
M17Q3/X:BA\07UQX=N9WUE(+6Y.J6AE\+Z5LMF:$*HN!N/G97[FHHH"[T71;>
M5SR7X\_&_P"'?[-7P7^)_P ?_BYJUUH7PQ^#W@K7OB#X[UFQTK4==O-,\+^&
MK&74=6O+;1](M[O4]2F@M89'CL["VGNIV 2*-F(%?Q1_MT?M^?\ !JI_P4%^
M(T7QA^-7Q/\ CCX;^*\ME9:;KOC_ .$_PE^-'@W6_%]AI=I#8:3#XNMKOX<:
M]H.M7.EV%O;Z?9:O+HT>N1Z=;6FFOJ<FGV5G:V_]O/Q2^%_P_P#C9\.?&WPC
M^*OA;3/&_P -OB-X;U7PAXX\(:TDSZ3XD\-:W:R66JZ/J"6\L$[6E]:RR0S"
M*:*38QV2*V"/RY_X<!?\$;/^D?7P(_\  +Q-_P#-)0";3NFT_(_EQO/VB?\
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M6 20@/OW#^@O_AP%_P $;/\ I'U\"/\ P"\3?_-)1_PX"_X(V?\ 2/KX$?\
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M^T'_  X"_P""-G_2/KX$?^ 7B;_YI*/^' 7_  1L_P"D?7P(_P# +Q-_\TE
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M^'K.TT--1\/V.KZ?#9KK8TZR_#W_ ()$M_P5^_X*[_#CQ3X5U_\ X*(?'7X
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MJ&E:BFGZ7XMU?QCKGB^RV>(-0U73]-O=/MKSZ,_X)M_MQ_MF_L_?\%$/&?\
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MGQROM>3QJ-.M_%,/AO6-/\'/HY\#7DXL]*BN%\4F-UL8?</%OCC]L'_@C?\
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M)J6A6WB'5V\1_$7X@>)[S1;F+1M1O?$/@;5M'\8Z19W&KZ#>>'=>T"]T^?\
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MT*C,%]\DLWJ,+S@_>MUF:73V=]6ONM_F%-8 J0<XQS@9Z<XP,YST(QSTIU%
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M_K\6OT"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%>61L'86Z6<WBWP[XRUN$0%[_6=5F:.2$&U'DC[S2YIV=F[JZZ)Z/;R/C?\
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M9KS3?A3^U3\*_B!XQEBAGE&G>&K[P1\6/AE#?3-#'(D$/_"5?$?PQ9--<-#
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MNZ\/O<Z;I<UD"4TG%W?P<CLM5YKH_0_#S]J3_@@O^R;^RU\ ?BC\=OC_ /\
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MC4IH-(T"8>.]>N;.&0V^M:EK^F?%_P",&MP6T,A>670(;"VFA@ATK[-]X_\
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M-S3A;[6S?]U-R7XL_FL_X-NO^3UO^"[O_9TG@+_U;/[9U1?\&X5Q!:?MS_\
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M>7&EZQHVL:7<+>:+XE\-:U9LEYHWB#1KQ%GLKV!FCDC:XT_4+>^TF^O["Z_
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M?%,.G>1I+^(9-*L-,L[(%S+F7O2TC92\WK\*2]WI;?KY'\U?[8?PA_X*"?\
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M-4L_L&I:>ZO;W)=X[VUF*QPW$$DOZ*IY;_,Y:8+DJW"LR=-Q $0R)&9,;5.
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M=_\ !5S7_P!AVX_9BU.#]F?2_AA#XSL?VGO^$?\ 'RZ9>>(I/ FB>)G\.?\
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M[HFE>&;W3?$?V'QY8Z?KC1ZG<ZQJ-LLZV_V&0Z>RV[M)'/C](:!M6;3Z?/\
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M\0/AK9_8KS52;^;[=8>#;74KGSS^[N[RXBB_<I'0.SM?I>WS:O\ D??E%%%
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M"L>HZ8MW_P (D^-0N(+C[4/+^T+^HOAS_E;?\?\ _9K5E_ZH'P51XC_Y6W_
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M&20Q>(#\/+?5-<^'^M:K>^./[+MHB-(U+XCW/BF&:>[\/6WQ"@U21M/?G/\
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MDT_7X],U/Q)/)X/\,Z5X-\3ZUXHL[NTBMHJ_?ZOX_P#]JZ[L_A1_P==_L/\
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M_"SO^%A/Y^[^Q_[4_LW_ (5[#C[1]B^WGR?M<OZUT4"YG=N^LKW\[[G\]/\
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M-J5Y;M(MC=3ZCX<ADNEB@EAB29IXOQU_9A_X)J_LX?MO>(OB7^V;_P $8/\
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M^D_$&ZCEDU#0=:\-7GA2#Q;;:VEFD5FT_P"X5?*?[8W[%/[.?[>?P>N_@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO6.BNWS*RZ6;[WZ:G]75%?S:_LH_\%E?VG_ '[9WA;_@GC_P5J_9Y\%_L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'/<>"?BA;^-=5>QUZS^'%]XREAN-*A:WT]KCP%;/+J!6*YCM+8F['2_MO?\
M!+;]H']I7_@C?^SE_P $\_ OC#X.Z3\:?A#\/?V4O"?B7Q/XL\0>-;'X7WVH
M_ OX?:1X3\6S:'K6C_#W7O%=S9:CJ-A--X<DO_!6F3W=DT4FIVVD3L]L@:J4
M;K5?Q92^36_H?H/^S):VMC_P33_9\L;&VM[.RL_V&?A/:V=G:PQV]K:VMO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*OX&_\$O/#_P2
M_P""G/[3'_!2JT^,.L>(=>_:1^&=U\-K[X37'@ZRT[2/"D%S>_!J\.K6GBV/
MQ!=WFK3(?@_:QBTFT*Q1AKL[>>/L,8N?U4HH&FU>W56?I_2"BBB@04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%1330VT4E
MQ<31000HTDLTTB1111J,L\DCE41% )9F8*!R2!6-_P )5X8_Z&/0?_!QI_\
M\D5I"E5J)NG2JU$G9NG2JU$G:]FX4YI.VMFT[:VMJ8U,1AZ+2K8BA1<E=*K7
MH4FU>UTJM:DVKZ72:OI>^AO45@_\)5X8_P"ACT'_ ,'&G_\ R11_PE7AC_H8
M]!_\'&G_ /R15_5L3_T#8G_PGQ'_ ,H,_KN"_P"@W!_^%F$_^:C>HK!_X2KP
MQ_T,>@_^#C3_ /Y(H_X2KPQ_T,>@_P#@XT__ .2*/JV)_P"@;$_^$^(_^4!]
M=P7_ $&X/_PLPG_S4;U%8/\ PE7AC_H8]!_\'&G_ /R11_PE7AC_ *&/0?\
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M_P#Y(H_X2KPQ_P!#'H/_ (.-/_\ DBCZMB?^@;$_^$^(_P#E ?7<%_T&X/\
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M4;U%8/\ PE7AC_H8]!_\'&G_ /R11_PE7AC_ *&/0?\ P<:?_P#)%'U;$_\
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M ,)\1_\ * ^NX+_H-P?_ (683_YJ-ZBL'_A*O#'_ $,>@_\ @XT__P"2*/\
MA*O#'_0QZ#_X.-/_ /DBCZMB?^@;$_\ A/B/_E ?7<%_T&X/_P +,)_\U&]1
M6#_PE7AC_H8]!_\ !QI__P D4?\ "5>&/^ACT'_P<:?_ /)%'U;$_P#0-B?_
M  GQ'_R@/KN"_P"@W!_^%F$_^:C>HK!_X2KPQ_T,>@_^#C3_ /Y(H_X2KPQ_
MT,>@_P#@XT__ .2*/JV)_P"@;$_^$^(_^4!]=P7_ $&X/_PLPG_S4;U%8/\
MPE7AC_H8]!_\'&G_ /R11_PE7AC_ *&/0?\ P<:?_P#)%'U;$_\ 0-B?_"?$
M?_* ^NX+_H-P?_A9A/\ YJ-ZBL'_ (2KPQ_T,>@_^#C3_P#Y(H_X2KPQ_P!#
M'H/_ (.-/_\ DBCZMB?^@;$_^$^(_P#E ?7<%_T&X/\ \+,)_P#-1O45@_\
M"5>&/^ACT'_P<:?_ /)%'_"5>&/^ACT'_P '&G__ "11]6Q/_0-B?_"?$?\
MR@/KN"_Z#<'_ .%F$_\ FHWJ*P?^$J\,?]#'H/\ X.-/_P#DBC_A*O#'_0QZ
M#_X.-/\ _DBCZMB?^@;$_P#A/B/_ )0'UW!?]!N#_P#"S"?_ #4;U%8/_"5>
M&/\ H8]!_P#!QI__ ,D4?\)5X8_Z&/0?_!QI_P#\D4?5L3_T#8G_ ,)\1_\
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M#<'_ .%F$_\ FHWJ*P?^$J\,?]#'H/\ X.-/_P#DBC_A*O#'_0QZ#_X.-/\
M_DBCZMB?^@;$_P#A/B/_ )0'UW!?]!N#_P#"S"?_ #4;U%8/_"5>&/\ H8]!
M_P#!QI__ ,D4?\)5X8_Z&/0?_!QI_P#\D4?5L3_T#8G_ ,)\1_\ * ^NX+_H
M-P?_ (683_YJ-ZBL'_A*O#'_ $,>@_\ @XT__P"2*/\ A*O#'_0QZ#_X.-/_
M /DBCZMB?^@;$_\ A/B/_E ?7<%_T&X/_P +,)_\U&]16#_PE7AC_H8]!_\
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M'_A*O#'_ $,>@_\ @XT__P"2*/\ A*O#'_0QZ#_X.-/_ /DBCZMB?^@;$_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;OVP_^36/C_\
M]DJ\8_\ IHN*_CXK^P?]L/\ Y-8^/_\ V2KQC_Z:+BOX^*_N/Z*G_)*\5_\
M9283_P!4D#_+;Z>__)>< _\ 9%YA_P"M/4"BBBOZE/X0"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#^R7]E__DVG]GC_ +(9\)?_ % ?#]>YUX9^
MR_\ \FT_L\?]D,^$O_J ^'Z]SK_)#B/_ )*+B'_LH,__ /5[G9_T*<&_\D=P
M?_V2/"?_ *RO# 4445XQ](%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'S=^V'_R:Q\?_ /LE7C'_ --%Q7\?%?V#_MA_\FL?'_\
M[)5XQ_\ 31<5_'Q7]Q_14_Y)7BO_ +*3"?\ JD@?Y;?3W_Y+S@'_ +(O,/\
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M7$8>5*=3$T:M"N=E1117ZP?SX?S9_P#.3O\ [N<_]V>OZ)?$?C;P9X.^Q_\
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M.DZ-XIT/5-3"VV?M+?8+*^GNMMO@^>?*Q%@^85Q7E7[)'_)L?P(_[)?X1_\
M33;U^*'_  3L_P"3T[G_ +!7Q+_]GK]DSSQ'Q648SPLPT,JPM=>(E?"4L5.>
M*Q,'E:Q.7Y5C7+#*%*2Q3A+,9TTL0Z:<:49.TIR2_FKA;P5P'$.7>/F.J\08
M["R\&L+F.(P-.E@,%5CGSP.;Y_ED88Z52O&6 52&2TZTG@U7<9XBI"*<:<'(
M_;F_Y/ZC_P"PK\'O_3?X=K^@37_B/\//"M\-+\4>//!GAO4V@CNAIVO^*-#T
M>^-M*SI%<"TU&^MK@P2M%*L<PC\MVC=58E& _G[_ &YO^3^H_P#L*_![_P!-
M_AVOK?\ X*S_  B_M;P;X%^-.FVVZ\\)7[^#/$TJ#+MH&NRO=Z%<S$C @TS7
M4NK1,,"9_$B@JX ,?Y)PUQ%F?"6(^D+Q'E668?-Z^4<:X?%U\#B*^(P\)X%5
ML?3QM:%7#4ZM3VF%I5H8CEY'"5.%;F:Y$S^B.-N#,C\0\']#G@K/\\QG#N$X
MB\,<9E^%S7!87!XVI3S5X;*:V68:I0QU:A1=+'XC#U,&YJHJD*U7#<BE[1H_
M7R&:&XABN+>6.>WGC2:">&1989H95#Q2Q2H622.1&5TD1BKJ0RD@@UQMK\2_
MAQ?:W_PC5E\0/!-YXC-Y/IXT"U\5:%<:W]OM6E6ZL?[*BOWOOMELT,RSVWD>
M="T4HD13&V/A[]G#]I>TA_8,;XIZM=)=:S\'?"&M>$=3CN9UE:[U_P )6L5C
MX/LKB4D2-<:Y87OA-)'G E>YU)V=YLB>7XD_X)7?#.[\:?%WQW\;O$'FWH\&
M6$UC87UT \E[XQ\;M=G4+\2NC>9/9Z)%J:7FUHY ^OVC[BK,A_4\1XI/$YOX
M991P_EN&S*MQ_@(YSBY5L57IK)<FA0IU,3B;8>G/VU:C6I9EAXPK.E3E/!1N
MTZDE'\#PG@(L%P[XY<1<7YWC<DPWA#FT^&<OAA<!A:SXGXEJ8JM1P."YL96I
M?5L-B<-B,CQDJN&6(K0I9G/EBU0C*I^^5?@9^W)\=_BY\7/VC?\ AF;X9ZYJ
MFB^'[#7- \#Q:5I6I7.CQ^+/%VM?V=+=W?B*[MFCFETO3+Z\BL(+2=I;"UCT
MR?5O*::YS%^^=9NI+I$,1U;5UTV*#1HKB_.I:D+5(M*@@C$]U>F\N@$L8H8H
M!-<7!DB2..$22.%CR/I/$+A+'<:9'2R3"\18CAW"2Q^&Q.<5L+3J.MF&5X>\
ML1EOUBGB\'+"4JR]I4J5G.I2;ITHUZ52A3JTZGQ/@YXAY5X8\55^)\=P;A.,
M\QAE&-P7#F'QU:DL-D^>XOEA@\[^IULNS&&8U\-)4J-'#JG1KQ5:O/"8BCBZ
MU"K1_F_^-_[)_P =?V*]&\,_%O1?BE'-]I\06VEW^J^"K_6]%O\ 1]>N+6[O
M;(7"7#1'6-,OHK34;>:>:-8Y"/LM]8&&^VM^NGP5_:JD\2_L<3_M"^-;6*76
M_!OAOQ,GB>UM!]EAUOQ%X4>>SM!:XA6&UE\5.-*F9(8OL>GWVK2VT>+>U!'Y
MD_MS_M2W'[4/C'P]\!_@KI][XE\*:3XHB:UN],@EN+SX@^,_*N=+LWT>W0;S
MH&F0WE]'83N%74I;F?5) EE;6$[?6OQK^#]W^SU_P3)\3_#F20W&O6]MX.O?
M%M_8SQK"-<\1_%/PKJ&LQK*'B:YL+47$?AN!X49[RRAMY9X?+DN77^>>$L3A
MN&>)_%/&>&^(S"OP#PUP1F%6I+$XS%9CE-3B_!X*K5HU,MJXERA7E'$4JM65
M6FN6MAJ6(E4E5P57"3E_9'B)@<;QSP+X"9=XV8+)\+XN<;^*63X>C#!9;@<E
MX@H^'.99I0H8JCG6'P*IU<)&I@JV'H0P]:7/AL=B,'"E"AFE#,*<?SW^%/P?
M^.__  4*\:^/O%?B#XA0P#PVMK=7FI^)&U2YT>QO=>DO6TKPWX8T6TWVVFV$
M<.FW3SQV9BCL+>*WEFBN[F\0R^__ + _QW^)7PI^/UY^S!\3]9U'4-#O=4\0
M>#K+3M4OI]0B\(>-_#;7IB31KFX66=-&UEM-N]*%C 8K&:[O-,U*%8%6Y-S[
ME_P2(@A7X9_%RY6>-KB7QUI$$ML$(EBAM_#Z203N^<-'</=7$<:8!1K:4DGS
M!CXE\832:?\ \%.+1[)A;-)^U!X&A<Q*B[H]3\6>'[>_4C;@F[BNKE9FQO<S
M2.6WMNKY7+L#/A3(?"/Q.P68YM4XFXJXO^J\2XG$9EB<33SC 9EF,L.\+B:-
M2K*G*,*/.FJCJ.4ZBJ.%&K0PWL?OLZS:GX@\6?2*\"\TR7A^CP-P!X<_VAP1
M@\'DF!P5;AS-LER6&,CCL%B:.'A6A.IB?92BZ4:,84Z4J*J8FAB\;]9_;+]I
M']K+X7_LRZ3;2^,9M0U7Q3K-E<W?AGP;HUM(^HZRMN_D-<3ZA,BZ9I.FQ7+1
MQ7-Y>7!N AD:PT_4IH6MS_/0WQD\8?'K]K#X>_$GQK)&NIZM\4?AS!8Z9:^:
MNG:%HEIXHTE-+T73(Y69TL[6%C*TC'S+V\N+O4K@M=7L[O\ T1?%[]E/X2?'
M7QWX2\<_$VPU3Q W@W2IM+TSPV-1>Q\.W8FU :B;G5XK..'4KYDE58UM!J4&
MGRP^9%>VEW'(5'XF?M)Z9INB_P#!2"UTC1]/LM*TK3?B/^SU9Z?ING6L-E86
M-I!X5^&,<%M:6END<%O!"BA(XHHT1% "J!7W'CUAN-9XK)\?F>8Y?A^#Z/'/
M#F7Y%DN!566+QU6K+"8FIF^<UG:G[6A4H8G#X+"WG&G"I*O&G3G-U)_EOT2<
M=X7TL!Q'E&19-G&,\1\3X5\9YOQ9Q/FKH0R[*Z&'AF&"H\.<-8=7JNABZ.*P
M.-S/'\M.5:K1CA9UJU*G&A3_ *-]5U.QT32]2UG5+A+33=(L+S4]1NI,^7;6
M-A;R75W</M!;9#;Q22-M!.U3@$\5_.-<>(?CO_P4?^.>J^%M)\23^&O!%E!J
M>LZ=H=]<7D7A?P=X0M;RUM;:;4K'2P\>M>)+Z6:P2:>X,DUYJ$LB6UQ9:3:1
MQVG[D_M67ES8_LT_'>XM)6@G'PJ\;0B5 I=8[K0;VUG"E@=K/!-(BR+B2,L)
M(F215=?YU_V0E_:+USQ=XD\!?LWZA#H'B7Q;HUI/XD\422Q6+Z#X9T*^$LDK
MZO-#=MIEE=ZE?V$%RUA876K74_V.VLRD#WB3>GX\9S5K\5< \%XFEGN-R#-%
MB\RSC)>'9SAFG$-2GB9X/ 952<*M'FA*I2<I>UFJ%%5*^*J1D\/3G1\'Z)O#
M5#"\ >+GB;@L1PIEG%V0RR_).'.)N,Z=.KD7!]&K@:>99MG]>-7#XGEJPHXB
M,8>PI/%XET,+@*-2$<76IXGZD^&7PQ_:W_8W_:*TOPYX4T3Q_P#$OX<QWVC/
MXFD\(>'?%NI> ?$'A/5I"U_-) MM-I>D^*-)A>_FM1YTEY::I#MCEO["]EBO
M?Z Z_!/PA^U3^T]^R1\<['X8_M.>(+KQAX2OI=+?6I]5N$UZ>ST#5Y6MX/&?
MA/Q%'!!JEY;6<D4YNM-OO.CG%CJ.G_8+'55%Q!^]E?7>!\LCHX'BC+,DQ?$^
M&CE^>N&*X0XJA0^N\(5:E.IRX+"5J5>O/$8+$Q@Y*K.5.]?#MNA"K*57%_G?
MTIH\58G-> \\XHR_@7&SSCA15,!XC< U,5_9GB-0HUJ/M,SS##5\+A*6#S/
MSJJ#H4H5N7"8R,8XJK0A3H9>4445^Y'\JA1110 4444 %%%% !1110 4444
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MDUIE/A1Q+@?"#BK@.MB,H>=9WFN.QN$JT\77EE\:.)Q^4XJFJ^(>#C5A45/
MUE*,<-42FZ:4FI-QQX@^D%P/FGTCN /%G#83B*/#/"_#^597F.'JY?A(9O/$
MX+*.(<!6EA<)',IT*M)ULUPSISGC:,I4XU9.$7",9_!FC?\ *)R;_LEVN_\
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M7<^(;.#[+;>*M O)-$\0K;# 2VN;R!7@U."''^BPZM:7\=IN?[*L/F2;O/M
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M3R^C3Q&-GAZ>$S:A*.&HU:V'IU:O/CJ+4)UZ47%5'SIQ2E\,?L@?\HX?$/\
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MM:P:CK\%N+>\E22>V'B'7ECB>[$D?G?U *JHJHBJB(H5$4!555 "JJ@ *J@
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M2/"?_K*\,!1117C'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  P9M_\ ('\I?\2=^/G_ $2V4_\ B6</_P#RT_G]HK^@+_AS;\./^BT>-O\
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MOPX_Z+1XV_\ "=T+_P"2*/\ B8?PI_Z'F/\ _#!FW_R ?\2=^/G_ $2V4_\
MB6</_P#RT_G]HK^@+_AS;\./^BT>-O\ PG="_P#DBC_AS;\./^BT>-O_  G=
M"_\ DBC_ (F'\*?^AYC_ /PP9M_\@'_$G?CY_P!$ME/_ (EG#_\ \M/Y_:*_
MH"_X<V_#C_HM'C;_ ,)W0O\ Y(H_X<V_#C_HM'C;_P )W0O_ )(H_P")A_"G
M_H>8_P#\,&;?_(!_Q)WX^?\ 1+93_P")9P__ /+3^?VBOZ O^'-OPX_Z+1XV
M_P#"=T+_ .2*/^'-OPX_Z+1XV_\ "=T+_P"2*/\ B8?PI_Z'F/\ _#!FW_R
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M_P")9P__ /+3^?VBOZ O^'-OPX_Z+1XV_P#"=T+_ .2*/^'-OPX_Z+1XV_\
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M^?VBOZ O^'-OPX_Z+1XV_P#"=T+_ .2*/^'-OPX_Z+1XV_\ "=T+_P"2*/\
MB8?PI_Z'F/\ _#!FW_R ?\2=^/G_ $2V4_\ B6</_P#RT_G]HK^@+_AS;\./
M^BT>-O\ PG="_P#DBC_AS;\./^BT>-O_  G="_\ DBC_ (F'\*?^AYC_ /PP
M9M_\@'_$G?CY_P!$ME/_ (EG#_\ \M/Y_:*_H"_X<V_#C_HM'C;_ ,)W0O\
MY(H_X<V_#C_HM'C;_P )W0O_ )(H_P")A_"G_H>8_P#\,&;?_(!_Q)WX^?\
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M>-O_  G="_\ DBC_ (F'\*?^AYC_ /PP9M_\@'_$G?CY_P!$ME/_ (EG#_\
M\M/Y_:*_H"_X<V_#C_HM'C;_ ,)W0O\ Y(H_X<V_#C_HM'C;_P )W0O_ )(H
M_P")A_"G_H>8_P#\,&;?_(!_Q)WX^?\ 1+93_P")9P__ /+3^?VBOZ O^'-O
MPX_Z+1XV_P#"=T+_ .2*/^'-OPX_Z+1XV_\ "=T+_P"2*/\ B8?PI_Z'F/\
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M_P#RT_G]HK^@+_AS;\./^BT>-O\ PG="_P#DBC_AS;\./^BT>-O_  G="_\
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MF/\ _#!FW_R ?\2=^/G_ $2V4_\ B6</_P#RT_G]HK^@+_AS;\./^BT>-O\
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MOPX_Z+1XV_\ "=T+_P"2*/\ B8?PI_Z'F/\ _#!FW_R ?\2=^/G_ $2V4_\
MB6</_P#RT_G]HK^@+_AS;\./^BT>-O\ PG="_P#DBC_AS;\./^BT>-O_  G=
M"_\ DBC_ (F'\*?^AYC_ /PP9M_\@'_$G?CY_P!$ME/_ (EG#_\ \M/Y_:*_
MH"_X<V_#C_HM'C;_ ,)W0O\ Y(H_X<V_#C_HM'C;_P )W0O_ )(H_P")A_"G
M_H>8_P#\,&;?_(!_Q)WX^?\ 1+93_P")9P__ /+3^?VBOZ O^'-OPX_Z+1XV
M_P#"=T+_ .2*/^'-OPX_Z+1XV_\ "=T+_P"2*/\ B8?PI_Z'F/\ _#!FW_R
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M_P")9P__ /+3^?VBOZ O^'-OPX_Z+1XV_P#"=T+_ .2*/^'-OPX_Z+1XV_\
M"=T+_P"2*/\ B8?PI_Z'F/\ _#!FW_R ?\2=^/G_ $2V4_\ B6</_P#RT_G]
MHK^@+_AS;\./^BT>-O\ PG="_P#DBC_AS;\./^BT>-O_  G="_\ DBC_ (F'
M\*?^AYC_ /PP9M_\@'_$G?CY_P!$ME/_ (EG#_\ \M/TC_9?_P"3:?V>/^R&
M?"7_ -0'P_7N=<9\.?!MM\.?A[X#^'MG>SZE9^!/!GA?P;:ZC<QQPW-_;>&-
M#L=$@O;B&(F**>ZBL4GECC)C221E0E0#79U_GMG.)I8S.<XQF'DYT,7F^;8N
MA)Q<'*AB\US/%4).$O>@Y4<31DX2]Z+DXR]Z,C_8#AO!XC+N&^',NQ<%3Q>7
M</</Y?BZ<9QJ1ABL!D.1X'%0C4A[E2,,3@L3"-2'N5(PC.'NSB%%%%>:>T%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M5[F5(8P\D@C 8#<=W4@\#:&.3]*JBX+?*I+*Q*%B<8/ (PQ#8 .<[<'G!.#B
M'.-[*47+LW9V[Z)O\+=V@L^S>MM%?^K=32HJJLT!90ASM#9X8%>V<8P<YYZ]
M0>.]E3N&<$>S#!_S]*J+;6JMKT:?XH;5N_ST%HHHIB"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK^
M4G1?^#LS]E7Q)%//X=_8\_;&U^&VD6*YFT70?AQJL5O*Z[TCGDL?',Z12,GS
M*DA5F7Y@".:!J,I7LF[;_P!71_5M17\L?_$51^SO_P!&._MP?^$;X'_^;*OT
MV_;C_P""NOP;_8/_ &6/V>/VK?B7\*_BQXE\+?M%S>#K?P]X1\*P^%HO%WAF
M?QE\.KOXD6L'B>'7_$&D:=#-IVG6<FF:A%8WMVZ:G\D:O K3 'R232L[O1;:
M_B?K-17\KEU_P=9?LVV-K<WU]^Q-^VS9V5G;S75Y>77A/P';VMK:V\;37%S<
MW$WC1(H+>")'EFFE=8XHU9W954D?I#_P3W_X+A_L+?\ !1WQ.?AM\)?$?C#X
M=_&;^S+K5K7X0?&70]+\,>*M?LM-CDEU:X\':EH6O^*/"7BO^SK>*349],TW
MQ#_PDL>BI-K%SX?M;*RU.2P <))7<79=?^&;/V"HHK\4O^"E_P#P7-_9A_X)
MA?%KP!\%_BKX&^*'Q(\:>-_!(^(%Y:?#&/PC<+X1\-W6NWV@:/<:^/$GB30G
M^TZW=Z/KLMA:6:SRBVTIYKCR4N[)IP23;LE=]D?M;17/>$?%GASQ[X3\,>.?
M!VKVGB#PCXT\/:+XL\+:]8,[V&M^'/$>FVVL:'J]D\B1NUIJ6F7EK>VS.B.T
M,R%D4D@=#0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKP']J
M+]IOX0?L<_ KQS^T?\>M>O\ PS\)_AS_ ,(S_P )7KFF:#J_B:^LO^$N\8>'
M_ FA>1HF@VE]JU[]I\2>)]'M)?LEK+]FAN)+N?9;6\TB=_\ "?XF^#_C7\+?
MAK\9?A[?SZKX!^+?@#P;\3? ^IW5A>:7=:EX/\>^'=.\5>&K^YTS4(;>_P!.
MGO-%U6RN)K"^@@O+.21K>YACFC=% L[7Z;7Z7['?T45Y-\._CO\ !KXN>)/B
M/X2^%WQ+\'_$'Q!\(=:T[PU\3+'PAK5IKZ>"_$FJ6D]]:^'=<OM->XTZVUY+
M6WEDO]&6[?4M*(6+5+:SEEBC< ]9HHHH **** "BH+JZM;&UN;V]N8+.RLX)
MKJ[N[J:.WM;6UMXVFN+FYN)F2*""")'EFFE=8XHU9W954D>8_"'XY?"'X_>'
M=7\7_!3XB>%OB?X3T/Q;K_@;4/%'@S4XM;\._P#"4^%YHK;7]+L=;M-^FZM_
M9EQ/'!->Z3<WNG/-OBANY7BE5 #U6BBB@ HHHH ***\N^%OQN^$/QN@\;7?P
M?^)'@[XF6/PY\=ZE\,/&VI>"=<L?$6E>'OB#HVBZ!X@UGPC>:IIDMQISZUH^
ME^*-"EU6TM;F=M-N;XZ=>F#4K6]M+< ]1HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HKY"_;3_;H_9P_X)^?"W0/C+^T_XMU;P;X!\3>/
M]*^&6D:GHWA/Q'XQNI_&&L^'?%7BK3["33/#&G:G?P02Z+X,\07#7\T"6<4E
MK%;R3+-=6Z2>H?LX_M#?"W]J[X)^ ?VA/@IK5[XA^%WQ+TZ_U7PCK.HZ+JGA
MZ]O[+3=:U/P_=R3Z-K5K9ZI8LFJ:1?0K'>6T3ND:S(IBD1F!V=KV=MK]+^I[
M;1110(**** "BBB@ HHHH **** "BBB@ HHHH ***\N\$_&WX0_$GQE\2/A[
M\/OB1X/\;>,_@]=Z%IOQ2\/^%M<L=<O? &K>)(M4GT;1/%1TZ6XM]'UZZM]&
MU"YDT*[FCU>RMHX+F^LK:"^L9+D ]1HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJ-I8D4L\B*HY)+  <$^OH#QUH 5WVYXSQGDX!X)(
M&>X"DGVKP?XZ?M*?!C]FOP9??$+XY?$CP=\,O"-BZ6XU/Q;K^G:.^I7DSE+:
MPT>UOI[:?5-0NBKI!;6H+2.DH4 0NP_.;_@K#_P5Q^&7_!.KP.?#VA'1?B#^
MTYXOT5;SX>_"F6ZO6M-)M9]1AL%\;^/IM*M9Y-)\/6!DN;_3],O+W1;KQ>^D
M7NF:1>+MN;RT_P ^_P#:@_:H^-O[8OQ>UGXU?M >+G\8>--6(MK5+/3X]&\-
M>&M&MVE.G^'?"_AZV)MM-TC3HG,4$L[7FIW3,T]_J%U<R/*WZ;P-X79IQ:HY
MAC:M7*<B]I%PQ$H)8K,$U%J."I5*;_V6:Y_]N:E3]U^R52USYC.^):&6PG1P
MGLL5CDW!Q;<J-"<=)QJN$E>K!VO2NN5Z5&K.!_63\:?^#H#P?JVJ:[X3_9>_
M9\\2ZW%;W-Y96/Q&^+.MZ;X:LKB.-6@CU?2?!VE6/B:[N(C<$36MOJ5];?:H
M(XO,1#<E%\K^'O\ P58_;L^)VJV]QJ7Q>T_0;6:2".32M&\#^$[:* 2H\I3S
M7TM+@B(,J@R9=E4[B<G/\E/A;4C8:S',YR&>,,6;;E=Z$<@'@  <8([8QFOU
M=^ OQ$MK:6R87,*E)+4;5_>X_<G(,FW[PR1\WS#OC(K]_AX9\(93E\98+)</
MB*ZA6I5,1CTLQK5GS:5+5W*E1<8\J7LZ$&T[J:MI\=A.*,RQ.)K4<5C.1ITI
MTJ5*,*=.4)17-)2A",[*:E9<^FBDG9-_VC?LG_M,?%[QHVFQ>/O%VG>(H)VF
M6>XO-+TO2KJ,938PFL+4!BI&%#G:0Q+$%@&_2O0/'&A^([B^L-,OK>74-)9?
MMUD+F.6=(V8HER%20N]LS ?O?N*73?\ ?7/\E'P@_:7?P];6^R^M<HLH()V_
M>=05#%7P!C) Z8SD=*^D/A;^VCJF@?'OX6ZA87EB\.O>,]#\*:W;D-/]LT/Q
M)J^G6=];A5CRDP"H]O)M)61><C(/XAQ#X?UG4QF(P-&.'IX?#5:_)"FZ=.2H
M<TY+W8<G,X*R2MNG=W:/NL'F4(QI0E*55SJ7;E.527*XQ2W;:5]>WS/Z>HG\
MR-'(*EU#%2<E2>2N0!G;TSCG%25'#Q&HR3C<N2<D[6(_ <<#L,#)QFI*_(4[
MI/ND_O/>"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P 7>'KQ+[1]>T/4X5GL[ZSG7##<I,=Q;3I#=V5U'/9WMO;W=O/!'V]? ?\
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MP%X;\9M;ZUI\PMM,\27?AWR[Z.>\L!/^87_!.+0_^#CS]A?]E;P7\'/V9O\
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MZ+]OLM8DT>SGU#1;+79;'0?$DMYX9TCQ#X3U>_L[?7/"]O%J.BW&K;'_  3
M_P""H?AC_@I'I/[0-BWPCUSX!?%;]FSXH+\-OB3\)O$WB_2?&.MZ5]IMKR'3
M]:GO]+TO1%MUN?$GA[QOX:ELCI\L,5WX3N)H-3O!=/!9?C9\:K#2_ '_  =I
M_LJS_"^UL(M5^+W[,VJW_P ;;:TB_LU=2U2+X._M#Z;+=:O<*LRWM_:>#?AS
M\-M7@E\N#[;+I>DZ8[++NNGWKNS_ .':?_!R/8:IYD>@_L]?\%8/A_?0S2NO
MEZ+9?'8W$<ES"99(8Y)/$6I?%70]-NI/*FFMX8_CZIE? $=B XQ=[)W<%.*O
M>UF^9>>B;770_7+]J?\ X*A^'_V>/V[_ -D?_@G]X3^#VL_&/XO_ +4*PZSJ
M=SI?C&R\,6'PG\"3:Y?:>?&FM6L_A_7;C7[:UT7PM\1?%%[IMK+I=U!I?@MQ
M').^KVSV_P ^_MI_\%PO!_P$_:03]BW]D_\ 9L^)G[>_[6]@TG_"9_#'X4:C
M-H'A_P  "/3K/4YK;Q'XTM_"GC=Y=4TVSU"TNO$-OI_AZ?1?"L7VBU\5^)-"
MU:VFTU/A7_@CQ:G_ (*"?\%7O^"B/_!5O55;5/AGX#\02_LO?LO7KF9],FTF
MQL=,TJ;Q#I+1RM;6VHP_"SP_X:U/4[-)KJV:Z^->LW(5IC;W=?E%_P $?_%7
M_!5-OVB?^"DOQ2_83^#_ .R'\4_B9XF^.TEM^T#K/[3^L^+V\;^&+O5?&WQ3
MU[2--\,W7AKXD^ [8:'XCUQ?%$^NRJFH-JNJ>%]-:=H8M*TY2#4(ZWM>,8WN
M[)RET;Z)*RTW9_1C^RG_ ,%Q+?Q]^TKX1_8U_;D_9'^*G_!/O]H[XD6VF_\
M"I])^).K2^*? /Q1U+49;FTL-+T'Q?-X3\&/8:CXAO[6?3O#"/IFJZ#JGB"&
MY\')XI/BT:;I.K_27_!3O_@K'\(O^":NC_#C0=3\ >-/CU^T'\;K^ZTSX,?L
M^_#<K'XE\6SVEU9:>VHZSJ:6&MW'A_1;K5]1L- TA]/\.^)_$7B'7;O[#X=\
M,ZM%INO7>C_S]_\ !1#]DO\ X+V?M]/^SX?CW\'/^">?PM\6?!#XCS>-_@]X
MO^&/Q,U?PAXTD\17*Z3)=:';WWCWXJ>.(]0TRYO]%\/:O/IFD6%I?/J>BZ3<
M&[V0^5)[WX[L]-\>?\':?PUTWXHVL&I6?P]_9EMKSX*66J"*\M1J6F?![Q=X
MKM[JTMI$N(XI]'UWQ#\1O$&G&06TMGK&GQZO;.MS%;/*!RQO?32,G*,975X[
M:[I.^O569\K_ /!7G_@K;^T#\5_^">_Q^_9>_;+_ ."</QL_8F\7_'>P^&E[
M\"_&6O:]=>./ 7C74/ /[07PI^(.O>$M6U2Z\#>"1X=\1:9X&\/ZKJ,D23ZO
M=7-S:V_VS2-!AU>P!_JK_P""97_*-S_@GS_V9!^RA_ZH;P#7P9_P<B^"_ _B
MS_@D!^TUJGC.WLC>^ -4^#?C3P'JMS:2WESH?CAOC)X&\'V=QI<<+!HKW6]
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MRZY=:'IUCX;DO)6DM;S2O"FGVL=O*T%PD@4X05XNR:C?F<U?FM?X>S/Z2O\
M@IM_P7@^&?\ P3(_:M^%?[-?Q&^!/B?QUI/Q!^&?@?XJZW\3M#\:VFE6_@WP
MWXL^)'C[P%J6[P@?"FLZCX@N?#UMX!OO$!ALM4M)=52\ATNVB@GC^T2^)_\
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MM(;#5YOV>/$TNJV-O,+B"SU&3QNKWUI!<*66>&WN6EACF#,)417!(;-?T/\
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MP[?^(/%RV-[-+:3?%WQ7J-WIMUI^H6A"VS:CX/\ #FC69M[A%>6W/BS4+;S
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M'(!Z9 .,Y_7O]:6F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3QZW;Z;>W<7B/4-/TFUMH=4OK2R?69X#<>/?\0E7Q._Z2Q>//\ Q'#Q#_\
M18T?\0E7Q._Z2Q>//_$</$/_ -%C0).-G'VB:;N[PDW?NGW,#]I+_@W0_;:_
M9K_:DUW]J3_@D1\?]'\!6NOZYKVHZ7X"U#Q?J'PW\;_#>P\6W<MYJW@G1M;.
MF:MX/\?_  SM)-L5IIOBV?3-1MM.AT?3[[3/%5]IDGB";<_9M_X-W?VS_P!I
MC]J;1/VJO^"QGQ[T'XIV_AV[\/W,OPSTSQ3?_$#Q'\0;/PK>)=Z5X%\2ZE'H
MOA_P7X"^%LDLES+J&A>"&U.YUA;W6[=+3PW>ZO<:[*__ (A*OB=_TEB\>?\
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M'B'_ .BQH_XA*OB=_P!)8O'G_B.'B'_Z+&@2:2DO:1:D[N\)/7NO,M?M0_\
M! 3]NO\ 9Q_;1\0_MF_\$??C7X4^'TGC/Q!XBU]_ .M:[:>#]=^'EQXRO!JO
MB3PGI4.M>'-?^'/C_P"$]UJ@EN;+PWXK@LWT6UCT31WT7Q)_92:ZG2_L6_\
M!!_]N_XI?MV:%^W]_P %7?CQX?\ %/BWPCXGT;QC:^$/ WB;^U/%/C?Q)X+-
MB?!NE:]-X5\.^%OA]X&^%>F2VMK<S>$?!J7<6N6EC<^';O0]"L-6O+V;D/\
MB$J^)W_26+QY_P"(X>(?_HL:/^(2KXG?])8O'G_B.'B'_P"BQH'S*UO:1VM?
MD?-;M<^J/^"Q?_!'+]K?]NS_ (*-?LS?M4?!+4/A%:_#'X2?#+X,^$/%4/CC
MQEK.@^)WU7P%\=?B?\1M<;2M*L/"6MVMY:-X?\7Z2MC-+J=J]QJ"W=M)#!'"
MEQ+_ %!:_H.C>*="UKPQXBTVTUGP_P"(])U'0==T?4(EN+#5=&U>SFT_4]-O
M8'^6:TOK*XGM;F)OEDAE=#PQK^-7_B$J^)W_ $EB\>?^(X>(?_HL:/\ B$J^
M)W_26+QY_P"(X>(?_HL:"7RM13J*T59>Y+U/,_B-_P &\'_!2+]B']HOQ#\;
M/^"1_P"TEIVE>$_$%SJ-EH^AZMX[G\!_$OPUX5U"Y&KIX)\8#7-(U3X>?%'P
MIIEY96-O;W^LWD5YJ-W!IE]?>$HI[:?5$]__ &"O^#=W]I+Q!^UCIG[;O_!6
M/XWZ/\:/'?ASQ)H/C?1_AQ8>*-:^)NH>,_%>AP1R^'Y/BKXQ\0Z7I.F67ACP
M1=VFEC2/ 'A*WUW0]5BT^TTR75-*\,:?)H6N\9_Q"5?$[_I+%X\_\1P\0_\
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MZ>"QN-,N?%5W9RSMI>GMJGAR;5M*MM<U#Z/_ ."9_P#P0$_::\/_ +9>G_\
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MW-Q:>'?%-O92:-:?V/HKZ+XD&F+KB;G[&?\ P0?_ &]?BS^W;X>_;X_X*O\
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M);2<W@O]2U2^=["SGENI9I6AT#3M&LXQY4*6B11K&OWKC:9-ZD@Y8LQY Q@
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M9S:3HWP9T#X<^&/BWXVEEU(M?WGB2YO? VE^+]2\4^--1@TBSC30/#_A]M-
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M1>Z[.[2L_F?W&45_)M_P2W_X.'_BU\<_VK+#]AG_ (*%? _PU\"_C;XDUI_
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MX4^ MY?:KXFT:.+4KKP7X8\>>)O%_P 7;F7Q3I^E2^$/#6A:AK<MS!I=YX+
MC@M;JX\1VYMFM-4!\DKVTVYKW5K=[[6/ZI:*_ERU+_@K?_P4D_X)Z_'[X(?#
M?_@KQ^S_ /L\V?P%^/\ KT/A;PW^TK^S/JWB2#1O VN7%[;QZC)XPLO$_B/7
MUU.P\)IJFEW&O::VC^"M1C\,'4?$?AS4?'5UHM]I$WT/_P %F?\ @LA\2_\
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MT8O1MMJZ=U9)6M^)[M11100%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]K>DZYHGBO1KFVTNS YE\+:LX.-U&T4VT]$M6KK5VZW2/EG_ (.I;WPA;_\
M!+"]M/$<]@FNW_[07PB3P#!=2Z<EW/XFMQXFN-1;3(KQ6NYKB'P4OBLS_P!D
M[+V.R>Y::3^S3?Q2_NC^RW_R;+^SI_V0GX1?^J_\/5_-;^T)_P &_P!^W;^W
M;X0OKK]O'_@J!)\6_B3X3M--TWX%Z=X?^$.F>'OA)X",VL:1/XN\3:_X2\,/
MX%LO$7B7Q#X<L+CP_%=6FB:/JD4K6FIZQXDU^&UM])M_ZB?A1X*E^&WPM^&O
MPZGU"/5IO /@#P=X*FU6*W:SBU.7PMX=T[0Y-0CM'FN'M8[U[ W*6[3SM L@
MB::0J78)E91C%.[3DW:]M4MKI=OO._HHHH("BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ****F2YHM=P,;6M'L]<TW4M(U%$N-/U>SN=.O+:9$ECDM[R%H)
ME,<@*.&5SE75E/?ID?Q;_P#!!_PIJ/P"^+7_  5U^&>H6T\'BCX0?#;4O"P2
MY'DWSGX?>(OBEI9N/*B+ B["V%VDL#LB>="8VD65&/\ :\R[A^><8.X>AR._
M'I@]"1U_ #Q!\$-)_9[_ ."Q6O>([**/1OA__P %&_V0_B-X&O)WG>:&Y_:!
M\%^*M,OM6MBH5%TPZQX5\2:;<V(,=U#=S0ZIL$<D+$_7\-9A*GD'&W#VG-G.
M2T\5AES1CS8C),0L;**DTY.<L).NZ=."M.5.2=K*3^8XDP\Y_4<7"3A.E+%X
M)3UM3GF6"QF&PT[\T81_VV6&A*<[V]I3MK*S_C9L5"11,"[(%,F\D[G::225
M]^1DDLY+D\DGGFOKO]C']FKQM^V#^T!X0^!_@^\U32;?58-1UOQAXILK<S0>
M#O"&D0/)>ZQ<&>>VM/-NKV2QT6R@DN%DDO\ 5+=EBF53&WS!KWAG4O!6O^(?
M"&L)+%JOAG6]6T2^25=KI<:=?36[94A3M945XSM&^)D<##5_7_\ \$ /@%HW
MA3]F/7/CG?::C>*OB_X\\36.GWSR.[Q^"O"5S8Z':VD48*QP12Z[HFHWSL6:
M:661,XA54'X%DV">+S&5.I.?LJ"G5K<K:YU"HHI6=E:<FK\R3M?JS_,3PD\.
MZ7B%XCY?D69TZGU#!5<5FF=P:G2JO+\LJ1EB<(VDITJN(Q-6CAI7<>6]52:E
M%7_;;X/?"SP9\%OA_P"$_AEX"TJ#2/#/@K0[/0=+LT@M[622"TC"2:C>BVA@
MBFU'4YP]]?W B!GN[B65LEP1Z9&NV5> .IXZ?=(S^GX]>N:D%O$N-J 8!'5C
MPS;F_$'D'.3D@TV3]VLQ08*H&'J#S]WIU'N.<9X)-?IUE&.B=H*R25K1NE9+
M1))6LNR^_P#U=H4:&$P]'#8:C2P^&P]"E0H8>C",*5&E0IPITJ5.,5%*%.G3
MA&*26BZMN_X@?\'$4T<7_!+#XUI,ZQR7/C7X-10*W'FS?\++\,SM&G/WA#!-
M)C^[&XZBOQ/_ .#5)2?C=^V,=[+CX3_#A<C/;Q1K)&2.,\$;NV>,'K^OW_!Q
MS>I:_P#!,#QC%-YDC:C\8?A)90E02J2IKEUJ):0 KA1%I\B!FW LZ#&6!'Y#
M_P#!J<H;XX?M@Y PWPF^&@8'G(_X2G6=X(Z<C(&"/Y$?MN1)Q\$.)]=7F]5+
MRMC<FC=]-[6MY;,^0QT_^,QR^*3O&CATF[6]Z&,J)K?1*5G=;['[L_\ !67_
M ()<^!?^"AWPAFN]+6/PW^T7\,_#VLW?P@\8VUGI5O)K=TKP:FGP^\6W]Y'!
M<WGA?7I[&73K)VU6UA\.ZCJT^J!)U6:"7_.?^(7P[\?_  F\9>(/AQ\4_!VO
M?#_XA^%+S^S_ !/X0\264FGZUHERT27,*7,$BC?%<V<]O?65U 9+2\L[JWNK
M66:":.1_]>IK:$1-*R@[4=^<\#:20.O&!T*MGH0:_ W_ (+5?\$G]'_;C^&.
MK_'#X0>'HX_VO_AUX>LK;PS(^K-I>G_$KP7HD^J:E??#W5X+A#I3:S/#?74_
MA+6+F33WBU6UM-+O]2CTRYD"\7A?XC?V#B%D.=5)/),564<+B:D^=Y56JRY;
MWG)?[#4FVY4TV\-4JNK33A*<:=<2\.QQE*>/PD8QQ=*G.6(IPA)RQD80T<8P
MYOW\8QM9149PA*;M53]K_!'\'/C!\2/@%\2_!_Q?^#WC#5/!?Q&\$Z@U[HWB
M#2[J[M',-Q%);ZEI>H"RGM);W1M7LWEM-2T]KA8;J%SOR50C_2&_X)=?\%-?
MAO\ \%&OA$OB'3(-+\(_&7P-%I.F_%_X6I?3S7VA:I<6,!7Q3I$5U;6UQ=^"
M_$.I+J,&C7T2WL5G-92:??WS7?EL_P#FB:]H&K^%->USPOXBTN[T7Q'X7UK5
M_#GB;1+U52]TCQ'HFH7&FZSI=TB22QBYL-0M;FUE,4LD+-$6AEEC9)&]L_9?
M_:=^,?['WQE\*?'7X#^(8] \;>&988+NWNX$N=$\7^&&U&PU'5?!GB6T;+7.
MA:[_ &=!!=O;26NH6Z@3V-Y:W"B4_MO'_ .$XURVG6PZH4L\PM!5<LQE+6.*
MARQ:PE9V;JX:O3G;G<I2I5+32]UJ?QV0YW6R;$*,N:IA*R2K4KZP49/WJ;;Y
M4X*=XO=Q:4O<ES4_[^?^#@8E_P#@E;^T.&.2+[X6#/\ W5OP.>O1A[KD=LYS
MC^?O_@UBTZWD_:__ &B]58'[9;_LU7>G1R'&T6MQ\2_AQ=S(1C/S3VL+9S@
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MG'^K-^P'I#:!^PU^Q_HRQQ6S6?[-?P9B-O$BK&COX T*8HBQXC509/E*J,]
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M,6F:QJ,S6UGIJI!>ZA*EG!.Z?O%_P<[_ +,WBKXD_L__  6_:+\(Z)=:O'\
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M965V)HIUD@DDB\F3?F/_ $\[<_NSM"@-)N1(\! BA F.R@@+&%Y "?E_!_\
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M!9RE"*A*K@L/6J22M>2J8BG&2:?QKZO"]TE9)^\VS_15_P""!W[9WB+]K?\
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M"*/_  2\^(G@3Q;X%_X8T^!_@7_A+-!U'0?^$Q^'/P^\)^&/'?AK^T;=[?\
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M&ZUXSU'3+*>6.6.&[O[/19K6VEDBD2.:5'>-U!4_SV_\$N?VYO\ @M7_ ,%
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M;J2A4G&?-#F@Y5'":FIV;4;Q=DI)OH#X.\+B0(WA7PX< D,NA:7C!+=A: $
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M=-\KMR.;BUS1DR>BBBOE3V HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>7=Q OC#2ELO%MCK$FR'7QJUQ>A+:]74-.L/R@\+?$+P]^V7_P '5G@OXB?
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MAECBB@^@O^",D43?\%EO^"\$YCC,T?QDT>*.8HIECBF^)GQ8>:-)"-ZQRO!
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M5*\N]Y:V?HK+RU/Y2_\ @N7^V7^WU\ ?^"A/[ OP6_8@^)%SHOB+XZ>#M?\
M"VG?#K6/L5Q\//%'Q!\9^++OX?\ A?Q!XNTZ^A>WNE\*3:S:Z]:/?-<:5;W.
MCVT^J:9JFGQW6G7?SO\ MW_LD?\ !8[_ ()P_L]:O^W[H/\ P5^^,GQZ\4_"
MJ[\':U\8/A-XBTO7++X8K8Z[XOT/P\9O"'@W7O&OBWP)KNBZ5JVOV=OK6GWW
M@#PK-J7A^.\U6 :=)!%HD?TA_P %641_^"^O_!%8.JN VIN RA@'C\9:NZ,
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M]MWIYW/L[_@JEXV_X*G?$#]H']G#]CK_ ()]Z/XJ^#/PY^*=E<:Q\?/VV8/
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MQK=UX@T^P\1:YHL,UZFI7NA16X5%6Y$[>]9V4.9R3;UDWMIV>B\S]NOV]/\
M@LGXJ_9W_P""1W[.'[9'PZ\,:&_[1?[8G@GX1Z9\,/"UY97.KZ'X1\>?$+P"
M/%_CCQ -%>5+KQ#I?@1;/5=/\/6D\DD&I>(M0\(_VM:W^E7-_8S_ "_8_P#!
M.'_@N;\.O@I!^UAIG_!5CXK^./VP=(\,1?$?5_V2O$FD7GB/X$Z[<VJW'B74
MO@U:6<OBBX\&W'B>\BDDT2WU72?ACHNDW&K-'X5TJ]TC18=-\8V?Y^?\%+_!
MGBJW_P""%W_!$[]H;3-!;Q)X,_9X'P*U?XA:>(#>06^F>*? FDC1K[5+)S#;
MR:/=:UX:M_"\\L]W;K_:/B?2K$$C4'E@_L<NOVR/V<[7]E*Y_;6_X67X>N?V
M=K;X8S?%C_A.K74]-FMI_#L.E-J/]EVR?;5BE\82W2_\(U#X2^T+K3^,&7PM
M]F&M'[)0)^ZERI.\I)W2>SLHZWMIVLWW/Y9O^#8G7=7\+?\ !*O_ (*&>)O#
M]_/I6O>'?B)\3M=T35+4JMUINKZ1^SEX7U#3;^V9E95GL[VWAN(2RLHDC4E2
M,@^7_P#!+_PU_P %B_\ @L7^S7?>)?%'_!33XF?LN?!;X4>(_%WPYT3Q]\/]
M$O\ 4OC7\9?B1>"#Q=JE_P"*O$/A[QK\-=>M?#'@73O%7A71-,GL/%%M87MK
M8W&A:?HEKJZ:WXI3U+_@W)U9->_X)7?\%0M<2RATY-9^(WQSU9-/MR&@L$U'
M]G30[Q;*!A'$##:B801D11 I&I$:#Y1^@7_!K/\ \HH_#7_9=OC-_P"G'1J"
MI.SJ.ROSQLVD[772^A^47[('QK_X+<_M(?'W]HC_ ((_Q_MAV'A+7?V=?B'X
MKU+XK_MPZKX:F\4?%C0OAAX5URR\)6OASP.]X_A_4_$/_"=ZWJ.E>*?#MUJV
MH:/XUCTJ34;*7QWINA6[6A^E_@AX^_;X_P""6_\ P6*_9S_8?_: _;4^)/[;
M7[.7[8GA34KSP]KOQ=N-?U/Q1X9UB_?QG;:)+:R^)M7\:ZOH6N:#XP\-6NFW
MUEHGBN;PGJ_A'Q/!=W.FZ9?V5A!H?J'_  2H_P"4^W_!:C_N%?\ J7Z/1_P5
M7_Y3[?\ !%?_ +BO_J7ZQ0#UDXVC9PYG9+?DYKWW6O:R\CW[_AJ?]H;_ (B0
M_P#AE+_A;/BS_AG3_AE/_A,O^%1?:K?_ (1#_A*?^$)_M+^W/LGV;S_M_P!N
M_P!)\W[3C?QMV_+7YY_$?X__ /!5;]I?_@M3^VU_P3K_ &5?VK=2^#WP[%OX
M8\1:EXWUS3;7Q+'^SS\)?"_@OX;7WBO5OAKHA6VF7Q%XM\7^-M!\/HUO=VNH
MO=:XB6^N>&[66^UNQ^CO^=L?_NRW_P!YY5K_ ()]Q1'_ (.5O^"N4YCC,T?P
M3\(Q1S%%,L<4T?[.KS1I(1O6.5X(&D12%D:&)F!,:$ M%K9:4D]4GK=:^I\J
M_':__P""FG_!#_\ :Q_8V\2^-?\ @H)\5?V[?V9OVF?BUIGPW^(/A7XS-K-S
MJMG<W&I^%[3Q58Z1I_C+QE\19/#,\UCKUUXB\!:MX2\3:5;V%WI+^'_$&F7.
MDI(VN?I3_P %4?VHOV@O@W_P5'_X(Z?!WX7_ !7\6>"?AA\=?BMJ^C?%[P7H
M=W#;Z+X_TN#Q[\,M-AL?$$+V\LMS;QV.K:E:JD<L7[J\G4D[\CYV_P"#GK_G
M%U_V>EI__NIU>_X+.?\ *9'_ ((.?]EHUS_U97PBH#?D;2NXU+Z)7LG;1*UU
MZ'*_\%./VO/VEOC5_P %7_ G_!+SP!^VQ%_P3B^",'PKTGQIXN^-UE+9Z'XS
M^)/BW7M)G\2VN@>&_&EWK?A.\TF66P2U\,>%-+TCQ?X7CN=>A\4W>J77BJ]7
MPWX9MO0_!G[-'_!:7_@GW^U=^S(OPN_:D^+_ /P5!_9%^*'B"+1OCWI/Q@OM
M#3Q3\+/";:WX7L]8\5P^*OB9\1]8U&>]CT?7;_Q-X(N=!\9QQZE-X;UCP_X@
MT 6#V.I7G3?\% ='_P""2W_!1/\ X*&V_P#P3G_:X^&7Q5^'/[5O@_X<6T_P
M[_:0MM4\(?#.Q\3Z5K6F:5XO\._#CX>^,'\4>(V\?7=U#XL\1:OH^A>.OAG<
M:7IGB+P]XKTW1"VJ7][::E^.W[:'[.O[2G_!NM\0?V</B%^QQ^WM\1_BKX#^
M*7Q230(OV./'EV%O?$VBZ84N[BWO_!=CJ>K^$/&&@ZW#<2^#;WQKHGP_\&^(
M_"&O^(-'E\-3'4]4BGTP!:I15DW'X9134M'[RDM4^UWI;70]3_X+1_LN?M-R
M_P#!7_\ X)^V4?[<GC*&Y_:5^-NO2?LY:@OPUM3+^Q@K>+/AMI1C\(J/'BM\
M0E&HWEAK:_:)O! 6XTM854&ZDN8_TS_X*(_MF_M@_P#!.KX#_L4_\$^O@E\6
M_P#AJC_@HM^U3XBU+X<Z+^T)X^\)6>AW=OIVJ^,DTBP\>7O@^\U_Q1HFE^(9
MM6\9Z'X9\-W7B#5O$7A72M*\(^)_$?B"SE@L;:P;RW_@MSK^A^%_^"O?_!"C
M7O$FL:9H&AZ;\9=9EU'6-9O;;3=+T^&3XH?!Z!9[Z_O)(;6T@\V6-&GN)8XD
MW NZKDCY+_X.5?AY\/K[]NW_ ()H?'SXVZOXGB_9!\7V;_!_XB_$'X7ZW!;:
MQX4M]"^)#:[XEUG1=?M(]6BL]4M/#OC3^W--\NPFFU"+PEK=O9"[N+.>.U 7
MO>S32MRR=K+5IRLM+7V5U?7U9]:?%?\ X)Q_\%H/V8/@IXD_:B^''_!83XL_
M'3X]?"_PM_PL?Q7\"?&_AV\E^"WC2S\(V[^(_$_@_P ,)XK\;ZYHB2+86VHV
M>G7=_P"!/#I\9".WM+QO!1NHI=-]7\>?\%4_B'^U-_P;Z?&O]N[X4:I<_!+]
MH+PCX;T_PEXLNO M\RCP3\5?#7Q2\ Z#XDNO"L]\]_=6>C^)O#NN6GB'2=.U
M.6]O]*T7Q3#I%Y?:I/:-JMYY1\<?^"(7_!([X!_LX>+?VJ/B!^U'^UL_P0\-
M^!YO'$/B[2/VI/#FL:5XTTNYTYKW0-.\#WL'A Z9XMU;QL[VNF>#M/TJ\N/^
M$CU'4;&UL'E^TJU> R>$_P!D'0O^#9?]N'Q/^Q!X._:5\&_ OXH>,+OQQ:6W
M[4C>#9/'FL>*;'XA? GX<^(=9T"?P+J&IZ#<^!VD\ 6NDZ9,MY)=MKFD^(UN
M4AV)#&!HTGO[\5?D45J]8NSU[K30W/\ @GC^S[_P6H_;U\+_ +*O[>_CK_@I
M%XK^#OPPO-1^&=A%\#=%O_$Z#Q_\%_AO?Z3X+\?>-/$NB6\4O@'4/B+\6#X-
MUSQ/9W/B[PYXJ2_OO%4^KG4O#NCW%KX?B[FU_:&_X*%?\%L/VS?VE/@Y^R%^
MT[JW["W[#?[)'BV;P#K_ ,7OAUHUUJ7Q2^+7BA=3UO0H+G3=7AU/PQJROXB'
MA_Q%K&E6.E>(_#>E^"_#3>'M0\06/B3Q'?6*2?MQ_P $>;.TL/\ @EO^P9!9
M6\-K#)^S)\+KQXX$6-&N]1T"WU"_N&50 9KN^NKB[N'^])/-)(Q+.2?XX_\
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MM?S*O_&WA_\ ;._X.J/@UXH^!.I6GBWP+^QA^SKXA\,?%OQ[X&N3-HPU'3?
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M\'4W_!,KQ%XLUBP\/:"/V,O$FCMK&K3K9Z='J?B'1_V\_#FC6DMW+MABDO\
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MW-<+#$X6M*G4LW*G5H5Z34J&+PF(A:M@\;AII5,/B\-.E6HS2<*G*YPJ>"?
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M'ACX;7FG>)IK#PO;Z7J:^*UNAK'AU+5XM5N"/&6M;)I+F+86M<*?(^?\J?\
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MVEWT_CW6_$TNI7OB2"XTZ2>PCT>[8>']/L+FZL-)TBPL;F:W?\MO$W_!LO\
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M;*,^(M=M-*L[:SM[*PN=2:X&GPI9VK"Q2W:6V@F:2)?X8OV4O^"7/P2^)_\
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MT+X&NK3X9/XIUGXP/I/QT71-2TV[U3PC>?%&*RBU:\^!TDD?ASQCI6BE-*U
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MG#^VY/!))#-#\;?%\L,T3M'+%+'\"/!;QR1R(0\<D;@,CJ0RL RD$ U\+_\
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M\(:AX:N(M:T_7ETRYN-5TZ.YO[O0K,Z3=J4DU&U3$>^SB(Z[_@K=I^HZ-?\
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MW$6H6VL^)KU+6<.28YH+NVMWDB9@5*LK=@?I_P#X* ?\%2[KP/K?P/\ @_\
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M:E.DL=E^'X8XARRO1PBJ5(?6*E/,9T\+["G&I4<\532I2A)V_';X+ZC/??\
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MMSJNEZ=H":L_AG1M,O9XX))=/T?1K"S#6MELA065H(<7]HO_ ()9_P#!/?\
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M(I-%'(OYV>!_^"*__!*[X=>.=,^(WA7]B7X-0>*M&NX]0TJ;6;+7O%FB6-_
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M2;XG6EQXP\/Z%/H.BKKT^O\ A/3;"SEU:.:Z\/:I)+J,XB@EE^AA_P $0_\
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M_M:.XU"XNV_X2#P?I.G:!?\ D74&ZQM(EB\N4-(P*,DDUWE!_P#@+NS\L/\
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MM?6L4SV_F':I^.O&'P%_8B_9Z_X+T?M@?#[_ (*N?"SP_-\ OVL-4\2?&3X
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M]5HHHH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)2
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M^(?B'2EN&\.Z/\4]1\,^(_#'AV[NDDMUU73]-M_#FGM)JME;22VUG=W5S+)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD4K]HU:.WL]?^('PT^)UQID:3WVN:3\/O&?A[4X-'(U'2M#U&>&WT[5_-O\
M@FS_ ,%P[/\ X)O_  ^3_@GS_P %7_AY\=?A9\5_@;KGBFQ\/_%+5/#>L>-I
M/$?A+6_%.M:Y9GQ3;M,WB?5;:SU"^U.T\'>.O"<'B_PWXN\)Q:1+;7,'V$W^
MJX'_  5L_P""NOP5_P""L/P4TO\ X)R_\$Z/A'\4OVFOBW\;/'?@34Y/$T_P
M\U#PWI?@G3O!WB&P\1R:CH$7B 6VNVNI-/:1Z5XH\5:WIGASP;X6\#7_ (EO
M]4\1M;32"$-[2;M.*DOYTK:?S<R=GIKKZ'T7_P '4?PG^ /Q%_8+^%/[8^A>
M']#\3?$J?X@_"/P3\/\ XO:?J>K3&Z^#?C;0OB)XXATW3+>+44T*[T?7+N>T
MURWOYM+EOV66/R;R.!O*/W7J'_!.^T\,?\$BM4^"'_!/SQ/\/OV*/$7[0WPS
M^%_Q"^,/Q7USQ'XWM=*6VU#X?^&+OXF:S/K\FI:W?>%[KQ;H>DP^&=8U*P-C
MINE>&M1UNZMX(;M("?BK_@O#^S5XR^#'_! +]GWX'P&]\8WO[+MS^R;X9\?:
M[8)J6H6Z6?@/X=ZG\,]6\1*TGVN:PT!O$^J:;!8I<RQ66E6%[8Z?"\4,-M ?
ME#_@IO\ MOZ5^W;_ ,$'/"$G[$6L>/\ Q)X=^!OCC]F[X?\ [9VC0>$/$NA:
MOX4\(:-\'M=O)[;Q"'MGT_5/ ]C\2M/\$R:UK6CWVI:,E_8Z9-)?'3$NI6!)
M-Q@D]%4:N]4MN6ZV]$^K->Q^ G_!K#^S9^SOIGPG^._QB^#_ ,:OBUI7@FRT
M_P"(WQ;^&/COXU?$[QCXD^(QTE+/7-<\!W7P?N-=\,Z+9#7[F>7POH]M9IH%
MC8PV#^*5U,6FJZE-U?\ P;,>&OAY^U)^Q[_P4"_8W^*MOJ?QA_94TGXV^$KC
MPEX0\9ZCJ]DMUX5\:#6-7-NT>D7>E:AX?CU'4/AUX<\4WVF:/>:?:#Q#=:M>
M"UCN-0U)[SH/V>OVZ_\ @W$_9:_9B^'/BSX'_!/X=?%#]H6'P%X9L-'^&$O[
M.NL^._VH?%?Q4?1DAN/#6I>//&O@;5[32=5U3Q1;31:MK6D^*O\ A$FDD@NO
M#%OJEI)H&GW-K_@U3U[6T\;?\%2/"?Q+TEO 7QI'QO\ A_XC\=_"[5[:[T?Q
M'X4U:75/C)8^)]-GT/5BNJVZ^&_%'VK0=2AG$MSI5X+2VU1H9[RU^T W?DG?
MGT<6G*V]]TEMZIVV1PO_  ;1?L;_ +,_B;XI?MH?&O7/A1H^H?%']F?]K+6/
M"OP,\72:IXEBO?A[X?NM+\8Z+<:9IMI;ZU%I=_#)I<TMH9-<L=4G".7659<.
M/@#]F3]I3_@G#_P4/_:__:8_;(_X+,?M$";0M-\:-X9_91_9N\2W7Q6M_ NA
M?#6275Y[222P^'>D3W-KI/A_2QX8MK;2H-2T1?$WBQ_%/B?QE::_?7SLWW1_
MP0(_;1^"'[+7[6'[<7[%7QTN_%W@3X__ !Y_;:UC3_AMX9O_  9KD]GJ>LV6
MJ^-='O\ 1-5U*SMYX_#>HV=W!$9/^$@BTZRGBOK-K&\NW-Q';>"_L-7_ .RW
M_P $8OVL?VGOV*/^"JG[//@E/A5X\\=2^.OV8_VEOB'\!;3XN^&M2\+6,MSI
M%G]EU>;PCXK\1W'AGQ)X?D\,-=R>';34X?!/C73M=T?QC!IT]Q=7]D#=^:?Q
M7:CRV>KCIS<K=_G;I<\X^)O[27_!/+]@7_@HM^R%^TA_P1X^/ZR?"KXI>-M)
M^&_[8'[.OA:^^)*>#)?!,_B3PY92ZC#%\5-+C-Q;>(=&UWQ#>:=:37NHV_@G
MQ?X8TO7- _L>/49((_I/_@MEK_PP\$_\%HO@UXP_X*@?#GXN_%'_ ()TV?P6
ML+7X2^'O!4_B%/",'BV]TR]7Q#>WD&B^*?"OV[4[+Q]:G4O'6D:1KFG^)M4\
M*VG@DZAIOB'0+.RT?5/H2[_;J_9]_:X_;W_9]_9D_P""0O[#'[&OQI^'%GJL
M&J?M0?M _$K]C&WM_!G@;PG-KFE"Z\1>$W2W^%>OZ'/X,T/3?$5QIVJ^(DAL
MO''B_4_#OA_PM;7_ ))N=1^M/V^O^"H_BG]CC_@H1!^SS_P43^!OPQUO_@EG
M\9OAXDOPU^*,?P7\0?$>[N?%CZ5X<;6E^)]KJ.O^,_#WBB/PAXFL?&&DZIX2
M\+?#^R\30^%O%7@WQ.=%U.$K)J(*[O'W7?D=[R2FU?39?$EM?5H^1_@'^Q__
M ,$F?VD?VR?V5/VFO^".G[:_PV_9;^)/PH\03^)?B9\#[6S\?:CXC^,/ABTO
M[*[O_#5C\)?BIXX^'_C32K'6-(C\1^"/B#/H!U/PS)X:US2]5LM,AO=/M[S7
MO[":_P ['_@H?H'_  33_:?_ &F_V0_!W_!"3P;?#]L'6OBU8:]K_B7X&^#/
MB1X&^%?A72K22RUW0=?N_"WC;1=$T+0=2\#ZP(?%5_K_ (,T#2?"_AGPS8ZY
M9>,[FXN+/3+#0_\ 1.H(J+X7>6STE;F23ZVW3Z-_D%%%%!F%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:\O&EU.>XABL5S<-(@CW#E?A#^P#_P %H/\ @G_X4O-6_P""0G[9GP-_;/\
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M^._@UXHU;7X+[PS>:]I'AC4-7^ =E-X@F=M*\.W$NFV271M;Z+2KF2-2\8D
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M??$VO2"*VC-UJUK^T%\3?!T,[O!;PRSLNA^$]%M1+>R75R%MEA2X6SAM+6V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M].L[>\\0ZG::; EI;W>J37,T2-.R,)+FY>7OZ!-WMI:R2Z:V6^G?^M3\//\
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MPU^$6D>$_#>HZE'866LZ?X@DU:_U'3?"]GJ0UN.Y;1$UF/6-;UW[8_X*(_\
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M'3=+M-?@M/"NLZIH-I8:3XHC\27>@Z=JMS]*_P#!._\ X(^_&3X2_M6>*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
MWO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_
M^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_
M $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QR
MC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5
M_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P*G_^.4?\03?_ $4B_P##2_\
MYX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\ WO\ X%3_ /QRC^TM1_Y_[W_P
M*G_^.4?\03?_ $4B_P##2_\ YX!_Q%-?]"-_^'%?_,9_J9T5_EF?VEJ/_/\
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M9IBZ6"P-&5?$5F^6":C&,8J\ZE2<O=ITJ<?>G.3M%6TE*48R_(RBO[6O$O\
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M+B67"JG7_M*-X^T]G#ZFZ\<,L4\,JWMN;VZINW)[*WM$Z?-S(^A?#&:+(EQ
MXTOJ+M+DYY?652==X=5W2]GR^Q<U?F]I?D:G:S/PPHHHKZL^>"BBB@ HHHH
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MC70<\3AH8NG["HZD?95).,5)NG3M.ZUC9V75A1117O'D!1110 4444 %%%%
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M>$K&.)[/4M*A1YK.6[CZLWXBH9]D>;8+BO(,[X6RUTL+[/,:]"IBG]=EBO\
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MZ,_@)_$JNUGK5K+?265QX<U5]3OII;#44LM3U"YO=.N=0N_ZB/AU_P %)?\
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M#?AK\.[R6'PY-HVEQVVIW,FK^)+99[RSLGO=8U2S6?3M'M^<^(__  3_ /V
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M:WIGA_5X5M]6T/3]5^,^@7]EH^J0(SI!J.F6UQ'97L*.ZQ7,$J*S!03^?O\
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M;R?!]E\9-'T72_(\:ZQI]@WG7GB7X>:_>^'=3\/:O=V=G<ZEJJZ9<W\&H/\
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M]3XI?%+PCH/BJPN+JX_L_P#M7PCIMEI<VD-=6[6J/I%F+F.2-9-WM7_!P?\
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MZ?-=ZOI^F6OA[PD^G16["ZBA*:=<ZA=75M&\97SI7WDAB*^^?V^_&-W\1/\
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M%% !1110 4444 %%%% !1110 4444 ?E?_P6O_Y1D?M+_P#=&O\ UH'X4U_
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M+.A27/Q%NOB+\(M?\86D>B!<:1+'>V&OW3:4=HT^*TEM0<PA3_/M_P $S/\
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M#O$+%/+%F>._LAUU+F4WEWM?8-7^PY./+[E_9^X>A_KMQ"Z7(\3AG6]B\/\
M7W@,)_:*I-<KBL;[/VJ=OM)*5_>^/WBYJ.HWVKZA?ZMJEW/?ZGJE[=:CJ-]=
M2-+<WM]>SR7-W=W$K$M+/<7$LDTTC$L\CLQ.2:_6+_@E-^W9\ ?V"?%'Q6^(
M7Q/^''Q#\=^._&FAZ+X/\*7W@R#PK]F\.^%8KZ76/$]O<7&O:WIETUSXAU6T
M\,NT=M'Y$4/A^-I))7N L'Y(T5]1FF5X3.,OQ&5XU5?J>)A"G6AAZT\-.5.G
M.G45-5*2<HTVZ5-2C%)2A%0?NZ'@9?F&)RS&T<?A73^LT)3G2G6I1KQC.<)P
M<W"H^64TJDW&3=XRDY+WM3[:_P""A/[7,O[;/[3_ (P^.%KINK:#X4N-+\.^
M%? /AK7)+274_#_A+P[IJ1I:7;V,US:"XU'7[K7_ !%<QV]Q<0P76MSP1321
MQHQ^?/@5\7/$7P%^,GPQ^,_A1W&O?#3QKX?\7V4"S&W348]'U"&XOM&N90KD
M6.N:>MWH^H*4=9+&^N(F1E<J?***O#Y=@\+EU+*:-"*P%'!K 1P\FYQ>%]C.
MA*G-O6;G3J5/:2?O3E4G-^]*ZBMC<57QM3,:E5O&5,3];E6BE%JO[2-53BEI
M%1G"')%>[&,(Q7NJS_?K_@IY_P %4?V9?V]O@-H_@#P[\)OBYX2^(W@OQKIO
MB[P5XF\1Q>#&TB**6"XT?Q/HFI2:7XFOK^*QU71[W[:AMK*X9]9T715E\JV\
M^9/8?V,O^"\WAWP5\'])^"/[9?PP\3?$[3/#^BVGA#3_ !SX.L?#?B*_\1^$
M;73QIMKIOQ \(^,-8T/3M9O;6WAAM;W6K?5Y&UNQ<R7^C2:G;SW6L?S245\Y
M+@+AJ>44LDGA<3/!8?%5<9A)2QN(>+P>(K\GM987%VC5HQJ.$7*DE.FY+FY5
M*TH^XN+\\CF53-8XBC'%5L/3PV(4<+16'Q-&ES>SCB,-=TZDH*<E&HW&:6G-
M:ZE_5!X;_P""^_[/?PT^(FD^%O@]^RUJ/PV_9=TK1?$-W=^'_"7AKX=^%?&F
MO^.=3GTP:7>Q^%/#VJVG@CPOHME:P:B^JM:ZUKFL:U>S:<YN+*VL9K>\_%7]
MK[]LV7XS?MW^+OVS/@@GBKX;7UUK_P ,/$W@C^V7TY/$N@ZO\/?A[X(\)^?>
MKI=WJ.F317.J>%KF?[)]INK6\TJ[6TOXF6:YMJ^":*Z,JX,X?R;%5<;@L+6^
ML5\#/+\3/$XO$8Q8JA5FJE:6)6)=7V]>LTE5K5)-S@E3Y%#0QS#B?.,SP]/"
MXK$4O8T<7#&4(T,/1PSP]:G%PI*@Z"I^RI4DVZ=.$4HR;GS.6I_5[X3_ ."^
MO[+/Q5^$]CX5_;)_9<UWQCXEM[*TFUK1- \'?#KXE_#+Q%K]G*T2:G8Z)\2O
M$ND3Z")@8[Z*TO(=<DTO?=6T.JWSP6\MZ[X9_P#!Q5\+])U/QI;>,_V?O&&A
M>!;6]T?2_@_X2^'(\(RC0/".E:?);SOXENM0U30+;^V-1NVC>#3-#L(]#T33
M+:STVU:ZGAN]3U#^4"BO)EX9<(25>#P6+]E6FZD:*S/&^PPLI34YO!4G.5/#
M.IRQIU)1C4G*C&-+VB@D>A'COB2+I26*PWM*45"55X#"^UQ$5%QBL5448SKJ
M%W.$7*$%4;J<CDS]7_\ @FA^W]\./V)/V@OC+\7O'O@OQMXMT7XD^$=6\/:7
MIGA#^PO[4L+G4/&VD^)XY]0_MG5=-M/(2TT^2W?[/<32?:'3:ABW./F;]O[]
MI#PO^UQ^UQ\6?VA?!F@Z_P"&?#7Q!_X0/^S=$\3_ -G?VY9?\(I\,_!G@B\^
MW?V5>7]A_I-_X:NKNV\B[E_T.XM_-\N;S(D^.:*^GHY#EM#.:V?4Z=59E7P-
M++JE1UZDJ3PM%4E3BJ#7LXS7L:=ZB?,[.ZU9X53-\=5RREE$YTW@:.+J8V$%
M2@JBQ%7VG/)UD^=Q?M9V@URJZL]$?K3_ ,$SO^"J7C+]@6?Q%X)UWPI-\3/@
M=XRU9?$.J^%+74TTGQ#X7\4&SMM.N/$OA.]N8KC3Y7U+3[+3[36]$U&.&#4E
MTW3)K;4])FMKEK[]='_X+H_\$Z_ &I>*OB?\'/V/?'%G\:/%T-VWB#Q!_P *
MT^"/PUU?Q;/=3K>W,?C#XE>&/%/BGQ/?PWNH1074\]SI&N/+*@NY[<W$2(W\
MD5%>-FO ?#><8ZMF&*PV*IXC%*$<;]2S#%X*CCE#DM]<H8>2IU[^SAS.23FX
M1E).I&-5>EE_%V=Y;A*6#P]?#SHX=R>%^M8/#XJIA'+FO]5JUHN=&W//E2;Y
M>:48M0;IO[E^+7_!0C]H7XJ?M?Z=^V?_ &W:>%OB=X5U33I/A[8:5 +K0/!7
MAC1OMT.F^#;:UOA(=3T:>RU/5H/$(ON=?GUS7;F>.W74C;P_N(W_  7$_89_
M:)\#:!H?[;'['.M^*=>T,M=06VE^%/AU\6?"=EJSV\27^I^'+GQSX@\(>(/#
M!U8VT<3V5M%?RK 8;&_UB_MXGN6_E6HKHS+@WA_,Z>7PJ82IA)951CA\OQ&6
M8K$9=BL+AXK2A3Q&&FJCI7<I<LW-\\ZLU-2K5?:8X+B?.<#/&2AB(8B.8577
MQM''8>CC:&(K/>K.C7BX*I91C>*BN6%.+C:G3Y/Z)OVP?^"WWA+QG\!=7_9G
M_8O^"-[\$/AYXA\,W_@J^U_6;/POX9OM!\&:F9;;5?#G@?P'X'N-4\.>'3K6
MFSW=E>ZO_;EU+90:E?C3+"#4S;:W!\Q_\$T?^"MWC/\ 83TW5/A?XQ\(7/Q3
M^!>M:M-KUOH=AJ=MI'BOP+KUZ(4U35/"]Y=VL]GJFG:O';PMJ/A?4YK"V-_&
MFJ:;JVE3S:M%K'XZT4J7!7#=+*<3DO\ 9_M<%C*RQ6*E7KUZV,KXJ-^3%3QL
MYO$_6*?-)4ZD91Y5.HN22JU54=3BG/*F8T,T^N>SQ6&I.AAU2HTJ6&I8>5N;
M#PPL(^P]C.T>>#B^9Q@^:+IT^3^KC2_^"QO_  2J^'7B>]^,'PJ_8C\6Z-\:
M+]+^5O$%E\(O@=X,U);Z]M6AOY#XNT?QOJU_IG]LF62+4M0TK2);S4HI;R?5
M()99WBN/P;_;L_;@^)'[>'QD'Q2\=:;8^%=&T72(_#?@+P#I-Y/J&F>$/#R3
MR7DT+:E<06DVLZSJE]-+>ZUK<ME9&]E^SV]O96.G6-A8VWQ713R?@[(\DQCS
M#"T\9B,<J+PU/%YEF&+S&M0P[23HX>6*G)4:;BE!J$;\BY%*,7)369<39KFN
M&6#Q$\-1PGM57GA\#@\/@J5:LM55K1P\4ZLTVY)R=N9\S4I*+C_07_P4X_X*
M]_!;]N+]F^T^"_@#X8_%#PCKMO\ $GPOXU;5?&'_  B?]DM8:%IGB.QN+1?[
M%\0:G>?:YI-9@>'-L(=D4N^16V!C]F7_ (*]_!;X(?\ !.F/]C77_AC\4-7\
M<)\-OCKX*/BG1_\ A$_^$4-_\5?$OQ'UO2+L?;?$%MJ_V33H/&=C%J7_ !+O
M.\ZTN_LL<Z>2TG\^E%8QX&X=AE6&R:.'Q7U#"9FLWH4WCJ[J1QRY6IRK<O/.
MG[D?W32AOKJ:RXLSJ685\S=:A]<Q& >6U9_5:2@\(^:\%2YN6,_>?[Q/F\M#
MZK_8@^/GAS]E[]JGX/?'KQ;HVM>(?#OPYUO5M4U/1O#OV'^VKZ+4/"VNZ%%'
M8?VG=V-CYB7&JPS2?:+J%?)CEVL7V(WUI_P5;_;^^''[??CWX2^+/ASX+\;>
M"[/X?>$=>\.ZE;>-1H7VF]N=5UF#4H9['^PM6U6+R(XHFCE^T/#)YA78K*21
M^4%%>Q6R++J^=83/ZE.J\RP6%JX+#U%7G&E&A6]ISQE02]G.3]K.TY-25U9:
M(\VGFV-I97B,GA.FL#BL13Q5:#I0=1UJ?)R.-9OGC%<D;Q2:>M]S^S_X1?M5
M?M^?L)?LU0:;^VK^Q[K/Q,^%WPD\,:+I-G\;?A;\3_A?XBU%?!,,FEZ%I=KX
MU\)VWB'4;[4QI%I?VE@WBJ)-.BNM/M4N-8M+@0:MXFD]K_X)R?\ !1;QQ^WE
M\:?B7;^$O@O_ ,*F_9I^%OP^BM=,=_*U2^UCXC:[XCTJ:Q34]9L],T[1M+FM
M_#MKKT]MX6T1;@PI=3ZEJVHZB;C2UL/QR_98_P"#@?XG_"'X:^&_A?\ '3X-
MV'QQM?"VCVWAS3/'.G^,Y?"'BZ[T+3K+[)I\'BNTO_#OBK2_%>I)#'#83ZM'
M+X>GN[15N]3CU35!=76H>J?$G_@XWU?_ (0RX\._ /\ 9>T3P!KLUK?06&O>
M+O&D/B#1O#TUTLI2\L/!V@^%/#=O?W4=S.]\IO-9@LOM*8N["_CGE4?B>/X+
MSW$RS6@^"LM_M''XB<:.=X+.)8?*:-.I6C.IC895B,36='$U(QF[QC:C]8K1
MAAE-)S_4\'Q1E-".7U5Q1COJ6$HQE5RK%9:JV8U9PIRC#"RS"C0I>TH0;@M9
M7J>QI.5=QNH_F%_P6-U^S\2?\%)_VG]1L#F"VUSP#H#_ #!_],\*?"/X?^%]
M1&0 !C4-'NAMZIC8Q)4D_F770^+O%GB/Q[XK\2^./&.KW?B#Q;XQU_5_%'B?
M7;]E>^UGQ!K^H7&J:QJEVT:1QFYO]0NKBZF\N..,22L(T1 JCGJ_=,JP3RW*
M\MR]S51X' 8/!N<;J,Y8;#4:,I13UY93A-QOKRN-[.Z7Y-F&*6-Q^.QJBX+%
MXS$XE0=FXJO7J58Q=M+J,HIVTYE*VEK_ -=GP_\ ^#AW]FGPAX"\$>$[WX(?
M'.ZO/"_A'PWX=N[FU'@'[-<7.B:-9:;//;^;XN27R)I;9Y(O,1)/+9=ZJV0.
MN_XB/_V8/^B$_'K\OA[_ /-A7\<M%?$S\*^#:DYU)8/'.4YSG)K-,4DY3E*<
MFDJ=DG*<K+HK+H?4Q\0.)H1C".)PBC",817U##OW8QC&.O/KI%:]=^I^[?[2
M_P#P6*L/&?[;_P"S_P#M@? 7P!XGT>/X0?#^\\!>)/!GQ%GTBT'C31]:UKQ)
M<>(=*%YX>OM=CL;>^T?7E33]2>.>?2M<M+34_P"SKV.T6WN/N/XF_P#!;3_@
MF_\ %JW\+^/_ (C_ +%WC+XE_&'P7;NWA&+QUX%^$&L6&@7L%S'J%M:6?C[4
M?$VJ:Q;Z3_:&V]MIH_!MP]K?QSWB:-%,8Y[C^4&BO0K>'_#5:&70]ACJ$LKP
MLL%AJV%S/&87$RPDJE:J\/B,10E3J5Z;EB*Z]YTY^SJ2I<[IOE7%2XQSVE/&
MR]MA:JQ]=8JO2Q& PV(H1Q*A2@JU&C54X4IVHTGHIQYX1J<JFN9_TQ?&;_@N
MC\(OVE_V0_BG\#?C!\$?'6A?$3XF>#?&.@/?>!7\-ZIX$T757U6^OOAY?PR>
M)=?AUV[325M?#%QXAF;3K>:;4[;5+C1H;.-[!+?RC_@F1_P5[^"W[#O[-]W\
M%_'_ ,,?BAXNUVX^)/BCQJNJ^#_^$3_LE;#7=,\.6-O:-_;7B#3+S[7#)HT[
MS8MC#LEBV2,V\+_/I15?Z@\,K+<7D\<+B:>78S'T<RJX:&.Q$8PQ5"$Z=-T)
MM3G2IJ$W%TE*<96BY2;BFU_KAGKQV'S*6(H3QN&PE3 TZ\\)1;EAZLXSFJL4
MXPJ3<HIJHXQ<;R2BE*R*_KY_89^.?_!0O]C']D[PQ_PN7]DG5/CG^S5X?^'-
MM\1OA_\ $OX9_%#X<77C?PE\.-5T>7QE!INL>$9/$%WJ_B#0]-T2634[&>#3
M]-N] LI8])EGU5?LEII?\@U?NU^P_P#\%S_BO^RO\+?#7P3^)'POT_XX>!/!
M5K'H_@K5E\77'@SQKX:\-Q,HL_#\^H2Z%XGTSQ%H^A0!K7P_:3V&E7MC8^1I
MC:Q)IUE86]IGQYE.89OE>'H8'*<OSJ-/&1JXG XRM5PF(=)0Y55R[&4Z]#ZO
MB8/GA/GE.-2E52=.IR.$KX1S#!Y;F%:KB\QQF5N>&=.AB\-2IXBBJCG=T\;A
MITJWMJ$ER2CRJ,H5*;:G#G4E^RG[#O\ P5*\2?MQ_M4Z;\,?@W\";OX7_ #P
M=X(\7>,/B'KU^EAJFK:GKTZ66G^&;._GTK3[?0/"EI/JE]//%96EWJ>O>(;F
MR%TM]:Z98:M8S?C!_P %V/'M_H7_  4CTSQ!X-UB?2/%GPR^&OPANK'5M/FB
M%]H7BK2]0UGQIHM];D>9]GO;%-4T?4;<3(&#&&;RVBDC9_KSQ;_P<>VMAX7O
MM.^#G[(^F>&O$5TUQ+:7WBGX@P7?ANPO)D ^WW?AWPSX.T*[UJ5W5/-A77=&
M=U1=UV_"C^;WXP?%KQW\=_B=XU^+_P 3=9?7_'7C_7+G7_$.IM$EO%)<S+'#
M;VEE:1 0V.EZ78P6NEZ3I\ $&GZ99VEE"!% @KYK@_A/&83B*MG%?(J7#V74
MLIJ9;A\NJ9A#-,5BZV(E%8G$XJLG44U.GSJ;J-*4?9T84N2,V_=XEXBPV(R6
MEEE'-ZF<XVIF,,=6QL,'++\/AZ=%-T*&'I-0Y>2?*XJ";3YZDJG,XI?TN?#_
M /X+V?LT_%GX5:7X _;K_9=U'Q]JEK_9+:ROA[P;\./BE\.?%&LZ<-J>*IO!
M/Q*UKP\GAB[1WDN([&U;Q0UI*\[6%[%'*EK%\^_MO?\ !<#P_P#%7X&:M^S9
M^R%\(M8^#7P]\2>'V\%ZUXB\0V_AKP_JEAX FM#87W@KP;X'\%7>J^'O#%EJ
MFG,^D7E\FO7J0:'->:=I^E6D]S%J-G_.Y17TN'\/.%<+C:6-I8+$/V&)^N8?
M!5,PQ=7+*&)YE-5J67SFZ$91E&#BFYI<E-/GA3IPCX5;C3B"OA:F%J8JBO:T
M/JU;%0P>&IX^M0LXNE4QD(*K*+C*2;2BWSS:Y)3G*17W#_P3L_:C\)?L;_M4
M^"_CUXW\/>(_%/AWPSHGC33+O1O"O]F?VU<2^)O"VIZ#:26_]KWVG6/EV]Q?
M1S7'F72-Y*/Y:N^U3\/45];CL'0S'!XK 8J,I8;&8>KAJ\83E3G*C6CR5%&I
M%.4)..THIM/5'SN$Q-;!8K#XS#N,:^%K4Z]&4HJ<54I2YH.4)64DGO%NSV9^
ML?[8O_!13PU\=?V^/@]^V1\*O"WB_P *67PJB^$\L>A>*6T==9OKWX>>,-4\
M1ZA#_P 2?4]0L'T[6+._&FM%+=J9HI+J&YC6%\M]G_\ !1C_ (+4_"_]KS]E
MWQ1\ OA9\-OBAX,U/QIXB\(S>(=6\7OX5CTR7PQX<UF'Q+/I\1T/7=4O7N[K
M6])T(K&T$5N]K%=B6<?+#-_.;17@/@W()5,AJRPM64^&Z<*65-XJJ_9PIUGB
M*<:ZY?\ :N2M)U(^UM:5K;'KKB?.%#-Z:Q%-1SN<JF8)4*:YYSI*C-T?>_<<
MU)*$O9WNC^@O]F7_ (*]_!;X(?\ !.F/]C77_AC\4-7\<)\-OCKX*/BG1_\
MA$_^$4-_\5?$OQ'UO2+L?;?$%MJ_V33H/&=C%J7_ !+O.\ZTN_LL<Z>2TGA?
M_!*[_@JRG[ ]EXT^&GQ#\#:UX]^#7CGQ'#XR*^$[K3;?Q=X/\6_V59:)JFJZ
M78ZO+8Z7XAM=>TG2-!LKW3;[6M%-I)HUI>6=_P#/=VMU^-%%$^#.'ZN'SK"U
M<)5J4<_QL<QS&,\56<GC(3J3IU\--)2PLJ<ZLY05+FBN9IJ46XR<.)\YIULK
MQ%/$4X5<HPKP6"<</226%E&$)TJ\6VJ\9QIP4G/E;Y4TXR2:_J)\4?\ !;/]
MB'X7^,KOXE?LG?L4IIGQ2\<ZYID_Q-^(OC'P3\._ 6MW7AZ^UFUU3QI%8R^!
M_$/B+5=:U_6K7[6"]WK6@Z7-XE:UUS65\0PV"V][\'?\%7_^"B?P+_X* V/P
M9U'X=_#_ .)W@CQ?\+KOQA97L_C)?#!TG5_#?BZ'0IVBC;1-?U6X34=,U3P]
M;O:JUM%#+;:GJ!FG+PVL9_&>BL<NX&X?RO'8/,\+3Q\L?@8U(4L5B<TQF*JS
MIU*3H>RKO$2J1JT:=%NE1I*-*%*&D(WU6F-XLSC'X3%8&O/!K!XMPE4P]# 8
M;#TXSA457VE+V,8.G4G52J5:C=2=26LGT?\ 05^W[_P5Z^"W[7'['L'[.?@S
MX9?%'PSXGAU/X=WQUWQ./"?]@M'X.,?VY!_97B"_U /=!3]D_P!#VYP)C'R1
M^1O[&_QNT#]F[]I[X,_'/Q3I.L:[X?\ AKXNB\1:II&@"R.LW]M'87UH8-/_
M +1NK*R\\R72-_I-U#&$5CNW8!^9Z*]'+N&LIRK*\7DV#I5H8#&RQDL13J8F
MI5J2>.INEB>6M.*G#F@VHJ*?(]8W9Q8W/,QS#,,/F>*J4I8O"K#*C.%"%."6
M$FJE#FI1;C+EDDY7:YUH[(_7+_@K!_P4,^&O[?\ XC^"VM?#CP1XY\%P?#/1
M/&NEZK%XV_L#S=0E\37_ (=N[233_P"PM7U5/+MTT:=;C[2T+;I8O+5QO*_9
M%E_P6<^!?Q=_8>C_ &5/VN_A5\6?'OBS4_AX? ?BGQ_X5/@_4([^_P!$FQX(
M^(5J?$?B#3KUO&6C-I_A[Q!?37<+PWGBG3KF\:1[2]:W3^<6BN.?!F0SR_*L
ML]AB84,DQ+Q>65:>,K4\9A:\JLJTI1Q<8^UE&51J4H27(W"G=/D][ICQ/F\<
M;F&.]M0E6S6@L/CZ<\-2GAJ])4U247AW+V<6H)Q4HOF2E.S][3]B/^"9O_!6
M;Q5^P;9:[\,O%OA"[^*/P*\1ZY/XECT:PU&WTGQ;X*\1W5K:6=_JWAFXO8[B
MPO\ 3M8MM/L5U3PM?W-C:+?0C5],U33[J;6(M<_4^7_@NC_P3S^%@\6^.?V>
M_P!CSQ?IWQ9\9PRSZ_?+\./@M\(7\67;7EW=>7XY\?>#?$7B_P 1:B[WVW4G
MEDT/Q"K->M<-(M\)X5_DHHKGS/@+AK-L=7S#%8;%4Z^+<'CHX/,,7@\/CW!P
M:>,P]"2IUVW"#DVHN4HJ;2J+VIM@.+\\R["4L'AZ^'G2PZDL++$X/#XFMA%-
M236&K5HN=))3DHI.7*FXIN'[L^E_CG^UA\6_V@OVC+_]ISQ]J-C/\0)?$FA:
M_HUG;6K+X=\-6GA2YM9O"WAO1],EED,>AZ+%96T(BFFEN]1E-WJ.J75WJFH7
MU[<?TRQ_\'!7[&7C?P)HK_%_]G#XJ:MXWTI[#5O^$67PM\,/&O@ZR\5P6=RJ
MZIX>\0^)O&.F7]K#:S--!#JDOA>UUBU@OT6WMKL&[:/^0.BNG-^#<@SNEEU'
M%X6K2AE--T<!]0Q-; RH4'&$70C*A=NDU3C[NDD^:2J7J5.?#+>)\XRJIC:N
M&Q%.I/,9JIB_K="GBU6JISDJS56R51.<M=8M<J<+0AR_N7_P3T_X++:Q^QMH
MVL_!OQU\/M0^)G[/<GB+7]8\":?I.H:?I'C7X:6NNZG?ZK>Z5IL-ZEQI'B/0
M]0N[HW4FAWVIZ7)INI7FHWMIKMQ;2_V9)]SZ-_P64_X)=_!G4=7^)'[/O[#_
M (FT'XMZU97GG:C9?"_X*_#.1Y+K[:;G3;CQEX=\5>*-4TBUU.Z6WEU(:)X?
MN[:\MKF.ZO(+J]LQ8+_*;17+C^ >&\PQ>(QE6AC:%3&\KQ]/ YGC<%A\>X\M
MY8S#T)JE7E-Q4JC:C[2;E4E'VDYSET83C#/,'AZ.&IU<+5AA>982>*P&%Q5?
M!IWTPU:M!U*2BFXP2;Y(J,(ODC&,?JG]LK]KGXD?ML?''6OC=\2H;#3+RXTV
MP\->%_"^D/<2Z/X-\&Z/->W.E>'-.FNV:YN52\U+5-6U&]F\LZAK>K:I?QVU
ME#<QV5O\K445]9A<+A\#AJ&#PE&&'PN%I0H4*%-6A2I4U:,(IMNRU;;<I2E*
M4I2E*4I/Y[$8BMBZ];$XFI*M7KU)5:U6;O.I4F[RE)I):Z)))))1C%*,8I%%
M%%;F)_IY_!3_ )(U\)/^R9> O_45TJO3:\R^"G_)&OA)_P!DR\!?^HKI5>FU
M_"V*_P!ZQ7_83B?_ %(Q!_66'_W?#_\ 7BA_Z8HA1116!L%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y7_\%K_^49'[2_\ W1K_
M -:!^%-?P'U_H1_\%;?AUX\^+/\ P3X_: ^'_P ,O"'B'QYXWU__ (53_8GA
M3PKI=WK6O:K_ &5\;?AMK6I?8-,L8YKJY^PZ1IM_J5UY4;>396=Q</B.)V'\
M5/\ P[J_;P_Z-$_:#_\ #7>*_P#Y75_1?A%F& PG#>-IXK'8+"U)9UB)JGB<
M9A,/-P>"P*4U"OB:,W!N,DI*+BW%I2;32_%?$?!XS$9WA9X?"8JO!971BYT,
M-B*T%)8K%MQ<J5"K%22:;BY*233:LTW\945]F_\ #NK]O#_HT3]H/_PUWBO_
M .5U'_#NK]O#_HT3]H/_ ,-=XK_^5U?J?]LY/_T-\J_\.>7?_-Q^?_V7F?\
MT+<P_P#"#&__ #(?&5%?9O\ P[J_;P_Z-$_:#_\ #7>*_P#Y74?\.ZOV\/\
MHT3]H/\ \-=XK_\ E=1_;.3_ /0WRK_PYY=_\W!_9>9_]"W,/_"#&_\ S(?&
M5%?9O_#NK]O#_HT3]H/_ ,-=XK_^5U'_  [J_;P_Z-$_:#_\-=XK_P#E=1_;
M.3_]#?*O_#GEW_S<']EYG_T+<P_\(,;_ /,A\945]F_\.ZOV\/\ HT3]H/\
M\-=XK_\ E=1_P[J_;P_Z-$_:#_\ #7>*_P#Y74?VSD__ $-\J_\ #GEW_P W
M!_9>9_\ 0MS#_P (,;_\R'QE17V;_P .ZOV\/^C1/V@__#7>*_\ Y74?\.ZO
MV\/^C1/V@_\ PUWBO_Y74?VSD_\ T-\J_P##GEW_ ,W!_9>9_P#0MS#_ ,(,
M;_\ ,A\945]F_P##NK]O#_HT3]H/_P -=XK_ /E=1_P[J_;P_P"C1/V@_P#P
MUWBO_P"5U']LY/\ ]#?*O_#GEW_S<']EYG_T+<P_\(,;_P#,A\945]F_\.ZO
MV\/^C1/V@_\ PUWBO_Y74?\ #NK]O#_HT3]H/_PUWBO_ .5U']LY/_T-\J_\
M.>7?_-P?V7F?_0MS#_P@QO\ \R'QE17V;_P[J_;P_P"C1/V@_P#PUWBO_P"5
MU'_#NK]O#_HT3]H/_P -=XK_ /E=1_;.3_\ 0WRK_P .>7?_ #<']EYG_P!"
MW,/_  @QO_S(?&5%?9O_  [J_;P_Z-$_:#_\-=XK_P#E=1_P[J_;P_Z-$_:#
M_P##7>*__E=1_;.3_P#0WRK_ ,.>7?\ S<']EYG_ -"W,/\ P@QO_P R'QE1
M7V;_ ,.ZOV\/^C1/V@__  UWBO\ ^5U'_#NK]O#_ *-$_:#_ /#7>*__ )74
M?VSD_P#T-\J_\.>7?_-P?V7F?_0MS#_P@QO_ ,R'QE17V;_P[J_;P_Z-$_:#
M_P##7>*__E=1_P .ZOV\/^C1/V@__#7>*_\ Y74?VSD__0WRK_PYY=_\W!_9
M>9_]"W,/_"#&_P#S(?&5%?9O_#NK]O#_ *-$_:#_ /#7>*__ )74?\.ZOV\/
M^C1/V@__  UWBO\ ^5U']LY/_P!#?*O_  YY=_\ -P?V7F?_ $+<P_\ "#&_
M_,A\945]F_\ #NK]O#_HT3]H/_PUWBO_ .5U'_#NK]O#_HT3]H/_ ,-=XK_^
M5U']LY/_ -#?*O\ PYY=_P#-P?V7F?\ T+<P_P#"#&__ #(?&5%?9O\ P[J_
M;P_Z-$_:#_\ #7>*_P#Y74?\.ZOV\/\ HT3]H/\ \-=XK_\ E=1_;.3_ /0W
MRK_PYY=_\W!_9>9_]"W,/_"#&_\ S(?&5%?9O_#NK]O#_HT3]H/_ ,-=XK_^
M5U'_  [J_;P_Z-$_:#_\-=XK_P#E=1_;.3_]#?*O_#GEW_S<']EYG_T+<P_\
M(,;_ /,A\945]F_\.ZOV\/\ HT3]H/\ \-=XK_\ E=1_P[J_;P_Z-$_:#_\
M#7>*_P#Y74?VSD__ $-\J_\ #GEW_P W!_9>9_\ 0MS#_P (,;_\R'QE17V;
M_P .ZOV\/^C1/V@__#7>*_\ Y74?\.ZOV\/^C1/V@_\ PUWBO_Y74?VSD_\
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M7?\ S<']EYG_ -"W,/\ P@QO_P R'QE17V;_ ,.ZOV\/^C1/V@__  UWBO\
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M\/\ HT3]H/\ \-=XK_\ E=1_;.3_ /0WRK_PYY=_\W!_9>9_]"W,/_"#&_\
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MOV\/^C1/V@__  UWBO\ ^5U']LY/_P!#?*O_  YY=_\ -P?V7F?_ $+<P_\
M"#&__,A\945]F_\ #NK]O#_HT3]H/_PUWBO_ .5U'_#NK]O#_HT3]H/_ ,-=
MXK_^5U']LY/_ -#?*O\ PYY=_P#-P?V7F?\ T+<P_P#"#&__ #(?&5%?9O\
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MEW_S<']EYG_T+<P_\(,;_P#,A\945]F_\.ZOV\/^C1/V@_\ PUWBO_Y74?\
M#NK]O#_HT3]H/_PUWBO_ .5U']LY/_T-\J_\.>7?_-P?V7F?_0MS#_P@QO\
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M_P#E=1_;.3_]#?*O_#GEW_S<']EYG_T+<P_\(,;_ /,A\945]F_\.ZOV\/\
MHT3]H/\ \-=XK_\ E=1_P[J_;P_Z-$_:#_\ #7>*_P#Y74?VSD__ $-\J_\
M#GEW_P W!_9>9_\ 0MS#_P (,;_\R'QE17V;_P .ZOV\/^C1/V@__#7>*_\
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M6S4N2M!P]E)J_+%J?O*4]$K.S;LDC^^07JL,J$8;D'RS*QP70,0J@DE%8OM
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MNP-K<[0&;MC@$'GKVYKA;25WHN[V^_Y'?N[+5ZZ==-_NZ]ACSB,N&1L*P56
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M\0/AWJS0WATK7O"/B/PUH^F7MNVDZA=MJ3:!>R7?AC6Y%:T\0:/J=C//;O\
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M@[1'NK"'4=:N[6QO[UFOM0TS2=.TZPO=2U?5-.T^UGND_B1_X*J?LGO^QO\
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M;PWME;3Q?V(I%%&TKQQQH\\@EG9$56FE$4< DE90#)((8880[DL(HHXP=B*
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MB7_BK3]<T6[LM-NM(UBRUVXO[;4]+N=.T^XT^]CGM)K*UDA:"/V*@YPHHHH
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M_P"#>C]HO ,?[0OP2DF9'*>;H/CF-"Z[=EN\RPS-!O9NT4Y4!W$;E-K?D/\
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M:7^1ZO\ 9."_Y]O_ ,&3_P C^25O^#>7]HM3C_AH+X*GC.5\,>.2/_UU!/\
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M$U,?@U*,\?@:M2&&G[2I&$/>K3I*%:BU)T*L?K6'Y?K-50_!..\)Q9]&7/\
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M99G6E3Q,,JH8Z<*]?+<'4A.=*O.OB*=/%8W&N%.<I2C@,-&EEF%PL*O\4O\
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M".G:=H%SHWB?S-3N+JX/]JWE_JUKA9!$/[-PJAMY/W31100]6]+>2Z'\OO\
MP;Q_L@?M-?LN_''_ (*F^(?V@O@QXT^%&B?&+XK?"C6?AAJ7BNRM[6U\:Z7H
MOB_]IN^U6^T1X+JX-Q!8VGB[PU<3LXCQ'K-D5#;V"_F]\9O^"*7[3^O?\%D/
M$7PWT#X:^++G_@FG\>OVLOAO^UO\3];LH88_A:3X8T;QWXVU_P )ZS&UVTFF
M:E;:GXW^*WPR\.VMI ;:.P\<:.88(HFM;:R_NCHH*]H^9RTNU;[DDFO-6N?S
M6_\ !S?^R=^T=^US^RA\ ?!?[-7P@\8?&3Q5X9_:&3Q1KVA^#;."]O\ 2_#_
M /PK;QOI1U:ZCGN;95M!J.H65F75F(FN8EVX;(R?^#@G]@/]J[]H'QG^QE^V
M/^R'X$TSXU^.OV//&-WK^O?!'5CI^H-XGL8/%_@?QUX>U32_"^MW5II/BRPA
MU;PC=:3XV\+12MK7B#1M1TR*PLM2BL;J&+^FBB@%-KELE[KE\^;=/Y=C^87Q
MG^WA_P %E_VY?AWJ?[./P#_X)9^._P!C/QI\2=!O_!WQ"_:0_:2\97FG^ _A
M;H>L6\>C^(]>\&:5KOP^\(ZKXDU,VMSJ:Z+<:99^*=3TXM9ZC9^%M<"O<V?
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M$<.IPZ%XJ\%^!]'TS7?LEO=2+-92W-I?",+<(TK64T>4(#5^?O\ P05\,_\
M!3/_ ()V?$V^_P"">_QK_8+\61? GQW\>_B#\2_&7[4EA->W_A?PA=S_  ?T
MSP[83:/KM@;CP7XI\+>(M:^&O@&&PN$U/3-<TFWUW7OMFEW^I"WTO2_[$Z*!
M\[?-=)\[N]]&KV:UZ7ZG\UW_  ;X?LG?M'?LQ>,?^"D][\?OA!XP^%=I\5OV
MA]!\4?#FX\56<%K%XO\ #]MJGQ8EGU;1F@N;@3VD46LZ4[NWED+?6YV_/QZ-
M_P %M/\ @F;^T%^T_P"*?V;_ -MG]A[6M(TC]LG]CW5TU3PQH.K:C#HL?Q+\
M,:;K]IXOT30+'5[Z2'1X]:\.>(X-4DL]%\07FE>&O%&B>+O%.D:WJL.ZP@N/
MZ"Z*!<[YN;2_;I:UFO1H_E"^*_\ P4K_ ."Y/QW^#VJ?LY?"[_@C[\4O@A^T
M3\0-!O? ^N?'S4_%E_#\+O""Z_I<VE7_ (N\"W'B7P]X:\->']:3S[^^T6\\
M1?%C7K#P9<V>FW%W_P )=+?110?JO_P1F_X)MM_P3'_8\T_X.>)M8T/Q-\8?
M'/BO4?B=\9_$?ATW,^A/XNU73=*T6Q\->';_ %"SL-2O?#?A/0-$TW3K.XN[
M*Q%]JTNO:W%I]C_;$ENGZS44 Y75DE%7N[7=WTNVWHNB.3\?>"/#7Q-\"^-/
MAOXSTZ/5_!_Q!\)^(_!'BO29<>5JGAKQ7H]YH.NZ=+E6'EWNEW]U;/E6&V4Y
M4C@_R$?LLZ1_P5<_X(0^)/B]^S'X._8>\>_\%$_V.?$_C[6?'?P,\9?"CQ#=
M6GBKP]<ZW%9V*C64T/PKX[O?#BZC:V&CP^-/#.K^"M(TFP\30ZSXL\*>(=3T
MF[O!JO\ 9'10"E9-633M=.^ZV=UJF?Q2?!W]G/\ X*O_ +0__!;C]C__ (*'
M_M:?LMZ_\+O >I)K<=MX6T?44\0:-^SI\+?#_@/XE>%O"7A'QC?S71GTW7-?
M\0ZIJ'B^_LG1+R?5?&<^J76D>'#JL?A_3/T)^-/[)W[1VO\ _!RQ^R+^UGHW
MP@\8:C^S?X(_9Y\2^%_%GQ@MK.!_!V@^(+OX+_M/:!;:3J%X;D3QW<VL^+O#
M6G(BVS W&LV2[@LA9?Z4J*!\[O>R7NN%E>UG?\?Z9_'A\<OV>O\ @H!_P30_
MX+)?''_@H[\!?V/M>_;L^!?[2GAG7M-UG1/AV9[KXC^"K+Q*OP_U3Q1IME8:
M1IGB/Q%H/BG0_$7@N!/#FHP>%O$&@>+?!5]>Z%)-INMW=S-H/#?\%/M+_P""
MSO\ P5Z_9K\1:'X>_8)UC]E#X _"?5=!^(*_";QYXUMM=_:$_:+\>V6IV/AV
MRTK1="31_#MUI6A^#](\5:WXO&DZSHFCZ1JDFB2W</B?7==M-&T/3_[2** 4
MW=/E3DDDF[[+;2]KVTO^I_-S\:O^":7BC_@H'_P1#_8__9D\<>'?^%"_M:_
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MPMX%TK5?$5_);-X9M=+BDNH]2U'7+[5Y-!TC3/VU_P""EW_!+?Q;_P %!_\
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MA_P<.?\ )U7P#_[(7=_^IOXPK\C_ -ES_DZ']FW_ +. ^#'_ *L;PU7;@O\
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M%4SW^HVUG I/."9I(%7C!9P"RCYA_H21G[O(<$2-Y@YR"X*#.3G<ASG.#MR
M!P*S[_>,+_UZE_Z7/8,E7[FO_P!?H?\ I$B:BBBO&/;"D/((]0:6D8@*Q(R
MI)'J,=._7Z&@-M3^33_@XI&WXU_LK# P/A[\1Y ,G(5M;TD(#D8SE"."0",Y
MQS7XD_L] CX__ 4'K_PO+X1?K\0?#6*_:_\ X.)KN%OCG^S!9K*CW,'PX\?7
M$\.<R1P3>(+-+5F7LLDMG=(G7YHGPJXY_%/]GD#_ (:"^ @Z_P#%\_A#VQ_S
M4'PT>AKZ_!)_V91[*A-_/_:'^I\CC;2S*L^TT]NWL(_E%:_YG^B/\-./AU\/
MQZ>"?"__ *9+"NXKB/AJ?^+>^ ACIX+\,?KHEA7;U\B]WZO\V?6Q^&/^&/\
MZ2C': 3%&@$<0W#(VAPZC=F#<ZAHT<D.VQ2H;)VEF8GX(_X*/:W^R'X4_9TG
MUO\ ;1\-#Q5\,QXN\/Z=HUG9>'M7UW7XO%D]U(]DOAV31;W1K[1KA=.L]2-_
MJ"Z]H=O<:/;7VFRSWIOX]*O^D_;6_;6^&7[&GPG\4>,=;UOPMJ?Q*M]-@;P+
M\*-0\0-:^(/&6M:FU]'HEM%::58:MJ]EI4\VEZA-=:Q+I8TN&WTV^2YU"Q&;
MF#^)_P#:E_:J^*G[7?Q2USXF_$6_OM/L[W5K[4O"WP]MO$'B#6/"_@.VOK/2
M]-DTWP]::SJ=[#974ECHVG_VM?Z=9Z7#JEY'>W/]G6L-Q!:67I99@:M6HJ_O
M4J,*BG&;7+4F[:V35];I<]ITI)MI;GEYACJ-*G*E95:U2#C*&\4FUK-O1-/5
MP=JD;:W3T^>-2?3I=6UB31H;F'0)-5U&X\/V]_@:C::/+<LVEP:B1=ZCF^@L
MA!'=_P#$TU0-.'_T^\Q]HDSRSL@$;B*68.H+CS%++D!F4JR/Y*D2;7&&&$!)
MR!]R?L-_L(_%/]MSQO)IWAVQUOP_\+O#VH:1!XY^)D&D6-_8:7#J&KZ/!<Z9
MI\VK:[X<M=0U\>'KS4O$ CTV36+FRAT^V>[T>2/5[!I/:/\ @H7_ ,$R/B%^
MQAXD75_A[IOQ%^)O[/\ )X=M=9U+XG:EH]A<-X*U&*\M--U/3?%=_P"'99(+
M2V>_O].GL-4U'1O#]I-:Z@UC VH2:1J-^/I7B*"JK#NK%5G'FY)2LN6]ES7:
M?.])+2[^)I+5?.K#UYTGB%!NGJN:,?>;UUBK64(J\-](IQUZ_I[_ ,$0?B?^
MQ9%HNA?#72?!\&B_MC0:3X[U'Q7XNU;P==ZCJ/B30!J.DSR7GA[QJLVM6^CZ
M%+HC:-8CPTDGAQ$O-*U:9=&#7WVW6/Z2D+0N9&XMDCD*JN&"J[)(&R=L@ 56
M/EA2%SL7A$S_ )F=G?ZA97%OJ6B:OJ6AZE;EWL-?T+4)M.U.S$L$EK,UG>6C
MI=QO=6TUQ:W$EO,@FM;JXB=3%)*&_K-_X)P_\%?_  A\4=)TCX-_M-ZMX,^&
M_CKPSX=\,>'_  SX\\0>(O$,R?%[7!JK^'86NY/$%K?0V?BFZM9=!O=2:^\9
MW][K&I7VKZA#;VUO!>0:;XF:9?5YI8FAS5VV_:4Y2]Z*WO3NM4M(\J22?O:7
MO+V<KQ]-0CAJO)2Y;>SDK*,V]+5&FK2LKW;?\JYM8Q_H&-RHR=DAP@=L;/E1
MLX)RXS]UN%W'Y3QR,TY> %P%B.' SGYD8LP48.T,B,"01C+$*Q.&$$7[MED,
MBMEHN"4VE5+[S@C:R;<9V \C+=%?N+OY2IY<48WB4\*&Z%?+(0J0'+YW=MV,
M&O!M=M7;C'F;=U%IV<;-/=Q4G?K=:)=/=>T6TEJHO24U+>32E':,TK:^ZFXN
M3[_SP?\ !07]D/\ X*-?&;]I#Q5XN_9P\2^*=+^&LG]BMI5EH_QWE\!)'CP1
MX(L+DOHR^(=*$<;ZWI6NRPJ1+Q*UR8X#=E&^*A_P3O\ ^"RI)+^+OB"6Y"/_
M ,-:W.4&#M.W_A,\-M)W8)_&OZ^8%"F0%LY((9.CYW'=@%N3G)))R23[58RO
M]]OS/^%?H^ \4,YRS 83+</E7#5:A@</2PU*KB<FI5\1.-&$8*=6NZD959RY
M;RE)>]=IJUS\"SSZ._"6?YUFF>XSB7Q"P^*S?&XC'XC#X'BG%87 T9XFI*I[
M'"X10G2P]&BIJG1A34>6,4TW+WE_'[_P[M_X+,?]#O\ $+_Q*Z?_ .;6LW5O
M^";G_!7S6;*?3-<U?Q;K^G3HL=YINI_M2)=6]\RW-M>6KSQ77BV6)_L<MJDD
M0DW8=4="KQJ*_L4RO]]OS/\ A58-FXD54!&%+NW[S^$;1L #*>2,L3D#@#/'
M:O%[B"]UDW"47&[YED=*BUI;25.K&;>NBC*+O:5_=/(?T7N!VI1?%7B=)37+
M*,N,,564D[Z.%>C5I-;\W/3E&4;PDG&31_.3_P $Q_\ @E'\:_@=\:M0^+_[
M0=CX&T+3]$\/6EEX/\+:-K8\3ZO_ ,)/%XL\)^)_[9GNM'%GI5E%IL'AT:<)
M)+W49[FZNO,2U-M!YL_]'2PN&4L^X9W,"6)+#H>>F,+W_AHA=7<LI'"E2"IW
M'D'.XXPO^R5.2<AN"*LU\7Q)Q+FG%692S3-I4O;^QAAZ=/#TI4*-*A3ORQA"
M52K)RDY2G.HYMU)-.R227Z_P#X?\.^&V11X>X;I8B.#6)Q&,K5\77AB<5B<3
MB7#VE2K4IT,/3481A"G1I4Z,:=&*FH7=2;>7,JCS=\8+EFVL9I-K1^:2 <*=
MA'/RA6&5SN^;-?R/_M/_ /!*7]M7XH?M9?&WXJ^$_AKX5OO!7C/XS:_XUT>_
MN?B1X0L)I_#>HZ]<ZC;7%UIUS?1WL%P;*9&NK62W:=)O,C3[1Q(_]="$[V&U
MI#YDH.]MJ@%F=0 Z_, I4+M)&.G (%:1"'5E65C"=VX2"/S5;:[F0,A+[2J@
MC.1N(/)XZN%.+\TX.Q6-Q650PE2KCL*L)46,ISJ0A2525;FARUZ/)*525E=R
MLU%VLF>;XD^&'#OBAE^59=Q'5S2E0RG,:F9X=Y76PU"I4KU,/#"N%;V^!QD:
ME.-*"^"--M3J1NW)VBMGCCE5# $=F3!WEF0DE=I&-J '@B)F0Y(&5 SM520!
MI Z?* P#[!L65L\NPX^;G)W%CT&<\U=KY57LKIJ5ES7DY-O76[W=FD_17U9^
MD=]K7TLDM--';1V:?O))--12M!'\X_\ P4#_ &-O^"DOQ<_:H\?^._V>O$OC
M/3?A/J[>$1X?M-)_:&NO MB@L/A[X)TC6#;^%D\4Z;'IH;Q%I>N23!;2#[;/
M*^HD2F\,S?&3?\$[O^"RS'*^-?B$GS-N _:PN"'!QM/_ ".H!P<\,!CJ.>G]
M@#G&=N2W3T XX/3D=,@'\129&0 S$<[CD\>G&.YSZXK])P/BEGF7X+!X"EE7
M#%6E@L-0PE*IB<DHUZ\Z>'I1I0G6JRJ)U*LHP3G-I.<FW;4_GW.OHY<'9YF^
M;9SB>(_$+#8C.,SQF:8FCE_%>,PF$I5\9B*F(J4L+1IQY:&&IU*DHT:,?=IP
MM%-V/X__ /AW;_P68_Z'?XA?^)73_P#S:UDZ[_P37_X*\>(=+OM#\3:KXM\0
M:'J(LC/I>M_M2)J]@\EC+%<1ROI]_P"+KBUEWW<:72*P7R)EBD4,\2%?[&,K
M_?;\S_A58\ [0'P[%0"(V&YF+%G;(ZG X4G/>NR/B_Q!&49K)N%$X24E*&14
MJ4HM.ZDIPJ)III6=U9[;M/RY?1<X'G%PEQ5XERC*-2,XU>+\1B(3C.G.E*G.
MEB*-6%2G4A4E&I3Y&I+E;LX0E'^>'_@E]_P2P^-/[/\ \8O$'QB^/]MX(T]+
M3PS8Z;X1\.:9K\WBC58?$,OBGP[XIN]3GN+!8='LK:Q'ANUL(I?M5_<7-S-(
MZ6<-K )+W^B".W:,H0RD@DR'',Q)P-V<[?*4#:06W'@[< F2$1C(C"  +NV*
M!\WS9R1PQ]Q]>A%3U\/Q'Q%F?%682S/-IT9UW3HTH4\/3='#TJ=!2]FJ5)U*
MKBWS<U1J=IS][E2T/V/@/@/AWPYR&'#W#5#$4L$L5BL;5JXS$?6\97Q6,G&=
M>I7Q'L,.YI./+2A[-*E3;IQDTM"BBBO#/LPHHHH **** "BBB@ HHHH S=:U
MG2O#NCZMX@U[4+32-#T+3;_6=9U74)TMK#3-*TRUEO=1U"]N92L=O:65G!-<
MW,\C*D4,3R.0JDU\Y? 3]M;]DC]J76->\/\ [.7[1?PB^->N>%M-M]9\1Z5\
M./&NC>*;_1=*N[K[%;:AJ-MIES/):VD]Y_HT<\BJC3$1@[B!7I7QV@\,W7P0
M^,EMXUO=3TWP=<?"KXAP>+=1T6&.YUBP\,R^$=7CUZ]TFWFCEAGU.UTMKJ>P
MAEBDCENHXD>-U8J?Y>?^#<WP/_P3 \*?&_\ :+N?V"_C;^U!\4_&-U\*O#,'
MCS3OCWX'\+>%-'TOPRGBX26%[H-QX?T;39KO4Y=4"P7$-Q+)&EJ=Z1[LL I)
M.,GK=6M976O=]#^MNBOQ@O?^"^W_  37T'X[_&W]GSQO\5?$GPZ\7?L^:U\5
M/#WQ)UWQQX,O](\%VFL_"#Q'>>$_%&F:'K4%S?7GB34]0U^RDT[PII.C:5=Z
MMXGNIK6VTNQFN;B*!OGSX??\'0G_  2K\>?$FP^'MUXL^,GP^T_4]6BT>R^)
MGQ!^&$>E?#8S7-TUG9WE_J&C>)=?\3:%I-Q)Y,DNK>(/"NE6&E6MPMYKD^EV
MEO?S6@')+^66U]NFY_0W=75K8VMS>WMS!9V5G!-=7=W=31V]K:VMO&TUQ<W-
MQ,R10001(\LTTKK'%&K.[*JDC\U!_P %E?\ @EHWC<_#R/\ ;E^ 4_B4:JNB
MH;7Q8UUX<GU%[Q[".*U\;VUG+X)NX9+E"D=Y:^(9K)XVBG2X-O-%*_PA_P '
M$?\ P4#^$'[//[#'Q$_9[G\4^);/XM?M?_"+7],^#E_X4TN35?#>L>';7Q'X
M*LO'"ZGXGLKM;;3;#6?!WB*]L[69%N8=3MKZ1$;RI S?R>_\$+_!?_!)_P")
M7CSPE\-OVT?#GQ9\3?M6^/?VCO >A?L[0>$[_P 7:=X&TZR0>'IM"D\17/AW
M5M*T\2:AXT>_CU7^V4U5%TJQM!!;V8DF>\"HPO%R?-9;))._=Z]%U/\ 3CHK
M\G_V[_\ @M3^P/\ \$\?%%O\._CA\1M:\1_%>6P35+OX4?"/0H?'7C?0;">V
MCN[";Q6CZIHWAWPA/JUO/;7.D:;XG\0Z3JVI6%U;ZM:V$FCRKJ%0_L)_\%K_
M -@3_@H7XPE^&?P0^(NO^'?BS]BO-3T_X5_%GPTW@GQ?X@TW3X7N=0NO"TD6
MH:UX7\3S6%K%-?7VDZ'XDO\ 7;/3;>ZU2YTJ+3+6XNX@GEE:_*[=[:'ZS45^
M:?[??_!6+]D7_@FQK'PTT/\ :;U3Q_I]_P#%G3?$VK>$5\%>";GQ;%+9^$KK
M1K/5VU"6"]M!8R+-KU@+=&$AG4S,"HC^;XK\8_\ !RW_ ,$PO"7QHN_@K;^)
MOC!XSOK*_;19_'G@7X:)X@^';^($4))H=CJ7_"1VGB+5IX]0W:4=4TGPO?>&
MY+Q'G@UR72A_:5 *,GJHMKR7;<_>S4M<T31I=)@UC6-+TJ?7]4CT/0H=2U"T
ML9=:UN6SO=1BT?28[J:)]1U233]-U&^CT^S$UV]G87MTL)@M9WC\7^/?[4_[
M.'[+6D^']>_:-^-OPV^">C>*]1NM(\-ZG\2/%6E^%K/7-3L;9;R\L=,GU.>!
M+NYMK5TN)HHBS1Q,KL "*_SKK7_@KOHOC?\ X+C>#/VW?C1\7?BSXO\ V3/A
M5\9/B9JGPHT;4M.O[N?P%\)M7\%^,?#GA+2?#'PVM;B'3M&O[AM3T>/6C:QQ
MZCJ5SYNIZ]J.H7:S7;?T4?\ !:?XI_\ !,/]M+]BO]B7X^_M/?%W]I+X:_ _
MXE>*_%?BWX):M\(? &AZCXMUN\N?#XL-4MO%^A^)+#6$T>VM[2R,EMY+K*\Y
M(:22,@*%.FTXIWM):V5[/5V7=KJ?T9:_^TU^SWX6^!<'[3GB/XR?#S1/V>KK
M1?#?B.W^,NI>)M-M?AW-H/C'5-*T3PMJ\?B>29=-:PU_5]<TC3=*N!-Y=Y>:
ME9P1%I)T!@^&G[4G[.?QD^%7B/XY?"GXU?#CX@_![PC_ ,)%_P )1\2O"?BC
M3-9\':#_ ,(CI46N>)_[4URSFDLK3^P='GAU+5/-E7[)9RI/+M1@:_GO_P""
ME6G_  FTK_@UYU?3?@/K_BWQ3\&;'X$?L:VWPQ\1^/+"TTKQGK7@R+]HOX!+
MH6H^)]-L(+6RL=:NK(1R7]M:V\,$4Y=(T"@5YE_P;T6W@R\_X(0?M2V?Q'U'
M6M'^'EUXM_:VMO'FK>&[:"]\1:7X,G^"OA*+Q1J.@6=TDMM=ZU8Z&U]<Z7;7
M$<D$]]%!%,CQNRD%RKE<KO2?+:W3OZ^1_2#\ OVROV4_VJ+SQ-I_[-_[0?PG
M^-M]X,MM,O/%=I\-O&6C^*9_#UIK4M[!I-QJT>F7$[6<.HS:=?Q6CS!5F>TG
M5"3&V/H*^US1-+OM%TS4M8TO3M2\27MSIOAW3[[4+2TOM?U&STN_UN\L-%M+
MB:.?5+VUT72]3U>YM;&.>>#2].O]0EC2TM+B:/\ D*_X(<^-/^"3G[(WA#]O
MKX^_LG_&W]JGXF^&?AA\(? OCKX]K\9?AWX<TFYT'P9X5N?'^I:9=>";'PWI
MFD3:WJEVRZVE[9W$[!5M[$0F,RR,?PS^#O\ P5QT"[_X+LZ1^WS^T7\5_BSX
MW_9E^'WQ9_:K_P"%307^GWNLZMX#^"7Q \ ?&3P1\(/#7A?X?QW5O9>'XX;+
MQ1X+@UVQL!#<R3Q7FK:W<ZGJB75Y<!2IMN25[15]59MVNE;O^A_IJT5^(GC'
M_@X*_P""=OP]^(_PJ^&7CK7?B]X4U?XQ^"?@5\1_!>M:S\+=0M_"L_@7]H;P
MAX6\;^ ?$]]K::E+':Z5!HWBRSC\3S1P7#:#JFFZ]IDZ2W6DSH?UF^.?QH\
M?LZ?!SXF?'?XJ:K)HGP[^$O@O7_'GB_48+=KR\BT7P]I\U_<P:;81LLNHZM?
M&)+#2--A83ZEJ=S:6,'[VX2@S<6K735]O/II\SU6BOSO_8$_X*>_LQ_\%)[/
MXFZI^S*?B1?Z1\)KKPO8>+=7\;^!Y_!^G?VEXNBURXTK3=(GNK^Z;5KV*UT"
M\NM3BMHR-,@GTQ[QXSJ=D)OT0H!IIV:L^S"BBB@04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&WWU_#^
M9J2J=Q<+#-"A5CYA4!AC:I+[1N)Z#)'//&>..4TY*R5VFI?*+YG]R3=MW;1-
MBDTDVW9:*_G)J*[[MI?GH?PX_P#!:3_E)%\9_P#L5?A5_P"JV\(5\]_L ?\
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M+6!(X+:VMH(TA@@A1(H8D2.-%10!9H,&VVV]VVPHHHH$%%%% !1110 4444
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M0,A/,A4HN">6,9;>FP'!?[JD/_>)X7&W+*PC96"1X0R XW"0;RBD98]LE>@
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M7_2-CP7_ .(\:_\ _/RH_P"'F'_!WU_TC8\%_P#B/&O_ /S\J_O HH _@_\
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M[;4H+:9+JTNK=D$MO*B=A0 4444 %%%% !1110 4444 %%<?XF^(7@#P5?\
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MVS6[@CN())K8S":))X7=%61"W4T %%%% !1110 4444 %%%% !1110 4444
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M\/?B'=Z1INF[3%9:/:>-K0Z]HUG!L&BB>72M->WT@_83\G_M1>,= _X)K_\
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M6>E:U<7.IW-Q>^4VHFVN[6YNVN5\>_X-V?VXM)@_X)??%GP5\>-4N?#VO?\
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MUZZG].'P7_;-_9D_:(^*'QL^"_P8^+.C^._B?^SGXCO/"/QJ\):?I7B:QO/
M7B/3_$.O>%+S2]1N]9T33=,OIH/$/AC7M,:71;[4[=I=.EE29K>2":5?VC/V
MS/V9/V2;SX9:?^T5\6='^&%Y\9?$EQX1^&<&JZ5XFU-_%GB.UETB"XTNR/AW
M1-96UFBEU[2$,FI-96Y-['MF(24Q_P XG_!!S_E+C_P7T_[.D\;_ /K3/[1M
M+_P=#?\ (]_\$E_^SI?$O_IX^"E <BYU&[LTG?KK'F_,3_@Y%_Y/6_X(1?\
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M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP)#1SPR(PX*F@?/K'1V2<;-W;4KWUM]W1'\;W_!<+]J;X6_MK?L[_P#!'/\
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M^&?#::*?#:>'M#3PZ5=#H"Z38+HI22Y:\=3I0MQ8[7O&:Z=?(PURS3D&4EZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+Q!X2<R:%=1?VWHXMI+RS"N5V4NCE;KY._IJ?M'17Y9?\$^_#WP5_8(_8?\
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M@GXY_#3Q+XHUNZBM&OIXO#VB:1XEN]0\1?9K2.66[?0X-0CM/)G2Y>*2"5$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!OBGX?ZYX/MDN8;G2O#6E>)/"T:V5G;'4I9_T6^*'_!Q-_P3)\,_LP:Y\=/
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M^!_@=X-\-:Y^SU8>&O$UU\4;[XD>#_"5CX?O/".B6<&EW.BRV6N:[I;+X?\
M%=[K=MX;&D7UCJ6M:EI,@OK2S_/O_@VI\#ZY\;_A?_P61^&WQ(T;4?AWXE^+
MWCNU\#^/?#][I]_9:MX&USQ_X>^.F@^*=&N]*U+[)J=IJ/AF_P!6OK*?3[_[
M-?P7-B]M=>3<))M!6:C4NFE>._\ B=[&=_P0X_X)Y?"3_@J'X=^/O_!3#_@H
MSH;_ +2OQ-^+?QL\7>%_!WAGQ?K7BI?!7A?2]#L=+O=8U*TT6UU:S2YM(;WQ
M#)X/\%>&KJ[U+PWX&\,>%;&WT6SAO7B?3/F[]IK_ ()U?#7_ ()X_P#!>_\
MX)I:#\!I]6TKX"_&KXW_  W^)?@OX;ZEK&MZU:_#+Q1!\1-.\/\ CK0-!O=8
MDNYKC0;X6/AK5=.GO-2O]<BCN6TG4YI+/2-'N;KZB_X(5_M]_"O_ ()EZ'\?
M?^"8_P#P42\167[,WQ2^$GQJ\4^*_!OB7QY!K-AX$\4Z1XAL=)LM7TZS\336
M;:?:VS7V@_\ "7^#]?O5TK0O&OACQ9:76C3SW=K(+WY__:W_ ."A?PO_ &^_
M^"]G_!,B;X W=_XI^!7P(^.?P_\ ASX<^)_V35;3PY\1?'NI>/= \1_$*_\
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M+XE\1^%M>\31>%+S4+Y-9T:T!1M[F]_9RY;6O?F>U]+VO;\-3QS_ (*.V/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ6<NG:GHNK:1?0SZ?J.DZCI\\]C?Z=>6\UG>6<TMM<0R02.AUJ* NWU?WO\
MS/.?A9\'?A'\#/"<7@/X)?"SX<?!WP-#?WNJP^#/A9X(\,_#[PG#J>I,CZCJ
M,7AWPEI>D:/'?W[QQM>WB68N+IHT:>20HI&A\0_AI\.?B[X2U3P#\6/ '@GX
MG^!=;6)-:\%_$/PKH7C7PEJZ02+-"NJ>'/$EAJ>CWZPS(LL2W=G*(Y%5T 90
M1VU% CX\^#7_  3X_8:_9X\7M\0?@A^R5^S_ /##QUME2#QCX0^%WA/2_$VG
M17#A[BWT?6X],.HZ):SLJ>?:Z1<6-O,(H5DB988@GUQJ%A8:K87NEZI96FI:
M9J5I<V&HZ=J%M#>6%_87D+V]W97MI<));W5I=6\DD%S;3QR0SPR/%*C(S*;=
M% 7;W;?KK^9^?Z_\$I?^":*>*X_&J?L'_LJ)XABNS?QS)\$O :::MZ9DN1=C
MP\NBCP[]H6>-9HY3I1>.3<T94NY;RS_@M+H;O_P2;_;3\/>&]'9O+^"+Z;H^
MAZ'IY;RX+;7/#T-I8:9IEA"=L5O!$L5O:VL 2*&-4CC5$ 'ZIT4#3=TW=V:>
MK?1W[L_GE_X)+?L'?LG_ +1G_!*;]A>^_:@_98^$7Q1\9>&/AYXLTZRU3XH?
M#/0]2\8:/8)\8OB#J,.C_P!K:IIJ>((-)::7[7_8TUU_9LOVB61[1UN9?,_>
MCX?_  Z^'_PG\(Z-X ^%W@?PC\./ OARV%EH'@SP)X<T?PEX6T2T!+"VTK0-
M!L[#2K"$L2[1VMK$K.6=@68D]E10#;;>^K;M=V5W_P 'L>5?%_X%?!3]H+PJ
MW@?X[_"/X:_&7P<;@7B>&?BAX(\-^.M$M[Y49(M1M-.\2Z;J5M9:G &)M=2M
M(X;ZU<+);7$4BJP\M^ _[#O['7[+^J7NO?L]?LQ_ _X/>(M1@DM+[Q/X#^''
MAC0O%5U8RX\S3IO$]MIPU]],8C<=-.H_8=Y9Q;AW9C]3T4!=[7=NUW;[KV_
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MN[T6_NM8\!ZKXGT;5+_PAJMS?^&_#M[<:AX?GT^[FN]!T6YDF:;2[%X/6Z*
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M6#6;I8_9_L<$$$?UO10.[VN[=KNWW7/-_BQ\'/A-\>/!.I_#;XU_#7P+\6?
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MK.VBBM[6UMXHX+>"..&&-(T51=HH'=O=M^K;_-L****!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6I-9T;4[,6]];O;V?A#P9X5;68M?\.^$I=:UOQK)I^IW+SZ3;?AI_P %6_\
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MRC(SL5_$-X9_9ATK_@C+_P %^/V,_@K^RA\0/B*WP"_:_P#!%I;^/OAGXO\
M$CZE \&M3?$+P=)I^J7=M:VEOXBMO#WB#P]HWCSPI?ZC8#6M+U%M0T47_P#9
MT\LMUA_\%=_@K\6OVE/^#BC]G3]G;X-?%#Q%\&_$OQJ_9J\'>"?$GQ#\)ZD^
MD^(] ^%0@^-_B/XQ2Z/>17%G,]_/\+_#_BN"VTR.]LQKLTB:%<7"VFI7"N!R
M*Z][1Q<DVNBW35_)G]N6D^,/".O:EJ>CZ'XI\.:UJ^B3/;ZSI6DZWIFHZEI$
M\8@:2#4[&SNIKJPFC6ZMB\=W%$ZBY@+*!-'N_$?_ (.+_CQ\9OV<O^";6O\
MQ*^ _P 3O&GPC\?V_P 9/A5HT'C#P%KU]X<\01:5JU]JT>IZ>FI:?+#<"TOD
MBC6Y@W[)1&FX':,?EU_P4?\ ^"!WP+_8:_9/U[]LO_@G?X]^,WP4_:,_9&TJ
MV^*,_BF]^*&I:C<^//"OAR>UD\87=Y=^181:!XKTW1UNO$.GKX:MM,\-:ZMA
M?^%-1\+3PZ[:7NCXW_!4C]KS4_VZ?^#:GX+_ +2_B1;*/QQXU^(_PFT?XCQ:
M?!#9VC?$7P#XR\8^ ?&FH6VG6Y,6E66OZ[X:N_$NEZ6A*V.DZS801L\:H[ X
MQ5X-.ZYDFFK-/?57:::_X)_5A^R#XCU[QA^R9^R]XN\4ZM?Z_P")_%/[.WP3
M\1^(]=U6XDN]3UK7M;^&OAG4]7U;4;N4M+=7^I:A=7%Y>7$C&2>XFDD<EF)K
MVRX\4^&;77+3PQ=>(]"MO$NH6\EW8>'KC5]/AUR]M8N);FTTF2X6_N;>,\23
M0V[QI_$PK^6K_@J3^WQ\9/V,_P#@CY_P3\^'_P"SAJVI>%_CM^U7\(_@#\,?
M"WC;1;L:=K_@WPSI/P:\$W_BS4_"FI,\::9XMU2]U3POX6TK5&D@DT>R\0:M
MK5A>6.KZ;IMW#K> ?^#5?]CS4?@E#%\=OBE\>_%W[5_BG28O$/CKX\:5\04,
M>E?%+4K1[W5[OPWX?U+1;BWUOP];>(KAIWG\7SZKXKU];9[Q_$.C3WYBLPGE
M5KR=DVTDE=Z/5[JR7](_J<HK^1__ ((^_$CXW?'F+_@I!_P0]_;V\7:C\8I_
M@;X5\8_#OPQ\2-:-SJ_B"3X97=Y=_"O6M/DUC496U#4].T6XU#P9XW^%E]J]
MU<^(M+@UJ]L9-7;3M%\.VND]K_P;$?%_Q=\/_"'[7_\ P3+^,4LEE\5/V+_C
MAXFN]%TJZEE_Y%#Q)X@U/P_XRT_0H7!5M%\/_$SP]J/B-[U66*^_X6GIUS:F
MXAE,H <+*6M^7E>G6,MI+\-+=3^JNBOY(/!<:?\ !3;_ (.3?&'C<G^W?V?/
M^"5?@>+PWH[F6";1;WXS:1>ZEI=M&R6;W")K5K\8=?\ &NNZ?=K.C7-E\$M+
M2_DA,::0W];] I+EMKJTFUVOJE]UG\S^4+_@MM\=_P!LKXK_ /!2G]A__@EE
M^RS^TCXX_97TKX\?#RU^(WCCXD?#K4=5\/>(9AKGB[XCZ=Y]SKOAG7_#GBV\
ML/"7AWX-^(+^#PII'B#PQ9^(;O7&L=7U&^BGMAI/[J_\$]?V3?BS^QG\!+KX
M2?&G]K?XJ?MI>-KSQ[X@\8R?&'XN3>+F\0V^E:MIGA_2],\&:;:>,OB7\5M2
MTWP_H46A/=6MG:^*$TY]1U;5+^+2[.YO;N2Y_CD_;4_X)/?LB>&?^"_'[)'[
M'.F:1X]_X4M^U1\+[_XQ_%>RN/&]Y+XBN/&OBCQ'^T]=:G/H&OBT2?1M.$_P
MZ\-/;:>D,\<7DW:LTJ7<BC[8_P""G#_$;X6_%+_@GS_P;U?\$]OB1XO^"'@3
MXB>'QK'Q(\>CQ/<WWC"+X>>-O''CN\/AW4O$=E)HVM2Z7X>TCPY\1_''B70+
M*_TZZ\:V-QX3\.R7$-@;J+4PT:34(IV3CS-N*6BNW)O5]+6]/E_8=8>*?#&J
MZKJ.@Z9XCT'4=<T?/]KZ-8:OI]YJNEX<1G^T=.M[B2\L<2,L9^TPQ8=@OWB!
M6[7\J7QK_P"#7/\ 98\%_ 75=<_8W^(/[0'P\_:_^&GAR7Q5\)_BK/\ $QS=
M>*/B+X:TM[O3M-UJUTG3M M_#"^*[^W:RMM=\$S>'+[PIJ5_:ZO%_:FG:=<:
M#J?G/[-'_!0;XA_M_?\ !NK^WQJWQLUQ?$OQO^!7P8^-GPB\<>)YEMH=5\;Z
M/#\.+7Q'X(\<:S;VB1Q+JFI:/K$_AS5;WRHY-:UKPEJNMSK]HU&:@CE35XRN
MN91=U9J[T=KNZ/ZU]5\3>&]"O=%TW6_$.AZ-J/B2];3?#MAJNK6&GWNO:BB"
M1[#1;6[N(9]4O5C(D:UL8YYU0AS&%(-;E?P/?\$F_P#@@_X2_P""F7[$?PY_
M:8_:K_:)^/NDQP7/B'X=?LT>#/ M[X3M/"/@CX7?#OQSKNF:TMQ;>(O#OB"Z
MO;;7_B$OCF46/AFY\%/9ZK'J&O:CJ.O:GK-PUK_>?HNCZ=X>T?2= T>W^QZ3
MH>F6&CZ7:>=/<?9=.TRUBLK&W\^ZEGN9_(MH(HO.N)IIY-N^:621F<@I1479
M.[3:>EDK=G?4O2RQ0123SR1PPPQO+--*ZQQ111J7DDDD<A$C1 6=V(55!9B
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MEWX9N(/ ?BKPWXH\1^(_#_BBRBFUGPU/K6J:%=74&I?DK^W=_P $M/V4+?\
MX.$/V7OV5DTKQRWPE_;"\ Z[\>?C+:/XSNSKMU\0?'/BW]J/5M<N?#FM+:K-
MH6E_;? /AV2STR.*XBMUBNHV>5+IP (QC=INZY)/;5.W57T:WM=W/ZG/^"A_
M[-/[??QX^,G[$/BS]C?]I'1_@9\-?@[\3-=\1?M2>%-3^(?Q#\$S_%_P->^*
M?@_J6E>'M/TOP5X(\6:9XLFL] \*_$?36L/%>H>&["%_%,%O#>2V^IZG/I_Z
MJ5_&=_P7-^"W@C]G+XX?\&ZOP'^&L.I6_@#X1_'#7_ 7@^#6=0?5M5B\/^'/
MB7^Q9IVFIJ&I21Q/?78MX4\^Y:.,ROEMBYP/H'_@NU\=?VA_CO\ MK_L3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^&[2RM9@Z0:)I>GZ?X?>SE;3[O2KJP2"VB!7BTE*ZLVTU9Z-WLT[?)GY0_\
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MQ^\27OC"SM;:&.6YN+JP\$WGB/7[.TLXI;O4+S1[?3K>-I+L"OW4_P""-_\
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M_5KC;=10:YHVK6^GSQ1?V1%I\4:Q#]AE5454151$4*B* JJJ@!550 %50
M    !B@E\MK13O>[;LGZ))OU;Z^1^%'_  <E^%M?\4?\$@OVDO[ TRYU5_#N
MM_!GQ3J\-G&TT]KH&D?&#P7_ &MJ9A0&1[;2X+@7VH2(K+9Z=!=W\Y2UM)Y8
MY/\ @F__ ,%0/V!?#'_!+;]D_P 2^-?VJO@KX&/P3_9=^$WPT^(_A?Q7X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBOYW?^"M7[=/[5'[,G_!13_@D1\"?@?\ %+_A"?A5^U!\>_"W@KXY^%?^
M$(^'/B3_ (3CPSJ7QR^"W@Z]TS^W/%WA'7_$?AGSO#GBWQ#IWVSP?K'A_4(_
M[0^V17<=_:6-U; TG)V79O[DW^A_1%117Y5_\%C_ /@H/XM_X)I?L8ZM^T-X
M!\ ^'_B'XXU/Q[X8^&/A/3/%FH:A9>%]'UGQ7IWB+48?$NOVFD^3JFO:=I4'
MAVX5] L-5T"XU&:ZA']N6$<4AD 2;:2W;LC]5**YCP3J]WX@\&^$=?OQ"M]K
MGAC0=7O5MT:. 7>I:5:7MP((V>1DA$TSB-&D=E3:I=B"QZ>@05Q]S\/? %YX
MQL/B'=^!_!]UX_TJT>PTOQS<^&=%G\8Z;826][:265AXFELFUJSM)+34M1M7
MMK>]CA:WO[V%D,=U.LG844 %%%% !1110 5XE\*?V9_V</@1J.OZQ\#_ -G[
MX(_!K5O%;,_BG5/A3\*? GP[U'Q*[SBZ=M?O?"&@Z/<ZRS7*BX9M1EN2TX$Q
M)D :O;:* "BBB@ HHHH **** "BOQA_:A_X*;^/?@[_P5I_8B_X)L^$/AWX8
MG\/?M!>"9_BG\2/B?KM_J-[K%OX?NX/C=INC^$O"&@6?]G6>DZC;:S\(O[3U
M3Q)JM]KL5[I^KQZ79Z%IT]I)J=U^SU VFK7ZJZ]+M?H%%%% @HHHH **** /
M&_BQ^SI^SY\>X;2W^.?P)^#?QH@T^"6UL(/BQ\,/!/Q%ALK6::.YFMK2+QAH
M>L);02W$,,\L,*I')-%'*ZET5ATOPY^%'PM^#V@GPM\(_AKX ^%OA@SFZ/AS
MX<^#O#O@C03=&-(C<G2/#.G:9IYG,4<<9F^S^88XT0MM50/RB_X+?_\ !3CQ
MW_P2\_9=\+?%#X8?#KPUX^^(?Q1^(8^%WA2X\9:CJ$'A;P9?R^%?$'B=O%.K
MZ)I26^H^+([>'07L[?0;?7?#2R7-W'>7&K-!:2:?>]#_ ,%T/VHOCK^QS_P3
MB^+/QZ_9P\<_\*Y^+'AGQ9\)],T/Q7_PC/@_Q?\ 8K'Q-\1O#V@ZW!_87COP
M_P")_#=S]MTF^NK3S+O1[B:V\WS[22WN4CF0*2;Y>TG9:Z7T3T^?8_7NBOEC
M]A?XD>-/C'^Q+^QU\7?B/K/_  D?Q#^*G[+'[/GQ(\>^(?[.TK2/[>\:>./A
M)X1\3^*=9_LG0;'2]#TO^U-<U2^OO[.T;3-.TJR\_P"S:=8VEG%#;Q_4]!+T
M;79M?=I^@4444 %%%?%G_!1SXM?$'X#?L&_M<_&CX3^(/^$4^)?PP^ GQ&\:
M^!O$G]E:)KO]A^)M!\/7E]I.I_V/XDTW6- U/[)=11R_8]8TK4-/GV[+FTFC
M+(0%JTN[2^_3]3[3HK\L?^"*7[1_QG_:W_X)E?LT?M"?M">,O^%@?%_X@?\
M"Y?^$N\7?\([X4\*?VO_ ,(I^T!\5?!&@?\ $@\$:'X;\,6'V#PQX:T73/\
MB6:+9?:OL7VV]^TZA<W=W/\ J=0-JS:?1M?<%%%% @HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXCO>:E^US\--$U&[?QQ#JB>)FN;_ $:ZNM(O9SJAENM,N9["=Y+6:2)OG_\
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MN];U'0M+\7?#?XLZ=JVL:#+KMWX8TS5_",4GA<Q'6KN;5_=?^#4/_E%WK/\
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MS?\ B$Z?XHO-/>]FTG1M+LM-_:/_ ()E?\HW/^"?/_9D'[*'_JAO -?SA?\
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MFH:'XS34[ :7XB]'_;#UC1?V"_\ @Y3_ &,?V@OB]=MH/P ^,_P-TCX5Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>+_M _L[_!3]JCX5>)O@G^T%\.O#OQ0^&/BVW6+6/#'B*W
MD>-;B(/]BU?2-1M);75_#WB'2Y':XT;Q)H%_INNZ/=8N=,U"UG DKVBB@#^<
M#1?^#6O_ ()HZ9XDTS4-3\1?M5^+/ FEZFFJP?!7Q'\:M,'PN>Y6Y>=]\.@^
M M"\=1>?%-=6,\]EXZM+QK2]NRMTEU+]J7]V9OV=O@3<_ V/]F>Z^$O@*[_9
M_B\&V?P^C^$%WX;TVZ\!KX-T^"&WL=!_L"X@DLVM;,6UO/;2LANX;^"+4H[A
M=0C6Z'LU% W*3M=MVV_K37SW\S^;SQ#_ ,&M'_!-/5]?U"]T3Q/^U=X$\$ZK
MJTNK:A\(/"7QIT<_#6[W3QW%M87$/BGX?>)_&<]II[06RV,TWC.35$6UMFFU
M*>6)9*_<#]F+]E;X _L;_";1O@C^S=\-M#^&/PZT6:6]&DZ3]JNK_6=9N8K>
M"^\1>)]?U2XO==\4>)-0BM+6*\US7=0O]0EM[6TLUG2RLK.V@^@Z*!N4GHVW
MZO\ K]3X'_81_P""<7[/?_!.[3/B[I'P!N_B'=6GQK\<0?$'QC_PL#Q)IOB.
M6+7K>WN[9%T9]/\ #^@BQL#%>S;K>=;R0L$(G&TAD\6?\$X?V>_&7[??PQ_X
M*0:O=_$-?VA?A-X'O_A_X6M+/Q)IT'P\?0=2\)_$+P;<-JOAI_#\VI7=^-(^
M)GB-H[B+Q!:QK>)ILQ@9+62&X^^:*!7=V[N[5F^Z>EON/B_]N_\ 80^"'_!1
M+X(6_P  /C_<^.+7P):^.-!^($4OP_U^Q\.:]_;WARQUO3]/5M0U#1-?MS8&
MWU^^^T6_V$222"!EGC$;*_\ .-_P=&^!/#_A#X!_\$ROAE8PS7_A7PO\<X?
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M\:ZM!KGB>30]+,HL(M5U2UT_2K6YDM(9%M+<6VFV5M;V<%O;06\44**/;Z*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 456O+VSTZT
MN+_4+NVL+&TA>XN[V\GBM;2U@B4M)/<7$[I###&H+/)(ZHB@EF &:LT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4456N[VSL(?M-_=VU
ME;^=;6_GW<\5M#Y]Y<Q6=G!YLSHGG75W/!:VT>[?/<S101*\LB*P!9HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOY]/^
M"@W_  7:_P"&$?VFO$_[.G_#+/\ PM/_ (1SP_X0UW_A,?\ A=__  @_VS_A
M*M"M=:^R_P#"/?\ "H?%_P!G^P?:?LWG_P!N3_:MGG>3;[O*7W>'>&<[XKQ\
MLLR'!?7\='#5<7*A]8PV&MAZ,J4:M3VF+K4*3Y95J:Y5/G?->,6E*W5@\%B<
M?6]AA*?M:JA*IR\\(>Y#EYGS5)1CIS+2]W?1;G]!=%?R-_\ $4__ -6*?^;.
M_P#Y/5'_ !%/_P#5BG_FSO\ ^3U7V_\ Q!3Q,_Z)O_S+9)_\\3U/]6<[_P"@
M+_RXPO\ \N/ZY**_D;_XBG_^K%/_ #9W_P#)ZH_XBG_^K%/_ #9W_P#)ZH_X
M@IXF?]$W_P"9;)/_ )XA_JSG?_0%_P"7&%_^7']<E%>1_L__ !4_X7I\!O@E
M\;O["_X1;_A<?PB^&WQ4_P"$8_M3^V_^$<_X6%X-T7Q;_87]M?V=I']K_P!D
M?VO_ &?_ &I_9.E_VA]G^U_V=9>;]FB_EW_XBG_^K%/_ #9W_P#)ZKYK(. ^
M*^)Z^:8;(\K^NU\FKK#9E#Z[@,/]6K2K8S#J'-BL31C5O6P&+AS474C^ZYK\
MLZ;EQ83*<?CIUX86A[66&FH5E[6E#DDY5(6O4G%2]ZE45XMKW;WLU?\ KDHK
M^1O_ (BG_P#JQ3_S9W_\GJC_ (BG_P#JQ3_S9W_\GJOI?^(*>)G_ $3?_F6R
M3_YXG;_JSG?_ $!?^7&%_P#EQ_7)17\C?_$4_P#]6*?^;.__ )/5?HM_P3)_
MX+1_\/&?CSXM^"/_  S9_P *<_X1;X1:]\5/^$G_ .%Q?\+"^W?V)XR\ ^$O
M["_L7_A5G@?[+]J_X3C^T/[4_M:X\G^R_LG]G2_;?M-IY^:^%''V29;C<VS/
M(OJV7Y?0EB<7B/[2RFM[*C&=*#G[*ACJE:=I5J:Y:=.<O>NE92:QQ&09MA:-
M7$5\)R4:,7.I/V^'ERQ3BF^6-64GK*.B3>NVC/W.HK\C?^"I_P#P5/\ ^'9_
M_"B?^+$_\+K_ .%U_P#"S_\ FI__  KC_A&?^%<?\*\_ZIYX\_MG^V?^$]_Z
MA7]G?V5_R_?;O]#_ "-_XBG_ /JQ3_S9W_\ )ZK+)/"_CGB++,-G&3Y)]<R[
M&>V^KXC^T<KH>T]A7J8:K^ZQ.,I5H\M:E4A[]./-R\T;Q:;6%R+-,90AB<-A
M?:4:G-R3]M0A?DE*$O=G4C)6E%K5*]KK2S/ZY**_D;_XBG_^K%/_ #9W_P#)
MZH_XBG_^K%/_ #9W_P#)ZKU?^(*>)G_1-_\ F6R3_P">)O\ ZLYW_P! 7_EQ
MA?\ Y<?UR45_,Y\(_P#@YT_9B\21VEO\:?@#\8_A7J=UJ M9)_!>I^%?BUX7
MTVRDG2./4]1U6]G^&7B,Q10L]Q>VVE^#-5NX@ABLXM0D9<_T,>#/B_\ #GXG
M_#2#XM_"?QEX7^)O@/4=(U/5M$\3>#M>L-:T+5QI(NHKVSAU73GNX(;RRO[*
MYTO5+.5?MVD:G;7>GZC:07UI<6R?)9_P9Q3PM*E'/\DQN6QQ%1T:%>K&G5PE
M>K'EO"EC,-5Q.&E+WDXQE5I3G%2G"G4A"<H>?B\MQV <5B\+5HJ<G&$Y)2IR
MDND:D)3@WK=)RBVKM1:3:]+HK^1O_B*?_P"K%/\ S9W_ /)ZH_XBG_\ JQ3_
M ,V=_P#R>J^M_P"(*>)G_1-_^9;)/_GB>A_JSG?_ $!?^7&%_P#EQ_7)17\C
M?_$4_P#]6*?^;.__ )/5'_$4_P#]6*?^;.__ )/5'_$%/$S_ *)O_P RV2?_
M #Q#_5G._P#H"_\ +C"__+C^N2BOY&_^(I__ *L4_P#-G?\ \GJOU._X)=?\
M%</^'D_C#XL^%/\ AG[_ (4O_P *N\->&_$/V_\ X6O_ ,+%_MS_ (2#5-0T
MW[']E_X5MX$_LS[)]@\[[1]IU#[1YOE^1!L\Q_,SGPLX[X?RS%9QF^1_5,NP
M483Q.(_M'*J_LXU*M.A!^RP^-JUIWJUJ<;0IR:YKM**;6&)R+-<'0J8G$87V
M=&DDYS]M0ERJ4HP7NPJRD[RDEHGO?:Y^RU%-=TC1Y)'6..-6=W=@J(B@LSNS
M$*JJH)9B0  22 *_E*\>_P#!T9X,T;QGXETKX>?L?:OXY\$:=J]Y9^&/&.O?
M'*/P-JWB72;>0QV^LW?A"/X.>+1X?-\%:>'3I/$.I7$-NT1NI(+EI;6#Q>&N
M#.)>,*F+I\.Y7/,7@84IXN2Q&$PU.BJ\IQHQE5QF(H4W4JNG4<*<'*;C3G-I
M1BV^;!9;C<Q=2.#H.LZ2BZCYZ<(Q4VU%.52<(WE9VBFVTF[65S^K>BORX_X)
MA?\ !3SP9_P4A\#?$'68?!6E?![XA_#[Q7_9FH?"L_$>'X@:Y<^#+K2-$N](
M^(*W;>$/ UQ'I6I:Y>ZYX<DMXM&NX;"[T*.2XU,OJ]K:0_J/7E9QD^99!F6+
MRC-\+/!YA@IQIXG#SE"?)*5.G5@XU*4IT:M.=.K"4*M&=2E--\LY<D^7#$8>
MMA*U3#XB#IUJ3Y9P;3LVE)6E%N,DU)-2BW%]&[.Q117XT_\ !47_ (*X?\.V
M/&'PF\*?\,_?\+H_X6CX:\2>(?M__"U_^%=?V'_PC^J:?IOV/[+_ ,*V\=_V
MG]K^W^=]H^TZ?]G\KR_(GW^8FN1Y%FO$F9T,GR7"_7,QQ,:TZ.']M0P_/'#T
MI5ZS]KB:M&C'DI1E*TJB<K6BG)I#PN%KXVO##8:G[2M-2<8<T(74(N<O>G*,
M5:*;U:OLM3]EJ*_FX_9#_P"#CGX/_M ?&WPY\)?C/\$1^S7H7C -I?A_XFW_
M ,7[;Q[X9MO%]Q<6L>CZ/XN2Y^''P_7PMH>KJ]U;+XL>_P!2L]-U7^S(-6L;
M+1[S4-?T;^D>NKB/A3B#A+%TL%Q#EM;+L17HK$4.>=&O1KTN9PE*CB<-4K8>
MHZ<UR5J<:KJ492@JM.'/"4],9@,7E]2-+&4949RCSQNXRC*-VKQG"4H2LU:2
M4KQ=E)*ZN445G:Q?_P!E:3JFJ>5]H_LW3KV_\CS/*\[[';2W'E>;LD\OS/+V
M>9Y<FS=NV-C:?GTG)J*U<FHI=VVDE\VTCCWT[FC17\L_P6_X.6O^%O\ QC^$
MWPF_X8L_X1[_ (6A\3/ GP[_ +?_ .&C?[6_L/\ X3;Q3I7AK^V/[*_X4/IG
M]I_V9_:?VW^S_P"TM/\ MOD?9OMUIYOGQ_U,5]+Q+P?Q%P?6PF'XBR_^SZV.
MHU:^%A]:P>*]K2HU8T*L^;!UZ\8<M6<8\M1QD[WBG%-G;C<NQF72IPQE'V,J
ML93IKVE.IS1C)1D[TYS2M)I6;3>ZT"BOY9_C3_P<M?\ "H/C'\6?A-_PQ9_P
MD/\ PJ_XF>._AW_;_P#PT;_9/]N?\(3XIU7PU_;']E?\*'U/^S/[3_LS[;_9
M_P#:6H?8O/\ LWVZ[\KSY/,_^(I__JQ3_P V=_\ R>J^JH^#/B1B*-'$4>'>
M>CB*-&O2G_:N31YZ5>E2KTI\LLP4H\U*M3ERR2E'FM)*2DEWQX;SJ<8SC@[Q
MG&,XOZQAE>,XQE%V=9-7C*+LU=7L]4S^N2BOY&_^(I__ *L4_P#-G?\ \GJC
M_B*?_P"K%/\ S9W_ /)ZK3_B"GB9_P!$W_YELD_^>)7^K.=_] 7_ )<87_Y<
M?UR45_/I_P $^?\ @NU_PW=^TUX8_9T_X99_X59_PD?A_P 7Z[_PF/\ PN__
M (3C['_PBNA76M?9?^$>_P"%0^$/M'V_[-]F\_\ MR#[+O\ .\FXV^4W[8R?
M%2ZC^(UK\-F^&?Q ^VWFG7^MP^(1=?#8^'/[!TW7=-T&YUES_P +$_X2%;;S
MM5M;Z.T_X1XZNUAYF=-%\@L6^-SWA3/^&L>\KSK +!8Z.#AF#H?6L%7MA*CJ
M1C6]I0Q4Z33=*=X1G*K&R;IVE'F\W%X#%X&LZ&*I>RJJFJKASTY_NY7M+FA-
MQ^R]$VUU6JOZU17YP_$/_@I_\!/AG^S#:_M2^(/!GQHN_#]UXVN/ ;?##0O"
MGAC5?C)8:K#X8UWXCP:AJOA>+QPF@Z5H5_\ !C0G^.]EJE_XLMT;X/:IHOC"
MXCMDOQ91_H]7FXS*LRR^G"KC<%7PU*KB<7@Z<ZJ@HSQ.!]A]<HP<:M1REA_K
M-#GDH^R?M8^RK5US.&%2A6I14JE.4(RG4IQE*UG.ER>TBK2=W#GA=VY7S+EE
M+6Q1117GF04444 %%%% !1110 4444 %%%?Y[_\ P=%?M:_MD>%/V[='^"6F
M?$?XJ?"OX">&OA7X&\4_#71O!?B7Q1X+\/>/M4UJ.^F\4>.M1GT:[TZ'Q/K&
MD^(H[[PA;23SWL/AZVT$1V,5C=ZGJLEZ%0BYRLFEHW=^1_H045^&?_!NU\=O
MVC_VAO\ @F9\/O''[2^N>)?&'B33/'_C[P9X#\?^,IKZ_P#%/CWX8>&)]+M=
M#UW6];U%!>>)+O3M>E\4>#U\074]_>ZG;>%X)-2U&]U1;V=_W,H$U9M=G8**
M**!'\V?_  =2:[K?A[_@F-H]_H&L:KH=\?VG?A3;F]T?4+O3+LP2>%OB6TD!
MN;*:"8PR-'&SQE]C,B%E)52/DW]GS_@V<^!OQA_9_P#@A\6]8_;5_;/TG7?B
MG\'?AK\1=4T[3?&'A!])TS5O&_@K1?$U[96"77A66\;3K.\U.6"U6XNY+EK:
M.,37+REI3]._\'7G_*+O1O\ LZ/X3?\ J*_$ZOBO]G3_ (+9?\%4?!'P&^!/
M@#P;_P $.OVD?'WA7PA\(OAAX.\*^/;#PE^T-_8_C3P_H'@W0]%T/Q?97UE\
M K[1O[,\1Z=:6NLVUU::I>:9]EO$F@U"XM=ERX;1YN1<KM[TKZQ716^+]#Y>
M_:>^'_[8G_!MW^T?^S#\6_A_^V#\5/VB?V//BYXG?0_'_P ,?'^H:J8)X?"P
MT7_A-?#6K>$+S6M;\++JE]X6U676/AOX]\-II&NZ7J.G7VC:G8IING^;XK_1
M?_@K]XB\0:9_P7/_ ."+.DZ;KNL:?I>J^*_"Z:IIMCJ=[::?J2-\9[2)EO[.
M">.WO%,1,96XCD!C)0C:2*^8?$G[,7_!6?\ X+F?M4_LYZS^W5^S+;_L:_L7
M_L]^*6\3ZQX3U+[9H6O>)+>\NM&N?$^DV6B^)]2U#Q;XL\8>,D\,V_AS3O$%
MWX7T+P=X)\-7E]?(M[J=PUIXJF_X.-_@M=_M'?\ !5#_ ()8? *T\3:CX,_X
M7+I]C\-K[Q9H\S0ZMX=T7QA\8[/0]?U?2V'RR:C9:'>:A/96TI6WO+E8K2Y9
M+>:5@#T<HW<>;DGS-6:V=KVT;2OL?TXC_@IQ_P $[3\1U^$B_MN?LOO\0FOW
MT@>'X_C1X#D UN.>2TDT!]636FT./Q$E[$]@WA^34UUH:B!IYL?MK+ ?N:OY
M;/\ @J'_ ,$,_P#@FW\)/^"9W[0_BSX._L_Z=\._B5\ OA!JWQ'\&?$_3O$O
MBZ_\:W^K> [(ZK>0^+=0U;7+ZU\3VWBJQBU&PU:UU.QDM+>2_CO=&@TJXTS2
MWLO:O^"=]C^T9^VK_P &[7PC\%>!OC5!\+OC9\1?@O\ $OX,:/\ &;Q(VMZH
M_A;PAX#^-_C[X3"=[NROH-<M]3;X2>#V\,Z;KMGJ$-YX<U"YM?$%GO?2H;.4
M,W&-E)-VYN5\R6EU=/2^F_F?IU\5O^"H/_!.[X(>+[KX?_%+]L[]G?PGXWT[
M5(-$UGPK<?$SP[J6N>'=5N'F067BG3]%N]2N/"LT'DE[[_A(TTM-.AEM9]0:
MVAO;22?ZA^$?QJ^#_P ??!ME\0_@?\4? 'Q=\"ZA(T%KXM^''BW0O&6@-=QI
M')/82ZEH%]?6UMJ=H)8UOM,N9(=0L96\F\MH)@R#^13X%?!G_@VH_82^ NE_
M"7]K'XO_ +*/[2GQ[TW3KJ'XS?$C2(?B!\<KK4_%M[>,U[IG@NV^&]AXP'A+
M3O#X@M]"L;;0(=(UBU6RN+W7FAU;4=6DE\C_ .#</X@_![3O^"N7[?'PH_8^
M\0>*;G]C/QE\$/$WQ2^&>B>)O[<M;N*+PC\6/A%I'A3[5IVO;-4\_P -V/Q1
M\9>'+*^UF.76KG2DM9+^\NYY);B8&X*TFN;W5>[C925[:=5O=7Z']=?[0_[<
MO['G[)LUC9?M(?M)_![X.ZOJEH-0TOPWXS\;:/8>+M3TXS-;_P!IZ;X/CN)_
M%&H:8LZM"^HV>D364<JF-YU<$5V_P*_:<_9V_:>\/WGBG]G?XW_"WXU:%IEP
MEIJ]]\-?&WA_Q;_8EW*9?)L]>M='OKJ\T*[N%ADFMK75[>RN+FW"W,$<ENZ2
MM_!UX6^*/[%G[-?_  5E_P""A#_\%POV?/&_Q0\9^/?C)K5Y\'/B%XP\)7_C
M_P"''ASX?OXM\2-H.L1?#@W4=WJG@_7_  !-X%_X0;7-)LO&S^'_  YH,7AJ
MPT'2+DZC)<?MC_P3Q_8T_P""=GB+_@HA9?MR_P#!*;]M[X?>&OA?:?#*?1OB
MY^Q1X"TC4[Z[\4P:_INL:;>ZQK.F>,_''A[Q[\./!O\ :MQX&\3Z7HNI?#/4
M;/3_ !]X7N_L6IV%M>/H-@ X)+7FV33M>+;2=DU=];7?7L?TD?$WXK_"[X*^
M$+_X@?&+XD> _A1X$TJ2WAU/QI\2/%V@>"/"MA-=OY5I!=^(/$NH:9I5O/=R
M_NK6"6[66YE(B@220A3X/\#?V^/V)_VF/$3^#O@%^U5\!OBQXS5=1E3P7X-^
M)GA75/&5S:Z3YQU'4++PFFI)XAO]*M(X)+B75K+3;C31:[+M;IK66*9_XSOV
M\_VK?V4/VI_^"X?Q)^&7_!3CXX>(_ /[ 7[&\-[X:\$?"O3[#XG^)?#GC_XI
M^%[+PWIVKZ3J^G?!7PUXDUZQO?$_BG7_ !CK.N>*)K>PU2#P?X1L? )\0Z9/
M<VT X/\ X*D?%?\ X($^)?@3IGQ4_P""8WQ:T?X$?MK?!'Q!X5\1?"8?!GX.
M?M,_",^.+:+7]'LM;TS5=<UCX7^'O#>G>(]%T9[OQ5X=\7ZAJNGZLVI:/)HU
MSJDL6NR-$#5/9/FO))W4;Q5]KO?UML?Z$E?*?[<?QB^+7P!_9+^.OQ=^ WPH
M\3_'#XS^#_!,\OPQ^&'@_P +Z[XUUSQ)XTUC4+#P]H4B>%/#-O<^(->TK0+W
M5XO$OB+3M(B%[-X=T;5?)FMB#<1</_P32_:2\0_M>?L%_LL_M%^,%A_X33XD
M_"?1+KQQ/;6\=G:W_CCP]->>$?&>K6=E%''%8V6L^*/#^K:K96$2M%8VMY#:
M1231PK*_W)09[/57L]5Z/;\#^/#]DO\ X(5?&#]O#X"Z?^UC_P %&?VT?VV-
M _:@^-5IJ/C'P[X1\/\ BE/!MM\'(+F:YM?#-EXM\'^-_">HZD;];?3M%U.Y
M\'^&%^&>G>'=*V>%[!A/;6VMVGTM_P $!?VK_P!IV?XS_MR?\$U?VI_B=J/Q
M[\1_L2^-KW1? 7QGU:_EU?6]3\-:!XSUWX>:YH&KZSJ-S=:]JVGB_P!*T;7_
M  D?$%UJ?B+1;;5==\.:QJ8MM)T33K#]!O\ @J!\,O\ @KE\5K;PUX:_X)J?
M&CX#_ [PP?!?BK_A9^O_ !(N[RW^(>OZ_=SVT6A:-\.;U/A1\1++PW/#ID5_
M_P 3^:^T"X34=1M)+?5-);31?2?C3_P;=^._A_\ L\_'S]KC]@[]H'X2^-OA
MK_P4DNO$FJ>/_C#\0_'WBZ/QI/\ &K3- OYM2^PZ->KIUH-"71K/QK#XYLO*
MU3Q<OQ0T[Q3JOQ$B\57.GPZ=I.D!I=RA)NSV:BDKPUWV5E;2UW?1L_L)KS'X
MF_&SX,_!2U\.7OQE^+GPQ^$EEXP\16GA#PC=_$WQ[X5\!6OBGQ9?QRS6/A?P
MY<>*M6TJ+6_$5[%!-+::+ICW6I7$<,KPVSK&Y'YL:E_P7D_X)(:/J.H:3J7[
M:7@6UU'2[VZTZ_M7\'?%EWMKVRGDMKJ!GB^'[QLT,\4D;-&[HQ4E&92"?Q;_
M .#G7X^>!/CO_P $[_V'_C]^SKXZ;Q?X,\5_M50>(/AMX\\,PZWI4]]=:+X$
M^)FFP:EHT>H66EZY9WMAX@TBXAM7>RM;I+NT66W!!BD8)C!N2332;M>WD^Y_
M3+X6_;S_ &+/&_QIU7]G/PE^U-\"O$/QRT;4;O1K[X7Z9\2?"]SXL.NZ=/+;
M:IX>L=/74,ZMXCTBXM[B'6?#VE/>ZUI$EM<IJ5A:FWF$?0?'[]LG]E#]E=;$
M?M'?M&?!KX+7FK6$NJ:-HWQ#^(/AOPYXDUW38)98)K_0/#%]J$?B+7;2*X@E
MMGN-(TN]B6Y0VY83D1G\D_A'_P $?OV /^"57PF_X;:\,?#/6O$'[1?[('[/
M/Q=^)WB'XJ>(_B#XYUK_ (3/Q!HOP<\3S>-]4OO!]QK;^"-,2ZL3K]IHP\,^
M&=%NM.L[\&2YO;V,7;?S0_\ !,G]H+_@D!\0M7^-?[7O_!:'XX6'QD_:W^+?
MQ'U>72? 'Q*^$O[0WQ+\'>"?!<(L[R#58;/P-\/?$_@.[GUG4KB\TK0?#DES
M?:9X$\'>']'TG1;'3!J-_:Q U!.[7,TK+1+F;?9:I*VMV?W_ 'P6_:$^!'[1
M_AB;QI\ /C)\,?C3X4M;M=.OM?\ A?XX\.>.--TS4VMXKO\ LK5KCP[J.H+I
M&K);30SRZ5J7V74(8I4>6V0,,[OQ1^+GPK^"'@^_^(7QF^)/@/X3^!-+DAAU
M#QE\1_%NA>"O#%I<7._[+:SZYXBO].TY+N[,;I:6GVC[3=R*8[>*63Y:_@/N
M/VO?^">G['?_  5I_9%^./\ P1_^,6J/\!OCKXKT#X9?M>? _3?#/QL\(^ M
M)TCQ%XRT3PS=7NGZ1\7O"7ABXU*ROM*\47GC+PMHFESZS9>#O&?@IY;!] T?
M6K+1Z_>G_@K=^P?\(OCO^V1^SO\ M*?\%"/VQO@_\.?^"?GPF\.W6CK^S=X^
M\9ZE\,=4\;>,$M->U+6;O0M;BUVS?Q#J?B/7+SP3:^)D\-BP\2IX&T)-)TU[
M.Z/]I70#@DU=M)IO6/O:;JW?MTMJ?J=\._\ @JE_P3@^*_B^#P%X _;8_9Q\
M0>+[V_72],T-?B=X=TRZUO473S([/P\^LW>G6WB&XF7B&/0Y]0,T@:*+?*K(
M/ORO\^S_ (+%>,?^#=CQ%^ROXF\,?L10?#O3OVL_#D_A.3X8:I\#?A[\5]%\
M/W5G:^*M,3Q7IOCOQ'J&BZ3X \26FI^#Y?$0L]1NK[7?$MMKMMH<XNH+ RK=
M?;O[=/[?GQL^&/\ P;5_L8:]I/C77+3XN_M0>%/A?^S[KGC_ $^]OK7Q1%X%
MT3PUXPE\6ZHVN"22Z?7/%'ACX<Z9X/\ $6I2W(U/5(?%^O:E'+'>,]Q #]G?
MEM=<TN6TE9[7OINK7/Z4+W_@IM_P3RT[XH+\&;[]M3]FJU^)1U-M$;PS-\7?
M!J/%KRSVEH/#UQJIU3^P[;Q%)>WL%C#H%QJ<6L3W_GV,%E)=VEW#!^!G_!$S
MXC+I7_!4/_@O[KWC[QVNG> _ ?[0OQ'UR\UGQ?XH%GX1\&>%M$_:&_:.O-5U
MBYU'6KZ/1O#OA_2-&L&N]0U"6:STZPTRR,]S-%:VQ=/M+]G#_@W:_P""<?AK
M]C?P9\&OC%\!-,\>_%?Q)\/-"N?BE\:[^^\0Z1\4H_B3J>BI=ZWJO@O6%NK6
MZ\#:9X>UR]N+?PWX6@L%TTZ;IFF6OC;3O%5\-6N=2_+3_@V?^ MQ\%OVR_\
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MMF^U6]M!X2\-6M]#::CJ"R:EX5\2VEH^C:-XA\':]>V6IQ7$UE:+)\R^(_\
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MZ-%X@AO_ !IX<G\1MXO\<>*4\)PBYUG7;SPUHNNV%WX;MI].;\%_^"UWC_\
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MG_!4#_@G+I_CX?#&\_;E_96M_&WVJZT^329/CC\/1;VNJV=R;*YT2_UL:\=
MT_Q!'>AK$>'[[5+?6I+Y6LXK%[E6B'\RW_!>+0_A9_P2J_8P^ 7_  3]_8P?
M5?V;?@_^V=\=?BAXY^,OB'3=<\8^+=;LO _A"V^&6F^*M$N]<OM6U7QYJOAS
M4/\ A+_"/V[3/[1U'6==\,^!F\(RZA=:7J>K:?JN#X>\4?\ !HGHW[/%M\ K
M_P <Z'XAOAX<BTO4OC=J7P'_ &OT^-^H^)!:[;CQM'XYM_@W'=Z5J,VI%]5C
M\/:7';>"K8[-*3PVVBI_9[!*@FK^^TV[6BF[+2[Z;[)=C^VVWN(+N""ZM9X;
MFVN88[BVN;>1)H+B"9%DAG@FC9HY898V62.2-F1T965BI!KY%^/?_!0#]B/]
MEW59?#W[0'[5'P-^%GBF"&&XF\&^)OB%X?B\<16URD4EO=2>"+.\N_%B6L\4
MT4L-RVCB"6)O-CD:,,P_G+_X-@?VHOB7\2/@O^VI^QEI/Q9;X@:1^S5K.G7G
M[+/Q6\3:5K][IUKX,\?)X]\.Z+$OAK7VTW7-/\"Z1K?@C1/&NB>"]2&GZG90
M>,M=T.1=-CL[>TL_._@/^Q[_ ,$:?V"M;^,NI_\ !6K]K/\ 9?\ VP?VQO&/
MQ.USQ1XMUKQ9K7B?XFWOAG3[Q+7S-,\0?##2/^$JU.U\=ZIXBN]>UGQ-<^*M
M)N]3DMI]&73X;&RT^:>[ Y$I23;=K645=N^M]=$K;WZZ']6OP$_:P_9E_:ET
MO4=8_9R^/?PF^-EEHWD?VXOPW\=>'O%-_P"'VN]_V1/$6DZ7?3ZMX?DNA&[6
MT>LV5C)<*I>%749K^<W_ (*0?\%1?^$+_P""Q'_!/[X!>"/VS?AUX6_9:\+>
M)UO/VK],\-?%CP!I7A7PW\2/#OCCQOX=USPC\?O%UCJ\<_AAO"\>AZ5'JGP]
M\;:SI6GZ=JFR\UC0VU!;26#\FOV1_B;^PYI7_!Q7^R]J7_!*76/$?AW]FOXE
M^&_$?A;XAZ%'I?CSPQX4U7Q1>^ /BU)XLT30- ^(OD^*9? MY!H?@'QCIUEK
MEA8P:3XP6X?1=+TRWT;2HX/J3_@J+^Q?^RU!_P %_O\ @GO\/(O@GX,7P3^U
M)+=?$+]H+PY]GOFT_P"*GC7QM\3_ (I77BKQ'XF5KUI9-1UJYBBGNGLI+.-9
M45X(XF -!2@HRL[ZP<DFE=:.]UW5KJW6Q_7])^U+^S)#IOPDUF;]HSX$1:1\
M?M6MM ^!&JR?%WX?IIOQKUV\O['2K31?A)?-XA%K\2-6NM4U/3=-MM-\'2ZS
M>3W^H6-G%"UQ=P1R>):S_P %-/\ @GIX>^*#?!C6_P!M']FS3?B;'JLF@W/A
M:Z^+?@Z.>Q\0Q7MMILGAS4M0_M0Z/IGB1=1NHK'_ (1_4-1MM9-VMQ;K8F:T
MNTA_FF_X.9?@=X=^&W@7_@DO\ OV=]/A^#^BZ-\:_B!X(^%-KX0?5+-? -[J
M5U\)8-"OM EL[O\ MFWN=(UF_35+.:SO5U&.[C62UN([@1NOO7_!4O\ X(@?
M\$Y_V<?^"4?QS\2_"CX(0^'OBM\!/AMH?BOPW\9QKVNW?Q&\1>(=!UW2(-6O
M?&%_>ZA<:5K%MXO@U#5HM:T=-)M='L$OH1X9L="&CZ&--"5&-HW<O>;2LEI9
MV3>OFMO/H?T0?M!?MM_LA_LIR:';?M&_M(?![X-ZAXFCBG\/:-XY\<:)I'B#
M6K*6ZBLCJFF>'GNGUR\T6WN9HX[[6X-/?2-/#&2^O;>)7=?9/AC\5OAC\:_!
M>D?$;X/_ !"\%_%'P#KT;R:-XR\ >)M'\6^&M2$1V3QVNLZ'>7UA)/;29AN[
M;SQ<6DZO;W,44R/&O\KO_!$O_@D/^R9^U'^PA\,_VL_VW/ 6H_M0_&KX\Z5K
M.GV>K_%KQGXPUI?A]\*?AIKNJ?"#X:^"O"*:;XHMX;6UM?"?@/3=5L]4ESKV
MCVVIVWAVRGTRRT:.T/#?\&\^KV/[)7[1O_!<']G.RU?7M0^ ?[*_QBU_5_#6
MEWMQ-?W^GV/PH\=?'KP+J>KVMOYBP2Z]XG\&>!O"]OKEP5,VH3>&-$02(EN0
MX#BK2LVW"U]%9W=M-;[]]S^I;X^_M9?LQ?LL:58ZS^T=\??A)\$[/5HKN;0X
M?B1X[\.^%]5\1I8/ E\OA?0M2OX=;\3S61N8#=V_A_3]2GMDE62:-(SN&G\#
M?VFOV=?VF]"OO$O[._QR^%'QMT32IK:VUJ^^%_CWPUXU&@7EW#]IMK#Q%;Z#
MJ5[=>']1GM\3QZ=K4%C?-"1+]GV$-7\ O_!/K]J?_@E?^T9\<?VCOVW_ /@M
MK\88?&GQW\;_ !%>Q^$/P5\;?#OX^_$SX=^#/A[%9#4XKR&P^'7@#Q7X4O\
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M.-65!QJV4:DH/V<7+1*,GK'9:]#^6_\ X.G_ /FQ/_NY[_WWFOSS_P""(O\
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MI[)H_:ZOXTO^#HO_ )+!^R;_ -DV^)'_ *E'A^O[+:_C2_X.B_\ DL'[)O\
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MM=+>TO:VM]]#Z[_XABOV.O\ HNO[2_\ X-/A;_\ .SH_XABOV.O^BZ_M+_\
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M$[_@E/JE_>ZGJ'[$/P:N[_4;NYO[ZZEM/$)EN;R\F>XN;B4C7@#)--(\CD
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MKX0:+);W>I6_A>1]47P3<_'RV\=VOBC^R4AM9?$<6G2>-0_@R#5V;^V7X2_
MSX)_ +P[)X0^!?P?^%_P8\*37+7L_AKX4^ ?"OP]T&XOGW%[ZYTGPGI6DV-Q
M>R%W:2[F@>XD9W9Y69V)I_&/]GSX#?M$:%9>&/C[\%?A1\;?#NF7,U]I>B?%
MGX>>$OB'IFE7]Q#]GEU#2K/Q9I.K0:9J+P 1_;[!+>\554+,-JX!J:3T3MRN
M-[^]KUOM?T25C^,G_@KQ^VM_P2DC_8A^)G[)?_!+OX1_!OQE\4?BII&AZUX_
M\8_LT_ FR\-:7\)?@]X!\7Z%XV\8^+/&GCW3_!.DSZE/K2>&[?PC<V2WU_\
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MQJ\-OX-^,GPQ^'GQ:\(23_:I/"GQ,\%^&_'GAM[K[-<V7VE]#\4Z;JNEM/\
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M!_X:WPY_\UM'_$+E\*_^CN?B!_X:WPY_\UM?IE_P_:_X)4_]'3_^80_:._\
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M>I1:AX;A\3>'8#H]UK\7B'2?VG_XA8/^KZ__ #6+_P#*%K\"/^"BW["_B?\
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MB;\-_AQ%93_$/X@^"/ 4.I221:=-XT\5Z#X6BOY85#RQV4FN7]BEU)$A#2)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/V:Y>=SU7-*[YF];K32P4445\B>>%%%% !1110 4444 %%%% !1110 4444
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M1H=GX9N[?7Y6GU4:<&\>94DX;\SV5W;R_7R/E+_@WV_:@_:/_8A_X*>>(_\
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MA?P#\-&N]/\ )U.30[;_ (1;6=<\0:':236?BFXUWPS;7B2#1I;2?QGXO?\
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M:/XFW%J]M-9W[R3> +;Q#!]BTW4M)OM761M&CU6PCU&6=>T_X+5_\$:_#O\
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M<>"XU'5-%X+XF?'/_@I5^RYX0L_CI\9['X">.?AY>ZOX=@\5_#[PY#JL.O\
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M?P+'XT^)OQ#^),>HFQ\))=1:/J5A:Z9:QPW<=U&UCX@\*6LUS:>'O&4UW?\
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MA7'H<<<KQB1EAED\;K+*5@FD"VV8QD%)/WI55151%5$50JJH"JJJ,*JJ, *
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_#3_P '?O\
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ML&_]&2_LC?\ B-WP;_\ F,H"[[O3;5_YG\H?QS_X.J?^"%W[3'PG7X'?'O\
M8H_;-^*?PLA_LI[+PGXK^#W[/5[#I-UHENUGI.IZ#JD?[5\.N>']:L+)Y[&W
MUS1-3L-82QN[ZS^W&UOKR*?XO^"?_!9W_@UI_9ZOO$VI_"W_ ()A?M@V&I^+
M?"WB+P7J^I>+O"'P_P#BEJ,7AOQ;HM[X<\2Z?H-]\5/VWO&EUX3DUO0-2U'1
MM0U#PK+HVIW&F7][9->?9[J>.3^XS_AW]^P;_P!&2_LC?^(W?!O_ .8RC_AW
M]^P;_P!&2_LC?^(W?!O_ .8R@$VE9-I=DW8_C\_92_X.4?\ @WV_8>E\<2_L
MJ?L-_MS?!T_$F/P_'XXBT/P?\+-5M?$0\*-K+>'9+RS\4?MGZ[:)/I/_  D.
MMK:7-K#;W"QZG=Q/*\<FP?+WQ-_X*_\ _!JM\8/BIK7QG\>_\$OOVR]0^('B
M/7)/$NOWFC:%X1\&^'-9UVXO)-0O=3U+P!X*_;I\/?#^\N=4OIIKO66G\+NN
MM7$TTVK+>/-(6_ND_P"'?W[!O_1DO[(W_B-WP;_^8RC_ (=_?L&_]&2_LC?^
M(W?!O_YC* YI)WN[O=W=_P S^,']HW_@X#_X-NOVN/%GA;QS^T9_P3U_;8^*
M7BSP5X T3X6^&-;UGPC\-;"ZTKP%X<U+7-8T7P[&F@?MK:1;W%O8ZEXEUR[2
M[O(;G49I-0E%Q>3(D*1?<WB/_@\K_P""2?C#0=7\+>+?V9?VX_%/AC7["XTK
M7?#GB/X,?LT:WH.M:9>1F*[TW5](U/\ :ANM/U*PNHF:*XL[RWFMYXV*2QLI
M(K^EC_AW]^P;_P!&2_LC?^(W?!O_ .8RC_AW]^P;_P!&2_LC?^(W?!O_ .8R
M@+O35Z;:[>G8_@]U3_@JQ_P:<:QXWE^(%W_P2K_;#AUZ:]>_>PTO0O"NA^"!
M/)Y@:.+X9Z+^W;I_PX@LAYK;--A\*1Z='B,QVJF&+9^I?PT_X/ O^"./P:\"
M^&_AE\)_V3OVUOAU\/?!^G1Z3X8\&^#O@I^S1H'A[1+"-FD\FQTS3OVHX+:)
MIII);F[G*-<7MY-/>7<L]U/-,_\ 3O\ \._OV#?^C)?V1O\ Q&[X-_\ S&4?
M\._OV#?^C)?V1O\ Q&[X-_\ S&4 VWNV_5MG\;OA;_@XG_X-U/!/[3]U^V?X
M6_8#_;9TC]IV]\1^,?%UU\6H/!?PLEUF;Q'X_P!#USPWXPU1M*NOVT)_#(FU
MS1/$FMZ?<1+H:V\,>H226<-O/'!+%W/[5/\ P<Y?\$#?VV]"\)^&?VIOV)/V
MX_B_H7@;5K_7?"FG:UX$^#^DQ:/JVIV<>GWU[ _A;]L;0IYI+BSBC@9+N6XB
M15S'&CDL?ZZ?^'?W[!O_ $9+^R-_XC=\&_\ YC*/^'?W[!O_ $9+^R-_XC=\
M&_\ YC* N]'=W6SN]/0^#/\ @B;_ ,%*_P!AS]OKX(^,_ '[!OP<^-?P2^$O
M[)S^"O L7@[XQ:'X1T@6=IXVA\4:SH]MX6G\-?%SXN7NHV=J=#U5M0EU[5;&
MZAEN;5+9;N)I&MOVLKRGX6_ ?X'? VWUBS^"GP:^%/P>M/$4UG<^(+7X6_#O
MPA\/K?7;C3DN(M/N-8@\)Z/I$6IS6,5W=1V<MZL\EJES<) R+-(&]6H$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'YM?\%8DO&_8O\ &K6Q<01^*_ #ZCMD5 ;,^)[*-!(K,IE3^T)+
M$B- ["0)*5"1NZ_?O@B:QN/!?A"XTMHFTR?POH$VG-"I2%K&72K1[1HD*J4B
M-NT9C4JI5, J",#Y]_;=^%'B;XW?LK_&#X;>#8DN?%&M:)I.IZ'8.P1M5O\
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MO$%O=7ME8:3X0O;:*_\ #.@ZQ;V\MIKNA7=M,-1:Q4I);S1-(AF,'T9\'?\
ME,5^U;_V0+PY_P"F/]FRJ>\WW3M_Y*2MH+LU?_R8^O\ ]K[XC_LT_"#P9X>^
M)/[17A/1/%S^'O$%O_PKK3V\+Z)XE\;CQ(UUI^HS-X&.KRV7]DW$"Z39:GJ]
M^-8T:Q-OIEK!>W<MQ)IUE<_E5^US\5?VY/CC^RI\1O'OB_X;_#7X0_LRZB?
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MZ%<WL?A3Q=?:?#>:?86-WJ2\^G)\MK6^\/+KS[?._P"1V/P=_P"4Q7[5O_9
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MI>AV<$.F6%O9VL-I:Q1V\2I_6502U:*EW<E;TM_F%%?R-_\ !K[\0?'OC?\
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MXZW_ .U5X&TKP=??$+]E[X^^(-0CUGQ??Z'9:/I_C)-"U37I-3UC4M8TR_\
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M.O6.J:'JG]EZYI=C??V=K.F:CI5[Y'V;4;&[LY9K>3Y5_P"",7[;OBW]O_\
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MA?:@5:6PGUCPUI'Q&N+TW*W-]IOC[5(I=2C6Y+0?2G_!L+^UWJGQK_8=U_\
M9B^(#W=K\6OV)_&DWPTU#2M53[/K,7PS\2W.KZM\/AJ5K+Y-U;7?AS5=.\;_
M  ^:RDM$^P:;X-T99IYKNYG2$'-)I\J7N/E=NJ:W?_;R:]+']*5%%?"'_!2C
MQ/\ MF^%_P!C[XHS_L!_#QOB'^T]J\.E^'_!$:ZOX(TM_!UAJ=]&OB;Q[;6_
MC_5M&T#7=5\/:#%?+H&B&XNKB?Q#>Z5>'2M7LK&]TZY#-*[2TU[Z+YGW?17\
MC_@W_@WC@\<? [1/C?\ \%"_^"B_[8.A_M2^*_#ECXH\:>(6^-OA2R^'WPP\
M7:S8#67\*:A=>-],\3:AXF;P?>O-97][HOC[PKI5_+I]R=!BT[3TMKD]9_P;
M8?M,_'_Q+X[_ &^_V+?C!\?;G]I_P=^R9\1=*TGX2?&*\\477C./6-''C+XF
M^!]9NO"_BO4KK6=4UWX=>*E\%Z%XJ\#17&OWUGH>GW=S#I+2V&IQK:A3BK-J
M5^6U]&MW;1O?7T/ZM**_S]?V#OV:?VK/^"F'[>O_  4=_9TU;]KC]H'X1_L<
M_#G]I/XC>,?CJGPX\=7EMXK\5:G=_%KXC>'OA1\,=%U'6)M3AT;2KG3M*\=:
MS!%<Z5K7A&P/AKSM2\+:KJB^&YM,^K/VEO!_QP_X-Q/VI?V9_C)\'_VBOCE\
M:?\ @GM\>O&4OP^^,GPC^.'BZ3QF?!MW%-8WFM3:<UE9Z9I":_\ \(K+?^*/
MA[XCT'PSI.O+-X+U?POXJNM:T:^==4!^SUY>9.5KI6>NB=K[7MT_'4_M>HK^
M,;_@XT^)'[5/A3_@H[_P3C\(?LE?$+Q7X/\ BW\0/"-_X,^'UGI&O7MAHMQX
M_P#'?Q('@;P[J6J:8SS:'<2V%SKD,T.HZOIM_;Z88([V:&2&T,9]1_:%_P"#
M?_XJ? 3]GCQI^T]^SU_P42_;+UK]O'X7>$=:^*^N>-_$?Q2DL/"'Q4UWPQI,
MFM>)/#^EVEI%:^+O#+:SIUA?V.@S^*/B!XQL;FYN5T[Q2L^C7\CZ4"Y%:+<D
MN;96;ZVUMLMM?PT/ZZ**_E5L_P#@HGX]_;N_X-NOVF_VA]=UF?0_CS\/OA_X
ML^$GQ2\1^$9G\.2S?$3P5J_@J]C\4Z4VBO9-HMWXK\$^*/"?B74[334L+.PU
M;6]3L-+MXM*AM%/YU?\ !-;_ ()'?M>?\%,?V8O@?^V-\:O^"A?QR^$4.B2Q
M>#_V<_"_A6?Q3JFHZ3\+OAGXKN_#7B#6WUY/'GA?4/#?B#QAXBT?Q6;+5=-B
MOK^2=;3Q;J%_J]M?6>BV8')HW*2C:7*]&];7TM_5M3^[^BOXX/B=XV_:Q_X+
M6_\ !3_]H/\ 84^$_P"TA\2?V8OV#?V)9M0\*?%+6OA;K-[;>-?B)XK\'ZW)
MX)OTUCQ%'?0:MXHUCQ5X[TSQ!;>&X/$>K:EX/TCPGX*N?%L^D:MXMG9=9Y#]
MO#]B/]J+_@@[X+\,?MV_L _MC?M'?$CX0^"_&'AWPS\>?@7^T;XLTSX@^'+K
M0?&NK+IEEXBU&UTO2?"?A+4=%U3Q3>:;X3N'MO!=EXX\-ZOXKTW7/#OBA"VI
MRV8')LG)*32:5GUU2;V3?ZJY_:=17\;W_!93X]_$73?!W_!)W_@N+^SMK?Q
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MGH6F70O="T"PM]-L[:^N ?(E=N5ES.*=F[M;Z+HN]S^O^BOYB?\ @B)^W?\
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M#Q]J>GVWB%_ _B.TN'O_ (A^)5T'7KB?1=;\2Z?\0]*L[UDN;ZU\(/;@:;=
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MB!XQ\,1-8/IUU_PASWMK9Z%X/N]1@N+Y-2U;PUH6EZU?6^HWFESZD^BM#IL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU>+1=/M]4U31@KD=FTXNVK49)NW>VC/ZCZ***" HHHH **** "BBB@ HHHH
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M'AG3?$D7AG7I(XHGU?1EU&&86%^\4,*-<0;)"L2 GY1CW.BB@ HHHH ****
M"BBB@ HHHH **** "BORF_X*U?&W_@HE\#?@S\-O$'_!.#X*Z9\;_BCJ_P 3
MET;QUH&J>#[OQG%I'@$^%?$%Z=8CL+/Q3X4>UD_X2&UT:R-VUY<H%N3#]FS*
M)4_5F@=M$]-;]==.ZZ>7<****!!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(1OFGEDFD9I'9B";Y8NR5_:25VD[))::W/Q0_P""+7[8'[;W[7GPU_X*.?\
M!/K]IKXPWNA_M4?LN#Q9\'O"?[36GZ/8^(/%G@SQ-XF/Q2^&$VNZG%:7?A>U
M\;ZQ\(/B#X.B\0^&K^X?1=2\4V4J6>LZS#/:1Z@WY(?\$POV.?VN_&G_  5Q
M_P""@GPV\'?\%$_'OPW^(7P*^(7V[XW?&/3_ (3VFKZQ^U%::%\6OLFKZ;XE
MT)_B3IB^#(?$ES!<W]T\.N>+%MY+LHT-V85E;]*O^"#G_*7'_@OI_P!G2>-_
M_6F?VC:7_@CG_P IWO\ @MK_ -C;XI_]75>4%-V=2R2]V+M96N^6^ZVU>FW7
M<_K7K^:[_@H;^UC^T=\+O^"Y?_!,+]GCX??%_P 8>%/@E\7_  SHMU\3/AKI
M5Y!%X9\9W%QXZ^(^FS3:S:R6TDDTDECI>GVS-'-$?+LX ,%,U_2C7\E'_!4O
M_E8Q_P""/7_8I>'_ /U9'Q6H,X:MW_EE_P"DLXW_ (*L_MI_\%)O /\ P6C^
M#_[(?[#_ ,6[G1KOXU? ;P-X<\(^!?$_V"]^&'ASQIX]U+XEZ5K?Q<UW1KW2
MM4ANY? GA[2I/%LCW6GZY! OAR&Z_P"$<U^2U31;_P M_;S_ &<_^"TG_!*O
MX*2?M\Z+_P %:OB1^TM;^"?$?@4?&CX8^-M!URU\ Z%9^*_$VF>%].?0?"'B
MOQMX^\&^)?#EWXO\1Z;X:U8:?X7^&NMQ:=JEEJ.G+#+91QZ7[_\ M"Q13?\
M!V[^PTDT<<J#]E_Q1*%D1742P? 3]KZ>"0*P($D,T<<T3@;HY421"'52/T>_
MX.//^4,?[9/_ ';S_P"M5_ V@M.SIJT;24>:\4V[R:W?EVL)^UO_ ,%=!^S_
M /\ !'_X<?\ !1+2O!^E#XE_'?X9?"(_"[P#J\S2>';/XO?%SPNNMO8Z@?M]
MMJ.K>'/!=M8>+/$+6ME<)J>O:7X:2T:73!?7.HZ=^</P1_X)U_\ !;G]J_X$
M^&OVKOBE_P %>_B_\!_C?\3O#%A\2O /P(\*:#JFF?#3P_I/B334USPUH7Q
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M=SVC_@BK_P %6/C=^TI_P3F_:@^+_P"T_:R>/?C/^Q5)\0CXCOK#0X?#.O\
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M7:L[VOOI=VT/UF_X)">)_P#@JEX3\9?M&_LQ_P#!1;P]K?Q&\*_!_6<? O\
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M,^EI?>'K?4+.R-[927H*R7/)\JTBTTKJTOM*/G;KHF_0_7?XC_M%_P#!1/\
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M#)X7U[7/!MY!97^J>'_^%;>-]5.DW4D]M<JUH=1T^RO"BJI,UM$V["X/+?\
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MQCI'@2?7=)L;"XT/3[36/A)JWAN75K7[+<^,GTW5-1\1/^NO_!#7]N;XG?\
M!0/_ ()_^"/C/\:AIUW\6?#/C+Q?\)O'GB/2M/M='LO&>J^#O[*O;#Q?_8MA
M%!INDZCK'A[7]&.O6FE06ND-X@@U6[TC3](TRZM-'L/T*_:D_P"39?VB_P#L
MA/Q=_P#5?^(:_!3_ (-0_P#E%WK/_9T?Q9_]17X8T$M\T&VE=2BE9)633NM.
MFG6Y_3#11109A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^)?M\>G_ !3U>[C^R:Y;V_VS3M-+0M!]JBG]S_;I_9 \$_MZ_LK_ !2_9/\
MB+XG\4^#?!OQ6_X0C^V/$G@HZ2/$VG?\(-\1O"/Q)T_^S#KFG:KI7^F:KX.L
M;"\^U6%Q_P 2^ZN_(\JY\F:/ZVHH"[T=]MO*VJM\SY(^'_[%GP4\*?L8^#OV
M%/&6CM\7_@9X8^$&A?!;4],^(,5K-=^,/"NA:;;:?;W.MMHL.DQ6NL;K2WU&
MVU/0TTN[TG5K>UU/1YK"^M+6XA_#S4O^#9;P%HUCXE^&WP9_X*&_MP?!O]F;
MQIJ>HZAXK_9RT/QV;_P1JD6JS,E[8/!!?:)X?U"W;2W.E"Y\6>$/%>I7$*I)
MJ=]J7[R.7^GJB@:E)7L]W=[/7OJGKYGYB:-_P27_ &4_ W_!/_XC_P#!.KX3
M6'B7X:?"#XIZ+J>G^,?&&EWVG:O\3M?US6;W3;S4_&FO>(=9TNYLM9\2W*Z3
MI^G1R76E+I>G:/96.BZ/IFG:5I]A9VWT[^QE^RUX1_8I_9D^$W[+O@/Q%XC\
M6>$?A%H^JZ+HOB'Q<=,/B/4X-6\3:WXHFEU0Z-8Z9IGG17>NW%O%]DL;=/L\
M,.Y6EWNWT]10)MO=MW=_GM<_)/\ X**?\$:/V3_^"C.N^&_B9XXF\<?!_P#:
M#\&0:99>&/C[\'-8M] \;QZ9H]Y+?:;I'B"UO;2_T;Q#::;<W$UQH^H2VEGX
MHT2;RX]'\1V6G_:-/NOBKP!_P;>_!?5_BKX8^*7[:_[7?[57[?3^!9H)/"'@
MOX\>-=1O?",,5G?K<V>F^(5U36O%?B+6]#CM;73;2Z\/V'B#P_H>JFVN$U;3
MKW2KP:/;_P!(-% U.25DW;\O1VNODT?G9_P45_X)C?LV?\%+O@WH'PD^-]GK
MWAVZ\!7]YK7PK\?^ ;FPTGQ5\.]7O=,32[J/38[[3]0TC4?#6JV]MIT6O^%[
M^P:QU*+2],EMIM,U33-*U6P_,SPC_P &Z7A_79/#WAC]K3_@HG^W/^UW\"O"
M=_IUSHO[.WCKXJ^*=#^%MS8Z*+4:-HFMZ>_BWQ/<C3+!K2(QGP;-X(OHE@LD
MT^\T];8^=_2-10"E)*R;2^6GIHVOE8_+7]@'_@D]\"O^">%U^TYIGPI\7>./
M&/PS_:<\16NNZW\(?B):^#]4\"^#;6UD\76_]@>&K+3O#>FRW6BWGA_Q6OAC
M5+37I-4CU'1]"T>&=2T5PT_YY>(_^#;/X:^#?'OBWQ7^Q;^W-^V)^Q!X9\=W
MK7GB;X;?"/QWJO\ PBYCN99$OM+TJ[TGQ!X.U\:.^FS26&GV?BC5/%LFGJ[
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M7ANX\2^+M9L/#NH&WU73M-37[*SUF']\Z**!-N6K=_T]%HE\D?FM_P %-_\
M@F1\)_\ @J-\)_ 'PC^+GC_XA_#W1OA[\0U^(VF:G\.6\-C5+W4U\-ZYX9^P
MWW_"3:'KMH; VFNW%Q_H]O#<?:(8?WWE[T9?^"@__!,CX3_\%%-9_9LUGXG>
M/_B'X'F_9E^(E_\ $?PI#X#;PVL7B#5-0NO"=U+8>(3X@T367^P(_A&R6/\
MLUK*XVW-UNF8^48_THHH!2:M9O2]O*^_WG'_ !#\&V'Q&\ >./A[JEU=V.F>
M._!_B;P;J-[8&$7]G8>*-%O=$N[JR-Q%/;B[M[>^DEMC/#-#YR)YL4B;D/QM
M_P $X?\ @GU\-O\ @FI^SW=_LZ?"OQKXX\>^&+OXA^)/B,^N?$ Z"=>74_$V
MG>']-N[%3X<TC1=/^P6\7AZVDM\V9N/,GG\V9U\L)]\T4!=VM?1ZV\UL%%%%
M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK\?_ /@L-_P5
M(7_@FG\'_AZ/ 7@"'XN_M+?M"^*[SP!\ ?AG<RW:Z;?:O8IID>L>*=?M=,>/
M6=6T?0;[Q#X8TN+P]HDMKJOB+7O$NBZ5!J.E6LU]JU@#2;:2W9^P%>8_&SQE
MXB^'/P9^+GQ"\(>')/&'BSP)\,?'OC+POX2B@OKJ7Q3XB\,>%=6UO1/#D=KI
M:2ZE<R:WJ5C;:8D&G1R7TS70CM$>X:-3_-9XE\*?\'2/P\^%E_\ M)W?[0O[
M*/CO7M!\/W/C37/V,],^&'@^]U$:78I'K%UX8TGQ)H_PTT;4?$/B^WLHKK3Y
M]"TKXNB&\"26OASQ1KFMSZ?))][_ +('_!5[3_V\/^"8'QZ_:[^&VCV_PV^-
M?P5^%7QDM_'/@N:6U\0:?X-^+O@'X77_ (ST;5M'6_C9M:\%ZXLND:[H8UBR
M#$'4O#=^=0N-%O;VZ!N+2NFI*Z3L]F^^B>O?8^G_ /@F+^U;\=/VS/V6=,^-
M?[1/P%O_ -F_XD7GC?QAX;N/AIJ6C^,-"N8-'T"YM(M*UK[!XYL=/UY8]6CG
ME=97M_LLIA8VTC*& _0NOY]O^"7_ /P4Z^+GQ(_X)!_$?]OO]K"[F^*7C7X8
MZQ\:+R\T_P $^$]'\-:AXHL? XT^/PKX3TG1O"VD16$&HZQJ5W;Z1'J1TV;R
M9+X7M]OM[9]OQ/\ LX?$3_@XV_X*:?#2+]K+X-?M'?LR_L/?!?QSK'B.#X3_
M  PUGX7>'/%6M:QX?T'7=4\/3:SJ-QXU^#OQ>\1V]M#JFD76EV^JZCJ^BS^(
M[BVU'7;#PAI7AVYT![X&XN\K\L4G;5NU^RT;?W']<-%?S2?\$G/^"C_[=^O_
M +=_[0?_  2W_P""CUMX!\6_'?X)^!9O'6D?%_X?:3I>AP>(+:Q'@2_6WU6Q
M\.Z5X=\.:CI?BWPC\1?#WC/PIK&G>$/!M]8VB7.F:_H:ZA>0P:9@_MF_\%._
MV\_V@O\ @H-XA_X)=?\ !)W1_A]X9\=_"_2I-0^/?[3?Q,TBU\0Z-\/Y8;'2
M)-;FTK3M6TWQ%H&G:!X+O?$NB^'=5OM5\%>-=<\2>/;J/0-"\/VFFZ;-J/B
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M\1:7;W.I:E<Z7;:NNC7FHWU[IUS<R G%I7NFKV=G>S\]%]ZT/T<K\Y_V&?\
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M=)\-:AIU[K=K;3Z7:W5G=7ZW<7S%^U)XY_X.<?V-_@CKO[;WQ+_:*_95\7^
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MAU(SR>'@.1]XWM?EOK:U^UKVUM>Y^M7_  41_P""GOC_ /8M_;0_X)R?LO\
MA7X8^#_&F@?ML_%W0/AQXL\4>(-5UJQUCP58:Q\5OA?\/9-1\/6FG$65]=PV
M7CV]U%(]2S"UU86L3#RI)<^B?M.?MO\ [2WP:_X*%_LC_LI?#O\ 9BU/XD?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=\06>HZ_/:0SWMOX>L-5N;."6XAC1NK_ &:?AE_P<#?\%./@_P""?VE/%O\
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M2Q%H5DN#?E9S("L,87Y@A-<DEU<HM>B3O^9^EE?R4?\ !KS_ ,CW_P %:/\
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M?@WK7PV^$^H:YXT\9>/=5L?$/Q;^+7BI(;?Q%\0=;TN*^@T9/[+LY9M/\/\
MASP[;ZGJ4'A[0+2:[>S_ +1U*\U'5-6U74;[4;C\P?\ @E+X2\7:-_P6(_X*
M\W>C?'77/V@O@Y%X@?5_^$@LM2UR[^'/PT^(_P 6/BQXL^(LOP/T0W^OZUHM
MYXC^&6@R3>&/$-QX=%M!87>E3Z==Z=HSK!8N$R]YR=[V2M=6OLNFB\O+3<_I
MEK^73]N+_@I)_P %"OCE_P %,[__ ()3_P#!,#4_A7\)/&'P[\,6/B7XO_M
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M#QG%I$OF:E<_:9K"2\7R4N%MXOFGX=?\$O-?\#?\%B/CU_P5'F^,.CZCX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXDDM)[P6<NM7.J:7)*+99+1$\R1OYE?^"^OPL_X*R>$OV9_@MXQ_X*1?M4_
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MWT-[?7/ZN*_DX_8/M?!<W_!SW_P5(N=;72W\96GP1T[_ (0<7_E&]CCGT_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWO\ \$S_ ([_ +4W_!2O_@G=^V1\/O%GPDT?X8_LD:YHNI_$?0O&6O>,=/\
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M=_$=UX@?4--_?.B@;FW?:[T;22;]7Y]=KA11100%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>v433932_chrt-org.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v433932_chrt-org.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( ET"?0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M;R//97-R^O\ @/QUK%U:K,RQZAI4FL#3]3LH8K66*)VN+BX^O:*ZXY7@8_\
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M--)*5>@F[Q<7;VU&\G3YE.#E2?[O]>J***\P^L"BBB@ HHHH **** "BBB@
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MU*52#M*,HO3R::O&46G&<)2A).,FCUC_ ()U_M<ZG^U[^SU;>(O'^CZ?X/\
MVA/A5XHUWX*?M.?#S3_,CMO!WQM\ RQV/B.72+>>:YG_ .$.\:V4FF>/_ =U
M]JOX;CPEXFTN(:E>W=I>2#[PK^<GQ9XT_P"&"_VT/ _[8\$W]F?LZ_M)3>#/
MV<OVV+=6\G2/"^NR7C:/^SE^TQJ@RD,0\(>(-23X1>.M6N)DBM? _B_2[TVU
MS+HJO'_1M7Q6+P\L+7G2=VD[PD_M0E=Q?K;1_P!Z+\C]^R;,Z6;Y=A\=3M&4
MX\E>FG?V.)II1K4^Z7-:=.^KI5*;ULV%%%%<QZ@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%4-5U.QT73-1UG4Y_LVFZ387FIZA<^7--]GL;"WDNKN?R;>.6>
M7RH(I)/+@BDFDV[8XW<JI /PK_:&UYOV@/\ @JKI_AY&FNO G_!/KX I<7"%
M;9+6/]I#]K18KD9!$DEW/X7_ &?_  E8RPO\L^G#XGR!?L=O?DZU]-U^?_\
MP3EN-6^(7P:\;_M5^*;9+?QA^VU\;/B9^U!J%NT:FYT?P?XRUD:'\(/"ANB\
MLTMGX9^$7AGP5:6MM)/*EC-->Q)+<RO<7UW^@%?99=1]C@Z2M:4U[67>]2S5
M_2'(C\)XKQSQ^>XV2E>GAIK!4>W+A;PFU_BKNO+SLF%<!\5_#.H^-?A;\2O!
MNCM;)J_BWP!XR\,Z6U[*\%FNHZ]X=U'2K%KN:.*:2&V6YNXC/*D,SQQ!W6*1
M@$/?UYIK?QH^#OAK4[K1?$?Q8^&GA_6;%Q'>Z3K?COPMI6IV<A4,$NK"_P!5
M@NK=RI#!98D8J0<8(KMERV:DTDTUJTMTT[-M:V;/!I*ISQE2A*<Z<HU$HPG4
MLX3C)-QA&3MS15[I)[7U/AOX2:_?^.?V7/V8O@9/X'^)7A;XP>!%_8^A^(G@
MWQ)\.?&VCVO@F^^!?C[X8>*/B -3\8ZSH.E>#+K2([3X;^(E\,ZYIVN7-IXT
MC?2+CPHFK?VO80S>%/\ #?Q?HGPI^*?Q)\(_#CXUZKXKM/VS_$VD?$;2]5T_
MXR+\0O&/['E[^U38>,O&>@?#7PSXJ O?&'A_6/ L"7]II_A_3;R3Q-X5N/%W
MA?P]>Q3^)9TG_9ZWN+>\MX+NTGANK6ZABN+:YMY4GM[BWG1989X)HF:.:&:-
MEDBEC9DD1E=&*D$S5@\.I*-YMN,.1248K10C"+W:NE&[MI+FDO=3/1CFCISJ
MN&'C&-6NZ\Z<JM1KFE7JUZM._)&7LY2J<L$_>I^RI3;JSA8_%WQOX)\;S>-/
M[6^'_A/XBZA^S_>?MZ?L;>/?AIX8TWX?^.YK/PE8^'='M)?CAXQ\.^%U\-KJ
M'@_X33ZM)HNIR7ALM/\ "C^*H_&VNZ<$BU.YO;SH_ 6A_&#7-9^$0U/PUX^\
M,?M5^#_VTOB%J7QJ\9R^'?%EIX5\8?L[WOBGXH7 #^.;G21X8\4?!W6OA)<^
M!-"^&'AN;4K@>'O&_A_P]HVFVT/B'P3JVHV_Z_USEQXP\)6GBG3O ]UXI\.6
MWC75](OM?TGP?<:WID/BG5-!TNXM[34];T[P_)=+JU[I&G75W:VU]J5M:2V=
MI<7-O#<31R31JR^KQ3NZC2;6EDE>]UR>]>+35H6NXQ<HI-29?]JU)PY%A82<
M*<DIJ524W%0<).LE3:J0E"2G7YTHU*L*5:<XRIQ;_%;P[_PA?B?]J'0]*^*_
MB'QW9CP]^U]^T7+;^+/$'PF_:5T6R^-7A_Q9XB\6> ?A_P# 3Q+\1(?A?9?
MK5/AS\//B#J_AK3O HD^-GBO2-<B\#>%?#MUX.T+6?%.O>'M.^L?V2OAAXP\
M,^--9^%OC*P%_P"#_P!CCQ!X[\"_"3QI>Z@=7U+QYI?Q?C\,?$?PIJ>L73S&
M]A\6?#'X:ZU9^ O%%QJ@>;Q9K&N77BMH(]VG7MS[UH/[/_[.WA?Q)=^"-&O=
M=L]8U&QUKQQ'\*I?CW\6+W1[#3-5UN5=0\7>&_A%J'Q'NO#?AC3K+Q7J1O-)
MUWPSX5TJU\->,);75=!NM+\10V=U%[+\-OAGX,^$GA2Q\%^!--O-.T.Q>2;?
MJVO^(O%VOZE=RK'')J/B'Q?XPU;7O%OBC57@AM[5M6\1ZWJNIFRM+*R^U_9+
M.UAAFE0E&2E+ETE*3<9-M]H25FFE+EFG[LDXKF3<KFF,S*G4HRITE62E1I4Z
M<:M-1C#5\^(I-.+A*I3=:@X)5*4HU9.E*$::@? WQ3^'GB[QC_P4F\%ZA9O\
M8O!?@J]_84^+?PWU#XJ^ O!MXVBV7BG7_C5\*?$=IX1D^(&L^!?%/@_0-7U+
MPYHVLZO9SK<Z=K$$VDH-.U&UO=D%QCZ1^S'X0\$_M!W'PZ^&'P]\9Z/X0^$/
M[)7PAC^ DFJI\7%^#.@_%OX>^.?BE<^'YYO$*7$7@O5?%5E;ZAX9OO$]LVHW
M>LZ[IVJZJ^O6]^=3U$3_ *FUSEIXP\)7_B;5_!5CXI\.7OC+P_IVF:OKWA*T
MUO3+GQ-HFDZTUPFCZIJ^@PW3ZKING:L]G=IIE[>VD-M?M:W"VLLI@E"VZ$+M
MMJ\JKJ)M*^J7N1O+:\5*Z7,W%-I\JMSQS+$*$*<(-0HX*.&<8RGR^Y*5L344
M:=[\M65%QE-4U"K.,9P]K)3_  XUG1_VF]0^"7PJ\2?LZ>$?B[X*_:2\-_LG
M_&+0/VJ],U[1O%/AO7_&?Q07P?X4A#3^(M;TFRT+Q[\;;[XFQ>(?%?P;\<:?
M=7=S/HFKZEKEI=6GA7Q/;6EY@?%OPQI^L^/OC-\3/V>/@U\7O#/@N/X#?\$[
M?&-C<6?P)^,?@S6GO_A'^VUXY\8_&?2],TS5_!FG:[?^/=,^#,LT7BK0]+BN
MM>UZTU'5K&\34I[[6S)_0316;PB:LZCVC]F.CC%Q4H^][KDG>I;XY+FT9TPS
MR4)<RPE/>IM6J+FA5K1K2I57[/\ ?0I-.GA>=?[/2E[-*:2/Q:\0:S\6XYOV
MV/&W@3X=?'"\^'%S^V+^RU\0=3\&VGPX^(GA_P 5_$']G2'X3_L^-\=[?X7>
M%M9TK0]3U^;6M9L/&>H^,/!NAI%KGBB ^+?#^J:7+K'B.;3+[TWPKX!^&)_:
M$_9B^*_@7X+?% _#?5KS]I2/P]KGC+X1?$1[CP3JGCN;X)^(/##6OACQ7X2M
M_%WP#^&LGB+P]XWNO!^F>*]&\%>&]'U"VU+6=&BL=/\ $VCRZA^K%<YK/C#P
MEX<U/PWHGB'Q3X<T+6?&6HW&D>$-(UG6],TO4_%6K6EE-J5UI?ANPOKJ"ZUS
M4;;3K>XO[BRTN*ZN8;*":ZDB6")Y%OZND[RJ72DI>]&.DO:RFN5N7NQ;GRN/
M5J,D^96>+S.<TX4\,XN5*I2?LJU:\Z3P=+#MU(PI7J5*:H>U55VY82K4I1=*
M3G'HZ***Z3R#S+XT_"WP_P#&_P"$7Q-^#WBJ"WG\/?$[P)XI\#:J+FW6Z2"V
M\2Z->:5]NCA+QL+O39+F/4+&:*6"XMKVVM[FVN(+B**9/>_^"3WQS\0?'C]A
M#X(:EX]D'_"V_A5I^M?LZ_&NT<3"[M/BS^SYKE_\*/%L^H><B$WGB&3PQ:>+
MG,:1Q^5XBA_T>RD\RQM>1KP?_@G]K4OP9_;^_;-_9J9F3PE^T%X+\#_MU_#:
MQCE1[;3_ !/%-I?P%_:+@\ML7$<NH:[I'P?\5,N'M_M/BB^>.8M*UM:>)G='
MFI4JZ6M.3A+_  U-5]TX_P#DQ^A>'^.]GB\9ETI>[B:2Q-)-Z>VPWN5$O.6'
MJI^?LNMC]P****^:/U8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:RGHKJ[TEC\LE.36 E"FYIP25!RIQ4L6UHY.%50C7H.-.3IJ4L/:51TY\L?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM4OW,KKFAB'[!VJ-TJT88BBEBKT>6<Z7/AO?4Y4_:0JPNX/XLUG]O[QWX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^>?X<Z!_PSQ^WU^W-^S!(GV+PO\2-?\._MW?!>
MWD.?/\/?'DW/AOXY6%BJ8AM[+P]\>O!VO:M]CC53;Q^/[.1EQ<HS?:%>,_\
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M[7)4?O-\'OA=X5^!_P )OAC\&? UK]B\&?"?P!X/^''A6U(0/#X?\%>']/\
M#FDK-L 5[@V.G0-<28S+.TDK$LY)^=SNNG*EAXN_)>I42Z2DK03\^7FE;IS+
MN?J7A_ETJ='&9I4A;V[CA<,VM94J4G4Q$X]>65;V=*^TG3DE=19Z-1117@GZ
M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OPT_P"#
M@?\ Y,L^%'_9[_[(_P#ZLF.OW+K\-/\ @X'_ .3+/A1_V>_^R/\ ^K)CH*A\
M4?7_ #/W+HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_#3_@X'_Y,L^%'_9[_ .R/
M_P"K)CK]RZ_#3_@X'_Y,L^%'_9[_ .R/_P"K)CH*A\4?7_,_<NBBB@D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K\-/\ @X'_ .3+/A1_V>_^R/\ ^K)CK]RZ_#3_ (.!
M_P#DRSX4?]GO_LC_ /JR8Z"H?%'U_P S]RZ***"0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^VP^)P^+I1KX6O2Q%&?PU*,XU(-Z-IN+O&2NN:$XPG'[4%UZ.BBBH-PHHHH
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M0_$3QSX>\,WVJ1;Y8U70](U*^AU?7IY)()TBM=%L;^ZF>"=8H7,,@7\]+_\
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M"WBEHU8Z7XP\+RR&6YT34 3<>%_&^BM?^$?%=CNDTK5&OK35--TW[0K^?O\
M:*_9>D^)&O\ A_XZ_!/Q6_P-_;!^%UG-_P *F^.VA1312SVHD6ZN/AI\6-,L
MRD?Q$^#WBF2+[!XA\*ZW#?G38;JXU7PZ+/4O.2]_0W]@;]M[3?VPO /B+2O&
M/AI/A/\ M0_!/4K#P3^TW\!;V\AGU+X?>-Y;(7%GK_A]Q=WDNN_"GX@VL<OB
M+X9>,(9[NRUO1'DM&O9]4TK4UC^3QN!J8.:N^>E-ODJ)6V^S-;1FEKO:2UCU
M2_:,@XAPN>T)."]AC**C]9PKES.*>BK49.SJ4)2]V[2G2DU3JJ[A.I][T445
MPGT 4444 %%%% !1110 4444 %%%% !117->,_&?A/X=>$O$GCSQYXDT7P?X
M*\':+J7B/Q5XJ\1ZC:Z1H/A[0=(M9;W4]7U?4[V2&UL;"QM(99[BXGD2..-"
M2>@( >,O&?A'X=^%/$/COQ[XFT'P9X+\):3>Z]XH\6>*-5LM#\/>'M$TV!KF
M_P!5UG5]2FM['3K"T@1I;BZNIXHHT&68<5^ ?Q0_:I^//_!34WW@O]F36?&?
M[-O[ UW-+I_BC]IF.UO_  K\?/VJ='25([S1?V>-.U&.TUGX2?"/6+<3Q7OQ
MAUW3X?&'BBSG@M?!^DZ9:#6I7X.^OO$W_!5[QW8_'3XU:/X@T#]@CPIJMIJ'
M[+/[,WB%;S2K7X_3:9<QWNF?M/?M!^&_.6/7=!U>=8[SX,_#/78YM'MO#HMO
M$^NZ7=2ZN'U;]$888;>&*WMXHX+>"-(8((8UBAAAB4)%%%$@5(XXT542-%"H
MH"J  !7NY?E7M%&OB4U!VE"CJG);J539J+W459R5G)J+2?Y[Q-QC]4G5R[*9
M1EB8.5/$8WW90H3U4Z6&7O1G7@[QG6ES4Z4TXTXU*D)2AX_\$/V>O@I^S=X0
MC\"_ [X;>%OAQX<#1S7L'A_3TCU'7;Z,./[6\4:]<&XU[Q5K3B202ZUXCU+4
M]4D5BCW90*H]DHHKZ*,8Q2C%*,4K*,4DDNR2227HC\LJ5*E:<JM6I.K4G)RG
M4J3E4G.3WE*<Y2E)ONY/MHDDBBBBF0%%%% !1110 4444 <?X^^'O@3XJ>$M
M9\!?$KP?X;\>^"O$5M]CUSPKXMT:PU[0M4MPRR(MWINI07%K*\$R1W%M,8Q-
M:W,45S;213Q1R+\8^ M5_:'_ ."6]S+J'P4TKQS^T]^P.+V74/%/[+XOKKQ1
M\=OV:;"XFEN-4\0?LN:IK%R;SX@_#RT5VN[_ .!'B/53JMC-$USX%UI9=4UB
M*/[^HKFQ.$HXJ'+5C[R7NU(I*<'Y.VJ[QE>+[)ZGKY1G>/R6NJN$JMTI->VP
MM1REAZ\=+\T+^Y4LK1K4U&K!VUG&]-_</P _:&^#/[4GPL\-_&GX">/]"^)'
MPX\50NVG:]H<TF^UO8 @U#0M>TNZCM]6\-^)]&F<6FN^&=>LM.UW1;P-:ZE8
M6TXV5[/7\W?Q*^$_Q-_98^*5_P#MK_L.Z)<-X\EU2'6OVF_V8M)OWTOP!^UW
MX&M[2^AUV6#P_$ATO0_VB]$@NFUSX>_$#3H;6[U_6;23P]XMBU^RUVXAD_<W
M]FG]I+X1?M;?!CP9\>?@AXE3Q+X"\:V+36YFB%EKOA[6+1S:Z]X/\7Z,9);C
MP]XQ\+:FEQH_B/0KMC-I^HVTJI)<6KV]U/\ )8O"5<)4Y)ZQ>L*B3Y9Q^>TE
MM*+U3[IIG[5DV=83.\+]8PS<)P:AB,--IU</4:NE*VDZ<]72JI*-2*::A4C.
M"]WHHHKE/7"OSP_X**_MB^)/V7?A[X&\#_!C0]*\:?M8_M+^*;OX7?LV>#-;
MEFC\/6NNVVG?VIXR^+'CPVL-S?1_#/X-^&W_ .$J\7-96ES<:A>3>'O#2BS'
MB$ZI8?H!JNJZ7H6EZEK>MZE8:-HNC6%YJNKZOJMY;Z?I>E:7I]O)=W^I:E?W
M<D-I8V%C:0RW5Y>74L5O;6\4DTTB1HS#^<S]G?Q#?_MF?M _%'_@H]XKLKN'
MPAXKL+OX'?L4:#JMF+6;P[^R[X4URXGOOB<UE*$NK'Q'^T-XXBU#QC.]]:Q:
MG9^!=/\ !NE0W=SI,J&3KP6&>*KPI:J"]ZI)?9IIJ]O.6D8^<K]#Q\]S:&39
M;7QCY95K>RPM.6U3$U$U335TW"FE*M5M_P NZ=KKVB9[-^S!^SCI7[.O@K5K
M6]\1ZK\2?BY\1O$%Y\0OCQ\:_%*V\GC/XO?%#6R9M:\2ZU<00PK:Z39R2/I?
M@_PU;A=-\*^&[>RTFQ1G6ZNKOZ4HHK[.$(TX1A"*C""48Q6R2_J[;U;;;;;9
M^"XC$5L57JXG$5)5:]:<JE6I-WE*<G=OLDM%&*2C&,8QC&,8I(KX-_X*@ZCI
M^G?\$]OVP6U"^L[%;OX"_$/3K1KRYAM5NM0O?#]Y#9V-N9W037EW*1%;6T9:
M:>0A(D=CBOO*BE4A[2G4A>W/"<+VO;FC*-[75[<U[75[#PM98;$X;$.+FL/B
M*%?D4N5S]C6IU>7F:ER\WL^7FY7:][.UC\%?VH_COX5^*'A?]H&S\;?%6WT/
MQ?\ #;]M/]B;3_A5\-8/B)'H^@Z_\ [OXY?LN>(_#OQ(M/"EOJEOI/Q%T7QE
M?ZKX\\52^-YK'59-#N_#1\/6^H:=#X*OHI_>M0^,WB/Q?^U!XX^'^O\ [5FE
M? #XA?#CX^^&H?"_P8NO"VKZIKWQ1_9SU'PCX8FN+SPAI%]\2-)\%>+?#/B?
M3M1\3^)=>^*T7PZ\8:]\$_$FC:QJ&LZI:>$_"Q\/O^LTEC92W"W<MG:RW21K
M"ES);PO<+"EQ'=I$LS(9%C2ZAAN5C#!5N(HY@!(BL*][)I%C-;ZGJ,FFV<Y>
M#1K34+UK6WF,FL7UG;VVE6]W.4<OJNI#3X(+&.3=?7PLXHXI;@0K6'U>?,Y.
MJM7'FTG'F474:NU43YESI1LU'W4G%W9Z?]IT/9QI1P;7)3JQIWEAZGLYU8X6
M,N2%3#3@Z<_J\W44XRK7K.5.K%TXM_SWR_%CQAXE^#GPBM9?VA_'_P 1Y?VD
M?^"9G[97BCQMITGQ(226Z\?_  ET3X077P]\1^#_ /A"FT'4?#WB=Y/$OCS3
M]3ET.XB?Q79I?6FL6^HG2%:U^Z_@Q\3]*U7]ICX3_#_PI\7+OQ)\(]=_8&OO
M&ECHUO\ $.?7]*N?$5O\4/"FD77B:QUQ]4NM;N]4M-*GU6R@U276KJ?1K".6
MUTJ73K*V$4?Z;T40P\HM-U.:W)>ZGJHV;5W4>DVFVG=7EL*OFE*M"I!8104U
MB$K2H)1E6YU"?+'"P7/0A*G3@X\K<:=KJZM^&OP'.L^%OV(H?CG\'/&OC;7=
M3^!7[6W[3WQ.^)W@70/B7XJ\20?$3X2^'/VN_CM+X\\'3Z'=^(M5LHM9N_AM
M?#XC^'XK*Q@U+QKXHT/1EU&34X/&&KSZC]T^-_&^K_#[]C7XX?&KQ1XO^)'A
M&]U_PC\3?BE8ZSHMM!XP\9_"[0/%"ZA<> (?#7ASQ7)-X?T[4_!GA:X\.7>J
MZ1J<J>$]*\1V^O7M]=6V@Q22V_T5\5/A1!\6;70])U3QQX\\->&+*\O6\6>$
M_"%]X>L-%^)_A_4M/ETW4/!?CR;5/#.M:Z?#%Y!/(;B/P?K7A#6I"S1-K9M7
MDMW[S1?$WAOQ(VL+X=\0:)K[>'=;O?#/B!=%U6PU1M"\2:=';S:AX?U@6-Q.
M=,UNPBO+26]TJ]$%_:QW5N\]O&L\19PHN"<.:R5)4XN^CGRR3J*/-S*T9)./
M-JUSIQOS$XC'PKRC6='G;QKQ-5<OO0H.K1G#"SK.@Z<^>K2J2A4]F^6$_82C
M4473/Q2D_:4\0K\/OVQ+:R_:"M_#FF?#_P#:C_8^M/A;KWAKXP6?Q*M].^&_
MQ5TK]F,^)]-T'XI^/=,N-5\9^$/$?B+Q#\2HX]3U"&6,ZE%XFT/1[PZ5HD]I
M#=A_:-UGP'^T!X_^!/C'XV^(9_V>--_;5T/P#XC^+7B3XA1P^(/!?A_QC^QE
MX,^+GA7X<:G\3=.N=)U/PEX;\9_M!WVJZ)H^NI?Z;=:?/ _PNLM6MH-9LK.R
M_;NH+JUM;V"2UO+:"[M9E"S6UU#'/!*H(8+)#*KQNH90P#*0" >H%3]7J:-5
MG=/M.S7--N#7M/A:DHNR3Y8JS3+6:8;WT\"G&<;:2H*4)^SP\%7A+ZLW[6+H
MSJ14I.FZE:?-&2O?\_/^":]UH<_P6^+MOX?\1)XITZQ_;._;6@MM;.N1>([O
M4[.3]IGXE76F:I?ZS'/<-J=SK&F3V>K?VG)*[:I%>QZDKRQW22/^A5,2..)2
ML:)&I>20JBJBF2:1I97(4 %Y97>21OO/([.Q+,27UT4X>SIQA>_*K72:OK)[
M-M_:MJWMYGFXNO\ 6<36Q"BX>UGS\K:DU[E*.LHQBFW[.^D8KWK)))!7S;^T
MY^SAHG[1?@O2;.'7]2^'?Q8^'?B"Q^(/P(^-?AF.$>-/@Y\4M"D2YT+Q9H,L
MHV7FGS30QZ?XK\,WA;2?%7AZ:[TJ_C5VM+RS^DJ*<X1J0E"<5*$TXRB]FG_5
MTUJFDTTTB</7K86M2Q&'J2I5Z,XU*52#M*,XNZ:Z-/52BTXRC*491E&4D^Q_
MX)S?MC^*/VGO 7CSX>_&_0])\%?M:_LS>)M/^&7[1G@[1IIY-#U35+O2(=5\
M'?&'P0+JPTZX/PW^,N@A_%/A1);5)--FCU?0I&G728KV[_1>OYOOVC?$.I_L
M<?'GX6_\%'?"%A?7/A?P586OP6_;1T#2+:6\N/$_[*WBC7(KF+XAIID$@>_\
M2?L\^-+BV\<64MO$+J7P5J/C>RO;I-,@3R/Z,-(U?2O$&DZ7KVA:C9:QHFMZ
M=9:OH^K:;<PWNG:II6I6T5YI^HZ?>6[R6]W97UI-#<VMS!(\,\$L<L3LCJQ^
M,QN&>%KSI:N#]ZG)_:IMNUWWCK&7FK]3]ZR+-H9SEM'&+EC67[K%4X[4\332
M]HDKMJ%1.-:E?_EW4Y;OV;9HT445R'L!1110 4444 %%%% !1110 5^+?_!1
M?]HGXG?$_P"*%C_P3B_9C\47?@7Q?XM\#Z=\0?VL_CQHEVL.N_ ;]G[Q!JUQ
MHUCX4^'US"TRV/QV^- T[6M+\+WE[ S>!_!\.I>-XK.>ZN-#OK']&/VM?VE_
M W['_P"SM\4_VB?B$LUYH?PX\-S:AI_AVRD9-9\<>+M0FATCP/\ #WPZL=M>
MRR^(_'GBZ_T;PIHBI9W*QZAJT-Q/%]EAG=/R _8R^#GCOX?>!/%/Q1^.=S#J
M_P"U#^TUXPO/CC^T7K,15[>Q\9>(K:"'0_AOH3$R26_@[X0^$8-'^'WAG3EN
MKJTMX]'OKRQD2#4O*3T,NPGUJO::?L:=IU.E]?=A?O)K7KRJ6UTSYOBC.O[&
MRYRHR2QN*<J.$32?([)U<0XO1JA!KENG%UITDTU&47[_ /";X4?#_P"!OPX\
M'_";X6>&=.\(> ? NBVNA>'-!TR(1P6MG;*3)/<2G,U_J>HW+SZCK&K7CS:A
MJ^JW5YJ>HW%S?7=Q/)Z)117UZ2BDDDDDDDE9))6226B2222/PV<YU)RJ5)2G
M.<I3G.<G*4YR;E*4I2;<I2DVVVVVVVV%%%%,D**\=_:#^-7A?]G/X)?$[XX^
M,EEF\/\ PS\(:MXGN;"W9DO-;O;6'RM%\-Z<RPW&W5/$VMSZ=X?TLM!)&-1U
M.V\U?+W$;'P;^*GA3XY?"CX=?&+P/=K>>$OB9X-\/^--"E\R.26*QU_3;?4%
MLKORB5BU'39)I-/U.V.)+34+6YM9526%T6>>//[/F7/R\_+UY>;EYK=N;0U]
MA6]@L3[.7L'6>'56WN>V5-5G3O\ S>S:G;MUOH>E445S?B7Q?X9\'1:--XFU
MFST=/$/B30_"&A"Z9_-U;Q-XCO%L=&T:P@B22>YO+R<NY6*-DMK."[U&[>WT
M^RN[F"FTM6[+N]/ZW7WF:3DU&*<F]DDVW9-NR2;>B;VV3>R;72445Y-\<_'W
MC3X7_"GQAX\^'GPG\0?''QEX=M+"XT3X5^%M7TO0M>\6RW6L:=I]W!8:KK(;
M3[5M,T^\N];N/-CFFGM-,GMK*WN+Z:V@D3:BG)WLDV[)MV2N[))MOR2;>R39
M5.$JDX4X<O-4G&$>:4(1YI-17-.I*$(*[5Y3G&,5K*22;7K-%>7?!'XHV7QN
M^#WPP^,&G:%K'ABP^)O@7PSXXM/#WB!;==9T:W\2Z3:ZK'IVH-:2S6DTULMR
M(Q=6DTEK=QJEU;.T$T9/J-":DE).ZDDT^Z:33UL]4T]D*<)4YSIS7+.G.=.<
M79N,X2E"<6TVFXRA)73:TT;5FRBBBF2%?%?[1OP:^)VB^/O"7[9?[)=S9Z)^
MUM\&-'N],AT+4+JXL_!G[2?PF=I[[Q#^SQ\4HHKRULY=-UR=SJ7@3Q3>)-=^
M _&T.FZU8RVJ>9=6GVI16=:C3KTY4JD>:$U9]T^DHOI*+U3[]TVGUX''8G+L
M51QF$J.G6HRNGO&<793I5(W2G2J1O"<7NFFG&482C]=?LE?M-^ ?VQ/V>OAI
M^T/\.([^PT+X@:*UQJ/AG6E2+Q+X$\7:5=W&B^-?A[XLM% -GXH\#^*K#5O#
M6MP;5C:]TY[FU,ME<6TTOT=7\^/[/?C4_L*?M]3^ [^;^S?V5_\ @H[XIN-1
M\.ACY6A_"S]NVPTI'O\ 34#%(+&Q_:F\'Z6]W%\]Q-??%/P6EK;6]J/$#O+_
M $'5\3B*$L/6J49[PE9/92B]8R7E*-GY.ZZ'[_EN/HYG@</CJ'P5Z:DX7NZ5
M6/NUJ,G_ #4JBE!W2YH\D[6F@HHHK$[@HHHH **** "BBB@ HHHH *_G7_:'
M\>ZM_P %.?V@?&?P9LKV2S_X)\_LI_$Z/PQ\28;&YN(Q^V1^T=X%N([S6_ N
MIO;W217O[/?P2\0"QM?$6F75L]A\1OB1ILD .K:!H<-Q:?>7_!4;]J'QK\$/
M@WX7^#/P'O3%^UA^U[XCO?@E\ '@\Y[GP0+C3#=_%#X\WD5M_I":%\"? T]U
MXPGNT#Q)XEF\(V%RAMM2E=/#O@'\$_!7[.7P<^'OP2^'MHUKX4^'GARST*RE
MF):^U6\4O=:UXBU:5GD:XUKQ+K5SJ&OZU<L[?:-4U*[E&%95'K95@UB*KJU(
MWI4FK)[3J;J+[J*]Z2V?NIZ-I_&<8Y[++,''!X6IR8[&J2YXOW\/A5>-2K%I
MWA4JR?L:,M'&U6I'WHQE'UN&&&WABM[>*."W@C2&""&-8H888E"1111(%2..
M-%5$C10J* J@  5)117U1^-!117P3_P4;U/XZ:1^SU:S_LU>/+WX=_&W5OBG
M\*O!W@37(HM.OM,N=2\:^-M(\.C1-=TK6[>\T6\TO6&O8[&>YN[1Y]+$IO;2
M1=D\-S%2?LX3GRN7)%OEC;FE:VBO97=U9-J[TN;X6@\3B*.'52%)UJD:?M:O
M-[.G?F?/4<5*2A%1;DU&344W9V:/O:BOSPMOVNM3^,?[$7@CXQ?"Q?\ A'?B
MW\;-!;P-H6DM8K=7/PU^+MM9:W9?%1[_ $C4Y +C_A1I\*?$+Q7?:7JDD9UF
MT\##3R7FU:U29W[)/[0TME^Q'^R-\3OB_P")?$_C[XH?'[PI\.K:TB46=[XK
M^(OQ2\;^'9M=ETG0=/:71?#FD0PZ7I.L:S=!I?#OA?0- T35=:U2ZLXH+^]E
MA5Z;DHIW3I*MS[1Y7*,8KOS/G3M;2]G[S2.F>6XF%*=2<4IPQLL"Z"NZKJTZ
M=:I4GI[BI05"HN=RM+E<D_9QE47Z&T5\3ZW^WG\'?#<UWI.O>&OBU8>,=&^-
MOA'X!>+/A_;^!6U[QEX.\;_$#3XM9\"7FLV'AG5=:L+[PIXRT.>#5_#'B+PM
MJ?B.UUR"1[+3DN-8M;[3+7J/#7[8_P *M=\&?%+Q;J^F^-? &H?!WXB:-\)O
M''@3Q]I&DZ)XUL_B'XKM?!UWX%\,V4%MK^I>'-0G\>K\0/!T7A6_M_$ATBXF
MUV!=2U#2TM=1DLZ]M2;M[2-TFWJU:R;=[I)-)-M7OH]-&9/ 8V,5)X:KRMQB
MGRQ=W.4(0<5&I*4HRE4@HS473?/%JI:2;^L**_-CXB?\%%M!TG48?!WPW^%7
MCGQI\2M&_:"^!7P9^(?@O^U_A-'?>#=/^--S'JWACQ"NI)\5!X3\00^.O#6G
M>)-,\%3Z)XJN[*P\4V%S%XWF\-V^DW<,_KMG\?/!-C\=OC_HBVOQZOO'OPU^
M!OPL\;^)_AC<P:;>^$!IFLWGCZ3PY#\,-(76?L%Y\1/$VJVVJ^%_$NHQ:I%X
M8U&XT#P_&NNI8V4FJ2S[>DW923M)1;U23<9RLFXVDTJ<KQ6JL^UG<LMQD(J5
M2C.'-3G4C'W)2<85,-3YI155.G3E+%4>2K->SDIQ:;4N:/V517Q ?V[?A]IG
MCWQ[\-_&OPU^+'P_\3?#;POX*\1>*AXAD^$.L:/I]_\ $_Q+:^$/A7X%N->\
M ?%SQKI&G?$/XF>(+N"W\(>$]:O-+O;C3G7Q'J;:7X9DBUF3U_X-?M)?#WXV
M^*/BIX#\.QZMHWCWX,:CX6LOB%X/UV7PU>:CI%MXYT:;7O!FMV^J>#?$?B[P
MMJNB^)=.L]2-A=:9X@NYH+O2=4T[4[:PU"QGMEI5:<FHJ<7)MQ2U3O&]U9I.
MZL]/)[V=LZF!Q=*$JD\/4C3C"%24_=E!4ZCBH3YH3FN23G!*2;2=2FFX^TAS
M_0%%%%:'*%?GOXO\0^)O^":OQH\2_MI?#&WN]1_94^)>L:9=?MX_ _2X;RYA
MT![B2ST<?M>_"G0K:Y2SL?''A>'["?C3I%A8E?B#X,M+KQ%>QMXET?\ MJ+]
M"*S=9T?2O$6CZKX?U[3K/6-#UW3;[1]9TG4;>.[T_5-*U.UELM1TZ^M9E>&Y
ML[VSGFMKJWE1HYH)7CD5E8@\^*PU/%494IK=-PEUA-)\LE\])+:46T^EO4R?
M-<1D^.I8R@VXIJ&(HWM#$8=RBZE*2VNTG*G.UZ=6,)I_&I_J3I&KZ5X@TG2]
M>T+4;+6-$UO3K+5]'U;3;F&]T[5-*U*VBO-/U'3[RW>2WN[*^M)H;FUN8)'A
MG@ECEB=D=6.C7XD_\$HOB=JOP5\2_$O_ ()B?$O5[V_U/]GS2(OB/^R5XCUJ
MZEN+WX@_L:^(]7;3O#OAU;RY9[C4_$'[.GB6;_A57B*:1H=WAV?P#<6EJ+5Y
M)C^VU?%5*<J4YTYJTX2<9+S3MIW3T:?5-/J?OV'Q%'%X>CB:$U.CB*4*U*:^
MU"<5)75W:2UC.+=XSA.+UCK^/G_!93QSJVJ?!3X._L=>$=6U/3/%7[=WQR\,
M?!#Q#+H,]S;:Y8_L]Z!;7?Q'_:8U:UN;62*6&RN/A;X8OO VJ,C[VMO'@B#6
MJ22:A9=-H6AZ/X8T31O#7A[3;/1?#_A[2M.T/0]'TZ!+73])T?2;2&PTS3;&
MVB"QV]G8V5O!:VL$:A(8(DC0!5 KYH^)NO1_M#_\%6?B1KJR1W_@?]@?X&:'
M\$/#)^UO=6:?'K]I%M)^*/Q<U33?) M8K[0?A9X>^$OA'5H3(\EM<ZM?VMP9
M;J%K?1_JROILFH^SPTJK7O5IMI]>2'NQ7HY<\ON9^3<>8]XC-*6!C)NG@*"Y
MHIZ?6<3:K4;6W-"BJ%.^Z4FM-4%%%%>N?#!1110 5^9W[=WA+XC_ +0%KJ?P
MN^$&B>,M3\3_  8T;2?C-X4\0>$-8\$Z78Z'^TUHNK67B7X!Z=XGN?$WC'PE
M=SZ+I5MH.NZGXTT/2[BZO8])\:^"M9DL)UETX3?IC7*:-X#\#>'-0\4ZOX>\
M&>%-!U7QSJ/]K^-M3T;P[H^EZAXPU;['#I_]J>*;VQLX+GQ!J/V"VM['[;JT
MMW<_8[>&V\WR8HT7.K#VD7"]HRTE;>UG9+HGS<KN]N56U.K!XE82LL0H\]6E
M9T5))TU-RBI.HKIN/LG4@HJZE[62E:+;7P%X=_:[U;]HC4?@+X6^&/BNU^#,
MWQS_ &6/B)\=M$\1Z]H^E:KJ4'Q,\$:YX,\)ZM\)I=*\40&RNA\,=<U[Q#-\
M7-&L[-/$\UOH]I'HVN>&+:UU/4KKD_C1^U=\2M/\%?M8S^&/B'X:\+^,?V4?
MV-/"/[0^FWFB:#HEYX<^,?C#Q3\/_B+XO74X],\9)K.KQ_"235/ NG^'-)M=
M"O=+\2'4=:U*WO/%<UU;Z=;5]I:K^R9^RUKGAK2O!>K_ +-_P)U#P?H?BJY\
M=:/X5N?A-X#?P[I?C.]F,^H>*K'1?[!&G6VOZE(SG5-5BMEO-3626._FN(Y9
M$;FOVHOV3/AE^TU\._B!X=U?PO\ #O3?B5XI^#_Q#^#WA#XQ^(/AMHWC?Q5\
M-='^(WA[4O#VIW?AUY[S0M81;*/5+C4+/3K+Q-I%O_:*I.T@#SI-A*GB.27[
MR+GRNW*YQYG[.2LEM%JIRSBT_>ORS:BM?1I8K*EB*/\ LU2GAU47-[2&&JNG
M%XNE-SE*SG7C+"^TH5J<E[G*JN&3JS:7QEXL_:P^-OA[PO\ M&ZBGBS3HM1^
M%?[4W["7@#P6M_X=\/!M7\"_M'Z7^RM)X_T6_A%A;C4(HKSXQ_$.3P[JVGI:
M:MIQ\/Z?#<:AJ"Z1JPOMFW^.OQ_UK5=9\.:!X[\(>$[G4/\ @H[X^_9KEUF/
MX<:5?2VWP^@^!VH>+]&FLK6;5(+:7Q-INN:;%=C5M:&M2ZK/Y%G>J=,C-A)]
MKC]EWX&:RFG:G\0OA'\)/B!XW7PWX$\/:_XSUOX:^'+G4/$0^'=Q8:CX7GN1
MJ\>NWR0Z-K6FVFK:-:W>JZE)I4]K9K%>2_8[=UZS_A0GP+^U17W_  I?X3?;
M8/&Q^)4%Y_PKGP?]JA^(S68TYO'\5Q_8_FQ^-FT\"Q/BI'&NFS MC?\ D )0
MJ-=ZNKI;;FG?5MN[6SL^71[16H/'9<E:."O*^LO9X9PO&$8+EC)IR@YP]JN>
M*=ZDDXJUG\4^$?C/^T?XQ^)FOZ#H/C[X-1V/P!_: ^'OP2^,FA^.]9;PGK?B
MWPGK7A;P-%JOC*#P1I/PW\0ZQH_CSXAZQXM?Q?\ !AK'XEZ1X!U.UDTOP3JF
MDW4T.J>*%_2ZO++[X'?!C4OBCI?QNU'X4?#N^^,6AZ7-HNC_ !1N_!V@7'C[
M3-+N(6MI+*R\5RV#:U;Q"TDGLHC'>*\%C=WUE T=I?WL,_J=;TX3AS<\N:\M
M'S2?NJ]M)+W79I-)M-QYKWDT>?BZ]&LZ3HT514:24TJ=.%ZCY7/WJ<FZD.=3
ME3E4C3G&-5TN5QIQ;****T.0**** ,S6]$TCQ+HNK^'/$&F6.M:#K^EW^B:W
MHVIVT5[INK:1JMI+8ZEIFH6<ZO!=V-_93S6MW;3(\4\$LD4BLCL#SW_!'3QA
MJ6@?!CXP_L<>*-5U'4O$O["_QN\1_!KPU-K=Q+>:U??L]^*K.S^)_P"S7JMW
M>222&ZM[/X9^*K;P#9R,5E3_ (5_/#,LC1"[NNTKY)^'6N2_L^?\%9/A+XC\
MV&R\!?MX? ?Q/\!/%2FZ-I:#XY?L[/JWQ;^$6L:@TQ6VFU'7?AOK?Q7\':3!
MN::ZGL;.VMC;W#+!J_D9S1]IAE52]ZC--OKR3]V2]%+DE^)]QP'CWA\UJ8*4
MK4L?0DHQ;T^LX9.K3:6W-*E[>G?=I):V2/W^HHHKY8_8 HHHH **** "BBB@
M HHIKLJ*SNRHB*6=W(55502S,Q("JH!))(  ))Q0!^%W[=^KP?M$?\%"?V:?
MV9Y7.I?#C]E'P!?_ +9WQ8TE+B[?2K_XO>)=;N/AS^R]I.M16LL,"ZCX572?
MBM\3+"PO6GWSV/A[4);>.W^SB_\ HNO@G]B'Q')\>-<_:K_;<O%DF3]K;]HK
MQ7?_  VU"::-VF_9S^!ZCX)_ J.*&+]W:VNHZ1X2U_QK''%F&YG\:76I12WB
MWW]HWOWM7V&5T?8X.FVK2JWJRTU][X$_2"5O\7F?A_&&/>.SS$Q4FZ6"Y<%2
M5[Q3I:UY)7LG/$3FI-;^R5]E8HHHKT#Y<**** /SR_:G\;W7B/XY_!_X0VOP
MD^(GQH\%?#F*'X_?&+PS\.](\&:RSZDT^M^&_P!GSP_XGM?''B_PEI,NA:AX
MMTGQY\2#'!<W&HVWB+X0^#V-NVG:A=D_+G_!)'QAJ/PH\1_M*_L">+?#GC3P
M))\#?'6I?%K]G_PI\1X]*M_%_P#PS5\7]<O]7T73YX]!U[Q/HER_@CQ1/=6>
MKW^FZR]I-=>*K&..UM;B*]M+7],_A+\!4^%'C7XM>.C\5OBA\0]4^,GB:S\5
M>([3X@#X9RV&DWVF>'= \)Z/8^&)/!GPU\%ZMINA:-X>\-V-CIVAW>JZEIT=
MQ=:SK4T$^OZWJNJW?E/C3]B3PMXQ_:T\'?ME1?&3XV^$?BEX)\$3?#73=&\)
MW/PDM_ VH^ ;N^U#5-0\*>(=+UOX1:[KVNZ;?:EJ5UJ!DO\ Q++J&G7PMKS1
M;W2[FRM)8>-TJOM85UK-5)*5.]-+V$ER-<^\FE&%2,=N?F6FY[U/&X+ZIB<M
MFVJ$L)3G1Q*AB9-YC1G]8A-X=VC3C4G6Q.$J54[_ %=47:27(OD_3/C#J'[%
M?[8O[1GP\^-OCWXH>,/A#\4_@C=?M&_LSWWC'QYXR\:R:0/A9:7EK\:?@+X8
MC\1:OJ#ZAXL6\O=&\6^$8[=6UFYT76-/T&;5-4OSI]M'XK^U#\!M1T?5/^"2
M%G\6?%WQ3\0_%'4?VHM(TCXAZL_QO^+I:UUGQ9\.?'?BOQ3I_AVYT_QK8II1
MT'6XH_#_ (8\4Z/#IWBBR\,:7;Z;;ZM#9WNHV]U]0:_XE^#'_!0'X[_![PWH
M/PZ\?7T7[&7[0GB/XC>/?''CKX;^,? 6G^&_%?P^T;6O"_A?P3X9U?Q)IFF6
MGBBX\<>--7T;Q==V6F-K%E!X3^'-Y)XEL-%U+6?!5[)]<?M*?LP>$OVF-/\
MADNN>+_'WP[\4?!WXH:#\7/ASX]^&NH>'K+Q1X;\6:'9ZEI9,</B[PUXP\+Z
MGIVI:3J^HV%_IVM^&]3M9DEC<Q'RF22/9.K"JH-5(*HG1]Z2NO;4JM6+E+1\
MDH3IP;NDGRW5M.E8R&$Q.!G7A/"XB>%G',&J=-N+6!QF!P=6-.DG)*O2Q%#%
MXB$>6<II5.67M$I?*_PTU7Q18_\ !3#]H+X'GQY\2-2^%5K^Q[\(_&&E^#M=
M^(_C?Q!9Z'XGU[QMXI\+ZQKF@ZAK6O7^M:/JM_I.C6*S:C8:G!>K=K-J$5Q'
M>SR3M>_X)H>(?$GQN_8WOO\ A;OB;Q-\1+B^^,'[1/@R^U'Q7XBUK5M8O_"O
MAWXQ^,?#VCZ%?:U<7S:O>:?::%8VNCM#<WLHNM-C:SO#<6\TT<GK7C+]BG0M
M?^.?ACX_>$OC3\;?A;XQL/A/H_P/\?+X-U[PS>CXM?#7P_K-SKVD:;XQU;QI
MX4\5:_9>)(-1O;\2_$'PKJF@^/1:WTXT_P 1:=?+;ZA!VW[*'[*O@_\ 9#^'
MNJ_#;P+XP^(?BS0-5\8^*O&P'Q URRUN;2M4\8:_J?B+5[;1GL]*TU[>PEO]
M4F=A>R:C?W4B"[OK^ZO9;BXFTA3JJJN:/[M2Q-W[1-.-7V4J:Y;WM&TXV>VK
MC[LCEQ.+P4\%)4JG^U2I90DEAI0E&K@HXVGBINLDHJ5;VF'JJ4&W444JC]K2
M3.$_;=F^-7A/X->"KS]G;P9J'C)_"7Q0\"7_ (X^$?@/Q?/\,O'7CWX->'K/
M6+GQ)X*^%7B'1[W1KO3/$UF]IH6NV^CZ5J&GR:[X8\.:]X8C\ZWU22PN<3]@
M7XU?"?XV>$OC#K_PO\:_&74GB^+]RWBSX2_M!WWC:X^+/[._B#_A!?!.B:G\
M+=9L_B%KWB7Q'I^DRZYX=USQEIT$.LW_ (?MM5\4>(=)T::+^R;RQLOH?XV_
M!4_&2'X;7%E\2?B#\*_$?PG^)5I\4_"7B3X>3>%OM-UKEKX,\;> YM \4Z;X
MP\+^*])U[P5K.@>/M<MM=T1+/3=1NV%G+8:[I5Q;K.8/A#\ _#?PF\2_%;Q^
MFK:KXL^)GQNU[P[X@^)OCC6;?1].N=<E\'^&;+P?X1TNRT7PYIND:'I6C>&_
M#]BMI81Q6,VJW<UU>WNMZOJUY.)X[Y*GUA37\.R33::T@TG"S4HOFM&491E"
M2]].,E9\RQ&%>5RP\[_6N=SA*G&:E)O$PFX8ESC.E5A[)2J4J]*I2Q%*=\-.
M%>C4<H>ZT445T'EA1110!\W?M<_ JU_:/_9V^)_PI5IK/Q+JWAZ?5_AOX@LK
MK^S]7\'?%?PNR^(OAEXRT/54FMI]*U7PWXUTW1M2AO;>\LW,,5Q:2W,=K=7&
M[]%_V /VCV_:V_8S_9V_:!O$,'B3QY\.-)7X@6#+'')H_P 4_"LESX,^*VAR
M0QI$('T7XC>'O$^E^2]O:S1K:J)K2UDW6\?SS7B__!+?6HO@_P#M!_MV_L97
M0BLM+M?B-HO[9OP6M3:R6:W/PX_:6AN[7XD:7I$2%K-=)\%?'3P5XP'EP"-8
M1XTLHX?W/^@:5X.=T;PI8A+6+=*;\I>]"_I)22];'Z1X?8]JKCLLG)VJ0CC:
M$6]%.G:EB%%=.:G*C4=M^1M[7/VPHHHKYT_4 HHHH **** "BBB@ HHKYO\
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M-T#Q1I%YH>L6G[V.:+_2-.OKF']Y%+'\_P \;KE3UW_!'?XJ^)OB%^PO\/?
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M>+%T,)3J484W*BJDI.HYU/;JC2C5J4X34Z::JJM24*\6H0::E#DC&2<?F?\
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M?7&N7FE7L]MI$?!>'/V)OB?\)A\(==^ _P ?M/\ #'C'X;Z1\3?A_JMM\3/
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M>'?#G]C3QM\(K;]ES6?!'Q>\/3^/OV=/V<;?]E;6=2UGX<ZNO@WXI?"ZSLO
M\6CWFH^%+;XDRW_AGQ;X<UOP)IGB6RU/3_$FH0Z@M[XA\,RPZ?8ZY%J6CU+V
MSE3E9V5-<Z3CI-U%S.W-%2:A>R?NO7:22,Z?]GJGBJ;G3;>)G["<XUDYT(8:
M<J47)TZDJ-.IB5%3G']]%\NKI2E(](O/VU?@[+I?PEU?P;I_Q)^*5O\ &_P)
MXB^(OPWB^&WP]UW7[K6O#WA&Z\-VOB6&X@N8],.D>(-$/B:U?4O#6K-9Z[:2
M6.I:=/8IK$-OIMU]<5\:?#S]DJ7X7Z_^S3=^%/'MDGASX!^"OB]X:UO1M3\&
M7-YJ_P 0=:^,^K>&_$OBKQ+;Z_#XSL[/P>/^$HT"?5X-'7P[XDA2+59M.BO(
M(+:!Z^RZUI^U:?M;)^[9)*WP1<FFI-OWW):VLDK7W?)BU@XR@L&YRA^]<IU)
M2<W^_K1I1E!TX1@U0C1F^1R4G-W<7>$"OSW_ ."ID$>J_L/?%GP:8WN;GXG>
M(/@M\)+'3X SWNIW/Q3^.?PV\!M8V$$1^UW-RUIKUU.8M/274$MK>XN+.)YH
M%%?H17PU^VE';>(?%7[!?PP>6*:?XC_\%%OV4_.T5O*FDUCP_P###Q;>_&KQ
M/'-8R BYTJWTOX<L=4ED>&"V6:WS)-=S66G7^6,ER83$R[4:B^<H\J_]*.O(
M:7ML[RJG9N^/PTG97=J=1UF_DJ-V^B5[H_;?_AEO]F7_ *-T^!/_ (:+X?\
M_P SU'_#+?[,O_1NGP)_\-%\/_\ YGJ]VHKX@_H.[[O[W_F>$_\ #+?[,O\
MT;I\"?\ PT7P_P#_ )GJ/^&6_P!F7_HW3X$_^&B^'_\ \SU>[44!=]W][_S/
M"?\ AEO]F7_HW3X$_P#AHOA__P#,]1_PRW^S+_T;I\"?_#1?#_\ ^9ZO=J*
MN^[^]_YGA/\ PRW^S+_T;I\"?_#1?#__ .9ZC_AEO]F7_HW3X$_^&B^'_P#\
MSU>[44!=]W][_P SPG_AEO\ 9E_Z-T^!/_AHOA__ /,]7YX?\%:?V5O@J/\
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M6*6"6PEUG1_"?BU[&XN_MMM?1^']4M[6TBGMI[R+S\TERX&M_>Y(?^!5(_\
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M'X]17Q.C_P!A0P:?/9ZYHFI:IH&JZ-K=]G>&?VL/@%\"/@?^PS:^"_A3\5M
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M4C?%'Q!IQ^(?CC2+L03'X=^$[%K25CKH\O\ HX55151%5$10J(H"JJJ %55
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M2I5:4Y4ZE.<7&<)P;C*,HO5--6^YIM--E%%%,S"BBB@ HHHH **** "BBB@
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M\1!"UH][XH\5VNGZOIT.I^&"[?L)355454151$4*B* JJJ@!550 %50
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M94,31JX>M!VE2K4Y4YKL[22O%V]V47*$EK&<EJ%%%%48A1110 4444 %%%%
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M5=7&].7X<T']R/C,;P!EM:\L%B<3@I/:$^7%T?3W_95XKTJ3MYGE5%<=<?\
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M,8Q2LHQC%1C&*6B48Q26B2"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K\-/^#@?_ ),L^%'_ &>_^R/_ .K)CK]RZ_#3_@X'_P"3
M+/A1_P!GO_LC_P#JR8Z"H?%'U_S/W+HHHH)"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
M#3_@X'_Y,L^%'_9[_P"R/_ZLF.OW+K\-/^#@?_DRSX4?]GO_ +(__JR8Z"H?
M%'U_S/W+HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_#3_@X'_P"3+/A1_P!GO_LC
M_P#JR8Z_<NOPT_X.!_\ DRSX4?\ 9[_[(_\ ZLF.@J'Q1]?\S]RZ***"0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OPT_X.!_^3+/A1_V>_\ LC_^K)CK]RZ_#3_@X'_Y
M,L^%'_9[_P"R/_ZLF.@J'Q1]?\S]RZ***"0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?F+_P41_;4\:?
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M;WXE:+I-UH.C?$.[\*:%<^.=)T.]<27NC:9XMFL'U^PTF[D >ZTZUU"*SN'
M:6%V -8SISE4C44DG#1*S:Y)1:J7_O.7)*/V?<5]V=]#%4:>%K8:I1E4C72J
M3DI1C)5Z-2$L,XN^E.-/ZQ3JMKVC6)FZ:?+$_(NRU[XL_&SXQ_L*?%GP]\7;
M.+QY\<OV#_VNOB'X$N;7PWX4OO!'PR\9^*A^R%XDL]*TF :,-3\1^#].U#5=
M)\/ZM:^++W5/$MQ8Z)J$\.LZ1JVI?\2SWOP?^U1XN\8?LU?$3X]S>/M&^';_
M  R^ W_"*>,CX]\+0ZSX<\%?M9:)'JMK\2++Q/I/A.UM?$^L)\//$\7A_P -
MS^'_  M?"TUZ[U>^TFQM(M=TYT7[%\(_LV_L^> /$=KXP\#_  0^%/A+Q583
M^)[G3O$?AWP#X8TC6M-F\:75K?>+FTS4K'3(;O35\2WUE;WNM1V,MO'J-VLE
MS=))-/.\O=7/P]\!WWACQ#X)O_!?A74/!OBZ;Q+/XK\)ZAH&E7_AOQ-+XRU"
M^U7Q:_B#1+NUFTW6/^$FU+4]1O==74+:X75+F^NI+U9FFDW9PH58\S=17DI.
M5G4:<O9PC&5VTT^>,I2M]F48KX$==?,,'5=**PLG3I2I*#E##1G&BL5B:M:B
MHQC*G*+H5:5*DY.RJTZE6=U7FC\P]*_:/_:*U/XH>(?A-!XM_P"$;7P]^VCX
M$^!2ZCX^\%> ]>^(+^ O'G[&6G?':6+6AX U?3? "Z]HGC>\FDLK[1;&6(Z-
M)INE:M'-=VNH/?1?!O\ :D^-?Q3\4P_L[:U\2=#\%_$+3A^W)IND_&6?PGX;
M@;XE>(?V7_VCYO@MX/AB\):DD_AN&.V\,36_C7XMZ%X>MTU6]MQ:7/AC5/!>
MF_;WK]!+#]FC]G#2KW2M2TO]G_X):;J.A:EH^LZ)J%A\*? EG>Z/J_AW3;W1
MO#^JZ5=6^@QSZ?J6A:/J.H:5H]]:20W6F:;?WMC92P6MU/$]+Q!^RO\ LR>*
MM$L_#/B3]GCX(:YX<L/&5_\ $2RT'4_A9X(N]'MO'NK73WNK^,XM-FT-K-?$
M^LW4LTVM:V(?[0UAIIQJ5Q=+/*KKV-=._MD]7=.51*47M&ZUBU?24?>T71LI
MX_+6G'ZC*-X0Y:D:6$<Z=:*M*MRR?+54K:T:C5-\\]%*-.1\>>-/V@_VAO$W
MC+QE\/\ X3^./@#H'C+X1_!3X&_&.[OO'OB74_"/@+XFZ=XS77M2\;^+FTQ_
MAS\1_%LWP9GMO#UUX;TG4O"OB+PSXB\&:\D]YKVL^(X[O3](C_3VO*_&GP,^
M"_Q&\4^"?&_C_P"$_P .O&OC'X;7JZC\/_%'BGP;X?UW7_!M[&_FQ7'AS5=3
ML+F]TEX+D1WUM]CFB6VU&"UU* 1W]I:W$/JE;4X3BYN<N:[7+K)V2_NM6BU>
MS<6^9)2=G<\_$UJ%6%"-&BJ+A!^U]RFG*H])-5(2<ZD)-*I&-2$'2E*=.#E3
MY6BBBBM3C"O@#XAQ_$+]@KXV:[^W7^SMX;U/Q;\,?%PTY?V[/V;?#%NC7/Q%
M\(Z;-''_ ,-&?"K1H8X+8_'KX8Z5-?WWB"PFGMK;XJ^#;>\TF]NK+Q%:6&JS
M_?\ 16&)P]/$TI4JBT>L9+XH26TH^:ZK:2O%Z/3T<JS3$Y1C*>,PLO>C[M6E
M)OV>(HMKGHU$OLR2O&27-3J*-2#4HM3_ $/^&/Q+\"_&7X=^"?BQ\,O$FG>,
M/A[\1?#&C>,?!OB?2I&DL-;\.Z_8PZCIE]")%CFA:6VG03VEU%!>65PLMI>0
M074$T*=S7X-?\$Z_&Q_8_P#VGO'?_!._Q#-)9_!GXQ?\)I^T?^PM=7#70TW0
MUEO'UK]HG]F727G86< \!Z[>R?%_P1HFFQMY'@KQ?XD:\G+Z5&A_>6OBJU*=
M"K.E-6E"3B^S[->4E:2\GZG[]@L71Q^%P^,P\N:CB*4:L+VO'F7O0G;13IS4
MZ<UTG!]'&Y11169TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AS_P5,UR
M7]H7X_?LO_\ !/"&_P!WPY\4Z;KO[6G[6.B0C#^)O@U\'O%/AS1_A1\-=7+2
M+'+X6^)_QJOH;GQ%9JBW=[I7PWO+:"5;5]04^^JJHJHBA54!550%5548"J!@
M        8%?#?[/.L'X^_M9?MY_MC3RF_P!#\4_&&#]EKX)W3XN+2/X.?LH1
MWW@G6-5\.7>YPVB^./C;J'Q1U^0P,8;N2SL[@858HXON6OK<IH*EA(S:M.LW
M4D^O+JJ:]%%-I?WKGXKQKF$L9G57#QFW0R^$<+"-_=59I5,5)+;F=24*;>]J
M/+LK!1117IGR(5Y1\>+V^TOX(_&#5=+O[_2]4TCX8^.]8TO4]+O;K3M0T_4]
M)\,:GJ.GWMI>V4T%S!-;7EM#,ICE4/L,<@>)W1O5ZY3QYX1L_'_@GQ;X%U'4
M-4TK3O&/AS6?#&HZCHK:>FK6NGZ[I\^F7TFG/JNG:MIT=W]DN9EADN]-O(HW
M8/Y#,JX4DW&26[C)+IJXM+7IJUKT-*4HQJTI2^&-6G*6G-[L:E.4O=^U[L9:
M==NI^7OP9_:/^,EG^S#\0_@YXR\27NL_M=?"SQ$_P<TOQIJ^EBZN/%VD>.?"
MVI?$CX0_'^ZLK:VMM,OK>S^!\>I>,/%-FUY##J7C#X7^-] >]@OKBV5Z/[/W
M[2]_H_[.O_!.[QE\3/\ A:GQ$\=_%3X#?$+XDZSXGM?B%JEM9:UKOA3X%:A\
M0O%">+/"YU'['XUO-:AL9(?"^G:C8)HWA?5IXM4TEK*XA6!_N#_ADWX6?\)P
M?B@KZ^GQ,?X%I^SY/XZ2;0EU:Z\$V]W-=V.IW6G#P_\ \(O/XOTW[9J=EINO
MOX?)L]+UC5]*AM%T_4+BV;E?AW^Q5\/_ (::3^RIHFC>._BAJ6G_ +(.B^(?
M#WPVCUR[\ 7#:[H_B3P=/X%N[/QV^G_#S33J@M?#TY@LIM!'AJX%PB7-Y+>.
M9/,XU2Q"<;R348*FFY7T5:G)2DG\4_9\R<M6W"*O[[/<GC,KG"K:DX2JXB6)
MG&-%P]^> Q-*5&E.FFZ>&^M.E.%.T5%8BI)P2P\$?,'@OQ/\4OB%_P $ZE_;
M,?XH>,]+^/\ K7P(\0_M+:+=6GB+7X/AIH6J6F@ZG\0M ^&C_">'55\"ZK\/
M++2;2T\ :G)J>B7?C#5]&:\\22^)8?&\UOX@M.3^,_[27C;X,Z7^R[^W9%X@
M\0R_!SX\_"OP[HGQ7^!'B?Q=XC3P_P##C7_BIX0TGQMX1^.>F6/GW=WHOAOX
M;WQ?P]\:EBM=6M?#W@"_D\6^'?#)\1:3>'5?LV/]C/P3;?#35?@'I_C;QYIW
M[.&M?VW9WWP3M9_#JZ/'X5\1ZE=:EKOPRTWQ8V@-XYT[X6ZHVH:E9S>&(?$#
M:E8Z+?2>%=#\1:1X-@L_#=MZ7'^S]X7GUOXAZGX@U[Q#XOTCQ[X /PLLO!'B
M/3?A]+X(^'GP[GBOX=6\(^ =$TOP+I3VNC^(TO+1/$\'B>\\5-X@@T#PQ9ZI
M)<V/A[2[6W?L:SC%)N,E3IQ<N>_[Z#<G6M?WE)7@XNW,JEY17LXL7U[ 1JU)
M2IJK1GBL3-4?8*#67UX1IPP,9<EJ52C)QQ$*L7*-&>%2IU)/%U4_G[XZZ#\;
M/A?\"/A=<?"\?%']H5?#7Q)T'Q3\?=+\)_$+4=&^+GQ.^%LWACQ8WB-/A3K]
MYKL5]I][IGC:Z\"^*=(\$>'_ !1HMQXB\'^'=5\#VFNO=^(;N\U'R311KO[2
MW[+_ ,3?%W[(7[0WQ:N?'.@_%2Z\4?#C0?'_ (I\7^&_%O@_Q'X/\/\ @HZ]
M^RM\;['Q9#:^*])TK5]2TS6-.N9O$9N?$FC:?XQTKQE8^)]825M3UKZ;^'G[
M)@^%_P (/@Y\(?#/Q_\ CQ?VWP)UV+5? /C+Q;?_  R\0^+_ .Q[3P;XJ\"Z
M9X%\32K\,=.T+Q)X*TW0O%EU;VEM>Z$GB.V&FZ*UEXFM)M*LIX/4?A5\$]$^
M%<OQ,UFSUW7-?\;_ !C\7Q>//B-XVU:+0;;4=8\36O@WPSX"TR73])T;1M-\
M.Z1I>A>%O"&@:5I&FPZ5.SK9/J&O7FO:YJ&K:MJ%>RG*2NG&$J?+./M+N#]G
M9.G.,E*ZEOS)Q;2JIJ7-"6/US#TJ4E3G"M7I8MU:-5X9PCB*;Q3FXXO#U:<J
M:A*CK#V4Z=2G&4\'.%2FJ5>EXI^S)\4#^UA#X9_::T5_'7@[X;KX0N/!OA_X
M>ZGKNKV$6H?$'3]7FL/BEJ/B[0HI(+#5+CX;^*]*U7X5:#>3((=1UC1_'6MS
M6NIZ8_@/5K3Y?_9H^*OBO_A;GP=^#/[1VM_&[X.?M9Z$?%NH>._#?C/Q;XD\
M1? ;]K6TMO!OBJWUCQ7\#-6DEO\ X>K::7K-_IGQ L/AQX9A\#^(? ^B6M]H
M^K>&M:LO"T&J:=]^?LW?L_\ AK]F+X4Z9\(/!WB;QEXJ\.:1X@\=>)++4?'4
M_AFZUY;[XA^.?$?Q$\1127/A3PMX1TV2T/B7Q5K$UC&=*\ZUM)8;0SRQP(:X
MGPW^RII>G7GP.;QA\4/B)\3M*_9QN[;5_A/IGC&#P)!/8>)+;P#XA^&=MXC\
M3ZWX6\&>'=7\5:CIGA#Q3KFFZ3'<W-I9--J$FL>(K7Q+XAM-)UG33V=6U%O6
MHK.JN9<C;E#FV::LHW@X76\)0<9R:/K6!4\?"*MAI<\,$U3G]8A3A3Q"H7<X
M3A4C.=51Q%/$<LW>.(I5Z=7#PA/ZMHHHKJ/&"BBB@#XV_;F^$?B;XC?!*X\;
M?"R9M+_:'_9UUJR_:(_9P\16]HEW>:?\7/A?%<:[H^@R6[8%_H/Q!L8=0\ >
M)]'G+66I:-XCG%Q!*]O;[/V@_9E^.?AW]IK]G?X)?M"^$Q%'H/QF^%_@KXC6
M5G%<"Z_LF3Q3H%CJM_H-Q-M0M?>']1N+O1-11XXY(K_3[F&6..2-D'Q17D__
M  1]\1)\.Q^V#^PU=R^4/V5OV@M2\8_"W3]I2"U_9W_:E2]^-/P[L;!Y LEU
M;^&/&NH?%3P8[H'ALT\/V=D'78L:_/YW02]EB(K5WI3:ZV7-3;^7-&_:R['Z
M=X?9A*4<;E=23:ARXW#1;^&,FJ6)C&^RYO856EI=RE97;?[04445\^?I0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>/_M"^.+CX8_ +XX_$JTG%K=?#WX/_$OQ
MQ;73)-(MM<>$_!>MZ]#.T=N#<2"&33UD*0 S,%VQ N5%>P5^;W_!8+Q;-X,_
MX)>_MUZE;"1[G6?V;OB-X!M888X9I[JZ^*.D/\-+:RMX9B!-<7T_BV.SMXH
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M>#_AQXAU72KOQY:7A\/>+=2TF:\LM?TR+4M&T_0Y[;6]>OM)TYIIH? ?B/\
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M=_9F^,<7[2/C_P (_LFZ/):^)/"O[./@OPMXB^%7[+OQJ\ ZWXKG\+ZUX?\
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MP_:<\*:I=ZY\,-8\ O\ $'1IX+-K36]4L?L<DT.@V^D:@]K,GBRYU&,^'(-
MF>.[D\2,FCKNN70-\B? /0OVBO@??_MNW,/[.7BS7M9^,7[6GQ"^,/PCNIO'
M7P7LO".J^'O$7PN^$OA+P]?>*[V/XH7'BCP]8KK_ (+U5]:M[?PIJ>NVNDB*
MXL-)O[N=+,7?A!^R[\0_A!\%?V7/V38[[Q3<^&O T^J_$[XL?&[P7<> ;;2%
M^(=CXQU+XF:1X1TCPYXZO]8\2-IEW\5O$H\6Z5J'_"%:YI]EH?@/3-%U18)_
M$$@TV83K:74I7A-/FA;EJ>VE"E9\L;IT_>DG>*45)R7/8VKX; )R494::A7P
MS@Z>(51U<+_9]*OC'-*K5M.&*O2HN+A4E.M.E&C/ZNI+[*^ WQB\-_M _!KX
M:_&GPG%<VFA_$?PEI/B:#3+X,NI:%>7D 76/#6K(T<)36/#.LQ:AX?UB,1(L
M>IZ;=HHVJ"?6Z^%OV3/A?\4/@)\1?VD/A1J7ASQ-J/P%U?XCR?&3X*_$O6M1
M^&2*^K?%&UCUOXR> W\,^#=7TW4=&LK+XH_V]XV\.RQ_#KPYH\EOXVU735*G
M2+22_P#NFMJ4I2A%S34U>,U:WO1;BVO[LFN:+5U:2LW8\W&4Z5+$U8T)J="3
M52@U)3:HUHQJTX3:;:J4E-T:L96FIT6Y13E8****T.8*^-_C+9-XP_;F_P""
M5?PX8$V<O[3/Q7^+]XZ'YX/^%+_LM?&74M.GD%NT%^MK)K'B73M/DD2Z733<
MZA9P:I:7Z7%O;U]D5\L>%;5?&G_!7C]D+05\QO\ A3?[)'[8/QFGC$BK#YGC
M'Q7^S_\ !W3[N2*=3%+-;1:SK%K;/9$:C;QZG>"1TT^XNDGX,SERX&O_ 'E"
M'_@52'^1]+PA2=7B++K*_LY5ZS\O986NT_OFK>;/WOHHHKXX_<PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *BN+>"[@GM;J"&YMKF&2WN;:XC2:"X@F1HYH)X9%
M:.6&6-FCDCD5D=&964J2*EHH _F\_8,L)_A%9?M%_L6:J+F#4?V*_P!HGQ[\
M+O"5MJ"N-0NO@'XUN5^+7[.NM3LP"R03_#'QKIOA^VD55)_X1>49N$$=_>??
M=?-7[8>@6_[._P#P4U^#7QK,46E_#_\ ;F^#MU^SAXVU+?-;Z>G[0WP*O=2\
M?_!*XU:XDC:T.L>./AGXD^)G@_0;03I)?2>#+:&W2&X1DU7Z5K['+*WML'2N
M[RIWI2[^Y\+?K!Q^X_#>+L!]1SS%\L>6EBW'&TM+1?M[NLEI;W,1&JFEMSJ]
MKH****[SYD*\B^._QF\/?L^_"OQ5\7O%NC^)-<\->#H;&ZUFR\)P:-=:XMK?
MZG9Z4EQ;6VNZYX>L9TANKZW,\?\ :23^46>&&9E*5RW[6<'Q:N?V:?C=!\"A
MJ+_%M_AWXB/@B#1;W^S=?O-42S:2;3_#6IB:V.F>*=1T];RP\,:FMU9OIVOW
M&FWJ7EF\"W,7Y_?&?2O"'Q(_8Q_:IUS]GGX._M"Z.GQ+T/X;0K\.?$/PG^+G
MA74YO&N@:OI5KK]AX.^"/B/PY:>(M/U73M.L[/\ X3WQ;X9\/W'ACQGKD#W4
M/B#Q!J6BZQ?)A5JN'/&*]Y4ISBVF[M*=E%*+4FG%<RNG:4;7N>E@<'3KNA4J
MS_<RQM'#5(QE&+C&<Z/,ZDW5A*C&<*D_95%"I%RHU%)PY4?L/17X\Z[9^(]<
M_:6\?P_$73/VNX?B?X2^,^C?%C]GV\^$G@'3;7X??$'X*6'@[PI$_@A_C/JG
MPQU.U\!>&OL[>)/#'Q@^%7C#XC> F\1>(KDZOX7L+WQKXGT?4&\0\!:-\27\
M#_M*6=E\,_V@_#/AOQW_ ,$R_A_IWAOPW#\)/VA/#7B<?'WPR_Q[M/$>B:]K
M6IZ+9>*?B)^T#!%XA^'5AXM^)T&GZ+KOQAN'@UW3M(N=&TZ\-A#Q-FU[-O62
MW=_=4_B7L_==X)6N]*D)*Z>O1'*%*$9/%03<*$W>$.5JM+#)>SD\4G52AB)2
MNH02GAL13GRRA:/[P:YH6B>)]'U+P]XET;2O$/A_6K.?3M8T/7-.M-6T?5M/
MND,5S8ZEIE_#<65]9W$;-'/:W4$L$R$I(C*2*Y7P#\)_A9\*;2\L/A=\-/ '
MPVL=1^R?VA9> ?!OAWP=:7WV!9TL?MEMX=TW3H;G[$ES<I:>>C_9UN)UAV"6
M0-^/7[4'PTO],^$;^$?A#\&?C=+XI\<_L<_M&^+_  ]XG?P9\;OB-;1?M#^*
M/!OPYL=$TR7P[")KCX3_ +0FHZIX8L=4\)?%GQO=^&U\(>3XQTS0--U?7O''
MB&?3\[QYX8\8:[IOQJ^)NB> ?VD[GXF:)^U#^P-XU^&6I7GP^_:(CU:VTAG_
M &9+/XY:OX6T'5-$2VET%/"]I\4]-^(MM9Z5)I=E8+X@T7Q!:VTCM8F98BTM
M:-Y1C?F5VTK<SC&3HWO9Z)-)O37I=/*^>DN7'N%*K4473ERQBY<[IPJ5*4<=
MR**E%ISG&4X15TEIS?NK17Y0_ )?%OB+6M=T_P 4^!_C+X?_ &T_AUX@_:9@
MUGXB:[X2^(7A[X0>*= \9ZYXRN/A+XBO?B!>Z8GPT^*_PX&D-\/+'X=_#NTU
MK5O$?PZETZ]CM_!_AZS\-:[+6M^P1H\&I:]:^.+^#]K+PO\ %/3_ (-Z3\._
MV@? WQE\":=X&^'D7Q.TG4= OO[;N-;B^&7A.'XV_$:29O$QT/XL>&O&WQ!%
MUX#U.7_A.M46_P!;\'I'I&OS."4+<[>[:M;1IIP7OQ?Q0NK+529RU<M5*GB)
MNNG]7C#2,(R51U%S4YQ<,1*V&JQTI5W%WG:%2C3;1^I%%?CKXY?X@W'[7W@_
MQ1H'PN^-.A)X9_;CTB#QOKY^&?Q7\4-XB^#6I?LD^*O!$'B/1?BII^FR>!K+
MX!ZC\0;GPE;3_"31)-8L?"OCZ#5_BAXTO]!O]6U"UT?@IO _Q)T36OA+X\^%
MG@;XV6_Q7LO^"@7[5^B_V[XL\(?'BYTRT^"7BSP;^TX_A23Q>OB73)[*#X,:
MSXYOOA#?66MWD*>'9;M="U32;\3V(NK>7B6FU[.3Y9-.W-=I<NL5[/5^\U:Z
M5T];:FT<IBXTV\73@ZE&-1)JGRQG)56H5)+$M0A:DGSI3ERU(MT[IP/UHUWX
MS^'O#OQO^'GP'U'1?$P\2_$[P)\1/'_A;Q!!!HDOA*33OA=J7@K3/%^E7UP=
M>7Q#9ZU:/\0O"ES:(?#<FE7UMJ,GV?5FN;&^MK?U^OQ7_9IT^36?V@/V$/&K
M_"CXN>'?B'HO[+/[2?@S]J#Q1XV^$GQ(T.^3XYWEY^S)/J?_  GWCC5_"]GX
M:U_6O$7B?0_B)J6C^)[/6+W2_$.FI;3Z+?RZ-<:!!7[45I1J.HIR:LN>T59Z
M1=.G*S;4;M.4HMVT:<?LG+F&%IX2I1I0;E)T&ZLG*+4JL<3BZ+E%1J5%&$X4
M:52FN=WA4A4T]I8****V. *\._X)I: ?C!^U]^WC^UU<M)=>'_!VM^$/V$_@
M_.\P*1Z7\%87\>?'B^M(HAY$EKJOQC\=1>'?M(DFE^U?#NZ@EE22-K*RK_M0
M?&_2?V;_ -GWXM_&W5PDX^'_ (+U?5M%TMD>67Q%XOGB&G>"?"=E;QO'+=:E
MXM\7WNB>&]-M8W1[B^U2WB#Q[MZ_<7_!-W]GS5?V7_V(/V=/A!XH64_$'3_
M-MXO^+-Q=0^3>WOQC^)U]>_$KXLW-\2D4LLX^(/BSQ#;I)-%#(+6"WB%O:QQ
M1VL/A9W6M3I4$]9R=6:_NP]V%_63;_[=/T;P^P#E7QN93C[M&G'!T9-:.I6M
M5KN+MO&C"E!VV]I9VN?;]%%%?.'ZD%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2LZU>=I5JSZWJ5+M)W<:<:</LL****P/0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *:ZJZLCJKHZE71P&5E8$,K*00RL"000002",4ZB@#^<;XV_"._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>v434644_img-testnasal.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v434644_img-testnasal.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 1H!QP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M/0X& ,G.<=/3G/UJEWU3[+Y636]WOYZV%W_KK_7R(B)W4!B W/'H!CMDCO\
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M;1W=W:[?3R[_ '=0NGOZ)=EW_KS*Y2,_=C&>OW1_]?VIK1HY&X=".>XJT5D
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M4*]GMOY]+?=;S'KIWZ=+7O=695VD-NV\]!CH!WX'/<?YS3]GRG@<L"2!T/3
M]/3G..]6&B;@84<$GG.?H>^,'/H:<B$ C:3U(V\]<?0'WQ]:>]M?-\NOIO\
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M<@+;3G[-93%UV3A<UX#9V^A)>1^%]48?"'_A(Y+^SUGX4^/2^L_#OQ/-;.%
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MK9C1_&-G=QIA4T_4MD5Y<3H 9/-EE:V8J5#$$"O,I!XR\*6Z7>DZKJ/B3P_
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M94Q,W)W;DM=FU:]NFWEYVU[GK4L#3;BX>XU:]TK.R>[>KNWS/M?2U['U_/\
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M$37]'\'> ?#VH:[X@U2=(+*QTZWDN;F5W<(TL@C5C#&N07D;:J)SD 5_4_\
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M%(_G[,\?B,VQM;'8N?-5JR;44WR4J:NJ=&FFVXPIQM%*]WK*5Y2;$ P /3V
M_04M%%;G#RKL@HP!T&*** LNR^X*#T./2BB@.5=D&!Z"BBB@.5=4G\E^@4$
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MNQO[O;?,]K-O82;R6A(E9=VPX*D8SD+SG/->;:W\5%MH%>1KA60",')='(&
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M9Z1<^*=:C\/>'H;MI%;5M;EMI[Q--M2D3AKEK6UN)5#[(RL3?/G /X$?#_\
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M*UM7[DG=QDT>N44U.G;J>F0#] <X%.KK/&"BBB@ JJ8R6?'F<, >?E9<9PH
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M[72=KI.R32=G973LK4C$_50RM@9/.2"<MN!.') *A>B;B1FG!'P>&'S8QR&
M&"-I4J-O)., 9R"">:MT4-7>H^EOZ_KS*NQB,A3W X"LH# D,#N7YFR1@<J1
MZ#"$2?\ //) )'+ [B3_ !Y)"D''ECH%'S8.!;HHL']?U^';8JLLN>!R<$L,
M@EAA?ESD ;0""P;ISWH"N",!CM('(/51D8)9LQ]N K'GDYJU11;S?]??\O\
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M=I,$^R6$]QODDA+ NVF7JL9E"]=C28]JEFL[3Q8PM&M)['4;58_+BDG^SZC
M\@VO(9RRO)&O/E@,23][/(-+2!%Y3W'A_4OL:222(;*4M)ID ;.Z-[=QNLY,
MD[61%*MR<'-78KJUU.XFL]7M6LM422*/3X)+@1 Y!1)=/U56"/-\PD6-I0<
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M]W[<P42Z:_.U)-GEK(5(?@UDVM@ AAUJ"*&2<*;&Z\R6/3KLLX&Q+@(\FGW
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M .!P,YQ7ZL>"_#;Z=X*\.6KQB*:2Q%[=  Y^T7NZ:0\XW G:#G#<C XK\O\
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MGZ??#K6O!WPWT&/PEX)T\Z3X9M+J[N;2QEO[S46C%]<23R,ES?W%Q<K$[/\
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M_+CBNDN3-G$DK'#,ZC'/\/W>.I)Z>],G\1%V!>Z*G<RE7;<50= 3G"XSQ@G
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M&O)\*H\]'W/9M*QSR\JY# %>:]2AFV'G)4ZS]A-V2<FG2D^T9[*_132TMJ?
M9IP?F6"YJN%3QN'5Y?NDUB(1[SHZ\]DK-TG+5-\B/TC\Q=RK@[FS@8[ ]<YQ
MCOP3QVIV3G&/Q_Q_R:RK.\M-1M;>]L;NWO+*Z03075K*L]O,'&Y'AE1F!5E(
M8C=P<@]*NB3S,DG&W/RJ0,GIG)Z8R.Q Z\XKUK=4[K>ZUT>ST_SZGQ[YD[--
M-/52NG=/9W2MKHTTK-?(LT57,AP/E^7 _B'(XQVS1YZ 'AMQ)XQGGOCCI[XY
M^E%K[/\ KS_,.;5NW1+?JNV_4GSR1CTY]<Y_E_6C([\?7'O[^U57(<Y\QTP%
M/3J/3L#SG/7(IK$*259B,#<6Q@8W'CCZY],"BVNOX!S/IIJ]_+I>V]MO4N9!
MZ$'\:,\D8/'?M^%4!*."22,XXX_ITJ3SPK9VD\>O;W..1^':G9=+[=5V]-!)
MR_'NNO2SU6I;R,X[]:12I'RG(%5A,6+%4SD$#YAZ#U''/J/QJ-9@%S'E5[YY
MY''<<?K0U;36^FGR?3^NH7;>ZMKJ^W;U=OF7=P !/RC'0]1_.F-*GIN&2,XX
MR.O7TSZ50$FYV.26!/WONGG/8<#KT_/GF3)(W94@]-O3(X(Z_2BWG=]OS_'3
M?>_83;VUMVZ6T:Z?TBV944XP>PX QCG'?^E->4<  @@@YP,8_.JH<JR_(23D
MXX.,8_#N/44LDK%CG: !SGIZ<=3Z\Y_3%%M_\]NFO3?_ (8%>Z>U][+>V^E_
MP)FE3<K9( .2&QS[#GWZ<#WIQN$QT(SD _IGVQ_DUGB1>I.>>01Z^G_UL=NU
M)N^[D@C/*]\$\<=\]^OM3MYWMIITLF[?YBMY6ZZ]5]Q;9T&5V*W?<&.T>Q)'
MM^=%5#* <*/E]QU^N>3S[BBFG;9[Z]/Z^[0?+)]#_&_N-.EMR'O=/)G:,R3R
M#?"SRHI9 7A*$[2!@$D>N<UDM!9311->VOG!3)(2^8[J*1P500ZA'Y<J$9P(
MV+;L[23G-??WB3X/S#S@ML!@,?\ 5<#KR/Q^OY5X)XA^%5P!+B%U)^^VPX;U
MRA!W#KC (7.0!7&Z4HKW9.6NJ>CMKLUI?7LC?FOVTWOY_P# [?(^:=;U*X@\
M)^(E,,D8LM/>TB2^MU^TNUVZQQ212 !I5Y^4DG/)Z\CVGX??&*]TK]FNZT:/
M[2OBZYA?PUI,%L6WW4=QEI96@YRT,3.OF#!7S?0FL?5_AQK+:5]@M+.XNYS-
M;O""LDJ3;)"$M1O++M^=BB 80\@<$CU[X8? J\\-P_VYXE42:O.&%EI8 -KI
M,,N&W^5]W[3*<!Y,!@L:C.%%=6&E3C!SEI5A-\L&M6Y1M%R76FK<^N[222>I
ME4<V^5)J,HZSNDDK^^D[WYK:*RZJ]DK/YD\!?!\Z#;IKVNJ;K6[AS-';2CS5
MLDEPZJ0PXE7.XD\[F8X'2O0;S1)"Y+(0Q/S <;3U(8]_8=/;BOIG4?#.YV_=
MAFR.%7:,=/DP/F(P22>Q'X\E>^&GW-M1AU^\#G/7ENW!_ ?0BH2W;;;>LI/>
M3U;;^;?IL4W=]+):1O:R2T7RTZ=-^WB&FRS:;,(Y 6B(V@L23$!_$O?KCW_(
M5[)I'B5D6&W"F9V4)ME<G.>I60'*<_P@CCCN17.7?A[:7S&W Z[<9YY.>O..
MO)JOI</V.X6WG8(OFC9-MP$?/KT"GH*\7,LOYU*O1C[UFZE.*^)=9P27Q=91
M6Z5UK=/[/AS/W1E# XRJU3;C'#8B;_AMV2I59-WY&VE";;47[DGR\KC[QIFK
MB_403A4=3L>,I@#!^4J>IYYZDUV-G*P5?DPT9(Z8^7!"# X(Z^_(&37G&G;I
M!$BNKL2ISL&Y<#.!)C)'?(YKN=.O'8-&WE,Z# ;(W<<8.<YQ_0]J^3K4.9OE
M7KILN^RU_P S]2P^*=-13D_YD^CZ+J]'===N_3KM.U%HLB5I2P8%54\9)(_F
M.G/O7I&C:Y>@!U91@[,NH#*HQR".3U.!FO([?:,NS*)&'(P&)'!/(Z$ \8QG
MMFNQT^6Y:*-8DS#D!RRG>".X'/ &.V/Q%<?LI)M6LEM=Z:_\-U[>IZJQ=U%W
MO?>]FK=4NGR=SVW1O$, =5=SYBL2\CLV#\P)VC..^,8 'M7K>G^*;5+-HXIH
MS(ZG8<C/(P>I..OYYX[U\P6=Y$"5VL)U!"D@;2,9YR,[:T['4I89\(Y?G@$
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M*K[.?O7=I.,Z]--^4M&_NXI5YTI.%?#UZ3BVG>#:T[*4:<K:Z:6=M-$?V?\
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M'NLZAL6)WN;*=M4L(9Y%"[W:/4E$;.2<$*O Q7ZUQ:_IMPN_S(X\L-K( A&
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MFE[OM_P.GF7$?;\I![9& ,'/7 XXSUQZ<T-+@MLY)'<<9'''(JJS;2=QR>H
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M\>VEENR)7.7A!!WJI  D;S"H!))!!R.01R*^JO!GQ6\+1QO$I0^3"K8.TL)
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MC9#@Y)Z$>ON/Q'0_M'K_ ( #;Q]F 8[CG8/FP>1T]_7OWQ7AOB/X<HYD9K8
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M/$/PR,HD+0$<MR$SV[@#U]1_*OU#U7P8F7WPJ<9/('S=>!QQGGD=/SKS#6/
M<<A9EB3&22N >/7_ #P*:?2UNWHOR#_AO+7U_KR/R:USX4NGFLL.<@GY4P#@
MGV[C_P"M7CVL?"^92V+8HW/+IG/'8X'Z>YK]<M8^'L<B,WDJ2RGJJ_R//Z>E
M>2:Q\..'S N.V4&,'K@$8(ZGIP:?]?U_PPNNU_/_ "_KJ?DYJGPWN8@?]'S\
MS9^7/KTXZ8Z?_KKSS5/A[M5M]J<DLQ^0\#IG@<=1C\:_535OADH#,L*8))R
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MKEL/^$<UVPU-(Y'>WNX_+-A=+<R2!@TAB('^K&:^:/#5M.LXEC+[6^4H,EU
MX/'\/3GV]J_I5_X(P^%K_P /^$OBKX_ODDCM-;O['1--/S+'=FU\J6=T8X\\
MPC*RC+#*%#GMW9-AH8_,:-#$1=2E*G7=1*4H-15)N,E)/22GRV;=N9[.]CYW
MB_,Z^29%B<=@*L</BH5<+&BY0A4C.3KQYJ<H5$XSC*GSJ6S4(W4HVN?B[XT_
MX)E?MC_"V^DL_$/P8U[6(8)2J:MX7A;6[*X"G!GBDMT8HC##8R!UKTKX&_\
M!-_]I_XGZW:65G\,];\.V$L\7VC6/$ME+I6GV,18*]PTDX7S/*7+.L95F VY
M(K^TC2_$"S!5<@,^%P<;<'L03C'Y8X/';I"1(N"0P.,@$$9XQTR/I7U:X0P+
MJJ;Q&)=.]_9/V2VL^5U%%-)_X4[=>I^6R\4\\]@Z?U'+HUW'E6(4:_NMIIS5
M!U'3YENKR<;I75D?''['O[(/@W]D[P&=$TR9-6\7ZTMO-XK\3[%2:^FC 9=/
MTQE 9+"*3.-Q9C\V6(;C["*$,3QEB<@<!6'.T XY"E<M_$?<4]43JN0>1D8!
MYZ\X!Y&*<% Z>F!G' &>!Z#D\>YKZ>C0A0IPHTJ<:=&G%1A&.R2_%MN[<OB;
M;;;NS\YQ>+Q&.Q%;%XJK.MB*\W.K4FTW*3>UM.6,5:,8KW8Q2221&/E/W>>O
M'O\ 3(--D,AR!D CD#(./Z_EU'X5.02."1]/Y'VIH4@@[B2/S_/-:V:T2NK^
M5OGU9S7(4&\ AG1E&,Y[C@D]C@@]234C#+XYQD?EQP?Z]*ER<8SP>H['\*3
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M7CIUY_#_ .O2_P NG^=_Z[A_G_6G]>A#M /3V([<>HZ&BIO)?V_.BC3M^'_
M'KW_ !_X)8V#U/Z?X4[:/0?D*6F[E'?]#_A2]U?W?O7YCU[)_<_R%P/0?D*"
MJGL/Y?RI-Z^OZ'_"E!!Z&G=/2Z?S3%9K6S7R:#:OH/RI< ]?Y9HHZ4))7?\
MPWY:?(&]E_P]WN)A?0?D*6F[U]?T/^%.I-*75:=M?UT&FX[IZ]]/TU"CCO\
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M@>CZ5<.FPKR5R3]TDYXX )SU_GZ"O4](O7VIN*_, #@C(_,#FO(M.@:/;-L
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A^[^K?XU)10WM;2WGO^078PQH3G:**?11=]PN^[^]G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>v434644_chrt-table.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v434644_chrt-table.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( .<$' ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M-4TS4+>2TO\ 3M1L+N.:UOK"^M9I;:\L[F*6WN;>62&:-XW93_)M_P '??\
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MQXGU[PQJFI:7>VECJ,=A&);%VMK:9/0/CI^UI^W?^Q7_ ,%W_P!C/]FCQ/\
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M30=!T6RGU+6-:UC5+Z6"RTW2M+T^VN+[4+^\FAM;.T@FN+B6.*-W'XN? _\
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MYA&!R[V_F2ZG]G]%?QY?M3_MW_M?_P#!,S]FS_@E-^VIK_[0/Q3^.^H?M/\
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M;JYNM%\3?$+XM^//&#ZQK>L:#\-_"K:;IOA^S\':GX>UGPIKFO7EOK*>'_\
M!)7]K+]O7_@I_P#\$G_VD(I/C[JWA#]KGX.>//$O@SX,?';P[HO@VQUOQ9J>
ME> /#WC?P5H7Q*TO4?#>H^$]0M-2U?6KCP?K^NV6A6.H3>'Y-.U>43>)M,O-
M7UD)MI>ZZ?C_ %KV/ZIZ*_DD_P""2/\ P4H^-W[3'_!/7]NS2?CW\;?BSK/[
M;?P/\1'0]%8MX)\.>-FUOQZMOX4_9^\+>!?#\7A/2M$LM>\1?&^TN_AEK6FZ
MUHVJ)/J^IZ-:ZQ>P0:W:6=G_ %%_!7P7XN^'?PG^'_@GQ_\ $3Q!\6O'/AWP
MQIMCXQ^)7BA=*CUKQGXG\KS]=URX@T/1] TFSMKK4YKG^S+"QT>Q@T_2DLK(
M1,UNTL@#5CX;^.__  4@T?P-^VG\,/\ @GG\#?AS8?&K]J;X@^"M7^)FNV'B
M;Q_=?"WX3?"KP#I.D:QK,>H?$/X@:+X ^+7B2U\1>(+;1I$\.>&-"^&^MS3G
M4=#NM=U#P]INMZ9?747_  3X_P""GOPT_;M\0?';X0W7@G6/@A^T]^S#XVUS
MP)\=/@3XCUNT\42Z'?Z#XAU'PI>>(/!OC*QT[1K3QMX07Q%I.H:+-JG]B:#J
MFGZA#;C5=!L;+5_#]]J_X.?M+>#/B[^P7_P<>:%^W]\3_A_\4/$W[(7[0'AN
MQ\-W_P 6? 7@3Q9\1M.\!)-^S[H_PBN]#\5V/@;P[K>IV%UX=\:>$M(\11Z6
MFG#4-3\$7JZCH[:]J6E:W;)Y;_P2!UH?%O\ X./O^"COQ:^%%OXGL_A:/#_[
M09\4R^(O#_BOP?J#W&I_%KX;:5'I6O\ ACQ3!H_B+P_K%_XUTC4M7@\->*]'
ML=7TV+1-0BO-!TB_TY[?3@JRM?\ NIW\[ZH_=SQI_P %:FUCXH_MN^ /V6?@
M-IW[0>B?\$[/ R>+/VH?&VO_ !C/PELXM>MH_%FHZ[\-?A!IL'PO^))\?^-M
M#T;P!XZBG_X2?4?AKX8F\6>&;OPT/$<5M/;Z^_WQ^QY^UI\(?VX?V=OAU^TQ
M\#]2O;WP'\1-.NIH;#6(+>S\2>%]<TF^N=(\1^$O%.G6UU>PZ?X@\/:Q9W5A
M>1P7=U8WD26^K:1>ZAHNHZ=J%W_%#_P;W^)==\:?LN_\'!7C'Q0S/XF\6? /
M0/$OB)G2:)FUW7?AY^VSJFKLT=S)+<1L=0NK@E)Y9)D)*RR.X9C^FG_!H=XE
MUW4?V%?VA?#-]<7-QH7AK]J;4[O0$GG6:*RE\0?"SX<2:Q8V2,[3VMMY^FVV
MH/;JL=F;S4;NZ@4W=UJ#N XI)^32];K_ #/W&_X*/_MK>)?^"?/[-/C?]JH_
M!S2_B_\ #CX:MX03QMI<'Q/G\">,K9O&_CSPY\/-&ET#3)_AUXKT;6K:+6_%
M6COJ+W?B'1;FWM'N9;>SO/L^'^8_V/\ _@I=^U%^W)^S=H'[4/P%_81\*:EX
M"\3ZCXHTK1-$\3?M=Z5X;\97E[X1\17OAG5HS877P*ET*V4ZAI]S):R77B.%
M)K15D8Q2NL!YO_@X\_Y0Q_MD_P#=O/\ ZU7\#:_#_P#X)K?M.?M??!;_ (([
M?L<^%_@[^SCJU_\ "?QY^V3X8\ _$/\ :<TSXB:*X^'G@SQI^UY9Z9XE2;X<
MZ8]MXVLY-?N;R/P#!XDE>;PY8QZS<W.I20S76CVM\"2]V]E>]M>UK]S^KC]B
M#]J7Q5^UK\)_$WCOQY\"O$?[.'CKP1\6_B%\'O&7PF\5^*-+\8:SX?\ $?P[
MO[73]2DEU_1=.TW2;^VO9+E9["YTQ+O3KNR,%]I^I7]E=V]P_P!C5_/3_P %
M]?\ @HS\0_\ @F[\"_A_X8_98TO0?#W[2G[8WQ'\0:=H/C*31-'U!] MO!VA
M^#-(\7^-[?2M6MKG0M:\<2)K/PW\):--XEL[[2K6RNYM0O+>YETJR@?Q#]I[
M]MGXV?\ !*?_ (*5_L)_ 'Q%\>?B5^T#^S9^U=X6\*^$_C!I_P :[G0M?\1^
M%/'NH^-9?AQ'\7? WBZ#3M-U?PSIAU/5]!\0^)_ LESJWAH:1I>N6VBV5KJ.
MHZ?=Z6!:^JTO=I>F_P#P#[D\"_\ !7L>(?\ @JYXE_X)3^*OV=YO#7C[PU9:
MCJMQ\5]%^*\/BKPG=:8OP=TWXUZ%-!H5W\._"NKK<ZIX6UK2K._M9;E5T?69
M+RWBN-5M;2.[NSP+_P %>QXA_P""KGB7_@E/XJ_9WF\->/O#5EJ.JW'Q7T7X
MKP^*O"=UIB_!W3?C7H4T&A7?P[\*ZNMSJGA;6M*L[^UEN571]9DO+>*XU6UM
M([N[_&#PA_RN,?%/_L0]._\ 7?'PXH\(?\KC'Q3_ .Q#T[_UWQ\.*!V7;[%_
MF?V@45_)+^R-^W7^TK_P5<UO_@JO\<_#_P"T!\4?V>O@I^R?X(CMOV0/"OP=
MF\,Z/9MK$ND?%W7].^(OQ,FU/1=5U#XA:O<6OPU\*:EK/A#Q%)/X-^R>+M1T
M;2;6S%H][/\ 0_\ P3[_ &ZOVI?^"MG_  26^-7B'P-\2M0^#?[>'P7O?%_@
MZQ\=_#O2?"MI8>-_'_AWPM;^-OAIJ-WX6UO1O$6A:9X;^)-IJMKX*\765MIT
M9M=<TK7O$'ANWTNU&E:5;@G%K[TGY7/Z4Z*_A_\ V;_^"FW[9O[2W_!'?X^^
M(O"?[1_QBD_X*2?!+X^OI6B#1=,^&DVL>,_"9\):K\5[[3M6\&:GX1BT6U\/
MZ?\ !?X8_'V^BMK#3+/Q"WBGX7_:+6YU&:^GT2]^^?\ @F1^VI\9/^"@7[$?
M[%^A)^TG\5[3]I_7?VI?B-X9_:2\:Z#=^![/75^&?P@TR_\ B3XSN9],N/ E
MYH=CX4U_P3XC^"'P[TNXT?P_:WVD^-OB;9W5OJOF6FJ7T8#BU\G;\+_<?I'X
M=_X*=ZYK_P#P5;\8_P#!,X_LK_$?3]%\*?#R#QPO[2=UJ]ROAB_,G@C3/&?F
MKX4?P?';1^#[JYU-O!6F^+HO'-S)=>-=/N=(.A)F26T_62OY5OAM^V?^UKI?
M_!RMX_\ V#+_ /:"\<^*?V6-%\/WFO:9\,_$UCX*NXK:YUO]DKPO\85MO^$@
ML?">G>))K+1O&?B*\FT:.?5I9H=/M[*RO+B^$,DLWA7[(W[1'_!0S]J#_@K[
M_P %#/\ @GW;_M[?%+P+\'?A'X5^/K^#?$4W@+X1^+O'_A'2?!GQP^%GA/P\
M?">JWO@O3;"'Q+!9^*1HDWB+Q#I_B&7_ (16XU^.SMK/QE>:+XT\/@./HO=3
MZ_U\C^QZBOY,_P#@@O\ \%3/VI/C9^P5^WS\2_VC-:UK]H?Q=^QMH6K_ !(\
M$WUW#9IX\\;Z7)\,_'?CI?AY>76FV5HFJW!UCP'+::!J-U%/J@'B,Z=-<266
MG:;##\U_"+]MG]O'XQ_\$9?VP_\ @JGJ7[8GQ.\*?M*_#KX[BR^''A_PWI?@
M.#X$^#_!.E>(?A%X?O/ T/P>UWPKKOA7Q#;ZII_Q$UY;?6O%4.M>(X-1LO#-
MV^IW5Y::Q<:^!RN[\FE\WL?VP45^<O\ P2;^*WQ7^/G[ _[/_P >OC3\1_''
MQ,\>_&;PLGCS5-3\>^&OA=X6U+13=,-'FT'1[#X2?#WX9^&KGPE]OT:^U[PO
MJ-[X<D\076CZ];+J>K:BL5L\?Z-4$O0**** "BBB@ HHHH **** "BBB@ HH
MHH *_FO_ .#C7]CG]L/]OKX)?!;X)_LI?LW>*_B9JG@3XQGXCZ_XON/B+\ /
M _A :0G@'7?#Z6-B/'_Q@\,>*[K5)-1\2K&8V\+06:)I>H2F]:-]/>^_I0HH
M&G9W['YT_L>^$_VCO!G_  38^$GP2O\ X9:U\"OVD_@Y^Q]X%^"F@VWCWQ!\
M+/%>A#XM_#WX,6'@71O$EGJGPQ\<_$G1KSPD?%VB66JJVJM97[Z5<1K=:,)1
M<VT?\L?AK_@ES_P6(\6_\$S?VWOV=_BA^R[\/+GXZ_&OX[^#OC=XA^,7CO\
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MA'Q4U_X-U"V@;2+%]*U?Q#8ZA^\5% ^9_BW\WU/YJ/\ @EC_ ,$IOCY\!?\
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MAZXOHH;73KOQ''H=U:7,V@1WOVC3[?\ JGHH'S/RVY?D?RE?LH?\$_OVHO\
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M59X8I0R+T=?SQWG[:?Q6_P""6_\ P1^^'G[3OQ]^('P^_:#O-2^"7[-'A/\
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M\3:/IEM->/;G4;J:Z335NQI>JFR_##_@G%^W'^TI^VCIW[-'Q(^&G[3?P/\
MV@_AEXOTCQ/I_P"UUX3/P/'P\^,G[+_Q>'P=UW6_">C7>B:;\3=FJ?!^^^(]
MB^CVVJ3Z*VK:Y/::.-"^)&JZ7K>IG1?R#_X)E>,OV[OV@O\ @N-_P4HMKC]K
M'P/:_$_X0VGQ1^$&M^-?&_[/VK?$#P;JOPP^$?[26E^"-.\%_#/X8V7QU\#C
MX1:3--IT>LZ:K^,?'LMA+<ZC)K;^*O$&JZIXGO0?+OKLK_IV/[>Z*_ '2_\
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M>-/4*"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_%IO^$9_;P_;P\;:+\5OAI^W1\+
MOAC^S/X&TCPE^S?XMM/#?[;_ .R#X>^(WQ(\>OXJU']H#XCZ7\9/AK'\'KA]
M#TCPWX7^'GPW\+:5XP\96NGZW)=>+-1\/:9JMOXGTNXD_:6B@:=C^''_ (+X
M_P#!-[XB?#']H3]EG]IK_@GE\+OVT/BW\=O">KI?^/=3L=/_ &ROVO?$&CZQ
M\/M2\.^*OA!XV7XM?$N]^+[11Z3<QZGHTOA6W\7I:V@L],:+18V?5)#] _\
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M)I^"?VFO@?\ \%1?^"RW[2=Y^RE^T?H_A_XO>&?VT/'/[-^K?%+]F/X]^$_
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M+=:QXET#1;O4M>TCPI>Z;<7&J:WI=IHMQH]_+</ID_V110*^VFWXZW/\Y/\
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MLM4N/[/**!\VVBT=^O:UC^53]MO]F#XW_P#!2_\ X(5?!CX;_"[X"_&'P/\
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MCV7[2WPK\1_M+_#"^GC9;/QIIGC'XI>#O&^L2Z+=32K)--INO^,?'>DZA:I
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M/A*P\._M.M\0]==O%/A3P)JVA:S-H_A!EU;4[;P_?ZK<:?DV-Y%#J2O9K?\
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M+-O[#T:[TG5?!N@PZ-8V5G8>%]&@=H8 :E>]^R6C[>JM_6A]3?\ !(_XE_\
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MZ WHL+JZ@U*WNK.#\]OV>/V<_&__  3._P""XW[:/Q]^)W@;XCZG^RI^VIX
M^*7C_P !_&SP)\-OB#\4-#T'XG^,_B;X4^+WB'X<>-K?X>:!XJU/PGJPO+/X
MBKH,>IV"1^(;:T\-QZ"UQ<7]Y9:=_5710*^_GO\ F?QN?\$O_P!@3X\_ ']D
MG_@KM^UE\9/@_P#%?PGXP_;#^&GQ=\,? OX'+\//%FO_ !NN?"VNZ;\3;K2[
MC5_A1X7T;7/'%CKGC3Q3XX\-:3IOAVZTBUUC1;3P]JFNZ]8V>A7EOJ4'Q;^S
M?^S3^U%X5_X-NO\ @H)^R[XB_91_:PTC]H7XA_MA_#CQ/X&^$-[^R]\?(_&W
MBKPW<Z]^R3K)\0Z'I(^'9>_T.QT_X-?$636-6A=K#0KC1;"PUJXL+_Q1X3MM
M<_OUHH'S;Z;M/[C^-OQM_P $^/VA/VMO^#:S]GC]G?PW\(_B9X6_:7_9F\97
M'Q-'P5^*/@+QI\)?'6M:YX3\5_%[3]8\/Z5HGQ"T7PU<ZK<ZG\.OBM?:WX5N
MK6*ZT7Q%J4$&AZ=J#:V);>T^QO\ @E-^T)/\8?A3^S_\$/&G_!*#XE?#3]J#
MX4Z=X)\'_%KXQ?%;]ES0_AG\'-"T[X?&PTR^^+3?$CQ=8:1XMU/XB:YI.DK?
MZ=\/](T*3Q5=_$NYGC>XTOP58ZGXVTO^EZB@.;1JW5O=]?S^9_*/_P '%/PT
MU?\ :A_:V_X(\?LC> XIM0\=_$'XW?$WQ+JJ669)?"G@#2[_ .#Y\1>,-3@6
M"XDCTO2O#VG>,/$,MRD,^RS\':N/(ED$44G]7%?&/PH_8\T7PQ^T5XZ_;!^+
M/B2'XL_M*>,?"EI\,O#_ (I&@GPYX0^#?P:TS4;K5K'X6_"/PM<ZOXBO=%LM
M3U6[GU_QYXIU?Q!J_B#QMXFN+N^C;PYX>DL?".F?9U F]$NWZGX+_P#!Q=X=
M\=_%C_@F_P#$GX$_"+X3?&[XP_%7QQXN^$6H^'?"OPA^"'Q:^*3S6'A_XBZ7
MKVL7.HZOX#\&^(-!T1;'2]"O[B6+6M4L+@DV,4<+R:GIZW/8?\&^>E^,OAO_
M ,$POV?/@+\5/A9\:OA#\6?A5-\98O&?A'XO_!3XK?"JXLQXJ^/OQ-\<:#-I
MFH^/O!_A[1_$,-]X;\6:+>[M U'4FMWFN+:Z2&XLKJ.+]N** OI;SN?Q]_\
M!9?X1?'+XA_\%MO^"8OQ<^'?[.W[2OQ%^%'[/7BG]F/5_B_\3/AY^SG\;O'?
M@/PE8Z#^TXWQ$U^3_A*?"7@/6='UV30O!KQZSJ\'ANZUB:P+G3;A$U>&XT^$
M\-_"+XY6/_!U/X\_::N?V=OVE8_V==<M[;P#IOQR/[.?QN_X55-X@MOV.O!W
MPIEF;QS_ ,(&/#T7AH?$#1=0\/IXUDOE\'2B*/68]=?P]/#JS_V"44#YM+6Z
M-?>?QZ^-/A3\;8O^#ISP1^U,O[._[35U^SAX<TZZ\%ZO\;M._9H^/6J?#6#7
M;C]CGQG\+(C!XLTWX=W6DZAH9\>:SIN@MXKTZXN_"L9G;4Y-:31[:ZU"'ZB_
MX.8?V$?V@/VJ/@A^SI\=OV:?!&K?$_XC_LC^//&.OWOP\\-Z=/K_ (KUCP;\
M0(?!=SJFK>&O"=M'/=>,;_0?$'PW\*/=>&M-M+S6;S2;_4;C3[2Y2SNX)/Z:
M** YM4^RL?BE_P $\?VD/"_[5<_PTU_PO_P2^\:_LK^,_#6D?VC\;/B-\6OV
M=O#'P<\)^"_$:Z!=65SX;^!WB"Y@L_&OQ)U;Q#K\Z1V5Q9Z/I%CX<\"R:EJ/
MC6_T[7YM"\*>)/Y_O^"?WPL^)7_!'?\ ; _:?_9C_:F_X)S_ !I_:H_9^^*?
MB6TU;X$_%SX0_LVM^T3Y9T/4=:MO"5SHEY=V,FE_8/&?A36M.M/&VC?VW%XH
M\)>*-$T2'4])>RNKO4(O[KJ* YM]-'YO\]SQC]GVTOK;X3^&)]0^#^A? *?5
M?[3UN+X/Z%;^'8#X%T_5M4O+W2=(\0CP@\OA1O&C:7+9WGC6/PU<:AH-CXHN
MM5TS2=:\16-C!XBU67X_>+++P=\'_B#JE[H_C;7OM'A'Q/IUII/P^^'GCSXG
M^)KZ_NO#NJM:VUEX4^'/ASQ3XDNFN'B-O%+%I;6_VJ6VM6F6XN[:.7V*B@D_
MC!_X-6/@]\>_V4O%'[9GA']I+]FK]J'X(ZC\9(?V<Y?AYJ'Q)_9H^.GA7POK
M1\ R_'*'Q3#<^,-5\ 6_A?0IM//CKPY(BZ_JVF+=Q7<\EH\RV5WY/VO_ ,'2
M7PM^+_Q]_8G^"GP@^ _P3^./QP^(4/[4WA'XDWN@_![X+_$_XG+I7@SP_P#"
M7XW>&-3U?6=5\$>%-<T;1FCUOQCX>L[?3]3U"UU.^%\US9V<]K:W4\/],]%!
M7-[W-8_AH_X+G_ O]HG]HC]@W_@D=\/?@C^R_P#M6_$KQO\ "[X,I%\2?#'A
MG]EK]H*ZU?P%=V_PL^$?A"33?&%K)\-X6\.ZQ_PD'AC7+./1=5^RZM-!8_VG
M#92:5<V=]<?2_P#P63\(_%_XM?\ !5O_ ()-_'OX4?LU_M9?$SX6? /Q=\#/
MB+\6?%'@K]E+]H76K+P?X?L_V@?"GQ$O+?4)(OAND1\0V'A73+R]U;PQ%*^O
M:%<Q#3==L--U%TMF_L HH#FVTVO^)_''^T+\+?C=K?\ P<S?L_\ [46B?LX_
MM1:S^SQX3L? ?AGQ%\8],_9B^/MWX TK5)OA!XP\+R//XAB^'1L9-*L=;\1Z
M59ZIKMO)-HNE^9=37U_!#IVH26OE'B?X*?%__@EW_P %J?VD_C]\3OV&_B7^
MV'^Q=^VAKWC[Q>/$'PM^"DOQ\O?"6L_$WQ;!\2;C4;;1'L+W3]&\:>$/'4OB
M'P]=^'=<OM&NM:\"ZO?ZWX9?43#:V)_MSHH#F\NEMV?BS\<=>\-Z_P#L?:3_
M ,)7_P $Q?$VJ_LZ?M"_'/P[X+^)'[+&B?!BVG^/UE\"]:\'ZW(OQR\3?"OX
M833W'A7XC>%?&^@^'?%=GX=T^?5O'OA7P7I>GL]QX?\ B;=1Z3X-_+3_ ((W
M?L&>+OV5O^"K?[2GB']E'4?CNO\ P3FO/@TEO<:U\;OAK\2?AE%XJ^(.N7WA
M_5_#?PXT;3OB/X7\"ZGXTUWX63W&ORIX]3PSNTC0;C4O#>J77]L:]<SW_P#7
MC10*^C7?S_K7S/'?C]XLLO!WP?\ B#JE[H_C;7OM'A'Q/IUII/P^^'GCSXG^
M)KZ_NO#NJM:VUEX4^'/ASQ3XDNFN'B-O%+%I;6_VJ6VM6F6XN[:.7^-'_@VP
MMOC)_P $\I/VU(OVK?V/?V\_A^_Q=T[X WGPY^P?L,_M5>,(_$E[\-I/C5'X
M@T0S^$_A1J]OH6HR_P#"P-!DTZ[\32Z+X?EC%^UWK=E]E E_N0HH!.R:MO;\
M#^3']F3_ ()F?M-?ML?\%=?%7_!63]LWX5:I^SI\)/!GB[PUXH_9P^!7C.\T
M&Y^*NO77PVT/2O"GPFU/QKX>TB]UZ'P/;>'ET&'XA^(K;5-3M]>F^($EG8Z+
M82>&S-J</8_\%&_%O[=7C3_@KE\!_@]XQ_9*_:>_:2_X)G^'=#T/Q-=?"SX%
M>%T?X9_&7QS/X4UFZMM3^._BO7+WP]\-=<\/^"OBE-X=74OAS\6?'WA?P2ND
M:!I6LW>F:B^L&U\1_P!3M% ^;79;67EZ>9_'I_P0X^&_[0/[)?[?G_!575/C
MW^R1^T3\,_#'Q"\5:IXNT;7]$^$7B?Q1\.['2="^)/Q2\2IIGA'7] TI&^)O
M]IV7BS0[+P58_"/0O&&HZ];R-J<>CZ?H=CJ%]8_''_!'WX#_ +2/P"_X)I?\
M%F_A)\8/V4_VNO GQ*^.O[/6O>&/A!X.UC]D_P#:*&L?$+7O$'P5^-7@73M,
M\-);?#.X@OKK_A)O%6@V=Y$)U?3K:_75+\6VEPSWD7]Z5% <V^F]NKZ?\,?S
MH?\ !LE\-/BM\$/V /%/PF^-WP>^,WP6^(FF_M">/_%,WA?XP?!_XE_"Z\N?
M#WB'PUX!M](U729_'?A;0+#7;6YGTK4(9#HEWJ#V<MJ\=\EL[('^1O@'_P $
MU?B=\!?^#@3XY>'? J7NA?L4_&#P+H7[:'B_1+2T4>&-:U30/BMI'B_X?>!(
MIOM-Q#I>L^"?VH=%E\6Z)IRQQLOPYTN_TJ"PM=.U6*YA_HG_ &]?@5\;_P!I
M3]E+XJ_!K]G+X_>(OV9/C)XLM- ?P;\8?#%_K6D:GH-UH?BC1M?O-,;7/#%S
M8^*]"L/$^G:9=^'-1UGPQ>V^L:?9ZG+/'%J5HMWH^HU?V./@-\8OA1X1;Q5^
MTU\0/#7Q5_:2\3>"_AAX"\<>-?"%OX@B\-)X5^$/AZZT;PMHVCW'BJXF\1:J
M^J^(M<\??%+Q/K6LQVU]?>-_B=XFMH8(M$TW0X80+[O372WW:GV711102%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!_.5\4/"O_!S1-\3/B)-\
M*/B5^P5:?"V7QUXMD^&MKXBL+IO$%MX ?7]0;P=;ZZW_  @%SNUB'PZ=.CU-
MOM-QF]6<^?+_ *QN%_X1'_@ZG_Z*E_P3R_\ !?=?_.ZK^F^B@?-Y1^Y'\R'_
M  B/_!U/_P!%2_X)Y?\ @ONO_G=4?\(C_P '4_\ T5+_ ()Y?^"^Z_\ G=5_
M3?10/F\H_<C^9#_A$?\ @ZG_ .BI?\$\O_!?=?\ SNJ/^$1_X.I_^BI?\$\O
M_!?=?_.ZK^F^B@.;RC]R/YD/^$1_X.I_^BI?\$\O_!?=?_.ZH_X1'_@ZG_Z*
ME_P3R_\ !?=?_.ZK^F^B@.;RC]R/YD/^$1_X.I_^BI?\$\O_  7W7_SNJ/\
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M  3R_P#!?=?_ #NJ_IOHH#F\H_<C^9#_ (1'_@ZG_P"BI?\ !/+_ ,%]U_\
M.ZH_X1'_ (.I_P#HJ7_!/+_P7W7_ ,[JOZ;Z* YO*/W(_F0_X1'_ (.I_P#H
MJ7_!/+_P7W7_ ,[JC_A$?^#J?_HJ7_!/+_P7W7_SNJ_IOHH#F\H_<C^9#_A$
M?^#J?_HJ7_!/+_P7W7_SNJ/^$1_X.I_^BI?\$\O_  7W7_SNJ_IOHH#F\H_<
MC^9#_A$?^#J?_HJ7_!/+_P %]U_\[JC_ (1'_@ZG_P"BI?\ !/+_ ,%]U_\
M.ZK^F^B@.;RC]R/YD/\ A$?^#J?_ **E_P $\O\ P7W7_P [JC_A$?\ @ZG_
M .BI?\$\O_!?=?\ SNJ_IOHH#F\H_<C^9#_A$?\ @ZG_ .BI?\$\O_!?=?\
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M[>+4H+665$(%V^B_\!1^-?\ PB/_  =3_P#14O\ @GE_X+[K_P"=U1_PB/\
MP=3_ /14O^">7_@ONO\ YW5?T.> OC7\,/BI\(_#WQV^&/BJ'XB?"OQ;X8C\
M8>%_%/@C3-:\5'Q!H,L;R+-I&A:'IM]XDO\ 44>*:TGT&VT>37K;4H+C2[C3
M(M2MYK2/@O@%^UK\"/VGY/%R?!'Q-XE\6Q^ M>U;PIXPO=0^%?Q:\$:7H'B[
M0+J&RU[P=?ZOX^\#>%]+7QAH5U<11:UX3CO)/$.D[B^H:;;QH[J!=]E_X"C\
M(/\ A$?^#J?_ **E_P $\O\ P7W7_P [JC_A$?\ @ZG_ .BI?\$\O_!?=?\
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MD/\ A$?^#J?_ **E_P $\O\ P7W7_P [JC_A$?\ @ZG_ .BI?\$\O_!?=?\
MSNJ_IOHH#F\H_<C^9#_A$?\ @ZG_ .BI?\$\O_!?=?\ SNJ/^$1_X.I_^BI?
M\$\O_!?=?_.ZK^F^B@.;RC]R/YD/^$1_X.I_^BI?\$\O_!?=?_.ZH_X1'_@Z
MG_Z*E_P3R_\ !?=?_.ZK^F^B@.;RC]R/YD/^$1_X.I_^BI?\$\O_  7W7_SN
MJ/\ A$?^#J?_ **E_P $\O\ P7W7_P [JOZ;Z* YO*/W(_F0_P"$1_X.I_\
MHJ7_  3R_P#!?=?_ #NJ/^$1_P"#J?\ Z*E_P3R_\%]U_P#.ZK^F^B@.;RC]
MR/YD/^$1_P"#J?\ Z*E_P3R_\%]U_P#.ZH_X1'_@ZG_Z*E_P3R_\%]U_\[JO
MZ;Z* YO*/W(_F0_X1'_@ZG_Z*E_P3R_\%]U_\[JC_A$?^#J?_HJ7_!/+_P %
M]U_\[JOZ;Z* YO*/W(_F0_X1'_@ZG_Z*E_P3R_\ !?=?_.ZH_P"$1_X.I_\
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MU_\ .ZK^F^B@.;RC]R/YD/\ A$?^#J?_ **E_P $\O\ P7W7_P [JC_A$?\
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M_A$?^#J?_HJ7_!/+_P %]U_\[JOZ;Z* YO*/W(_F0_X1'_@ZG_Z*E_P3R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^/?\
MP6%_9-^'_P"W)X6_8J_99^)M[JND^$_BW^UYXSTF;7M",8UGP[K.A?\ !/S]
MNSQGX1\0V*2E8;QO#_C+PSX>UR72KETL]8CTTZ;>L+:YD9?V$K\L?VZ/VEOV
M?/AE^T[_ ,$T/!_Q"^-'PU\&^*+3]LGQEKVH:'XB\7Z+IE_I&BZC^P;^V)\/
MM.U77(;F[3^P[#4O&GQ8^'/AS3KG5S917^I>+]'BLVF69WC!K?3^M&?RV?\
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M?_@Y$\&:E^U_^RU^Q[^WC^SEI_B7XL?!+]FKXE^.=5\6W.A:!K-O;^(?AO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U"_L-*L+W5-4O;33
M=,TVTN;_ %'4=0N8;.PL+"SA>XN[V]N[AX[>UM+6WCDGN;F>2.&"&-Y975%9
MA;K^:W_@NE^T#XD\;_M ?\$]/^"5OA35K_0_#7[:WQL\%7G[2]]IEW<V.HZK
M^S_8_$/P_H=WX#MKG3)FU%=,\:+%XQNO$2&.PM[R#PGINCW&HR:)J_B*&$&E
M=V_K0_H&\ ?&/X9?%'P"OQ5\"^+M.USX:2PZG>V?CWRK[3/"6JZ/I/F-=^)]
M#U[6;73]-U[P;)##+>:=XUT:XO\ PGK&GHVHZ1K-]8C[17F/[/W[6_[+?[3&
MO_%GPW^S=\7O OQ;O_@_KFBZ=\4+SX=RS:QX;TC7_%<&J7&F11^,;&R'A+Q3
M>WD6A:D+V;PSK>N&PEL_L^K26D\EO'+WGQ._9_\ @?\ &CX<CX0_%CX2_#[X
M@_"Y;*'3H/A_XI\*Z/JWA*SM+33I=)T^/3M#N+5K#36TFPF,6BS6$-M/HLD=
MM=:3)9W=G:3P_P CO_!G/_R3#]NW_L?/@1_ZCWQ.H!*Z;[6_$_J8_:4_;!_9
M(_9)T/1_^&E?C/\ #?X7VGB";3M.\,^%/$%VNH>)_$S7%]'I]A%X7^'6B6FK
M^+_$=M!?(D+S:'X=O[33FBWW4EM'"77ZANK6UO;>:TO;:"[M+B-HKBUNH8[B
MWGB<8>.:&57CEC8<,CJRL."#7\.O_!U#\$?A!\.?V@_^";_Q&\ _#7P7X-\=
M_%KQY\<&^*'BSPUX?T[1M<^($WA;Q7^SI>>';OQ??6$$$NOW^C2^,?$D=AJ&
MI&XOH+34VL%N/L-K96UM_<C0#5DGWO\ @-=5=61U5T=2KHX#*RL"&5E((96!
M((((()!&*S=(T/1/#]H;#0='TO1+$S/<&RTC3[33;0SR*BR3FWLH883,ZQQJ
M\A3>RH@9B%7'Y:?\%@/^"B'CS_@F/^S?X8_:.\)?"CPC\8-(O?B9H_PW\1>&
M?$7C+6?!>I6L_B;2-9U31-6T6^TSPUXDM;N&W;P[J=OJMI?16;XNK&:TGD,=
MQ"WYG_M!_P#!?']I?]F3X9_L-_M4?%W]B7P;X;_91_:Y\.>#M7G>T^-#^(/C
MAI\>K^#/#GBW7]?TCPU9^'K7PI9^'[BR\02ZU\-+/4];U'6/%_AO3+:3QFOP
MMUW7ET;1P$F]NM_P/Z>?[ T+[?9:K_8ND_VIIEH;#3=2_LZS^WZ?8E70V5E>
M>3]HM+0I)(AMH)(X2KNI3#,#?NK6UO;>:TO;:"[M+B-HKBUNH8[BWGB<8>.:
M&57CEC8<,CJRL."#7\['QJ_X+4?M ?LS?M[?LJ?LY?M#_LA^'/AM\#_VO]5\
M*Z=\/-?/Q0EU[XV^#=-\:>+;7P'HVN?%'PMINBMX1T'6-.\0W^FWGBSP'HFL
M>(CH>D7=Q%I_C77]7TR:RG^B_CO_ ,%4O$-I_P %,/AM_P $L?V9/A_X+\5?
M&?6/#LWC+XP?%#XH:]JUGX"^$^CIX!U#XEVWA^U\*>&(4\1^,?%NH>#8-(UE
M8AK7A[3+-/$WAV'[1>I=ZM=: !9_A?Y'[1UCZ-X>T#PY!+:^'M#T?0;6>;[1
M/;:-IEEI<$TY1(S/+#8P01R3>7&D?F.I?8B+NVJ /Q<_8*_X*M?&']KK]L?]
MHS]C'QI^S9\+_ASXG_9*\1^+/"OQ@\;Z+^T-XCUZ\U]O#>N:WX5L/&?PV^&%
M_P# ;2X;[PAKWB/3-,@N;?6?BO::]X8L/$>EW5S::M*)+8_J]\?/CC\._P!F
MGX+_ !-^/OQ9U>30_AS\)?!^L^-O%FH00?:[T:9H]LTWV+2[$/$VH:UJMSY&
ME:)IJ21R:EJ][96,;K)<*0!9IV_K4]=KQ_X\?M ?!C]F'X8>(OC-\?OB/X:^
M%GPR\*QPMK7BSQ3>/;V<4]W((+'3K"UMXKG4]:UK4K@BVTK0M%LM0UK5;DK;
M:=874Y$9_ Z;_@N9\:/#O[%'PV_X*?\ C']F3P)%^QA\3?C9K/POM/ GA_XD
M:I>_M'>'O!MCXM\8?#^R^)MQ<WVB67P[UR\E\8>!=:L[WX>QC0[B""ZT^6W\
M775F)]3KX%_X.M_BAXU^*7[(G[&7CKX=WW@3Q!^R'\3/&/A?XC>$_&VD^*]>
M;QGXN\:^)OAOXXUCPQ-<>"+CPA;Z%%X#3X<:C#J^@^)D\;3:]+K>M:SI&I^#
MM-MK+3]6OP:B[I/J[?=NO4_J#_9X_;\_95_:E^)7Q(^#7P=^(NI:A\7/A'IF
MC:[\0/AGXR^'?Q+^%WC?0/#OB."QN] \0R>'/B;X0\):E>:3J=GJNCW1FL8+
MF;2DUK2(-=@TJ]U&UM9/KG5=5TS0],U'6];U&PT?1M'L+S5=7U?5;RWT_3-+
MTS3[>2[O]1U&_NY(;6QL+&UAEN;R\N98K>VMXI)II$C1F'R#^QW\%='\->"M
M ^./CGX&?L__  W_ &H_BIX"\+:=\8_&OP6AD\13>,-&\.6Z:?X"AU3XFZ_X
M ^'GC;Q2R>#+'PS<:I::UH%K;Z3KD<^C6,^LZ;HFE:U=_P ]_P#P<_\ [7O[
M57P9M/V6?V;/AW-X)\+?!3]I_P 4:S+XEUFP\1:Y)\0O'EU\*?$?PPNK[P#X
MIMV\)0:;X%^'5QJ'COPY=7-WX;UOQ?KWC,6M[8ZI;>&]%TZYT?QF"2NTE_7?
M_@'];M%?D3^U_P#\%(OB-_P3V_9>T+XE?M4_"3X7:]^T?\3_ (K6OPD^!/P*
M_9[^+7BOQ9X7^(/B#6K6";19M6^(7Q%^$WPXUKPS86'EZC)XKOT\ :Q9:9YG
MARPL9]1U'Q##!:W/AK_P40\?>%_^"AFA_P#!-K]K#P/\.O#/Q>^)WP&LOC]\
M$O'_ ,(_$.NZEX(\;:=!_P )9%XL^'VHZ'XKM8_$&D^)_#S?#SX@ZIINL"ZF
ML/$7A_PO=7\^E^'9Y[&TO +/?U_#?[C]:JH:CJNF:/;QW>KZC8:7:S7^E:5%
M<ZC>6]C;RZGKFIV>B:)IT<US)%&]_K&LZA8:1I5FK&XU#4[ZSL+2.:ZN88G_
M )U?@C_P6O\ C'^UKX#_ &H?C/\ LF_!WX!_$_PM^SSXZU[0$_9^U?XK^-=
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MNNO"R:CXBT&"TL)/ &@ZEKVJQ^([*UN]/T_0;C6GW?@I_P %.]3'_!0[Q?\
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M:UX9L+#R]1D\5WZ> -8LM,\SPY86,^HZCXAA@M;GPU_X*(>/O"__  4,T/\
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M:O[/Q1Y\-EHMCXBUJ;Q5<:!X;D-AH%_K/CGP\!9_A?Y=S^DZBOQ/_P"".?\
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M@T$M:)]'^:.GHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&\(:I^T!X:\1:?XCUJZBO&31M(N]"M[C5H;S4_LD36%O<7.X1V\S)]I?MO\
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MI:EX9LM1\7ZC\4=5%BNIGP9IV@6XU_\ 0Y55%5$541%"HB@*JJH 554 !54
M       8H)OI;S;/&/VB/B!X$^&GP5^)7B?XB^-/"G@/PW#X)\6V\FO>,?$&
MD^&M'6Y;PSJ]REM_:.LW=G:&YDM[6YFCMUE,TD=O,\<;+$Y'\77_  9Y_$3P
M#X8\4?MX>"/$GC7PIH'C'Q[#^RY/X'\+ZUK^EZ7K_C"+PW+^T-!KY\,:5>W4
M%[KK:--XDT"/4H],AN9+-M8T[SE0741;^ZZB@$[)KO;\#^83_@[(\2>'M/\
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M_#+Q3XC_ &&?V@? ?@3P7?:[HDWBV;P_X,BT'X.:+\)=5T71-2\*R:?K9O\
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MPWM1J'C9KX^'+&V'CJ^MO"]U?W6HPV&GZJTD-_<VRP7#Q?Z#M% D[7\U8_C
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M[^UW#K]I=^#I5NRGB:WN="==9@ET8WJ2Z4PU!";4^;7M7_!;?]F_X\?LV?\
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MK#Z%H?Z)4";T2]7]X4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAGQL^EIJ>D^+OA[XJDLKOQ5\'OB=I<4ME>^(/AUK^JZ3HGB&T%CJ6GZ]X/\
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MQS\2_&=A\3/CK\5)/#T_Q0\?Z-X6/@7PO/;>$K*\L/"/@WP%X)?7/%-YX5\
M>$(=4UF70]-UOQ9XP\27.J:_XAUK7O%6JWFK%;4&VO\ +5^FJM^K/R@_X+-_
M"/\ :+TKXK?\$[O^"@'[/'PK\1_'F?\ 8'^+_P 1];^*/P6\!61U7XE>+/A3
M\:-)\#:#XRU7P-H@MKF;7-5T71_!=YIJZ=IT-WJT-QXELM9AL)=.TC5KS3_F
M#]MKX_>(_P!K/]KO_@C_ /&?X"?LH_MI>,/A[\%OVA/B'XL^(6J:K^S5X]\
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M/#7Q \=ZW%%K3P-?Z9X9NM8T:UNTMM9DM)@25_Z[:G[LT444""BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR;;28[6W!6T?E^I^Z-%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMKFWD2:"X@F19(9X)HV:.6&6-EDCDC9D=&5E8J0: :2M;[[WO^"MZ'F?Q?\
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MX_\ [26K:?>2L8H-:TG3M7^"'@'4'M%,\0TO5].?[)&]T=7]/U_/[97Q_N/
ML:6]]^RQ^ROXXL;GXEO-';7>F_'/]J/PO/I^N^&?AQ&DBSPWWP\_9QO/[/\
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MMI&CZA\4/%5CK&DZ+:K;V$%[/XCU9+2"?7)9+D!KXK=/RO8_=FBBB@04444
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M4[3QMK7A[1+7Q_XQT[51<S^'?$_C/5?"EC>W6B:#I4I_*[_@B-X(U/6_&_\
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MVS\,6D[[;[7+/PY!+:1>(M8L;;>=(TC4-3TK29;]X;G4[JXLK6;2]0XWX _
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M_P!G;_HS;XT_^'"\#?\ R!1_Q&%_L[?]&;?&G_PX7@;_ .0*** Y(]OQ8?\
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M\#?_ "!110')'M^+#_B,+_9V_P"C-OC3_P"'"\#?_(%'_$87^SM_T9M\:?\
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M"\#?_(%'_$87^SM_T9M\:?\ PX7@;_Y HHH#DCV_%A_Q&%_L[?\ 1FWQI_\
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M_P!G;_HS;XT_^'"\#?\ R!1_Q&%_L[?]&;?&G_PX7@;_ .0*** Y(]OQ8?\
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M\#?_ "!110')'M^+#_B,+_9V_P"C-OC3_P"'"\#?_(%'_$87^SM_T9M\:?\
MPX7@;_Y HHH#DCV_%A_Q&%_L[?\ 1FWQI_\ #A>!O_D"C_B,+_9V_P"C-OC3
M_P"'"\#?_(%%% <D>WXL/^(PO]G;_HS;XT_^'"\#?_(%?TG?L!_MA^'?V^OV
M2?A-^UIX3\&ZU\/O#_Q8_P"$[^P>$/$6HV.JZQI'_""?$OQE\-+K[9?Z;'%9
>7'V^]\&W.IV_DQKY5K>P0R9FCD)**"9Q26BZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>v434644_chrt-line.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v434644_chrt-line.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$(! D"V0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M:ZN8;=6D2)6FD6-6D<@(BLQ +,3A0#DG@58+ $#N>W7\_0?XT +136=4!+$
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M M%(2 "?09QWQ].M!('7C\_\_A0 M%,#J<=1DXY!'.,_EQ3LC_\ 4"?SQTH
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MG66-U5D8,CHLB..49&&58-T((((.<$4 244@8$9!XR1D\=*"P R>F"?R&?\
M]7K0 M%,5U?&,\C=@C! SCD=CGM3R0.O^?IZT %%(&!Q[]N_XCJ*,CU__7Z?
M7VZT +13=ZX)ST.#P<@YQR.N.106 [Y.<8')!]P.E #J*3</7\N3^76C</7I
MP?;Z^GXT +13=RYQGZ>_7IZGCM7#7WQ+\%Z;XSTGX?W>N647BW6XYY=.T<S1
M?:[B.VB\Z5EB+B3"Q_,2$/% '=T4TL![\%N.>!UI2P&.>IQ]/KZ?C0 M%)D#
MN, 9)[ 8SDGH!CUJ&&ZMKGS#;SQ3")S'(8W5PDBX)1BI(##/*GF@">BF%U!(
M)QC'..#GI@]#[XZ4[(_^OR1^?2@!:*:751DG\N2?8 =3[#FH#>6@G6V-Q#]I
M<%EM_,7SF4=66/.\A1]X@$#O0!9HI,CUZ9_3O[CWI0<\T %%%% !2-C:<G:,
M=?3WI:" >",CT- $..!YF,G)RO3"$$9SG/!Z_P#ZZ_D__P""[5Q\-H?VP/V6
MI/BS>3P> 'T>V3Q"()643Z?_ &XXN(-N=K321$[0PQC&:_K"XZ_P@?+WX)&[
MCJ<GC\>*_ S_ (*.?LM_%+XU?MV_LC^-O#WPPMO'7PS\+7&D#QG=Z@;*;3+*
MWBUPS7"W6GW:,EPHM_F*[2&'&.E 'PC\>/$7[#&F?L-^)5_9ZT76+SPE/XC@
M768]D7VL7#ZM8AF4J578T^,Y/W >.,U][VO_  4(OOA1X9^ '[./P(\#Q^(_
MB;XD\,6URMC?6\D^F:=9116K8F2WE6=97BF5QR06W=L5Z?\ \%8_V2M;^)7[
M+%SX(_9O^$WAX:X-<M+R?1?"NFZ3X:$T:7]E+(TAM+>VBDP(G<Y4DD'!-? G
MQ#_9._:N^ _Q9_9J_:D^&/@'3_BAJ.@>%X=(\<?"H^(='T#6-.NFCL+6(1ZI
M?S@3*$@=W:&,A<X)H ^C? '_  5F^..H?'SXC_ ;X@_"O2?"OB#X?^&+S6)I
M9;.ZA%_+9W/D&:VWSL6M')PNX!L^E>I_#3_@J%XT\?\ ['/QG_:.7PCH=OK?
MPR\1W6AV6E>3<"PO/LVMRZ4TLZ^:9"=D0DRK+\WM7Y,_!JU^+'[1?_!3+XQW
MGC#P>OP[UWQ=X!U#39-$34K3Q-_PC$L^I?\ 'K=WVGL\,S0N K$E,Y!(QU-#
M_9U_X*+?"7X!?M'_ +(&D_LQ77BG1?%?BZZUW3?B;;^*-'M+:XT^]\07.J0,
MFE.3/N,+*I ?<I89]* /T=^/?_!7KXB?![X$_LT_%.Q^'&F^)M;^.5I;R76A
MZ=;7,S07=QJ<UA'!81F=6WLL8*B1FRQZXX.WXI_X*Q?$WX5?"CP[XL^,GPG'
M@?QQ\0]8FT[P'X1U*RFM;R2U:)+BSU2_@>=G:TG@9COB;)*'"BOD[XF_L8_M
M(Z_\%?\ @GMHEI\,)[W4/AJ^BGX@63:A:%O#UQ#XBFNI6E+Y\\1V[>8?+&#T
M%?97_!3S]@SXD?M%^#/@MX[^%^CGQ)\0?A']AO)O!C7<-H-9@MK$6[6,-W<L
M+>V=LR*K$'D# YH ] _8Q_X*5ZS\>/CK=? +X@:9X9C\4OI<FL:7JOA&.Z&C
MW5M'9B^DA$EV[2&>W1EAN /E$JL!QBOUA\:>&-*\:^%=>\*ZVDK:5KVFW-EJ
M,2$!WM)5_>Q8/'S $>F3^7XN_L!>!/',GQ@T3Q)XC_8AU'X"IX;T2_TK4?'>
MJ>-=)\0RWE^UFL#"*UMXDN52[FC? 5F"*XS\HS7[*?$?4_%.@>!?%>K^!O#C
M>+?%]EI5U=:!X;^V161UG44 \FQ%Y<?N;839*[Y3M Z\4 ?R"?')_@1;?MY_
M!3P1^SGI]]^S=J/AGQE?VGC#Q5KF=%T?QS+;E(Y(8;BW:0W4C2Q.2) JEI@<
M\U_9!H[B32]+D6XCNE_LZS N8VWQW!^SQAIU;^)'8;MWHV:_E_\ VI/A]^V#
M^WYXV^''@6#]B.#]G^'P7XI.J>*/B,->\-WNH2CSK9Y9H+G3X+6[ 8VSMD2R
M.WF'<QK^E#X7>$9_ 7@#PIX.N]1GU2X\/:39V%U?SM(\L\\42AMSN6=OFRN2
MS<#'3% 'Y0_\%G+;P==_#OX!1_$)+&7P6WQ7F_X2%-5+_P!EFP_LQ#(UZ(R&
M,& #C)X [CGXM^#B^#I_VB_',O[(5Z]]^S0/@CXIB\=#PLTO_"!6^NQ^!YTM
M5MU8+BX&H^:)=Q)\X-@^OZ;_ /!2_P"#OCOXQZ)\!-*\%>#X_&5MI'Q2?4?$
MEA.]O]FM](;3UC,]S#<@QSQ%LJ864]ACK7UOJ7PG\.>&?@5XP\,> / GAKPU
MJFJ_#74]/;3/#6CZ;HBWFJS>'I85AE-A;P))(]TS*99-[%B6+'.2 ?C3^R3^
MU=<? ;]E_P"'/@+P;H1\5?%3X@>([?2_#6E2*\]F@OI+F*&^OD5UG-G',NR1
MXSGG R:^N?"'[9_QOTSXEZQ^SO\ ''PSX7\+?%/7/#%SJW@37-*ANX/"=]+)
MIUU>K8RO<R-<M>6<$0\Y4 "R%<9&:^&_ _[&O[2G@7X7? OXS>'?A^^L_$GX
M6>(]/NKWX9G4;2VNM5T*RN+F[E,>IS-Y$$CNRH,@NO7':OJ#P5\-OC_^U5^U
M'X=^/7Q.^#EQ\%/"7P_T2\L=.T[4M:L==O=:UBZTBYTNZ@CEM?+DMUMI9D<2
M%!&X!"8!H Y[_@E_XU_;!\;>)OBM=^/?$?P]U_P):>+Y;?6'N)=3G\3078>[
M6QBTMF_T=;,P*?-$N/G6/'. /T-_:[_:DL?V9_".@W%KI;Z_XS\;ZP/#7@W1
M(%\S[3K3P^;%]HC#([6Y7.=A#Y4_2OA_]C'PU^T=^S1\5_B=\*==^ U_K'@_
MQIXM37M(^)</B33XK-]+C$PGE?3"'F4PBXP$+*[F,[3@XKW?_@HC^SO\1OB]
MX>^&_CGX0Z6OB+QS\)/%T?BVR\+27$-J?$B06YA73H+NY98;*9R['SW!/RXQ
MDT >.O\ ML_M(?#[Q?I'PT^._@_P=X9USXE^'=7U#X<^)-(@U"'P\+B#2WO(
M+;4IKJ5IC<V[2P13K"-JRJP7(KYC_P""7_@WXZ^-/C7\>OB;X\T3X*Z_>V/Q
M,>R\1^+/(U6?QA:W,ELDZVWA^XD8PQ:>;<1NRRKGSP.U>HZOX"_:7_;9^*OP
MEU;XA? Z[^"7@GX,:-K4,FI:EKMAKD_B+6[K3([=H+=;81S6B17EJ(BQ#+(#
MN!(Y/TS_ ,$Z/A!\1?A1<_M(IX^\/2>'X_$GQ675-%WSQS?VE8+I<4"WL7E\
MQH67'ED$DF@#[ ^.WP*\(_'?P_8:%XZU/4X/#&EW,U_J>EV4Z0V.MV_E@RVF
MLK(");5%C+E5*\LQSBOQA_9@\-^"_#G_  45\<WO[,.F6'A3]GCP'X>U2U^(
M9T@/!X+CU4:8ABGAVL4,ZM%<22,Q/[[><\U]-_\ !4OX@_MHVG@_3_AQ^RI\
M)+_Q?#XD98O%GB*RUFSTVX72I!%(]E9M-MFM)R$>,W$;@GS.^ *\E_8VU7XF
MW/A:V_9J\9_L(^+/@]X(\0Z1>VWC#XA_\+(TV_U?5+FZ5C>7%Y>64":E<23O
M/-Y)EG<0QD*HXY /E#_@I#^T;XS_ &DI-1L_AMXGET#X'_#;Q$NFZMJ%G>BW
M;Q9XCL)T6XLXWCDV7&G36[AT5@')&20,U_0U\*?&7A6T^%/PN^U>(-,@\WP)
MX32)9KN)7E=-#L59<LWS,K#GN&!R:_#O]M'_ ((O_!+2OA-=-^SUX<^*U]XK
MU#7%O+S1Q\4=:;3YEDV--=&SG=+83E@!YNUG*C&<#G[]L?\ @F=\ _&OPO\
MA/H/C.?XL6=YX0\-:$Q@TKXG:_ILT.J?V99?;X+J6UDS<QQ74;H$8E H(&0<
M  ^%?BMX^^+'A_\ X*>27/P)\+V7C#Q9K'PS\1VUA<:C%-<^'K.VGNK=7O-1
M-M(LH6)P"SQ<A 2O.*_0G]BC]L#QE\>/$WQ(^%OQ5\-:?X<^*7PPFE&NQ:+%
M-#H]Y;)>_8$N+(7+O<,DDP9D,A^[[]?'/A+^S7XS^%?_  4 TOQ!H?AW5?\
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MCZS\%+^'2?$.M:AXK\-_$P>(;(65[<6LE[?65E_9X_>)]HDN4B#NX5<$GN*
M/?? ?_!43QA/XL^'NJ>/=,\&0_#;XJ:I#8>&[30TO#XOT;[7'+/"/$:S2-:Q
MM'&@68P C>1CBK'A3_@H?^TE\0_V@OB#\._ _P (-/U;X=_#1;/4?$7BO[#=
MOC1KU9KA9+>=)Q'YT5K [2%TV[AP,9KQ?]F;X+>//#-_X \ _$7]A_7;GQ+X
M+NHK*]\;W/Q TRXTD6UO#)'_ ,)%#IAC=%\R1@! C>:!WZFOK?\ 8O\ @/\
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M\(/C-^R9JMSX>;4]-T_QQ?\ C+XB:C:W4$,?AJ]U?1I%N[7RU9OM @NOW0>
ME6!&WB@#ZX^ G[</Q4N/C1XR^!'[27A#1?#WB_PWH&I>*[*_\,07,.DWFCZ7
MIS:K= -?2O(T]M;E(Y,!4$H;/%?/?B+_ (*O^+Y-0\2_$'PGH7A+_A2_A#Q'
M-H.IZ=JJ79^(&J06[*TFK:.D,OV!["1&"Q/( ?-!!&*]M\;_   ^)'B/]O\
MN?&#^&WC^'/BGX5>.O"\OBM9XBMK<ZOH TV)3 /WP9I&(!XQC/>O@#X??LJ_
M$KX":SXJ^%?BK]C[Q'\:=+U3Q)<W?@OQA9_$"PTC3M1T^20);V]WI\RS>7DA
MY'-R1TVMT% ']%/@CXB:#XU^'6C?$G2IE;1-4\,V_B5@I^>"*335U"X@E'03
M0(2D@Z!U(Z9K\S_#/[:?[2/[1/C'Q;'^S+\/O#3_  \\&>(%TJ[\2^.K6^9=
M7CBW&?\ LF6PF\MYFV2)'YB@!UP>AK])_"GA6UM_A9IWA.#0T\("\\('3)=!
M62.Z&B3WVE&UGLVGA BN#9-(T9D3Y9-F1UK\>O@5#^UM^PSKOQ!^%FD_L]77
MQE\"^(O$SZGX"\4Z1K^F: DL<HE*6MU;S+)*K23SNIFF*;5 )('- 'TM\1?V
MP_C'J/Q#L/@3\"O"7A[Q!\7++PKI^O>,+G5X;N;PSX>FG+I<QW1M95NHHQ-$
MT,>[<0[(#ZGS^S_X*/\ B6S^&GQC3Q;X/M-"^-_P?CMEU3P;=P2Q6^HRS13R
MI/I]N93<-;3)#YD)=PQC=">37#:_X'_::_9V_:)E_:D\ ?!"Z^(.G_%CP/I>
MF?$/P'!XAL+74/!.KF62_NU_M28NNH1Q7;I;A;9-I(WJ<5Y=>?LL?M#_ !/\
M,?M(?M"?$#X<MX6^)_Q9_L>+PS\-EU"SNKC3['3;6XLD>XU*W/V>X-S;F*;!
M 9=Q5N<T =EHW_!1G]J/1_!'PB^.'Q*^$F@Z7\'?B/=:=971L+*^3Q#8M?R3
M$7BM-.ULMHD4+?,2Q#\]*^@?''[=7Q!\>?$VU^$7[*GA'3?%GB6+P_I7B37M
M?\10W%QX:TBRU>U:XM(+F6QD2>.Y!5H'!!7S< $C->9?&CX _&3Q%_P3Y_9\
M^&ND^#IM0\?>%1H4OB+P\+R"-K(6@OUG4RL?+D\L2Q_*F<ELBO-]#^$W[3_[
M&GQHT_XQ?##X3M\6? 7Q ^'OA'0_'F@V6I6&D:EX=U/2=/W%4N;D/)-OU&4Q
M'R8]H"DL"IH ^E/C7^W/\0_V>?A]X%TKXE^&]!M_CC\1+F.ST73;6.X7PW9K
M)=FQDU+44ED%V-/M)2CSM&VX19(!->7^$O\ @IAXIM/#7QNT7X@6/A&3XJ?"
M_P $?\)EI,OAQ;O_ (0W7+26_CL[>V@:X<W<ET[.78;E7;C&.E<%^V-\#OV@
MOVL-$^%OQWD^ .IZ3XM^'-Q''-\*7\6Z>U_K6@37YOM0:/6(Q';VTIBCVHOE
M[\N"%)!S1TGX.>*?B'\$?C_;Z#^QSK/PJ\5ZW\.4TC0]8USQMI_B*[UK6X=1
MMI9-!A7RDFMA#&#.+ECY6/E7DT 7+;_@H[^UCH7@+P;\?/''PA\-VWP2\0Z[
M8Z-J$VGV5^/$-A]MU"+3X;AVEN#;+%*\ADA.22@R1VKD?BI\9?VP/%O_  4+
M^%%C\*_$OP_M_ WBGX<?\)%X:\/:Y+J7V23P\^IQJ]SK4,'R-KB2EHT:,^6(
ML BO=OB9\ OC!K7_  39\,_"?3_!TMU\1;+Q!X4N[OPQ]L@#+;V6M0W-U(;A
MCY1$,"M(!WZ 9KSCXG?"O]H?X6_&[]FOXZ^#O@W=?$73O"_PGMO VN:)8ZS9
MZ5=66NW&IM=+;27$NYC&(TYDV^7D8)S0!V-_^WS^U=JO[27B#X"?#SX/:+XL
M'@C3=(NO%^O6%C?3VD$MW.UM=O;2"X7$*R1N8S(F0N-W/-3_ +2W_!1'XL?L
MX>([>]\5/\)])\*P:YH&A7?A'4#J0^(6J7&LB/?<:1!&YLC;VDA=)S*0RDKC
MO7<?LF_"GXR:+^U+^T;\2O%_@6Z\&Z?\1/AOH;Z*)-2AO!;ZY--=7,VE^9"<
M/)822(IN!A7(#+TX_+3XC?LT?MD:WH_QA\'ZI^S+>?$+Q9<>/-/\16GQ0USQ
M3I=]%%I-G+<7 MM*T^_\V:T,ML\2!K>0%74-C(% 'UI^T#\:OVM?%_[7'[,T
MWP@\0^"]+\.^._#/A[Q%H_AOQ'+J*Z8TFHS3-OUN"V)W Q;D?RR3D* >]>LV
M?[0&A?!G]KKXXW7Q,\(^%;?Q)X;\%>%-0UK7_#MO*CW&HW&CRS)%9R7,G$=S
M<*8XU=0Q#@''6N,^)'PB_:(\%:I^QY\?/"/P@N_'5W\._ WA30_&W@J#6;.P
MO-&DL8YGNF-Y,"L_EO($Q&A)YP,"LCQ-^RW\<OVD_P!H?X\^)_%GP[N?AIH?
MCSP5X1FTB>ZU.VU-VU/2](EF@M6D@V?>N3'$PX103D 9H ]5G_;_ /VC]!\(
M^&OV@O%/POT*U_9[\2:S;:="D-G>CQK9:?=SS(-8O"\QLEL(8X)#,ZC(." 1
MG'1?&/\ ;Y^,J_'7P1\'?V>_!/A[Q8/B!X%T'Q?HNJ:Q!>3Q6']M6LMXK:F]
MI,A6V:./9$8U+;R!DBOFS4M _;2\>_ 3PM^Q7JO[-%UI(T>ZM=%U3XHS>*-)
MFTJ3PNEQ<I<:S%I8&]71+D$0"5I&VC8 22?H?P7^S)\2/AY^VY\*==L_#TU[
M\//!OP=\#^$;WQ:+F-(9-3T6QFMKL"T),H&[:0.0-W4XH ]@_9+_ &V/%OQ,
M\<?$/X/_ ![\-Z?X$^)OP]NK6'4EL4DM-'GBN8'N4>,W<LDWS0A"NXCAB>]<
M=_P57^*'Q'T7]EZ_U?X">-/#^GZK'JPBUV[:\EW_ -C&(%TLWM6)%UYNW[_R
M[,]Q7#P_LBZ_\3/VT?VD[SXF>&->T_X3_$)=(?3?$N@:]+H^HWS66A_9@+:[
MLF%W9A93L;!^;AAT KHOC9_P36\*^%?V9_B#X$_9V?QIJGB:^L[B_P!.TKQK
MXRU'Q1+K%WA"-.@N]7DV6;2[!ME8[5Y]<4 >#_%KQ[\8?#?[/'[.VM_M)Z#\
M+O&NI:K-X/\ ^$=?PY!J,X6"].CK%=7QO'0F_%O+%+</'^[^TJY&>:[GQC^W
MY^TK)\:/C)\)OA'\+_#>KZ3\';&&^FU;4[.^DMWTVVT6UU":V=[>=?\ 3&6;
M; H"IM7YJ\I^*V@?M1_M!_!+X,^#[_\ 9NU/P-??"O5?"VDR27'B;3]0_M4:
M%=:59ZA<Q11(IMXXX[*2Y&[=N#;48C KZ&^"?P(^+.D?M&?M?>*-9\)36/AK
MQG8_9?#%^UW$Z:Q,WA>QM !$IW*@N(Y(B'R#@^HH \9L/^"G7[27BWX/:C\;
M_"?P0@@\#^ M6FT7XBOJ^G70N#<Z?/;VU_+H/ESF+R?.N%\HW&?D/(!Z_2?Q
MI_X*1Z3X+^''P?U#PEH\)\>_&JS:7P_;^(%/]B:'):-!!>SZZL#B>.UCEF$@
M,1+")6."0*\P\#_ 'XO0_P#!/_\ :0^%4_@Z6T\=>*?&GBNXT#0DNH8VU&SN
M=5TJXMIHY5Q'&LT5M*V&Z;<')X/SK\:_V'_C%XG^$G[,7Q&T3X9W_C'Q;\)+
M/5[/Q?\ #&#7[;2KK4;*^NH/-EM]4F801M!;0O)L52TA.T<XH _0O]C7]M;6
M/CMXZ\8?"#QW!X</Q"\&6\UY>:KX-6X_X1C5K*!XHVNM*DNV:XDA:250IDY)
M4\#&:]$_;(_:\C_9IT[P=H>A:!<^+/B/\1]2GTCP;H4$8G!O(!$TLU[$K))]
MG2.3?F([MJL37CO["OA-[;Q3KOBD?LKZM\"X[C1Y+!O$&L^+K/Q%=:E()8G:
MR6.*..XC5\"0NQ*@ISR:J?\ !0_]G7XN>/-7^$WQK^!&BQ^*O'OPDUNZU23P
ME<7%O"-<LKI8898;6YNV%O:2QP+*^X99SA0-W% $/B?]IK]KGX/?";Q9\3/C
M'X+\ VZZ>]N^A0Z#;:FHDM[FU:X5+[[5*3YZL!&1&0N5:NQ^,?[:/BCX<?!;
M]FGXF6&@Z;=:A\;]1TFTU.RN(Y3#IRW^EI?N]LJN&5E9]@WLPQZGIX_\3]=_
M:?\ VP_@9XW^'%W^S=J/PQG32)I]-U/5/%>F:DFL:S86$D=OIL-NBPM;"[N"
MT:S2%DC^\QY)/QK\1M!_;<^*O@']E/X.W7[*FH^$]-^"WB+2;/Q-XHG\7Z1J
M$5T=+TU-/GN(;2)1)&CF-9!\[\E@"1@  ^JOBG^WS^TU:_M-ZQ\!/@[\)-'\
M6PZ3H'AW6;C4IK*]G>/^U])AU&996AN%4!"S!,+PJ\YP,^S?";]OB76?A=\>
M->^)]EHGA?XB_!B[U&WN/"L(EMYM0-C8K<DQ03NTD@,KK'G>"2?45SGP3^"O
MQ2T+]O;XH_$G5_#,]AX'OO!O@:PL-;>[26.[N[/PREK?0I IWKY-P#$Q(PV,
MCBO"?VKOV&OBQXQ_:\\&^)?AC8!?A)X]OH+_ .,;QR10K*)KSRKZ)XRRN^^T
M16.U6';!H ZGQ/\ \%,O'MIH_@/P;IGA?PYH'QD\?J^M6+^*HKJ'PCI'A:ZM
M!J&CZAJOD2B]C?4+4/'&R95YBF %S48_X*K7.G_ [XD>)]6T'2'^*'P[\5:'
MX0O[.SAN&\/7EWKD<K1:M""WVDZ5:; ]Q(7#JAX'-<K^VY^QIXST[XV?#GX[
M?#GX4ZA\8?#/A3PUH_A3Q#X%TG7K?PY=IHVAV'V*PEBO9\@G+ L(XRWRX/6N
ME\)Z!XMT#X.^.M2T+_@GO=RV_BG4--M]0\.ZQXZT+4=2UO0IX7M]6U>&[N;<
MR6MQIL?F)"67SBP#1$8H ^]/V0OBM\7/C'X"M?&GQ+/@&:UU>W2]T:X\"->-
M:I%*H=(K@WCLPN%5CO Q@X[U^7O[;'CWQ[\/_P#@HQ\#=2^&7A6;Q7XTNM,U
MFQT>Q\F6?3XI+S28K=[G5(XG206MOYGG2-'\RQAB.<5]-?\ !,/X*_&7X5VG
MQ/O?&WA?6/AYX \1^*M3U+X?> M;UU?$5UI.CW#PM9%+U7(CB2)6C6'RTQC.
M!R*\R_;+\#?M0>'/VV/@Y\=/@=\')?BGI'A>RU@:U:IJ]CI96WGTV.*;;+><
M A%?:!R2!MY(H L^*_\ @H7^T!\'M3\7?#GXP>!/"EG\4?#_ (6U'QCI/]D6
MU\N@>)-%TY5,LNDB>4W,P,KB$L<?O%8"O:_&7[?]TGP"^#_Q%\ >'8-8\>?%
MW4K7P[IOAVX0RP0:_;PVUQK,$D,4HF"6\4LK( 2X*C=P*\=^'OP*^,7[6/[3
M4O[1?[0OPS;X3^"/#G@O4O!/ASP?J&I6>L7&L6%Y-'=OJ$U[;X6"!)4EC>"=
M!N&&X6OGK]@_]G:[\1_M>?$RXO\ 6I];^%7P.\=:]XF^'5MNEETB#Q'JFH3:
M?J.FQJ7>V<V5L4&  H !4"@#]O/BIJWCF'X&>*]:\-R:98>-$\ ZAJ@-WYRV
MMG>KH<MU)Y>S]XLD,N1"3G#*O4C-?BY^QW^T'^V#X(_9<^._QN\=ZEX \9^&
M_!-QKNKVL-P^J7'B>;6;86P^R,S%8#8>6R[$R)-Y8J2-U?O'X[T27Q)X)\6^
M'+-A'=:UX<U?2;=MN-DM]8SVT/'&55I!P#@ 8XK\#?"OP^_:L\"?LW?M,?LN
M7O[.NHW[Z[_;M_X9\:0^)M.2UUBPN9+6&WN%L0K21NWELWEL^[!Y!X( /8?A
M[_P4P^,FG?!'6OCG\>?A;8^%O"\RV,/@R"PM+B&XURZOIU@3ROM,[K*D32Q/
M-M((C)(&:ZSX._\ !2#QGJ/Q4\'>"OBOIGA";3/BC8->>#(_!27AU/19YK@6
MUEIGBK[9(8HKV=V$A2#Y3$<Y!K/^*'[%7Q!^,/\ P3[\$?"R?2Y[/XE>$;?3
MM6T_P^UZ@%S<6LMG=2V+W&X0HUP(#"&<@(3G&.*\@^"OPJ^)&J6\>AZA^Q5K
MW@GXDZ/X:NK&3X@ZAX_TW4;31]>A CLKBTLA&OS.%CN$>&0;""I8$F@#T#X[
M?\%)OBK\ ?B;I>G>+S\*%\)ZSXUNO"=CX+A.I'XFB.&0)#JSP;_[.%E<;U\M
MRVXE7&W@5Q1^)/[96N_\%'GT#P/XC^'H\+W'AJPU>QT#Q%+JATVWT34-#M[[
M4L06YR-36"8FV8';]HP3QT^)O&'[+_[7WB/P9JGAV[_9;U'6O%_A_P"*^I>(
M]6^*NN^+=+U6\U?1)K^V6&VTFWNM]YIR1%&G00RE1&=@&*_0WQ=X$_:+^%'[
M5/@GX]>'_@C??$3PKXF\#:9X5UVQL-?L])NO#%XWA^PT8;YI TEP6E5Y-\:@
M+M.3WH _8_3/%VC-]CTO4-?T67Q 0EK=VEC=(0;T@>9%!&S>9G?]P$?=[=37
M:+]T#.<9'/7@]#[CO7Y_>!OV _@E;?$G0_V@KRU^*6A?$M[V'Q%<Z#=_$[6M
M1\/Z;JQ;S6M9M(5SIUS#&W!7'ENO'%?H&!C^O;)]: "BBB@ I""00#@XX/I2
MTA. 3TQZ]/QH A/RG<!TPJ@\=<AL_CC_ ":0HC,6*HS(1C<BG#=?E;!8<CC'
MK3S]\9&0X^4'D#'.3V&>.G/X\5\'_M-_MZ> OV9OB-X3^%NM^$?$7BOQ5XST
M:35]$M=!DMT>Y9+K[*EH%F1F\Z23&UB0H'4]Z /NUMC$+@;5)+JX!!&/]KKR
M*^&/VF_V*O\ AHO6-/\ $&E?&;QS\)M4TZ*6&*X\)VUG<%TGV^8'AO)!$00N
M 0I('(Q7@VF?\%:_A)K=KKUCI'PY\::CX_\ "S2GQ!\.H7MF\0:;:0N8VO)Y
M##]F\DE)",L6_=MWKZ!\+_\ !0/X ^)?@0_QZ;7$TG0[>X&G76CWT@&J6NL2
M326\&DN5C"&YN)XFBC*KL##YL4 4_P!D[]@#X4?LI:OKWB[0[_4O&'Q$\4I)
M_P )'XYU^&-=7U1YV5YGE6.22&,R2*'(C"@'@*.M?=)"C<TD49W8#E$5RX X
MWDCMU&<].*_/7X<_\%%_AQXQU;5=$\4^#O$7PVU9- D\3>%K+Q'>V,TOC+0=
MY2VO])^Q@B)+I@_EK/MD&P[E'%>,0_\ !7KX7WVE7/BC1OA/X]U;P1I/B*Z\
M.>)O%UK/8C2O#=S;:A_9OG:B7B$DD<MSN5!"&(()8]Z /UQ$:!<(J%B=V0B[
M1@D<#&%..@ &3G%.PHV,#L4,3C&"Y(((.>V"?Q[=*_&/]N#]OGXB_#+4?V9]
M2^!G@#6OB#X/^+&LZ%?2:AH<ENAOX[C43;'P_!)-)'_IMZ,I$S Q!@=QXK]7
M?AEXQU_QWX4T_P 1>)? FN?#G5;D W/A;Q));3:G9916!E>T9H3EFVC:2<K^
M- 'H*QHG"HB DEDC4+N.?E;"@$GOS3B3DG)(QR!V'X<[ATQZ<]J_-KXP_P#!
M2CX=_"'X]R_L]3^ O%GB?QG%/I\;SZ-+;?9EBOXXYOM#*\;2+%;QR@R;G!V@
MXJU\0/\ @I%\-/".M3:'X9\'>(OB'>:'8#5/'_\ PCUY8P+X#TM&5+R\UL7@
M4NMF642K;[Y#N&T8S0!^B^Q%8;(HQNY=MH0D9!&"HYQSGZ9J08^7 XSP/_9L
MC.0.GI7Q#XS_ &]/@KX7^&GA/XCZ?<3^*&\=//:^%O#>D31MJVJZC:)&;C3[
M<,A03QF5$<L%4$X)QFO =$_X*A?#3QCXU;X)>)OA_P".OAE\0]6\-:IJ-QHN
MM75HFIZ/!"H0$2VT?EB=XY8[B&2%R%RN?F% 'ZJ(]M.S^6T<ICE9"RX<QS#A
MU(((5AW[]JE4[@HSMSN 0@<@>H///88[U^,'PN_;9^%W[-_P1\2^.->N?'WC
MC2M:^.7BKPO;RZSK$>I:I;:A!'#*;>">9"5L@&V0P(,J6SZUZ!9_\%:_@Z/$
M2^#?$7@+QEX6\::E9QWOA3PUJDD#:AXJA: 7 .F-#"8U_=O&<RE<[UW=. #]
M7\  !55 #AE4#H.H"]"#QVS35"# C38B-O8*@0$GJP"@9;UKXF_9W_;L^%_Q
M_;QS8'3=3^'WB'X=&YD\5Z!XGEA-]IEG9QI+<7LK6Z*BPQB1 2"Q!;//;RP?
M\%/?A._BEK6+PGXBD^'']N/X<3XMB]LAX5DU:*[6SEM%@(%\'BG=$9MFUBZX
M8C- 'Z7,BJ=PC02#Y4< %PK8W8.-P'7@''Y4)RY()W+\I+##-WP1_=[@BOS6
M^*7_  4L\"?#_P"*OB?X/Z)\-/&7Q!\8^&K"'4Y;/PW<61:\TR6PBU![VV,J
M%4BB@F0N&?>2>!Q7T7^S!^U=\/\ ]J/PQ?:[X0@N](U31KZ73->\,:HZ/J^B
MWL 03PWC1JJ9C=PC;<\XY- 'TX$1?EV(%<DE(U4 $8()V@9)YSG^E*J@;F"J
M"2#N4 ,WIY@ &/0GL*\I^-'Q8L_@WX-N_%MSH.H^(WBEM[:ST72'BBOK^[N9
M1#!;Q23?N4>:5U12Y506RQ S7S#\'/V^?"'Q1U3XA^%]9\ >)/AUXY^'&CZA
MK>N^#?$%_IEWJOV/3HEEE=9-.+VXW(Z8RYP6P: /O9T20C<B-QR2BN!^)!_G
MZ4J11(>(X@P& 51%;GDYP!UZ\?C7Y%67_!7CX6ZII-]XFTWX4^/;SP7HOB6]
M\->(_%<,]F-+T&YL;I+.:YOCY0=H?.D5 (]S GDXKZ>^*?[=OPA^'?AGP1K>
MDK>>/=9^(EB;[P;X5\.2Q_VQK:J4CDBMS*C1JR3.D+M+M4,03QT /LN2^T];
MM=/DNK5+QTWQVKNAN'BS@.L3<["V1NP1VJR %4!$*KG"@#&22 V1V! ./6OP
M%\#_ +6MY\=_^"DOA#3;!/%G@(:7\/-.L?$WPUUR[8RZ9JL>J/\ :1>PP*+2
M6=0RHTD65/ !K]O/BSXKU?P/\._&'BK0?#]_XGU;1M!U*]LM'TYXEN9Y;>SF
ME653,0GEV[*)902&**P7G% '?.8HM[R;55$)\QPJJB 9.Z3&X+GKS@"F@QD)
M)'M:.500R!2'0X89<#)3!R#G%?A+^S3^VE\7OVB/V=_CI=?%;X9>/?">D:)X
M8\4:HOQ2TJ_M+'2[3^S8)UCTJU*2/=Q:A,%$D4@78I0DG.*]+\"_\%$_A5\$
M? 7P7\$2Z3\0_'^M>/["TCT26]U6'4=5O[QM.%T\#3S(Q=1&A*@@ $DG/& #
M]D@RE2V"W\/ W  _+@9Z@X^;.>M(1P(T"*@7. H"$@X*XQMZY.,8Q7Y2:3_P
M5C^$^L-XDT#2_AYXSNOB1X0#2:_\-(Y+<>(;"TV-.;R5FB^R^4MJIN" Q8H<
M#!Z?17P\_;M^"7CKX)>(?CE=:@WA7PYX4N)[+7['5YD%[I^I6\*S26$PB09G
M56 P$(YXH ^T1\N!'A>P3:J)G!R1@#))Y]Z-D>69%C:0?+(^T!L$<[B!\QP!
MP<Y^E?GY\*O^"A?P_P#B'XZT#P5KO@OQ#\//^$Q>8^!-:\17EA-8^+88XO/6
MYTU+3=+''+;E)D$X5@DBC&<@?<_B/7;?PSX?USQ#/$T]KH^FW.JSI"0LDT5M
M"TS(&/!>1!\I/'(S0!O;4( "*< ,H9%"\],<<' QQZ4W:@(8*!@X*@!>3CG
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ML-K$!^[W -@<T ?LRJJ<AXEW?Q+MR@ ] 1C)'L.?U<R]$&40X*D 8!(Z$=
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M#^M*51F4E%9E.X,P!VL1_ <9ZCH.<=:_-O0?^"C_ (5O/B-X?^'WBWX3^,O
ML_C:;R_A_JVMZCI,UMXPW7)M(7TVWMF>YA$]PIC1;A8\,,D5[G\+/VP_A?\
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M 4+M9$7& RJJE2.=H (QP.V/Z5&53 #)N4':$:-2@?/#\@XP.X ZU\0>"?\
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MG^)?Q:^-&B_$7X+>+(/!OA+5+Z*;Q;!/80:+X/T[29[U3-JR/*TK_:HH %,
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M<2>3)%,8@D+&.4M&6B+*2IP<=.0_X*"?M ^/?V=?V?-;\??#GPI>>*=?CO\
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M_@CQ[I1N?%]Y\1HB_@KPCHDT7]M:[B<6KK;>8AB4)<E86\P*-Y&< 9H ^U2
MNT*0HS@;  %3G P,  'TII."&9$+<JS  M@\#;P>,?>'3\*^!?AU_P %!/AO
MXWA\<Z?K?A;7_A_XW^'^AS:_K7@3Q'-:_P!M-80R")FB,*B!E,AVKM+C<*\2
M\/\ _!6SX9^*=$F\9Z#\)_'E_P##K2M6NM'\4^/8IK(:)X8N;>Z:R7[>#$L\
MBSSHT:?9U?:5._C% 'Z!_';X5^(?B[X$F\&>&?B?XC^$]Q=W,;7?B+PG:V5S
MJ-Q8;9([C36CO (5M[G>/,=<.I48(S5'X#? GP1^SEX#3P?X5&4-S/JWB'7K
MT+'>Z[J]V%-_JU^^6"SWLR^=*J/Y:N3L '->52_ML_"]O&?P@\(Z-:WVN+\:
M/#J>)O#6LV%Q +&'3VO?L#"='7S2RS YV[>AXZ5YQ^TE^U7X=M]7^+_[/&FV
MNKV7C?0?A]:>)_[=M[B..W%OJC2B!(=H\])8_);+%@N#P!S0!^@UI?6E_#%=
MV,]O=6K!U6YMY!*C,"598V7(?YA@]<$$58VQ@;V0.S_*S,BE]I_A;C..,[3W
MK\E/V0?VA]4^&O[$'PQ\5:YH7BCXG^(=3U+Q-:06=C>0G5+^Y/B*ZAM+8W5\
M1"'8E(HS(RJN1R *G\;_ /!2(ZY\#/CCK?P]^&/B73_BS\+-$U*76_!6HWFG
M7E_X<N[-H5>XU*2U?[/+#"\@C812LQ8C'% 'ZQ2306R%YFC@B! 9G8(@W'Y!
MDX +$@8XR3@>E2;54%D2-'<_,P4*3U&XD#)(&.IK\)])_:N\>?&K]A_6O'OQ
MA\ _$WX3IH^I^%IH_&MCJ]KI\/BA]0UFSC:WT=[:22>(6N=LPF !60!<8K[%
MUS]N'X=?"CPU\.O"'AO1/%WQ;\;>(/#46IZ;X3TV^M[KQ5-9Q,(Y;B_NKJ,P
MO()& +NRG#+UQF@#]$@D9X,:X8E6^1?G(P<N,8/3/.>::Z@J,JDF&R58*R\'
MY2,@X95QM QG&.HKX3\+?\% /A1XF^$'Q)^*2Z;JFFWWPFAFE\<>!+R>$>(M
M(FM[A+2XMIGVK!YD5P_ELR;D)!VY[^&:#_P5F^&.J77A6_U7X6>.?#G@/QA?
MPZ;I/Q$U*>Q/AV2[FN4M%C98XA/N^T.(\D#+ X..: /UB 7:6"D*^2V<[O3&
M.>G)Z]JD3A1R3Z9&#CWK/TW5+#6-/L]5TVZCNK'4($FLKF,DQ3Q2@,DB>H;L
M3Z5I#WZT %%%% !0>0:*1NAYV\=?2@"+)<Y"Y4GDD[2"O;'H3U]J_'3]IC0;
MO5?^"EW[.UTWA^[U33K3X=7+7%Z=(>]TVTE&NJ=LMTT+P1R ?,-S!@.E?L8&
M;C</4*!SNZ<L#V'!XSU/?%4)=)TVYOHM4DL[635+:)K>&],:M/%$S;FA60C<
ML;,<D#&3S0!^/7[,G@'2M/\ VS?VQ+F7P8+9KSP0DMM<7>@J+2Z:;4;T@V=U
M-;^7+(X/*0DG:W3!K\K-5^!?Q(\9_LH>.=5T#0O$5C%X!^+UIK.O^&TT2[CO
M+[1[;Q)?7UU<V6G>2LMZT5K&6CC@B8R;@%^\*_K7CTC3[>\NM2ALK2*_O(5@
MN[I(PLLT*'*)(X7<X!).#1:Z5IMA]H^R6%M"+I@]WY4,:^>V#AI%"A6&"<DC
M.#WH _FC^%_AC]G3XE/;>*]#UOXMZ[\3[#P(D^F:-K'PY\2:+8Z($+!=+>^N
M(Q"IAE+?Z,ZJ<$$I@FO=/@?X,:;_ ()<_%.RN?!MU#J]QXV\>2264GAYTU>[
M,7B*5XI?LS6XNIESEX9,'(.Y".#7[M6/A[P]I<U[)INB:?92:C(\U[-;6L,9
MNGDQO9B$P6?NO"\9Q5RVT?2[2RDTV#3[2VT^1Y'>UBB589'G;=*S1[=I:0G,
MAQDDT ?SA?$?2?$OAK]D/]@GXJW/AKQ+<>&/AUXL\-7?BV"PTB_U#7M*LK?Q
M)?7,UQ)HT,37NV&"%G)9%V KR,C/[[?!?XS^#?COX,M?'O@4:\- N+B6TC;Q
M'H=YH&HO+"J%R=/ODCG\H^8NR;;M?G&<&O2$T?2$TXZ,NFVJZ4T3P&P,$?V/
MRI-V^/R2"H#;FR !R<CG!JQ9V-EIEM!9Z=:Q6EI;H(XK:TC2.*-%&%4(N  .
M!GKVH _'+P%X8FU'_@J7\:[W4_#,UQIW]A:7'8:QJ.AF;3TD;PZ@8VE]<0-
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M;H_AS6H;9!+<07\-[_;>J7AM6_>1M<*KJTF%+#(+'FOZ%M5\+Z?%H5S:>']
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M^D>&/!EKI?BY_#FC:CXAF\/7]SKDU\D+V^GQ2LL"6K([G")&3@XP<%]\4?\
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MI!:VF@2?VS:Q_P!OQM<RM:Q0?:H5PNZ9L  #<QQ7[T?V9I9T\Z5]AM1I:PI
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M>"_ 7[?W[+^M>-_%?A[PAHT7A%S)J?B75;;2+&$_\)&Q"M<73I&&V@M@GUH
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M+!*LD$J"5'5A(KHP#*Z.I((*D$8/?@U_(G\!_A?JWQ5^#_B#P3J?Q?\ AWX
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M)_Z)IG@O]L_]KWP5X9D_L_PQI'C6_CL?#\4[/;6F+.T8&&-W;8J[CC:H )-
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MCZ;:WL^I6]FT1/[J*^NG>>Y15/\ K969CGDU^6?_  6CFBA^"_P[::18H_\
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M%M!\9^&;RYT7QGX5ED:671M3L)_LEP!*P4S1/<)*(Y50)($!4G-=9^T1\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A ((/(/6EHH
M :%QCG.,]AG'89]J0H&#!L-N4J<C@J1@@K]TCZ@T^B@!FP84*=FT8&T # Z
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M2(K=>J*Q#'\ : )51%+(% ^8OA1M!!Z'C&2.AI&@1QM=58$@L'4.I(^Z=K9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>N:_I+_:;_9#_9O_ &I/#YM/CY\,=%\=PZ38S1:9=:E'<&\TM3NE\RP:&XA
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MZOZ#Z_GP\4_\K"%G_P!F;>$?_4QOJ /Z#Z*** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN6OZE]=LTU'1M6T^XMDO5N["YMVLW4,ES'+&5:-E;*D/T(;CL:_CA\/^)O\
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M  M\&_";]N;X.?#7XAZSI&M>'_#WP>\:K:7=]<176D3ZF_A&,W*1O.&A)AO
MRQD+N! [FOO[QK_P0._9"\;_ !/\1?%Z;XD?M,^'?&7BB^DU+5K[PO\ %_4=
M%2>>:Y%U)A8+)F$+2](RYPI(.:]M^/'_  2,_9T^.OPZ\#>!=4\0_$[1-5\
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M,XYZU_/CXI_Y6$+/_LS;PC_ZF-]0 _\ X*@?\I-_^"4W_7]\:O\ TT:75?\
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M_L[_  4\2ZWJ \0_#:\\;0:-'<VTI\ZY_LVQLX)(C:RQ?NHB[9Z@],G]I?\
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M ?[0GQT^!7B6]\2:D/'_ (>\,:KI^DZ'J,[74AO9HH$@D=UFE+'+G) &<=:
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MXZ\G'0_7\O>C(SCOS^&/4]J\T'Q@^%S%0GC[PV_FN(DV:I;$"0L %^]U9B%
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M_P#P2F_Z_OC5_P"FC2ZA_:-_Y3Q_LE?]FA^*O_4Z:@#\YOV7/^"7/[._C_\
MX*A_M6?LY>(_&?[0MW\*_@?\+_AMXY^'^D)\:_%T%Y:^(=2\2O!>3ZE?I<M)
MJ%O)%;1K]FE38?F!.&./[&]*TVWTC3M.TNU,K6NEV%IIUH9Y&FF^S65O';0F
M>9OFFF\N-?,E;YG;+'EC7X!?L3?\IM_^"A'_ &0#X4?^I5=U_0;0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,V/<GH/
M7\>@_&EK\D/^"FO[=G[1G[$OAW4_'WPO^ ^C?$_X?^%_",GBGQAX@U:[U>T3
M1H;>Y,5PF^P'DA41HVS*PQNYZB@#];=PR!W/7V..F<8]NM+DX)(QC/&<U^2'
M_!-_]N7]IC]LFSE\2_%/]GW2/A;X%U#0](UKPSK^FW6LW":O'J4*W#;6OU\E
M@D;HP,;'A@37ZV=.,D$X^8]]O9NPS[=0: %+X .." 2<C*@^HZG\!3^M1<G+
M!!N/RG<2,@?_ %ZE^M !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5Y=\;+^33/A#\3=0BL(-5>Q\">)[M--N(A-!>M!I-U(
M()XFPLL#[=LL9^^A*GK7J-<!\5/L)^&WCU=5OVTG2F\'^(1J6K1VWVR33K(Z
M7<BZNTL^MRT$&^40_P#+39M[B@#^*?\ 9P_9V_X*P_%M/'OC[]G#]ICP!\-O
MA]K/C+4[R'P(]SJ%A:>'I9>1806$5]#%;F&, 8C7;C@5_2+_ ,$Q_A#^V;\*
M/"7B^T_;%^+>C?%7Q#?26S:->:-=SW5K9QK/(S@I<7%P\9:,HIY )'%?R ^-
M]=_X)E>&/B%XY@7_ (*6_M$>%]2NO$.H2ZUI?A[X.>,;?2H[YI2LT=O]@U"&
MU*H0%62- "/:OZ3/^"%,_P  M1\(_%+5O@3^TU\3/VC--N_[)CO[WXB^%==\
M,RZ+Y,\RQ"QCUJYN#/YK91_*(P%!8D4 ?NQXQGTVV\*>([C5K1[W2(M'OI+^
MR #-=6J0N9H8U;Y29$RN&&.1GK7\M?P+_9!^"7[;.G?M6Z/\'_%OC;X774?C
M3Q);^&I/$?B2#/A;QHFL(-1U?2+:T"SVEG+'B.!88_,1 0QQG']/WQ$\:^!/
M!7A^^U#QYXQ\,>"]+EMIK<:EXIUC3=(L<2(PVAM3GMX9Y"02D +.^,*IP:_B
M%\*_L+Z;\<?CS^T'\6_@;_P5'\+?!K3[WXB^+&N_#L^H:!I-G,R:A),\EE'<
MZW:QWD#D@17$,;+*H!4L.@!_2!_P3-_X)P:Q^Q?_ ,);XA^(OQ?G^,WQ&\32
M6R2^)IM1NKZ1;2VADMXX9WO1]H=E@,:)@X55P..OZ^5_-G_P12F_L'XD?&+P
M'JG[5VK?M'ZUH%W:P/J$MB5TD!(9O-:QO8KRZM9UR,[H6*G'-?TF4 !. 3Z4
MW/ (((Y)]2!Z?Y]*<0#P:JS21PJ]PS(B1+\\DCB..*( L\C,V%"KU)/  YP!
MP 3EC\G;=S@]3D=![_7CCZT@8CEOE!^Z.XQUS]3TK\A/B[_P6C_9(^$7QNB^
M"FJW7C'5KJ#4%TO7/%6B^$M7U/PMHVHF<P307VO6<4FFVOE2;5=IIXPNX<#(
MKU[]JK_@I[^S7^R?X5\(>)?%VK:SXB;QY:QZAX>T?PAHM[XDU2:PVQ2RW$MG
MI2SW,210RK)(73"+DG % 'Z0$@8R<$\#/KZ<4T,3QC##J#T'OUZ'M7PQX._X
M*%_LY>-OV<;[]IK3O$5[;?#W3('.J_;M.GM-7L=06 W!TZ33)RMT+LQ+D0E%
MER0-G<^>?LB?\%2?V<OVQ?%^L> ? 3^*=%\5:=A[/3/%WAG5/#4FKV;,_DWF
MF_VI'"UY!+$AFCDMPZ-'\RL5.: /TMK^?#Q3_P K"%G_ -F;>$?_ %,;ZOZ#
M@, <8]NN*_GQ\4_\K"%G_P!F;>$?_4QOJ '_ /!4#_E)O_P2F_Z_OC5_Z:-+
MJ']HW_E/'^R5_P!FA^*O_4Z:IO\ @J!_RDW_ ."4W_7]\:O_ $T:74/[1O\
MRGC_ &2O^S0_%7_J=-0!+^Q-_P IM_\ @H1_V0#X4?\ J57=?T&U_/E^Q-_R
MFW_X*$?]D ^%'_J57=?T&T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^<'_!7QE3_@F7^VDS@%1\$/$>X'D%3/8@C'?(
M.*_1^OS?_P""OK%?^"97[:1&!CX'^),DC.T>=99;'?'7'>@#\$_B_P"//^"D
M_P"S+^P)\,?VJ?@+\:/@]HW[/GAWX8?!C1K+X;Z_X?URZ\:C5_$$.A>';N\;
M4K>1---L+Z_CNEA'[T6\9^7O7[Y?\$WM$_;&LOA%?^(_VPOB?\./B;KGC>XT
MKQ#X(N/AWI.IZ7;:%X>N-.#SZ=JXU-W-Q?FXD1TD@(C55(89(Q^2'[83[?\
M@WJ\)N.AT+]GL$[=V\'Q+X0&-IZ<]^.1U[U^\W[.OCCP-I?P0^&&G:AXP\,:
M=>V_@_11<6-[KNFVUW;R?88#LF@GN8Y8VVX)5D&01QB@#Z>9@"H#'<1]WNPQ
MG@] ?>I:R-*UC1]?MC?:+JVFZO:^8T#7>EWMM?V_FQX+1F:VDDC6101O3=N&
M1D"M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJHF2XCBM8WA$A*&1WW# KZ6_;$_Y5Y_"G_8!_9[_ /4F\'5W'_!6?=_P[O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5R"5N;021L89@<2(0PXKZ/\ ^"^PD/@#]D]8V5/^,K_@82SMM4JOCFR)49R
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MYR<D]S[>WI0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OS?_P""OO\ RC*_;3_[(?XC_P#1]C7Z05^<'_!7P%O^"9?[:0 R3\#_ !&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_:)UK4;S_@Z6\-Z5<7,K66C>#O#DFGVPP5W7GA&%IVV^@P#G\Z^X_P#@J?\
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M'?([GZ^_KP^F@$>AXZ_Q$^_;UIU !1110 4444 %%%% !1110 4444 %%%%
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M"7]KGX+^"O'^FW)(OK1]+^),6FZ+)<QO^\4W.FV44ZEOO!MW>OU+_8M42_\
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M8Y8GB?1I60H\;.O(8<;N">>>*_&3_@WG_P"30/%7_9:/BY[_ /,_Z[WKQ/\
MX-O/CA\8/C3_ ,$^/$$_Q0UF77K7PQ?^)O#NA:A<SB:X73[#2UCM[69N65XX
MN65F++WKVO\ X-Z?D_8_\5D@@CXT?%SY",-C_A/]=P<'G!XP??- &1\;_P#E
M/W\"/^S.;_\ ]3^>OZ#J_GN^-[G_ (?^? ?Y?E;]CF_&1S@GQ_.1QW&._K7]
M"- !12$X'_U\4T/P,XSD@[3D ^Y[4 /HHR/6B@ HHHH **** "BBB@ HHHH
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M_P ,B^*<MP&5O^$XXP>N,=AQUH 3]BPB?_@MG_P4+MSO$;_L]?"R-@<;CO\
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MC\9_L._L0>/?$?@3P]J7BU_CY\ ?!LVMW5A$^H77AKQ!<.-5TAYS\SVMX+=
M\39#<YKI?VR C?\ !O1X6#$JG]B_L^'>&P"?^$G\('( (VJS<!0> >,]^W_X
M*T\_\$[OV']PPW_#4G[,Q0YSM87-UM.!U'<C\^: /E;XJZ[/_P $$?&GAGXH
M^%DUSQ+^Q9^T5IMS8>(?AI9NDEWX.\;:CIES?ZEJ?AZSS%96D+,UM;J\A=S
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M"/EM?F!9+CXU?MLZRGV=R\;6FL>*'N[3YC_RU$4B^:F,(^1R!FOV!_:-(/\
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M/4GL8/&/A7XFW-DVO>%;R..2&.VNK2T+"V:0B3:&))"BOWVH **** "BBB@
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M_(S_ ((1?\HN/V9_^O#QK_ZGOB2OU[H 15V@#KZGU/<^V?0<#M2T44 %%%%
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M[_@W7_:B\26-J;"S^(?P9\1>,8%$93,5X+&)6"X'41$# Z&N+_X.0/$)\/\
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M@'XI:Q;W?A;P1<0&R^UP1_:8S<26B1VXB,1*N!- K$L"O<G^C6ORH_X)W?\
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M^%N@1>%M1OO#6IOJOAF]CA&LQ:A#ODABE24;(<;DP3G/%?W]5_/A_P $5/\
MDLG_  4@_P"SR_BW_P"G*VH R;[_ ()-_M>?LQZE?>)/V#_VQ-=T'2;/,]AX
M ^,/]N?$S[0B'*V5K=:I>BVM5QB-<(%5=O0+4-E_P4E_X*%_LII!I_[:G['>
MN^*?#B3K!<_&/P+J6D0:5) C;)+U?#&E0WMXBLJM*8MN\ 8ZFOZ*)"0I(SG@
M<<D9ZG%4[S3[&_B$%_965_"0 T5];PW*8/7,<Z2)T[8H _-W]GW_ (*U_L3_
M +0WDV'AGXH)H/B,%(;_ $+QAH^K>%9+&[8A&MS=:]:6%M-LDRGF(X5B,@8P
M3^C.D^(= UZ(7&A:WI&M0,H<3:3J5GJ,14C(;S+.:9,$=#GGM7Q=^T)_P3@_
M8Z_:?M[G_A;/P:T#5;V6,K'J6F->>'KNWE'W)D.A3Z>K&-P&&]6W$<GO7YFZ
MQ_P2*_:<_9X?4-?_ &$?VSOB#X&MUD\VQ^$VM0Z7+X4N$C&8["?6M4DOKZ*!
MQB)GW;PI)["@#^AK</7'&><C^>*0LH(!/)Z#D]/IT_&OYST_X*$_\%*OV17T
M[0_VROV2K;Q_X7M)%BN_B#\#9=>^(>OW-FGRO?W>F6%M':Q3,B^8R#Y59@ >
M:^[/@-_P5\_8H^.5P-+;X@GX1^(RJ(WAOXSI:?#_ %LW!'S6\=CJUXLKR!@4
M&54L<8 SB@#]0R0>G\+9/T'7KU_#-?SZ:+_RL+_%T?\ 5I?P>]O^7Z]/'K^%
M?O=H/B+0?%>F0:WX9UG3]>TBZ3S+74])NH;ZTF0@$>1/ [QR!ASE6.?Q&?Y]
MO#_B3P_>?\'#'Q9AM];TJX=OV6_A/ID4,%[%).VI6EY?_:K(1J23<V^,S0\M
M&/O <T ?T49'7WQ^(./Y\4N1G'?&?PJ'YAN+=,XV+\V >_J/7]*D&<X[8XX_
M+/OCJ* '4444 %%%% "$9!'3((S]:_C0_P""E7_!/"X^%G[8'[(OA7PE^TK^
MTAI^B?M;?&#XF#QO96WQA\8PVVF16FGQZ_!;:1"EZJ:?:1379AA@M@$BC0(H
M"J*_LPK^?S_@KC_R?!_P28_[*_\ %3_U$-/H _6W]E3]GC3?V9?A#X<^%VE>
M+/%_C2TTFUCQKGC;7[_Q+K=PS#S&-QJ6IR2W4Q)D(!=B0,=<5]+56LO^/.T_
MZ]H/_1259H **** "BBB@!"0" 3U.!]:0NH&2>,XS@]1]!2.Q (7&X#(W<*?
M;/\ G&*^"?VBO^"D/[+?[+/C";P1\8/&4OAS7;:"UN)(#%;F!DO8EEBQ)-<1
MDL588  R3C- 'WN&4Y(/3KP?ZC^5!900">3R.O\ D?C7R?\ LS?ME_ []K;3
M]9U3X+^(9]>L]"N?L>HO/#%#Y<K1B4!!'++N&T@Y)&2<5]7?[)^X1D9P,^Q^
MG!]Z )*0@$$'H1BEZ44 1E<,N#ST.1G@<\#L?<>E?SZ?\$UX]O\ P5!_X*Q,
MK*?,^/6G/(NWYD(\(V VECR3SG-?T&G[R_\  OY5_/I_P36_Y2A?\%9O^R\Z
M=_ZB.GT ?T%8(R0!@#  QD^^?Z&G*"!R?PP!C\J6B@ HHHH **** "BBB@ H
MHIK8XS_>'?'/^>U  7 )')8#.!U/^>]?C9_P4Q_X*Y_"/]@'Q%X.^%7Q!^!_
MQ&^,5]\6-*U2*UTWP5<:/#"]DC)9W<%X-4*!EF6XVX#J"N<U^QX+-R/O*3P1
M@$= ,_K^/%?AI_P5Z^"O_!-GXD1>#-5_;?U_4_#^N:1I^I-X2N=!O-4&LB%I
M%:Y>UMM)EBNYF255.U,DG P: /Y,OV@!\(?B]\5[OXD?"W]EK]O#X>Z7J^IO
MKK>&/#WC?PK::;::E<2;GNM&M+*1TMX3&3'$N2Z@D9P:_K1_X(?^*?@W=?!?
MQ%X,^&7P3^+7P>U7PX]M=^*_^%P7&G7GBG7;W4)V+WDU[IZ[)TEG629-Y+!7
M.>2:_D9\>W;>!_'T6E_\$K_BA\3O'$NGW(N;>/QY\/?$2V5LB2>6EDMSXH2:
M"Z1/E_>9*L"3C%?U[?\ !%G6OVQM:^%WBF]_;$\+:%X?\921:>;"\T>VTNV?
M4XC(Y\RYBTV&(1D1[6$<N=A8C@@T ?LWXGUI/#?A[7/$$T4DT>C:;=:B\2?,
M95MHFE9$7GDA<#CK7\.WQ2\?_%#X^_M5:/\ &"[\;Z-X2\)Q_&3QAX+@\#>'
M)GTJ"^M](M[@P7GB>R=_+NY)#(KS2\!Y4SUK^Q?]I']IOX-?LQ^$'\6?&G69
M-"\/7A^Q?:FL9;RQDEF5PMO<R >3"LH5LF0@!3GD=?XD/'W@S_@FE^V!\7/B
M%\6HOVCK[]EQAXX\0R0Z)I^IW_B"R\4SBY9Y=>MH8]0MH=&_M97+ 1)B-?W8
M8T ?OK_P1R^+WB1O'GQL^"7BP:+XDN?#.IV-UI?C'0X"0]O>13WAM=1NW+&:
M2)76WA"'"[,'C K^@ZOYLO\ @A#XQ_9TT:?XM_"+X&:)?ZQ#HM_8M<?%:]U2
M\UM_&I"7$QN3/=M.;(1<J(!<-G<$' K^DV@!&Q@Y..G.<<YX_ G@U7EB#1.C
M,8]ZM'OC(0C<#\R'HKCH&.,58;H>,^U5+BVANK>:VEWF"XC:*3:[(X#@@[67
MYE.,X(((SF@#^57_ (*G_L+_  W^'UIXR^+OPX^&&L?$SQ3K>NR>(O&GQ:UJ
MYTS6;GX:+=7\4T[Z5>^9'>:;':2$)'&B.8A(RC(.:\U_X0[X9_M4_M,? /X8
M_$'46^)?PFT7X/>*+ZRLO$<RZAI\NLZ=X2M[AV,=R!&[V5_&3&0,HRC!)K[S
M^-7_  2 ^/OB_P")?BS_ (5O^UWKWA3X&?%CQ#=ZK\1_ASJFC2^(3-:7UR+N
MYM+/4;^^,MK$SQHL:6ZHJ \ #(KM/V@_^".4OB'P_P##&Z_9L^,5U\%OB+\-
M-*N]$B\2+I!UE=7L]:ABM=8::UFGCC0SPK(5#%P@8@$'% 'XWVOC#6O"O['W
MQ_\ @UX<NI;'P!:?M"?\(Y:163O%%8Z(VD!#ID3*?+CLB"28@=G-?:OP/^%7
MP[_9S_X*%_LD:+\%M TOP9IGQ'^%WA.]\;6'AN"*RL-;OYO";7=QJ.I0VYVW
M%Y=71:>::3YGE)<\YK]"_!O_  28\(:7^R3XL_9Z\3>.)-;\9^-M5;Q5KWQ)
M33#;SGQ>;,V@U:/3A+A4088VZRA"1[YKE/V)?^"7'Q'^!OQ>L_C+^T+\>)?C
M;XH\%VT>A?#3_BGH]!C\/Z!I\+V.G1.()I$N673RL+-+\VX;FYH _0[]K[]I
MW3?V1_A!>_%_5? 7BGXBV5EK&FZ3+X<\'"W&M2_VBTBB\0W ,7V:U\LF?<"<
M,,5_G#?\%1_^"IOAG]I'_@IU\+?VN_AG\.M=\,+\"=$T7PC=>%?':6MU<7&J
M:#J<]S=2216Q2(QLEP553A@RC/ )K_4!UK1-'\2:?<Z3KFEV6L:=>+LN+'4+
M6&Z@(8%=^R='0.H8E6"A@<D$5_FT_P#!6K_@F?X?L?\ @M!\./V5OA/JRZ:_
M[5C:?XQBVV0CMM"U#Q)JET)[=59A%(D4=J=I!12"!@=* /[PO^"='[:?@?\
M;K_9B\!_&SP9IUUHL=[IL>E:II%Z8S/::EI,<5C>O$(OD2VFN4=H%R66/:&/
M K[N7E=O<<@'DCN"3ZC/4?SKX<_X)\?L4^%?V#_V;_"'P+\,WYU>;18'GU?5
MS";<7M]>LMQ<[8"[+&L<Q=0RM\PYP.E?<:CH1\R]CG&,']><\T .PP'!SD<Y
M)X^G^?2FA-NXY/<]3G'?/JP_A/8XJ2D)P,]?QQ^M 'A_QS_:#^#/[.WA:U\2
M_&KQ]HOP^T#6[R31=+U36S<+#>:I);22+90_9X9F:X,:EQN55(&-PXK\ ?\
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M<9X!_P %_?@,PFB)_P"&.-0RHD3(4^/Y_G)W;0,\8SD]LYK^A3<.".0><CD
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M0^ O#VM^&9O#5]IT427"R0O%=V=K=W9:4 >;.6;D,"=QK^CB@ HHHH ****
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M17V-_P ,4?LM?]$3\ _^$WI'_P ATUOV*/V60.?@EX //0^'-)'KZ6>?P[T
M?&P_X+F_\$M"Q/\ PU;X9R 8^?#GC79G&3D'P[G< ,DY Q3+7_@NO_P2KN4+
MVG[6O@^Z169'>WT3Q?<!70[61FAT!PK*P(92<J<@@'BOLB?]BG]EQXYEC^"7
M@#>UO*B?\4YI RSQM&%YL^#R#N/(/7(&*_,3_@E[_P $K[#X!?#/XF:-^TW\
M'OAS>^)M>^+OQ$\1^'9;>+1]?5/"&L^*+Z_\.QM*EJPMWCTR6 -;D@PD>61Q
M0![Y_P /SO\ @EK_ -'5^&/_  G/&O\ \SE'_#\[_@EK_P!'5^&/_"<\:_\
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M'/!'P5^'R>+=7\-ZI9:"[Z-I-FJ:E<6<T=J[7!M (1YSH3)QC[V>* /#[?\
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M#X[_ .'YW_!+7_HZOPQ_X3GC7_YG*/\ A^9_P2V8''[57AC@9S_PCGC7@?\
MA.@\^U?8O_#%'[+7_1$_ /\ X3>D?_(=,?\ 8I_98&-WP3\ X)Y8^'-) '<9
MQ9@<GCF@#XY?_@N;_P $M$C:9_VK?"R1D%VED\/>,UC1$SN9F?P^JQJ!G+,0
MJXR2*2'_ (+I_P#!*^>-9;?]K'PC<1. 5EM]"\83QL#T(DA\/NC=^0V,YKW3
MXZ_L&_ /Q;\%/BWX6\$?!CP!%XR\2_#?QIH/A*5M#TBT5/$6J:!?VFBR-<FS
M M534Y+9C.2 B@N2,9'S+_P3<_X)F^"O@?\ LE_##X<_M%?!SX>7?Q7T'1;>
MU\47,-GH^N0S7Z>9YC1ZBMHRSCYA\P8Y[=* .K_X?G?\$M?^CJ_#'_A.>-?_
M )G*/^'YW_!+7_HZOPQ_X3GC7_YG*^Q/^&*?V6?^B)^ ?_";TG]/]"Y_"E_X
M8H_9:_Z(GX!_\)O2/_D.@#XZ_P"'YW_!+7_HZOPQ_P"$YXU_^9RF/_P7*_X)
M;D[3^U7X:RV'VKX=\:9PHYY_X1[&/4=:^R/^&*/V6O\ HB?@'_PF](_^0Z:/
MV*OV6U#$?!'P"-W!!\.Z5T'?)LSCIT[T ?&G_#]7_@E8)Q W[6G@Y;AT$J6S
M:'XN6X:/./,6!M!$S+GCS A7/&<U8_X?G?\ !+7_ *.K\,?^$YXU_P#F<KP#
MXC?\$K+/7O\ @IQ\-?CQH/P@^'*_LT:#\!;CPAXBL3'HUO</X\_X21[V"=-"
M^RAYXQIGEJ;L(5W*4SR17ZB?\,4_LM$D_P#"E/ .3R?^*;T@8SST^Q\4 ?'7
M_#\[_@EK_P!'5^&/_"<\:_\ S.4?\/SO^"6O_1U?AC_PG/&O_P SE?8@_8I_
M99/3X*> #CKCPYI!_P#;.E_X8H_9:_Z(GX!_\)O2/_D.@#XX?_@N;_P2V(S_
M ,-6>&%QR3_PCGC7'!SR/^$=!/3M4$G_  71_P""5\4;S2_M8>%880#+)--H
M'C*.)(UX9C))X?58E&<[G8 9Y/2OLQOV*?V6!C/P2\ G)P/^*;TG(_ 6?/OU
MQ7S/^V;_ ,$]/A)\3_V5?V@/A[\'?@Q\/;?XI^,?AEXE\/\ @.>72='TR.+Q
M+>V9339'U V:K9(L^TM.2 @YR.M '(0_\%TO^"6$T:R0?M8>$YHG 9)8= \9
M2QN"."LD7AYT?/JK$&I/^'YW_!+7_HZOPQ_X3GC7_P"9RMG]B;_@G/\ "GX5
M_LR?"7P%\9?@Q\/9_B5X=\(:)IWBV:+3-(U:.76;73;:"^D2_%HPN%:Y24B0
M,0_!!YKZK_X8I_99_P"B*> ?P\-Z2<?7%GQ^- 'QW_P_._X):_\ 1U?AC_PG
M/&O_ ,SE'_#\[_@EK_T=7X8_\)SQK_\ ,Y7V+_PQ1^RU_P!$3\ _^$WI'_R'
M1_PQ1^RU_P!$3\ _^$WI/_R'0!\<_P##\K_@EL6*?\-5>&<C+[1X=\: @#(S
MG_A'L8ST'N*@'_!=7_@E;YYMO^&L_!YNE02M:_V'XN%PL;GY'-O_ &"9@&Z*
M^S:P'!-?9:_L5_LM;6"_!+P"N6PP/AS2>O3()LR3QR .IZCDU^7EE_P2MLX_
M^"I?C?\ : NO@_\ #IOV8M5^"7@7POH5D(]&-Q%XWTFXN7UV9O#XM=\,;Q21
MA;DH!+C&<B@#Z _X?G?\$M?^CJ_#'_A.>-?_ )G*/^'YW_!+7_HZOPQ_X3GC
M7_YG*^P_^&*_V6"6S\%/ (QC.?#>D@'//RDV?/X9[4H_8J_99;./@GX!X)!S
MX;TD<C_MSH ^._\ A^=_P2U_Z.K\,?\ A.>-?_F<I/\ A^;_ ,$M6/\ R=5X
M8X!)/_".>-!\HR3G/AW./;O7V-_PQ1^RU_T1/P#_ .$WI'_R'2?\,3_LL[@W
M_"D_ .X9P?\ A'-)S@^WV/!'U% 'QG)_P72_X)7Q1/+-^UAX4MX(P'DFN-!\
M8PQHK$ ,9I= 2.-2<8+,,G@5,G_!=#_@EDZ*T?[5WA21" 5>+P_XSD1@>05=
M/#S*P(YR"0>O>L[_ (**_P#!-GP'\:?V,OCI\,/V>O@Y\.['XQ^+O#MC9^";
MB;3]'T:*/48-<TVZF9]3:T5;4&PANUSN&20HZ\^U?LY?\$__ (%^!O@A\-_"
MOQ"^"_P_D\9Z)X6T>P\1R)HVD7ZOJL%C;PWCB[%F?.4W$<A\S)#<G/.* /*/
M^'YW_!+7_HZOPQ_X3GC7_P"9RC_A^=_P2U_Z.K\,?^$YXU_^9ROL,?L5_LL-
MG'P4\ \''_(MZ3S[C_0^1[]*=_PQ1^RU_P!$3\ _^$WI'_R'0!\=?\/SO^"6
MIX_X:J\,'/;_ (1SQKS^?AVFM_P7)_X);!P#^U5X:W("^T>'?&G Z<_\4[@J
M.<#ZFOL<_L4?LM8/_%D_ )]O^$;TGGV_X\Z;_P ,6?LM(%0?!/P#R1D#PYI+
M%>.I_P!#)([<\=* /C1/^"ZO_!*TW$ULO[6G@][J$(TUNFA^+VGB609C+P+H
M+2Q[@<Y=!N'(JQ_P_._X):_]'5^&/_"<\:__ #.5X!\&?^"5MKX;_P""C_[4
M_P <?&GPA^'$W[/7Q T3X>6WPMM(X]&N9[>^T?06M?$9ET,6I:Q634""C,JB
M4?,"<9K]0_\ ABG]EG_HBG@'TX\-Z2?Y6= 'QW_P_._X):_]'5^&/_"<\:__
M #.4?\/SO^"6O_1U?AC_ ,)SQK_\SE?8@_8I_99/_-%/ /'_ %+>DC^=G2_\
M,4?LM?\ 1$_ /_A-Z1_\AT ?'#?\%S?^"6@^=OVJ_# "]_\ A'?&N/R_X1W)
MZ^F*KS_\%U/^"5EK%YUS^UIX2MH5(S+<Z'XPA0-(P"*99= 1%+$@*I;+$[1S
MQ7V=_P ,4?LM;LGX)> .,$,?#FD]N>GV/''N#_*OSW_X*=_\$Q_#/QZ_9+\1
M_#C]FCX._#FQ^*]]XV^'.K:?/<6NC:#%_8FB>*[&_P#$2_VDUJBIOTF.X40Y
M_?,PC R<4 >AK_P7/_X):$ K^U9X692 0R>'?&C*0>05*^'2"#Z@FE_X?G?\
M$M?^CJ_#'_A.>-?_ )G*^B?AA^PC^SIH'P^\(Z+XC^"G@ Z[INAV-IJI70M(
MN0;Z.%5G(G%G^\4N"0_?KFN[_P"&*?V6?^B*> ?Q\-Z2,_3-GS^% 'QW_P /
MSO\ @EK_ -'5^&/_  G/&O\ \SE'_#\[_@EK_P!'5>&/_"<\:_U\.U]B_P##
M%'[+7_1$_ /_ (3>D?\ R'2']BC]EDC_ )(GX!/M_P (YI(S[?\ 'G0!\;?\
M/S?^"6F2?^&K?#1,9RV/#OC7 +] 1_PCN#^!/>O8?@#_ ,%4_P!@C]I[X@K\
M*_@9^T-X9\?^/GM9;X^'-.TWQ!!>I;1,JR2.;_2K:*#:74%)9%?D$*1R?9T_
M8M_99&P+\$_ (YSM_P"$;TG*D<\@V19@2,<\8.1[?G9^PI_P3J\0_LX_MR?M
MK_'/Q#\//!>A_#[XG_$6VU3X(WFC3:;-?V7A3^Q+6VN+>:QMH4ETH-J$3L8&
MV@@B3'(H _;48WA%(RAW,K<G!& 0?3)^N>M2+SDY!R>"!CH2.?ITJ$D8SG()
M.[ &3U^48YQGH14D9RNXKM)SD9ST./P_QH DHHHH **** "BBB@ HHHH ***
M* "HG.#P,'&,] PP<CW(ZBI::RAL9Z Y_P GM_6@#/OK&RU&UFL-0M8;ZSGB
M:&:UNHTE@N(GR'5D<,&R/EY'0=>:\I\)?L]_!#P&^J2^#OA7X.\/2:W>SZCJ
MK:9I%O"][?W+^9<7-QD,&EE?#,P(W'L*]EV<'GJ>3CMC&!Z>N1WIIBR0Q8[U
MZ$$[?;*YP>.IH S[#2],TR%;?3;"VL8%/,%I!'#&<G()6-5Y'WN1UZ=>=6FA
M2,<C&.<#!)[<CI_GU-.H **** "BBB@"-\YQC!(P&QT;/K],G I@ 3((&#U5
M0 !V+$<<L0.??\3,1GOVXXS@^M)M')[D $XST]NE ##G!!^9R05!Y4$=QGL/
M?^E?&'QR_P""@'[)O[-OB[1/ OQ>^,7A3PCXGUZYA@M]-U'4%AFCDF8HAE4(
MQ5"XVY..>XK[-VC>J\\,&'S<G;T.>PYY4]:_DZ\1^ O 'Q7_ &B_^"CFI_%G
M1M#\1WOA+P%KZ^%I/$-K9W\^AI:^((OLM]HQO%D>RNE!VK+;;) ,J#@T ?U4
M^%_$_A_QGH>G^)O"^KVNN:#K%M%=Z?JEC*)K6Y@D19(WCD  *LCJ<XY].:Z
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MQ"S88 D9']1GP6\*:AX&^$GPW\':M=_;=4\,^#M!T*_NMV_[1<Z;816\LOF
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ME2.3SFOZH0..>O?_ "/3I0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M>Q"YM;V)K:X@8?(\,F0Z-MP<$=>1UJ_2;1G/0YSQQGZ^M 'Y;?M*_P#!)/\
M9._:&\+ZAH4/A6+X<ZQJNIQZE=>)_#EL9[^2:.\2\GWQ7<Y@/VDJZ.3CAS@
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MCC/UQUI0,?XGJ?K0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBACC!9Y))&PJHJC<[,P4 $D@#(Y@>/? LL!NX_&OA*2VCF^SO<KXBT=K87
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M#BOU+H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJ.>?UKIJC3&3T..-PZ<?PCN,=AZ=S4E !1110 4444 %%%% !1110 4444
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MXVUGQ#X<UVTLQ]HN+*/38Y;?3K<3$H%;R&"JNWD<5Y1\7O\ @N]XY^(/PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKX/_ /7I??\ HV.OT;;^'_>']: '4444 %%%% !1110 4444 %%%% !1110
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M]+[&OOC(R1Z=?QKX(_X*A G]@3]J(#DGX9WO_I?8T <Q_P $G?\ DQGX._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M((_9N\08*]1_Q,_$/(]_3WKZ[^#?_*%;7?\ LE_C;_TU75?(<?\ RK.>"_\
MLVWQ!_Z<_$- &O\ \%&F8?\ !"#X ?<#/\)?V>0TKHN8^/!QR&QN5FZ-V))X
M&3G^DSX5Y/PQ^&Q."Q\ ^$-Q  P?^$>T[ICH">W3TK^;3_@HUS_P0?\ V?\
M/.?A+^SQG/.?D\'5_2;\*O\ DE_PW_[$+P?_ .H]IU '>T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1156\NK2RMYKN]N;
M>SMK>,RS75W-';VT$:GF2::5DBC0$\L[*!GDT 6J*\_'Q1^&>50?$?P$)=^Q
M4'B_0'9I&8*$"_VAN+DX4* 22< 9Q7=P2PSQ1S021S0R*'CEBD66-T;D,DB$
MJZD'(*D@]C0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?H\JD$D]3Z?=QVP/4>O>@!]%%% !1110 4444 %%%% !1110 4444 %%%%
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MJU'X2T2_L=<\22^'$\7:+9WD9M&N[G[,NDR>*8+Y9Y2F8X8K1M[2(JY.0O\
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MND$EJ);B>.T220,KJRP&<2_.I&8QGCF@#^2/]E[_ (*R^!?@S\-[/X4_$?\
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MGIQZ_P#UAR.>.<>O2OYZ_P#@DK_R>/\ M\_]E3\8?^I,M?T*$$%MH.YAG/\
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MY\ "&TNXIY"P[!48MZ8_.M\$, 1GGUX- "T444 %%%% !1110 4444 %%%%
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M.'AUN>*.-9M2"@&60+DYK^:W0?VZ/V\/V>?A)KG[#%S^P5X4U:_6/6/"EO\
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MX>M[.Y0X.])(KB"2-E=5(93C(P3_ )@W_!6?X8_'_P /ZA^S%XW^(^F:Q>^
M]7_94^"\/A?78K:>31HX(O#<,L5H;V-#:P7$%NT9D!D$H)&X=*_J>_X-<O#_
M ,7[/]C7XL>(_%>J:A??#7Q$GG>!!?ZA-?+Y5K:7L%X+2.:1S9Q1S;U:.+".
MV&(R* /OO_@A BOX6_;W1AE6_;B^)J$'NIL-,!4^Q!((]S7R3^UY^QI^R?\
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MMC7[7T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP < <?3F@#]1U;)((P?X0>I ZFGTQ!P#D,,?*V.<<<9Z\\T^@ HHHH ****
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M032:/KOQDTNXL+N()YNG:NO@>UAM+N)G5_+\AI"X95+ \KZ4 ?@%_P $+O\
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M FI7^HSO\-CHFIW,]IIM_<R37&EPZQ_:H<Q3),\6X! @Z)C&?WS_ &0_V6/
MG['WP7\._!WP$9Y['2((?[2U2YDEFN-6U1$"2W\QF+2[I #D,[?4YK\,O W_
M  7!_:)\:_$3Q!ID'[,ME:^!1H?BOQ!X06Y@UN/QEK6G^&;:>XDN6TPRF!H)
M1$DGF1<>5(&'45^V/[$?[5VC_MA_ GP[\6M/TFZ\/:M/&EIXG\/W<30/HVMJ
MA>>P"2,\JI&A0CS3OR>>"* /KU0IZ#@$_-G!+#J"/0=OI4M1JHPN.026SZ$\
M\8X]N:DH Y/QQX/T7Q_X4USP9XB@-UHGB+3[C3=0MP2ID@G0C[Z\J5<*P(ZD
M8K^>_0O^")GQ<M/B+;>&]6_:;AOOV5]'\6KXNTCX3?\ ")!+Y+HZG_;'V<>(
M/M!N JW0 )*[2/;K_1TP+# .,]2.N*C$9X_AQD @],9Z>N[))S[4 ?S[?M(_
M\$:?B%XS^)FL:Y^SW\?E^$?P]^)-PME\5_"$OAUM9DU[2;D(FHQQZ@\\;VWG
MPQ(G[M6*G!&237H_[0G_  2!N/$?@#X3Q_LZ?%AOA'\5?A#8):Z1XRFTI]8C
MU%Y;"+2[Z22Q>:-$\ZV$I"LS8+\'(&?W%VMA1G(!P?=<$<^_3_&FE"3V4*<J
M1U.?7/\ G\* /SV_X)^_L0/^QKX&\11>)?&"?$+XE>/+^VU;QKXQ&F_V?_:-
M_;QR1*8K0M)]F0H^&2-MI."<]*XG_@L7X4\,:]_P3C_:OU/7?#.@ZUJ&B?"W
M4[_1+W5]+L=3N](O5N[%!=Z=<74,LME<*CL@DMWC?:Q&>>/U!968?>VX(.5[
MCN#GU]J_.'_@KN@'_!-?]L'^'/PCU8Y7)/%[I^#@]_6@#^(']BK0]#U?PC^S
MOJ=OHVDZ;K/@OX7_ +3)DU33=/M;>^U4:MX2O@(]6GMXDFF$*@BW^U,P4<1@
M=_Z (G/_ !#0^#&9!S^S=XA&S@; =3U_!/N",XQW]J_!/_@E)GQ'X'^-;)_I
MS> _A/XV$SM\\FBMK/A/4_+9@.(1=$<;OO8XSTK]YX=R_P#!L]X+#-YC#]F_
MQ%O88+.PU/Q!C '7@C/3 &#0!M_\%&_^4$/P _[)-^SS_P"@^#J_HK\+G'P(
M\+GH/^%5>'\GT'_"*V63[X&3COTK^='_ (*..!_P0?\ @ 2&_P"22_L\DC'(
M&WP<.1VR>*_HM\+X/P)\+K_U2KP\3^'A6R(S]<?SH _#?_@C'J=CI'P<_P""
MDFJZGI<>KZ;9?MC_ !<GNM,EC62/4K5-)T[? \3(XQ+N(P5;!'3C-?P=ZU^V
MQ\3_ ("?MMZG\8_@=<S^$X?A3\8?B%>>#O#UY)]NM=*76]>NHO$R0Q7&V)!J
M%LKQHBQ@1Y 7/%?WW?\ !"JQ@U/P;_P4 L;^)+JSO?VW_B=;7%O*,QR6[Z?I
MB21L.X921CV_&OPH_P""F?\ P19^#WB7_@IS\&/A/\)KZY\&6W[2-E\1O%-U
MI5E%!%967B/PGH$WB6+R"VYBNLZEB.[W9.QR8^3B@#^NS_@G9^U'J/[87[)O
MPJ^.FJZ7)IFJ^+- M[K4;>5#'YMZ"T3S("B *S1EL*,<BO>/VC/ ?Q"^)OP5
M\>^"/A;\1$^%'C_7]':V\.?$!]*77$\,WL<\4QO6TMI(Q>#RHY(BF\']YGDC
M!_*?_@BQ^T!9Q_".Z_8E^(&BZ?X$^.W[+[2>#O$?A8;[:77+:U>:[_M_389]
MMQ=V:P3VR3W 1460[<<U^W=UQ:W6TAO]'G)4$'!\ISD=^3QR>E '\D_[#_@K
M_@IK\?/VJ_VA_A-XA_;^L;?0_P!DKXA?#BTUTI\*[1_^%CZ5KEN^LWMI&QO$
M_L@-!:-8EP9&S.)-IVG']<:9V)EMS!0&;&-S 8)P>1DY..U?S[_\$G23^W[_
M ,%9(A(9%C^(?P@VJV/D)\,:D2#CD$X! /IS7]!5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?E%_P %KOB'+X#_ ."<?[2%I9(SZOXT\"ZE
MX5T?RW*2"^O7MW39CDMMC. "#P:_5VOP>_X+S:M)<?![]FOX90-.T_QA_:,\
M/> Q;P*'\Y+[3[F8K<+R1!F(;S@\XXH ^$OV$O 2?#;_ (*3?!KP]]H5Y[C]
MF'X-:W>ND B\R]U?X>0W-U&R#[KQ2LP>0_ZP_-U.:^O_ /@G(L:_\%5/^"KX
M"G+?&O1FW;MP+#P=9=?0X&>?45P'PTT4^&_^"S/AOP\R-$WA_P" 'PLT7 &$
M8Z=X*%HRCT">7@@=.?>N_P#^"<2J/^"J7_!6'9C!^-FC%L=,_P#"'672@#SK
M_@G5X%\*_$O]H+_@I'X%\=:;;:OX2\2^-_'UCKME=1I)%)8'7G<L\;A@WEE1
M(ORG#*I!! -?RA?&W]O9_P!D+]JWP;\&O"FK7?Q>^"'[+GQ#UZ]^'U_=I+IE
MW#9^(/$+:MXDTMS<^;<^5I\\;6=NSG88XU,("X%?UX?\$H;.*_\ VNO^"@=G
M<DLMW\2?'%E*?^F$_B'R6Q[E';CIP*_FD_X+$_\ !%#Q]\._VT=#@^%?BNQU
M70_VG-4U2[\(1:U<I#=:;J4,L?V^&_2",B" WE\$B92Q:( ]1P ?U[>,/VO_
M (=?MN?\$H_C;\<?AP[06.O?!'6WU327WN^AZG+9+))IK32!3<&) #YH'(8=
MQ7>?\$<?^3$_AE_U\:C_ .B[*OP8_95^,O@C]CS_ ()[_M8?\$\_VB;>U^#_
M ,=?!7PR\326,^OL=+\/?$NWAL;:UCU+PE>WKK+JSW4\ACA\B()+L;;@J<_N
M-_P14\6>&?$_["7P[/A[7=,UD6=YJ45W_9]U'<?9Y52T5HY@ARC*RLI!Z%2*
M /UI'WF_X#_*G4W(!+9!#8Q@Y)P.WJ?I7P%\7?\ @IW^Q7\#/&E[\/?B9\</
M!?ACQ=I[,M[HNI:U96U[;E',;"6&:5'4JX*D$<$=: /O^BOGW]G_ /:A^"G[
M3WAZZ\4_!;QQHOC?1+*18KF^T:]@O(8G9F55=X790248#GM7T#N4<EA@]#D<
MT +12 Y_S^H]CV-(6 7=SC^7U]J '44 @\@Y'J** "@Y[''OUJC?ZGI^E6[W
M>I7EO8VJ'#SW4BPQ+QGEW( X!/7L:YV'X@>";F18K?Q5H<LK_<C2_@9W &YM
MJ[LGY03QVH _D,_X.)/%$OQ'_:O_ &;_ (1Z=(T^C>&/A?\ %/6?%%L/FB75
M+:*&^TDR]0K*!\F[D]1WKZ:_;':4?\$4?V5/E!?_ (1+PAO'&!MM9 >,=<?2
MOCG]MUD^,_[7/_!0KQ]:Q_VEI/[/47A/PEIVLQ@RVMHWC#P@TMS$DP)1/-FC
M.0."1R.M?8W[8A<_\$5/V5"KA@?"OA(LW]X&VF(QQTR<?E0!T_\ P5;('[*7
M[!DA)! ^% QDX.;/PEGIQW]*^>?^#H#XG^"_AK^SI\"]1TW2)+?XV0:MX3U3
MPGXN@=H);#P[9LW]HZ7)(JJ)+:\N?*DDMWE"/Y9RAS7T1_P5:^7]E+]A ;01
MCX48SR<_9?"7\L@U]O?\%8?^"?'PN_;O_8^U32_&CR:7XG\!>#5\4>%M?M(X
MVNHKG2M)^U1:?*TORQV5Q,6:9E!<<8Q0!_.[_P &UO\ P5:\2ZEX^O/V-/B%
MI(U(_$'Q5J7BCP]XA@5(3!KNNNDMZDL$41+1B&V #.X0G@<\U^Q=^2/^"[_A
M CY ?AWXN#=]^?#,.,#G'?)[9[8K^<?]@S_@FA\5OV<_V?-9_P""EWP/^(T=
MW\6_V=/B1XGL=1\"^(+J*U\(:]X;\,?9+>..2YMXFO7N)&O68HA4':,'&17!
M>$_^"_&KW_\ P4N\#?M4>-?AKI=CI5K;MX#US2M-%W(;9M5M;?0=6O+19)%9
MC&Z2SP,S<C:6 SP ?Z1!7A5"<@8QNZ+D<Y]<C@]?:INE>;?"?XF>&_C)\.?!
MWQ1\(R3-X;\;:)::[I3W"JET+2[!9%N$5F6-Q@[@#@'&.HKT7S%'4GL#GMGH
M3]>Q[_B* )*B.X'((#=#GD%>@/. ">.*=O!.,'GU&!R/7W[4.FX;<#!&"><@
M#D8_&@#$U+Q#H&D/'%J^NZ/I1<9B34M3L[!Y\#+&,74T3,!GYM@;\ :33_$?
MA_5W:+2->T;4I54R21:=J=G?R+&, DQV\LCJH)ZD#DU^*_\ P6I_9IN_&WP+
MU?X[:/\ %WQWX"U_X:6I_LW2?#;V\>FZD=0_=R&^9R)0T?E[H]@QDG)%:G_!
M';]DV7X??!#X8?M':K\9/B!\0/$OQ5^'27>JZ'XG:V?2-.GO+V=6:R:-C,6C
M6V0(7'\1R>,  _;!1SD# *C!S^F.W_UJ?2 8S[\_CW_#I2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %1OC(&<,<  ],$\G'KCO[5)3
M6X.['(!^;/W1ZX[^OX4 >9_$/X2?"GXI636/Q+\ ^$?'%BD;1-!XJT:PU6&.
M,@@C_3HG5%P3T*XSUS7R/X;_ ."=/_!/WPGXF3Q3I'P"^"4&JPSW$\32^'?"
M\D,4]P269(C%A71CE01PP!YQ7B7_  6+^*'QD^'/[-FD6GP:\7S> -7\<>*D
M\*ZKXVMX(;AM TN[M&=K^19QY*)'( 3)(R 'JPYK\4O!W_!(/]J?Q/IOA[QC
M!_P5$O[M=9M]-UZX@@NM%DA::Z2*_GM2RZD53>7,3C'[LD@ 8Q0!_7OX9\->
M%O">E0Z5X/T;1]!T= IAM="M;:ST],#:NR*U58R O *@\<5Y)^U+\&X_V@/@
M)\1?A)-JMOHI\7Z)+91:I=$BVM9XW2X@FFP1B-98TW E<#DD8R+W[-_@S6?A
M[\#_ (=^"]?\2)XNUG0=#BL=0\2)/'<IK$T<LI>[$\;/&YD##E'.",9XKRG]
MO\^)Q^R%\;W\':M'H6OKX4D^QZM+=K8I9HMQ"+F0W3L@A*VYE"ON5BQ !R10
M!_%[X@\'_P#!1KX!_'&W\+VWC'X4Z@W@S2_%?@;3/&$D6FS65IX6\71R65T]
MY&=4,TUS'8%1#(#F-D/RCM_6Q_P2I^#-A\%OV7=(T>W\:Z3X[UW7[Q-=\5:S
MHY+:?'KUQ $N((U+R;54 $('8#/6OYG?V=_V,_\ @D-\9OAO9>+?BS^TW+9_
M$6]O-37QA#K'Q&O[&7^U([V6.8*LWB!#Y2RARA50FPC QBOZD?\ @G)\'O@'
M\%/@9+X3_9V^($?Q%^';:Y]KL]6BU0ZO%:2?9E06BWYNKPRJL:A\M+GD'WH
M_0-5(.0>> P_A.!@[1VY]N:DJ-2#@*W0GC'49/7/0>A[\$5)0 4444 %%%%
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MLOVNRN?"=]/#-\A( V21Y.>"PYYK^AD,?EZ$G[WS#CW'KZ_2@!]%-# D]L'
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MV/TJ?_@G$ /^"J/_  5BQT_X7;HW_J'655R(Q_P7BUX@-YA^&?@_<V"5V_\
M"-SX&>@]/7D5:_X)Q[3_ ,%4?^"L6W.1\;=&WY&,,?!UD0%_O#KR/3TYH J?
M\$E?^3Q_V^?^RI^,/_4F6IO^"N4J)^V-_P $^Q@!GUOQ*8Y2,JFW4]+W#'7+
M C&/3/:H_P#@DNCI^V-^WP'"AF^*/C!P P)VGQ,NTGTS4O\ P5R _P"&Q?\
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MU\ /@;+IO[,WB^7X/_#RZ\6>)_CO'IOB#Q')X7THZWJ^GMIHE-IJ&H& 7-Y
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M]ZP?VNCG_@MU_P $WQGIIGQE^7'0?\(40#GWZ_C[4 ?T(U^)7_!P%>VNG_\
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M3Z\;O?\ E/!X3_[)OXN_]1B&O9O^"$8 _9*\<X[_ !Z^(A/U\RP']*\9O?\
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MY&?4BF[HU+?,H9@2I=T#$=V7)'RCUP>1]:=P6.W&2/F]N..> <GCCUK\+O\
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M+'B2U\%1^*/$'CY7LX-.@U2_N-9:-I;&UG-RZK(#!'L#)M&XY]*^3;[]K_\
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MY:\O4:27]T/.=D4+N?<< ]LU2_X*R ?\,,_&#C_EUL?UDES^>376?\$P@/\
MA@;]ET8&!\,K$@8X!%_?8('8B@"+]H?_ ()G_L7_ +3CW5[\5O@IX;U/7[E&
M\C7[ WFD7UA<XW)<Q'2;FRB+J^&'F(0Q Y[U^;&K_P#!+3]M7]F>^.L?L*_M
MD>-I/#P=G3X*^/YM,T[P/!L/^CV\.JLEYJ30H@"[C+N&6SVK^B# ]!SU]Z3
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MW\'_  ^\2>'=:U>_\07MYK?C35(M'TN^?6-7N9[QE$XDE?)VJ#@X &?Z,O\
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M NW\ZXTCPO:S6MI,ZL7#2)-<7!ZLQ4!A@D]*]S!QC(').WL5C/7.3QC\OYD
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M]/O&@#]B.=V!P%ZGCD'H .V.F:?42D@@'[Q)X S\O.W/I@5+0 4444 %%%%
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MK?@EX'^#FM^&9(M%T6U\'>([[7X-5TJSMXTBU"X:\BB$$\K@AHHUVC!.<DT
M?H7D#//3&?QZ4 @@$<@]*A4E2=XR>,$'+8/'S#MUXJ8=!SGW'?\ *@!:***
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M?![]E7X;?#GQGXGU^+Q+HT%U'?V]GX4\3W<"2,T9PMQ:Z1-!N4C#*LI(((8
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MXUN(XG*,DB,L@4HX/#'FO<8\8(&  <[1U&?4]\G)'M0!)1110 4444 %%%%
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MKXG?M$?M-:;I'A;XE_$Z\M73P?X?U--;T_3+:&R.GR?Z>%C?,@C27#H/O'G
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M?PCXV@M+;45M(3$K3"*UEF 3S)449;DFOTLH X4_"_X9X/\ Q;KP*?\ N4=
M_P#E?3#\,/AK@$?#OP'R <'PEH (!_[<.?3M7>GH?Z]/QKP#]I+]H7P1^S+\
M*O$'Q5\>.[:3HEI)-%9VREKS4+A0 MM:J0P:21G4(I&#D9- 'BG[:_[)VC?'
MG]G/QY\,? '@CP%8>*?$$%NFG73>'= L!&T3,SXNQ8J8CR/F4@X..YK8_9"_
M9AT#X+?LT?!SX6>-_ G@*_\ %W@CPC;:/KUT/#7A^]\R]AN;F5I/M?V%C<,4
MF4!V8LW3.%&?@/\ 9L_X+/Z)\7?BA#\//B=^S]\4/@I9>(K;4=2\">)_&]E8
MV&C^)--TN$W-S=6CQS22R(T'ER(2J_?7-4]<_P""V?@[2/C//X1M?@1\3M5^
M$6G^*H?!NL_&RQM+!_!5AXBF97CMY[YIA*I^SGSL>63LSSD4 ?LZOPP^&9)Q
M\.O H'7_ )%'P^"3WR/[/S^-/_X5=\,_^B=^!?\ PD= _P#E?6]X;UVP\4:%
MI'B32Y!+IVNZ;9ZK82@@^99WL*SV\F1P0\;JP(X.>U;E '"?\*O^&F2!\._
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M;)C\6^'M5^&/C/X._$KP([#Q3X&\;P6MMK%@@N!:AY(+6254S.'4Y<_=(P*
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M;\,KFVU_PE9?#?P79ZEKFCA)=,2[B\)" 6[W5N9())(IE,;+YA*."" <U_2
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MG^+'_!);_@GI\</&NK?$3XI?LQ^"?&'C77"C:IK^H7.O17ER4!VDR6FJP*"
MQ'RHH.<4 ?FSXX^//[+W_!-+]B_X>:9X-O\ P%\7/C/J,=II?@CQ)=+H[F7Q
M1J/VA[35].U2Z-PFGV=I=MC9#<+%O!<L*]U_X) ?#^S5OB3\;_&/Q1\.?$#X
MY?%F%=:\8Z9X=N+&>#PUI6H7J7]GIDDNGW-Q;RSVL\LD,DB[78KE@*^M/$__
M  2<_P"">WC+PCX8\!>*/V9/!.M>$O!=O':^&=)O9]=DATB*.1I(TM6_M43'
M8[E@\DKL"W6O:OV;OV(OV7/V1EU9/V=OA%H/PP371MU5-$N-4G6\0/YH$O\
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MTZYFM+VWF:^22WN(7:.6-F^R!25D!7*%@3T)'-:&E?\ !1_]B;5XEETOX_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Q9=_"[QC#X6TOX>>'K75/$,^G8TC3;J.PO5ECO)V)$4B.RHPQD,5'?)ZO\
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>v433932_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v433932_img1.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( 3P!1@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MV0W,$A #Y')C_@X>U6!6%Q^R_<8BWB0KXV5CN5P[*EU-8)9,_D2(5A>57#,
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M2Q5:,E*"J<T;)044[VY7%MZ]=M#^?9?^#B+4&,>[]F=(?-9FD\SQ[%&J6R8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHS_A_G_/3GI1G_/Y_X4 %
M%8.J^*?#.A31V^M^(=%T>XFA^T10:IJEE8320;F3S4CNIHG:/>CIO4%=R,N<
MJ0//=9_:!^"&@VE[>:C\5O @33V1+FWLO$NEZIJ(DDE2!8H=*TRXO-2NI?,=
M0T5K:32(H:1U6-'95=+=I?- >P45\D:]^V[^SOHEK%=0^+=2UYYKA8!9:-X:
MUPW$:-'+(;F5M5LM*M4A3RA&P-V9S)-'Y4$B>8T?G.H?\%&_@79.JPZ)\1M0
M5E9FEM=&\.Q)&5;:4*ZAXJL9"QX(V1NHS@L&!4',N_Z_DF&JZ?IY];??MYGW
M[17Y.^-?^"G.E-;ZY9>!_AIK0,^GSVVA:]KGB+3-/U&SO[BP")J-SH-KHWB;
M36&FZB[206AU>[BU"WMHVN3:M=26T'R7XB_X*!_M*WUFL&@^+&T&]$X=KP>'
M/ VJJ\0!S (;WP6L0!#*QE'S*5VC(8D/WGM&3]%_G8-+7;2]7_PY_0M2 YS[
M8_,\X]<XP>G?ZX_ER\1_M7_M.^(M3EU34?C)\0HKJ1(XC'X?UJ7P?IH2&*.,
M*NC>%1H^CPR'86DN8K&.>5RTD[.Y8OX)XB^)/Q UC5;W6?$'C3QAK&JWK1R7
M>IZMXDUK4K^Y$$,=M#Y][?7<]Q*(+:"*WMP\I6""&.&()'$BAJ-25[4WUW:5
M[=MW^6UR7**^TON?4_L(SC'O_G_/O]:7]/\ /M7\<6A_&/Q]X6U>#7/#_CKQ
M=HNJ6@GCM=1TOQ%JEG>6XNK>2VG,<\-RD@62":2*2/<$9&=2><C]IOV8?^"F
M_A/Q0OAKP-\;)[K2O$5T]Y;7GQ+O7T6U\.W-]>ZO=/HT>JZ?I.G:5;>'M/M]
M/GL],N-8:$6%M+:_;]6DMK*6[U.WKV<^5MQ:MNOSU_KRN0JL&TD[WV[W]+?Y
MKKW/UWHI 1[GMR#_ (?G^M+4&H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !17)^-O''A;X=>'-1\6^,M6BT3P]I,4<VH:A)!=W9@CEN;>T1DL]
M/M[N_N2;BZAC*VMK,Z[PS*J;F7Y3OOV^_@'!.XTJ3QCXDT\!3#K6C^'HK?3;
MIMB-*D4?B#4]#U5&MW8PRBYTR#+HS0^;$4D>7.,6E*23>R;U?HMRE&4E=1;2
MW:6GI?:_E>_D?;'^?\_F**_-[6?^"C7@RUU"Y@T?P%X@O=/C,8MKO4;RPTZZ
MG+1*SF2SMI-2CB59"R*1>2,R*'*(24'E'B3_ (*0>*KA(!X9\!^'=&97G-S-
MJNI:AXA^T+A%MA%;V\/A];5X]DC2LUQ>>:'2-4B\MI)3G5KKF>^T9/;Y(5FN
MR]6E^%V_4_7BC(]?;\?2OPSUW_@H!\;=2O8IM/OM!T&"*W2(VFFZ%"\,LN^6
M1KB5]6GU29I&61(L1S0PB.%?W?F,\C^:>(OVR?CCXDL-4TC5O'4\NDZO;S6E
M[IRZ'X;BMGMIQMD@66/11=QH1@"1;KSAGB09S3]]JZIR?;97[;MNWR#3?F5O
MF_R7ZVZ'] VJ:OI.AV;ZAK6J:=H]A&R))?:I>VVGV<;R-MC1[F[EAA5I&^5%
M9P7;A03Q7#W7QE^$%E((KSXJ_#>TE*[A%<^.?#$$A7^\(Y=45R#@@$ Y/ K^
M;"X\72SQ+$6!5#\N(^5& !GW  Y()'!QG-9K>))92!\S= 3M QZ'CGIC SSC
MZ4*-9Z\D5I=WDW;OLDOQ!N"=KR?FHI?@WTZZ_P"9_0O<?M??LZ6SRH_Q)M9#
M$&):U\/>+[V%@HS^ZN+/P_/!-D'@PR2 G(!)!QX[XC_X*!_"S3H<^'_#_B;Q
M!<B]\CRYEL-'@DLPLVZ]BFGN;B;#,L&RWFM(9MDQ:01R1-"?Q&75;B9B< #
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M*$EDMX!<PF.XCC19-JS4IN#ND^5WLSNI5.>-]G977;^OZZGIM%%%9FH4444
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M7^$O@XY\,_#GPII+9W^:FF6UQ.KDD@F:YCD;J/DVCCVX-=KB&RA6*TAAM(0
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MKVBM^JU=EO==/+\>YUGBB"[CU^ZMYG*M:V&F01Q-G9&L=C:!RN "!Y[3LV"
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M$$=R#VXI0JQQ#:J0=&-[0]F^=II6YIN5KJ5W[L=59/J>Q6Q62?V9"E2P&/\
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MWT-E&*V5K*VG2^K?S?G]QT]P$#%E;)4 8#9&,GMWYX_B(XY[UEW,C-'\H+<
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MY7\]$1KQY8@DDGFX3SI9VB._[H1D('(' (\;GB?'*^5LSF3"J"!W;E50<%B
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M:WLB02F"2"Y@G\R&ZL'28W46R6!&\PF-X3+&$F9B37V@W[/WA'6W:33[J_\
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M1K6G6&KZ5J$#VM_IFJ6=OJ&G7UM*,26UY97<<MM=6\@XDAFC>-QPRD<5?HH
M_AF_X+"_\$A_&/P-\0>*?C1\%?#8USX*:OXC6[\/I#KCZAXE\#-J&G6$MUX9
M\32:E9V=SJ.G2:^VJ:?X)G-SKVJ2:';:)8:WKNH^(9;NYO?YL)H6BE:*5"A0
MG>DGWPZD#!!SVR#W]N0:_P!:/XK?"OP5\:/A_P"*?AKX_P!'M=8\,^*](O\
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M!+!HUY<2+F%F0E2[;U# ]]I8\#&!T&5Z9P376V5O;6RL76/;@E=RH#E<\C(
MP"IZ'/3OG#SK5C#/%:!C-=S"1[>Q@ GNKA8D9W^SVD8,\VR)&=_+1MD:.Q 5
M21P2DE:3?Q:;_?U^>G^1UPY;+6_?1Z76W7[S^A#_ (($:/%I_P"T)XJF%N(Y
MF_9U\9QO)D$LK?%/X7/M)7CD(I &<8['(HKW;_@AS\#OB;X<^(/C[XIZYHUI
M:>#-)\#^)OA%>7T>KZ9<SQ^.KO5_A'\08M-2P@NY+R2V'AJ]BN&U&. V(G!M
M?/\ / 0E8TU:/_;TGM;=_P!:]1S?-*^^B_+T7XZ]S^E"BBBK("BBB@ HHHH
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MM+?UKKZFLDH)JVEU%VM_P+[?>5]2UJVM$D>21(HXT9I'>5(XH@!N+2N75$C
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M?:M%$R?;V /P)/YCI].^/7GM2T5GKU=S9)+9)?U^+\]PHHHH&%%%% !1110
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M1I )&5&D5V"GUGX??LR_'GXT:MH>E:/I=YX=BU<O+9Z?;V%QXM\<ZQ8Q6O\
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MJ@*H &*DHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M16#;>[;_ *Z(:26RZW# &?<Y/U_R****0PHHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>v433932_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v433932_img2.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW____; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( )(!IP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /[[[V[BL;6>\G.(K>-I'/ .!T R0,DD
M >Y[GBN07Q[I+6QNMDH4.B!"\>XEUE8=\#B,XYP<\E2,&WXZ /A/6<Y(\B'(
M&.1]KM_4&OD:YUR*WB2U/"B= 244G #CYB7&/E?/('/L*Q]LNB7S?_!0OF?6
M:^.]"95)>97:(2E-L1P".1N$W.#QP.>N*K-\0='#;0DI]]T8[GW/'&?7VKX%
M\>?&;PSX/E@@%_;&[\F-'A+VLCJN;R-V:/[?"ZXEMMFXK@-\I&37C5[^U)I\
M;'R)K=N1@_9HR>K9("ZN>G4>@/>LIXR$)<K2O9/=]?FCJHX2=6'/%NS;6RZ/
M7[/F?K"_Q T.)4:4RKY@)4*8V^[C.=SICJ/7OZ<Q_P#"Q_#W]ZX_[YA_^/5^
M2C?M5V;X%T8<)D1XLU'7&_).KC/W5QCWIO\ PU1H_K%_X"K_ /+BI^O4_P"Z
MO+F-O[/J]V_DO_D3]<X_'^ARJ60S$ [3GR0<@ ]/-/8BG?\ ">:)ZR?]]0__
M !VOR2A_:CL'4F&2!5W$$&U7.[ )/_(6/8CO4O\ PU#:_P#/:W_\!D_^6M+Z
M]2\OD[_J@6%C'2=^9:/U\]?3HC]8V^(>A(Q5A<DC'W4C9>0",,)<'@C/H<CM
M3?\ A8N@>EW_ -^H_P#X[7Y3I^T_E08H[21,8#FR8EB"<G*:L!P<KQSQR>U+
M_P -/2=X;/\ \ I?_EO1]?I=OQ_X)7U2']-_Y'ZM+\0-$?&!/@]V\I#Z<@R<
M<^_3FIQXZT,]9''_  * \YQC_7>O?O\ C7Y.M^TO XR[6Z2G.52T 4$' X;5
M"PRH!()/7/' %-_VD<DE'@(SG_CT!XR?^HD3DX],#'?/!]>I]OQ_X(OJL-NU
M^KU_K_AS];_^$ZT+_GK)^<'_ ,?H_P"$ZT+_ )Z2?G;_ /Q^OR0'[2*XY>//
M?%HN,]_^8EZT?\-(K_?3_P  U_\ EE2^OTNS^[_[8/JL//\ $_5L?$K0!,8'
M>Y#?WC'!M'R[O^>HZ]OK^=F+XB^')))$\Z8"-"[,PMU^Z<' \_\ $9.<#WK\
MA=<_:HTKP[&+WQ%-8V:Y"[IH5M^3Y:8_TG6(@>)(LX;^($YR,\#_ ,-^_!!&
M6-_$.G*]PP@8K<Z, #,=I^_XGXP0#R& XR" :?US%/\ YE>(2VNJ>,_7"[K\
MOO.3%TL/E2_X5LZR.@NK_MC)HVV_FS&@K>]'6_75]_W!3Q]X=D!V7+$XSR8!
M]/\ EN3CD= <>E1R>/\ 0XVP9-R<9*2PM)SG&(]XSR.?G! R<''/XRZ;^VW\
M$+G&/%NE1YXRVH:"I +*,G=XA8YR0>1T[5T47[87P4WK*OCK1(" 6W2:SX;B
M4;@P(.[6V W!L#/K[BFL5B6TO[,Q#NTK\F->_:V%6IAA\5P]C&I4.+<A5.+3
MJ?\ "QP\_=3O+5Y\VM+]O5'Z]+X^T!L?/<#_ (!#CZY,XX^H'TJ0^.] "[C+
M.!_N19ZX_P">U?DI'^V/\%P<_P#"Q_#?!_Z&#PSQD$#'_$ZXQDXR,$XXX%7#
M^V+\%GC*'XD>'-IQT\0^%@ORD'/.M8!R">G/7MQJZN)_Z%F*^4,9]_\ NFRZ
MGH?\8W_T5^0]/^9SP[_]$']6/U<_X3_P]_SVG_[]Q?\ QZE'CWP^QP)9_7E(
MA_.<5^3?_#7WP3_Z*3X;_P#"B\*__+JI(OVP/@F&)'Q(\-G@_P#,P^%CW'IK
M5'M<5_T+<5_X!B__ )D%+_5N,7+_ %OX?T5],ZX=OT_ZGY^L7_"=Z!_SUF_[
MY@_^2*3_ (3S0!_RUG_[XA/\IZ_*7_AL+X*_]%'\.?\ A0>&/_ES3A^U[\$Y
M,Y^)'AP;1_T,7A8<'KUUGV_''?%#J8FW_(LQ7_@.+_3"MF/MN&_^BNR#_P /
M/#O_ -$)^K'_  GGA_\ YZS_ /?$7_Q^C_A//#__ #UG_P"^(O\ X_7Y3?\
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MS)\1_#\8/ 9?$'A4$D\[27UXKMP"2,9R <X!IO\ PVU^S]_T4W0/_"C\(?\
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M'^>H9$^HF"/;I>V50?-^098EB%R0X/ !/)8'(QTR&?:]6Z?V<W&#C#?7IO\
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M!S7]G\-\+975IM8[+</B)*_O5E/O6UTJTTK)15_[J3\_\1N-/%/C7C"M&?\
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M@F&I;)$+20H)()I@LQ2ZVMA;>;)Q#(/FXY.6^;!^=M0^(O@R&*6:33;69PQ
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MAAL;AY?4ZDX_5)N%>]2DJ.)E2J*;P>%@VZ,:%2<(KDFI\T;14;8=FLC7<L1
M,8C0@,02."Q&_E^3D]2!T''%?:W[!+O'X^U*T1F%NMM"1&3G_EP\22'#L#)D
MNQ)&XC!P.% 'Q?ISH=0F#-D".,YY )"$GLOIWX'OC)^S_P!@T ?$?4\#D6D'
M<G+?V;XB'<GGKTX..XKE\1Y5L%DTN6-KM:VDGIB,'IHXW2YG;=ZL]7P"K?\
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M[H8K$SKXO$\K5'+L'[.@X0]Q*KBZ,:E.RI.$4^=5/^77>S3=WT-JP1?E&UB
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M#;'R.?,8_P 73"]NH_+Z\UJ1PX&".RG'S'KQV'?&/Y47DF[-O\;_ *?D!=#
MJ, 9/4D#/!XYH\IG&06 _P!DD=/P-5R2I/. .>^/7H>?S%+]L6,E0W YQD<\
M=@3@_GUJU)-:JUOS[Z>8#+^!'B8*BAX[8B1@HW%E!W%S@LV206W $\9(Q7"^
M)K%=9\#Z_I9CCE@>+5(Y+>5!)#(TE@L+>;"5DC<NH*ONC(9<JP(R*[-+CS/M
MF3N#PW!0\?Q'CJ??C!Q7-7DXLM!UR5QA2U^YR0/E%N#SNX/ !QR".?>NG)<9
M+"YC1@KKFJ235_[M67?NEYZ_,\#B.I0K</<286M%2Y<NPTE=1:]_'8?92C)_
M#%IVMN]U='\8WQ.TI-)\9W(\F*-3%:D1QHB*<V*9R@C09W,6]\Y)SG'O_P"Q
M$[O\4;Q8G= +0<QDH2#I.O'^$D] <'CH1Z ^'?&:]2Y\:S$!1^ZM5X*YP+"-
M@ !],>H[U[=^PBW_ !=2_)_AM$&?KI'B$\>@]S@9ZXXS_8?%]-5.$>?2[JR;
MZZ_7,''Y['^0O@A0E_Q&+)L1>T84<;""U5E_8N<)MVM'[5M4K)>;/[K?AU_R
M)/AG_L#6'_HA:*/AU_R)/AG_ + UA_Z(7THK^-C_ &<J?Q)_XG^9K>*1*WA_
M51  93;':"5 ^^F[);Y1\N[K^'.*^+O%9DBA07(&))]ORX)R8I.Z'Z<YX'3!
M&*^TO%!E'A_5C#_K!:.5^Z>A4MPWR_=SU_#G%?%?B'SKI'^T?\L9MV1M.XB*
M0\;-O;Z^N*\_$[M::WW]6=6%^&2\WKUV7](^7/BO\/=,\1V\$DTB1G,<B%WN
M_P#6E-1(!$)ZG[0Q^;$><9((6OF8_ ;53*TNFWUFJ$L<MYA."QSGS)0W]WIZ
M>YKV?XT_%Z#PA<I:06;7<V!;"/S_ +/L?=JT0EW/I]V#AK4*4/RG?G<=IS\H
MM\4_&NL3%K>Q2"W<LS9O-,? !8@9;2XW/#J,CNN"*YXX:E5CSSG:5VOM;)V7
M5>?_  YZU)^XM>Z[_P"?38W[[X+:V9V6;6+",HQ _<2,2=JDYV,1\O8D\YXP
M1BB'X+ZIT_MRP]0/LUQ@'GG/!_D>@SC%<F/&WBJ*64V"K',Q7[82UBV64?N<
M>;8L@P#)_J\=?FSQBW%X[\?-_P M(QD=O[)/(..^G_RQ].AJ_J6'>\]O\?\
MGKZ+[]3372SM;R\E;_@_H=)+\%=5+ASKNG\+M_X]KGIDD\\>O7T]N*9_PIG5
M6X&N6 S_ -.US]/T./Y5DMXY\?- S>8A8%L\:4#@(3T&GD8.0#G'?%9L/CWQ
M^TVPL@&3_P! C/)XZ:?GW[CC/:N.>"H*<ES:-^:[:ZW_ #OZ'#5QE:G4J0C"
MZ4K)IK:RUMRZ*[\SK4^$.JP*(QK>GX!)R+6Y_B);T/\ >[DFG?\ "IM6)'_$
M[L/_  %N?_B>E9B>+?'DBAS+&"0,C9I1Q@8Y)L%YXXX&>@IW_"5>.\X\Z/\
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MW24O3W%=?==Z=5OY$_7*/\NWE/\ KR_0H210O(Q,;2$XS(_F(6P /NJ5 (
M P,@ ]2349B@!XAX^;(WRY.0!V8XX&#Z?7FM.;P?XK=S(P$6\C"1MJ!08 4;
M<V2CG;DXP=V>.3EG_"%>*@"Y+A>?F*W^WGD\_8\="/P^M=="$HTJD'>ZO%IK
M5M.*NK+K;HFNQE4J0=9332C*E3:]Z*M=R=G>6C5U=-W75(K1K;PP-LEE4R.Y
M9%B=PA*#*AB"2 > 3R0,GGKXY^TQ:2-\.YV@>YD)N[/A;;<<+?V(X 0GOR<<
M=^O'OEMX(\6M9S.T%KD.[0K*=3$TT0C0HX']G<^9D\KN!.[!;!KPSX^6OBZ/
MP/,MY8VT$ NK4F6X;44A!-]9<-(]BJ#+$*"5.790.2*Z\DC*.(DY1<5SZ<T9
M)/\ C=9**UNNO4\?C"=-<)XI.<(MTJK2E.$7)?6L)JDYKFM=-VOH_-7_ )_]
M:_X_8_\ @?\ Z*BKGG_UUU_URG_FM='JZL]VCHI=1NRR@LHS'$HRPR!D@@9(
MSBL!X91)<MY;[3%-@[3@YP1@XYSCC'7MU%?W9'WI2<?>5WK'5?%+JKK\3_ '
M#)K#X9---4J-TTTU[BW3LU\TC.7[C?C_ "%$7^L7\?\ T$TY4<*1L;)S@;3D
M\ <<=ST]:=%#*'#&*0*,Y8HP X/4D8']:]"G."@XN<%)Z*+E%2;L]$G)-OR2
MOY&\OB?K_D6*DB_UB_C_ .@FF[6]/U'^-/B4B09&,9Y. /NGOTIV?9_<Q6?9
M_<_\BW4T)PQR0!M/7ZJ?Z5#Q_>7_ +Z7_&C)[?-G@A2"<=R0N3BD[I-[6ZV?
M^06?9_BC%U 2,V4B<\-T4X(#@X QGID@C.>F> #SS1S)#,I4HLJKN+# .PAA
MR??&!D9)'/8]]Y"28W/\W/'!//)& <C'3UX/0UGW6F^;:R11,GG.(Q&S$[5'
MF(7RR(Q * KPK9Y' -9T9QA.7-&_/H[II;26_P UY*VAU4:BDZ<=(R@TX-IM
M74N:\E>*:O&UKW=VM+GG\NVXMH+>Z?,EC/'=V8VXQ/$SRY^7:'^<QG;)YG "
M_=!%??WPK_X*8_M*?#32-#\*VL>BSZ!H>FZ;IEHMWINA0S?8]-M=.TV!23HC
MW4@^Q6"@R&1RS$@R/(I8_#%WHMU%*D94R-\Y,D"/+&"-G5@@(SNZ%1RC#!VF
ML>\AN[:1H[E6:5)V2,@.4-NK,$<%T0["RL1M#+Z,>17S&=\*X3-:RKUX<\8J
MR?-#5*,+*7[V,KKE2T5F]^A^I\)\:9QPY6C+*<=&E)PJ-T[T_=<Y2C*5->SJ
MKV<I*4Y1FW*',E%<N_ZZ3_\ !73XYQVS_P!GZ5X>ANY$W&1K.U;,G!SB?1'A
M)SDD %23BODOXN_MP?M$?'!+ZQ\7>+K2ST:[N$E32++P_P"#PEL(&LI(PE['
MH$%])YDNGV]PV^9BK,8AB,;!\;W-\8XDW&/(!SAP'P%'!R1R.2,^IZYJI_;P
M0B)+**1H\%IY&(5R4#X+ N"%!*'C.X!6.37E8+AO X#$)4L._=<6Y/GM?FB]
M.6<K^O?R/?SKQ1\1<_PKPL\TE##5/:4G3ISP<;P:J0ESNO@8KEG&<H\L7=WN
MFM6=;HZI97&9IV(VD&:5%CW ACR0J1KMR%' W8]22=KQ%XKM[>P:TL98KC;;
M^3OCQ)O"!HAM">9NW[5.Y"0%.0<;<\#/XD%U$L)L$C89)DM(RP/.<%F=<C&.
M@'.1Z9S+2"XFD G$OEI\JM*K_.B[2IRPVDL,YVG!.X 8P:^RK8BG@\/A886E
MS5>:U22A6=DJ<6KV4UI*[3TN^O0_.(9<ZU6ICLTJ-XCGE4JN<J+52VK2<.2#
MYG>\8P;2VLFB>V,M],;BXC9 <D?*8R,LKC^Z1C>W4>O/IZ38B9UL7YNY;>*V
M-J8HMRV_EQQQP*_V;"DQ(!$S7'0Q_O09 QKD8(!E8TVKP%!8,%'0=1D ]QD$
M^Q[^A:5+#900JD;L[11"1Y51%W8!D,;;]S)O+;-P!V@9"DXK/$X19G0M6BKN
MUVVHO[/2<J>GF][[W.3$9]C\#5OEE>6&<;*"A[)II)V;<Z=1+M9?9MIHD?</
MP>_;A_:"^#%H]M:ZK8:A8/)O^RG1O#T[Y_TW)/V;1)KP_O=0\SEL 1Y_U:OC
M]<_A-_P4<^#'CH6X\6^,]%\)7DUQ)"!?Q76FN@5I1'*5U2WLU <+$0S@#Y\G
MJ"?YQX9VW%UN@[' V3NJKQN R%9CSD]NRXQU$,^G+/=QW2&"P6,H1'9@CE0O
M()5""2O.,=<$'FOBL=X<X/-)0?);V/-\$Z,KJHHO5NLK6Y-.^UC]5\/OI$\=
M\ T\QH1Q=/'4<<L)RK$5)P=&6'EB7+DCA<#4O[7ZPN9S:^!6MJ?UL0_M<?LU
M&-Y+GX\^"UQ&S0&35]#C0N!E"6\Y0HP,MO) YW 5 ?VPOV:@>/C[\/F';_BI
M/#8R<=#_ *5@=^_<5_)E>V=Y=K!'%K-["D3J9%9\"6,9#(0K '<#MY#9 PP.
M 1 =$E_Z"D_XJI_J*X'X1X*_VW_X3O7R:K?)^A^I4/IG<612^L83!2;WBZF9
M7M?K_L*M=6>C/ZUX?VP/V;I)%6+X[_#V20YVQMXI\-H&PI)R?M8 P,MR1DC'
M4U>_X:Y_9Z_Z+9\./_"O\-?_ ";7\C7]C3I\R:O<QL.CQX1QG@X8,",@D'U!
M(H_LV]_Z#^I?]_3_ /%T/PDP/1S6FMWAUK\Z]WZEUOIH\4*4?891E=6/(N:5
M7$9Q&2E=WBE'!VY4K-/NV?UQ2?M<_L[;?WOQL^'&W/0>+_#A.<''W+X'&,Y[
M=.^*A_X:X_9N_P"BU?#G_P *[0/_ )/K^25--NP27UO4I  <+YI/.1SC>1ZC
MIWJ3[!<?]!34/T/_ +/37A)@+:N5_P#KYA5^>)1SOZ:7%]_^1)DR_P"YO.E_
M[IH_K87]KC]G/.(?C7\.0^#G_BK?#OW,_-][4.>2O09QGL.;L/[6_P"ST!@_
M&[X<=N1XM\-CKD=3?$G(Y'XX )Q7\C#:==,,KK6H0D'[VX*",$;?OXZX.3GI
MW[68M.N /F\1W_08_?1KW.<9;OT/3IZUS2\),"J[DG*W+%:3PK6TNOUAW_X)
ME5^FAQ>H\\LNR^E#K"E/-ZT=+>\O]@G-WZI[=-+G]@GA_P#:3^!/BF^32=-^
M+_@75=1N'2*STRP\2Z#=75Y(RR2&..&VO&G9E2$R8C#,55R1A<U[_IVMW6DQ
M1RVUVME82,74.D#I)N8))M>XCDD82&-HUVOU4A,-DC^*CP/KVO\ @3Q?H'C+
M2O$>J2OX?NY+N73XKMT:_62WFMEC_<2(28EEE9<L#EN3M)K]_OV>/^"D/P[\
M<Z!I'ASX@V3>'-96]FM_M?B/5-"T]-K7%O\ 999)=7\0)<[0U]+M;R,;8) F
M3&<_$<6^'=3"TO\ 9*&)J[:4J?MI7:VY:,:[_"_<_:/"_P"E5PWQ+75'BBK@
M\')\SYL1#,\/32C):NKBU@8+W)1O=I-R2NW>W[#66NVEVT=U/-&CX +GY/-R
M YE 95!$A=CE/W9QA>^.D?Q-8)'A;B#)7G$F<X SR!@8QQR?<&ODW1_BSX!\
M2007&B>,_"-Q;%(XX4L?$^BW.%$:2*&^R7LR;Q'-&&56.T%<':RD]E;ZUIUP
M@<ZSIY7CY_[0MV3& P.[S"IXYX/.1^/YC0R_%T*BP=3"8N,Z,E3DIX7$J2:M
M)J2>&C;XUNENM+/7^K:'%61YUA\-BLKSG)_[+Q5-5<%*&:Y7&/U;GE%-*MF<
MII.4:NLJDGI\6UO98?%EK#/(5U*.+;M*K*L<<',9W 3RHJOP2Q ?AR$R"17.
MZEXKN]1NO*MT1@53;/:H;A,JH;.\1R0\$D-DG'3@DX\VU?QA\/=)L,Z_XR\'
MZ3#:!GFN+GQ!HEI=OYDL;(9!?7EO&P4O#&I:09CD'.YE#?$'QI_X*3?!#X5>
M=HO@RSE\9:E$+67[;I-WX3O+=Q=#SG3SM,\622[HED17'E'!3)Y%?78+A>MB
MHIRPN)=[/3#UNJB[:T59:O\  ^:XH\3.&>$<+.K5S?),16IQO*$,UP.(J-\M
M2Z]E@LSK5+ITI77LT]59.\4_JWX__&3PU\'_ (7>+M=N/$VAP^)DT_7DL+6Z
MU"P%S)?Q>'=:NX81IZEW,[7^GK%Y+6Y/FDQ%,D1G^3[XM_%?7_C5X\\3>)_$
M(3S+?5M9BTN2&VCMHYK5]9U+4('58[:U616^WR,#L=B&4DGC;W/Q\_:E\>_'
MW5K^>YO=4T329]6U#4/[*NM2N_+$-W<ZG(;40-)/%\MMJC6Y3<=JHR!RI!KY
M_MEPJG&#M!E.W!E?";V.0-[/CDG[V.<D5_2? W#E+*,NYJE*=.K*G=1JPE3=
MINC*/*I<DI:-R^%WW5UJ?Y<>./C#F/'>88K#TZB67QKN%!P4[SC3J5XQ515:
M*7+.$(0IN$G:+BYV;<W2C;.H2;<$A%Z<G.SN".#_ "_4_;/[!I_XN/J!];2/
MT_Z!?B,>GY_EQ7Q#;2(^I2")ED.Q2VQ@V/W9'."<<\=LXZ9-?;O[!A4?$?4!
MN4-]FCX) /\ R#/$A.0>?SI^($?K.6QIR3CRMV37*]:V%=K2Y=+I/S6M]SSO
M :DEXK\-PC[S<,SYHK5V629LXW2NTFKV;2O9VOT_NJ^'7_(C^%/^P'IW_I,*
M*7X=@CP/X4R"/^)'IW4$'BV4<@\CJ./\#17\<O=G^S<_BE_BE_Z4S8\3'&@Z
MGCO;%>?]IT7^M?%WB+;%/<  9=I.O.1L&202N>N2!V-?:/B;!T+4L]!;Y[]I
M$(Z GJ!V_+K7PYXL:9KJ\=5_=1B<DDC"@1JPP-V[(P2,+Q@UY^(W?S_4Z\+\
M,O7\TCQGQ3XFT+0K2Z;4;^VM"WGHK/=V=L3*T5P50&>5.3Y,G'))4D A6(^;
MY_BSX9F:>T.HVT@9G(']I:?)D!@!@?;>>G7;T/ ]?"OC7XNUC7/'U_X:M[J]
M:RM6N;MT2X>W11!K>JV!.&F4LHAE (6,D@C'(P/.M,TK3;:]CFF6>;*,#ND+
MCD9/W^N"N">1R2,XR.'ZS*E[JOW[ZRUT5_)_=ZG>L,JJYV]=NG2]M_G?\#ZG
M7XI^'V'D0FWF%N2"3/92 >:2PX%V0,X/.U>G?FHV^+&C0D$+;X. /WMK[$_\
MO8Y^G\Z^=+FSM5G=[2T:V2;:=Q:)?."(H'$3EOW9+##J/O\ R@+G#O[&+KOE
MB 49Y,F[OC@ G'3TH>-DM6_S_KRT_4KZBK)WUWZ>O1?J?0#_ !<T"4AI7@C8
M#:%%Q9(, D\JUX><D@XX./7-,_X6OX<_Y[1?^!=A_P#)E>%6NEZ04?SK(W$@
MD(+KY>%&U"$_>[6)&2W V_-USFK/]E:%_P! M_\ R6_QH^OR[?G_ )B^HKS^
M2C_F>TK\4M$>0M&('4XPQFM&WXX(RMU@D$$ 9Z#CH:MS?$_2-@^2WP1U\RUX
MP5."1<]3QZY-> -IMBLS>3%Y$0*%8SC*8 ))\M67EB2,'D,-V34DEE9LN ?P
M._GIWV>V>M'UV79^>C_S^[\1?45Y_<NNW_!/>[;XJZ#)&L4EK S1;B3FQ.<L
M9%)+79)X;'(Z9QQ4@^+OA^1S;"SMP,D?\N0S@[2.+O!(^GH>.:\)M]-LXXE9
M+8/(0X9AY8)_>$$$L%+80#.,_C4YTW3UQ(ML/-;)X$0()7=@M@#KMR<G)XR1
MFN98V7M)6O\ $]&GW>_RT.:M@HRHSE_).:=]]++\+]=.G4^@G^)VC"(8BMU"
MVZ;1OM!A<': /M7&!P,$"OEC]HKXAZ7?_#:^26*(*+FP)^:V.2-4T_&TM<L.
MQSP?;K75R:8LBI/&O^CQP(EPV_;Y<B9,JF/ 8[$9?N!PV<*6/%>2_M!^%K;4
M/A?=QZ)"EW>-=V?[M3Y!94U:P9L/<+;I\J(YYD!(&U<DA3Z='&R5M+I=T]+_
M ''D<6Y1]?R%0@KOV-2.BO:]7!Z[/^7Y[>GX.WD:JA.>I' QGJO7 _\ K_K7
M+75RX21 C'*2+\JMD'!!Q\W?^$D9ZCUSJW$U[-.UG&@-P-I,7R @;5D!W.^P
M?)SPV<9'7 K*"RO<2VSA!)&KLZ8'#*5!RV"A'SC@,1Z<U_>638J-6C*^!@DU
M+?VO\U7=J23T/\$JF"K8:2IUI04[*[4M](V=I)22L][:?(Q1-,)%'EO\Q7!*
MMP<D $ALX''0^^6S6K#/*\?ELK8)).%;'R@D?,21V .<YST.2:L"QD)7Y$.,
M8RW&>HZ\GM[< >M67LYHH&,:J6!&,E,#YD'.2 ?E))^8 L,%>:[(T*-6<IPP
M5)5(IR@_WB]]6<97N[6=G>SVVZ.)1Y$O?IO:R4H[W=D_7RN[>>U/RP.#G(X/
MU[]1G\Z<J9; R3V_7/0>@]_Y4ODWG_/%?^^D_P#CE2PQ70D4R1A4&[G<IQ\I
M( ^<]6/8=_QJ_9XU?\N:7_@=3_Y .:>R]GK_ 'F)Y3^GZ'_"D,;CL3] 3_2K
M^QO3]1_C3'27'[M=QSR,KTYYY([XHG3Q?)+]S2V_GJ^7]PFU3_IW_P"!_P#!
M?Y,I;'_NM_WR?\*4"0#&UL=Q@X/U']>HZCD"K&V[_P">1_\ '/\ XNC9=?\
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MC:&+S(\MYVY'<CY2$QM91\Q+;@V<\8P,U=,DT\J7%M+)9W,;(592\!5D;<C
MQMO'S;#D.#\HZ$*:KNEX7C\EHHX\MYP<%BPXV[-I'0Y)+8ZC ZFK"!UX(&2.
M73C!)]VW8 ZXSG\<4+!XNR7L:=KWMSSW\O=NGZ_\$QG)N4I*.'<^5PB^>I).
M$DN95(S3A-7Z13NK)W=T=WI'Q.^)GAL1QZ7X[\26*QA62+3_ !)X@M(1A4CR
M8[;4HAO*Q(A9<?(J+G"+CT.Q_:D^.MK$(#\1_&!484;_ !?XPY 55_Z&%1R%
M[+@YP,"OGV3S%<$,A 49,BN[=3G&"0!CH.Q).<9I_F$@@"/L"?+ Z=>,9[]\
MGL:\2MPIA:N,JXROAJ+JUJCJ5+\TVY-4TVY<ZOI36Z\K:'OX/BKBW"8##X'"
M9]BL-@J%+V-"AAJE+#4J%+GJR]G2C+".:@I5*DDG4>LY.]G&WJGB;XR?%7Q0
MT\VL_$KQ=+:W817M3XO\1O !$L$6TQ76JW,8#/!$_P V?G^;C"[?&)XH+VX,
MTFN:E<W#*H+OJ*3NP"KM!9Q(Y^4*H]1CKUJPT-P\C$RPM$V L)5]J@#D$8VG
M<WS=.3UY-!LR/F@CM(7ZES;J23W.4&XGTR3T'%>UA<!E^$27L*2LDOA36BCT
M=1);;:V6G0\O$8W,L9>>.SO%5YMMNI*I351O5^]*-)NI)W=Y/E3OHEHB%X!%
MT9V^<#<Y#,Q)!W,=HRS8Y;KZXZ5KPR81$)!*HF>1GH ,\@>OOSZ5591Y:+*0
MT@"B0J"%+A<.5# X4MG /.,9J2-1SC."!W//H?\ .,5L_K.+KT_:8J$*<'RP
M7M(6C",94X1U@M%!06LG:UKNUWA4C&OAJ=2K.;Y)U-91C[UN6/.[J-^:_-IO
MS75M!=.M(+>[EF11EU4$G8. K=PHXS@8)QG@@ [J^TOV#Q#)\0[^90&46T8!
M 5AQIWB-2 0#U((&#WXR:^-8GMHX'N&E B QNQ(Q8^<J8*JC'@Y!P%QP>17Z
M-_\ !//X<ZC-JM[KC641L'MXPER;BV)^4>++<YB$AG!\U-AS&.?FR5Y'Q/B1
M.E'#)+&T6W%35JU)[SPW5;627RZL_;_HT9=BLU\7,OQV'^L*CA?K=&I)TFH0
MDLASJFE?D:3E4D[IM-22Z22/[7/ /_(E>%O^P'IW_I.E%.\!JR>"_"ZL,,-#
MTX$<'_EV3TR/RHK^.WN?[&K9?UW+WB?9_8&J>82J?9^2 3@^8FW@ GEL \<=
M3@<U\/>($@EOKV#SF42^:A 1SPZ*IY &<9)P.>_%?=VK:>FJ:;=V$F=ES%L.
M,YRK+(G1D/WT7^)1ZG&17QM\0OA7X@BOC-I5DTR&:4AC<Z?&3&T892%N+_.6
M('!&0<] :XJ\)MOEC)WNO=3>_HG^7H=F'G&*:E*,=?M-+2RVN]=OD?G-\3O@
M1+/KU]XAT^2:XENFN$:,&V@V)->ZC>L1)+?H?E9D7&P;BP.!M('SG>_#S7],
MN=RZ>\F"00;^Q&=Q?D'[6^.@YP3SUK]57^&OQ!N5VBS-IQDRBYT28LN,>68V
MO3@'.XMP00 ."<4C\'_'))9DD9CS_K-$ +8([7X ZD].2>?6N:.$<_>E!J6R
M4D[VOYQOWM^B.KZWR>[&46M'=--7WW3Z?F?F'/H6OB*V/]C,=JR#/]I663DJ
M,_ZW///Y]!TJM]@\1E=AT-L>VJ6'\BW^'7MQC]-;GX2_$#="#:D(OF '[1H9
M_N8X%Z",XSQ^(&34Q^$WC 1DBW<R8.!Y^D8SSCK?8/;V^M5]0B]6K_+_ ( ?
M7I=)?>_NZZ_UZGYBKI.OID?V.?F.[G4;(GH!S^\/IW_*E_LW7_\ H#_^5"R_
M^.5^E!^$GCTEB;9AR,?Z1HG3 _ZB'KFC_A4?CS_GV;_O_HG_ ,L*7U"'6/\
M7_@(?7WW_%?YGYM#3]9  ?1CN&=W_$PM/?'23'3'I3OL&K_] 8_^#"U_^.5^
MD9^#_C=N6MG+'&?](T7C''&-0QTQV_Q(/@[XUR/]&?KWN-&Q^.-0Z57U%=$U
MTZ?K$7U^7?\ &7Z2/SGBM-9$:J-'/4C_ )"%IQECW+$?U[>M/%KK1Y.CG')Y
MU&SZ_@<]CCZ>^*_1E?@]XT'!A<#G!$VC?_)^<GDYZ8XQG!I3\'?&70PN>>\^
MCC]1?>XX/ SU]>99>_:2]V5N9O9ZJ[U7NV_'Y$?7&\-B4[<[G4<5]IIRAR\J
M;NT[-Z)]6?G1%::^)/L@T;*3G><:C9 _O2$( +]E7(R<\\CO4<VB:EKK?\(_
M<:,5B?\ >$KJ%H6W(OVD'&X+]Z(#E^O..U?HK#\(_'OG,TEJRJC;82;C1#F-
M&(5N+_NHZ,"W;'05I0_"#Q;%<B[6-Q.H( ,NE="C)DDWQ3[I)/R]"/K7?3P<
M5:_S\^W3T_4UCB(8C+Y4:LH<UI)1J-1EK.#TC*5_LK96T/YQ?B7_ ,$S_$.O
MZY_:'A;6+M8B?G#6VCD?\>FGPC:;KQA9.N'M[CHG?D ;2W@FH?L%?%70]0FM
MTN'N$N'D@GE>/PVK1QM*%>4*?%[LS( 6V*22> ,G-?U6#X/>+8XS#;61A4_Q
M?:M+<_>+D8DU$C!9F')  R>F!7+7G[-OB"1_,C>:3S21<*3I:?(['>,G5AD9
MZ;<,2V  >*_4,H\4.(<-AY\[BG9VC4A73=G5LK/$+NN^Y_,_%OT6O"#%58/!
MT<\DN;26&J90[)QHWO[/+Y*UU/>^J=NI_+LO["WQ'7D7T@*G)/DZ$,]6Y \6
MD'!(QP05QP14I_8;^)4J&%;YB)#P?(T+J"&Q@^+/8=N.G;-?T\C]F+6>T<O3
M.//L>O\ X.L'MGV!/L%7]F/6]P*0R-+R5'GZ>,\8/+:R0#MW<G^9K2GXO<3*
MK.*I1BIWC&HZ.(48MV2DY?6=+/K9V2V9\S3^B!X65%"<L5Q)"THRE!XS*H-I
M-MQY7E#;32LTVKWWZG\P/_#!GQ+_ .?Y_P#OUX?'_NV&I8/V#?B<)E,5X[2$
M,%4Q>'<<JP;[_BX+]WIQUSUS7]/W_#,GB?\ Y]9/_ G2O_ES3D_9D\3[A^XE
MCZ_.+C2FQP?X3K)SGIT/7-='_$5^*MOK.'_\N/P_?G8_HA^$MOXO$/\ X5Y1
M_P#.H_F._P"&#/BS_P ]S_WZ\+__ #6U-!^P=\5%<F74A9KM($KV/ANZ#-D8
MC\N+Q@C*2,MO)*C85(RP(_IQ_P"&9/$W]Z;_ +[TG_Y;T]/V:/$T1+&.6?(Q
ML,^E1@<@[MRZODXQC'3G/:IEXJ\6.,DL30O;37$>7_3\G_B4/PE>CJ<0VZ_[
M7E/_ ,ZC^93_ (80^)O_ $,L?_@BT+_YLZG@_8-^);;BWB9.-H'_ !(]#Z$G
M/3QH.G'Z5_31_P ,W^)?^?%__ W3/_EM3T_9R\3)G%B_./\ E\TP],_]1<>O
M/T'O7/\ \13XOZXG#O\ \*'_ .YB7]$#PCMI/B&_GBLIM_ZJS^9S_A@OXD?]
M#.G_ ((]$_\ FUH'[ 7Q*E.__A+%0?=Q_8&B-QG.>?&H]<<==O;O_3-_PSKX
MG_Y\G_\  O3/_EQ3&_9P\2R'<UJZXP,"ZTPY')S_ ,A?\/R]:7_$5>,()RCB
M*,FM+16(NT]'_P ONBU)?T0O"2G[W-Q!*S6BQ.5-Z];?V8MC^9QO^"?7Q+/S
M#Q@I&.O_  CVA#I_W.PS^M1G_@GK\2V.\^,0/IX=T # !_ZG<=\]>@Z=J_IE
M_P"&;/$?_/M)[_Z1IG_RX^@_SFI5_9M\0;<-!(,]1Y^FG'/J-8_&E_Q%WC1;
M5H*VFL<2]/G6.BE]$GPB=N:/$"T_Z",K6N^G_"=J?S)?\.\OB4<9\7X/<_\
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MHY^E.B_X)X?$8_>\7J>PQX>T3@Y'4_\ "='L3GKTK^DJ7]G7Q257_1W^\/\
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MAN7_ ,)_1/\ YN:_I)_X9W\3?\\9?^_^E?\ RTH_X9W\3?\ /&7_ +_Z5_\
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MCDG.:*^8/TA?E_P_ZFA2%5;&Y5;!R,@'!]1GH:** >S^7YH7ITHHHH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>spacer.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 spacer.gif
K1TE&.#EA 0 ! (           "'Y! $     +      !  $   ("1 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA 0 ! (       /___R'Y!       +      !  $   ("1 $ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
